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
Abstract: This editorial aims to summarize the 19 scientific papers that contributed to the Special
Issue “Adipokines 2”.
The Special Issue, “Adipokines 2.0” of the International Journal of Molecular Sciences is a follow
up of the Special Issue “Adipokines” published two years ago.
Proteins secreted from fat tissues are collectively referred to as adipokines. Circulating levels
of these proteins are—with a few exceptions—increased in obesity. Hundreds of adipokines were
discovered and annexins, well known as regulators of membrane-related events such as exocytosis,
may affect adipokine release from fat tissues [1].
Adipokines promote metabolic and cardiovascular diseases and are biomarkers for obesity-
associated comorbidities. Metabolically healthy obesity is associated with an adipokinome similar to
that of normal weight mice, providing more evidence for a central role of adipose tissue produced
proteins in metabolic diseases [2]. Weight loss improves the parameters of insulin sensitivity and
hypertension, but most patients regain weight. Adipocytes cultivated in medium with low, and later
on high glucose, showed a different secretome in comparison to the control cells. These differentially
released proteins may contribute to worse metabolic parameters in obese patients after weight regain [3].
Physical activity is linked to improved metabolic health in normal weight and obesity. Adipo-
myokines are proteins secreted by adipose tissues and skeletal muscle and seem to have a role herein.
These molecules may be useful to classify different types of obesity and develop individualized
therapeutic strategies [4].
Excessive gestational weight gain increases the risk of neonatal and maternal complications.
The adipokine secreted frizzled-related protein 5 (SFRP5) improves metabolic function. Serum as
well as umbilical cord blood levels were low in women with an extreme increase in weight during
pregnancy [5]. Leptin was higher in the serum and cord blood of male infants born from mothers
with excessive gestational weight gain. Such an induction was not observed for female babies [6].
Adipokine levels correlated with neonatal anthropometric measurements and may contribute to greater
risk of obesity and metabolic disease in later life [5,6].
Excess body weight is a risk factor for insulin resistance, hypertension, and cardiovascular diseases.
Epicardial adipose tissue contributes to cardiac enlargement in the obese and this involves deregulation
of prostaglandin E2 [7]. Overweight and obesity are, moreover, linked to a higher risk of different
cancers [8,9]. This was studied in detail for the adipokine chemerin. Of note, chemerin was shown to
impair and to improve insulin sensitivity, to have pro- and anti-inflammatory activities and to exert
pro- and anticancer effects [8–10]. These antagonistic effects may be in part attributed to the different
biologic activities of the chemerin isoforms [8]. The role of chemerin in cancer diseases was nicely
summarized in two review articles [9,10]. An original investigation tested whether chemerin may
serve as a biomarker to discriminate patients with primary and secondary liver tumors. This study
identified an association of serum chemerin with hypertension and hypercholesterolemia in the tumor
patients [11]. Serum chemerin could, however, not distinguish patients with hepatocellular carcinoma
and colorectal liver metastases [11].
Int. J. Mol. Sci. 2020, 21, 849; doi:10.3390/ijms21030849 www.mdpi.com/journal/ijms1
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Adipokines are involved in the pathogenesis of reproductive disorders. The roles of chemerin,
visfatin, resistin, and apelin in fertility and associated diseases were summarized in a review article
with various informative and clear illustrations [12].
A potential role of chemerin in reproductive function was supported by the finding that plasma
levels as well as the expression of its receptors, chemokine-like receptor 1, G protein-coupled receptor
1, and C-C motif chemokine receptor-like 2 fluctuated throughout the estrous cycle and pregnancy in
the porcine hypothalamus [13].
Other approaches have been to determine the release of adipokines by tissues other than fat. One
study analyzed the levels of chemerin, apelin, and omentin in follicular fluid and ovarian granulosa
cells. Study cohorts were women with polycystic ovary syndrome, women with a polycystic ovary
morphology, and the controls. Differential abundance of these adipokines in the patients suggested a
possible role in the pathophysiology of polycystic ovary syndrome [14].
Adipokines are expressed by different cells in the joint microenvironment. Locally produced as
well as systemic adipokines contribute to osteoarthritis and rheumatoid arthritis. Different studies
have analyzed the pathophysiological role of various adipokines (e.g., adiponectin, leptin and so on).
These studies were nicely summarized in a review article [15]. Interestingly, the serum levels of most of
these adipokines were higher in the patients [15]. A separate study investigated the effect of treatment
with the anti-interleukin-6 receptor antibody tocilizumab in patients with rheumatoid arthritis. Four
months of therapy was associated with higher resistin levels and lower adiponectin whereas leptin
was not altered [16]. After treatment, adiponectin and resistin serum concentrations were similar to
the controls, suggesting the normalization of these parameters [16].
Moreover, adipokines were also analyzed as potential biomarkers in sepsis and critical illness.
Here, prospective studies are required to finally evaluate the prognostic relevance of the different
proteins measured. The heterogeneity of these patient cohorts may limit the diagnostic potential of
circulating adipokine levels [17].
The role of adipose tissue in the pathophysiology of most diseases is greatly unknown. There
is mounting evidence though that adipokines act in the brain, and the role of leptin in the control of
food consumption has been well described. Adiponectin protected mice from high fat diet induced
hypothalamic inflammation [18]. Microglia, as the resident macrophages of the central nervous system,
expressed both adiponectin receptors and were essential for the protective activity of adiponectin [18].
The neuroprotective effects of the adipokines leptin, adiponectin, chemerin, apelin, and visfatin
indicate a potential role for these molecules as therapeutic targets in neurodegenerative diseases [19].
Overall, these 19 contributions published in this Special Issue further strengthen the essential
function of adipokines in health and in various diseases. Different adipose tissue depots may have
specific functions and detailed analysis of their secretome may provide more insight into the connection
between fad pads and physiology.
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Abstract: Obesity and the associated comorbidities are a growing health threat worldwide. Adipose
tissue dysfunction, impaired adipokine activity, and inflammation are central to metabolic diseases
related to obesity. In particular, the excess storage of lipids in adipose tissues disturbs cellular
homeostasis. Amongst others, organelle function and cell signaling, often related to the altered
composition of specialized membrane microdomains (lipid rafts), are affected. Within this context, the
conserved family of annexins are well known to associate with membranes in a calcium (Ca2+)- and
phospholipid-dependent manner in order to regulate membrane-related events, such as trafficking
in endo- and exocytosis and membrane microdomain organization. These multiple activities of
annexins are facilitated through their diverse interactions with a plethora of lipids and proteins,
often in different cellular locations and with consequences for the activity of receptors, transporters,
metabolic enzymes, and signaling complexes. While increasing evidence points at the function of
annexins in lipid homeostasis and cell metabolism in various cells and organs, their role in adipose
tissue, obesity and related metabolic diseases is still not well understood. Annexin A1 (AnxA1) is a
potent pro-resolving mediator affecting the regulation of body weight and metabolic health. Relevant
for glucose metabolism and fatty acid uptake in adipose tissue, several studies suggest AnxA2 to
contribute to coordinate glucose transporter type 4 (GLUT4) translocation and to associate with the
fatty acid transporter CD36. On the other hand, AnxA6 has been linked to the control of adipocyte
lipolysis and adiponectin release. In addition, several other annexins are expressed in fat tissues, yet
their roles in adipocytes are less well examined. The current review article summarizes studies on the
expression of annexins in adipocytes and in obesity. Research efforts investigating the potential role
of annexins in fat tissue relevant to health and metabolic disease are discussed.
Keywords: annexins; adipose tissue; adiponectin; cholesterol; glucose homeostasis; inflammation;
insulin; lipid metabolism; obesity; triglycerides
1. Introduction
1.1. Obesity
In most countries, the increasing prevalence of obesity represents a rapidly growing risk factor
for chronic liver diseases, type 2 diabetes (T2D), cardiovascular diseases and most types of cancer.
The mechanisms contributing to obesity are multifactorial and are far from being completely understood.
Moreover, life style changes with less caloric intake and increased energy expenditure appear insufficient
to reduce body weight in the long term. Hence, the identification of the multiple processes that
contribute to excess adiposity is required to enact innovative strategies to combat this epidemic [1,2].
Int. J. Mol. Sci. 2019, 20, 3449; doi:10.3390/ijms20143449 www.mdpi.com/journal/ijms5
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Some key features and cellular machineries that contribute to increased and dysfunctional fat mass are
listed below.
Adipose tissue is central to the development of obesity and is composed of different cell populations
including fibroblasts, preadipocytes, mature adipocytes, macrophages, mesenchymal stem cells,
endothelial cells, and vascular smooth muscle cells, with cellular function as well as their quantity
being affected by obesity [1]. All these different cell types, through various mechanisms, contribute
to obesity and associated comorbidities, which has been reviewed in detail elsewhere [1–3]. In brief,
storage of nutrients and their mobilization for energy production are critical functions of adipose
tissue. Yet, increased lipolysis in obese fat tissue is closely associated with the development of
insulin resistance and T2D [1–3]. In addition, the excessive accumulation of fat in adipocytes due to
overnutrition can lead to an inflammatory response that creates further metabolic complications [3–5].
In fact, even the physical stress triggered by the swelling that occurs in adipocytes upon increased
fat accumulation seems to contribute to inflammation and insulin resistance [6]. In regard to the
inflammatory process, macrophages accumulate in adiposity and in response to environmental
signals in the fat tissue, undergo polarization to pro-inflammatory M1 macrophages [3]. In addition,
in adipose tissue other myeloid cells, as well as T- and B-lymphocytes, have been linked to macrophage
homeostasis and the inflammatory process associated with obesity [7]. Moreover, the growing tissue
is not appropriately supplied with oxygen causing hypoxia, which contributes to inflammation and
fibrosis. This pathological progress, adipose tissue fibrosis, hinders tissue growth and is linked to
metabolic impediments [3]. Further complexity is created by truncal or android fat distribution, which
was recently identified as an independent risk factor for metabolic diseases in obesity. Also, visceral and
subcutaneous adipose tissues differ in blood flow, cellular composition, adipocyte size and endocrine
function, thereby contributing differently to whole body physiology [2,3].
Additionally, the identification of brown fat in humans [8–10] has initiated new exciting research
in the field over the last decade, as its highly elevated expression of uncoupling proteins leads to the
production of heat, which favors weight loss [3,11]. Due to its therapeutic potential, the process of
browning has created great interest, where white fat cells become so-called beige or brite adipocytes,
acquiring characteristics of brown fat, in particular the upregulation of uncoupling proteins. Hence,
molecules targeting brown or brite fat to increase energy expenditure are being investigated for
their potential to reduce body weight and improve metabolic health [12]. Actually, besides increased
thermodynamic expenditure, the activation of brown adipose tissue additionally accelerated other
cardioprotective and clinically relevant events, such as clearance of plasma triglycerides, a process that
was dependent on the fatty acid transporter CD36 [13]. Furthermore, brown fat also contributed to
lipoprotein processing and the conversion of cholesterol to bile acids in the liver, enabling the removal
of excess cholesterol from the body [14]. Moreover, especially under thermogenic stimulation, brown
fat releases several bioactive factors with endocrine properties, including insulin-like growth factor I,
interleukin-6 (IL-6), or fibroblast growth factor-21, which influence hepatic and cardiac function,
contributing to improved glucose tolerance and insulin sensitivity [15–17].
Given that obesity is characterized by an increased accumulation of triglycerides, research in
the field over the last two decades has focussed on the dysregulation of the fatty acid metabolism.
However, obese adipocytes also accumulate calcium and cholesterol crystals, which was demonstrated
to contribute to oxidative stress and cell death [5]. On the other hand, plasma membrane cholesterol
was depleted in obese fat cells which probably impaired the function of cholesterol-rich membrane
microdomains (lipid rafts), causing an elevated release of C-C motif chemokine ligand 2 (CCL2), a major
chemoattractant for monocytes [18]. In other studies, inhibition of the Niemann-Pick type C1 (NPC1)
transporter, which facilitates cholesterol export from late endocytic (pre-lysosomal) and lysosomal
compartments, impaired insulin signaling and glucose uptake in adipocytes [19]. Cholesterol is also
essential for the proper functioning of endo- and exocytic vesicle transport, which control the release
of distinct adipokines like adiponectin [20], an anti-inflammatory plasma protein that improves insulin
sensitivity, but is reduced in obesity [21].
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A more detailed analysis of the various pathways listed above and affected in obese adipose
tissues clearly is essential to develop strategies to combat obesity. However, it would go beyond the
scope of this review to list all pathways contributing to adipose tissue dysfunction and we refer the
reader to other excellent articles [3,4,22]. In the following, we will summarize and focus on the current
understanding of how a group of evolutionary conserved proteins, the annexins, may influence fat
tissue function in health and disease.
1.2. Annexins
The annexin family in humans and vertebrates consists of twelve structurally related Ca2+-
and membrane binding proteins (AnxA1–AnxA11, AnxA13) [23,24]. All annexins contain a variable
N-terminus, followed by a conserved C-terminal domain with four (or eight in AnxA6) annexin repeats
(Table 1). Each of these repeats encodes for Ca2+ binding sites, allowing annexins to rapidly translocate
to phospholipid-containing membranes in response to Ca2+ elevation [23,25,26]. Hence, annexin
functions are intimately dependent on their dynamic and reversible membrane binding behaviour.
Nevertheless, their similar structure, phospholipid-binding properties, overlapping localizations,
and shared interaction partners have made it difficult to elucidate their precise functions. Yet,
despite in vivo studies in knock-out (KO) models strongly suggesting redundancy within the annexin
family, specific functions of individual annexins have been identified [23,25–31]. Interestingly, besides
often subtle differences in their spatio-temporal and Ca2+-sensitive membrane binding behaviour to
negatively charged phospholipids, the diversity of N-terminal interaction partners, affinity to other
lipids, including phosphatidylinositol-4,5-bisphosphate, cholesterol and ceramide, posttranslational
modifications, and most relevant for this review, their differential expression patterns seem to facilitate
opportunities to create functional diversity within the annexin family [23,25–31]. The subsequent
chapters will review recent knowledge on the expression of individual annexins in adipose tissue, with
quite diverse implications for adipocyte and macrophage function in health and obesity.
Table 1. Domain structure, expression patterns, and potential functions of annexins expressed in
adipose tissue. The different length of the N-terminal leader and C-terminal annexin repeats 1–4
(1–8 for AnxA6) for each annexin are indicated. AnxA13a differs from AnxA13b by a 41 amino acid
N-terminal deletion [32]. Relevant references for each annexin are listed. AnxA, annexin; GLUT4,
glucose transporter type 4; HFD, high-fat diet; HSL, hormone-sensitive lipase; SV, stromal-vascular
fraction; TZDs, thiazolidinediones. N/A, not available.
Name Structure Adipose Tissue Expression Function References
A. Prominent Annexins in Adipose Tissue.
AnxA1
adipocytes, SV, visceral fat,
subcutaneous fat, obesity ↑,









fat, epididymal fat, mesenteric










subcutaneous fat, perirenal fat,
epididymal fat, visceral fat,
brown fat,
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Table 1. Cont.
Name Structure Adipose Tissue Expression Function References
B. Other Annexins in Adipose Tissue.







AnxA5 SV, subcutaneous fat,intraabdominal fat






AnxA7 SV, subcutaneous fat,intraabdominal fat















C. Insufficiently Studied Annexins in Adipose Tissue.
AnxA4 N/A lipolysis? [90]
AnxA9 N/A ?
AnxA10 adipocytes, SV, subcutanousfat, intraabdominal fat ?
AnxA11 adipocytes, SV, subcutanousfat, intraabdominal fat




2. Annexin Expression Patterns in Adipose Tissue and Their Potential Functions in Obesity
2.1. Annexin A1 (AnxA1)
AnxA1 (previously known as lipocortin 1) is expressed in most cell types, and abundant in
macrophages, neutrophils, the nervous and endocrine system [23,27,92]. Like other annexins, AnxA1
is found at multiple locations inside cells, including the plasma membrane, endosomal and secretory
vesicles, the cytoskeleton and the nucleus, participating in membrane transport, signal transduction,
actin dynamics and regulation of metabolic enzymes related to cell growth, differentiation, motility
and apoptosis [25,26,92–94]. In addition, AnxA1 has a prominent extracellular function, acting as an
anti-inflammatory, pro-resolving protein which exerts its effects via binding to the formyl peptide
receptor 2 (FPR2). Both molecules are induced by glucocorticoids and contribute to the beneficial
activities of these anti-inflammatory drugs [39,42].
The inflammation-related functions of FPR2 are diverse and complex, with multiple FPR2
ligands exercising various and sometimes opposite activities [36,95]. While the loss of FPR2
reduced inflammation, the overall FPR2 activity in fat tissue in vivo is most likely the net result
of the distinct expression patterns and the localized distribution of different FPR2 ligands in this
tissue [36]. Importantly, resolvin D1 and lipoxin A4, both bioactive lipid mediators that have been
identified in adipose tissue, are agonists of this G-protein coupled receptor [96,97]. These lipids have
anti-inflammatory activities and highlight the requirement to fine-tune the balance of ligands with
opposing activities, in order to activate the immune response and thereby accelerate the termination of
inflammation [96].
Recent studies suggest that the AnxA1/FPR2 axis is highly relevant for obesity and related inflammation,
as well as other complications, such as insulin resistance, T2D and atherosclerosis [36,37,41,42,45].
As levels of FPR2 and its ligands critically influence strength of biological response, it is interesting
to note that in obese mice, adipose tissue FPR2 mRNA and resolvin D1 levels were decreased [95].
Most relevant for AnxA1 in adipose tissue, the FPR2 peptide agonist WKYMVM, which is derived
from the N-terminus of AnxA1, greatly enhanced the insulin response of diet-induced obese mice [45].
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Somewhat unexpectedly, FPR2 deficiency improved the metabolic health of mice that were
fed a high fat diet [36]. In this study, FPR2 was increased in fat of diet-induced obese mice and
diabetic, leptin-receptor mutated, animals. Loss of FPR2 in macrophages blocked polarization into
pro-inflammatory M1 macrophages [36]. FPR2 knock-out mice were less obese and higher thermogenesis
in skeletal muscle was most likely responsible for enhanced energy expenditure [36]. Although the
lack of FPR2 signalling events induced by ligands other than AnxA1 probably also contribute to the
phenotype of the FPR2 knock-out mice described above, one can speculate that up- or downregulation
of AnxA1 may also have profound effects on FPR2-dependent energy metabolism in adipose tissue.
In this context, it is still unclear which cell types contribute to extracellular AnxA1 levels in adipose
tissue. In fat tissues, AnxA1 was more abundant in the stromal-vascular fraction than in adipocytes [43],
indicating that infiltrating monocytes and macrophages expressing AnxA1 may represent the main
source of extracellular AnxA1 in fat [39]. In support of this hypothesis, when these immune cells
became activated, AnxA1 translocated to the cell surface and was secreted [39].
Besides the contribution of non-adipocytes to AnxA1 levels in fat mass, its expression appears
tightly regulated during adipocyte differentiation, as murine 3T3-L1 adipogenesis identified AnxA1
mRNA and protein downregulation [44]. In contrast, in mature adipocytes from patients with Simpson
Golabi Behmel syndrome, an overgrowth disorder leading to craniofacial, skeletal, cardiac, and renal
abnormalities, AnxA1 mRNA and protein amounts were approximately 65-fold higher compared to
their corresponding preadipocytes. As FPR2 levels were markedly reduced in this model, it remains
to be determined if drastically upregulated AnxA1 expression alters the repertoire and availability
of other extracellular FPR2 ligands and impacts on FPR2 activity [38,44]. Simpson Golabi Behmel
syndrome is associated with glypican-3 loss-of-function mutations [98], implicating a possible link
between adipocyte AnxA1 expression and this poorly characterized cell surface proteoglycan. However,
a more likely explanation could be the higher concentration of glucocorticoids used in this study,
possibly causing an elevation of AnxA1 levels irrespective of adipogenesis. The analysis of purified
preadipocytes and mature cells may be an appropriate approach to better define transcriptional and
post-transcriptional regulation of AnxA1 expression during adipogenesis.
The therapeutic potential of AnxA1 is further underscored by its upregulation in the subcutaneous
fat of obese men given rosiglitazone for two weeks [33]. Glitazones are insulin sensitizers and agonists
of peroxisomal proliferator-activated receptor-γ (PPARγ), a master regulator of adipogenesis [99].
AnxA1 is a target gene of this transcription factor in breast cancer cells [100] and most likely in
numerous other cell types [39,101]. Whether this PPARγ-dependent transcriptional control of the
AnxA1 promoter also applies for adipocytes needs additional studies.
Further documenting a relationship between AnxA1 and obesity, AnxA1 mRNA was strongly
increased in adipose tissue of mice on a high fat diet [34]. This upregulation was observed in
both leptin- and IL-6-deficient animals, strongly pointing at transcriptional pathways not directly
regulated by these factors being responsible for AnxA1 upregulation in a lipid-rich environment [34].
AnxA1 mRNA expression was also higher in visceral adipose tissues of obese compared to lean
children [102]. Proteome assessment of adipocytes isolated from subcutaneous fat of young and old
overweight patients revealed higher AnxA1 protein levels in the latter [35]. Hence, as older subjects
more often suffer from insulin resistance and cardiovascular disease, these findings further support a
function of AnxA1 in metabolic health. Interestingly, under inflammatory conditions, AnxA1 may
undergo protease-mediated degradation, leading to pro-inflammatory AnxA1 fragments that lack the
FPR2-binding motif in the N-terminal AnxA1 region [103]. Indeed, cleaved AnxA1 was more abundant
in adipose tissues of obese individuals independent of their insulin resistance status [40].
Whole body physiology critically influences adipose tissue function and in the following, we will
briefly summarize some observations that could impact on AnxA1 levels and functions in fat tissue.
In contrast to upregulated adipose AnxA1 levels in obesity-related disease settings listed above [33,34,102],
one study identified that circulating levels of AnxA1 were decreased in obesity [38]. Yet, more recent
research described that serum AnxA1 amounts increased with body mass index (BMI) and positively
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correlated with IL-6 [40]. In the same report, an association of serum AnxA1 levels with T2D was not
apparent [40]. The opposing outcome of these two studies clearly illustrates that further research is
needed to resolve the role of AnxA1 in adiposity and metabolic diseases.
Over the years, many studies have established that dysregulation of the inter-organ cross-talk
beween adipose tissue and other metabolic organs contribute to significant changes in energy
homeostasis, glucose and lipid metabolism in obesity and associated complications. Adipose tissue
releases numerous adipokines that influence liver, muscle and pancreas physiology, which in turn,
have potential to modify glucose and lipid handling in fat tissue [3,4]. This may also include alterations
in AnxA1 expression, secretion, and protein stability, which may impact on serum AnxA1 levels or
influence other AnxA1-related biological activities with indirect effects on adipocytes. For example,
non-alcoholic fatty liver disease is commonly diagnosed in the obese and is a spectrum ranging from
benign liver steatosis to hepatitis and fibrosis [21]. Hepatic AnxA1 protein expression was reduced
in patients with bridging fibrosis when compared to those with mild disease [104]. In mice fed a
methionine-choline-deficient diet to induce non-alcoholic steatohepatitis (NASH), hepatic AnxA1
protein levels were nevertheless increased [104]. While these findings may suggest a link between
AnxA1 expression levels and hepatic neutral lipid accumulation, oleate-induced lipid storage was
normal in AnxA1-overexpressing Huh7 hepatocytes [61]. Accordingly, hepatic triglycerides levels
were also comparably induced in murine NASH of wild type and AnxA1-deficient mice [104].
Yet irrespective of neutral lipid storage, liver inflammation and fibrosis were clearly enhanced in
AnxA1 KO-animals [104].
AnxA1 was expressed in liver macrophages and contributed to anti-inflammatory M2 macrophage
polarization and IL-10 production. Accordingly, macrophages developed into a pro-inflammatory M1
phenotype in the AnxA1 null animals [104]. Galectin-3 is produced by activated macrophages and
contributes to liver fibrosis, and recombinant AnxA1 prevented galectin-3 expression [104]. Strikingly,
AnxA1 protected the liver from NASH in this experimental model, which is characterized by body
weight loss [104]. Furthermore, inhibition of hepatitis C virus replication by AnxA1 showed a protective
role in the development of chronic liver disease [105]. Again, steatosis grade was not changed by
AnxA1 in the liver cells [105]. Hence, these studies suggest protective roles for AnxA1 in liver function,
which could also support a healthy communication with adipose tissue.
Beneficial effects of AnxA1 were also described in muscle and pancreatic beta-cells, both highly
relevant for glucose homeostasis [106]. The saturated fatty acid palmitate, which is elevated in
the plasma of obese patients, induced insulin resistance and suppressed AnxA1 expression in L6
myotubes [45,107]. On the other hand, AnxA1 released from mesenchymal stromal cells improved
the glucose-induced insulin release of human islets in a co-culture model demonstrating protective
functions on pancreatic beta-cells [108].
Taken together, most of the data summarized above point towards disease-preventing activities of
AnxA1 in obesity (Table 1). In further support of this model, AnxA1 null mice were in fact more obese,
had larger adipocytes and increased leptin levels when fed a high fat diet [34]. Common measures that
occur with high fat diet feeding, such as upregulation of lipolytic enzymes and downregulation of
11-beta hydroxysteroid dehydrogenase type 1, was only significant in fat tissues of the obese wild type
animals [34]. Corticosterone levels were higher in the AnxA1-deficient animals and may have further
promoted adiposity in these mice [34]. Moreover, the high fat diet fed AnxA1 KO-mice displayed
elevated glucose and insulin levels, and were less insulin-sensitive. Interestingly, despite the prominent
anti-inflammatory features of AnxA1 discussed above, adipose tissue inflammation was not induced
in these mice [34]. The exacerbation of obesity-associated metabolic diseases in AnxA1 null mice was
confirmed in a further study. The treatment of these mice with recombinant human AnxA1 reduced
body weight, fat mass, and liver steatosis [41].
Finally, others analyzed AnxA1 null mice fed a control chow diet. Body weight and adipocyte
size were normal, whereas epididymal fat mass was reduced in AnxA1-deficient animals [43].
Catecholamine-induced rise in cAMP levels and lipolysis were more pronounced in adipose tissue
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explants of the control animals [43]. Adipose tissue explants from the AnxA1 KO-mice further displayed
a lower production of IL-6, which was not attributed to a decline in the number of macrophages in
intra-abdominal fat pads [43].
Overall, the studies summarized above indicate AnxA1 as a metabolism-improving molecule in
models of metabolically stressed animals (Figure 1, Table 1). This may provide exciting therapeutic
opportunities [37,39,41,42,45,104], but more research—exploring for instance the comparison of energy
expenditure measurements in controls and the AnxA1 null mice on chow and high fat diets [34,41]—is
still needed to better understand the various molecular pathways regulated by AnxA1 in adipose tissues.
Figure 1. The multiple roles of AnxA1 in metabolism. AnxA1 increased insulin release of pancreatic
beta-cells [108] and improved insulin response of skeletal muscle and whole body insulin sensitivity, thus
lowering circulating glucose and insulin levels [34,45]. AnxA1 further ameliorated hepatic inflammation
and fibrosis in a murine NASH model [104]. AnxA1 null mice were more obese, produced more leptin
and had higher adipose tissue lipolysis, inflammation and corticosterone levels. AnxA1 did not alter
the recruitment of adipose tissue macrophages [34].
2.2. Annexin A2 (AnxA2)
AnxA2 is ubiquitously expressed and most abundant in endothelial cells, monocytes and
macrophages. In addition, AnxA2 is also often upregulated in cancers [23,25,94,109–111]. Most AnxA2
proteins form a heterotetrameric complex with p11, a member of the S100 protein family, at the
plasma membrane and intracellular compartments, while only small amounts of AnxA2 monomer are
present in the cytosol, endosomes and nucleus. In these multiple locations, AnxA2 contributes to the
regulation of endo-/exocytic membrane transport, microdomain organization, membrane repair and
nuclear transport, relevant for many different cellular activities [23,25,26,93,94,109]. Also, extracellular
AnxA2 activities related to fibrinolysis and not discussed further in this review have been well
documented [109–112].
AnxA2 is expressed in the adipose tissues of humans and rodents [53,57] and has been linked
with two prominent aspects of adipocyte function (Table 1). Firstly, several studies implicated AnxA2
in glucose homeostasis, in particular the insulin-inducible translocation of GLUT4, the main glucose
transporter in adipocytes, from intracellular compartments to the cell surface. In one study, the silencing
of AnxA2 in 3T3-L1 adipocytes improved insulin sensitivity and glucose uptake [59]. In striking
contrast, others reported that AnxA2 inhibition or depletion, using antibodies or knockdown approaches,
strongly reduced insulin-inducible GLUT4 translocation [51]. As insulin exposure promoted GLUT4,
but not AnxA2, trafficking to the cell surface [55], it appears unlikely that direct interaction or GLUT4
translocation along AnxA2-positive vesicles occurs. Alternatively, the underlying mechanism could
involve a possible role of AnxA2 in insulin signaling through the modulation of insulin receptor
internalization [46]. Indeed, the fact that insulin induced AnxA2 phosphorylation [46,56,60], AnxA2
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sumoylation [50], and enhanced AnxA2 secretion [60] further indicates that the expression, localization
and activity of AnxA2 is closely connected to insulin signaling and glucose handling in adipocytes.
Hence, further studies are needed to clarify these current gaps of knowledge and discrepancies.
Secondly, AnxA2 has also been associated with fatty acid accumulation. In fact, in endothelial cells
and adipocytes of white adipose tissue, AnxA2 was critical for the cellular uptake of fatty acids. AnxA2
was found to bind prohibitin and the fatty acid transporter CD36 in both cell types, and assembly of
this complex at the plasma membrane was enforced by the presence of fatty acids [57]. This protein
complex not only improved fatty acid uptake in these two often neighbouring cell types, but also
enabled the transport of fatty acids from the endothelium to adipocytes. In further support of these
observations, palmitate-inducible expression of inflammatory genes like IL-6, IL-1 beta and tumor
necrosis factor alpha was markedly diminished upon AnxA2 suppression, while AnxA2 overexpression
amplified the proinflammatory capacity of this saturated fatty acid [59].
Several in vivo studies addressed the aforementioned potential roles of AnxA2 in glucose and
fatty acid metabolism (Figure 2). However, AnxA2 null mice had reduced steady-state glucose levels
and a normal glucose tolerance [57]. As the glucose uptake of white adipose tissues was comparable in
the control and AnxA2-deficient animals, it was concluded that AnxA2 did not have a central function
in GLUT4 translocation in vivo. On the other hand, AnxA2-deficient animals had a delayed clearance
of infused fatty acids, indicating that the lack of AnxA2 compromised CD36-mediated removal of
fatty acids from the bloodstream [57]. Given that thermogenic activation of brown adipose tissue
accelerated CD36-dependent clearance of plasma triglycerides [13], and palmitoylation-dependent
CD36 localization and trafficking in adipose tissue being sensitive to acute cold exposure [113],
testing cold tolerance in AnxA2 KO-mice in future studies could provide further critical insight.
Taken together, these findings might point at AnxA2 contributing to a more rapid clearance of lipids
and the improvement of postprandial hyperlipidemia.
Figure 2. The diverse roles of AnxA2 and AnxA6 in adipose tissue function. AnxA2 improves
uptake and storage of fatty acids [57] and may have a role in glucose uptake and adipose tissue
inflammation [51,59]. On the other hand, AnxA6 modulates lipolysis and adiponectin secretion [68].
More recently, others investigated adenoviral-mediated AnxA2 up- or downregulation in mice
fed a high fat diet. Animals with low AnxA2 levels had reduced body weight at the end of the study,
displaying improved fasting blood glucose and insulin levels, as well as glucose and insulin tolerance.
Overexpression of AnxA2 did not change any of these parameters. In addition, AnxA2 depletion
was associated with less adipose tissue macrophages and inflammation, which was enhanced by
AnxA2 overexpression [59]. Hence, several AnxA2 functions observed in cell-based studies might be
relevant in stress-induced conditions in vivo, and, as outlined above, cell and animal studies support an
involvement of AnxA2 in adipose tissue function. In line with these observations, expression studies in
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humans and animal models suggest that AnxA2 levels are tightly regulated, often responding to changes
in whole body and adipose tissue physiology. For instance, AnxA2 was detected in preadipocytes
and was modestly induced during 3T3-L1 adipogenesis [54]. Guggulsterone, a natural drug which
inhibits adipocyte differentiation and induces apoptosis, increased AnxA2 expression in these cells [54].
While AnxA2 mRNA remained unchanged, post-translational processing of AnxA2 protein was
induced by guggulsterone [54], indicating that truncated AnxA2 isoforms may exert so far unknown
inhibitory functions during adipogenesis. However, in another study, troglitazone-induced PPARγ
activation, which promotes adipocyte differentiation [99], upregulated AnxA2 mRNA and protein
expression in 3T3-L1 adipocytes [51]. Likewise, the PPARγ agonist rosiglitazone also induced AnxA2
levels in subcutaneous fat of obese but otherwise healthy men. Together with the abovementioned
studies suggesting AnxA2 to promote glucose and fatty acid uptake, one can speculate that this
drug-induced upregulation of AnxA2 may contribute to the beneficial therapeutic effects of the
rosiglitazone-induced lowering of fasting insulin, glucose, and free fatty acids in plasma [33].
Interestingly, in murine adipose tissue AnxA2 protein levels were approximately two-fold higher
in large compared to small adipocytes. This differential expression pattern was abrogated in fat-specific
insulin receptor knock-out mice [47]. As the increased size of adipocytes is associated with an
elevated capacity for insulin-inducible neutral lipid storage, this further supports a function of AnxA2
upregulation in insulin-dependent metabolic changes during adipocyte differentiation and growth.
Indeed, a comparison of wild type and AnxA2-deficient mice revealed that AnxA2 was essential for
adipocyte growth, whereas adipogenesis was unaffected by the loss of AnxA2 [57].
Proteomic approaches to identify changes in weight loss and physical activity identified altered
AnxA2 levels in adipose tissue. Although a two-week high-intensity intermittent training of overweight
men neither improved BMI nor the parameters of insulin sensitivity, the inflammatory marker IL-6,
as well as AnxA2 and fatty acid synthase were significantly reduced in subcutaneous fat [53]. Likewise,
dietary changes, such as a low-fat, high-complex carbohydrate diet supplemented with long-chain
n-3 polyunsaturated fatty acids not only improved glucose and fatty acid metabolism, but also
downregulated AnxA2 expression in subcutaneous fat [52]. In contrast, a five week very low calorie
diet improved metabolic health and BMI of obese subjects, yet AnxA2 and GLUT4 levels increased,
whereas CD36 expression declined, in subcutaneous adipose tissues [49]. AnxA2 was also higher in
subcutaneous fat after weight loss achieved by a very low calorie diet [48]. In summary, the human
studies listed here do not consistently imply a common theme that associates similar changes of
AnxA2 levels in fat tissues upon weight loss. Likewise, discordant findings were also published on
the regulation of AnxA2 expression in murine obesity. Here, AnxA2 was expressed in epididymal
and mesenteric fat. Diet-induced obesity led to elevated AnxA2 protein levels in both fat depots,
which was also increased in the liver and skeletal muscle [59]. In spite of this, hepatic AnxA2 protein
amounts were found to be reduced in mice fed a high fat diet in a separate study [58]. Thus, for a
clearer picture of potential AnxA2 functions in fat tissue (Table 1), more studies are needed to improve
our understanding of the regulation of AnxA2 protein expression, localization and interaction partners
in adipocytes and other cells of fat tissues.
2.3. Annexin A6 (AnxA6)
AnxA6 is found in most cells and tissues, with abundant levels being expressed in endothelial and
endocrine cells, hepatocytes and macrophages [23,25–27,114]. The plasma membrane and endocytic
compartments represent the most common AnxA6 localizations [26,30,63,66,115–118], but AnxA6 is
also found along the secretory pathway [23,25,119], mitochondria [120] and lipid droplets [61,121].
Like other annexins, and depending on the cellular localization and repertoire of interaction partners,
AnxA6 participates in many cellular activities, some of which potentially relevant for adipose
tissue function, such as endo- and exocytosis, signal transduction, cholesterol homeostasis, stress
response [23,25–27,30,64,94,116] and lately, neutral lipid accumulation [61,62].
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The multifunctionality of AnxA6 has made it difficult to assign specific AnxA6 functions to
particular cell types, but despite a still limited number of studies addressing AnxA6 in adipocyte
biology, several cellular processes that are modulated by AnxA6 could possibly be relevant for adipocyte
function (Table 1). To begin with, AnxA6 upregulation inhibits cholesterol export from late endosomes,
which perturbs cellular cholesterol homeostasis similar to mutations in the late endosomal/lysosomal
NPC1 cholesterol transporter. This leads to reduced cholesterol levels in other compartments, such as
the plasma membrane, Golgi apparatus and recycling endosomes [63,73]. Consequently, membrane
trafficking is compromised, and we initially observed reduced numbers of caveolae due to caveolin-1
accumulation in the Golgi [63]. This could be highly relevant for adipocyte function, as caveolae are
most prominent in adipocytes, with roles in endocytosis, cholesterol and fatty acid uptake, lipid droplet
formation and signal transduction [122,123]. In follow-up studies, we then identified AnxA6-induced
cholesterol imbalance to cause mislocalization and dysfunction of several cholesterol-sensitive SNARE
proteins in the secretory pathway [72,73], all of which are fundamental for the metabolic response that
facilitates GLUT4 translocation in adipocytes [124]. Also, recent findings from our laboratories indicate
that cholesterol accumulation in late endosomes of NPC1 mutants promotes the interaction of AnxA6
with the Rab7-GTPase activating protein TBC1D15 (Rentero, Grewal and Enrich, unpublished results),
which has recently been implicated in Rab7-dependent pathways that regulate GLUT4 translocation
to the cell surface [125]. Impaired insulin signaling and glucose uptake in 3T3-L1 adipocytes upon
NPC1 inhibition [19] extend support for a model of upregulated AnxA6, through cellular cholesterol
imbalance, to impact on GLUT4 trafficking.
Secondly, AnxA6 associates with secretory granules in a Ca2+-dependent manner [67], participates
in Ca2+ homeostasis through store-operated Ca2+ entry [70] and alters catecholamine secretion [71],
all of which with links to the secretory pathway that enables adiponectin release [126]. Thirdly,
the scaffolding function of AnxA6 is critical for the formation and activity of several signalling
complexes [26,29,64–66], with roles in GLUT4 translocation and lipolysis [127]. Finally, we recently
identified the association of AnxA6 with lipid droplets in hepatocytes to influence their capacity to
store neutral lipids [61], which could also be relevant for neutral lipid storage in fat tissue.
Initial insights into AnxA6 functions in fat tissue were lately obtained from the characterization of
differentiated 3T3-L1 adipocytes overexpressing or lacking AnxA6. In this model, siRNA-mediated
AnxA6 knockdown impaired preadipocyte proliferation. Moreover, maturation of AnxA6-depleted
3T3-L1 adipocytes was associated with increased storage of triglycerides and elevated release of
adiponectin [68]. The latter finding was not observed in oleate-loaded cells [68], possibly indicating
independent mechanisms that cause changes in triglyceride accumulation and adiponectin release
upon AnxA6 depletion. Vice versa, AnxA6 overexpression in 3T3-L1 cells lowered cellular triglycerides
and adiponectin release (Figure 2). In addition, the catecholamine-stimulated phosphorylation of
hormone-sensitive lipase (HSL) to promote lipolysis was impaired in AnxA6-depleted cells and
coincided with AnxA6 localization on lipid droplets in adipocytes, implicating a scaffolding function
of AnxA6 at the lipid droplet membrane possibly relevant for HSL phosphorylation and not directly
linked to adiponectin release through the secretory pathway [68]. Importantly, this function of HSL is
not critical for fatty acid metabolism in non-adipose tissue [128], which might contribute to explain the
opposite effects of AnxA6 up- or downregulation on neutral lipid storage in cells from liver and fat
tissue [61,68]. Notably, AnxA6 levels did not change lipopolysaccharide response of 3T3-L1 adipocytes,
and basal as well as lipopolysaccharide-induced IL-6 levels were comparable in groups with high and
low AnxA6 levels [68].
Follow-up studies in AnxA6 KO-mice, which have normal body weight, glucose and insulin
levels, support some of the cell-based studies summarized above. In particular, serum adiponectin
levels were higher, while reduced amounts of adiponectin were found in the subcutaneous fat of the
AnxA6 KO-animals [68]. As cholesterol is critical for the release of adiponectin through the secretory
pathway [20], we speculate that the regulatory role of AnxA6 in cholesterol homeostasis [31,63,64,72,73]
could be responsible for alterations in adiponectin plasma levels in the AnxA6 KO-animals.
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Despite increased lipid storage in AnxA6-depeleted 3T3-L1 adipocytes, circulating triglycerides,
free fatty acids and cholesterol were normal in AnxA6 KO-mice [68]. Systemic lipid levels of
AnxA6-deficient animals were also comparable to controls after a high fat diet for 17 weeks [61,62].
Most interestingly, AnxA6 KO-mice gained less adipose tissue during high fat feeding [61,62], which
might be in line with the impaired proliferation observed in AnxA6-depleted preadipocytes [68].
On the other hand, and in contrast to the cell-based studies described above [68], circulating leptin and
adiponectin levels were slightly reduced in high fat diet fed AnxA6 KO-mice [61,62]. Lower fat mass is
usually associated with higher adiponectin and improved glucose homeostasis [21]. Such improvements
were not observed in the AnxA6 KO-animals [61,62] and AnxA6-related functions in other organs may
need to be considered to possibly explain these up till now opposing obervations.
Strikingly, AnxA6 deficiency in mice compromised regulatory steps to downregulate hepatic
gluconeogenesis that only became apparent after high fat diet feeding [61,62]. Likewise, dysfunctional
hepatic glucose homeostasis in AnxA6-KO mice was also observed after induction of metabolic stress
upon partial liver hepatectomy or starvation [129]. Given the prominent role for adipokines in the
coordination of hepatic glucose homeostasis, we speculate that so far unidentified changes in the
inter-organ metabolic communication beween fat and liver tissues of AnxA6-KO mice may contribute
to the fine-tuning of hepatic glucose metabolism, with potential consequences for the systemic control
of glucose in health and disease.
The abovementioned and in-part profound effects of AnxA6 up- or downregulation on the central
aspects of adipocyte function, including growth, lipid storage, and adiponectin release, suggest that
complex mechanisms might be in place to control AnxA6 expression levels in fat tissue. Several
studies provide some insight in this matter. AnxA6 protein expression modestly increased during
3T3-L1 cell adipogenesis and was clearly induced in mature human adipocytes when compared to their
respective preadipocytes [68]. AnxA6 protein levels were, however, not changed upon lipid loading of
adipocytes [68]. Likewise, exposure to high glucose or lipopolysaccharide did not impact on AnxA6
protein levels in 3T3-L1 cells. On the other hand, oxidative stress, which suppresses adiponectin
release and contributes to insulin resistance in obese adipose tissues [130], was associated with AnxA6
upregulation in 3T3-L1 adipocytes [68].
AnxA6 was also highly expressed in human monocytes, which can infiltrate fat tissue, and further
increased in monocytic cells of overweight patients [74]. How this might impact adipose tissue function
is still unclear, but high AnxA6 levels in phagocytes may accompany the process leading to foam cell
formation and atherosclerosis [64,74]. Alternatively, AnxA6-induced changes in membrane order at
the plasma membrane [131] may influence the distribution and activity of lipoprotein receptors and
cholesterol transporters at the cell surface responsible for cholesterol efflux [132]. Of note, adiponectin,
which protects from cardiovascular diseases [74,133], reduced AnxA6 protein expression in human
monocytic cells [74,133], but not in 3T3-L1 adipocytes [68].
Complex and differential AnxA6 expression patterns have also been observed in animal and
human studies. In subcutaneous, perirenal and epididymal adipose tissues from mice fed a high fat diet
for 14 weeks, AnxA6 levels were strongly induced [68]. This may in part be related to increased AnxA6
expression in macrophages [74]. Additionally, obese murine adipocytes also displayed higher AnxA6
protein levels [68]. AnxA6 protein amounts remained unchanged in the visceral fat of overweight
patients when compared to normal weight patients, illustrating that AnxA6 levels do not increase
when body weight and adipocyte size grow in humans [68]. Furthermore, AnxA6 expression was
induced in adipocytes during aging [35], which is associated with oxidative stress and a decline in
adipocyte function [134]. Hence, increased reactive oxygen species rather than cell hypertrophy seem
to mediate the upregulation of AnxA6 in adiposity.
Visceral fat accumulation has deleterious effects [2,68,69] and AnxA6 protein levels were higher
in human and murine visceral compared to subcutaneous adipose tissues [2,68,69]. In adipocytes
purified from the respective human fat depots, AnxA6 protein amounts were also more abundant
in the visceral fat cells [68]. Remarkably, fat depot distribution of AnxA6 changed in obesity. Here,
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AnxA6 levels were higher in subcutaneous adipose tissues compared to intraabdominal fat. Such a
change in fat depot expression is uncommon and cell-type specific regulation of AnxA6 may need to
be evaluated to identify the underlying mechanisms.
In murine epididymal fat, AnxA6 protein levels were approximately 60% higher in large when
compared to small adipocytes. This size-dependent change in AnxA6 expression was only detected
in insulin receptor knock-out mice but not in the respective control animals [47]. This indicates
that adipocyte growth is not associated with higher AnxA6 expression as long as the cells respond
to insulin [47]. Whether a differential insulin response of subcutaneous and visceral adipocytes [2]
contributes to altered AnxA6 protein needs further studies. Insulin did not change AnxA6 protein
levels in 3T3-L1 cells, excluding a direct effect of this hormone [68].
Finally, in brown fat, which is quite distinct from other fat tissues as its main function is to
produce heat, AnxA6 protein amounts remained unchanged in obesity [68]. Altogether, AnxA6 is
differentially expressed in the various fat depots and in some cases, response to diet was observed
(Table 1). Altogether this may indicate differential AnxA6 functions in the various fat tissues, which
still need to be resolved in future studies.
2.4. Other Annexins
2.4.1. Annexin A3 (AnxA3)
In comparison to the depth of literature on AnxA1, A2 and A6, up to date only a limited number
of studies have examined AnxA3 expression and function (Table 1). AnxA3 is most prominent in
neutrophils and macrophages and was detected in heart, lung, placenta, kidney and spleen, with highest
levels in murine adipose tissue [77]. Besides its Ca2+-dependent membrane binding behavior, its intra-
and extracellular locations and physiological functions are still poorly understood. Most AnxA3-related
studies focussed on its potential as a biomarker in several cancers and the association of AnxA3 with
chemotherapy resistance [135], with possible roles in the proliferative and invasive properties of cells.
Interestingly, a recent study identified the recruitment of AnxA3 to lipid droplets of hepatitis C virus
infected Huh7 hepatocytes [76], facilitating the interaction of viral proteins with apolipoprotein E
(ApoE) during virus maturation and egress. Given the prominent role of ApoE in mouse and human
adipocyte differentiation and lipid accumulation [136], one can speculate that yet to be identified
environmental signals may also trigger AnxA3-driven interactions with ApoE or other proteins on
the lipid droplet membrane during fat cell differentiation. In fact, one report identified AnxA3 to
negatively regulate adipogenesis. In this study, AnxA3 protein was highly expressed in preadipocytes
and strongly downregulated during 3T3-L1 cell differentiation [77]. Marked suppression of AnxA3
in early adipogenesis suggested an inhibitory function of AnxA3 in adipocyte differentiation [77].
Indeed, when AnxA3 was depleted by siRNA transfection of preadipocytes, expression of PPARγ2 and
lipid droplet accumulation were increased, enhancing terminal adipocyte differentiation [77]. Of note,
AnxA3 mRNA levels were comparable in the different white fat depots [77] (Table 2), indicating similar
roles in the various fat locations. Interestingly, stromal vascular cell fractions expressed higher AnxA3
mRNA levels compared to adipocytes [75]. Analysis of publicly accessible DNA microarray data
confirmed higher AnxA3 mRNA expression in murine stromal vascular cells (Table 2), suggesting that
AnxA3 might fulfill multiple cell-specific functions in fat tissue.
2.4.2. Annexin A5 (AnxA5)
AnxA5 is the most abundant annexin and except in neurons, is expressed ubiquitously [25,137].
During proliferation, differentiation and in many cancers, AnxA5 levels are often up- or
downregulated [138]. Ca2+ elevation triggers AnxA5 binding to various cellular sites [23,139,140] to
participate in cell growth and death, Ca2 signalling and homeostasis, membrane domain organization
and transport [23,30,140]. Therapeutically relevant, extracellular AnxA5 binds to outer membrane
phosphatidylserine, allowing detection of apoptotic cells [137]. Furthermore, AnxA5 has prominent
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extracellular roles in blood coagulation, phagocytosis, viral infection, membrane invagination and
membrane repair [137,138,141,142].
Although one can envisage several of these intra- and extracellular functions listed above being
relevant for the proper functioning of several cell types in adipose tissue, such as macrophages,
endothelial and vascular smooth muscle cells as well as adipocytes, current knowldege on AnxA5
function in fat physiology is still insignificant (Table 1). Analysis of publicly available expression
data (Geo profiles) revealed that AnxA5 mRNA was mostly expressed in murine adipocytes when
compared to the stromal vascular cells in subcutaneous and intraabdominal fat. Whereas adipocytes of
both fat depots had similar AnxA5 mRNA levels, stromal vascular cells in subcutaneous fat expressed
less AnxA5 mRNA (Table 2). In line with other differentiation models, AnxA5 protein expression
was induced in adipocytes during aging [35] and one study demonstrated an association of AnxA5
polymorphisms with obesity in a Korean patient cohort [78], which may suggest a function of AnxA5
directly or indirectly contributing to fat deposition, storage or mobilization.
2.4.3. Annexin A7 (AnxA7)
AnxA7 is the only annexin that contains a long (100 amino acids) and hydrophobic N-terminus.
Due to alternative splicing, a 47 kD splice variant is found in most tissues, while a larger 51 kDa
isoform is expressed in the brain, heart and skeletal muscle [143]. In these various cells and organs,
Ca2+-inducible association of AnxA7 with secretory vesicles, the plasma membrane and the nuclear
envelope has been observed [144], with possible roles in Ca2+/GTP-dependent exocytic pathways,
prostaglandin synthesis, cardiac remodelling and inflammatory myopathies [81,145,146]. In addition,
the GTPase activity of AnxA7 has potential as a tumour suppressor in several cancers [147].
The AnxA7 functions listed above and related to membrane transport, Ca2+ signalling and
hormone production could be relevant in fat, but very little is still known about potential roles for
AnxA7 in adipocytes or other cell types in this tissue (Table 1). Nevertheless, in other cells and tissues,
several AnxA7-related tasks may also influence adipose tissue function. For example, one mouse model
lacking AnxA7 displayed defects in Ca2+ release and Ca2+-dependent signal transduction, affecting
insulin secretion [82,83]. On the other hand, another independently generated AnxA7 KO-mouse model
was strikingly different and did not reveal a role for AnxA7 in Ca2+-dependent insulin secretion [79].
In addition, in some cell types, AnxA7 negatively regulates cyclooxygenase-dependent prostaglandin
E2 formation [80]. Hence, elevated plasma prostaglandin levels in AnxA7 KO-mice may contribute to
decreased glucose tolerance and elevated glucose-inducible insulin secretion [81]. Most relevant for fat
tissue in obesity, cyclooxygenase-dependent prostaglandin E2 production has been associated with
pathologic complications that lead to inflammation and fibrosis, impaired adaptive thermogenesis and
lipolysis in obese white adipose tissue [148].
Although the latter might indicate that AnxA7 plays a role in infiltrating immune cells in
dysfunctional adipose tissue, at present, very limited information on AnxA7 expression patterns in
normal and obese fat tissue is available. AnxA7 mRNA was comparable in adipocytes and stromal
vascular cells in subcutaneous and intraabdominal fat (Table 2). Evidently, more studies are needed to
possibly identify yet unknown AnxA7 functions in fat tissue.
2.4.4. Annexin A8 (AnxA8)
AnxA8 was first identified in human placenta [149] and, with the exception of acute promyelocyte
leukemia [150], is only expressed at low levels in lung, skin, liver, and kidney [151]. Earlier reports
described AnxA8 to inhibit blood coagulation [152], but cellular AnxA8 localizations and functions are
still not fully understood. AnxA8 may provide opportunities as a biomarker in several cancers [153–155]
and more recently, has been linked to the transdifferentiation of retinal pigment epithelial cells [156].
Nonetheless, within the context of adipose tissue function, the unique affinity of AnxA8 towards
phosphatidylinositides and F-actin relevant for membrane-cytoskeleton interactions, might be most
important. In fact, these distinctive membrane- and actin-binding properties of AnxA8 affect
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the functioning of late endosomes [84,85] and in endothelial cells, this contributes to control the
delivery of CD63 from late endocytic vesicles to the cell surface for leukocyte recruitment and
migration [86,89]. In addition, AnxA8 is associated with cholesterol-rich late endosomes, and similarly
to AnxA6 overexpression or NPC1 inhibition [19,31,63,64,72,73], AnxA8 depletion results in cholesterol
accumulation in this compartment [87]. This may indicate a coordinated mechanism to control AnxA8
and AnxA6 expression levels and their relative amounts in the late endosomal compartment. Along
these lines, and as discussed for AnxA6 overexpression and NPC1 deficiency above (see 2.3.), it is
tempting to speculate that late endosomal cholesterol accumulation triggered by AnxA8 downregulation
might compromise adipocyte function leading to the improper performance of molecular events in
caveolae [63,122,123], or related to insulin signaling and GLUT4 translocation [19,72,73,124].
The findings described above suggest that changes in AnxA8 expression levels may cause cellular
dysfunction However, little is so far known if AnxA8 expression levels correlate with metabolic
complications in obese fat tissue (Table 1). AnxA8 mRNA was expressed in human adipose tissues and
was similar in subcutaneous and visceral fat depots of obese men [88]. In mice, AnxA8 mRNA levels
were higher in adipocytes than stromal vascular cells. Interestingly, AnxA8 expression in adipocytes
was more abundant in subcutanoues fat depots (Table 2). This observation adds AnxA8 to the list of
candidate proteins that are differentially expressed in the various fat depots, and possibly relevant to
further evaluate the deleterious effects of visceral adiposity [88].
2.4.5. Other Annexins
Up to date, it is unknown if the remaining annexins AnxA4, A9, A10, A11 and A13 contribute
to the proper functioning of adipose tissue (Table 1). Out of those annexins, current literature has
associated AnxA4 with cAMP production, which could be relevant for lipolysis [90]. Also, roles for
AnxA11 in exocytosis and cytokinesis could influence fatty acid release or adipokine secretion [91].
Of note, expression data for AnxA4, AnxA9 and AnxA13 in fat was not publicly available, but AnxA10
and A11 are indeed expressed in fat tissue. AnxA10 expression was similar in adipocytes and stromal
vascular cells in subcutaneous and intraabdominal fat (Table 2). AnxA11 was mostly expressed in the
stromal vascular cells of subcutaneous adipose tissues when compared to the respective adipocytes and
to intraabdominal stromal vascular cells (Table 2). Differential levels of AnxA11 mRNA between the
cell populations did not exist in intraabdominal adipose tissue (Table 2). Further studies are evidently
required to unravel their possible functions in fat tissue.
Table 2. Expression of annexins AnxA3, A5, A7, A8, A10 and A11 mRNA in murine adipose tissues.
Analysis of publicly accessible DNA microarray data (Geo Profiles; DataSet Record GDS2818) was
done with unpaired Students t-test. A p-value < 0.05 was regarded as significant.  ,  and indicate
higher, lower and unchanged mRNA levels, respectively, in adipocytes relative to stromal vascular
cells (SVC) or in subcutaneous (sc) fat compared to intraabdominal (intra) fat. The mRNA expression
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3. Conclusions
Annexins bind negatively charged phospholipids and cholesterol in a Ca2+-dependent and
reversible manner, and together with transient interactions with membrane-associated proteins,
this contributes to dynamic changes in the structural and functional organization of membrane
domains [23,25–31,64,93,94,109,116,118,137,157]. As outlined in this review, this membrane organizing
function of annexins also seems highly relevant for adipose tissue physiology. In particular, AnxA2
has been linked to the insulin-dependent translocation of GLUT4 as well as CD36-mediated fatty
acid uptake [51,57,59], the latter providing a protective function in the postprandial state. Likewise,
AnxA6 affects signaling events relevant for lipid storage and, importantly, regulates adiponectin
release, an essential adipokine in metabolic health [61,62,64,68,70]. Alternatively, the most prominent
disease-preventing functions of AnxA1 in adiposity, glucose and lipid homeostasis are facilitated
through its extracellular activity as a FPR2 ligand [34,37,39,41,42,45,104]. While functions and
mechanistic insights for these three annexins in fat tissue are emerging, up until now all other
annexins have been barely studied in the context of obesity, adipocyte physiology, and adipokine
production. Future experiments, combining biochemical and imaging techniques in overexpression
and knockdown cells and animal models, together with high-throughput and innovative technologies
addressing transcriptomics, proteomics, lipidomics, and metabolomics in adipocyte-specific knock-out
models may identify the impact of individual annexins in the molecular pathways that contribute to
dysregulated adipokine production and fat cell function in obesity.
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Abstract: Adipocyte and hepatic lipid metabolism govern whole-body metabolic homeostasis,
whereas a disbalance of de novo lipogenesis (DNL) in fat and liver might lead to obesity, with severe
co-morbidities. Nevertheless, some obese people are metabolically healthy, but the “protective”
mechanisms are not yet known in detail. Especially, the adipocyte-derived molecular mediators that
indicate adipose functionality are poorly understood. We studied transgenic mice (alb-SREBP-1c)
with a “healthy” obese phenotype, and obob mice with hyperphagia-induced “sick” obesity to
analyze the impact of the tissue-specific DNL on the secreted proteins, i.e., the adipokinome, of
the primary adipose cells by label-free proteomics. Compared to the control mice, adipose DNL
is reduced in both obese mouse models. In contrast, the hepatic DNL is reduced in obob but
elevated in alb-SREBP-1c mice. To investigate the relationship between lipid metabolism and
adipokinomes, we formulated the “liver-to-adipose-tissue DNL” ratio. Knowledge-based analyses of
these results revealed adipocyte functionality with proteins, which was involved in tissue remodeling
or metabolism in the alb-SREBP-1c mice and in the control mice, but mainly in fibrosis in the obob
mice. The adipokinome in “healthy” obesity is similar to that in a normal condition, but it differs
from that in “sick” obesity, whereas the serum lipid patterns reflect the “liver-to-adipose-tissue DNL”
ratio and are associated with the adipokinome signature.
Keywords: Nonalcoholic fatty liver disease; fatty liver; free fatty acids; label-free proteomic profiling;
adipokine; obesity; visceral fat; sick fat
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1. Introduction
Obesity is a worldwide health burden. Obesity is prone to severe co-morbidities, including
diabetes, cardiovascular disease, and lipotoxicity due to ectopic lipid accumulation. However, some
obese individuals do not suffer from obesity-associated syndromes, which is the so-called phenomenon
of “fit and fat”. This was due to a healthy metabolism and insulin-sensitive adipose tissue, which
might increase the likelihood of the incidence of a fatty liver. In contrast, “sick fat” people show an
elevated lipid load, inflammation, hyperplasia, insufficient vascularization, and fibrosis of adipose
tissue [1–3]. Unfortunately, the “point of no return” from healthy obese people, with functional adipose
tissue, to unhealthy obesity, prone to comorbidities, still remains unknown.
There is a close interaction between adipocyte and hepatic lipid metabolism. Adipocytes are
essential in whole-body energy homeostasis for the storage of dietary lipids and of lipids generated by
de novo lipogenesis (DNL) from alimentary carbohydrates in adipose tissue or the liver. While it is
an elementary process for survival, excessive hepatic lipogenesis is a key feature of many models of
obesity and diabetes. Therefore, hepatic DNL is thought to be a health burden, as it correlates with
ectopic hepatic lipid accumulation and insulin resistance [4–6]. One key regulator of hepatic DNL is
the transcription factor sterol regulatory element-binding protein (SREBP)-1. SREBP-1c activity persists
even in insulin resistant states, as seen in obesity and T2D. In this context, we have shown that the
hepatic overexpression of the transcription active domain of SREBP-1c increases hepatic DNL, without
severe insulin resistance, resulting in a fatty liver and a massively increased adipose tissue mass in
mouse models [7,8].
In contrast to the liver, adipose tissue stores lipids from blood circulation, without the need for
synthesis, and only a marginal amount of lipids is produced by adipose tissue DNL [9]. Therefore,
it is unlikely that the role of adipose tissue DNL is primary for lipid storage, but it may act solely for
signaling or regulation processes, initiated by the physiological status of the adipose tissue.
It is well accepted that adipose tissue secretes endocrine- and exocrine-acting proteins, i.e.,
adipokines or adipokinome. These secreted proteins influence food intake, energy metabolism,
and insulin sensitivity [10–12]. The alteration of adipokinome in regard to metabolic conditions or
diseases has been shown to have an impact on fat mass, either by affecting adipocyte hyperplasia or
hypertrophy [13–16]. We recently showed that adipokinomes are correlated with clinical parameters in
diabetes [17]. Thus, adipokinome changes in relation to the lipid composition of the adipose tissue
and reflects the overall physiological condition of the adipose tissue. Furthermore, there are hints that
certain adipokines interfere with the mechanism of hepatic fibrosis [10–12,17].
It is therefore tempting to raise the hypothesis that adipokinome is also involved in the adipose
tissue-to-liver interaction for energy homeostasis regulation.
In the present study, we compare the adipokinomes of mice with increased hepatic DNL by the
genetic overexpression of the N-terminal domain of SREBP-1c [7], as a model for “healthy” obesity,
with hyperphagia-induced morbid obese mice (obob), as model for “sick” adipose tissue or lean mice
(C57Bl6) by label-free proteomics.
2. Results
2.1. Physiological Characterization of the Mouse Models
SREBP-1c and obob mice had a marginally higher body weight, fat mass, and liver weight than
C57Bl6 animals (Table 1). Blood glucose (BG) and triglycerides (TG) were also increased in the obese
mouse models, and additionally, cholesterol was increased in obob mice. Food consumption was
comparable in C57Bl6 and alb-SREBP-1c mice and increased in obob animals. Interestingly, the weight
gain per unit of food consumed was increased 1.5- to 2-fold in obese mice. Liver enzymes ALT, AST,
and GLDH indicated gradual hepatic impairment in the obese mouse models. Overall, alb-SREBP-1c
mice were intermediate to obob and C57Bl6 mice. Relevant metabolic hormones showed higher levels
of insulin in the obese mice. Leptin was higher in alb-SREBP-1c, compared to C57Bl6, and a leptin
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deficiency was confirmed in obob. Surrogate parameters for insulin resistance (HOMA-IR) and insulin
secretion (HOMA-β%) confirmed a mild insulin resistance (IR) in alb-SREBP-1c and a strong IR in
obob mice.
Table 1. Metabolic characterization of the lean mice (C57Bl6), transgenic mice (alb-SREBP-1c) with
“healthy” adipose tissue, and of the “sick” adipose tissue obob mice used in the study.
Parameter C57Bl6 alb-SREBP-1c obob
body weight [g] 28.62 ± 2.54 35.23 ± 3.44 ** 56.82 ± 6.76 **
liver weight [g] 1.56 ± 0.20 2.10 ± 0.30 ** 3.72 ± 0.80 **
fat mass [g] 0.40 ± 0.13 1.79 ± 0.57 ** 5.31 ± 0.87 **
blood glucose [mg/dL] 148.4 ± 15.24 184.41 ± 10.01 ** 769.20 ± 142.31 **
cholesterol [mg/dL] 92.67 ± 12.98 111.18 ± 22.01 140.13 ± 33.70 **
triglycerides [mg/L] 123.60 ± 16.07 244.00 ± 52.86 ** 403.60 ± 54.47 **
ALT [U/L] 48.75 ± 22.15 78.45 ± 13.19 ** 181.87 ± 46.14 **
AST [U/L] 102.67 ± 24.19 156.36 ± 35.77 ** 274.80 ± 102.36 **
GLDH [U/L] 13.46 ± 6.08 29.36 ± 13.68 ** 139.75 ± 66.59 **
insulin [ng/mL] 1.06 ± 0.24 3.90 ± 1.39 ** 16.51 ± 3.05 **
leptin [ng/mL] 0.90 ± 0.60 12.08 ± 3.48 ** n.d.
HOMA-IR 0.38 ± 0.0.08 2.12 ± 0.36 ** 34.43 ± 3.05 **
HOMA-β% 96.26 ± 35.21 324.19 ± 175.06 ** 180.71 ± 94.68 **
food uptake/bodyweight (kJ/g) 10.33 ± 2.95 11.84 ± 2.61 16.06 ± 1.79 **
weight gain/food uptake (mg/kJ) 1.55 ± 0.19 2.48 ± 0.25 ** 3.14 ± 0.45 **
Data are expressed as mean ± SD (n = 8 of each phenotype). * p < 0.05, ** p < 0.01 ***, and p < 0.001, by Student’s
t-test in comparison to controls.
2.2. Lipid Composition of Serum, Liver, and Adipose Tissue
Serum-free fatty acid (FFA) was increased more than 2-fold in alb-SREBP-1c mice and more than
3-fold in obob mice. However, the total fatty acid (TFA) content of adipose tissue was similar to C57Bl6
mice, independent of the cause of obesity. In contrast, hepatic TFA was increased to a similar degree as
free fatty acid in serum (Figure 1A). The change in the lipid composition in serum revealed increased
cC16:1 and decreased C18:0 in obese models, compared to controls (Figure 1B). Both obese models
differ in C16:0 and C18:0 and show inverse levels for the FFA cC18:1. FFA cC18:2, cC18:3, and cC20:4
were comparably altered. In adipose tissue, lipid composition, compared to controls, indicated, in
alb-SREBP-1c mice, an increase in C18:0 and cC18:3 and, in obob mice, a decrease in cC16:1 and an
increase in cC18:1. The obesity models differed only in the essential FA cC18:3 (Figure 1B). In the liver,
the obese models mainly differed in an increase in cC16:1 and cC18:1 and a reduction of C18:0 and
cC20:4, compared to the control mice, whereas the essential FA cC18:2 was more pronounced in the
obob mice (Figure 1B).
In further detail, the percentage of serum lipid classes is shown in Figure S1A. The grouping of
lipids showed that the amounts of saturated FA (SFA) were decreased, while the unsaturated FA (UFA),
mono-UFA (MUFA), poly-UFA (PUFA), or essential FA (EFA) were increased, in the serum of obese
mice (Figure S1B). The percentage of adipose tissue lipid classes is shown in Figure S2A. Here, only SFA
was changed in both obese mice, compared to the controls, whereas UFA, PUFA, and EFA differed only
in the obob mice (Figure S2B). The percentage of liver lipid classes is shown in Figure S3A. In the liver,
a decreased SFA and increased UFA and MUFA were present in the obesity models, the latter being the
highest in the alb-SREBP-1c mice. Compared to the controls, the content of EFA was higher in the obob
and lower in the alb-SREBP-1c mice, and vice versa, for the non-essential FA (NEFA) (Figure S3B).
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Figure 1. Lipid compositions of the C57Bl6, alb-SREBP-1c, and obob mice. (A) Total and specific fractional
composition of the serum free fatty acids (FFAs) and the liver or adipose tissue total fatty acids (TFAs);
(B) the percentage changes in the serum FFA and the liver or adipose tissue TFAs in alb-SREBP-1c vs.
C57Bl6, obob vs. C57Bl6, and obob vs. alb-SREBP-1c. Data are expressed as mean ± SD (n = 8 of each
phenotype). * p < 0.05, ** p < 0.01, and *** p < 0.001, by one-way ANOVA, with a Sidak post-hoc test (A) or
students’ t-test (B).
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Lipid indices and surrogate parameters for the enzyme activity in lipid metabolism were calculated
based on the lipid compositions determined in the tissues. In WAT (Figure S4A), the Δ6 desaturase
activity was reduced in the alb-SREBP-1c mice. However, the elongase activity was elevated in both
obese mice. In the liver (Figure S4B), the Δ9 desaturase activity for C16:0 as well as C18:0 was elevated
in obese mice. The Δ6 desaturase activity was comparable in the C57Bl6 and obob mice, but lower
in the alb-SREBP-1c mice, whereas the Δ5 desaturase activity was comparable in the C57Bl6 and
alb-SREBP-1c and higher in the obob mice. Furthermore, a lower elongase activity, compared to
controls, was observed in both obese mice.
2.3. Adipose Tissue DNL versus Hepatic DNL
In adipose tissue, DNL declined according to the degree of obesity and insulin resistance status
from C57Bl6 (1.21± 0.18) to alb-SREBP-1c (0.93± 0.07) and obob mice (0.83± 0.07) (Figure 2A). Analyses
of the hepatic DNL showed that it was higher in alb-SREBP-1c (2.33 ± 0.55) but lower in obob mice
(0.96 ± 0.17), compared to the controls (1.62 ± 0.17) (Figure 2B). In regard to the serum lipid levels of
cC16:1 and cC18:1, solely a correlation to the adipose tissue DNL in alb-SREBP-1c mice (cC16:1 to
DNL: R = 0.940, P = 0.017; and cC18:1 to DNL: R = 0.941, P = 0.017), but neither in the lean control nor
in the obob mice, was observed. (Table S1). A direct comparison of the adipocyte and hepatic DNL
indicated that alb-SREBP-1c mice have the largest difference in “liver-to-adipose-tissue” DNL ratio
(2.58 ± 0.67), whereas obob mice have a ratio of 1.14 ± 0.23, which is a comparable DNL-ratio to C57Bl6
mice (1.34 ± 0.3) (Figure 2C).
Figure 2. Tissue-specific de novo lipogenesis (DNL). (A) The DNL index (C16:0/cC18:2) of adipose
tissue; (B) DNL index (C16:0/cC18:2) of the liver; and (C) “liver-to-adipose-tissue DNL” ratio. Data are
expressed as mean ± SD (n = 8 of each phenotype). * p < 0.05, ** p < 0.01, and *** p < 0.001, by one-way
ANOVA, with a Sidak post-hoc test.
2.4. Adipokinome
The secretome of the isolated adipocytes from visceral fat depots of the mouse models, analyzed
by electron spray MS, identified 922 unique proteins. Of all of the proteins, 543 (59%) were predicted
as classical or non-classical secreted proteins (SP +/SP−). The remaining 379 proteins identified were
not predicted to be secreted (NP) (Table S2).
The intensity patterns of the proteins were predicted to be either classically or non-classically
secreted (SP+/SP−) or not predicted to be secreted (NP), and the various mouse models were
distinguished in PCA analyses (Figure 3A). Component 1 of the PCA accounted for 30% of the total
variance and clearly separated obob from lean mice. The separation of C57Bl6 and alb-SREBP-1c mice
was not so clearly achieved in these analyses, as the 95% confidence levels overlapped. Nevertheless,
PLS-DA analyses (Figure 3B) and unsupervised cluster analyses segregated mouse models according
to phenotype, indicating specific differences in the adipokines patterns.
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Figure 3. Classification of the mouse models according to the identified differential adipokinomes:
(A) classically or non-classically secreted (SP+/SP−) proteins and (B) NP proteins. Principal component
analyses (PCA), partial least square discriminant analyses (PLS-DA), and a heat map of the top
100 proteins with the greatest difference (ANOVA).
2.5. Differential Adipokinomes
Overall, 60% of the SP+/SP− and NP proteins were differentially abundant in the comparisons
between C57Bl6 vs. alb-SREBP-1c, C57Bl6 vs. obob, and alb-SREBP-1c vs. obob (Table S3). In the
comparison of alb-SREBP-1c and lean C57Bl6 mice secretomes, 121 proteins were identified (70 SP+/SP−;
51 NP) with significantly different secretions. SP+/SP− proteins mainly point to cell cycle modification,
including cellular component organization or biogenesis (adjP = 4.67 × 10−5), actin cytoskeleton
organization (adjP = 0.0006), or actin remodeling (adjP = 0.001). Further alterations can solely be
annotated to metabolic GO category superfamilies, e.g., cellular process (adjP = 0.0002), but are not
specified in more detail. NP adipokines also annotate to cellular modifications, e.g., cellular component
organization or biogenesis (adjP = 3.93 × 10−7), macromolecule localization, (adjP = 8.79 × 10−7) or
inhibitory signaling processes, e.g., inhibitor activity to phospholipase A2 (adjP = 0.0003) or lipase
(adjP = 0.0016), with a moderate stringency (Table S4).
The overall comparison C57Bl6 vs. obob identified 376 differentially abundant proteins (235 SP+/SP−;
141 NP). SP+/SP−proteins were involved solely in metabolic pathways, like the preamble cellular process
(adjP = 1.22 × 10−13), and a vast amount of detailed metabolic relevant annotations, including metabolic
process (adjP = 7.87 × 10−17), organic acid metabolic process (adjP = 3.64 × 10−13), or NAD binding
(adjP = 2.63 × 10−8). Of 141 differentially abundant NP proteins, metabolic processes, e.g., pyridoxal
phosphate-binding adjP = 1.33 × 10−5 and the carboxylic acid metabolic process adjP = 6.78 × 10−8, as well
as cell modifying functions, e.g., the protein complex adjP = 8.75 × 10−13, cellular component biogenesis
adjP = 1.00 × 10−6, or actin-binding adjP = 1.33 × 10−5, are equally present (Table S4).
A direct comparison of alb-SREBP−1c vs. obob adipocyte secretomes identified 396 different
adipokines (156 SP+/SP−; 150 NP). SP+/SP− adipokines were exclusively annotated to metabolic
processes (adjP = 4.47 × 10−26), including, e.g., organic acid metabolic process (adjP = 1.44 × 10−27) or
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NAD binding (adjP = 1.56 × 10−12). NP adipokines also solely annotate to metabolic processes, e.g.,
the metabolic carboxylic acid metabolic process (adjP = 1.27 × 10−15) and oxoacid metabolic process
(adjP = 4.68 × 10−15), or energy-producing organelles (mitochondrion; adjP = 5.10 × 10−16) (Table S4).
2.6. Knowledge-Based Analyses
Venn analyses revealed comparisons of C57Bl6 and either alb-SREBP-1c or obob, as well as
alb-SREBP-1c vs. obob bare overlapping, but also specific different adipokine patterns of SP+/SP− and
NP proteins (Figure 4, complete analyses in Table S5).
Knowledge-based analyses of protein interactions indicated the common and individual specificity
of all three different adipokinomes. The common pathways affected by secreted SP+/SP− proteins are
involved in ECM modeling, inflammation, lipid uptake, and gluconeogenesis or FA degradation. In NP
proteins, the transport and glucose metabolism proteins were common, while in SP+/SP− proteins,
C57Bl6 and alb-SREBP-1c differed in the proteins involved in class A receptor signaling, and proteins
involved in the formation of extracellular matrix proteins dominated in C57Bl6 vs. obob.
No specific pathway can be identified in the NP proteins, compared to the controls. The comparison of
both obese models focusses on proteins involved in central metabolic pathways, with a major participation
of lipid metabolic processes in SP+/SP− proteins and the proteasome complex formation in NP (Figure 4).
Figure 4. Unique pathways activated by differentially secreted adipokines. The prediction of secretory
protein classification as classical SP+/SP− signaling sequences or non-classically secreted proteins was
performed with SignalP 4.1 or SecretomeP 2.0, as indicated in the methods section. The functional
annotation of differentially abundant proteins was performed separately on (A) proteins with classical
SP+/SP− signaling sequences and (B) non-classically secreted proteins. Abbreviations: AA: amino
acids, BCAA: branched chain amino acids; ECM: extracellular matrix; FA: fatty acids; n.d.: not detected,
TCA cycle: tricarboxylic acid cycle.
To determine more informative interactions of the different adipokinomes, we used integrative
annotation to extend the information to the suggested up- or downstream interactions of the identified
proteins. Within these analyses, the most prominent functional overlap was the differential protein
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patterns per genotype, set to fatty acid metabolism or proteins initially identified to be related to steatosis
(Figure 5). There was a differential overlap with fatty acid metabolism in the protein sets of C57Bl6
vs. alb-SREBP-1c (n = 38, p-value = 8.3 × 10−12), C57Bl6 vs. obob (n = 58, p-value = 1.9 × 10−17), and
C57Bl6 vs. alb-SREBP-1c (n = 72, p-value = 8.1 × 10−21) (Figure 5). In addition, the number and
significance of the proteins related to steatosis processes gradually increased with the severity of
obesity in the comparisons of C57Bl6 vs. alb-SREBP-1c (n = 20, p-value 3.35 × 10−7), C57Bl6 vs. obob
(n = 28, p-value 8.9 × 10−9), and obob vs. alb-SREBP-1c (n = 39, p-value 9.5 × 10−17) (Figure 5).
Figure 5. Differential enrichment of FA metabolism and steatosis-related proteins in the adipokinomes.
The annotation of specific differentially abundant proteins to lipid metabolism or steatosis is shown.
Data were analyzed with IPA® core analyses (default settings). Coloring represents proteins with
different abundances in the comparisons C57Bl6 vs. alb-SREBP-1c, C57Bl6 vs. obob, and alb-SREBP-1c
vs. obob. (Red: more abundant; green: less abundant; grey: not regulated in the specific comparison).
2.7. Adipokinome—Marker for Tissue-Specific DNL?
To account for the hypothesis that adipokinomes reflected, a marker for adipose tissue functionality
and the physiological status of the adipose tissue, we analyzed the different adipokine patterns,
identified for correlations, in relation to the specific “liver-to-adipose-tissue DNL” ratio. Of the
922 proteins observed, 55 proteins in C57Bl6 showed a correlation with the “liver-to-adipose-tissue
DNL” ratio (Table S1). These included proteins involved in lipid droplet formation, like perilipin,
actin-binding or assembly molecules; echinoderm microtubule-associated protein-like 2, plastin-2,
-3, or villin molecules; metabolic enzymes, like acyl-CoA dehydrogenase, glycogen phosphorylase,
L-lactate dehydrogenase, or NADP(+)-dependent alcohol dehydrogenase; and molecules of the
glutathione metabolism involved in ROS clearance.
A total of 50 proteins were correlated with the “liver-to-adipose-tissue DNL” ratio in alb-SREBP-1c
and 42 in obob mice. In alb-SREBP-1c mice, more metabolic active molecules were present, e.g., pyruvate
kinase; NADPH-cytochrome P450 reductase; fructose-1,6-bisphosphatase; and l-lactate dehydrogenase
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or the peroxisomal delta(3,5)-delta(2,4)-dienoyl-CoA isomerase (ECH), an auxiliary involved in lipid
metabolism. Other proteins were regulatory, like farnesyl pyrophosphate synthase, and protease
regulatory subunits were present. In obob mice, the share of relevant correlative metabolic proteins
included glycolysis and glyconeogenesis-related proteins, like pyruvate and malat dehydrogenases,
and fructose-1,6-bisphosphatase 1, but also proteins involved in redox clearance, like peroxiredoxines,
carboxyestherases, lipid droplet formation proteins, and the laminin and catepsin family; or metabolic
signaling molecules, like carboxylesterase 1C, 14-3-3 protein, and dipeptidyl peptidase 3.
For the functional annotation, the proteins that correlated with the DNL ratio were used for IPA®
core analyses to extend the information to upstream regulating proteins. As our analyses revealed
a marked difference in the abundance of proteins known to be regulated by or related to fatty acid
metabolism or fibrosis (Figure 6), we generated virtual pathways for all proteins related to these
keywords in order to visualize the IPA® analyses. Based on these pathways, lean and healthy obese
mice, due to increased hepatic DNL, showed similar patterns, in contrast to the “sick” obese obob mice
(Figure 6; differential adipokines and upstream regulator molecules that causes different patterns were
summarized in Table S6A,B).
Figure 6. Differential abundance of FA metabolism and steatosis-related proteins in adipokines
correlated to the “liver-to-adipose-tissue DNL” ratio. Virtual pathways were generated from proteins
related to the keywords to cC18:1 or fibrosis. The proteins that correlated with the “liver-to-adipose-tissue
DNL” ratio were used for IPA® core analyses to extend the information to upstream regulating proteins
(Supplementary Materials Table S6). Coloring represents the different abundances in the comparisons
of C57Bl6 vs. alb-SREBP-1c, C57Bl6 vs. obob, and alb-SREBP-1c vs. obob. (Red: more abundant; green:
less abundant; grey: not regulated in the specific comparison).
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3. Discussion
In the present study, we provide evidence that (i) the “liver-to-adipose-tissue DNL” ratio shows
genotype-specific differences; (ii) this DNL-ratio can be monitored in the serum lipid pattern; and (iii)
the pattern of the secreted proteins of adipocyte cells are different, indicated as a shift from secreted
proteins, mainly involving tissue remodeling in lean and “healthy” obese mice, to metabolic active
adipokines and fibrosis in morbid obese mice, corresponding to the health status of the adipose tissue.
To determine the systemic interaction of liver and adipose tissue in obesity, we choose a mouse
model with obesity, according to hyperphagia and leptin deficiency (obob). Obob mice are an accepted
morbid obesity model with a fatty liver, which develops cardiovascular complications and increased
oxidative stress, including increased macrophage infiltration in adipose tissue and an inflammatory
marker concertation [18–20]. On the other hand, we used a transgenic animal with a liver-specific
overexpression of human SREBP-1c, which has previously been shown to induce obesity under
isocaloric conditions due to increased hepatic DNL [7,8]. In these mice, a fatty liver, as an initial
pathophysiological burden, is captured by the massively increasing visceral fat mass. The development
of massive obesity in these mice is only accompanied by hepatic insulin resistance (IR), but without
signs of inflammation in serum or adipose tissue. Therefore, alb-SREBP-1c mice resemble a “healthy”
obesity phenotype, compared to obob mice. In regard to insulin secretion, alb-SREBP-1c mice showed
a compensatory beta cells effect, whereas the beta cells failed to offset IR in obob mice. Nevertheless,
IR poses a risk, as it increases lipolysis in adipose tissue, resulting in a release of fatty acids to serum,
which finally elevates the triglyceride content in the liver [21].
The models showed a characteristic profile, with a decreased saturated C16:0 and C18:0 in the
obese model, accompanied by increased levels of desaturated FA in serum. The main sources for the
composition of the serum lipid profiles are nutrition, tissue-specific DNL, and the mobilization of FA by
lipolysis from adipose tissue [22]. However, the tissue-specific FA patterns we determined in the liver
and adipose tissue did not completely account for the different serum lipid patterns. Overall, adipose
tissue lipolysis does not seem to be essential for explaining the differences seen in the serum FFA
composition. In contrast, alterations observed in the hepatic FA, especially for cC16:1 and cC18:1, were
also seen in serum lipids, except in the EFA cC18:2. There is controversy regarding the role of serum
cC16:1 in health, as it increases insulin sensitivity in healthy subjects [23,24] but has adverse effects
in obesity [25]. On the other hand, insulin resistance or the progression of NAFLD to non-alcoholic
liver steatosis is accompanied by an increase of lipids, including cC16:1 and cC18:1 [22]. In NAFLD,
cC16:1 and its elongation product, cC18:1, were increased due to the SREBP-1c-regulated increased Δ9
stearoyl-CoA desaturase 1 (SCD-1) activity [22], as seen in the alb-SREBP-1c model. Hepatic DNL was
higher in alb-SREBP-1c mice, which is consistent with our previous observation [8]. Especially, the
essential cC16:1 is, in general, very present in adipose tissue, making it a direct product and marker
for adipose tissue DNL, and its presence in the serum lipid pool favors a role in signaling [23,26,27].
Thus, the data derived support the hypothesis that DNL in adipose or liver tissue might have further
physiological functions beyond simple nutrient conversion.
Adipose tissue secretome has been thoroughly studied in metabolic disturbances and has been
accepted as a model for various metabolic alterations [10–12,17]. As the FA composition of adipocytes
was not grossly altered, thus excluding a predominant lipokine, adipocyte-secreted adipokines might
act as a signaling moiety to adjust tissue-specific DNL rates. Overall, analyses of the adipokinome
indicated a close relation between the adipokinomes of C57Bl6 and those of alb-SREBP-1c mice. This
might indicate the healthy status of the adipose tissue in alb-SREBP-1c mice, in contrast to obob mice.
In proteins with a secretion motive, both obesity models differed in regard to proteins associated
with metabolic processes. There was an accumulation of proteins found to be related to or involved in
fibrosis-associated processes in obob mice, compared to the controls. This is consistent with the excess
accumulation of adipose tissue extra cellular matrix (ECM) components and IR in obesity [28], and
to a recent observation of the ECM organization and assembly markers that were increased in obese
humans with a high serum FFA mobilization from adipose tissue [29].
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Proteins without a secretion signal are probably related to the endomembrane system for vesicular
secretion processes [30]. In this context, we have recently shown that adipose tissue-secreted exosomes
are enriched in relevant metabolic proteins, without signal peptides [31]. Here, both obesity models
differed in proteins related to, e.g., proteosomal degradation processes. In obesity, a proteasome
dysfunction further aggravates the cell toxic effects of increased oxidative stress or unfolded protein
responses to ER stress in adipocytes. Proteasome function has also been found to maintain insulin
sensitivity in adipocytes [32]. In the context of adipose tissue, this might indicate that the fibrosis of the
adipose organ is a marker for functionality defects, which is in line with previous observations [10–12].
The most striking difference within the obese mouse models was still that the “healthy” obese
alb-SREBP-1c mice showed the largest difference in the “liver-to-adipose-tissue DNL” ratio, and
the serum cC16:1 and cC18:1 correlated to adipose tissue DNL solely in the alb-SREBP-1c mice.
The correlative adipokines indicated a specific and gradual difference for the obesity models, but the
patterns were not conclusive of a certain pathway. Nevertheless, a differential accumulation of cC18:1-
and fibrosis-associated proteins in the adipokinome can be determined.
The interaction of adipose tissue and hepatic DNL is in a tight balance in lean healthy conditions,
but runs out of control in obesity, IR, or NAFLD [33–35]. In obesity, adipose DNL is reduced [36]
and can be restored by caloric restriction [37]. Increased adipocyte DNL seems to be beneficial in
regard to IR or glucose homeostasis, independent of obesity in humans [4,13,38]. This idea identified
adipocyte-derived lipokines, cC16:1 and cC18:1, as essential systemic mediators that interfere with
adipose tissue physiological functionality, with hepatic lipid metabolism and DNL [38,39]. In conclusion,
whole body energy homeostasis is mainly dependent on hepatic and adipose tissue communication.
The concept of communication by -kines identified cC16:1 and cC18:1 as adipocyte-derived DNL
products, as mediators for the adipocyte DNL status to the liver [10–12,27,38].
Our study indicated that the obesity models differ in circulating cC16:1, compared to lean controls,
and further by cC18:1, which might act as marker. As the concentration of the lipokine cC18:1 also differs
in the serum in the obese models, our observations point to a central role of adipokines as indicators that
differentiate healthy and metabolically diseased models. It is noteworthy that a recent study of a mouse
model showed that oleate (cC18:1) specifically featured a nuclear accumulation of the master-regulator
SREBP-1c of the DNL in hepatocytes, suggesting cC18:1 as central in SREBP-1c-mediated signaling and
therefore in DNL [40]. This further supports the hypothesis that an increase in hepatic DNL is essential
for maintaining adipose tissue health, and adipokine secretion is part of the systemic regulation.
The composition of the serum lipids reflects the “liver-to-adipose-tissue DNL” ratio. Interestingly,
adipokine patterns that correlate with the “liver-to-adipose-tissue DNL” ratio seem to be rather
phenotype-specific, as only a marginal overlap can be observed in the models. However, in both obese
models, but not in the controls, mitogen-activated protein kinase 14 or isocitrate dehydrogenase show
a comparable correlation, whereas acetyl-CoA carboxylase 1, catalyzing the rate-limiting step in the
lipid synthesis of malonyl-CoA synthesis from acetyl-CoA, is inversely correlated in healthy and sick
obesity. On the other hand, proteins involved in free radical scavenging, like glutathione S-transferase
Mu 2, were equally correlated in the healthy obese and the control animals. This, and observation
that peroxisomal ECH accounts for alb-SREBP-1c, further supports our previous finding, i.e., that
peroxisomal function might play a role in preventing increased hepatic lipid accumulation in metabolic
syndrome or diabetes [17,41].
Our data further support the idea that the adipose tissue returns information back to the liver
also regarding its status of plasticity and metabolic capacity. Thus, depending on the degree of
the “liver-to-adipose-tissue DNL” ratio, adipokinomes show fibrotic pathways as a marker for the
beginning of a loss of adipose tissue health.
Conclusion: our analyses features the concept of impaired adipose tissue functionality in obesity.
We provide evidence that the “liver-to-adipose-tissue DNL” ratio is a marker for the shift from healthy
to diseased adipose tissue. Adipose tissue “health” can be maintained in obesity as long as the hepatic
DNL can be increased according to the metabolic requirements. This can be monitored by serum
39
Int. J. Mol. Sci. 2019, 20, 2559
fatty acid cC16:1 and especially cC18:1, as biomarkers, and is accompanied by altered adipose tissue
secreted proteins, as the adipokinome of “healthy” or “sick fat” differs in regard to cC16:1 and cC18:1
and fibrosis-dependent proteins.
4. Materials and Methods
4.1. Animals
C57Bl6 (C57Bl6), B6.Cg-Lepob (obob), and B6-TgN(alb-HA-SREBP-1cNT) (alb-SREBP-1c) [7] mice
were bred and maintained under standard conditions (12h light/dark cycle; 22 ± 1 ◦C, 50% ± 5%
humidity). At 6 weeks of age, male littermates of each genotype were kept under standardized
conditions, with free access to water and regular laboratory chow (13.7 mJ/kg: 53% carbohydrate,
36% protein, 11% fat (Ssniff, Soest, Germany)). At the age of 18 weeks, the mice were fasted for 6 h
and sacrificed by CO2 asphyxiation (7:00 am). Blood samples were collected by a left ventricular
puncture, and organ samples, i.e., the liver and visceral adipose tissue, were removed. The Animal
Care Committee of the University Duesseldorf approved the animal care and procedure employed
(Approval#84-02.04.2015.A424; 2 April 2015).
4.2. Animal Characterization
Phenotypical characterization; serum diagnostics of clinical measures; as well as the surrogate
parameters of insulin resistance, lipid profiling in serum, and liver and adipose tissue by gas
chromatography were performed, as previously described [7,42]. Serum-free fatty acids (FFA), hepatic
as well as adipose cell total fatty acids (TFA) content, and the specific fractional composition of
FAs were determined by gas chromatography. FA data of adipocytes were further used to calculate
the Δ5-desaturase index (cC18:2/cC20:4); Δ6-desaturase index (cC18:2/cC18:3; Δ9-desaturase index
(cC16:1/C16:0 or cC18:1/C18:0); DNL index (C16:0/cC18:2); elongation index (C18:0/C16:0); as well
as the sums of the total FA, non-saturated FA, monounsaturated FA, saturated FA, essential FA
(cC18:2+cC18:3), and non-essential FA (C16:0+cC16:1+C18:0+cC18:1) [43]. The nomenclature of FA is
given according to IUPAC. The liver-to-adipose-tissue DNL was calculated by the liver DNL/adipose
tissue DNL.
4.3. Secretome Profiling by Liquid Chromatography (LC)-Electrospray Ionization (ESI)-MS/MS and
Data Analyses
Mature adipocytes were isolated from minced biopsies by collagenase digestion. Adipocytes were
cultured (2 days), washed extensively, and supplemented with an FCS-free culture medium to harvest
and process the secretome, as previously described [17,44]. Data on all mouse models were acquired in
parallel, as described in detail previously [17,45].
4.4. Data Annotation
The functional annotation and prediction of secretory proteins was performed with SignalP 4.1 [46],
(http://www.cbs.dtu.dk/services/SignalP/), SecretomeP 2.0. [47], (http://www.cbs.dtu.dk/services/
SecretomeP/). We identified 922 individual unique proteins in the secretomes of the mouse models
investigated (Supplementary Materials Table S1). Of all proteins, 543 (59%) are characterized as
classically or non-classically secreted proteins (SP+/SP−). The remaining 379 identified proteins do not
contain classical secretion signals.
4.5. Statistical Analysis
Clinical values are presented as the mean ± SD. Statistical analysis was performed with Student’s
t-test or one-way ANOVA, with a Sidak post hoc test, calculated with Prism 7.04 (GraphPad Software
Inc., San Diego, CA, USA), as indicated. Secretome data were further analyzed with the Metabolist 3.0
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package [48] or SPSS (IBM Ver. 22). Pearson correlation coefficients, with a two-sided p-value, were
determined in SPSS (IBM Ver. 22).
4.6. Web-Based Functional Annotation
For the functional annotation, web-based tools from public database sources were used: https:
//www.ncbi.nlm.nih.gov/, http://www.informatics.jax.org/mgihome/, http://bioinfo.vanderbilt.edu/
webgestalt/ [49], https://toppcluster.cchmc.org/ [50], David Bioinformatics Resources 6.8 (https://david.
ncifcrf.gov/) [51], and IPA® (IngenuityTM, Qiagen, Hilden, Germany). The fold change of different
adipokinome patterns was analyzed, and the t-test-derived p-values of the comparisons C57Bl6 vs.
alb-SREBP-1c, C57Bl6 vs. obob, and alb-SREBP-1c vs. obob were entered for the IPA® analyses.
Furthermore, a spearman coefficient and two-sided p-value were used. Data were used for core analyses
and comparison analyses. The pathways were generated from respective networks, as suggested by
IPA®. For expression analyses of different protein sets, an expression fold change (1.5×) and expression
differences (p-value <0.05) were analyzed, following the core analysis modules. Differentially abundant
proteins (1.5× fold difference, p-value < 0.05) (one–way ANOVA, posthoc, Welch test) were analyzed
separately for C57 vs. obob, C57 vs. alb-SREBP-1c, and alb-SREBP-1c vs. obob mice.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/10/2559/s1.
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DNL de novo lipogenesis




FCS fetal calf serum
FFA free fatty acids
GLDH glutamate dehydrogenase
GO gene ontology
HOMA-%β Homeostatic model assessment of β -cell function (%)
HOMA-IR Homeostatic model assessment of insulin resistance
IR insulin resistance
MS mass spectrometry
MUFA monounsaturated fatty acids
NAFLD nonalcoholic fatty liver disease
NEFA non-saturated FA
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PCA principal component analysis
PLS-DA partial least square discriminant analysis
PUFA poly unsaturated fatty acids
SCD1 Δ9 stearoyl-CoA desaturase 1
SFA saturated fatty acids
SREBP sterol regulatory element-binding protein
T2D type-2 diabetes mellitus
TFA total fatty acids
TG triglycerides
UFA unsaturated fatty acids
WAT white adipose tissue
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Abstract: Adipose tissue is a major endocrine organ capable of secreting adipokines with a role in
whole-body metabolism. Changes in the secretome profile during the development of obesity is
suspected to contribute to the risk of health complications such as those associated with weight
regain after weight loss. However, the number of studies on weight regain is limited and secretome
changes during weight regain have hardly been investigated. In an attempt to generate leads for
in vivo studies, we have subjected human Simpson Golabi Behmel Syndrome adipocytes to glucose
restriction (GR) followed by refeeding (RF) as an in vitro surrogate for weight regain after weight loss.
Using LC-MS/MS, we compared the secreted protein profile after GR plus RF with that of normal
feeding (NF) to assess the consequences of GR plus RF. We identified 338 secreted proteins of which 49
were described for the first time as being secreted by adipocytes. In addition, comparison between NF
and GR plus RF showed 39 differentially secreted proteins. Functional classification revealed GR plus
RF-induced changes of enzymes for extracellular matrix modification, complement system factors,
cathepsins, and several proteins related to Alzheimer’s disease. These observations can be used as
clues to investigate metabolic consequences of weight regain, weight cycling or intermittent fasting.
Keywords: adipokines; SGBS adipocytes; glucose restriction; in vitro fat regain; weight regain;
complement factors; cathepsins; extracellular remodeling
1. Introduction
Obesity has become a worldwide critical health issue because it is frequently accompanied by
the development of health complications such as type II diabetes, cardiovascular diseases, respiratory
problems and certain types of cancer [1]. Obesity is characterized by excess body fat mass, which is
mostly stored in the adipose tissue. Additionally, adipose tissue is known as a major endocrine organ
capable of secreting various signaling and mediator proteins, termed adipose-derived secreted proteins
or adipokines [2]. Studies have shown that the secreted proteins are hormones, cytokines, extracellular
matrix related proteins as well as proteins involved in cardiovascular, lipid and glucose metabolism [3].
These adipokines have a variety of effects on homeostasis and metabolism by autocrine, paracrine
and endocrine activity, which could contribute to the development of obesity and obesity-associated
complications [4,5].
For overweight and obese people, weight loss is an indicated remedy that can reduce the risk
for comorbid conditions [6]. A calorie restrictive diet is part of a common practice to try and lose
weight. Losing 5% of body weight already results in significant improvement of health parameters
such as lower blood pressure, plasma glucose and insulin levels [7]. In parallel, in vitro studies have
illustrated that calorie restriction (CR) results in an altered secretion profile of adipocytes, comprised
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of a less inflammatory phenotype and a reversed expression of detrimental adipokines [8]. However,
weight loss is often followed by weight regain. Generally, up to 80% of people who lost weight on CR,
regain weight and often return to their original weight or even beyond, within one or two years [9].
Moreover, it has been suggested that weight regain after weight loss could worsen metabolic health [10],
possibly mediated by changes in the adipose tissue secretome. Consequently, prevention of weight
regain after successful weight loss is a critical challenge for obesity management and it is essential to
obtain more knowledge on the causes and consequences of weight regain [11]. So far, the number of
biological studies on weight regain has been limited and secretome changes during weight regain are
largely unknown.
A growing body of data suggests that Simpson Golabi Behmel Syndrome (SGBS) cells are
an excellent tool to study adipokine secretion [3,12–15]. SGBS cells display a much more active
differentiation capacity compared with primary pre-adipocytes in culture, and retain this capacity
over at least 30 generations while being similar to primary cells in morphology, physiology and
biochemistry [12,13]. Moreover, it has been reported that in vitro differentiated SGBS adipocytes
behave similar to human primary adipocytes in functions such as glucose transport, lipogenesis
and lipolysis [12,15]. Based on their origin and gene expression comparison, differentiated SGBS
cells are regarded as subcutaneous white adipocytes [13]. Therefore, SGBS cells have been widely
accepted and used for in vitro adipocyte experiments. Using these cells, we have earlier reported on
secretome changes induced by glucose restriction (GR) and found several novel adipokines [8,16].
However, the effect of GR plus refeeding (RF) on adipokine secretion has not been investigated.
Recently, we established a protocol for GR followed by RF for SGBS cells and examined the influence on
the cellular proteome [17]. Here we report on changes in the in vitro secretome when normal feeding
(NF) is compared with GR plus RF in an attempt to obtain leads on possible threats to metabolic health
as a consequence of weight regain after weight loss.
2. Results
2.1. Proteins Secreted from Human SGBS Adipocytes
In total, 1326 proteins were identified from the collection medium. By filtering these proteins,
SignalP 4.1 detected the presence of a signal peptide in 328 proteins. Deeploc recognized 230
secreted proteins by predicting the extracellular location. In total these two groups represented 337
different proteins (Figure 1A; Table S1). 221 out of 337 proteins both contained a signal peptide and
were located in the extracellular space, nine proteins (membrane primary amine oxidase (AOC3),
cysteine and glycine-rich protein 1 (CSRP1), galectin-1 (LGALS1), D-dopachrome decarboxylase
(DDT), trypsin-3 (PRSS3), metallothionein-1G (MT1G), proteasome inhibitor subunit 1 (PSMF1),
ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2), small proline-rich
protein 2G (SPRR2G)) were only predicted by the extracellular space and 107 proteins only had a signal
peptide for secretion (Figure 1A). In addition, we manually checked the list of proteins which were
not recognized as secreted by SignalP or Deeploc, for proteins known by their function to be secreted.
So far, only complement factor 1Q (C1q) was found to be missed by the programs. Thus, C1q was
added to our analysis list with a total of 338 secreted proteins (Table S1).
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Figure 1. Secreted proteins identified in human Simpson Golabi Behmel Syndrome (SGBS) adipocytes.
(A) The number of identified secreted proteins by SignalP or Deeploc. (B) Pie graph on functional
categories of overall identified secreted proteins.
2.2. Newly Identified Secreted Proteins of Human SGBS Adipocytes
Literature on secreted proteins from adipocytes or adipose tissue was searched online and in total
24 research papers and five reviews were found (Table 1) [2,3,8,16,18–42]. Comparing our secretome
data set with the data reported in these papers, 49 secreted proteins were identified as novel secreted
proteins that had not been described before for adipocytes or adipose tissue (Table 2). Of these proteins,
46 proteins were annotated as classical secreted proteins (S or S +D in Table 2) and three as non-classical
secreted proteins (D in Table 2; MT1G, PSMF1, SPRR2G).
Table 1. Literature Reports on Adipocyte Adipokine Profiling.
Order Reference Refs Source Secreted Novel
1 Wang et al. (2004) [18] Mice (3T3L1 cells) 26 15
2 Chen et al. (2005) [19] Rat fat pad 84 53
3 Molina et al. (2009) [20] Mice (3T3L1 cells) 147 NA
4 Celis et al. (2005) [21] Human adipocytes 359 NA
5 Mutch et al. (2009) [22] Human primary preadipocytes 213 NA
6 Alvarez-Llamas et al. (2007) [23] Human visceral fat tissue 108 68
7 Zvonic et al. (2007) [24] Human adipose-derived stem cells 101 NA
8 Lim J.M. et al. (2008) [31] 3T3L1 cell line; primary rat adipocytes 97; 203 54; 132
9 Roelofsen H et al. (2009) [32] Human omental tissue (control; test) 155; 141 NA
10 Kim et al. (2010) [25] Human subcutaneous adipose tissue 307 NA
11 Rosenow et al. (2010) [3] Human SGBS cells 80 6
12 Zhong et al. (2010) [26] Human adipocytes 420 107
13 Lee M.J. et al. (2010) [27] Human adipose tissue derived stem cells 142 NA
14 Rosenow A. et al. (2012) [16] Human SGBS cells 40 2
15 Lehr S. et al. (2012) [28] Human primary adipocytes 263 44
16 Roca-Rivada A. et al. (2011) [40] Rats (visceral; subcutaneous; gonadal fat) 188; 85; 91 NA
17 Sano S. et al. (2014) [41] Mice (3T3L1 cells) 231 NA
18 Roca-Rivada A. et al. (2015) [38] Human adipose tissue (visceral; subcutaneous) 136; 64 NA
19 Hartwig S. et al. (2018) [36] Human adipocytes 884 67
20 Laria A.E. et al. (2018) [37] Mice (3T3L1 cells) 839 80
21 Renes J. et al. (2014) [8] Human SGBS cells 57 6
22 Li Z.Y. et al. (2014) [29] Human SAT/ VAT NA 1
23 Ojima K et al. (2016) [34] Mice (3T3L1 cells) 74 NA
24 Ali Khan et al. (2018) [30] Mice primary adipocytes 499 NA
25 Mariman et al. (2010) [33] (Review)_Human and rodent adipocytes NA NA
26 Lehr S; et al. (2012) [2] (Review)_Human adipocytes 928 NA
27 Renes J. et al. (2013) [35] (Review)_Human and rodent adipocytes NA NA
28 Pardo M. et al. (2012) [39] (Review)_Human and rat adipocytes NA NA
29 Lee M.W. et al. (2019) [42] (Review)_Human and rat adipocytes NA NA
The number in the “secreted” column refers to the number of identified adipocyte secreted proteins, the “novel”
column shows the number of newly reported adipokines in that report. NA: there is no exact number for secreted
proteins mentioned in the article or supplemental materials.
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Table 2. List of 49 novel adipocyte secreted proteins.
Order S or D UniProt Gene Symbol Protein Name
1 S O00763 ACACB Acetyl-CoA carboxylase 2
2 S + D P04745 AMY1A Amylase, Alpha 1A (Salivary)
3 S O43570 CA12 Carbonic anhydrase 12
4 S P55287 CDH11 Cadherin-11
5 S P19022 CDH2 Cadherin-2
6 S + D Q9BWS9 CHID1 Chitinase domain-containing protein 1
7 S P26992 CNTFR Ciliary neurotrophic factor receptor subunit alpha
8 S + D Q9UI42 CPA4 Carboxypeptidase A4
9 S + D O75629 CREG1 Protein CREG1
10 S + D O00602 FCN1 Ficolin-1
11 S Q10471 GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2
12 S P23434 GCSH Glycine cleavage system H protein, mitochondrial
13 S + D P06280 GLA Alpha-galactosidase A
14 S + D Q9UJJ9 GNPTG N-acetylglucosamine-1-phosphotransferase subunit gamma
15 S O75487 GPC4 Glypican-4
16 S + D P35475 IDUA Alpha-L-iduronidase
17 S + D P08476 INHBA Inhibin beta A chain
18 S + D Q96I82 KAZALD1 Kazal-type serine protease inhibitor domain-containing protein 1
19 S Q6GTX8 LAIR1 Leukocyte-associated immunoglobulin-like receptor 1
20 S P38571 LIPA Lysosomal acid lipase/cholesteryl ester hydrolase
21 S O75197 LRP5 Low-density lipoprotein receptor-related protein 5
22 S Q8ND94 LRRN4CL LRRN4 C-terminal-like protein
23 S Q5JRA6 MIA3 Transport and Golgi organization protein 1 homolog
24 S + D P22894 MMP8 Neutrophil collagenase
25 D P13640 MT1G Metallothionein-1G
26 S + D P41271 NBL1 Neuroblastoma suppressor of tumorigenicity 1
27 S Q04721 NOTCH2 Neurogenic locus notch homolog protein 2
28 S + D P48745 NOV Protein NOV homolog
29 S + D O95897 OLFM2 Noelin-2
30 S + D Q8NBP7 PCSK9 Proprotein convertase subtilisin/kexin type 9
31 S P50897 PPT1 Palmitoyl-protein thioesterase 1
32 S + D P42785 PRCP Lysosomal Pro-X carboxypeptidase
33 S + D P07477 PRSS1 Trypsin-1
34 D Q92530 PSMF1 Proteasome inhibitor subunit 1
35 S P10586 PTPRF Receptor-type tyrosine-protein phosphatase F
36 S Q15274 QPRT Nicotinate-nucleotide pyrophosphorylase [carboxylating]
37 S Q6NUM9 RETSAT All-trans-retinol 13,14-reductase
38 S + D O00584 RNASET2 Ribonuclease T2
39 S Q9H173 SIL1 Nucleotide exchange factor SIL1
40 S Q99523 SORT1 Sortilin
41 D Q9BYE4 SPRR2G Small proline-rich protein 2G
42 S + D P10124 SRGN Serglycin
43 S + D A1L4H1 SSC5D Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D
44 S Q8NBK3 SUMF1 Sulfatase-modifying factor 1
45 S Q8NBJ7 SUMF2 Sulfatase-modifying factor 2
46 S Q5HYA8 TMEM67 Meckelin
47 S + D Q8WUA8 TSKU Tsukushin
48 S Q06418 TYRO3 Tyrosine-protein kinase receptor TYRO3
49 S P98155 VLDLR Very low-density lipoprotein receptor
S: secreted proteins identified by SignalP, D: identified by Deeploc, S + D: identified by both software packages.
2.3. Functional Categories of Identified Proteins
To get information of the 338 proteins (Table S1) secreted by SGBS adipocytes, functional
classification was done according to information on genes/proteins in databases: GeneCards [43],
UniProt [44] and PubMed [45]. Generally, these proteins could be classified into nine categories
according to biological function with “extracellular matrix (ECM) and cell adhesion” (80 proteins, 24%)
and ‘ECM modification’ (65 proteins, 19%) representing the largest groups (Figure 1B). Notably, 12 of
the 30 proteins in the immune system category appeared to be complement factors and seven of the
29 proteins in the lysosome-based group were cathepsins.
2.4. Adipocyte Secretome Changes after GR Plus RF as Compared with NF
Recently we have reported that the growth rate of fat droplets during NF and during RF after
GR shows similar kinetics, which allowed us to investigate the combined influence of GR plus RF
on the cellular proteome [17]. In the present study we focused on the secretome of those samples
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and searched for secreted proteins, of which the abundance was influenced by GR plus RF. For that,
protein abundances were quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS)
after NF (T18) and after GR plus RF (T22RF). 39 proteins were significantly changed by GR plus RF
compared to NF (Table 3) with 18 proteins being up-regulated and 20 proteins being down-regulated.
These 39 proteins can be divided into nine functional categories, which seem to parallel the functional
categories of the total identified secretome. 13 out of 39 proteins were related to the ECM with seven
proteins belonging to the ECM and cell adhesion group and six proteins belonging to ECM modification
group. It indicates that GR plus RF induces specific changes to the ECM. Four of the 39 proteins
were up-regulated with a FC > 4: complement factor B (CFB), ADAMTS-like protein 1 (ADAMTSL1),
target of Nesh-SH3 (ABI3BP), liver carboxylesterase 1 (CES1), and two were down-regulated with a
FC > 4: sortilin (SORT1) and dermokine (DMKN). Changes of protein expression during GR plus
RF could be due to different mechanisms with major changes either during GR and/or during RF.
Therefore, we examined the changes of abundance of the 39 proteins during the separate phases of GR
and RF (Table S2). The results confirmed the existence of different regulatory mechanisms. For instance,
ADAMTSL1 was up-regulated 10.47× during GR but remained at this level of expression during RF.
A similar pattern of expression was observed for prostaglandin-H2 D-isomerase (PTGDS) that was
up-regulated 8.44× during GR but only up-regulated 1.51× during RF. ABI3BP did not change during
GR, but was 5.04× up-regulated during RF. SORT1 was only slightly down-regulated (1.56×) during
GR but 4.07× down-regulated during RF.
Table 3. Proteins significantly different between GR plus RF and NF.
Order Category Gene Symbol Accession Description
T18-T22RF
FC_(GR+RF)/NF p Value
1 Actin filaments GSN P06396 Gelsolin −1.73 0.007
2
Complement factors
C1Q Q07021 Complement 1q subcomponent −2.94 0.030
3 C4B P0C0L5 Complement C4-B 2.85 0.002
4 CFB P00751 Complement factor B 4.06 0.018
5 CFD P00746 Complement factor D −1.93 0.002
6
ECM and cell adhesion
CDH13 P55290 Cadherin-13 −2.06 0.044
7 COL15A1 P39059 Collagen alpha-1(XV) chain 1.83 0.012
8 COL5A3 P25940 Collagen alpha-3(V) chain −1.69 0.047
9 LUM P51884 Lumican −1.48 0.025
10 MCAM P43121 Cell surface glycoprotein MUC18 −1.91 0.028
11 NRCAM Q92823 Neuronal cell adhesion molecule −2.39 0.046
12 SERPINE2 P07093 Glia-derived nexin 1.58 0.020
13
ECM modification
ADAMTSL1 Q8N6G6 ADAMTS-like protein 1 9.57 0.006
14 MMP2 P08253 72 kDa type IV collagenase 1.48 0.010
15 MMP8 P22894 Neutrophil collagenase 3.72 0.001
16 P4HA1 P13674 Prolyl 4-hydroxylase subunit alpha-1 −1.80 0.004
17 PPIC P45877 Peptidyl-prolyl cis-trans isomerase C −1.47 0.012
18 SERPINH1 P50454 Serpin H1 −2.19 0.001
19
ER-based
CALU O43852 Calumenin −2.36 0.002
20 HYOU1 Q9Y4L1 Hypoxia up-regulated protein 1 1.78 0.009
21 RCN1 Q15293 Reticulocalbin-1 −2.23 0.002
22 TXNDC5 Q8NBS9 Thioredoxin domain-containing protein 5 −1.39 0.024
23
Lipid metabolism
ACACB O00763 Acetyl-CoA carboxylase 2 −1.90 0.044
24 AZGP1 P25311 Zinc-alpha-2-glycoprotein 1.59 0.041
25 PCSK9 Q8NBP7 Proprotein convertase subtilisin/kexin type 9 −1.90 0.003
26 PTGDS P41222 Prostaglandin-H2 D-isomerase 3.67 0.000
27
Lysosome-based
CTSA P10619 Lysosomal protective protein 2.75 0.009
28 CTSL P07711 Cathepsin L1 1.24 0.029
29 DNASE2 O00115 Deoxyribonuclease-2-alpha 2.97 0.033
30 SORT1 Q99523 Sortilin −5.13 0.005
31
Tissue homeostasis
ABI3BP Q7Z7G0 Target of Nesh-SH3 5.71 0.008
32 GRN P28799 Granulins 1.73 0.008
33 MYDGF Q969H8 Myeloid-derived growth factor −1.93 0.046
34 NRP1 O14786 Neuropilin-1 1.74 0.029
35 RBP4 P02753 Retinol-binding protein 4 −1.91 0.011
36
Remaining
APP P05067 Amyloid-beta A4 protein −1.44 0.033
37 CES1 P23141 Liver carboxylesterase 1 4.05 0.008
38 CHI3L2 Q15782 Chitinase-3-like protein 2 3.43 0.005
39 DMKN Q6E0U4 Dermokine −5.40 0.000
NF: normal feeding, GR: glucose restriction, RF: refeeding. FC_(GR+RF)/NF: fold change between GR plus RF
(T22RF) and NF (T18). When FC >1, the value was described as FC; otherwise, the value was described as −1/FC.
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3. Discussion
In the present study, we performed GR followed by RF of SGBS cells as a simple in vitro surrogate
for in vivo weight regain after weight loss and investigated the changes of human adipocyte-derived
secreted proteins. Comparison between NF and GR plus RF was made to gain information on changes
induced to the secretome that could serve as leads to get further insight into the consequences of
weight regain for metabolic health. Our results show that GR plus RF induced adipocyte secretome
changes involving biological pathways of ECM remodeling, lipid metabolism, complement system,
and tissue homeostasis. Furthermore, 49 secreted proteins were described here for the first time as
being secreted by adipocytes.
Harvesting secreted proteins from the culture medium inevitable leads to contamination with
leaked cellular proteins. We have applied bioinformatics analysis to identify the secreted proteins either
as classical secreted proteins, which are typically targeted to the endoplasmic reticulum by a signal
peptide, and non-classical secreted proteins without a signal peptide. Till now, SignalP [46] has been a
well-accepted method for sorting classical secreted proteins and SecretomeP [47] has been widely used
for non-classical secretion. When we first used SignalP in combination with SecretomeP, this yielded
739 potentially secreted proteins in the current study. However, recently Henrik et al. [48] reported that
SecretomeP induces more than 20% false positives. Instead, Deeploc obtained the highest accuracy
(78% for subcellular localization; 92% for membrane-bound or soluble) on predicting non-classical
secreted proteins when compared with other methods [49]. Therefore, in the current study we used
the combination of SignalP and Deeploc, which led to 337 secreted protein candidates, of which 66%
(221) were ranked as secreted by both programs. Yet, it should be noted that even with our stringent
method of selection, a certain level of misclassification cannot be avoided. Additionally, some proteins
may be aberrantly classified as non-secreted as observed for complement factor C1q.
The largest change in abundance induced by the combined effects of GR plus RF was the 9.57 ×
up-regulation of ADAMTSL1. This is a metalloproteinase located in the ECM and known to degrade
aggrecan [50]. Two other metalloproteinases (MMP2 and MMP8) are up-regulated as well, suggesting
that after GR plus RF, the ECM is in a catabolic state. Moreover, three proteins involved in the
maturation of collagens, P4HA1, PPIC and SERPINH1, are down-regulated. Recently we have shown
that inside the cells GR leads to an upregulation of certain focal adhesion proteins [17]. It suggests that
upon GR plus RF adipocytes intensify the cell-cell interaction while going through a phase of increased
ECM flexibility. At the moment, it is not clear whether this also occurs in vivo and whether it would
influence weight regain or the metabolic condition after weight regain. Still, in a previous weight
loss/follow-up intervention study, expression of the ADAMTSL1 and MMP2 genes were significantly
up-regulated (FC = 1.09, q = 0.05; FC = 1.24, q < 0.0001, respectively) four weeks after return to a
balanced diet [51]. This indicates that ECM adaptations occur also in vivo during weight loss and
weight regain.
It is well established that adipose tissue secretes various components of the complement system.
During development of overweight and obesity, the secreted levels of complement factors change,
which is thought to contribute to the chronic low level inflammation of the adipose tissue and the
development of health complications such as insulin resistance, type II diabetes and cardiovascular
disorders [1]. In this respect, it has been suggested that modulation of the complement system
could be a target for the prevention and therapy of obesity-associated metabolic diseases [11,52–55].
Twelve proteins with an influence on complement activation were identified in our in vitro system and
eight of them were complement factors (Table 4). Of those proteins, complement factor B (CFB) and
complement factor 4B (C4-B) were significantly increased by GR plus RF, whereas the abundances of
C1q and complement factor D (CFD) were significantly reduced. Such changes in vivo after weight loss
and weight regain might lead to systemic changes in complement activity, especially in people with a
high fat mass [52]. More generally, it could have local effects in the adipose tissue itself. Reduction of
C1q and of C1s (p = 0.13) indicates a lower classical complement pathway. Yet, the increase of C4-B and
mannan-binding lectin serine protease 1 (MASP1) suggest an increase of the C3 convertase C4bC2b.
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Together with the strong increase of CFB, a local increase of C3a and C3b could be expected. C3a can
be converted to C3desArg (acylation-stimulating protein, ASP) by carboxypeptidases B and N [56].
Here we found that adipocytes secrete carboxypeptide E, which is similarly able to remove arginine
from the carboxyterminal tail of proteins. An increase of C3desArg would stimulate triglyceride
uptake and glucose transport into adipocytes [57]. In the mouse it has been shown that CFB promotes
adipocyte maturation and growth of fat droplets [58]. It is tempting to speculate that GR plus RF
could have the same consequence. In addition, C3a has immune-modulatory properties and is often
regarded as a pro-inflammatory factor [59]. Factor C3b in interaction with CBb converts C5 into C5a
and C5b. C5a has chemotaxis activity and attracts neutrophils, basophils and macrophages. C5b forms
with C6–C9 the membrane attack complex, which could be counteracted by the increase of clusterin
(FC = 1.40, p = 0.09) [60]. Altogether, our in vitro observations suggest that changes in the complement
system through GR plus RF may trigger uptake of triglycerides and glucose by adipocytes and may
promote the attraction of immune cells (Figure 2). In fact, in the present study triglyceride content
was measured by ORO staining and by measuring the diameter of the five biggest fat droplets [17].
The OD value was higher by about 10%, being 1.55 after NF and 1.69 after GR plus RF (p = 0.13).
In line, the diameter was higher by about 14%, being 1.13 μm after NF and 1.29 μm after GR plus
RF (p = 0.02). Although this is keeping with the proposed hypothesis, we have no absolute proof to
attribute the increased fat content to the influence of complement factors. Regarding the involvement
of the innate immune cells, gene expression studies in vivo have indicated that poor ability to reduce
myeloid activity from the adipose tissue after weight loss is associated with increased risk of weight
regain [11,61].
Figure 2. Complement activation pathway comparing GR plus RF with NF. Secreteome changes during
GR plus RF vs NF indicate the up regulation of MBL and alternative pathways of the complement
system, which may trigger the uptake of triglycerides and glucose by adipocytes on one hand and
promote inflammation on the other, which both may have an effect on health after weight regain.
Proteins in blue means that the expression was down-regulated (p < 0.1), red means up-regulated
(p < 0.1), white are proteins that were not detected in our results. RF: refeeding, NF: normal feeding,
GR: glucose restriction. MBL: mannose-binding lectin. MASP: mannose-binding lectin serine protease.
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Various lysosome-based proteins were identified by our secretome profiling (Table 4). Lysosomes
function as a key degradative compartment of cells, of which lysosomal cathepsins display an essential
role in maintaining cell homeostasis by autophagy and extracellular matrix degradation [62–64].
Their extracellular function is mostly associated with pathology and disease including metabolic
syndrome in people with obesity [65,66]. In the current study, we observed seven different cathepsins
(A, B, D, F, K, L and Z) secreted by adipocytes. Five of the identified cathepsins were up-regulated
by trend (Table 4) and two cathepsins were significantly up-regulated (Tables 3 and 4) after GR
plus RF versus NF. In detail, cathepsin A (CTSA) and cathepsin L (CTSL) were significantly
increased while other cathepsins showed a trend (Table 4). CTSA is able to stabilize the extracellular
beta-galactosidase/neuraminidase-1 complex, which is involved in the formation of elastic fibers [67].
In addition, it processes important vascular proteins including endothelin-1, bradykinin and angiotensin
I, which are important for the regulation of blood pressure [68]. Pharmacological inhibition indicates a
role of CTSL in adipogenesis/fat storage and glucose tolerance. Inhibition of CTSL reduced fibronectin
degradation and increased the levels of the beta-subunits of the insulin receptor and insulin-like growth
factor-1-receptor [69]. Studies have also shown that CTSL, like cathepsin S (CTSS), has proatherogenic
properties [70]. However, those studies did not specifically look at the extracellular function of CTSL.
Yet, a literature survey has shown that CTSL is one of the cathepsins involved in extracellular matrix
degradation and tissue remodeling [63]. Serum levels of CTSL did not alter following 6-month CR in
obese women [71], but were reduced after an 8 week lifestyle intervention [72]. Here we show that GR
plus RF significantly increased the extracellular CTSA and CTSL level. It seems therefore warranted
to study the in vivo consequences of weight regain on plasma levels of cathepsins and assess the
influence on fat storage, blood pressure and glucose tolerance.
Table 4. Complement factors and cathepsins.
Order UniProt Gene Symbol Description Category FC p Value
1 P00736 C1R Complement C1r subcomponent Complement factor −1.00 0.716
2 Q07021 C1Q Complement C1q subcomponent Complement factor −2.96 0.011
3 P09871 C1S Complement C1s subcomponent Complement factor −1.53 0.131
4 P01024 C3 Complement C3 Complement factor −1.03 0.840
5 P0C0L5 C4B Complement C4-B Complement factor 2.85 0.002
6 P00751 CFB Complement factor B Complement factor 4.06 0.018
7 P00746 CFD Complement factor D Complement factor −1.93 0.002
8 P08603 CFH Complement factor H Complement factor −1.15 0.277
9 P13987 CD59 CD59 glycoprotein Complement factor 1.10 0.634
10 O00602 FCN1 Ficolin-1 Complement factor −4.42 0.578
11 P05155 SERPING1 Plasma protease C1 inhibitor Complement factor −1.83 0.190
12 P48740 MASP1 Mannan-binding lectin serine protease 1 Complement factor 2.33 0.196
1 P10619 CTSA Cathepsin A Lysosome-based 2.75 0.009
2 P07858 CTSB Cathepsin B Lysosome-based 1.19 0.097
3 P07339 CTSD Cathepsin D Lysosome-based 1.16 0.309
4 Q9UBX1 CTSF Cathepsin F Lysosome-based 1.33 0.239
5 P43235 CTSK Cathepsin K Lysosome-based 1.45 NA
6 P07711 CTSL Cathepsin L1 Lysosome-based 1.24 0.029
7 Q9UBR2 CTSZ Cathepsin Z Lysosome-based 1.08 0.466
Fold change (FC) was calculated with the abundance of T22RF/T18. When FC >1, the FC value was described as FC,
otherwise the value was described as −1/FC. NA: abundance data available for only one sample. RF: refeeding,
NF: normal feeding.
A number of proteins that change abundance significantly between GR plus RF and NF, has been
described in relation to Alzheimer’s disease. Amyloid-beta A4 protein (APP), which is a major
component of the amyloid plaques in the brain of Alzheimer’s patients [73], is 1.43× down-regulated.
Extracellular SORT1, which has been reported to be involved in plaque formation [74], is 5.13×
down-regulated in our study. PTGDS was 3.67× up-regulated due to GR plus RF. Interestingly,
an up-regulation of the gene for PTGDS after ingestion of soybeans could lead to reduced amyloid-β
accumulation and improved cognition [75]. A fourth protein, chitinase-3-like protein 2 (CHI3L2) is
3.43× up-regulated as the consequence of GR plus RF. CHI3L2 is known to bind to glycans, but lacks the
required domain for chitinase activity [44]. Recently, it has been reported that the regional expression of
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CHI3L2 in the brain of late-onset Alzheimer’s patients is altered in comparison to healthy persons [76],
but its function is presently unknown. Together, it would be worth to investigate whether weight
cycling in humans could influence the expression of those proteins as well.
It should be noted that there are limitations to the present study. Firstly, SGBS cells have widely
been used in vitro as a substitute for human white subcutaneous adipocytes since 2001 [13], but a study
by Yeo et al. [77] indicated that SGBS cells may also have browning potential. Secondly, arguments
including the fact that MS data are based on multiple peptide quantifications per protein, make it
convincing that MS quantification is highly accurate [78,79]. Validation by another method has the
risk of devaluating the quantitative data. Therefore, such validation was not performed. Thirdly,
an in vitro model for weight loss and regain preferably is based on ‘obese’, hypertrophic fat cells.
However, a hypertrophic phenotype of adipocytes differentiated in culture is difficult to define. For the
present model it can be said that after 12 days of differentiation, SGBS cells contain 4× as much
triglycerides than differentiated primary adipocytes [77]. Here we used 14 days differentiated SGBS
cells with a 24% higher diameter of the five biggest fat droplets as compared to day 12 indicating an
even higher fat content on day 14. Therefore, we feel confident to regard our findings as valuable clues
for the consequences of weight loss and regain in overweight people. This can now be examined in
human intervention studies.
4. Materials and Methods
4.1. Cell Culture
Human SGBS cells were obtained from Prof. Dr. M. Wabitsch (University of Ulm,
Germany) [12]. SGBS pre-adipocytes were cultured in 6-well plates (Corning, Sigma-Aldrich,
Zwijndrecht, The Netherlands) with Gibco™ Dulbecco’s Modified Eagle Medium: Nutrient Mixture
F-12 (DMEM/F-12, 1:1) media supplemented with 66 mmol/L biotin, 34 mmol/L D-pantothenate,
10% fetal calf serum (Bodinco BV, Alkmaar, The Netherlands) and 1% penicillin and streptomycin
(Life Technologies, Thermo Fisher Scientific, Bleiswijk, The Netherlands) as described before [17].
Differentiation started once pre-adipocytes reached 90% confluence. During two weeks of
differentiation (T0–T14), SGBS cells first went through four days with quick differentiation medium
(serum-free DMEM/F12 medium containing 2 mg/mL human transferrin, 200 μmol/L human insulin,
5 mmol/L Cortisol, 20 μmol/L triiodothyronine, 1 mmol/L 3-isobutyl-1-methylxanthine and 5 mmol/L
rosigilitazone). The other 10 days cells remained in 3FC medium (serum-free DMEM/F12 medium
containing 2 mg/mL human transferrin, 200 μmol/L human insulin, 5 mmol/L Cortisol, 20 μmol/L
triiodothyronine) as described before [17]. All chemicals were purchased from Sigma (Sigma-Aldrich,
Zwijndrecht, The Netherlands) unless otherwise stated.
For GR, mature adipocytes on day 14 (T14) were cultured in basic DMEM/F12 medium (without
glucose and phenol red (Cell Culture Technologies, Gravesano, Switzerland)), supplemented with
20 nmol/L human insulin and 0.1 mmol/L D-glucose for 96 h (T18GR). As the feeding control, mature
adipocytes at T14 originating from the same pre-adipocytes were cultured for 96 h in NF medium
(T18): DMEM/F12 medium without glucose and phenol red, but supplemented with 20 nmol/L human
insulin and 17.5 mmol/L D-glucose.
For RF, after 96 h of GR, the cells were transferred to DMEM/F12 medium without glucose
and phenol red (Cell Culture Technologies) but supplemented with 20 nmol/L human insulin and
17.5 mmol/L D-glucose for another 96 h (T22RF). From T14 onwards, the medium was gently refreshed
every second day. Figure 3 provides an overview of the experimental approach.
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Figure 3. Workflow of the secretome profiling. Firstly, human SGBS adipocytes were cultured and after
NF, GR and RF, medium was collected for all the time points. After sample preparation, proteins were
identified and quantified by LC-MS/MS. Finally, bioinformatic and statistic analysis were performed
for functional interpretation. NF: normal feeding, GR: glucose restriction, RF: refeeding.
4.2. Collection of Secretion Medium
In order to avoid interference of phenol red with MS, for collecting the secretome at T14, adipocyte
medium was changed to collection medium: basal medium (DMEM/F12 (1:1) without glucose and
phenol red (Cell Culture Technologies, Gravesano, Switzerland)), supplemented with 20 nmol/L human
insulin and 17.5 mmol/L glucose for 48 h (T12–T14). The collection medium at T14 was collected in a
separate vial for each well. For NF, GR and RF, the medium was already without phenol red from
T14 onwards. To collect the secretome after NF, GR and RF, the medium was collected at day 18 (T18
and T18GR) and day 22 (T22RF) from each well separately. The collected medium (4 mL per well)
was centrifuged at 5000 rpm for 10 min (Universal 30 RF, Hettich Benelux B.V., The Netherlands).
Thereafter, the supernatant was gently moved to a new tube. The whole experiment was performed
three times with triplicate samples. The first time the experiment was performed, the triplicate medium
samples per time point were pooled to serve proper protocol assessment. For the second and third
time that the experiment was performed, the triplicate samples were kept separately. This provided
seven replicate samples per time point with in total 28 samples. These were snap-frozen in liquid
nitrogen and stored at −80 ◦C for further analysis.
4.3. Sample Preparation
All samples were treated similarly according to the FASP protocol as described by
Wisniewski et al. [80]. In short, after thawing and brief vortexing, the medium of each vial was added
to a pre-rinsed filter device (Amicon® Ultra−4 Centrifugal Filter Units, Sigma-Aldrich, Germany),
centrifuged at 4000× g at 20 ◦C for 30 min. The fluid was discarded and the concentrated protein
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sample on the filter was washed with 3.5 mL 50 mmol/L ammonium bicarbonate and centrifuged at
4000× g at 20 ◦C for 30 min. For reduction, 15 μL of 200 mmol/L dithiothreitol was added and the filter
was incubated at room temperature for 45 min. Next, to accomplish alkylation 18 μL of 400 mmol/L
iodoacetamide solution was added and the filter was incubated at room temperature in the darkness
for another 45 min. To stop the alkylation, 30 μL of 200 mmol/L dithiothreitol was added and the filter
was incubated at room temperature for 45 min.
The alkylated protein sample on the filter was washed with 50 mmol/L ammonium bicarbonate at
4000× g at 20 ◦C for 40 min. To each concentrated protein sample 3 μg trypsin/Lys-C Mix was added,
and after gentle mixing the filter device was incubated at 37 ◦C overnight. Peptide concentration
was measured by the Pierce Quantitative Colorimetric Peptide Assay according to the manufacture’s
protocol (Thermo Fisher Scientific (#: 23275), Bleiswijk, The Netherlands). Then, digested peptides
were diluted to the same final concentration of 0.25 μg/μL by 50 mmol/L ammonium bicarbonate.
4.4. Label-Free Protein Identification and Quantification
The mass analysis was performed using a nanoflow HPLC instrument (Dionex ultimate 3000,
Thermo Fisher Scientific, Bleiswijk, The Netherlands), which was coupled on-line to a Q Exactive
mass-spectrometer (Thermo Fisher Scientific, Bleiswijk, The Netherlands) with a nano-electrospray
Flex ion source (Proxeon, Thermo Fisher Scientific, Bleiswijk, The Netherlands). An equal amount of
Pierce Digestion Indicator peptides was added to all peptide samples as internal standard. 5 μL of
this mixture was loaded onto a C18-reversed phase column (Acclaim PepMap C18 column, 75 μm
inner diameter × 15 cm, 2 μm particle size, Thermo Fisher Scientific, Bleiswijk, The Netherlands).
The peptides were separated with a linear gradient of 4–68% buffer B (80% acetonitrile and 0.08%
formic acid) at a flow rate of 300 nL/min for 120 min.
MS data were acquired using a data-dependent top-10 method, dynamically choosing the most
abundant precursor ions from the survey scan (280–1400 m/z) in positive mode. Survey scans were
acquired at a resolution of 70,000 and a maximum injection time of 120 ms. The dynamic exclusion
duration was 30 s. Isolation of precursors was performed with a 1.8 m/z window and a maximum
injection time of 200 ms. The resolution for HCD spectra was set to 17,500 and the normalized
collision energy was 30 eV. The under-fill ratio was defined as 1.0%. The instrument was run with
peptide recognition mode enabled, but exclusion of singly charged and charge states of more than five.
The entire experiment was repeated three times.
4.5. Database Search and Quantification
The MS data were searched using Proteome Discoverer 2.2 Sequest HT search engine (Thermo
Fisher Scientific, Bleiswijk, The Netherlands) based on the UniProt human database [81]. The false
discovery rate was set to 0.01 for proteins and peptides, which had to have a minimum length of six
amino acids. The precursor mass tolerance was set at 10 ppm and the fragment tolerance at 0.02 Da.
One miss-cleavage was tolerated, oxidation of methionine was set as a dynamic modification as well as
carbamidomethylation of cysteines. Label free quantitation was conducted using the Minora Feature
Detector node in the processing step and the Feature Mapper node combined with the Precursor Ions
Quantifier node in the consensus step with default settings within Proteome Discoverer 2.2.
4.6. Data Normalization
The LC-MS-analysis was done in seven runs, each run containing a sample from each time point
(T14, T18, T18GR and T22RF). Data normalization was done in two steps.
First, to correct data for possible differences between runs, we chose the 426 proteins, which were
present in all of the test samples. We calculated the mean abundance of those 426 proteins in all seven
runs (M) and mean abundance of those 426 proteins per run (mx for run x). Normalization factor 1 for
run x (f1x) =M ÷mx. Data were firstly corrected (D1) as follows: D1 = f1x × original tested protein
abundance in run x.
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Additionally, the Pierce Indicator added to each sample was normalized by f1. The second
normalization was then performed to stratify the protein abundances according to the Pierce Indicator.
Normalization factor 2 for sample y (f2y) = Pierce’s mean abundance from all 28 samples ÷ Pierce
abundance in sample y. In general, the second normalization step was: D2 = f2 × D1. More specifically,
the abundance of a protein in sample y of run x was normalized as f1x × f2y × original tested
protein abundance.
4.7. Validation of Secreted Proteins and Imputation of Missing Values
To verify the secreted nature of the identified proteins, their amino acid sequences were obtained
from UniProt and analyzed with SignalP and Deeploc. SignalP 4.1 Server [46,82] was used to recognize
classical secreted proteins by the fact that they contain a signal peptide for secretion, Deeploc−1.0 [49]
was used for prediction of the subcellular localization by creating a recurrent neural network relying on
protein sequence information per se. Proteins containing a signal peptide or located in the extracellular
space were chosen as secreted proteins for further analysis.
Performing LC-MS analysis of proteins, values could be missing for various reasons [83]. When per
time point three or less of the seven samples had missing values, the Multiple Imputation routine of
SPSS was used to impute those values. Finally, only proteins recognized as secreted and with no more
than three missing values were used for further analysis.
4.8. Statistical Analysis
Data were described as mean ± SEM, variable abundances were log2-transformed. To determine
possible effects over time between NF and RF after GR, two-tailed dependent T-test was carried
out with a cut-off for significance of p < 0.05. Statistical analyses were conducted using SPSS
(version 22.0 Chicago, Illinois, USA). Fold changes (FC) from T18 to T22RF were calculated as follows:
FC = 2 (log2 T22RF − log2 T18).
5. Conclusions
In summary, in this study we reported for the first time 94 proteins being secreted by adipocytes.
In addition, our in vitro study demonstrated that GR followed by return to NF leads to changes in
the secretome of adipocytes in comparison with NF alone. Major changes are related to extracellular
matrix modification, factors of the complement system, extracellular cathepsins, and several proteins
relevant for Alzheimer’s disease. These observations can now be used as clues to investigate the
metabolic consequences of weight regain, weight cycling or intermittent fasting.
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DMEM/F12 Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
FC fold change
C1q complement factor 1Q
AOC3 membrane primary amine oxidase





PSMF1 proteasome inhibitor subunit 1
SPRR2G small proline-rich protein 2G
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase family member 2
ECM extracellular matrix
LC-MS/MS liquid chromatography tandem mass spectrometry
CFB complement factor B
ADAMTSL1 ADAMTS-like protein 1
ABI3BP target of Nesh-SH3




C4-B complement factor 4B






APP amyloid-beta A4 protein
CHI3L2 chitinase-3-like protein 2
MASP mannan-binding lectin serine protease
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Abstract: Obesity is now a worldwide epidemic. In recent years, different phenotypes of obesity,
ranging from metabolically healthy normal weight to metabolically unhealthy obese, were described.
Although there is no standardized definition for these phenotypes or for metabolic health, the influence
of lifestyle and early-life factors is undisputed. In this context, the ratio of muscle-to-fat tissue seems to
play a crucial role. Both adipose tissue and skeletal muscle are highly heterogeneous endocrine organs
secreting several hormones, with myokines and adipokines being involved in local autocrine/paracrine
interactions and crosstalk with other tissues. Some of these endocrine factors are secreted by both
tissues and are, therefore, termed adipo-myokines. High (cardiorespiratory) fitness as a surrogate
parameter for an active lifestyle is epidemiologically linked to “better” metabolic health, even in
the obese; this may be partly due to the role of adipo-myokines and the crosstalk between adipose
and muscle tissue. Therefore, it is essential to consider (cardiovascular) fitness in the definition of
metabolically healthy obese/metabolic health and to perform longitudinal studies in this regard.
A better understanding of both the (early-life) lifestyle factors and the underlying mechanisms that
mediate different phenotypes is necessary for the tailored prevention and personalized treatment
of obesity.
Keywords: adipokine; myokine; fitness; metabolically healthy obese; early-life programming
1. Introduction
The overall prevalence of obesity increased dramatically over the last few decades [1–3]. The World
Health Organization (WHO) reported that more than 1.9 billion adults around the world are overweight,
and nearly one-third of the population is obese [4].
From an epidemiological perspective, obesity is linked to so-called non-communicable diseases
(NCDs), a set of diseases of long duration and slow progression, including cardiovascular diseases,
diabetes mellitus type 2, respiratory diseases, and certain types of cancer [5]. These NCDs kill 41 million
people each year, equivalent to 71% of all deaths globally [6]; 1.6 million deaths annually can be
attributed to insufficient physical activity [7].
In general, obesity is still defined on the basis of body mass index (BMI), and BMI in itself is
generally accepted as a strong predictor of overall early mortality [3]. The increased health risk is
particularly linked to high amounts of white and/or visceral fat because of its endocrine activities.
Visceral adipose tissue produces more than 600 so-called adipokines that regulate not only metabolic
processes such as insulin secretion, hunger and satiety, and energy balance, but inflammatory processes
as well [8]. An increasing accumulation of visceral fat in terms of chronic overfeeding results in
dysfunctional adipose tissue with excessive adipokine secretion and an altered secretion profile
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characterized by increased leptin, interleukin (IL)-6, and tumor necrosis factor (TNF)-α levels, as well as
increased oxidative stress and a reduction in adiponectin [9], leading to chronic low-grade inflammation.
Whereas physical activity/exercise can be protective against these pathological conditions [10],
physical inactivity enhances the inflammatory mechanisms described above [11]. This might be
explained by the specific function of skeletal muscle mass. Skeletal muscle is the largest organ in
the body; its energy production and consumption are fundamental to metabolic control. Currently,
skeletal muscle is also identified as an endocrine organ secreting hundreds of so-called myokines such
as myostatin, IL-4, IL-6, IL-7, IL-15, myonectin, follistatin-like 1 (FSTL1), leukemia inhibitory factor,
and/or irisin [12,13]. Not only do these myokines act locally in the muscle in an autocrine/paracrine
manner, but they are also released into the bloodstream as endocrine factors to regulate physiological
processes in other tissues. The release of myokines from contracting muscle is assumed to be at least
partly responsible for the health-promoting effects of physical activity that protects against major
chronic, low-grade inflammatory diseases like type 2 diabetes, insulin resistance, metabolic syndrome,
and many others.
In 2013, Raschke and Eckel [14] described the interplay between muscle and adipose tissue as
a two-edged sword. They pointed out that certain cytokines are released by both skeletal muscle
and adipose tissue, exhibiting a bioactive effect. The authors suggested calling them adipo-myokines
because they are both mediators of exercise and mediators of inflammation. For this reason, as well
as for the development of tailored prevention and treatment, it is important to better understand the
molecular mechanisms and potential influencing factors that predispose obese (or inactive) individuals
to the development of metabolic diseases. Increasing evidence also suggests that early-life exposure
to a range of environmental factors, including parental BMI and lifestyle (e.g., maternal nutrition),
plays a critical role in defining an offspring’s metabolic health. According to the Developmental
Origins of Health and Disease hypothesis, environmental exposures during critical periods—such
as the preconception, fetal, and early infant phases of life—can influence development and have a
persistent impact on metabolic health and gene expression, thereby influencing offspring phenotype

































Figure 1. Illustration of the interaction of parental factors on offspring in pregnancy, affecting epigenetic
regulation and different organ systems in the development of different obesity phenotypes in terms of
metabolic health.
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The particular aim of this article is to explore the extent to which biomolecular findings can
substantiate the concept of metabolic health and to investigate the role of physical activity/exercise,
using cardiorespiratory fitness as a surrogate marker considering early-life factors.
2. Definition and Epidemiological Findings
A striking limitation of BMI is shown by the different phenotypes of obesity. In the early 1980s,
Ruderman et al. [17] described the manifestation of cardiometabolic risk factors in non-obese subjects,
termed “Metabolically Obese, Normal Weight” (MONW); while they are characterized as having
hyperinsulinemia, hyperglycemia, insulin resistance, impaired glucose tolerance, hypercholesterolemia,
and hypertriglyceridemia, they have normal adipocyte volume and BMI. On the other hand,
obese individuals who showed no health risk factors were also described [18]. This phenomenon—called
benign obesity or MHO (metabolically healthy obese)—is characterized by a high BMI or high amount of
fat mass in the absence of insulin resistance, increased blood lipids, high blood pressure, or inflammatory
dysregulation in contrast to metabolically unhealthy obese (MUO). Discussions about whether the
manifestation of MHO is clinically relevant, or whether it might be a form of “honeymoon obesity”
(alluding to a temporary absence of metabolic illness), are still ongoing. Nonetheless, it is becoming
increasingly clear that a distinction between the various forms of obesity is important given the
difference in therapeutic approaches [19]. It is likely that fat distribution and/or body composition play
a central role due to different health risks.
To date, there is no uniform classification for this phenotype, while up to 30 different definitions
were proposed in several studies (summarized in Reference [20]). Depending on which definition is
used, information about the prevalence of MHO varies in the literature [21]. The prevalence of MHO is
3% to 32% in men and 11% to 43% in women using BMI, 6% to 37% in men and 12% to 58% in women
using abdominal obesity, and 6% to 43% in men and 12% to 56% in women using body fat as the
defining parameter. A similar inconsistency in the literature is found regarding the actual manifestation
of the condition. As such, some authors do not recognize the phenomenon as a condition itself but
suggest that it is a temporary state which will sooner or later result in a pathological condition [22]. In a
meta-analysis, Kramer et al. [23] showed that MHO individuals had an increased risk for cardiovascular
events compared with metabolically healthy normal-weight (MHNW) individuals when only studies with
10 or more years of follow-up were considered (+24%). In contrast, all metabolically unhealthy groups
had a similar risk: normal weight (risk ratio (RR), 3.14), overweight (RR, 2.70), and obese (RR, 2.65).
Approximately 30% to 50% of MHO individuals seem to convert to the MUO phenotype after
four to 20 years of follow-up (summarized in Reference [20]). A major factor in this transition seems to
be the development of insulin resistance, which is enhanced by a high BMI, weight gain, older age,
and a poor lifestyle index (including physical inactivity).
These controversies underline the need for specific, individualized treatments based on individual
diagnostic findings and risk. They further highlight the importance of promoting a healthy, active
lifestyle. Moreover, additional factors should be included in health risk assessments. Smith et al. [20]
suggest basing the risk on the absence of cardiometabolic diseases and on the cardiometabolic profile,
including normal blood lipid, blood pressure, and blood glucose levels, as well as intrahepatic fat
content, as advanced criteria. From our point of view, however, body composition and cardiorespiratory
fitness would be missing as protective factors in this list of criteria, at least of the advanced type.
Similarly, Ruderman et al. [17] noted that physical activity should be added as a therapeutic agent,
with maximal oxygen uptake added as a criterion, in reference to MONW. However, Velho et al. [21]
demonstrated in the CoLaus Study, a cross-sectional investigation aimed at assessing the prevalence
and deciphering the molecular determinants of cardiovascular risk factors in the Caucasian population
of Lausanne, that MHO individuals were more physically active. For this reason, Stefan et al. [24]
suggested defining MHO using the following six parameters: waist circumference, insulin resistance,
blood sugar levels, blood pressure, cholesterol levels, and physical fitness.
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3. Physical Activity, Cardiorespiratory Fitness, and/or Sedentary Behavior and Its Relation to MHO
In general, physical activity is defined as any bodily movement that results in energy
expenditure [25]. Exercise is a subset of physical activity that is planned, structured, and repetitive,
and that has, as a final or an intermediate objective, the improvement or maintenance of physical
fitness. The “dose” is expressed as energy expenditure, and the intensity is expressed as the rate of
energy consumption in selected activities, usually expressed as a percentage of VO2 max engaged
during exercise (or relative to individual body weight) or metabolic units (METs). Activities with <1.5
METs are classified as sedentary or inactivity [26]. The current physical activity recommendations for
adults can be found in Table 1.
Table 1. German physical activity recommendations for adults according to Reference [27].
German Physical Activity Recommendations for Adults
• Adults should be physically active on a regular basis, which can help to achieve significant health effects
and to reduce the risk of developing chronic diseases.
• The greatest health benefits take place when individuals who were entirely physically inactive become
somewhat more active; this means that all additional physical activity is linked to health benefits and that
every single step away from physical inactivity is important, no matter how small, and promotes health.
• To maintain and promote health comprehensively, the following minimum recommendations apply:
– adults should have moderate-intensity aerobic physical activity for at least 150 minutes/week,
where possible (e.g., 5 × 30 minutes/week); or
– at least 75 minutes/week of vigorous-intensity aerobic physical activity; or
– aerobic physical activity in a corresponding combination of both intensities; and
– should group the overall activity in at least 10-min individual units distributed over days and
weeks (e.g., at least 3 × 10 minutes/day on five days per week).
• Adults should also have muscle-strengthening physical activity at least two days per week.
• Adults should avoid long and uninterrupted sitting times and should regularly interrupt sitting with
physical activity, where possible.
• Adults can achieve further health effects if they increase the volume and/or intensity of physical activity
above the minimum recommendations.
Even though there is a large consensus about the recommended levels of physical activity, the
broad range of methods used to measure such activity makes the final decision-making process complex.
Studies may use subjective or objective measurements, test endurance, strength, or co-ordination,
and different intensities, volumes, and training methods like interval or continuous training in their
intervention. Hence, testing cardiorespiratory fitness levels as a surrogate marker may still be the
most sensible option. Many studies showed that well-trained individuals have a better prognosis
with regard to NCDs than those with lower fitness levels [28,29]. In the concept of fitness instead of
fatness, this would also concern overweight and obese individuals [30]. There are, however, only a few
studies investigating these connections with MHOs, and most of them are cross-sectional analyses [31].
Between 2010 and 2013, the Maastricht study investigated the relationship between MHO, MUO,
metabolically healthy non-obese (MHNO), and metabolically unhealthy non-obese (MUNO) groups,
as well as physical activity and sedentary behavior in 2449 men and women aged 40–70 years [31].
Based on accelerometry data, the MHO group was more active (ca. 15 min) and less sedentary (ca. 30
min) than the MUO group. Furthermore, Camhi et al. [32] analyzed National Health and Nutrition
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Examination Survey (NHANES) data from obese adolescents and adults from the 2003–2005 cohort.
The adult MHO group was 85% more likely to engage in active transportation and nearly three times
more likely to be involved in light-intensity, usual daily activity versus sitting (self-reported). A higher
level of moderate physical activity was also associated with the MHO group.
In a systematic review and meta-analysis, Ortega et al. [33] explored the differences between
physical activity, sedentary behavior, and cardiorespiratory fitness between MHO and MUO individuals,
as well as the prognosis of all-cause mortality and cardiovascular disease (CVD) mortality/morbidity
in MHO individuals only. The analysis of 67 cross-sectional studies showed that MHO individuals
were more active and less sedentary, and they had a higher level of cardiorespiratory fitness. However,
cardiorespiratory fitness was only measured in 19 studies, and the difference in VO2 peak or VO2 max
was usually not more than 1–2 mL/kg body weight. Only one study—the Aerobics Center Longitudinal
Study—examined the role of cardiorespiratory fitness in the prognosis of all-cause mortality and
cardiovascular disease mortality/morbidity, collecting the data of 43,269 participants. This study
explained the differences in the risk of mortality and morbidity between MHO and MHNW subjects
through the differences found in cardiorespiratory fitness between both groups. The MHO group had
a 30% to 50% lower risk of all-cause mortality, cardiovascular disease, and cancer mortality than the
MUO group; no significant differences were observed between the MHO and MHNW groups [34].
The median follow-up period for mortality was 14.3 years, and it was7.9 years for non-fatal CVD
incidence. In another longitudinal study, Pigłowska et al. [35] demonstrated in 101 men that both fat and
muscle mass components are important predictors of an individual’s metabolic profile. Maintaining
regular, high physical activity levels, and a metabolically healthy status throughout young and middle
adulthood may have a beneficial influence on body composition parameters and may prevent the
age-related decrease of fat-free mass and endothelial dysfunction, defined according to the National
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines. Moreover, in a
six-year-long cohort study of over 200,000 Taiwanese participants, Martinez-Gomez et al. [36] showed
that physical activity can cause a shift in status from MUO to MHO.
4. Myokines, Adipokines, and Adipo-Myokines
The regulation of metabolic health in obese individuals may be mediated by the effects that
an active or inactive/sedentary lifestyle have on individual endocrine and inflammatory responses.
Myokines, adipokines, and particularly the so-called adipo-myokines are at the crosstalk between
muscle and fat tissue. Raschke and Eckel [14], as well as Görgens et al. [37], defined IL-6, TNF-α, visfatin,
myostatin, FSTL1, angiopoietin-like protein 4 (ANGPTL4), and monocyte chemoattractant protein-1
(MCP-1) as adipo-myokines. Today, meteorin-like hormone (Metrnl) [38], glypican-4 (GPC-4) [39],
and irisin [40] need to be added to the list. Although the number is increasing, only a limited number of
cytokines and chemokines were investigated in terms of lifestyle. Main findings are briefly summarized
in Tables 2 and 3. In terms of myokines, many other cytokines seem to be involved in the crosstalk
between skeletal muscle and adipose tissue. In addition to IL-6 and myostatin, IL-15, irisin, and
adiponectin seem to have the decisive role in this “conversation” between adipose tissue and skeletal
muscle influencing metabolic health (modified By Reference [41]). A general overview of the already
more or less known adipo-myokines, myokines, and adipokines is summarized in Tables 2 and 3.
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Table 2. Adipo-myokines, myokines, and adipokines in different tissues, according to References
[13,14,37–48].
Name Effects—Skeletal Muscle Effects—Adipose Tissue
Adipo-Myokines
Interleukin-6 (IL-6)
Induces muscle hypertrophy, glucose uptake,
glycogen breakdown, and lipolysis;
anti-inflammatory effect
Increases lipolysis and free fatty acid (FFA) oxidation





Stimulates glucose uptake and lipid metabolism;
involved in muscle growth




Stimulates muscle growth and glucose uptake,
enhances mitochondrial activity, and exerts
anti-oxidative effect





Increases mitochondrial FFA oxidation and
ameliorates insulin signaling;
anti-inflammatory effect
Increases mitochondria FFA oxidation and browning
in adipocytes; reduces hepatic de novo lipogenesis




Causes an increase in whole-body energy
expenditure; improves glucose tolerance in
obese/diabetic mice





Induces muscle hypertrophy, satellite cell
proliferation, regeneration after muscle damage,
and glucose uptake
Inhibits adipocyte differentiation
Myostatin Inhibits muscle hypertrophy
Inhibits myostatin results in adipocyte lipolysis and
mitochondrial lipid oxidation; accelerates
osteoclast formation





Insulin-responsive myokine involved in the control
of glucose homoeostasis, insulin sensitivity,
and ketogenesis
Thermogenesis and fat browning in brown (BAT)
and white adipose tissue (WAT); increases expression
of mitochondrial uncoupling protein 1 (UCP1) and
other thermogenic genes in response to cold exposure
and β-adrenergic stimulation in both fat depots
Myogenin Transcription factor; involved in muscledevelopment, myogenesis, and repair Unknown




Increases fat oxidation in a 5’ AMP-activated
protein kinase
(AMPK) -dependent fashion





Recruitment of monocytes and T lymphocytes;
impairs insulin signaling Involved in low-grade inflammation
Follistatin-like 1
(FSTL1) Affects glucose metabolism





Increase in FFA Unknown
Adipokines (main effects)
Visfatin Involved in glucose metabolism? Reduced by exercise?
Resistin Unknown Correlates with body fat mass and waistcircumference; may cause endothelial dysfunction
Leptin
Increases muscle mass by increasing myocyte cell
proliferation and reducing the expression of negative
regulators of muscle growth including myostatin,
dystrophin, or atrophy markers muscle
atrophy F-box
(MAFbx) or muscle RING finger 1
(MuRF1); upregulates FNDC5 expression and
enhances irisin-induced myocyte proliferation, as
well as the muscle growth enhancers myogenin and
myonectin; post-exercise decrease
Regulation of energy homeostasis; increases energy
expenditure through the stimulation of sympathetic
nerve activity in BAT




Reduced after training; increased after very intensive
exercise in response to muscle damage; reduced by
chronic exercise
Correlates with body fat mass
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Table 3. Effect of physical activity in human studies (subject age range 18–65 years).
Name Effects of Physical Activity
Adipo-Myokines
IL-6
Plasma concentration of IL-6 increases during muscular exercise. The combination of mode, intensity, and
duration of the exercise determines the magnitude of the exercise-induced increase of plasma IL-6 [42].
IL-6 levels were 13.2-fold increased directly after a 35-km long-distance trail run [49].
Irisin/FNDC5
Controversially discussed:
Two-fold increase of circulating irisin after 10 weeks of endurance training [40] vs. no increase in irisin after 8
weeks of intermittent sprint running or after 21 weeks of combined endurance and strength training [50,51].
Reduction of circulating irisin in response to 12 weeks of combined endurance and strength training [52] vs.
an increase acutely (~1.2-fold) just after acute exercise [52].
IL-15
Controversially discussed:
Strength/resistance training leads to an increase in IL-15 messenger RNA (mRNA) level in skeletal muscles
dominated by type 2 fibers [53,54].
Short bout of endurance exercise also increases levels of IL-15 in lean subjects, as well as in overweight/obese,
subjects [55]. A 2.22-fold increase in serum IL-15 levels following an acute long-distance trail run was also
found by Yarcic et al. [49]
In contrast, neither sprint interval training (SIT) or combined aerobic and resistance training (A + R) altered
IL-15 measured 48 h after exercise in overweight type 2 diabetes (T2D) [56].
BAIBA
Acute aerobic exercise induces a 13% and 20% increase in R-BAIBA and S-BAIBA, respectively [57]. A chronic
elevation of 17% was also observed following 20 weeks (3 days/week) of aerobic exercise in previously
sedentary and healthy subjects [58].
Metrnl
Lack of data in human studies:
Aerobic exercise/swimming (40 min on three non-consecutive days) in temperate (24–25 ◦C), warm
(36.5–37.5 ◦C), and cold (16.5–17.5 ◦C) water leads to an increase after exercise in temperate and warm water
and a significant decrease in cold water in overweight women [59].
LIF
Aerobic exercise and concentric muscle contractions regulate muscular LIF mRNA expression in humans and
lead to an induced expression of LIF in human skeletal muscle [60]. This was also confirmed for resistance
exercise [48,61].
Myostatin
Myostatin mRNA expression was reduced in skeletal muscle after acute and long-term exercise and was even
further downregulated by acute exercise on top of 12-week training in previously sedentary men [62].
15 units of a high-intensity circuit training (HICT) program (3×/week for 5 weeks) with own body weight
induced the drop of myostatin concentration but significantly only among middle-aged women [63].
IL-7 Lack of data in human studies:Cyclists show higher serum levels of IL-7 compared to less active counterparts [64].
Myokines (main effects)
FGF21 Increase in serum FGF21 levels in runners after 2 weeks of training [65] and after an acute session of runningexercise [66].
Myogenin Myogenin increases after eccentric resistance training [67,68].
Myonectin
Controversially discussed:
Aerobic moderate-intensity exercise leads to a significant reduction in the amount of myonectin in older and
younger patients [69]. In contrast, Seldin et al. [44] and Poranjibar et al. [70] found an increase in myonectin
expression in muscle and circulation.
BDNF
Increase in BDNF concentrations after aerobic exercise is associated with the amount of aerobic energy
required by exercise in a dose-dependent manner [71]. High-intensity and high-volume resistance training
lead to elevations in BDNF concentrations [72].
MCP-1 Lack of data in human studies:Low-intensity exercise (walking 10,000 steps/day, 3×/week for 8 weeks) downregulates MCP-1 [73].
FSTL1 Acute sprint interval exercise, as well as acute aerobic exercise, increases FSTL1 [74,75].
ANGPTL4
Controversially discussed:
Increase in the gene expression of ANGPTL4 after 4 and 8 h following muscle contraction stimulated in
myocytes during exercise using electrical pulse stimulus [76] vs. downregulation of ANGPTL4 in the
exercised leg after acute endurance exercise [77].
Adipokines (main effects)
Visfatin
Lack of data in human studies:
Circuit resistance training (3×/week with intensity at 55% of one-repetition maximum) for 8 weeks reduces
levels of visfatin [78].
Resistin
Anaerobic exercise might decrease levels of resistin [79]. Resistance training leads to a decrease in resistin
after 24 and 48 h compared with baseline and a decline in baseline and immediately after levels compared
with pre-training [80].
Leptin Aerobic exercise leads to lower leptin levels in different population groups (prediabetic/diabetic adults;overweight/obese adults; different age and sex) [81–83].
Adiponectin Aerobic exercise leads to an increase of adiponectin levels in different population groups (prediabetic/diabeticadults; overweight/obese individuals) [81,82].
TNF-α
Only highly strenuous, prolonged exercise such as marathon running results in a small increase in the plasma
concentration of TNF-α [42].
The serum level of TNF-α was significantly downregulated after eccentric resistance exercise in non-athletes [54].
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Surprisingly, no investigation in the current literature explicitly investigated the link between the
MHO or MUO phenotypes and myokines. Only one study by Carvalho et al. [84] examining 61 adults
aged 20–45 years was able to show a correlation between myostatin levels and TNF-α, and between
leptin/adiponectin ratio and VO2 peak [84]. In a different investigation, 10 metabolically healthy obese
women had higher cardiorespiratory fitness and lower TNF-α levels than 10 age- and weight-matched
women with metabolic syndrome [85]. However, these investigations were cross-sectional analyses, as
were most other studies that explored adipokines and myokines in this context. In the Copenhagen
Aging and Midlife Biobank, Wedell-Neergaard et al. [86] examined cardiorespiratory fitness levels,
plasma levels of cytokines, and high-sensitivity C-reactive protein in 1293 participants aged 49–52 years.
Fitness was inversely associated with high-sensitivity C-reactive protein, IL-6, and IL-18, and directly
associated with the anti-inflammatory cytokine IL-10, but not associated with TNF-α, interferon gamma,
or IL-1β. In a parallel study, lower fitness levels were associated with both abdominal adiposity and
low-grade inflammation independent of BMI [87].
Lee et al. [88] analyzed the association between the adipokines IL-6, MCP-1, TNF-α, and adipocyte
fatty acid-binding protein (A-FABP) and metabolic health in 456 subjects (303 men and 153 women;
mean age 40.5 years). In a model by Wildman et al. [89], participants were separated into four groups:
metabolically healthy or unhealthy and obese or non-obese. Differences in TNF-α levels and A-FABP
were found between metabolically healthy subjects and MUNW, but no differences were shown in IL-6
and MCP-1 levels. In light of their results, they called for more research to explore these correlations;
unfortunately, neither physical activity/exercise nor cardiorespiratory fitness were taken into account.
Arsenault et al. [90] investigated the effect of exercise training on inflammatory markers in
hypertensive, postmenopausal, metabolically healthy overweight or obese women. The participants
(32.0 ± 5.7 kg/m2; mean age = 57.3 ± 6.6 years) underwent a six-month exercise intervention program
four times per week at 50% VO2 max. The training significantly increased cardiorespiratory fitness,
but no changes were observed for plasma levels of C-reactive protein, IL-6, TNF-α, and adiponectin.
A possible explanation for this could be that participants were considered metabolically healthy per
se, and that body composition was not considered because BMI and waist circumference were used
as parameters. Training intensity may also have been too low. While we can only speculate about
the reasons behind the findings, it does underline how much the chosen methodology and study
population may influence study results.
In an investigation by Gómez-Ambrosi et al. [91], the inflammatory potential of 222 MHO and 222
MUO individuals was compared with that of 255 matched normal-weight individuals. Both groups
showed an increased cardiometabolic risk and no differences in adipokine levels compared with
normal-weight subjects. Consequently, the authors asked for a more precise definition of metabolic
health. This issue is certainly relevant for most studies presented in this article. For instance, an analysis
of sedentary behavior in the English Longitudinal Study of Aging which counted 4931 participants
(mean age 65 years) could not show any differences between the MHO, MUO, and MUNW groups [92].
5. Body Composition and Its Influence on Metabolic Health
The previous paragraphs illustrated that exercise and sport are not just means to increase energy
consumption, but that the associated development of a high amount of muscle mass elicits the release
of myokines, generating an intensive crosstalk between organs. Brown adipose tissue (BAT) and its
influence on health may present an important crossover point between fat and muscle mass. In contrast
to white adipose tissue (WAT), BAT dissipates lipids in the form of “heat” via β-adrenergic stimulations
(e.g., during exercise) or cold exposure. Adipocytes in BAT appear as multilocular cells with small lipid
droplets and have a large number of mitochondria and upregulated mitochondrial uncoupling protein
1 (UCP1), which is embedded in the inner membrane of the mitochondrion and uncouples oxidative
respiration from ATP synthesis. Whereas classical BAT is observed in specific regions of the body such
as the interscapular region and kidney and constitutively sustains its thermogenic activity without any
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external stimuli, the inducible BAT, known as brite (brown in white), beige, or brown-like adipose
tissue, is present within the WAT, and its amount and activity are induced by external stimuli [93].
The adipo-myokine irisin is thought to play a central role in the browning processes. First described
by Boström et al. [40], irisin is secreted mainly in skeletal muscle, especially in the perimysium,
endomysium, and nuclear parts, although adipose tissue, pancreas, sebaceous glands, and cardiac
muscle were identified as secretory tissues [94]. Irisin is secreted into the circulation after transcription
from its FNDC5 gene and proteolytic cleavage at the extracellular surface of cells [40]. This is thought
to be triggered by the peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1α
(PGC-1α) [95]. Exercise stimulates cell signaling pathways that converge on and increase PGC-1α,
a well-known activator of the transcription of mitochondrial transcription factor A (TFAM) and
mitochondrial biogenesis [96]. The relationship between physical activity or exercise and PGC-1α and
its effects on mitochondrial biogenesis and function are not clear [97–99]. There are some studies [51,52]
which investigated the link between PGC-1α with irisin/fibronectin type III domain-containing protein
5 (FNDC5) in muscle in response to acute exercise and showed an increase in muscle FNDC5 messenger
RNA (mRNA), while one study [100] detected a positive association of PGC-1α with FNDC5 in
muscle. According to chronic exercise, only two studies [52,101] showed increased PGC-1α and
FNDC5 mRNA in muscle, while a predominant number of studies [51,102–104] showed no effect of
chronic exercise [97,98]. No intervention explored a possible link with MHO. However, Bonfante
et al. [105] showed that a higher level of FNDC5/irisin in 20 obese men was associated with better
triglyceride levels (p = 0.01), lower insulin resistance, risk of type 2 diabetes development, and the
tendency to lower serum resistin. Exploring mitochondrial health in this context would exceed the
scope of this analysis, and research about metabolic health and sport is sparse. However, a study
with 60 participants [106] indicated that MHNW subjects have the most favorable metabolic profiles,
while MHO subjects show small alterations, and abnormal diabetic obese individuals have the most
unfavorable metabolic profiles [106].
6. Early-Life Programming and the Influence of Different Adipokines, Myokines,
and Adipo-Myokines
Today, it is undisputed that early childhood influences metabolic health (see Figure 1). For instance,
in the Generation R Study, a population-based prospective cohort investigation among 4871 mothers,
fathers, and their children, Gaillard et al. [107] examined the associations of both maternal and paternal
pre-pregnancy BMI with childhood body fat distribution and cardiometabolic outcomes six years after
birth. Children from obese mothers had a nearly four-fold increased risk of childhood overweight and
clustering of cardiometabolic risk factors (odds ratio, 3.00) compared with children from normal-weight
women. Furthermore, higher parental pre-pregnancy BMI was associated with higher childhood BMI,
total body and abdominal fat mass, systolic blood pressure, and insulin levels, and lower HDL levels.
Cytokines seem to have a central part in this association. In 2016, we published the so-called
adipokine–myokine–hepatokine compartment model [108]. Based on the knowledge at the time,
the interrelations between skeletal muscle mass, adipose tissue, and maternal liver, and the questionable
role of the placenta were investigated in terms of their influence on metabolic regulation in children and
how they may be affected by exercise [108]. Knowledge about cytokine and hormone production and
secretion of a specific organ is broad, yet little is known about the complex interplay of cytokines, especially
with regard to their activities at rest and during different types of physical stress, and how this might
affect metabolic health. Below, we explore different biomarkers that are known to be affected by exercise
and physical activity during pregnancy, including leptin, brain-derived neurotrophic factor (BDNF),
IL-6, irisin, and myostatin. While most studies examined the effect of exercise on those markers, only a
few focused on associations taking cardiorespiratory fitness levels or body composition into account.
In a comparative study, we analyzed the long-term effects of an exercise program during pregnancy
on metabolism, weight gain, body composition, and changes in leptin and BDNF [109]. Human and
animal models were synchronized according to study design, age, and serum parameters. Regular
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physical activity led to a 6% lower fat mass, 40% lower leptin levels, and an increase of 50% BDNF
levels in humans compared with controls, which was not observed in mice. However, with regard to
long-term effects, the offspring of exercising mouse dams had significantly lower fat mass and leptin
levels than controls. Furthermore, serum BDNF levels were elevated three-fold in the exercise offspring
group compared with control [109]. In summary, this shows that lifestyle factors, especially regular
physical activity, can shape the metabolic profile of children in the long term.
Because leptin seems to have far-reaching influences in early childhood, this biomarker is discussed
in a little bit more detail. According to Vicker et al. [110], leptin is posited to exert programming
effects on central and peripheral energy-regulating pathways during a critical period of fetal and infant
development. Accordingly, several researchers [111,112] investigated leptin as a candidate prognostic
biomarker for obesity risk in later life. It was documented that umbilical cord blood leptin levels
are positively correlated with neonatal body weight and fat mass [113]. Moreover, there is evidence
that maternal serum concentration of leptin correlates with pre-pregnancy BMI, weight gain during
pregnancy, and cord leptin levels [114].
In a follow-up of a cross-sectional study with 76 mother–child pairs, our research group [111]
examined the effects of maternal anthropometric, sociodemographic, and lifestyle factors on maternal
and cord-blood leptin levels at birth, and on the development of BMI standard deviation scores (SDS)
in offspring up to one year of age. We demonstrated that higher maternal and lower cord-blood leptin
levels are associated with a higher BMI SDS increase during the first year of life. Maternal leptin is
influenced by maternal BMI and weight gain during pregnancy, and cord-blood leptin is influenced by
maternal physical activity [111]. These results are in line with findings by Simpson et al. [115], who found
that higher cord-blood leptin was associated with higher z-scores of fat mass, waist circumference, and BMI
at nine years of age, although they did not take lifestyle factors such as physical activity into account.
The abovementioned myokine BDNF is necessary for placental development, fetal growth,
glucose metabolism, and energy homeostasis. It has functions in cognition and neuroplasticity in
the hypothalamus and has an influence on appetite regulation and insulin sensitivity in peripheral
tissues. Although it is still unknown where exactly BDNF is produced peripherally, BDNF levels in
the brain seem to correlate with serum BDNF concentrations [116]. BDNF crosses the blood–brain
barrier in a bidirectional manner [117]. Lommatzsch et al. [118] suggested that blood levels of BDNF
may reflect brain levels and vice versa. Moreover, we demonstrated in a previous human study
that umbilical-cord BDNF is correlated with maternal BDNF levels [119]. In human studies, there
is no evidence to date as to how changes in the mother’s BDNF values have a long-term effect on
the metabolic pattern in the offspring. Camargos et al. [120] evaluated adipokines, cortisol, BDNF,
and redox status in 25 overweight/obese infants versus 25 normal-weight peers between six and
24 months of age. Overweight or obese infants presented higher levels of leptin, adiponectin, BDNF,
and cortisol and lower levels of thiobarbituric acid-reactive substances (TBARS), as well as catalase and
superoxide dismutase activity, than their normal-weight peers. The authors stated that these results
indicate neuroendocrine inflammatory response changes in overweight/obese infants. Regarding the
effects of physical activity on BDNF levels in children, Walsh et al. [121] examined the associations
between changes in diabetes risk factors and changes in BDNF levels after six months of exercise
training (aerobic and/or resistance training) in 202 14–18-year-old adolescents with obesity. In this
study, exercise-induced reductions in some diabetes risk factors (most notably fasting glucose and beta
cell insulin secretory capacity) were associated with increases in BDNF in adolescents with obesity.
The authors suggested that exercise training may be an effective strategy to promote metabolic health
and increase BDNF. These findings are in line with the results of Mora-Gonzalez et al. [122]; evaluating
the effect of physical activity on BDNF levels in 97 overweight or obese children aged eight to 11 years,
they found that physical activity was positively correlated with BDNF levels. Although there is
currently no evidence about the long-term effects of physical activity during pregnancy on BDNF
levels in children, based on the presented results and animal experimental data [123,124], it can be
postulated that the metabolic and neurodevelopment profile of children can be shaped in some way.
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IL-6 appears to be another important biomarker in early childhood. Our cooperating working
group [125] aimed to identify molecular mechanisms of cytokines in the offspring who are affected by
maternal exercise during pregnancy. The authors found an almost four-fold increase in serum IL-6
with a clear activation of Janus kinase/signal transducer and activator of transcription signaling in
the WAT and hypothalamus of obese offspring, which was completely blunted by maternal exercise
during pregnancy. The altered hypothalamic global gene expression in obese offspring showed partial
normalization in the obese running offspring group, especially with respect to IL-6 action [125].
In a human-based study of 124 children aged 10.0 ± 0.9 years, Hosick et al. [126] compared
markers of inflammation (IL-6, TNF-α) between normal-weight youth of high or low aerobic fitness
to obese youth of high or low fitness. They found that higher levels of VO2 max are associated with
lower levels of IL-6, independent of obesity.
Furthermore, irisin may play a crucial role in the interplay between adipokines and myokines
during early childhood. It is known that the level of irisin in pregnant women is higher than that
of non-pregnant women. Irisin may also contribute to the physiological insulin resistance found in
pregnancy [127] and it has an important role in controlling maternal and fetal glucose homeostasis.
Low irisin cord-blood levels are associated with newborn growth delay [128] and low proportions of
brown fat tissue. Ökdemir et al. [129] aimed to investigate the relationships between irisin, insulin,
and leptin levels and maternal weight gain, as well as anthropometric measurements in the newborn.
Eighty-four mothers with a mean age of 29.8 ± 5.2 years and their newborns were enrolled in the
study. The authors found a negative correlation between the anthropometric measurements of the
“appropriate for gestational age” newborns and irisin levels. This correlation was not observed in
“small for gestational age” and “large for gestational age” babies. To our knowledge, there are no
studies that examined the associations between irisin levels in pregnancy and the development of
children in later life. In addition, the association between physical activity during pregnancy and irisin
concentrations in the offspring remains to be investigated. Irisin recently became a focus of research in
the field of pediatric obesity, because it might play an important pathophysiological role in metabolic
dysfunctions and its complications. The positive correlations between leptin levels and anthropometric
and metabolic parameters in children with obesity and metabolic syndrome are well known [130,131].
In a cross-sample of 126 Mexican children aged 6–12 years, Gonzales-Gil et al. [132] characterized the
association between irisin and adipokines, as well as the cardiometabolic risk factors and anthropometric
parameters in children with obesity or metabolic syndrome and in normal-weight children.
They demonstrated that irisin plasma levels were negatively correlated with leptin levels.
Furthermore, irisin levels were significantly lower in the obese and metabolic syndrome groups than
in the normal-weight group. Stepwise multiple linear regression analysis was conducted to determine
whether body composition (lean-fat ratio), metabolic parameters (triglyceride, HDL, and glucose levels),
and physical activity in hours per week influenced irisin levels. The lean–fat ratio was found to be the only
significant determinant of irisin levels with the model explaining 22.7% of the variance in irisin levels.
Myostatin is secreted during embryonic development, and its function is to limit muscle growth
physiologically during development [41]. In the human placenta, the expression of myostatin is
negatively correlated with gestational age, and, in placental explants, myostatin acts to facilitate glucose
uptake [133]. Myostatin expression is known to be higher in the placenta of pregnancies complicated by
preeclampsia [133]. Moreover, Peiris et al. [134] found complications in myostatin protein expression
in human placenta from women with gestational diabetes mellitus compared with normal glucose
tolerant pregnancies. Compared with lean women, the placentas of obese normal glucose-tolerant
women were lower in myostatin dimer expression [134]. The authors concluded that myostatin
expression in placental tissue is altered under stress conditions (e.g., obesity and abnormal glucose
metabolism) found in pregnancies complicated by gestational diabetes mellitus. In a longitudinal study
with 125 infants, De Zegher et al. [135] tested whether large-born infants from non-diabetic mothers
develop an early surplus of lean mass while having a lower myostatinemia. They confirmed that
breast-fed large-for-gestational-age infants from non-diabetic mothers developed a marked surplus of
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lean mass at four months of age while maintaining low levels of circulating myostatin. The authors
concluded that the fetal–neonatal control of myostatinemia deserves further attention, because it might
become a target of interventions aiming to reduce the risk for diabetes in later life by augmenting
myogenesis in early life [135]. No studies were conducted to date to investigate the effect of regular
physical activity during pregnancy on myostatin in both mother and child. Based on the results of
Peiris et al. [134], it might be postulated that placental myostatin could affect glucose homoeostasis
and/or cytokine production, which in turn might be influenced by exercise.
7. Discussion
In addition to obesity, physical inactivity/sedentary behavior is a global health problem,
and recent data indicate that approximately one-third of the world’s adult population is physically
inactive. This means that these individuals do not perform the minimum of 150 min per week of
moderate-to-vigorous aerobic physical activity recommended by the WHO [27,136]. Importantly,
physical inactivity is directly related to higher risk rates for the majority of NCDs. The purpose of
this review was to illustrate the association between exercise/physical activity or cardiorespiratory
fitness and metabolic health with regard to myokines, adipokines, and adipo-myokines, as well as the
influence of early-life factors. Although further research is needed to specifically recommend the type of
exercise to be used, as well as corresponding duration, volume, and intensity that would be required to
elicit the desired effects, the benefit of exercise in the context of obesity and NCDs remains undisputed.
It seems critical that an (exercise) stimulus needs to pass a certain threshold level to be effective [99],
but this assumption may be based on a methodological problem. For instance, blood parameters might
need to reach a certain level to detect significant differences, although this does not necessarily imply a
treatment effect. From a public health perspective, it seems most important to simply “get started”,
especially because people with a low fitness level will see the greatest health benefits from taking up
exercise, particularly in the beginning [10,137]. Regularly performing moderate-to-vigorous intensity,
endurance-based activities, for example, walking, jogging, or cycling, leads to an increase of ~10% in
“fitness” in different populations (e.g., those who are healthy or obese, or who have coronary artery
disease or diabetes) or different obesity phenotypes (e.g., MUO, MHO), which highlights how the
majority of adults can acquire clinically important gains in cardiorespiratory fitness. It may not be possible
to find an answer as to what is the “right” type of exercise because of the great complexity of the topic.
Myokines, for example, were studied for 20 years; many new mechanisms were discovered, some of which
we tried to cover in this paper, yet the analysis shows just how many questions are still left unanswered.
There are several limitations to our article. This is a narrative review in which we attempted
to explore the interrelations between exercise and, in particular, cardiorespiratory fitness, metabolic
health, and obesity, taking into consideration underlying mechanisms and developments in early
childhood. We did not perform a systematic literature review about the influence of different
types of exercise or training methods. It should be taken into account that the presented results,
for example, irisin/FNDC5, may be affected by different subjects’ age, conditioning status, and exercise
intensity [97,98]. Moreover, different analytical measurements might lead to different results, which
were not taken into account. Studies that were included were mostly performed with adult participants.
We focused on human interventions and only integrated animal studies to elucidate a specific aspect
in more detail. The analysis of adipokines, myokines, and adipo-myokines mentioned herein does
not claim to be exhaustive. For instance, epigenetic aspects and/or the role of hepatokines were
not taken into consideration. The demand for one uniform definition of metabolically healthy or
unhealthy obese individuals (MHO/MUO), or even of metabolic health itself, reflects the difficulties
and basic issues involved in this topic and highlights the need for a general consensus. This consensus
should consider cardiorespiratory or muscular fitness and should subsequently be tested in future
investigations. Equally, interventions should be designed in a manner that allows for an appropriate
comparison to make final assumptions. It can only be speculated as to what extent novel techniques
such as the secretomic technique can help unravel the underlying mechanisms and their complex
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interrelations. Mitochondrial biogenesis seems to be one of the central aspects in this issue. Already
in 1967, it was shown that physical activity leads to an increased number and improved function
of mitochondria [138]; over 50 years later, this issue seems to be more relevant than ever before in
light of the rising prevalence of obesity and the adverse changes in body composition toward an
unfavorable ratio of fat to muscle mass. As such, there is now an increased focus on sarcopenia, which
is usually mentioned in the context of aging and chronic disease [139]. In light of the imminent cost
explosion that is to be expected due to the far-reaching consequences of these health issues, it is crucial
to understand which patient groups require more or less intensive treatment concepts and prevention.
From a practical point of view, it seems sensible to choose an approach that first and foremost focuses
on individual tendencies and individual health status to get and keep people physically active. Finally,
a political dimension is added to this discussion. Especially in terms of epigenetic aspects, it is crucial to
create active living spaces to provide the groundwork for healthy aging. Findings from basic scientific
research can help explain and clarify theses connections and their meanings, and facilitate resolving
them on a political level.
8. Conclusions
At present, a great body of research on metabolic health and different phenotypes of obesity
(MHO/MONW/MUO) exists. However, several questions remain unanswered. Despite the knowledge that
different “obesities” exist, no refined metabolic health definition was developed. A better understanding
of both the (early-life) lifestyle factors and the underlying mechanisms that mediate different phenotypes
is necessary in terms of the tailored prevention and personalized treatment of obesity.
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Abbreviations
WHO World Health Organization
NCDs Non-Communicable Diseases
BMI Body Mass Index
MONW Metabolically Obese, Normal Weight
MUO Metabolically Unhealth Obese




NHANES National Health and Nutrition Examination Survey
CVD Cardiovascular Disease
NCEP APT III National Cholesterol Education Program Adult Treatment Panel III
FSTL 1 Follistatin-like 1
ANGPTL4 Angiopoietin-like protein 4
MCP-1 Monocyte Chemoattractant Protein-1
Metrnl Meteorin-like hormone
GPC-4 Glypican-4
TNF-α Tumor Necrosis Factor alpha
A-FABP Adipocyte Fatty Acid-Binding Protein
BAT Brown Adipose Tissue
WAT White Adipose Tissue
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UCP1 Uncoupling protein 1
FNDC5 Fibronectin type III domain-containing protein 5
PPAR gamma Peroxisome proliferator-activated receptor gamma
PGC-1 alpha Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha
TFAM Mitochondrial Transcription Factor A
BDNF Brain-Derived Neurotrophic Factor
SDS Standard Deviation Scores
TBARS Thiobarbituric Acid-Reactive Substances
Jak Janus kinase
STAT Signal Transducer and Activator of Transcription
FFA Free Fatty Acid
MuRF1 muscle RING finger 1
MAFbx muscle atrophy F-box
AMPK 5′ AMP-activated protein kinase
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Abstract: Among the new adipokines, secreted frizzled-related protein 5 (SFRP5) is considered to
prevent obesity and insulin resistance. The umbilical cord SFRP5 levels have not yet been investigated.
The main aim of the study was to investigate whether the umbilical cord SFRP5 concentrations are
altered in term neonates born to mothers with excessive gestational weight gain (EGWG). Two
groups of subjects were selected depending on their gestational weight gain, i.e., 28 controls and
38 patients with EGWG. Umbilical cord and maternal serum SFRP5 levels were lower in the EGWG
group. Umbilical cord SFRP5 concentrations were directly associated with the maternal serum
SFRP5, hemoglobin A1c and lean tissue index, umbilical cord leptin levels, as well as newborns’
anthropometric measurements in the EGWG subjects. In multiple linear regression models performed
in all the study participants, umbilical cord SFRP5 concentrations depended positively on the
maternal serum SFRP5, ghrelin, and leptin levels and negatively on the umbilical cord ghrelin
levels, low-density lipoprotein cholesterol, pre-pregnancy body mass index, and gestational weight
gain. EGWG is associated with disturbances in SFRP5 concentrations. Obstetricians and midwives
should pay attention to nutrition and weight management during pregnancy.
Keywords: adipokines; secreted frizzled-related protein 5; leptin; ghrelin; excessive gestational
weight gain; neonatal anthropometry; obesity
1. Introduction
As a novel adipokine mainly secreted from the adipose tissue, secreted frizzled-related protein
5 (SFRP5) contains a cysteine rich domain as well as a netrin-like function domain, and it plays a
regulatory role in the wingless-type Mouse Mammary Tumor Virus (MMTV) integration site family
member (Wnt) signaling pathways [1–3]. Preliminary clinical and basic research reveals that the
biologic function of SFRP5 may be similar to adiponectin, which exerts an anti-inflammatory effect
in the metabolic homeostasis [1,2]. SFRP5 has been reported to be implicated in obesity, insulin
resistance, dyslipidemia, and metabolic syndromes [4–10]. Circulating concentrations of SFRP5 have
been measured in healthy and diseased individuals in several studies, but there are still limited data
concerning SFRP5 in obstetric aspects [3,11–14].
As far as we know, there is no reported study investigating the SFRP5 concentrations in the
human umbilical cord blood. We hypothesized that SFRP5 concentrations would probably be impaired
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in the umbilical cord of full-term neonates born to excessive gestational weight gain (EGWG) mothers.
The aim of this study was also to investigate whether the umbilical cord SFRP5 levels correlate with
selected maternal parameters and neonatal anthropometric measurements.
2. Results
Compared with the healthy study participants, the EGWG mothers had comparable age and
pre-pregnancy BMIs, but they presented significantly higher BMIs at and after delivery. The EGWG
women were also characterized by increased levels of hemoglobin A1c (HgbA1c), triglycerides and
indexes of fat (FTI) and lean (LTI) tissues as well as lower concentrations of high-density lipoprotein
cholesterol (HDL). The maternal SFRP5 levels were decreased in the serum in the EGWG group. Lower
SFRP5 concentrations as well as higher ghrelin and leptin levels were observed in the umbilical cord
blood of neonates born to the EGWG mothers. No significant differences were noticed between the
groups with regard to other analyzed parameters, including the maternal serum ghrelin and leptin
levels as well as neonatal anthropometric measurements (Table 1).
Table 1. Comparison of characteristics of the study subjects.
Variables Control Group (n = 28) EGWG Group (n = 38) p
Maternal characteristics
age, years 29 (24–38) 29 (28–32) NS
pre-pregnancy BMI, kg/m2 20.3 (19.5–24.4) 23.2 (21.6–24.09) NS
gestational weight gain, kg 15 (11.5–15.6) 23.9 (21–26) <0.001
gestational BMI gain, kg/m2 5.4 (3.0–5.6) 8.4 (7.07–9.4) <0.001
BMI at delivery, kg/m2 26.3 (24.2–29.1) 31.3 (29.7–32.05) <0.001
cesarean delivery, % 14 26 NS
BMI after delivery, kg/m2 22 (21–23.9) 28.6 (26.2–29.7) <0.001
FTI after delivery, kg/m2 10.1 (9.1–13.8) 14.7 (13.2–17.2) <0.001
LTI after delivery, kg/m2 10.1. (9.4–13.1) 12.9 (11.2–13.9) <0.01
Maternal Serum
albumin, g/dL 3.68 (3.43–3.73) 3.55 (3.41–3.81) NS
total cholesterol, mg/dL 249 (188–287) 225 (197–249) NS
HDL, mg/dL 78 (75–82) 71 (59–79) <0.05
LDL, mg/dL 129 (93–152) 106 (87–128) NS
triglycerides, mg/dL 177 (150–254) 204 (178–258) <0.05
HgbA1c, % 5.3 (4.6–5.4) 5.5 (5.0–5.5) <0.05
SFRP5, ng/mL 3.1 (2.62–8.0) 2.47 (1.2–5.0) <0.05
ghrelin, ng/mL 0.933 (0.646–1.115) 1.187 (0.343–2.433) NS
leptin, ng/mL 10.43 (6.04–14.9) 14.87 (12.6–47.6) NS
Umbilical Cord Blood
SFRP5, ng/mL 5.08 (3.74–5.69) 3.33 (2.3–4.25) <0.01
ghrelin, ng/mL 0.0195 (0.187−0.282) 0.525 (0.265–1.826) <0.001
leptin, ng/mL 7.53 (4.9–14.01) 10.99 (8.5–13.4) <0.001
Neonatal Anthropometric Measurements
birth weight, g 3630 (3200–3920) 3520 (3400–3650) NS
birth body length, cm 56 (55–57) 55 (54–56) NS
head circumference, cm 34 (33–35) 34 (33–35) NS
chest circumference, cm 34 (34–35) 34 (33–35) NS
The results are shown as the median (interquartile range: 25–75%). Statistically significant values are given in bold.
BMI—body mass index; EGWG—excessive gestational weight gain; FTI—fat tissue index; HDL—high-density
lipoprotein cholesterol; HgbA1c—hemoglobin A1c; LDL—low-density lipoprotein cholesterol; LTI—lean tissue
index; SFRP5—secreted frizzled-related protein 5.
In the control group, the umbilical cord SFRP5 concentrations correlated positively with the
maternal serum HgbA1c, SFRP5, ghrelin and leptin levels, and the neonatal chest circumference.
We found negative correlations between the umbilical cord SFRP5 and BMIs (pre-pregnancy, at and
after delivery), total cholesterol, and umbilical cord ghrelin levels in the control subjects (Table 2).
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Table 2. Correlation coefficient between the umbilical cord SFRP5 levels and clinical parameters in the
control and EGWG groups.
Variables
Umbilical Cord SFRP5
Control Group EGWG Group
Maternal Characteristics
pre-pregnancy BMI −0.829 *** 0.152
gestational weight gain 0.371 −0.435 *
gestational BMI gain 0.143 −0.442 *
BMI at delivery −0.6 ** −0.105
BMI after delivery −0.486 * 0.074
FTI after delivery 0.086 −0.342
LTI after delivery −0.086 0.527 **
Maternal Serum
albumin −0.143 −0.603 **
total cholesterol −0.406 * −0.436 *
HDL 0.058 −0.567 **
LDL −0.371 −0.087
triglycerides −0.058 −0.081
HgbA1c 0.667 *** 0.636 ***
SFRP5 0.429 * 0.452 *
ghrelin 0.771 *** −0.394
leptin 0.6 ** −0.171
Umbilical Cord Blood
ghrelin −0.657 *** −0.817 ***
leptin −0.086 0.495 *
Neonatal Anthropometric Measurements
birth weight −0.2 0.781 ***
birth body length −0.309 0.739 ***
head circumference −0.206 0.532 **
chest circumference 0.494 * 0.516 **
Statistically significant values are given in the bold type. * p < 0.05; ** p < 0.01; *** p < 0.001. BMI—body mass
index; EGWG—excessive gestational weight gain; FTI—fat tissue index; HDL—high-density lipoprotein cholesterol;
HgbA1c—hemoglobin A1c; LDL—low-density lipoprotein cholesterol; LTI—lean tissue index; SFRP5—secreted
frizzled-related protein 5.
In the EGWG group, we observed a direct correlation between the umbilical cord SFRP5 and
the maternal serum HgbA1c, SFRP5 and LTI after delivery, the umbilical cord leptin levels, and all
four newborns’ anthropometric measurements (i.e., with neonatal birth weight, birth body length,
and head and chest circumference). Negative correlations were revealed between the umbilical cord
SFRP5 concentrations and gestational weight and BMI gains, albumin, total cholesterol, HDL, and the
umbilical cord ghrelin levels in the EGWG subjects (Table 2).
In multiple linear regression models performed in all the study participants, after adjustment
for the maternal serum SFRP5 levels, the serum and umbilical cord ghrelin and leptin levels,
maternal low-density lipoprotein cholesterol (LDL), triglycerides, HgbA1c, gestational weight gain,
pre-pregnancy BMI, BMI at delivery and gestational BMI gain, we noted that the umbilical cord SFRP5
concentrations were positively dependent on the maternal serum SFRP5, ghrelin and leptin levels
as well as negatively dependent on the umbilical cord ghrelin levels, LDL, pre-pregnancy BMI and
gestational weight gain (Table 3).
The Benjamini–Hochberg correction for false positive results revealed that all of the originally
significant associations were still significant.
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Table 3. Multiple linear regression analyses for the umbilical cord SFRP5 levels.
Independent Variable B β 95% CI p
maternal serum SFRP5 0.33 0.50 0.32–0.69 <0.001
maternal serum ghrelin 0.12 0.39 0.19−0.59 <0.001
umbilical cord ghrelin −0.26 −0.79 −0.99–(−0.59) <0.001
maternal serum leptin 0.06 0.72 0.52–0.92 <0.001
maternal LDL −0.01 −0.23 −0.38–(−0.07) <0.01
pre-pregnancy BMI −0.12 −0.27 −0.47–(−0.06) <0.05
gestational weight gain −0.08 −0.29 −0.48–(−0.11) <0.01
Adjusted for the serum SFRP5 levels, the serum and umbilical cord ghrelin and leptin levels, maternal LDL,
triglycerides, HgbA1c, gestational weight gain, pre-pregnancy BMI, BMI at delivery and gestational BMI gain.
Unstandardized β coefficients with 95% confidence interval and B linear regression coefficients are shown.
Statistically significant values are given in the bold type. BMI—body mass index; LDL—low-density lipoprotein
cholesterol; SFRP5—secreted frizzled-related protein 5.
3. Discussion
We decided to choose EGWG and not pre-pregnant obese women, as EGWG is mainly linked to
overnutrition during a relatively short period of time (with regard to life expectancy), i.e. within the
last nine months. Gestational weight guidelines of the Institute of Medicine (IOM) [15] provide ranges
of recommended weight gain for specific pre-pregnancy body mass index (BMI) categories in relation
to the least risk of adverse perinatal outcomes. It is recommended that in order to prevent adverse
maternal as well as infant outcomes, women with normal weight at the time of conception should limit
their total weight gain in pregnancy to 11.5–16 kg, overweight women to 7–11.5 kg, and obese women
to 5–9 kg [15]. Goldstein et al. revealed in a systematic review of 23 cohort studies in 1.3 million women
that 47% of women exceeded the upper limit of IOM-recommended weight gain [16]. EGWG, which is
usually due to improper nutrition during the pregnancy period, has been regarded as a potentially
modifiable, independent risk factor not only for the development of maternal overweight and obesity
but childhood adiposity as well [17,18]. EGWG may expose the developing fetus to persistently raised
concentrations of glucose, insulin, amino acids, and lipids as well as imbalance between pro- and
anti-inflammatory adipokines derived from maternal adipose tissue [19,20].
SFRP5 is an anti-inflammatory adipokine that regulates metabolic homeostasis [5,21]. The classical
molecular mechanism of SFRP5 is designated to inhibit the combination of Wnt protein with its cell
membrane receptors (frizzled protein) and block the downstream Wnt signaling pathways through
binding with the extracellular Wnt-5a or Wnt-3a [2,22,23]. Sfrp5 knockout mice fed a high fat diet
developed adipose macrophage infiltration, severe glucose intolerance, and hepatic steatosis [1,2,24].
SFRP5 is an inhibitor of Wnt signaling, the crucial signaling pathway in the placental vascular
development. Placental angiogenesis is a pivotal process that establishes feto-maternal circulation,
ensures efficient materno-fetal exchanges and contributes to the overall development of the placenta
throughout pregnancy. Any failure in these processes will definitely result in the development of many
gestational complications such as preeclampsia, GDM, and intrauterine growth restriction [25–27].
Nevertheless, there are limited data concerning SFRP5 in the obstetric aspects. A previous study
demonstrated that first trimester serum SFRP5 levels were significantly lower in the pregnant women
who subsequently developed GDM in comparison to the healthy pregnant women [3]. Based on
the mechanism that SFRP5 is an inhibitor of the Wnt signaling pathway, which is implicated in the
regulation of insulin resistance, inflammation, and placental vasculature, it was suggested that altered
levels of SFRP5 may contribute to the development of GDM [3,28,29].
It is worth highlighting that some of the previous studies evaluating the levels of various
adipokines in the umbilical cord blood did not take into consideration the maternal BMI and weight
gain during pregnancy [30–33]. Our study comprised both participants with normal pre-pregnancy
BMI and different gestational weight gain; i.e. an excessive increase in body weight during pregnancy
in the EGWG group and an appropriate gestational weight gain in the control group and their offspring.
Our results revealed differences at the periparturient period not only in the gestational weight and
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BMI gains between these two groups of mothers but in the laboratory results as well. Lower levels of
HDL as well as higher HgbA1c and triglycerides concentrations were present in the EGWG group. It
seems that in many ways the pregnancies of women with EGWG resemble pregnancies complicated by
gestational diabetes mellitus (GDM). What is important in this context is that the women with a history
of GDM exhibit altered risk factors of cardiovascular diseases, including lower HDL concentrations,
when compared with mothers with healthy pregnancies [34–36].
Nonetheless, the offspring of our control and EGWG groups had comparable anthropometric
measurements, including birth weight. However, in light of the previous studies, the fetal metabolic
programming may occur within normal birth weight ranges [37,38]. Lawrence et al. [39] reported
a potential role of genetics for the existing association between the maternal weight gain during
pregnancy and offspring BMI change. The association between the gestational weight gain and
offspring BMI change attenuated by 28% when a genetic score was added, but the offspring’s genetic
variation did not play a role in the association. The authors speculate that epigenetics may underlie this
finding [40]. DNA microarray analyses on the placental junctional zones performed by Gao et al. [13]
revealed that the Sfrp5 expression was decreased in the rats fed a low protein diet, which may activate
non-canonical Wnt signaling. Christodoulides et al. [41] reported that Sfrp5 mediated epigenetic
silencing of the Wnt signaling pathway in the white adipose tissue could lead to an increased
adipogenesis with a significant likelihood of increasing susceptibility to diet-induced obesity in the
mice models. In addition, SFRP5 has been demonstrated to inhibit the activation of c-JunN-terminal
kinase (JNK) downstream of the Wnt signaling pathway [1,5,42].
To the best of our knowledge, this study is the first report evaluating the umbilical cord SFRP5
in the offspring of healthy mothers as well as of women with excessive gestational weight gain. We
also investigated associations between its levels in the umbilical cord and in the maternal serum. Our
study revealed that the umbilical cord SFRP5 levels were lower in the offspring of the EGWG mothers.
However, what is also extremely important is that the studied mothers with EGWG, when compared
with the healthy controls, presented lower SFRP5 concentrations in the serum. The umbilical cord
SFRP5 levels were positively associated with the maternal serum SFRP5 levels in both groups. Apart
from this, we performed multiple linear analyses that revealed the dependence of the umbilical cord
SFRP5 concentrations on its levels in the maternal serum. Each 1 ng/mL decrease in the maternal serum
SFRP5 concentration was associated with a decrease in the umbilical cord SFRP5 level by 0.33 ng/mL.
The study of Prats-Puig et al. [43] reported concomitantly decreased concentrations of SFRP5 in
obesity markers of prepubertal children. The cited authors found that lower serum SFRP5 potentiated
the association between Wnt-5A and insulin resistance. Previous studies showed that circulating
SFRP5 was decreased in patients with impaired glucose tolerance or T2DM and was associated with
various obesity-related metabolic parameters [8,9,43]. SFRP5 sequesters Wnt-5A, thereby attenuating
the activation of c-Jun N-terminal kinase 1 [43–45]. Prats-Puig et al. [43] concluded that SFRP5 may
be an anti-inflammatory adipokine that could be negatively regulated during obesity development,
leading to a less-favorable metabolic phenotype. Their results also suggested that a failure to upregulate
SFRP5 in obesity may lead to unrestrained pro-inflammatory actions of Wnt-5A, resulting in metabolic
dysfunction [1,43,46].
The expression of Sfrp5 is slowly induced in the process of differentiation of white and brown
adipocytes and increased in mature adipocytes [47]. Lower SFRP5 levels have been detected in obese
subjects in contrast with lean subjects in studies analyzing correlations between SFRP5 and adiposity
indicators such as BMI, waist–hip ratio, body fat percentage, and lipid profile [9]. In our study, a
positive correlation was found between the umbilical cord serum SFRP5 concentrations and maternal
LTI, but only in the EGWG group. LTI, which is defined as the lean tissue mass divided by the square
of the body height, expresses the muscle mass [48]. Mori et al. [49] revealed that SFRP5 promotes
adipocyte growth by repressing Wnt signaling and decreasing oxidative metabolism as an endogenous
suppressor of adipogenesis. Rulifson et al. [50] and Van Camp et al. [51] found that a significant
increase in Sfrp5 expression was observed amongst adipose tissues in obese mice and that genetic
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variation in Sfrp5 could determine the distribution and volume of both subcutaneous and abdominal
fat in obese males, respectively.
As far as progressive metabolic complications are concerned, it should be pointed out that
SFRP5 levels decreased with age in the prepubertal children [43]. On the other hand, increased leptin
concentrations during puberty were found to be a reliable indicator of insulin resistance associated
with increasing age [52]. Thus, the possibility that reduced SFRP5 levels may contribute to the state of
insulin resistance associated with increasing age and pubertal development cannot be excluded [43,53].
In this study, we evaluated the concentrations of leptin and ghrelin, which were higher in the
umbilical cord blood of EGWG patients than in the control subjects. However, concentrations of the
maternal serum ghrelin and leptin were similar in both studied groups. The previous results suggested
that ghrelin may play a role in the fetal adaptation to intrauterine malnutrition [54]. Moreover, it
is interesting to point out a negative correlation between SFRP5 and ghrelin concentrations in the
umbilical cord of both the control and EGWG newborns. What is more, we were also able to find a
positive association between the umbilical cord SFRP5 and leptin levels but only in the EGWG group.
We observed that the SFRP5 umbilical cord levels were associated with the maternal BMI
values. We found out that the umbilical cord SFRP5 negatively correlated with the maternal BMIs
(pre-pregnancy, at and after delivery) in the control subjects as well as with the gestational weight and
BMI gains in the EGWG group. Besides, multiple linear regression models performed in all the study
participants revealed that the umbilical cord SFRP5 concentrations were negatively dependent on the
pre-pregnancy BMI and gestational weight gain. It is noteworthy that every 1 kg of gestational weight
gain was linked to a decrease in the umbilical cord SFRP5 concentration by 0.08 ng/mL. Similarly, we
made an observation that the umbilical cord SFRP5 levels correlated with the maternal concentrations
of total cholesterol and HgbA1c and were negatively dependent on LDL. These results seem to confirm
the impact of maternal weight and metabolic imbalance on SFRP5 in newborns. We cannot relate our
results to the previous ones because no such results are available. However, a comparison with the
observations made in non-pregnant humans concerning the serum SFRP5 levels negatively associated
with BMI values [3,8,9] as well as with insulin resistance and lipid profile [5,9,28] might confirm the
existence of a feto-maternal unit and fetal dependence on the maternal nourishment status.
Our study methodology relied on an accurate selection of the study subjects. We decided
to choose EGWG and not pre-pregnant obese women. In the case of pre-pregnancy obesity the
analysis of the results would have to take into consideration the influence of modulators such as
dyslipidemia, hypertension, insulin resistance, pre-pregnancy treatment of obesity, and disorders
of the carbohydrate–lipid balance. Because we chose the EGWG group, we were able to reduce the
number of interfering and confounding factors in the analysis of the study results. The study groups
were formed on the basis of women’s similar age, normal pre-pregnancy BMIs, and term pregnancies.
Selected women were to be free of any chronic and gestational diseases and receive only vitamins
throughout their pregnancy period. On the other hand, this study has an important limitation as a small
sample study. Our results require further verification. It also appears of great clinical significance to
monitor the circulating SFRP5 levels in all trimesters of pregnancies as well as in future life of children.
4. Materials and Methods
The study comprised infants of mothers who were in a singleton term pregnancy (after 37 weeks
of gestation) and delivered at the Chair and Department of Obstetrics and Perinatology, the Medical
University of Lublin. The data collection was performed between March 2016 and February 2017.
All the study subjects included in this study were Caucasian. The study included women receiving
only vitamin-iron supplementation during pregnancy, without any exclusion criteria given below,
with normal pre-pregnancy BMI values and three normal results of the two-hour, 75 g oral glucose
tolerance test at 24–28 weeks of gestation [55,56]. Depending on the achieved gestational weight gain,
two groups were strictly selected:
90
Int. J. Mol. Sci. 2019, 20, 595
• healthy controls—28 pregnant women with normal gestational weight gain;
• patients with EGWG—38 pregnant subjects with excessive gestational weight gain.
Exclusion criteria from the study were as follows: multiple pregnancy, chronic infectious diseases,
urinary infections, anemia, metabolic disorders (except for improper gestational weight gain for the
EGWG group), mental illness, cancer, liver diseases, cardiovascular disorders, fetal malformation,
premature membrane rupture, and intrauterine growth retardation. We had to rule out, among others,
all females with gestational hypertension, which is a common complication observed in patients with
high BMI values in the third trimester of pregnancy.
Anthropometric measurements of the mothers were performed immediately before and after
delivery. Calculation of pre-pregnancy BMIs values were based on body weight measured at the first
prenatal visit, occurring in the first trimester (before 10 weeks of gestation). We defined total gestational
weight gain as the difference between the mother’s weight at delivery and her pre-pregnancy weight.
We calculated gestational BMI gain as well. Neonatal anthropometric measurements, including birth
weight, body length, and head and chest circumferences, were performed immediately after birth. The
maternal serum levels of albumin, HgbA1c, and lipid profile were measured at a certified laboratory.
The cord blood samples were taken during delivery but without any interference with its course. The
maternal serum samples were taken after delivery, taking into account a 6 h fasting period. After
centrifugation, all the collected cord blood serum as well as maternal serum samples were stored at
−80 ◦C. Concentrations of SFRP5 and ghrelin in these materials were determined using commercially
available kits and in compliance with the manufacturer’s instructions (Wuhan EIAab Science Co.,
Wuhan, China) via traditional enzyme-linked immunosorbent assay (ELISA). Concentrations of leptin
in the cord blood serum and maternal serum were determined using commercially available kits and
in compliance with the manufacturer’s instructions (R&D Systems, Inc., Minneapolis, MN, USA) via
ELISA. The survey was performed in duplicates for each patient.
Maternal body composition (LTI and FTI) were evaluated by the bioelectrical impedance analysis
(BIA) method with the use of a body composition monitor (BCM) (Fresenius Medical Care) in the early
post-partum period (i.e. 48 h after delivery).
All the patients were informed about the study protocol and a detailed written consent was
obtained from each patient who agreed to participate in the study. A separate information sheet was
prepared for the parents of newborns. Written signed consent from each infant’s legal guardians
(mothers) was obtained after informed consent.
The study protocol received approval of the Bioethics Committee of the Medical University of
Lublin (no. KE-0254/221/2015 (25th June 2015) and no. KE-0254/348/2016 (15th December 2016)).
All values were reported as the median (interquartile range 25–75%) or numbers and percentages.
Differences between groups were tested for significance using the Mann–Whitney U test. The
Spearman’s coefficient test was used for the correlation analyses. Categorical data were compared
using the chi-square test. The Benjamini–Hochberg correction for false positive results was performed.
Multiple linear regression model was used to examine the association between the umbilical cord
SFRP5 levels and the selected biophysical and biochemical parameters of the mothers and their
offspring. Regression models were adjusted for the serum SFRP5 levels, the serum and umbilical cord
ghrelin and leptin levels, LDL, triglycerides, HgbA1c, gestational weight gain, pre-pregnancy BMI,
BMI at delivery, and gestational BMI gain. All analyses were performed using Statistical Package
for the Social Sciences software (version 19; SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was
considered statistically significant.
5. Conclusions
In light of our study results, it becomes understandable that maternal condition, including
gestational weight gain, should be of utmost importance when doing further research into the
umbilical cord SFRP5 concentrations and investigating their relationship with the fetal and neonatal
anthropometry and metabolic state. Evaluation of the umbilical cord SFRP5 levels in the offspring
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of EGWG mothers as well as of the relationships between the umbilical cord SFRP5 levels, maternal
laboratory results, and neonatal anthropometric measurements is a new idea.
It is also quite obvious that obstetricians and midwives should pay attention to nutrition
and weight management of their pregnant patients and should educate them on the dangers of
overnutrition and on how it predisposes not only them but also their children to metabolic disorders
later in life. On the other hand, it should be emphasized that, in order to avoid potential future
metabolic complications, the offspring of mothers with excessive gestational weight gain during
pregnancy should be carefully monitored by their pediatricians.
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Abstract: Two-thirds of pregnant women exceed gestational weight gain recommendations. Excessive
gestational weight gain (EGWG) appears to be associated with offspring’s complications induced
by mechanisms that are still unclear. The aim of this study was to investigate whether umbilical
cord leptin (UCL) and ghrelin (UCG) concentrations are altered in full-term neonates born to EGWG
mothers and whether neonatal anthropometric measurements correlate with UCL and UCG levels
and maternal serum ghrelin and leptin as well as urine ghrelin concentrations. The study subjects
were divided into two groups, 28 healthy controls and 38 patients with EGWG. Lower UCL and
UCG levels were observed in neonates born to healthy mothers but only in male newborns. In the
control group UCG concentrations correlated positively with neonatal birth weight, body length
and head circumference. In the control group maternal serum ghrelin levels correlated negatively
with neonatal birth weight, body length and head circumference as well as positively with chest
circumference. In the EGWG group UCG concentrations correlated negatively with neonatal birth
weight and birth body length. UCL correlated positively with birth body length in EGWG group and
negatively with head circumference in the control group. In conclusion, EGWG is associated with
disturbances in UCL and UCG concentrations.
Keywords: excessive gestational weight gain; neonatal anthropometry; leptin; ghrelin
1. Introduction
According to the current state of knowledge, excessive gestational weight gain (EGWG) as well
as pre-pregnancy obesity appear to be associated with long-term sequelae in the offspring. Prenatal
life may be of importance as a ‘critical period’ since it is the time when the risk of development and
persistence of dyslipidemia, overweight, obesity, impairments in cognition, neuropsychiatric disorders,
cardiovascular diseases and metabolic syndrome in the future life of the offspring is increased [1–4].
Maternal hyperinsulinemia, hyperleptinemia and inflammation are associated with excessive nutrient
transport at the placental level. EGWG, which is usually due to improper nutrition during the
pregnancy period, has been regarded as a potentially modifiable, independent risk factor for excessive
offspring growth and serious metabolic disorders [3,5].
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Gestational weight guidelines of the Institute of Medicine (IOM) [6] provide ranges of
recommended weight gain for specific pre-pregnancy body mass index (BMI) categories in relation
to the least risk of adverse perinatal outcomes. In order to minimize the risk of maternal and infant
complications it has been suggested that weight gain in pregnancy should not exceed 11.5–16, 7–11.5
and 5–9 kg in women with normal pre-pregnancy BMI, overweight and obese subjects, respectively [6].
More than two-thirds of pregnant women exceed gestational weight gain recommendations of the
IOM [7].
Leptin, an adipocyte-derived satiety factor, is known to reduce food intake and raise/boost energy
expenditure. However, due to the increase of leptin levels in the maternal blood in the second half
of pregnancy, leptin resistance develops [8,9], which, especially in late pregnancy, is thought to be
mediated by the placental secretion hormones, i.e., prolactin and placental lactogen family of the
molecules [10,11].
Ghrelin, an acylated peptide hormone, plays a crucial role in energy homeostasis and it has
been demonstrated to stimulate fetal development by binding to the growth hormone receptors [12].
Ghrelin is also an important factor linking the central nervous system with the peripheral tissues that
regulate energy homeostasis and lipid metabolism [12]. A physiological increase of maternal and fetal
ghrelin levels has been observed during pregnancy in mammals (including humans) [13,14]. In light
of this, it seems plausible that ghrelin is likely to be one of many peptides engaged in the process of
fertilization as well as in preimplantation embryo development and implantation; intragestational
ghrelin participates in reproductive fetal programming [15]. Ghrelin levels can be affected by multiple
factors, including diet composition, exercise, environment and lifestyle [12].
Disrupted leptin and ghrelin secretion homeostasis may result in production of improper
hypothalamic signals, thereby bringing a feeling of hunger, which will lead to excessive food
consumption and lipogenesis. All of this has been displayed in both animal and human models [11].
Even though numerous studies have performed leptin and ghrelin blood concentration
measurements in both healthy and unhealthy individuals [11–13], the data on the relative role
of maternal and fetal leptin and ghrelin in the fetal growth are still patchy. The aim of this study was
to investigate whether the umbilical cord leptin and ghrelin concentrations are altered in full-term
neonates born to EGWG mothers and whether neonatal anthropometric measurements correlate
with the umbilical cord blood and maternal serum leptin and ghrelin levels as well as with the
maternal urine ghrelin levels. This statistical analysis was also performed taking into consideration the
infants’ genders.
2. Results
Comparative characteristics of the study groups are presented in Tables S1 and S2. Data presented
in Table 1 revealed that higher umbilical cord blood leptin and ghrelin concentrations were observed in
the neonates born to the EGWG mothers. We compared the levels of leptin and ghrelin in all the tested
materials depending on the sex of the newborns. Higher umbilical cord blood concentrations of leptin
and ghrelin in the EGWG group were observed in the male neonates, while no such observations were
made in the female infants. In the EGWG group, the mothers of the male newborns had significantly
higher serum leptin levels (Table 1).
We checked correlations between the neonatal anthropometric measurements and leptin and
ghrelin levels. Taking into consideration the relatively small group of female infants in our study,
we performed the correlation analysis only on male newborns in the EGWG and control groups.
In the EGWG group the umbilical cord ghrelin levels correlated negatively with the neonatal birth
weight and birth body length in all infants (Table 2) as well as in the male subjects (Table 3). Negative
correlations were also found between the maternal urine ghrelin levels and neonatal birth weight and
chest circumference in all studied infants in the EGWG group (Table 2), whereas in the male subjects
only the chest circumference was negatively associated with the maternal urine ghrelin level (Table 3).
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The birth body length correlated positively with the umbilical cord leptin levels in the EGWG group
(Table 2). This relation was not observed in the male subgroup (Table 3).
Table 1. Comparison of the study groups.
Variables EGWG Group (n = 38) Control Group (n = 28) p
Male infant, n (%) 24 (63.2) 20 (71.4) 0.66
Female infant, n (%) 14 (36.8) 8 (28.6) 0.66
Cord blood ghrelin,
ng/mL 0.52 (0.26–1.83) 0.19 (0.19–0.28) 0.00001
Male 0.49 (0.27–0.8) 0.19 (0.19–0.2) 0.0001
Female 0.56 (0.25–20.11) 0.28 (0.23–0.29) 0.44
Cord blood leptin, ng/mL 10.99 (8.5–13.4) 7.53 (4.9–14.01) 0.00003
Male 10.8 (8.7–12.6) 7.3 (4.9–7.8) 0.03
Female 21 (8.2–22.3) 14 (11.7–14.6) 0.36
Maternal serum ghrelin,
ng/mL 1.19 (0.34–2.43) 0.93 (0.65–1.12) 0.63
Male 1.1 (0.44–1.73) 0.97 (0.9–1.1) 0.42
Female 2.7 (0.2–16.7) 0.25 (0.21–0.39) 0.34
Maternal urine ghrelin,
ng/mL 0.12 (0.04–0.3) 0.1 (0.1–0.29) 0.75
Male 0.25 (0.05–0.34) 0.1 (0.1–0.29) 0.92
Female 0.08 (0.03–0.12) 0.1 (0.1–0.25) 0.26
Maternal serum leptin,
ng/mL 14.87 (12.6–47.6) 10.43 (6.04–14.9) 0.06
Male 15 (14.6–61.7) 14.6 (6.04–14.9) 0.01
Female 12.3 (11.8–33.4) 6.5 (6.3–7.3) 0.09
The results are shown as the median (interquartile range 25–75%). Statistically significant values are given in bold.
EGWG—Excessive gestational weight gain.
Table 2. Correlations of neonatal anthropometric measurements in the EGWG group (Spearman’s rho
coefficient).





Umbilical cord ghrelin level −0.560 * −0.727 *** −0.203 −0.331
Maternal serum ghrelin level -0.105 −0.309 −0.170 0.001
Maternal urine ghrelin level −0.452 * −0.320 −0.174 −0.596 *
Umbilical cord leptin level 0.326 0.572 * 0.063 −0.044
Maternal serum leptin level −0.151 −0.133 0.066 −0.228
Statistically significant values are given in bold. * p < 0.05; *** p < 0.0001; EGWG—excessive gestational weight gain.
The controls presented umbilical cord ghrelin levels correlating positively with the neonatal birth
weight, birth body length and head circumference (Table 4); whereas only with the head circumference
measurements in the male subjects (Table 5). The maternal serum ghrelin levels correlated negatively
with all these parameters but positively with the chest circumference in all control newborns (Table 4).
In the male subgroup the maternal serum ghrelin level was negatively connected to the neonatal head
circumference (Table 5). The urine ghrelin correlated negatively with all the anthropometric parameters
of the neonates of the healthy group (Table 4), but in male subjects except for the head circumference
measurements (Table 5). Positive correlations were found between the maternal serum leptin levels
and all the neonatal anthropometric measurements except the head circumference, which correlated
negatively with the umbilical cord leptin levels. These associations were statistically significant in all
newborns in the control group (Table 4) as well as in the male subjects of this group (Table 5).
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Table 3. Correlations of neonatal anthropometric measurements in the EGWG group in male subjects
(Spearman’s rho coefficient).





Umbilical cord ghrelin level −0.733 ** −0.829 *** −0.271 −0.747 **
Maternal serum ghrelin level −0.300 −0.393 −0.140 −0.378
Maternal urine ghrelin level −0.450 −0.419 −0.420 −0.615 *
Umbilical cord leptin level 0.445 0.445 0.437 0.413
Maternal serum leptin level −0.133 −0.265 0.061 −0.351
Statistically significant values are given in bold. * p < 0.05; ** p < 0.001; *** p < 0.0001; EGWG—excessive gestational
weight gain.
Table 4. Correlations of neonatal anthropometric measurements in the control group (Spearman’s rho
coefficient).





Umbilical cord ghrelin level 0.486 * 0.525 * 0.794 *** −0.278
Maternal serum ghrelin level −0.543 * −0.617 * −0.706 ** 0.432 *
Maternal urine ghrelin level −0.771 *** −0.833 *** −0.441 * −0.463 *
Umbilical cord leptin level −0.286 −0.092 −0.559 * 0.061
Maternal serum leptin level 0.600 * 0.494 * 0.294 0.833 ***
Statistically significant values are given in bold. * p < 0.05; ** p < 0.001; *** p < 0.0001.
Table 5. Correlations of neonatal anthropometric measurements in the control group in male subjects
(Spearman’s rho coefficient).





Umbilical cord ghrelin level 0.200 0.289 0.669 * −0.335
Maternal serum ghrelin level −0.200 −0.289 −0.667 * 0.335
Maternal urine ghrelin level −0.700 ** −0.866 *** −0.205 −0.671 **
Umbilical cord leptin level −0.500 * −0.577 * −0.820 *** 0.112
Maternal serum leptin level 0.900 *** 0.866 *** 0.410 0.783 ***
Statistically significant values are given in bold. * p < 0.05; ** p < 0.001; *** p < 0.0001.
3. Discussion
Maternal pre-pregnancy BMI as well as gestational weight gain, connected to nutrition, have
both independent and interacting effects not only on the fetal growth [4]. The majority of studies
have investigated the relationship between the umbilical cord leptin and ghrelin and neonatal
anthropometric measurements [9,16–21], however, their associations with the maternal serum and
urine ghrelin concentrations are less studied. To the best of our knowledge, this study is the first to
show the umbilical cord, maternal serum and urine ghrelin levels as well as the umbilical cord and
maternal serum leptin levels in women with EGWG and the relationship of these parameters to the
neonatal anthropometric measurements.
Our study showed that levels of leptin and ghrelin in the umbilical cord blood were statistically
higher in male infants of the EGWG group in comparison to healthy subjects. We hypothesize that
these differences can be connected to disparities in body composition and hydration status. Our
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previous study revealed that mothers with EGWG were characterized by increased fat and lean tissues
in the bioelectrical impedance analysis [22]. Unfortunately, the evaluation of these parameters seems
to not be feasible in the case of newborns.
Lecoutre et al. [23] observed a link between maternal obesity and adult rat offspring, where the
latter were sensitized by the obese mother to increased visceral adiposity in a sex-specific manner.
The cited authors demonstrated that maternal obesity programs visceral depots only in the male
offspring in the group with a high-fat diet (HF; containing 60% lipids). Perirenal fat pads, yet not
gonadal ones, were found to be involved in determining features in HF male offspring. On the basis of
previous studies, the heterogeneity of the adipose lineage was proposed. It has been demonstrated
that adipogenic stem cells and adipocytes act differently in the course of adipogenesis [24,25].
Previous studies revealed that females tended to have higher serum leptin levels than males [26].
Similar findings were observed in our study. Karakosta et al. [27] observed gender-specific differences
in leptin levels in the umbilical cord blood of approximately 400 healthy neonates. The cited authors
revealed that female subjects were characterized by higher levels of this adipokine than males [27]. It
has also been observed that later in life the leptin levels are consistently higher in females in comparison
to males [28,29].
Many authors are of the opinion that leptin concentration is higher in the mother than in the
newborn [17,18,23,30]. Similar results were observed in the present study in all studied subjects
and in groups of male infants. In both studied groups the leptin concentration was about 1.4 times
higher in the blood of the mothers in comparison with the leptin concentration in the newborns. The
discrepancy between leptin levels in the maternal serum and cord blood of male and female subjects
can be connected to the phenomenon typical of this period of life when infants may be affected by an
energy imbalance correlating with leptin levels [31]. Interestingly, a higher level of leptin was observed
in the umbilical cord blood than in mothers in the group of female newborns. A similar dependence
was described by Okdemir et al. [32] in the large for gestational age babies, however, these authors did
not take into account the division of the group by sex of children.
Previous studies reported high ghrelin concentrations in the umbilical cord blood of pre-term
and small-for-gestational-age infants. It was also reported that ghrelin levels were increased in the
offspring of those women who had cigarette smoking habits and suffered from hypertension during
pregnancy [33,34]. A limited and contrary amount of data is available on the umbilical cord ghrelin
concentrations in the offspring of mothers with metabolic disturbances. Hehir et al. [35] did not detect
a significant difference between healthy and type 1 diabetic pregnant women in this respect. However,
Karakulak et al. [36] found that the umbilical cord blood ghrelin levels were decreased in the offspring
of the gestational diabetes mellitus (GDM) women even after adjustment for birth weight, whereas
Kara et al. [20] were able to notice similar ghrelin and leptin concentrations in the serum of the control
and GDM mothers’ newborns. It has been suggested that ghrelin may play a role in the fetal adaptation
to intrauterine malnutrition [34]. Our previous study detected lower serum and higher urine ghrelin
concentrations in the early post-partum period when GDM women were compared with the health
control group [37]. It is presumed that ghrelin in the cord blood is mainly secreted by the fetus. It is
worth noting, however, that ghrelin is mainly secreted by the pancreas during the perinatal period
rather than by the fundus of the stomach, which is typical of adult humans and rodents [38]. On the
other hand, our findings of significant correlations between maternal serum and urine ghrelin levels
and neonatal anthropomorphic measurements seem to be connected to the fact that a pregnant woman
and her child may be perceived as a functional, complex unit. We decided to focus on urine as an easily
obtainable biological material. Nonetheless, we are aware of the fact that small groups of participants
represent a study limitation and we are not able to discuss these results in detail. Furthermore, it is not
possible to relate our observations to the previously published papers of other authors since no such
data exists.
There are many studies showing higher umbilical cord leptin levels in neonates born to obese
mothers [17,21] but there are still limited data about leptin concentrations in women with EGWG.
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Previous studies concentrated on gestational weight gain in the first two trimesters of pregnancy,
where EGWG was associated with higher levels of leptin and other parameters in the cord blood [8,39].
Allbrand et al. [21] observed increased level of the umbilical cord leptin and C-peptide in the infants
born to obese versus normal-weight women. The present results confirm that the level of leptin in
the umbilical cord blood was significantly higher in the EGWG patients than in the controls. These
findings are similar to those reported by Biesiada et al. [17] who observed that leptin concentrations
in the large for gestational age (LGA) children born to obese mothers were higher than in the LGA
children born to mothers with normal BMI.
It is worth highlighting that many of the above-quoted studies did not take into consideration
the maternal BMI and weight gain during pregnancy. The results of our study revealed differences
not only in the gestational weight gain between two groups of mothers but in the laboratory results
as well. Lower levels of high-density lipoprotein cholesterol (HDL) as well as higher HgbA1c and
triglycerides concentrations were present in the EGWG group. These results are consistent with the
observations reported by other authors. Nonetheless, the offspring of the mothers from both studied
groups presented similar anthropometric measurements, and their birth weight was also comparable.
However, previous studies seem to confirm that the fetal metabolic programming may occur within
normal birth weight ranges [40,41].
Researchers studying the relationship between ghrelin and anthropometric measurements revealed
an inverse correlation between ghrelin concentrations and birth weight, height as well as BMI [42–46].
In their study, in which blood samples of diabetic mothers’ newborns were taken after birth before
feeding, Kara et al. [20] found that only serum ghrelin negatively correlated with the birth weight.
The authors concluded that this negative correlation of ghrelin, which seems to be a regulator of
appetite, body fat mass, and energy balance, could potentially be advantageous to infants since appetite
reduction might prevent postnatal excessive food intake and subsequent weight gain. Ding et al. [16]
also suggested that ghrelin may play a role in regulation of body weight and energy homeostasis from
the fetal period to adulthood. In our study the umbilical cord ghrelin levels negatively correlated with
birth weight and birth body length in the EGWG group, they were also positively associated with the
birth weight, birth body length, and head circumference in the control group. In the literature there is
no clear evidence of consistent relationship between the ghrelin levels and neonatal anthropometry.
There are also studies in which no correlation whatsoever has been reported [19,47–49].
The positive association detected in this study between the leptin concentration in the maternal
serum and umbilical cord and neonatal anthropometric measurements confirms what was reported in
the previous studies [9,17,30,50]. Schubring et al. [30] detected a significant correlation between leptin
levels in the umbilical vein and artery and birth weight of the neonates. Biesiada at al. [17] observed
moderate correlations between leptin concentrations and Ponderal Index, birth weight and the placenta
weight. Samano et al. [9], similar to our findings in the control group, showed a correlation between
the maternal leptin concentration and length of the newborn. This positive correlation between the
cord blood leptin levels and birth weight could be indicative of leptin as a regulating factor responsible
for fetal weight and its development.
As other studies have reported, in our study the mean leptin concentrations were also higher
in female neonates than in male neonates even though the birth weight in both sexes was similar.
This may suggest participation of sex hormones in leptin secretion [17,50,51]. This is contrary to
the study results published by Palcevska-Kocevsa et al. [50], who found no differences in the leptin
concentrations between the male and female infants. In our study we observed significantly higher
levels of leptin in the female neonates only in the control group. Similar levels of leptin between the
males and females in the EGWG group may result from the fact that the male newborns had statistically
higher levels of leptin in the umbilical cord blood in the group of patients with EGWGthan in the
control group. Similar relationships, however, were not observed in the female newborns.
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Our results seem to highlight the importance of maternal condition, including gestational weight
gain, in further research into the umbilical cord ghrelin and leptin concentrations and their relationship
with the fetal and/or neonatal anthropometry and metabolic state.
The strength of this study lies in its novelty—the evaluation of the umbilical cord ghrelin levels of
the EGWG mothers’ offspring as well as their associations with the maternal laboratory results and
neonatal anthropometric measurements is an innovative approach. Nevertheless, the presented study
has certain limitations. Firstly, it is indeed a relatively small-sample study. Secondly, we measured the
levels of ghrelin and leptin in all the material only once. Therefore, it would be interesting to check
how they change in time both in the mothers and in their offspring, which is quite motivating for us to
continue our research into this issue and verify our results.
4. Materials and Methods
4.1. Study Population
The study consisted of Caucasian, singleton-term-pregnancy mothers (who completed 37 weeks
of pregnancy) and infants delivered at the Chair and Department of Obstetrics and Perinatology, the
medical University of Lublin, Poland. The study material was obtained between March 2016 and
February 2017. The women were recruited at the time of delivery. We took into account only those in
full-term pregnancy, i.e., after the completed 37th week of pregnancy calculated on the basis of the date
of the last menstrual period or ultrasound examination in case the date of the last menstrual period
was unknown. Two groups were selected on the basis of gestational weight gain: one group included
women with normal gestational weight gain (11.5–16 kg; n = 28), while the other consisted of those
with excessive gestational weight gain (≥20 kg; n = 38). Informed consent was obtained from each
study subject and infant mother.
Characteristics of the study subjects also included: normal pre-pregnancy BMI values and three
consecutive correct/normal results of 2 h-75 g-oral glucose tolerance test performed at 24–28 weeks of
pregnancy [52,53], no concomitant diseases, and only vitamin-iron supplementation.
Exclusion criteria from the study included: multiple pregnancy, chronic infectious diseases, current
urinary infections, abnormal laboratory results (e.g., the complete blood count, creatinine, glomerular
filtration rate (GFR) findings); metabolic disorders (except improper gestational weight gain for the
EGWG group), mental illness, cancer, liver diseases, cardiovascular disorders, fetal malformation,
premature membrane rupture and intrauterine growth retardation.
The study protocol received approval of the Bioethics Committee of the Medical University of
Lublin (no. KE-0254/221/2015 [25 June 2015] and no. KE-0254/348/2016 [15 December 2016]).
4.2. Measurements and Data Collection
Anthropometric measurements of mothers were performed shortly prior to and after delivery.
Pre-pregnancy BMI values were determined during the first visits in the out-patients clinic, which were
carried out up to 10 weeks of gestation. The following formula was used to calculate the gestational
weight gain: the mother’s pre-pregnancy body mass subtracted from the weight at the day of delivery.
We calculated gestational BMI gain as well. We defined gestational BMI loss as the difference between
the mother’s BMI after delivery (during 48 h after delivery) and her BMI shortly prior to delivery.
The newborn weights, lengths as well as the head and chest circumferences were measured right
after delivery.
The cord blood samples’ collection was performed during delivery causing no hinderance to its
course. The maternal serum and urine samples were taken after delivery, taking into account a 6 h
fasting period. Samples were centrifuged at 1000× g, at 20 ◦C for 15 min. After centrifugation all the
collected cord blood serum as well as the serum and urine samples obtained from the studied mothers
were stored at −80 ◦C. Ghrelin concentrations were determined with the use of kits available on the
market and in agreement with the manufacturer’s instructions (Wuhan EIAab Science Co., Wuhan,
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China) via traditional enzyme-linked immunosorbent assay (ELISA). Detection range for ghrelin
was 0.156–10 ng/mL. Concentrations of leptin in cord blood serum and maternal serum and urine
were measured by means of commercially available kits and in agreement with the manufacturer’s
instructions (R&D Systems, Inc., Minneapolis, MN, USA) via ELISA. The threshold of leptin sensitivity
was equal to 7.8 pg/mL, while the reference range for women was 3877–77,273 pg/mL. Since the leptin
urine levels in the majority of the studied subjects were below the threshold of sensitivity of the ELISA
test, the “urine leptin” parameter was not included in our study results. The measurements of maternal
serum levels of albumin, fasting blood glucose (FBG), hemoglobin A1c (HgbA1c) as well as the lipid
profile were performed by an authorized laboratory.
This is the second analysis based on subjects from the control group that was previously used in
our study [37]. In the cited study we compared women diagnosed with gestational diabetes mellitus
(GDM) with the aforementioned control group [37]. The cohort analyzed in the present study was
used to measure SFRP5 and was described in our previous study [22]. Comparative characteristics of
the study groups are presented in Tables S1 and S2.
4.3. Statistical Analysis
All the obtained results are presented as the median (interquartile range 25–75%) or as numbers
and percentages. Differential significance test was conducted by means of Mann–Whitney U test.
Correlation analyses used Spearman’s coefficient test and were performed with the use of Statistical
Package for the Social Sciences software (version 19; SPSS Inc., Chicago, IL, USA); p < 0.005 was
assumed to be statistically significant.
5. Conclusions
Our study revealed that the umbilical cord leptin and ghrelin levels were significantly higher in
the offspring of the EGWG mothers, but only in the male newborns. Our study results indicate that the
condition of the mother, i.e., her BMI values both in the periconceptional and periparturient periods as
well as her metabolic parameters (e.g., her lipid profile), may affect her offspring’s ghrelin and leptin
concentrations at delivery.
Differences in the correlations between the leptin and ghrelin concentrations (both in the umbilical
cord blood and maternal serum as well as in urine) and the anthropometric results of the neonates are
dependent on the studied group. This can be exemplified by the umbilical cord ghrelin which correlates
negatively with the birth weight and birth body length in the EGWG group, while its correlation with
the birth weight, birth body length and head circumference is positive in the control group. These
significant correlation differences result from different levels of ghrelin in the umbilical cord blood
(significantly higher level in the EGWG group, at p < 0.0001) with comparable birth measurements
in both studied groups. However, the possibility of fetal metabolic programming occurrence within
the normal birth weight ranges, as has previously been reported by other authors [40,41], should be
stressed once more.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/10/
2398/s1.
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Abstract: There is recent evidence that the dysfunctional responses of a peculiar visceral fat deposit
known as epicardial adipose tissue (EAT) can directly promote cardiac enlargement in the case of
obesity. Here, we observed a newer molecular pattern associated with LV dysfunction mediated by
prostaglandin E2 (PGE2) deregulation in EAT in a cardiovascular disease (CVD) population. A series
of 33 overweight CVD males were enrolled and their EAT thickness, LV mass, and volumes were
measured by echocardiography. Blood, plasma, EAT, and SAT biopsies were collected for molecular
and proteomic assays. Our data show that PGE2 biosynthetic enzyme (PTGES-2) correlates with
echocardiographic parameters of LV enlargement: LV diameters, LV end diastolic volume, and LV
masses. Moreover, PTGES-2 is directly associated with EPAC2 gene (r = 0.70, p < 0.0001), known as a
molecular inducer of ST2/IL-33 mediators involved in maladaptive heart remodelling. Furthermore,
PGE2 receptor 3 (PTEGER3) results are downregulated and its expression is inversely associated
with ST2/IL-33 expression. Contrarily, PGE2 receptor 4 (PTGER4) is upregulated in EAT and directly
correlates with ST2 molecular expression. Our data suggest that excessive body fatness can shift the
EAT transcriptome to a pro-tissue remodelling profile, may be driven by PGE2 deregulation, with
consequent promotion of EPAC2 and ST2 signalling.
Keywords: epicardial adipose tissue (EAT); prostaglandin E2 (PGE2); EP3 receptor; EP4 receptor;
exchange protein directly activated by cAMP isoform 2 (EPAC2); stimulating growth factor 2 (ST2);
interleukin(IL)-33; Cardiovascular Diseases (CVDs); fat mass
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1. Introduction
Perturbations of signaling in the heart and vessels of the body are the leading causes of
cardiovascular disorders including coronary artery diseases (CAD) and valve heart diseases (VHD) [1].
Among different stimuli which can contribute to alter cardiac and vessel molecular responses, excessive
fat body can be considered one of the primary causes associated with maladaptive heart response [2].
Obese patients are at increased risk of cardiovascular disease (CVD) and heart failure (HF) due to
the hemodynamic stresses related to abnormal body mass and increase of volume overload [3]. The
excessive hemodynamic stresses lead to cardiac microvascular rarefaction and fibrosis, especially with
abnormalities of cardiac diastolic filling [4].
The first effect of chronic volume overload on left ventricle (LV), directly related to fatness,
is characterized by typically LV and left atria (LA) dilation, with a preserved ejection fraction (EF),
suggesting proportional expansion of plasma volume with body mass. For this reason, the capacity of
LV to dilate in response to hydrodynamic volume overload is impaired and disproportionate.
Since overweight is the most deputed cause of these cardiac outcomes, it is assumed that visceral
adiposity drives both vessels derangements and heart fibrosis [5], but the molecular patterns relating
to these abnormalities are not fully understood. There is recent evidence suggesting that during
maladaptive adipose tissue remodeling, dysfunctional fat responses of a particular visceral fat closely
surrounding the heart and all arteries- known as epicardial adipose tissue (EAT)-can be a metabolic
transducer of both local and systemic inflammation, through the direct release into myocardial
microcirculation of bioactive fibro-adipokines [6,7] involved in heart metabolism [8–13]. EAT thickness
varies 1 mm to a maximum of almost 23 mm [13]. This wide range probably reflects the substantial
differences in abdominal visceral fat distribution [13]. Previous studies found median epicardial
fat thicknesses of 7 mm in men and 6.5 mm in women in a large population of patients who were
examined by transthoracic echocardiography for standard clinical indication [13]. Variations in EAT
size can be considered a potential cardiovascular risk factor due to the shift in the production of
active cardiometabolic mediators. Among these, one peculiar adipokine known as soluble stimulating
growth factor 2 (sST2) [14] has attracted attention on account of both fat mass enlargement and
maladaptive heart response due to its role in silencing the main mechanosensitive system [15,16]
expressed and activated both in adipose tissue and in the heart [17]; this comprises by two immune
mediators, the transmembrane isoform of ST2 (ST2L) and its natural ligand, the interleukin (IL)-33,
one of the main alarmin proteins in the body [18]. The IL-33/ST2L system in adipose tissue tries to
maintain the size of the fat mass, controlling intracellular nuclear factors that regulate adipocytes
number and size of the adipocytes [19,20]. In the heart IL-33/ST2L system has cardioprotective effects
since under biomechanical stress it promotes cell survival and prevents apoptosis and fibrosis [21].
However, in pathological conditions such as obesity and cardiovascular disorders, both adipocytes
and cardiac cells release larger amount of sST2; this functions as a decoy receptor, sequestering
IL-33, losing its cardio-fat protection properties through ST2L binding, and consequently promoting
an increase in fat mass, and heart damage [14,16,19,22]. In a previous study [23] we identified
as potential molecular inducer of this system in EAT, the exchange proteins directly activated by
cAMP (EPACs), which are the main effectors of the second messenger in the body, the cycle adenine
monophosphate(cAMP) [23,24]. The EPAC protein family is composed of EPAC1 and EPAC2 which in
adipose tissue control adipogenesis and lipolysis and are induced by cAMP [25,26]. We reported that
when EAT thickness increases, the local upregulation of EPAC2 promotes an alarm profile associated
with maladaptive remodeling in which ST2 gene, encoding for both cardiac stretch proteins, ST2L and
sST2, correlated with local expression of EPAC2 [23].
Prostaglandin E2 (PGE2) appears to have a crucial role in intracellular cAMP concentration in
visceral fat [27–29]. PGE2 is a potent lipid mediator secreted by various cell types in visceral adipose
tissue and it appears to be implicated in the regulation of inflammation and adipocytes functions [30].
Different studies have noted that the excess accumulation of visceral fat depends on depot-specific
110
Int. J. Mol. Sci. 2020, 21, 520
expression of key enzymes involved in adipose tissue functions, including PGE2 biosynthesis-related
enzymes [31].
PGE2 is the principal prostaglandin produced by visceral adipose tissue including EAT deposit [27],
which regulates energy metabolism and, particularly in obesity, contributes to fat-inflammation and
obesity-related insulin resistance, through the activation of prostaglandin-endoperoxide synthase 2
(PTGES-2) [32], known also as cyclooxygenase 2. PGE2 regulates adipose functions and exerts its
biological effects through its four receptors (EP1, EP2, EP3 and EP4) [27]. The EP1 receptor is involved
in intracellular Ca2+ level. The EP3 receptor is designed to lower intracellular cAMP concentration
through the inhibition of adenylyl cyclases (ADCYs), thus promoting adipogenesis [33,34]. EP2 and
especially EP4 have opposite effects, stimulating the increase of intracellular cAMP levels with the
promotion of lipolysis [35–38]. The different role of PGE2 receptors in the control of intracellular cAMP
concentration, led to them being considered the master regulators of adipogenic and lipolytic processes,
and their deregulation can be associated with obesity-related disorders. By eliciting signaling through
cAMP and its effectors, the EPACs proteins, PGE2 can potentiate the expression of mechanosensitive
system IL-33/ST2L in immune cells [39].
Due to the importance of ST2 gene both in heart and fat metabolism, we set out to identify a
new molecular gap among PGE2 metabolism in EAT of overweight CVD persons and the expression
of ST2 cardiac stretch mediator via EPAC2 gene, as new potential molecular pattern of maladaptive
heart response.
2. Results
2.1. CVD Patients’ Main Characteristics and Echocardiography
Anthropometric, clinical data and body fatness measurements are set out in Table 1. The CVD
subjects had higher indices of body fatness and different in BMI (27.95 ± 5.19 vs normal range
18.50–24.99), waist circumference (106.70 ± 15.08 cm vs normal reference value less than 94 cm)
and waist:hip ratio (WHR) (0.98 ± 0.13 normal cut off less than 0.95 ), indicating that CVD patients
were overweight.
Biochemical parameters associated with body fatness were intra-male reference ranges except for
N-terminal pro B-type natriuretic peptide (NT-pro-BNP) (453.92 ± 596 pg/mL) and C-reactive protein
(CRP) (0.98 ± 0.38 mg/100 mL) which are the clinical parameters currently most used for cardiac stress
assessment and body inflammation.
Echocardiography parameters of our CVD subjects are reported in Table 2. EAT thickness
was evaluated both in end-diastolic and end-systolic echocardiographic frames and we used the
end-systolic frame as EAT measurement because it is considered the best cardiac moment to detect EAT
thickness [13,40]. The average EAT was about 7 mm. A normal upper-limit value for EAT thickness
has yet not been established.
Echocardiography showed that overweight CVD subjects typically had left ventricle (LV) and
atria (LA) dilation, with a preserved ejection fraction (EF), CVD subjects presented an eccentric LV
hypertrophy (relative wall thickness: RTW < 0.42% and indexed LV mass: LVM/BSA ≥115 g/m2),
the first effect of chronic volume overload on LV, directly related to fatness [7].
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Table 1. Cardiovascular disease (CVD) patients’ main details and echocardiographic assessment.
Cardiovascular Patients Mean SD Reference Range
Age (years) 66.86 10.47 /
Systolic blood pressure (mmHg) 130.6 9.66 115–120
Diastolic blood pressure (mmHg) 73.53 4.92 75–80
BMI 27.95 5.19 18.50–24.99
Weight (kg) 83.29 20.48 /
Height (m) 1.71 0.06 /
Waist (cm) 106.70 15.08 <94
Hip (cm) 110.5 25.22 /
HOMA 2.36 2.38 <2.50
WHR 0.98 0.127 <0.95
Family history
Hypertension 3 / /
Diabetes 2 / /
CAD 4 / /
Biochemical parameters
Creatinine (mg/dL) 0.99 0.38 0.60–1.30
Fasting glucose (mg/dL) 46.11 45.04 60–99
HbA1c (%) 4.55 1.43 <6.30
NT-PRO BNP (pg/mL) 453.92 567 <300
Total cholesterol (mg/dL) 155.9 28.86 <200
HDL (mg/dL) 42.48 11.4 40–59
Triglycerides (mg/dL) 132 52.47 <150
Acid uric (mg/dL) 6.64 1.44 4.0–8.0
CRP (mg/100 mL) 0.98 0.38 0.50
ALT (U/L) 28.09 24.67 9.0–60.0
AST (U/L) 32.32 37.33 10.0–40.0
Bilirubin (total) (mg/dL) 0.57 0.31 0.3–1.00
Table 2. Echocardiographic assessment of the overweight CVD subjects.
Echocardiographic Data Mean SD Reference Range
EAT thickness in systole (mm) 6.73 2.164 /
LV internal dimension
LV diastolic diameter (cm) 5.68 0.91 4.2–5.8
LV systolic diameter (cm) 3.99 1.13 2.5–4.0
LV volumes (biplane)
LV EDV (mL) 147.5 80.64 62.15
LV ESV (mL) 71.06 49.07 21–61
LV volumes normalized by
BSA
LV EDV (mL/m2) 75.97 37.04 34–74
LV ESV (mL/m2) 35.71 24.25 11.31
LV EF function
LV EF (%) 55.65 11.38 52–72
LV mass by 2D method
septal wall thickness (cm) 1.22 0.2 0.60–1.00
RWT (%) 0.41 0.11 <0.42
LV mass (g) 294.3 119.5 88–224
LV mass/BSA (g/m2) 146.9 53.15 49–115
LA size
LA (cm) 4.2 0.67 <4
RV function
TAPSE (mm) 23.2 5.71 >17
Pulmonary artery pressure
PAP (mmHg) 32.23 13.53 <35–40
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2.2. Anthropometric Measures of Body Fatness Are Associated with Maladaptive Heart Remodeling in
Overweight CVD Subjects
The acknowledged parameters of fat body distribution as BMI and waist circumference, directly
correlate with echocardiographic indexes of heart maladaptation (Table 3). BMI is not only a predicting
factor of insulin resistance due to the positive correlations with Homeostatic Model Assessment
for Insulin Resistance (HOMA), fast insulin, waist circumference and an inverse relation with HDL
cholesterol. It also directly correlates with both the diameters and volumes of LV, with its mass and
LA size. The LA enlargement and dysfunction are the most predictors of (HF) in overweight patients
with CVD. The alternative measure that reflects abdominal adiposity waist circumference, which has
been suggested as superior to BMI in predicting CVD outcomes, is directly related to EAT thickness
and with the indexes predicting insulin resistance. Waist circumference is also related to both LV and
LA enlargement.
Table 3. Anthropometric measures of body fatness are associated with maladaptive heart remodeling
in overweight CVD subjects.
BMI (x) Spearman r p Value
LV diastolic diameter (cm) 0.48 0.02
LV systolic diameter (cm) 0.47 0.03
LV EDV (mL) 0.48 0.03
LV ESV (mL) 0.47 0.04
LVM (g) 0.40 0.05
LA (cm) 0.53 0.03
Insulin resistance predicting factors
Waist (cm) 0.70 0.0004
Fasting insulin (microU/mL) 0.62 0.005
HOMA 0.53 0.02
HDL (mg/dL) −0.43 0.05
Waist (x) Spearman r p value
EAT thickness in systole (mm) 0.48 0.02
LV diastolic diameter (cm) 0.45 0.03
LVM (g) 0.45 0.03
LA (cm) 0.60 0.01
Insulin resistance predicting factors
BMI 0.70 0.0004
Fasting glucose (mg/dL) 0.46 0.03
Fasting insulin (microU/mL) 0.58 0.001
Triglycerides (mg/dL) 0.43 0.04
2.3. Prostaglandin-Endoperoxide Synthase 2 (PTGES-2) Expression in EAT is Directly Related to Maladaptive
Heart Remodeling Indexes in Overweight CVD Subjects
In view the importance of body fatness on heart maladaptation, we investigated the PGE2
molecular alterations in EAT from overweight CVD patients. Considering the role of PTGES-2 as a
mediator of adiposity and its involvement in fat-inflammation and obesity-related disorders, including
cardiovascular complications, we ran a correlation analysis between PTGES-2 molecular expression
and echocardiographic parameters of heart remodeling (Figure 1). There were linear correlations
among PTGES-2 molecular expression in EAT and the diameters (diastolic and systolic), volume (EDV)
and mass (LVM and LVM/BSA); this suggests that PGE2 biosynthesis in EAT of overweight CVD
people is involved in maladaptive cardiac responses.
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Figure 1. PTGES-2 molecular expression level in epicardial adipose tissue (EAT) of overweight
CVD subjects.
2.4. EP3 Receptor Molecular Expression in EAT Correlates with Body Fatness of Overweight CVD People
EP3 expression correlated substantially with body fatness and waist circumference (Spearman
r = 0.43, p = 0.05) and WHR (Spearman r = 0.44, p = 0.04); and also with factors predicting insulin
resistance, such as triglycerides (Spearman r = 0.46, p = 0.04) and fasting glucose (Spearman r = 0.50,
p = 0.03). This suggests that EP3 molecular expression in EAT is related to the increase of body fatness
in overweight CVD subjects (Figure 2).
Figure 2. EP3 molecular expression in EAT is associated with body fatness.
2.5. EP3, EP4, and PTGES-2 Are Involved Differently in cAMP Production in EAT
Since PGE2 drives both adipogenesis and lipolysis in visceral adipose tissue, acting on intracellular
cAMP production by silencing adenylyl cyclase (ADCY) enzymes through its receptors, we ran a
correlational analysis between the PTGES-2, EP3 and 4 receptors and the molecular expression of
ADCYs in EAT to clarify their effects on cAMP intracellular concentrations in case of excessive (Table 4).
PTGES-2 and EP4 were mostly associated with the increase of intracellular cAMP due to the positive
correlations between them and ADCY isoforms, suggesting their pro-lipolytic effect on EAT when
fat mass increases. In contrast, EP3 molecular expression in EAT seems to be related to anti-lipolytic
signaling due to the inverse associations with the main ADCY isoforms in cAMP production, suggesting
a protective role against lipolysis during fat mass increase (Table 4).
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Table 4. EP3, EP4, and PTGES-2 are involved differently in cAMP production in EAT.
PTGES-2 Spearman r p Value EP3 Spearman r p Value EP4 Spearman r p Value
ADCY1 0.73 <0.0001 ADCY1 −0.37 0.04 ADCY1 0.47 0.01
ADCY2 0.66 <0.0001 ADCY2 −0.45 0.01 ADCY2 0.51 0.002
ADCY3 0.04 0.84 ADCY3 −0.34 0.05 ADCY3 −0.19 0.27
ADCY4 −0.13 0.47 ADCY4 −0.11 0.56 ADCY4 0.02 0.89
ADCY5 0.58 0.0005 ADCY5 −0.40 0.02 ADCY5 0.43 0.01
ADCY6 −0.41 0.02 ADCY6 0.62 0.0001 ADCY6 −0.42 0.01
ADCY7 −0.39 0.02 ADCY7 −0.64 <0.0001 ADCY7 0.24 0.16
ADCY8 0.74 <0.0001 ADCY8 −0.46 0.01 ADCY8 0.53 0.001
ADCY9 0.55 0.001 ADCY9 −0.54 0.0011 ADCY9 0.11 0.52
ADCY10 0.78 <0.0001 ADCY10 −0.36 0.04 ADCY10 0.45 0.01
2.6. The PTGES-2 Gene Correlates Directly with EPAC2 as the Molecular Inducer of the ST2/IL-33
Mechanosensitive System
Considering the role of PGE2 in the regulation of cAMP concentrations in visceral adipose tissue,
and of EPAC2 cAMP effector in the control of cardiac stretch genes such as ST2 and IL-33, we explored
the relations between the expression of PTGES-2 and EPAC2 cAMP effector gene (Figure 3a).
Figure 3. PTGES-2 gene directly correlates with EPAC2 inducer of ST2/IL-33 mechanosensitive system
in overweight CVD patients. (a) The expression level of PTGES-2 directly correlates with the local
expression gene of EPAC2 cAMP effector, powerful inducer of ST2/IL33 mechanosensitive system in
immune cells. The local immunolocalization of EPAC2 cAMP effector in EAT biopsies of overweight
CVD subjects is demonstrated by EPAC2+ cells in the stroma region (black arrows; magnification 20×).
(b) The PTGES-2 controller of cAMP effectors directly correlates with ST2/IL-33 mechanosensitive genes
associated with fat and cardiac maladaptation.
PTGES-2 correlates positively with the local expression of EPAC2 (Spearman r = 0.70, p < 0.0001)
which was recently recognized as one of the main inducers of ST2 gene in EAT. The local protein
production of EPAC2 in EAT biopsy suggests active control of EPAC2 in adipocytes due to the stroma
immune-localization of EPAC positive cells (black arrows).
That PTGES-2 is involved in sST2/ST2/IL-33 cardiac stretch mediators is further confirmed by the
molecular relations between PTGES-2 and ST2, IL-33 gene expression in EAT (Figure 3b). PTGES-2
directly correlates with ST2 gene (Spearman r = 0.70, p < 0.0001) which encodes for both ST2 cardiac
stretch mediators (ST2L and sST2) and inversely with IL-33 gene (Spearman r = −0.36, p = 0.04),
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which transducer for the main alarmin in the body able to block the circulating isoform of ST2 gene,
promoting cardiac cell survival and preventing fibrosis and heart remodeling.
2.7. Increase of EAT Mass Deregulates EP3 and EP4 Molecular Expression with Direct Induction of ST2 Gene
via EPAC2 cAMP Effector
In the light of the opposite effects of EP3 and EP4 in cAMP intracellular concentrations and the
PGE2′s role in the induction of sST2/ST2/IL-33 cardiac stretch mediators in immune cells through
EPAC2 cAMP effector, we explored the molecular interaction between EP3 and EP4 and EPAC2 and
sST2/ST2/IL-33 mediators in EAT of overweight people (Figure 4). Regarding EP4 receptor, which
is closely involved in lipolytic processes, gave a positive relation between EPAC2 cAMP effector
(Spearman r = 0.46, p = 0.001) and ST2 gene (Spearman r = 0.63, p = 0.002), and an inverse relation with
IL-33 molecular expression, although close to the statistical significance (Spearman r = −0.36, p = 0.05)
(Figure 4a). Noteworthy, there is a positive association between EP4 molecular expression and EAT
thickness (Spearman r = 0.70, p = 0.0003) (Figure 4a). There was an interesting inverse relation between
EP3 adipogenic receptor and ST2 gene (Spearman = −0.37, p < 0.03) and the soluble protein of ST2
receptor sST2 (Spearman R = −0.60, p = 0.008) (Figure 4b) which is a powerful mediator of maladaptive
heart remodeling released in response to cardiac overload. The EP3 receptor was inversely related to
EPAC2 as cAMP effector and inducer of ST2 gene (Spearman r = −0.47, p = 0.006) (Figure 4b).
Figure 4. EAT mass increase deregulates EP3 and EP4 molecular expression levels with direct induction
of ST2 gene via the EPAC2 cAMP effector. (a) EP4 lipolytic PGE2 receptor directly correlates with genes
associated with mechano-tissue responses including EPAC2 cAMP effector (Spearman r = 0.46, p =
0.001) and ST2 gene (Spearman r = 0.63, p = 0.002) and inversely with IL-33 molecular expression,
although close to the statistical significance (Spearman r = −0.36, p = 0.05). (b) EP3 anti- lipolytic
PGE2 receptor correlates inversely with both ST2 isoforms and with EPAC2 cAMP effector. (c) EP4
pro-lipolytic isoform of PGE2 receptors is more present than the EP3 anti-lipolytic PGE2 receptor.
To verify whether the increased EAT mass in overweight persons influences the local protein
expression of PGE2 receptors, we used western blot analysis to quantify EP3 and EP4 proteins in
EAT (Figure 4c). The EAT of overweight persons produced less EP3 anti-lipolytic receptor than EP4
pro-lipolytic receptor, suggesting that an increase of EAT mass can deregulate PGE2 control on lipolytic
processes via EP3 reduction, contributing to a local increase in cAMP.
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3. Discussion
EAT is a transducer in obesity and inflammation due to the release of different adipokines that
can influence the metabolism of neighboring tissues, especially of the myocardium, on account its
anatomical position [41]. In obesity, EAT changes its biological characteristics, with consequent
structural and functional abnormalities, leading to impaired myocardial microcirculation, increased LV
volume and size, and LA dilatation [41,42], as in our overweight CVD subjects. The anthropometric
parameters of abdominal obesity—BMI and waist circumference—are currently used for predicting
CVD events associated with insulin resistance [7]. We observed associations between body fatness and
echocardiographic parameters of heart maladaptation. The waist circumference, recognized as the best
anthropometric measurement of abdominal fat, directly correlates with EAT thickness and both LV and
LA dilatation as predictive factor of maladaptive heart response in overweight CVD patients [43]. The
question whether the molecular pattern of EAT can shift to a dysfunctional state when abdominal fat
mass increases, with the promotion of maladaptive LV structural changes, could be partly answered
by our molecular study, where PGE2 molecular regulation is pivotal in the activation of ST2 cardiac
stretch mediator via EPAC2 cAMP effector.
PGE2 is a potent lipid mediator secreted by various cell types in visceral adipose tissue and it
appears to be implicated in the regulation of inflammation and adipocytes functions. Different studies
have noted that the excess accumulation of visceral fat depends on depot-specific expression of key
enzymes involved in adipose tissue functions, including PGE2 biosynthesis-related enzymes [38].
In obesity, PTGES-2 promotes adipose tissue dysfunction, with sustained inflammation and fibrosis,
impaired adaptative thermogenesis and increased lipolysis. PTGES-2, also known as cyclooxygenase-2,
has in fact been shown to be linked to the early onset of type 2 diabetes and insulin resistance in
chronic low-grade inflammation state, especially through the production of PGE2 [38]. In view of
the involvement of body fatness in heart metabolism, we explored PTGES-2 expression in EAT from
overweight CVD patients and echocardiographic parameters of LV enlargement. Our overweight
CVD subjects showed a linear correlation between PTGES-2 molecular expression in EAT and cardiac
abnormalities associated with LV remodeling, denoting a possible involvement of dysfunctional EAT
metabolism and maladaptive heart response. Since adipogenic and lipolytic processes are driven by
intracellular cAMP concentrations under PGE2 control, we examined the molecular relation between
PGE2 metabolism in EAT and the expression of genes linked to adenylyl cyclases. There was a positive
association between PTGES-2 and the main isoforms of adenylyl cyclases responsible for cAMP
synthesis, underling its involvement in intracellular cAMP concentrations during fat mass increase.
This is confirmed by the molecular association of PGE2 receptors with ADCYs genes. There was an
interesting inverse relation between EP3 receptor and ADCY isoforms, confirming its involvement
in adipogenic processes, and noteworthy direct associations between EP4 and ADCYs involved in
intracellular cAMP increases. The increase of lipolysis driven by cAMP intracellular level, may be one
of the factors contributing to obesity-related insulin resistance controlled by PGE2 receptors in visceral
adipose tissue. The EP3 receptor leads to lower rates of lipolysis and in adipose tissue its deletion
may promote an obese phenotype in adult mice [27]. We found EP3 molecular expression correlated
positively with the factor predicting insulin resistance, suggesting its potential protective role against
obesity-related disorders in overweight CVD subjects. In view of the role of cAMP intracellular levels
in the regulation of adipogenic and lipolytic processes driven by PGE2 metabolism, and the pivotal role
of PTGE-2 in obesity-related disorders, we investigated the involvement of PTGES-2 in the expression
of EPAC2, known as a cAMP effector and recently associated with ST2/IL-33 mechanosensitive system
involved in the maladaptive heart response. We previously demonstrated when there is an increase
in EAT mass, EPAC2 can upregulate ST2 gene, which is a powerful inducer of both cardiac and fat
remodeling [23]. Through alternative splicing this gene can transduce for ST2L and sST2 proteins
with opposite biological effects: the transmembrane isoform, ST2L can promote cell survival and
anti-fibrotic signaling through binding with the IL-33 alarmin protein in cardiac and fat cells [15,18].
In contrast, the truncated soluble isoform, sST2, functioning as a decoy receptor, sequesters IL-33
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alarmin protein into extracellular space, preventing ST2L/IL-33 signaling and promoting cardiac and
fat tissue maladaptive responses [18]. In view of the role PTGES-2 in obesity and in the control
of intracellular cAMP concentrations through PGE2 receptors [30,32], we investigate the possible
association between PTGES-2 and EPAC2 cAMP effector and ST2/IL-33 mechanosensitive genes.
We found active expression of EPAC2 in EAT from overweight CVD subjects and an interesting
direct association between PTGES-2 and EPAC2 genes EAT mass increases. Moreover, PTGES-2
inversely correlates with IL-33 alarmin expression and positively with the ST2 gene, reinforcing the
hypothesis that PGE2 metabolism, which controls intracellular cAMP levels, can also influence the
molecular expression of the ST2/IL-33 mechanosensitive genes, through EPAC2. Since in a murine
model of macrophages PGE2 played a pivotal role in production of IL-33 through EP4-cAMP-EPAC [39]
dependent pathway, we looked into the molecular involvement of EP3 and EP4 expression in EAT from
overweight CVD subjects and ST2 and IL-33 expression as molecular transducers of maladaptive tissue
response. The EP4 receptor correlated directly with EAT thickness, suggesting that EAT mass increase
promotes EP4 local expression. Moreover, EP4 directly correlated with EPAC2 and ST2 genes and
inversely with IL-33, suggesting its involvement in maladaptive tissue response through EPAC2/ST2
signaling. In contrast, EP3 seems involved in ST2L local expression in case of EAT mass increase and
inversely correlates with total sST2 circulating levels, suggesting its possible role in the prevention of
maladaptive tissue responses. The local protein production of EP3 and EP4 receptors is expressed
differently in EAT from overweight CVD patients. EP4—implicated in lipolytic processes—are more
present than EP3 receptor protein, suggesting that when EAT mass increases, deregulated PGE2
metabolism seems to be addressed to increased intracellular cAMP level, with consequent upregulation
of EPAC2 cAMP effector which is closely involved in ST2 gene expression.
4. Materials and Methods
4.1. Study Population
This study is conducted on 33 male CVDs patients enrolled at I.R.C.C.S. Policlinico San Donato
(San Donato Milanese, Milan, Italy) who underwent open heart surgery. Patients with recent acute
myocardial infarction, malignant disease, prior major abdominal surgery, renal failure, end-stage heart
failure (HF) and more than 3% variation in body weight in the previous 3 months were excluded.
Demographic, anthropometric and clinical data including age, sex, and family history of hypertension,
diabetes and CAD are recorded. In accordance to the preoperative coronary angiographic examination,
23 were ischemic patients with CAD undergoing elective coronary artery bypass grafting surgery and
10 were VHD patients receiving valvular replacement. Before surgery, EAT thickness was evaluated
by echocardiography. The study protocol was approved by the local Ethics Committee (ASL Milano
Due, protocol number 2516; date: 28 December 2009) and patients gave their written informed consent
to the examination protocol, conducted in accordance with the Declaration of Helsinki, as revised
in 2013. A flow chart which shows the experimental procedure of the study setting is included as
Supplementary Figure S1.
4.2. Blood Collection and Measurements
Blood samples were collected after overnight fasting into pyrogen-free tubes with
ethylenediaminetetraacetic acid as anticoagulant. Plasma samples were separated after centrifugation
at 1000× g for 15 min and were stored at −20 ◦C until analysis. Fasting glucose, glycated hemoglobin
(HbA1c), creatinine and N-terminal pro B-type natriuretic peptide (NT-pro BNP) were quantified with
commercial kits using Cobas 6000 analyzer (Roche Diagnostics, Milan, Italy). Plasmatic level of sST2
was assayed by enzyme-linked immunosorbent assays (ELISA) (R&D Systems, Minneapolis, MN,
USA).
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4.3. Quantification of EAT and SAT Collection
Pre-surgical EAT quantification was quantified by echocardiography with a 2.5- to 3.5-MHz
transducer probe (Vingmed-System Five; General Electric, Horten, Norway). EAT thickness was
measured along the free wall of the right ventricle from both parasternal long-and short-axis views
as previously reported [13]. This point is where EAT generally shows the major thickness and is
measurable more easily [13]. EAT thickness at level of the right ventricle free wall is normally 7
mm in both male and female healthy lean individuals; no clinical cut of value is currently validated.
EAT biopsy samples were harvested adjacent to the proximal right coronary artery prior to initiation
of cardiopulmonary bypass pumping. For gene expression analysis, EAT biopsies were stored in
Allprotect Tissue Reagent (Qiagen, Hilden, Germany) at −20 ◦C until RNA and protein extraction.
For immunohistochemical staining assays, EAT biopsies were immediately fixed in paraformaldehyde
4%. To validate RT-PCR assay we collected subcutaneous fat depot (SAT) as control tissue and SAT
biopsies were treated like EAT (Supplementary Figure S2).
4.4. Echocardiography Data of Left Ventricular Mass (LV)
Pre-surgical resting echocardiography (Vingmed-System Five; General Electric, Horten, Norway)
was performed to assess systolic, diastolic and valvular morphology and function. LV hypertrophy
was defined according the current guidelines for echocardiographic chambers quantification.
The outcome measures were LV diastolic diameter (reference values (RV): male 4.2–5.8 cm),
LV systolic diameter (RV: male 2.5–4.0 cm), LV end diastolic volume (EDV) (RV: male 62–150 mL), LV
end systolic volume (ESV) (RV: male 21–61 mL), LV ejection fraction (EF) (RV: male 52–75%), septal
wall thickness (RV: male 0.6–1.0 cm), relative wall thickness (RWT) (RV: male < 0.42%), LV mass (RV:
male 88–224 g), indexed LV (LVM/BSA) (RV: male 49–115 g/m2), left atria (LA) (RV: male < 4 cm),
tricuspid annular plane systolic excursion (TAPSE) (RV: male > 17 mm) and pulmonary artery pressure
(PAP) (RV: male < 35–40 mmHg).
4.5. DNA Microarray Chip Array Expression Assay
Total RNA was extracted from EAT biopsies with the RNeasy Lipid Tissue Kit (Qiagen). RNA
concentration was quantified by NanoDrop 2000 (ThermoScientific, Wilmington, Germany) and RNA
integrity was assessed using the Agilent RNA 6000 Nano kit and the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). Gene expression analysis was performed by one color microarray
platform (Agilent). 50 ng of total RNA was labelled with Cy3 using the Agilent LowInput Quick-Amp
Labeling kit-1 color, according to manufacturer’s instructions. RNA was purified with the RNeasy
Lipid Tissue Mini Kit (Qiagen) and the amount and labelling efficiency were measured with NanoDrop.
Hybridization was performed using Agilent Gene Expression hybridisation Kit and scanning with
Agilent G2565CA Microarray Scanner System. Data were processed using Agilent Feature Extraction
Software (10.7) with the single-color gene expression protocol and raw data were analyzed with
ChipInspector Software (Genomatix, Munich, Germany). In brief, raw data were normalized on single
probe level based on the array mean intensities and statistics were calculated based on the SAM
algorithm by Tusher. From microarray chip analysis, the gene expression of RAPGEF3 (encoding for
EPAC1), RAPGEF4 (encoding for EPAC2), gene associated with PGE2 signaling including PTGES-2
(encoding for PTGES-2 enzyme), PTGER3 and 4 (encoding for EP3 and E4 respectively genes, and
remodeling mediators including IL1RL1 (encoding for ST2L and sST2) and IL-33 were evaluated and
expressed in arbitrary unit (AU).
4.6. Real Time Reverse-Transcription PCR (RT-PCR) Assay
To validate our microarray results, we performed RT-PCR assay for only our target genes. Briefly,
total RNA was extracted as previously described in the above section. First strand cDNA was
synthesized using RT2 first strand kit (Qiagen). Quantitative PCR analysis was then performed with
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RT2 SYBR Green Fast Mastermix (Qiagen) and PCR technology (Rotor Gene Q, Qiagen). Relative
quantification of mRNA expression in the gene of interest was calculated using the comparative
threshold cycle number and the difference between EAT and SAT was evaluated using 2−ΔCT method.
Data were normalized by GAPDH levels and expressed as percentage relative to controls. All PCRs
were performed at least in triplicate for each experimental condition. GAPDH (Qiagen, PPH00150F),
PTGER3 (Qiagen, PPH01838B), PTGER4 (Qiagen, PPH02677A), PTGES2 (Qiagen, PPH16120A), IL1RL1
encoding for ST2 (Qiagen, PPH01076A), IL-33 (Qiagen, PPH17375E), RAPGEF3 encoding for EPAC1
(Qiagen, PPH02838A) and RAPGEF4 encoding for EPAC2 (Qiagen, PPH10495C) genes were measured.
4.7. Western Blot Analysis
EAT tissue was homogenized using MinuteTMTotal Protein Extraction kit for Adipose
Tissue/Cultured Adipocytes kit (Invent Biotechnologies, Inc), according to the manufacturer’s
instructions. Aliquots of 30 μg of total proteins were electrophoresed on SDS Mini-PROTEAN®
TGXTM Stain-Free Precast Gels (BIO RAD, Hercules, CA, USA) and transferred to nitrocellulose
membrane of Trans-Blot® Tranfer System Transfer Pack (BIO RAD) on Trans Blot® TurboTM device
(BIO RAD). Membranes first blocked with 5% nonfat dry milk/TBS with 0.1% (Vol/Vol) Tween 20
for 1 h and then incubated overnight at 4 ◦C with primary antibodies for: vinculin (Cell Signaling,
Denver, MA, USA; 1:1000), PTGER3 (Proteintech, Manchester, United Kingdom; dilution 1:500) and
PTGER4 (Proteintech, Manchester, United Kingdom, dilution 1:700). After washing, membranes are
incubated with appropriate horseradish peroxidase (HRP)-labeled secondary antibodies for 2 h at room
temperature. Immunoreactive protein bands were then detected using ECL chemiluminescence kit
(BIO RAD) using ChemiDoc MP Imaging System (BIO RAD). Desitometric analyses were performed
using Image Lab 5.2.1 software (BIO RAD). Data were normalized on total protein quantity after
stain-free blot or ponceau staining and presented as percentage density volume (%). All Western Blots
were performed at least in duplicate. The full blots were provided in Supplementary Figure S3.
4.8. EPAC2 Immunohistochemical Staining in EAT Sections
Deparaffinised EAT sections were rehydrated and antigen retrieval was performed by autoclaving
in sodium citrate buffer 0.01 M pH 6 for 5 min at 120 ◦C. After rinsing in PBS 1X, quenching of endogenous
peroxidases activity was performed in 0.3% H2O2 in PBS for 20 min. To block unspecific binding,
sections were incubated with normal swine serum (Dako Cytomation) and then with the following
primary antibody: mouse monoclonal anti-human EPAC2 (diluted 1:400 in PBS, Cell Signaling)
overnight and overnight. Sections were then rinsed in PBS and processed for the amplification of
immune signal using anti-mouse HRP-polymer complex (MACH 1 Universal HRP-Polymer detection,
Biocare Medical, Concord, CA, USA). BIOCARE’s Betazoid DAB was used for color development
Sections were counterstained with Mayer’s hematoxylin and mounted with Mowiol 4–88.
Immunohistochemical reactions were observed with a Nikon Eclipse 80i microscope and images
acquired by the digital camera and the image acquisition software.
4.9. Statistical Analysis
Data were expressed as mean ± standard (SD) and analyzed by GraphPad Prism 5.0 biochemical
statistical package (GraphPad Software, Inc., San Diego, CA, USA). The normality of data distribution
was assessed by the Kolmogrov-Smirnoff test. Comparison between groups was performed using
two-tailed unpaired Student t test or Mann-Whitney U-test as appropriate. Spearman or Pearson
correlation analyses were used to examine the association between different variables. All differences
with p < 0.05 was considered statistically significant.
5. Conclusions
In summary, our data reinforce the current knowledge on PGE2 control of cAMP levels through
EP3 and EP4 receptors, and, in case of EAT mass increase, EP3 deregulation seems to be associated
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with the increase in lipolytic processes with consequent molecular upregulation of the newer inducer
of ST2/IL-33 mechanosensitive system, the EPAC2 cAMP effector, in overweight CVD subjects. Further
research is now needed to clarify the role of PGE2 metabolism in the induction of ST2/IL-33 so as to
pave the way to potential therapeutic strategies to prevent cardiac/fat tissue maladaptation driven
by obesity.
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Abbreviations
CAD Coronary artery disease
VHD Valve heart disease
EAT Epicardial adipose tissue
sST2 soluble stimulating growth factor 2
ST2L Transmembrane isoform of ST2
IL-33 Interleukin-33
EPACs Echange proteins directly activated by cAMP
EPAC1 Echange proteins directly activated by cAMP isoform 1
EPAC2 Echange proteins directly activated by cAMP isoform 2
PGE2 Prostaglandin E2
PTGES-2 prostaglandin-endoperoxide synthase 2





EDV LV end diastolic volume
IL-33 Interleukin-33
LVM Left ventricular mass
LVM/BSA Indexed left ventricular mass
BSA Body surface area
NT-pro BNP N-terminal pro B-type natriuretic peptide
CRP C reactive protein
HF Heart failure
RTW Relative wall thickness
HOMA Homeostatic Model Assessment for Insulin Resistance
WHR Waist hip ratio
ADCYs Adenylyl cyclases
RV Reference value
ESV LV end systolic volume
TAPSE Trycuspid annular plane systolic excursion
PAPs Pulmonary artery pressure
RAPGEF3 Gene encoding for EPAC1
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RAPGEF4 Gene encoding for EPAC2
PTGER3 Gene encoding for EP3 receptor
PTGER4 Gene encoding for EP4 receptor
ILRL1 Gene encoding for ST2 proteins
AU Arbitrary unit
PBS Phosphate buffered saline
SAT Subcutaneous adipose tissue
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Abstract: Overweight and adiposity are risk factors for several diseases, like type 2 diabetes and
cancer. White adipose tissue is a major source for adipokines, comprising a diverse group of proteins
exerting various functions. Chemerin is one of these proteins whose systemic levels are increased
in obesity. Chemerin is involved in different physiological and pathophysiological processes and it
regulates adipogenesis, insulin sensitivity, and immune response, suggesting a vital role in metabolic
health. The majority of serum chemerin is biologically inert. Different proteases are involved in
the C-terminal processing of chemerin and generate diverse isoforms that vary in their activity.
Distribution of chemerin variants was analyzed in adipose tissues and plasma of lean and obese
humans and mice. The Tango bioassay, which is suitable to monitor the activation of the beta-arrestin
2 pathway, was used to determine the ex-vivo activation of chemerin receptors by systemic chemerin.
Further, the expression of the chemerin receptors was analyzed in adipose tissue, liver, and skeletal
muscle. Present investigations assume that increased systemic chemerin in human obesity is not
accompanied by higher biologic activity. More research is needed to fully understand the pathways
that control chemerin processing and chemerin signaling.
Keywords: proteolysis; Tango bioassay; biologic activity; chemerin receptors
1. Introduction
The protein chemerin is a chemoattractant for immune cells and it plays a role in adaptive and
innate immunity [1,2]. Chemerin is also an adipokine that regulates angiogenesis, adipogenesis,
and energy metabolism, which demonstrates a multifaceted function of this protein [3–6] (Figure 1).
Positive correlations of systemic chemerin with obesity related phenotypes, such as insulin resistance,
body mass index (BMI), and serum triglycerides, suggest a function of this adipokine in metabolic
diseases [2]. Chemerin deficient mice had higher hepatic gluconeogenesis and increased skeletal
muscle glucose uptake. In the null mice, the phosphorylation of protein kinase B (Akt) was improved
in the muscle upon insulin injection. Of note, glucose stimulated insulin release of pancreatic beta-cells
was impaired in the knock-out animals. Fat pad weight was not changed in the null mice, and serum
leptin and adiponectin levels were also normal. Interestingly, there were less detectable adipose
tissue macrophages. Although this suggests improved insulin sensitivity, insulin induced Akt
phosphorylation was reduced in the fat tissue [7]. A separate study describes that the injection
of recombinant chemerin reduced serum insulin and tissue glucose uptake in the obese mice but
had no effect in the normal-weight animals [8]. In low density lipoprotein (LDL) receptor deficient
mice, the overexpression of chemerin was found to induce insulin resistance in muscle, but not the
liver or gonadal fat. There were no changes in body weight, levels of serum lipids, and severity of
atherosclerosis [9].
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Figure 1. Effect of chemerin on the metabolic status of different organs (inconclusive results indicated
by reverse arrows). Data published so far mostly agree that chemerin impairs skeletal muscle insulin
response. This was not observed in the liver, here gluconeogenesis was enhanced in chemerin deficient
mice. The function of chemerin on blood pressure was modified by gender. Chemerin further
stimulated angiogenesis and vascular inflammation. Adipose tissue weight was not changed by
chemerin. This adipokine may even improve insulin response of fat tissue although the number of
adipose tissue resident macrophages was increased. Stimulatory and inhibitory effects of chemerin on
glucose-induced release of insulin by pancreatic beta-cells was reported. Inconclusive findings may be
partly explained by the different models studied.
Chemerin-stimulated angiogenesis was illustrated in-vitro and in-vivo [10]. Enhanced
angiogenesis and increased endothelial-monocyte adhesion upon chemerin incubation indicate a
proatherogenic role of this adipokine [11] (Figure 1).
Data on the role of chemerin in metabolic disease are not conclusive so far (Figure 1). Chemerin
most likely impairs skeletal muscle insulin sensitivity, although it seems to have a modulatory role in
the liver and adipose tissues. The overexpression of chemerin was shown to increase glucose induced
insulin secretion, whereas the injection of recombinant protein blocked this process in the pancreatic
beta-cell of mice [7,8].
Duration of chemerin signaling, the concentration of chemerin, cell type/tissue analyzed,
chemerin processing, and chemerin receptor expression may vary in the different experiments.
Pathological characteristics of the murine models used may further modify chemerin signaling [2].
The G protein-coupled receptor chemokine-like receptor 1 (CMKLR1) is one of the two described
chemerin receptors with signaling activity so far. The second one is G protein-coupled receptor
1 (GPR1) [6,12,13]. Chemokine receptor-like 2 (CCRL2) is an atypical chemokine receptor that does
most likely not exert any signaling activities [6,12,13]. CCRL2 is supposed to present chemerin to
CMKLR1 and possibly to GPR1 [14]. Chemerin binds with low nanomolar affinity to all of these
receptors [15]. The binding of chemerin to CMKLR1 activated the three Gαi subtypes and the two
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Gαo isoforms. Chemerin stimulated the rise of intracellular calcium and the decline of cyclic AMP
in CMKLR1 expressing CHO cells that are dependent on Gαi signaling [13]. None of the G-proteins
were activated upon binding of chemerin to GPR1 or CCRL2 [15]. Nevertheless, the recruitment of
beta-arrestin 1 and 2 was observed for both signaling competent receptors [15]. Chemerin further uses
the RhoA and Rho-associated protein kinase-dependent pathway downstream of GPR1 and CMKLR1
to activate the transcriptional regulator serum-response factor [16].
Extracellular regulated kinase (ERK) 1/2 was phosphorylated upon chemerin treatment in various
cells, including endothelial cells, adipocytes, and skeletal muscle cells. The activation of ERK1/2 at
low, but not high chemerin concentration, was described in adipocytes [4,17,18]. Chemerin further
activated p38 mitogen-activated protein kinase, Akt and phosphoinositide 3-kinase [2,19]. Short-time
incubation with chemerin was shown to activate Akt in hepatocytes, whereas prolonged treatment up
to two hours led to a decline of phosphorylated Akt in these cells [20]. Notably, one study reports that
chemerin binding weakened the association of phosphatase and tensin homolog (PTEN) with CMKLR1.
This enhanced the activity of PTEN and subsequently led to decreased Akt phosphorylation [20].
The activation of the protein kinase C by chemerin stimulated the internalization of CMKLR1. Blockage
of this pathway enhanced calcium flux and ERK phosphorylation, showing that this mechanism
terminates signaling via desensitization [21]. The nuclear factor kappa B (NFkB) pathway is activated
by chemerin in skeletal muscles cells [18]. In adipocytes, the inhibition of chemerin signaling increased
NFkB activity [22]. Chemerin thus activates various signaling pathways and the effects depend on
incubation time and dose.
As an adipokine chemerin is released by adipocytes [23], but also hepatocytes produce
considerable levels of the protein [24]. Serum chemerin is increased in overweight/obesity
and correlations with obesity associated traits, like low grade inflammation, blood pressure,
and insulin resistance, were identified in some but not all of the patient cohorts studied [1,25–30].
Hence, the associations of systemic chemerin levels with the metabolic syndrome are not fully
resolved [1,25–30]. The serum chemerin levels are heritable with about 16% to 25% of variations
being attributed to genetic factors. Polymorphisms in the gene encoding chemerin (retinoic acid
receptor responder 2, RARRES2) were linked to increased systemic chemerin levels, visceral fat mass,
and a higher incidence of the metabolic syndrome [31–34].
Positive correlations of systemic chemerin with inflammatory cytokines and C-reactive protein
were described in chronic inflammatory diseases [35–37]. Chemerin has a role in the pathophysiology
of rheumatoid arthritis, inflammatory bowel disease, psoriasis, and chronic renal disease [35–37].
More recent findings indicate a function of chemerin in cancer, and the pro- as well as anti-carcinogenic
effects have been identified [38]. It was shown that chemerin suppressed hepatocellular carcinoma
growth but enhanced squamous cell carcinoma migration [39,40].
Whether chemerin is a pro- or anti-inflammatory protein is still debated. Discordant results were
obtained in cell culture studies and animal models [5,12]. Murine (m) Chem156, which is a highly
active chemerin isoform, antagonized the activation of peritoneal macrophages that were triggered
by lipopolysaccharide (LPS) or interferon gamma [41]. Anti-inflammatory effects of mChem156 were
also described in a mouse model of acute lung inflammation induced by LPS [42]. In a colitis model,
mChem156 aggravated inflammation and suppressed M2 polarization of macrophages [43].
Chemerin is secreted as an inactive precursor and it is activated through C-terminal
processing by proteases. Thereby, different isoforms are generated, which have varying biological
effects [5,12]. Chemerin derived C-terminal peptide chemerin 15 acted via CMKLR1 and suppressed
inflammation [41]. The effects were already obvious at picomolar concentrations of the peptide
demonstrating its potent activity [41].
This review article briefly describes the various C-terminal processing forms of chemerin.
The expression of chemerin and its receptors, the distribution of chemerin isoforms, and analysis of
chemerin bioactivity in obesity will be addressed in detail.
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2. Expression of Chemerin and its Receptors in Different Tissues
2.1. Chemerin Expression in Adipose Tissues
Chemerin is most abundantly expressed in white adipose tissues, in the liver, and to a lesser extent
in brown adipose tissue, the lung, skeletal muscles, the kidney, ovary, and the heart [2,25]. Serum
chemerin levels are increased in obesity as a result of enhanced synthesis in fat tissues and possibly the
liver [2]. The explants of adipose tissues from obese donors indeed released higher chemerin protein
amounts than fat tissues that were obtained from lean individuals [18].
2.1.1. Expression of Chemerin in Human Tissues
Chemerin mRNA expression in subcutaneous and omental adipose tissues of patients was higher
in obesity, and it decreased upon bariatric surgery evoked weight loss. Serum chemerin levels changed
accordingly, indicating that adipose tissue is the main site controlling circulating protein levels in
obesity [44]. The inflammatory factors tumor necrosis factor (TNF) and LPS enhanced chemerin
production in adipocyte, thus demonstrating a close association between adipose tissue inflammation
and chemerin synthesis [45–47]. Higher chemerin mRNA expression in visceral fat in obesity was
related to the degree of inflammation, thereby confirming this relationship [46].
Another study described a negative correlation of chemerin mRNA levels in subcutaneous fat
with circulating chemerin protein [48]. In obese patients with non-alcoholic fatty liver disease, neither
subcutaneous nor visceral fat chemerin mRNA expression was associated with its systemic levels [49].
Studies so far mostly suppose that systemic chemerin concentrations are defined by its production in
adipocytes. Whether this is regulated by transcriptional and/or posttranscriptional mechanisms has
not been studied in detail.
2.1.2. Expression of Chemerin in Experimental Models
Whether chemerin expression is upregulated in obese adipose tissues was also analyzed in rodent
models. In mesenteric fat of Psammomys obesus, a rodent animal model of obesity, chemerin mRNA
expression was induced [25]. Female mice that were fed an atherogenic diet for eight weeks had
increased chemerin protein in subcutaneous and visceral fat, and higher systemic chemerin levels
than animals fed the control chow [45]. In epididymal fat of leptin deficient ob/ob and leptin receptor
activity deficient db/db mice, such an induction was not observed when chemerin mRNA expression
was measured [8]. In the db/db mice chemerin protein was two-fold higher when compared to the
lean animals [8]. Chemerin protein was also strongly increased in the gonadal adipose tissue of male
ob/ob mice. Injection of 0.5 μg leptin per gram body weight reduced chemerin protein levels in the
white fat depot [50]. This indicates that leptin resistance, which accounts for metabolic disease in obese
patients, may contribute to elevated chemerin protein [50,51]. In male rats that were fed a high fat
diet for 12 weeks, gonadal adipose tissue chemerin protein levels were nevertheless similar to the
respective controls [50].
Thus, studies in rodents mostly identified higher chemerin protein levels in obese adipose
tissues. Chemerin mRNA and protein expression were analyzed in lean and obese fat and they were
not concordantly regulated. Therefore, posttranscriptional processes seem to control cellular and
eventually soluble chemerin protein levels.
2.2. Chemerin Receptor Expression in Adipose Tissues
The knock-down of chemerin or CMKLR1 in 3T3-L1 adipocyte cell line impaired adipogenesis.
Further, these cells showed reduced expression of genes that are involved in glucose and lipid
homeostasis [4]. Thus, chemerin–CMKLR1 signaling may enhance adipogenesis in obesity to allow
for the storage of surplus lipids. However, when compared to studies measuring chemerin in obesity
(see 2.1.), the expression of the respective receptors has been analyzed in less detail.
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2.2.1. Expression of Chemerin Receptors in Human Tissues
One study showed that CMKLR1 expression was upregulated in visceral fat of obese patients.
TNF induced chemerin in human adipocytes but it had no effect on CMKLR1 mRNA [18,46]. LPS
was a strong inductor of chemerin in murine 3T3-L1 adipocytes, but it did not change the CMKLR1
protein [45]. This argues against a co-regulation of chemerin and CMKLR1 expression in adipocytes by
inflammatory mediators that contribute to insulin resistance and metabolic disease in obesity [52,53].
CMKLR1 is expressed by macrophages and its induction in obese fat tissues may be related to the
increased number of adipose tissue resident macrophages [54].
2.2.2. Expression of Chemerin Receptors in Experimental Models
An experimental model where female mice were fed an atherogenic diet for eight weeks showed
higher CMKLR1 protein in subcutaneous and visceral fat [45]. In mesenteric adipose tissue of
Psammomys obesus, CMKLR1 expression was also induced in obesity. This upregulation was, however,
only seen in the fed state [25]. In epididymal adipose tissue of the ob/ob mice CMKLR1 protein levels
were about five-fold higher when compared to lean wild type animals. The injection of 0.5 μg leptin
per gram body weight reduced CMKLR1 protein level in this white fat depot [50]. An effect of leptin
on CMKLR1 gene expression was, however, not observed in bovine adipocytes [55].
In contrast to the studies suggesting higher CMKLR1 in obese adipose tissue, further analysis in
rats showed that the CMKLR1 protein was strongly reduced in the gonadal fat of male animals that
were fed a high fat diet for 12 weeks [50]. CMKLR1 mRNA expression was also low in the epididymal
fat of ob/ob and db/db mice [8].
Yet, whether CMKLR1 protein is indeed increased in obese fat tissue awaits clarification by
additional studies. Adipocytes and stromal-vascular cells in adipose tissue express CMKLR1 [25,45],
and immunohistochemical approaches have to identify the cell type specific regulation of CMKLR1
in obesity.
Adipose tissue GPR1 is primarily expressed in stromal-vascular cells [56]. Yet, the individual cells
that present this receptor have not been described in detail. GPR1 mRNA was unchanged in gonadal
fat of ob/ob and db/db mice when compared to lean animals [8]. GPR1 mRNA was also comparably
abundant in epididymal fat of mice that were fed a control chow or a high fat diet [56]. The GPR1
protein has to be analyzed in future studies to confirm that GPR1 protein levels are indeed unchanged
in obese adipose tissues.
To our knowledge, only one article regarding CCRL2 levels was published, showing that CCRL2
mRNA was significantly induced in the fat of db/db animals and tended to be higher in the leptin
deficient mice [8].
2.3. Chemerin in the Liver
Chemerin and its receptors are expressed in the liver, but a detailed role of chemerin in hepatic
function and metabolic liver diseases has not yet been explored [3]. Adeno-associated virus mediated
overexpression of human chemerin in the liver of the LDL receptor knock-out mouse model led
to increased systemic chemerin. This illustrates that hepatic chemerin synthesis may presumably
contribute to its systemic levels. Chemerin surplus in these mice was associated with impaired insulin
signaling in skeletal muscle, but not in the liver (Figure 1) [9]. Various hepatoprotective effects of
recombinant mChem156 were identified in murine hepatocellular carcinoma models, but whether this
isoform exists in the liver is still ambiguous [20,40].
2.3.1. Expression of Chemerin in Human Tissue
Human studies that have been published so far describe normal, lower, and higher chemerin
mRNA expression in the liver. Doecke et al. analyzed chemerin mRNA in controls and patients with
non-alcoholic fatty liver disease and described higher hepatic levels in the overweight [57]. In morbidly
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obese patients, hepatic chemerin mRNA showed a trend to be induced in those probands with a BMI
> 40 kg/m2 [58]. In a separate human study, such an association of hepatic chemerin mRNA levels
with BMI was not reported [59]. Another investigation even showed reduced hepatic chemerin mRNA
expression in obesity [60].
2.3.2. Expression of Chemerin in Experimental Models and in vitro Systems
In the db/db mice, hepatic chemerin mRNA, but not protein, was induced [8]. Similarly, chemerin
mRNA was higher in the liver of mice that were fed a high fat diet, whereas cellular chemerin protein
was not concomitantly upregulated [24]. Whether the hepatic release of chemerin protein in obesity is
enhanced needs to be further analyzed. Leptin deficient ob/ob mice develop severe liver steatosis,
whereas the hepatic chemerin mRNA and protein were not changed [8]. Separate investigations even
report reduced hepatic chemerin levels in murine obesity [60].
Inflammatory cytokines, like TNF and LPS, are elevated in obesity and upregulated adipocyte
chemerin [18,45,47]. These factors did not change chemerin expression in hepatocytes [24,47,57].
Leptin did not induce human hepatocyte chemerin levels [24].
Current data show that obesity is not necessarily associated with altered hepatic chemerin
levels. For which reasons the different research groups identified normal, higher, and lower chemerin
expression in the liver of overweight humans and mice is still an open question.
2.4. Chemerin Receptors in the Liver
Analysis of CMKLR1, CCRL2, and GPR1 in the liver of ob/ob and db/db mice revealed that
only GPR1 mRNA was strongly decreased [8]. In mice that were fed a high fat diet hepatic CMKLR1
mRNA was found to be reduced [61]. Human studies described a positive or no association of hepatic
CMKLR1 levels with BMI [57,62]. The CCRL2 mRNA levels were not different in normal-weight and
overweight patients [63].
While CMKLR1 mRNA was found to be expressed in various liver cells, including hepatocytes,
hepatic stellate cells, endothelial cells, and Kupffer cells, CCRL2 seems not to be expressed in
hepatocytes [61,63]. The downregulation of CMKLR1 in Kupffer cells by a phosphatidyl inositol
3-kinase inhibitor improved hepatic insulin resistance and inflammation, suggesting that the
chemerin–CMKLR1 signaling pathway contributes to metabolic disease in obesity by modulating the
function of these immune cells [64]. Here, it has to be considered that resolvin E1 is a further ligand of
CMKLR1, which is well described to have a function in the resolution of inflammation [65].
2.5. Chemerin and its Receptors in Skeletal Muscle
Analysis of chemerin, CMKLR1, CCRL2, and GPR1 in skeletal muscle of ob/ob and db/db mice
revealed that CMKLR1 mRNA was strongly increased in both of the strains. Chemerin was only
upregulated in the muscle of db/db mice [8]. GPR1 mRNA was markedly reduced in soleus muscle
but not in the gastrocnemius muscle of mice that were fed a high fat diet [56].
Although chemerin induces skeletal muscle insulin resistance [18] (Figure 1), the expression of the
corresponding receptors in muscle was not studied in detail. Analysis of chemerin and its receptors
in skeletal muscle tissues of rodents and humans is needed to further understand the role of this
adipokine in skeletal muscle insulin resistance.
3. Chemerin Isoforms and Activity in Adipose Tissue and Serum
3.1. C-terminal Processing and Activity of Chemerin Isoforms
The open reading frame of the human chemerin gene codes for a 163 amino acid protein.
The secreted form is shorter by 20 amino acids due to the removal of the N-terminal signal peptide [2].
N-terminally cleaved chemerin with an intact C-terminus is traditionally named hChem163, although
it only consists of 143 amino acids [19]. The number in the abbreviation thus corresponds to the
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respective amino acid position of the full-length protein. The analogous murine chemerin protein is
one amino acid shorter and it is designated as mChem162. Human and murine chemerins are 64%
identical with a similarity of 78% [6,66].
HChem163 and mChem162 need to be processed at their C-termini to become active proteins.
Proteolytic cleavage by extracellular proteases at distinct C-terminal sites generates highly active, high
active, moderate active, and inactive isoforms [2,66] (Figure 2). The similarity between human and
murine chemerin suggests that protease cleavage sites are conserved between these two species [66].
Chemerin isoform bioactivity was mostly determined by chemotaxis assays and/or the analysis of
intracellular calcium release. These assays revealed that hChem157 had the highest activity [2,13,67].
Analysis was undertaken with primary monocyte-derived dendritic cells and murine pre-B lymphoma
L1.2 cells overexpressing human CMKLR1 [13,67].
Figure 2. Processing of human chemerin. The proteases contributing to C-terminal processing of
chemerin and the respective isoforms generated are shown. Inactive isoforms are in grey boxes,
biologic active isoforms in red boxes. The intensity of the red color corresponds to the activity of the
chemerin isoform (intense red: very active isoform). Activity has been mostly analyzed using Ca2+ flux
and migration assays in chemokine-like receptor 1 (CMKLR1) expressing cells. Angiotensin converting
enzyme converts hChem154 to hChem152. This is not shown in the figure. HChem154 is produced
by different proteases and the enzymes upstream of angiotensin converting enzyme have not been
identified yet.
HChem157 is produced by cathepsin K and L, and human leukocyte elastase cleavage of
hChem163 [67,68] (Figure 2). HChem156 was as active as hChem157 when it was analyzed in
a signal transduction assay using cells with CMKLR1 overexpression [69]. The analysis of Ca2+
mobilization using L1.2 cells stably expressing human CMKLR1 revealed that the shorter isoform
was by far less active than hChem157 [70]. HChem156 originates from hChem163 by cathepsin G
and chymase cleavage [70,71] (Figure 2). The serine protease kallikrein 7 also produced hChem156
from prochemerin, and it may contribute to chemerin activation in the skin [69]. HChem158 and
hChem155 are low active isoforms. HChem158 was produced by plasmin, tryptase, and factor XIa
cleavage [67,72] (Figure 2). HChem155 derives from hChem163 by elastase, proteinase 3, or tryptase
mediated proteolysis [67,71]. Elastase, cathepsin K and L, and chymase also contribute to chemerin
inactivation by further C-terminal processing [67,68,71] (Figure 2).
Angiotensin converting enzyme is a carboxypeptidase and it removes C-terminal dipeptidyl
residues amongst others from angiotensin I to obtain the vasoconstrictor angiotensin II [73], thereby
controlling blood pressure. This enzyme was shown to produce hChem152 from hChem154 [74].
Chemerin affects several pathways that control blood pressure, indicating a function of this adipokine
herein [17,75] (Figure 1). Of note, systemic chemerin was increased in patients with hypertension
indicating that this adipokines may increase blood pressure [76,77]. Surprisingly, hypertensive male
rats with knock-out of chemerin had elevated mean and systolic blood pressure. In female rats,
chemerin deficiency was associated with lower pressures, as one would have expected [78]. A second
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study using male rats observed decreased arterial blood pressure upon chemerin knock-down [79].
These studies show that chemerin has a causative function in blood pressure control, which is
modified by gender. Analysis of chemerin isoform distribution in females and males and normo- and
hypertensive patients may clarify the role of angiotensin converting enzyme mediated proteolysis of
chemerin herein. Murine mChem156, which is a highly active isoform, increased blood pressure in
male mice [75]. Whether this isoform is present in hypertension in biologically relevant concentrations
needs to be elucidated.
Proteolytic cleavage sites for human chemerin, which are described above, are conserved in
mice [66]. Here, mChem156 and mChem155 had nearly similar activities in Ca2+ mobilization and
chemotaxis assays. A 15- to 20-fold lower potency was measured for mChem161 and mChem157 [66].
The authors of this paper failed to express recombinant mChem162, and mChem161 was detectable in
the supernatants of the transfected cells. It was suggested that mChem161 had similar properties to
mChem162. MChem154 did neither have chemoattractant properties nor did it induce Ca2+ release [66].
Activities of the various chemerin isoforms may deviate from the activity ranking that is described
above in men and mice when biologic effects other than chemotaxis and Ca2+ influx are tested.
For analysis of chemerin isoform activity, mostly cells with CMKLR1 overexpression were used [66,71].
These results may differ from chemerin induced GPR1 signaling that has been studied in less detail.
Which of the receptors is more relevant for the biological and pathophysiological effects of chemerin is
mostly unknown.
Processing of chemerin by various proteases produces different isoforms that differ in their
activity. Short variants are mostly inactive and they may even antagonize the active isoforms [80].
This demonstrates that a complex regulatory network controls chemerin bioactivity. The analysis of
total chemerin protein levels cannot provide appropriate information regarding its biologic activity.
There was even discrepancy when measuring total chemerin protein with a pan-chemerin ELISA
or isoform specific ELISAs. The EC50 values (the concentration of antibodies showing half-maximal
binding) of the human pan-chemerin ELISA were lower for hChem163, hChem158, and hChem155
when compared to hChem157. Thus, the analysis of samples with a low level of Chem157 using this
pan-chemerin assay will underestimate the actual chemerin concentration [81]. EC50 values for the
different murine chemerin isoforms vary by up to two-fold when using a commercial pan-chemerin
ELISA kit. Using this assay to measure total chemerin will give too high values in samples that contain
mChem155 and mChem154, and too low values when mChem162 and mChem157 are the abundant
variants [66].
Chemerin isoforms in body fluids, cell supernatants, and tissues can be exactly defined by liquid
chromatography/mass spectroscopy [81]. Isoform specific chemerin ELISAs have been established
and they were used for the quantification of the individual human and murine variants [66,81].
The so-called Tango bioassay was developed to determine G protein-coupled receptor ligand induced
beta-arrestin 2 recruitment [82] and it was applied to measure chemerin bioactivity in cell culture
supernatants and plasma [47,83,84].
3.2. Quantification of Chemerin Activity with the Tango Bioassay
The Tango bioassay can quantitatively measure CMKLR1 and GPR1 beta-arrestin 2 activation [47].
In this analysis, human embryonic kidney (HEK) 293T cells that constitutively express a tobacco etch
virus (TEV) protease fused to beta-arrestin 2 are used. Furthermore, these cells encode a reporter
gene whose expression is induced by a transcriptional-transactivator (tTA). To test for the bioactivity
of chemerin, the HEK293T cells are transfected with a plasmid encoding either CMKLR1 or GPR1.
The C-terminus of these receptors carries a TEV N1a protease cleavage site and the tTA. Chemerin
induces the recruitment of the beta-arrestin 2–protease fusion protein to GPR1-tTA or CMKLR1-tTA.
The protease cleaves the TEV N1a site and it releases tTA, which passes into the nucleus. Here,
tTA enhances the transcription of the respective reporter gene. By using appropriate standards,
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the biological activity of chemerin in different samples can be quantitatively determined. One has to
keep in mind that only the beta-arrestin 2 dependent pathways are analyzed by these activity assays.
The human CMKLR1 based Tango bioassay revealed that murine chemerin activated this
receptor. CMKLR1 activation was confirmed in murine adipocyte and hepatocyte conditioned
media, demonstrating that both cell types produce bioactive chemerin [47]. TNF induced total
chemerin protein in 3T3-L1 adipocytes and chemerin bioactivity in the supernatants was accordingly
increased [47]. Mice that were injected with TNF had higher serum chemerin, which had a higher
potency to activate CMKLR1 [47]. Therefore, the inflammatory cytokine TNF enhances chemerin
production and concentrations of bioactive chemerin isoforms.
TNF is increased in obesity and it contributes to insulin resistance [85]. One may assume that low
grade chronic inflammation in obesity may activate chemerin, which subsequently impairs skeletal
muscle insulin resistance. However, recent research that is summarized in the next paragraphs did not
report on higher chemerin activity in obesity.
3.3. Ex-vivo Analyzed Systemic Chemerin Activity in Human and Murine Obesity
Among the most widely used rodent models in obesity and type 2 diabetes research are the ob/ob
mice and the db/db mice [86]. In both strains, the total serum chemerin protein and ex-vivo activation
of CMKLR1 were about two-fold higher than in C57BL/6 controls [8]. A second study did not find
higher CMKLR1 activity in the ob/ob mice [83]. The ob/ob mice in both of the studies were about
three months old [8,83], excluding that different age contributed to this discordant findings. GPR1
activation was measured in the second study and it was found to rise in parallel to the total chemerin
protein [83]. In mice that were fed a high fat diet for 14 weeks, CMKLR1 and GPR1 activities were
induced. The ratio of bioactive chemerin to total chemerin was higher in the overweight animals
with respect to CMKLR1 activation. This effect was not identified with regard to GPR1 activity [83].
This indicates that these receptors may vary in their affinity for distinct chemerin isoforms.
These experiments clearly show that chemerin bioactivity does not always correspond to
total systemic chemerin protein levels, at least when measuring chemerin-induced beta-arrestin
2 recruitment [8,83].
To our knowledge, CMKLR1 activation was measured in only one study in human obesity. Here,
the total circulating chemerin protein was detected by a pan-chemerin ELISA and ex-vivo CMKLR1
activity was determined with the beta-arrestin 2 Tango bioassay [84]. Obese females had higher total
serum chemerin and unchanged CMKLR1 activation when compared to normal-weight women. Thus,
the ratio of bioactive to total chemerin levels was significantly reduced in the obese [84]. This even
reflects impaired chemerin activity, despite higher total systemic chemerin protein.
In this study, circulating chemerin protein and CMKLR1 activation were also investigated in the
postprandial phase. Chemerin levels and ex-vivo CMKLR1 activation were similar in the fasted and
the postprandial state [84]. This is in line with a previous analysis in a cohort of healthy individuals,
where serum chemerin was similar in the fasted state, 1 h and 2 h after oral glucose uptake [87].
Impaired postprandial glucose and lipid clearance contribute to metabolic disease in obesity [88].
Current data principally argue against a function of chemerin herein.
3.4. Chemerin Isoforms in Serum
In human plasma, inactive, full-length chemerin (hChem163) was by far the most abundant
form [81]. HChem157 was about 25-fold and hChem155 about 300-fold less present (Figure 3).
The plasma levels of hChem157 were below the EC50 of about 1.2 +/- 0.7 nm, which was determined in
the calcium mobilization assay using CMKLR1 expressing cells [80,81]. Type of diet, gender, and age
were not associated with changes in chemerin isoform distribution, which was relatively invariable in
lean volunteers during three years of follow up [81]. Systemic chemerin may thus reflect a reservoir of
biologically inactive prochemerin that can be very quickly activated upon request.
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Figure 3. Chemerin isoform distribution in human obesity. The different chemerin isoforms identified in
human plasma, subcutaneous and omental adipose tissues are shown. The concentrations analyzed by
chemerin isoform-specific ELISAs in the tissues are given as ng chemerin/mg adipose tissue. Truncated
(trunc.) isoforms are relatively short and they are most likely not biologically active. Comparison of the
chemerin levels in the lean and the obese probands revealed that only the truncated forms in plasma
are significantly induced in the latter.
Total chemerin protein that was analyzed by an ELISA supposed to measure all isoforms was
higher in the overweight and the obese. The concentration of the chemerin isoforms hChem163,
hChem157, and hChem155 was, however, not markedly changed in the overweight individuals or in
obesity (Figure 3). So-called unattributed chemerin variants appeared in the plasma of the overweight
and the obese. These chemerin forms were detected by commercially available chemerin ELISAs,
but not by ELISAs that were designed to specifically measure hChem163, hChem157, or hChem155.
These short variants had relatively large C-terminal truncations and hChem144 was significantly
induced in the plasma of the obese [81]. The truncated chemerin variants were most likely biologically
inactive, demonstrating that higher chemerin protein in obesity was not linked to increased chemerin
bioactivity. Positive correlation of unattributed, truncated chemerin levels and elastase in blood
suggests that this enzyme may participate in chemerin processing and inactivation. Because truncated
forms of chemerin were not present in adipose tissues, proteolysis has to occur in the extracellular
space and/or in blood [81].
In mice that were fed a high fat diet for 26 weeks (starting with six week old animals), the total
plasma chemerin was increased and this was attributed to higher levels of inactive mChem162.
Of note, 12 weeks high fat diet feeding raised mChem157 and mChem156 in plasma, and here, these
two isoforms represented about 55% of systemic chemerin. Indeed, the levels of mChem157 and
mChem156 were highest in the 12 week high fat diet fed mice when compared to animals that were
fed a low fat diet for 12 or 26 weeks and the mice fed a high fat diet for 26 weeks. The authors of this
work suggested that production of the highly active chemerin form coincides with the time of early
adipogenesis that is promoted by chemerin [4,66]. The biologically modest-active mChem157 may
be the source for mChem156 production, a hypothesis that has to be proven in future studies [66].
The levels of the isoforms mChem157 and mChem156 were similar in mice that were fed a low or a
high fat diet for 26 weeks. MChem155 and mChem154 isoforms were not significantly different in the
lean and the obese mice and when analyzed 12 or 26 weeks after starting the experiments [66]. ELISA
only detected mChem154 at low levels in the older animals, while in the younger mice this isoform
was not measured at all. MChem155, which was as active as mChem156, accounted for about 6.4–7.7%
of total plasma chemerin, irrespective of age and diet [66].
The total chemerin protein levels and mChem162 were higher in the older mice, irrespective of
the diet, while further isoforms were unchanged, showing that the aging of mice is associated with
elevated levels of biologically inactive plasma chemerin [66].
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3.5. Chemerin Isoforms in Adipose Tissues
Serum chemerin is supposed to be mainly derived from adipose tissues [1,2,8,47]. Unexpectedly,
an analysis of chemerin isoforms in human subcutaneous and omental fat revealed that hChem163,
which is the most prominent chemerin protein in the circulation, was not the dominant form in these
tissues [81]. Indeed, in human subcutaneous adipose tissue, hChem157 represented about 90% of the
three isoforms analyzed, which were hChem155, hChem157, and hChem163. In omental fat, about
80% of the chemerin isoforms was hChem155, while about 20% was hChem157 (Figure 3). HChem163
constituted approximately 1–2% of total omental fat chemerin protein [81] (Figure 3). The levels
of the active hChem157 isoform in the fat depots were 1,000-fold higher than in plasma and by far
sufficient to induce calcium mobilization in CMKLR1 expressing cells [80,81]. The total chemerin
protein was more abundant in the omental fat depot, but it was unchanged in both adipose tissue
depots in obesity. Truncated chemerin isoforms that were detected in plasma of the obese did not exist
in the fat tissues [81] (Figure 3).
In murine epididymal adipose tissue of 18 week old mice, mChem155 was the predominant form,
representing nearly 100% of total chemerin protein. This was completely changed when analyzing this
fat depot 14 weeks later. Here, 85–91% was mChem162, approximately 5 to 10% was mChem154, while
mChem155 was about 1–2%. MChem157 and mChem156 were not detected in the adipose tissues
of the mice. High fat diet feeding for 12 or 26 weeks did neither affect total chemerin protein nor
chemerin isoform distribution [66]. In this animal model, mChem155, but not mChem156, was the
active chemerin isoform in the intraabdominal fat depot [66]. Chymase positive mast cells are localized
in adipose tissues and this protease may generate mChem155 from prochemerin [70,89].
In the older mice, total chemerin protein in epididymal fat even declined in obesity, and it
was negatively correlated with body weight, amount of fat, and plasma total chemerin protein [66].
Adipocytes differentiated from murine primary mesenchymal stem cells secreted chemerin and
mChem152, -156, -158, -159, -160, -161, and -162 were detected in the supernatants [22]. Chemerin
isoform abundance was, therefore, completely different in murine epididymal fat tissue and in-vitro
differentiated murine adipocytes. This indicates that proteases that were produced by stromal-vascular
cells contribute to chemerin processing in the fat depots.
Brown adipose tissue expressed about 15-fold lower levels of total chemerin protein when
compared to epididymal fat of mice. While high fat diet feeding for 12 weeks did not change chemerin
protein, it was induced in obesity when this diet was given 14 weeks longer [66].
Chemerin isoform distribution in adipose tissue was completely different from the variants that
were found in the circulation. Prochemerin was released into the circulation, while further processed
chemerin was present in fat tissues. Isoform distribution was not changed in obesity in mice and men.
In murine fat tissue chemerin isoforms abundance was mostly affected by age and this may be related
to the phase of life with increased adipogenesis [66,81].
4. Conclusions
Chemerin’s importance in physiological and pathophysiological processes has been illustrated
in numerous clinical and experimental studies. The role of chemerin is, however, incompletely
understood. Systemic chemerin is increased in obese mice and humans, while its bioactivity is not
concordantly changed. The signal transduction pathways and the physiologic function of GPR1 are
mostly unstudied. The biologic activity of the chemerin isoforms binding to this receptor has not been
characterized in detail. Chemerin processing seems to be changed in obesity. The respective proteases
that are involved herein are still not defined. Synthetic chemerin-derived peptides that resemble the
C-terminal amino acids of this adipokine reduce inflammation and enhance phagocytosis [41,90],
and they may be used as therapeutic agents for the treatment of metabolic diseases and possibly
further chronic inflammatory disorders.
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Abstract: Chemerin is widely recognized as an adipokine, with diverse biological roles in cellular
differentiation and metabolism, as well as a leukocyte chemoattractant. Research investigating
the role of chemerin in the obesity–cancer relationship has provided evidence both for pro- and
anti-cancer effects. The tumor-promoting effects of chemerin primarily involve direct effects on
migration, invasion, and metastasis as well as growth and proliferation of cancer cells. Chemerin
can also promote tumor growth via the recruitment of tumor-supporting mesenchymal stromal cells
and stimulation of angiogenesis pathways in endothelial cells. In contrast, the majority of evidence
supports that the tumor-suppressing effects of chemerin are immune-mediated and result in a shift
from immunosuppressive to immunogenic cell populations within the tumor microenvironment.
Systemic chemerin and chemerin produced within the tumor microenvironment may contribute to
these effects via signaling through CMKLR1 (chemerin1), GPR1 (chemerin2), and CCLR2 on target cells.
As such, inhibition or activation of chemerin signaling could be beneficial as a therapeutic approach
depending on the type of cancer. Additional studies are required to determine if obesity influences
cancer initiation or progression through increased adipose tissue production of chemerin and/or altered
chemerin processing that leads to changes in chemerin signaling in the tumor microenvironment.
Keywords: cancer; obesity; adipokine; chemerin; chemokine-like receptor 1; G protein-coupled
receptor 1; C-C chemokine receptor-like 2
1. Obesity and Cancer
Overweight and obesity rates have increased steadily for several decades and at present are a
major global health crisis of epidemic proportions [1]. Recent estimates indicate that approximately
1.5 billion adults are overweight, while a further 600 million are obese [1,2]. While the rise of obesity
prevalence has slowed in some countries, it is predicted that global rates will continue to increase with
time and thereby exacerbate the health impact of this disorder [3]. Obesity is directly linked to a decline
in quality of life and overall reduced life-expectancy as well as being a major risk factor for several
prevalent metabolic, cardiovascular, and malignant disorders. Among these, cancer continues to be a
leading cause of death worldwide that is attributable to an estimated 14 million incident cases and
8 million deaths annually [2,3]. In addition to other well-established risk factors for cancer (e.g., genetics,
tobacco use, ionizing radiation, environmental exposure), obesity is now recognized as a risk factor for
several malignancies [4,5]. These include cancers of the digestive and secretory systems (e.g., colon,
stomach, liver, esophagus, kidney, gallbladder), female and male reproductive systems (e.g., ovary,
postmenopausal breast, endometrium, prostate), and hematological systems (e.g., non-Hodgkin’s
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lymphoma, multiple myeloma, leukemia) [6–9]. Thus, with the increasing prevalence of obesity in our
society, it is predicted that this disorder will soon surpass smoking as a leading significant preventable
cause of cancer [10].
2. Role of Adipokines
While the linkage between obesity and cancer risk is an active area of investigation, the underlying
biological mechanisms are not well understood. Moreover, many tumors develop in an adipocyte-rich
environment. For example, adipocytes are a major cellular component of the mammary fat pad, and
recent evidence indicates that these cells have dynamic interactions with cancer cells to modulate
tumor growth and metastases [11,12]. Thus, local and ectopic fat depots may have an impact on cancer
development that is not reflected or predicted by overall fat mass. The local and systemic alterations
in physiology that are associated with obesity have the potential to impact cancer in many respects
through direct effects on cancerous cells or indirect effects on the tumor microenvironment or immune
function. As such, obesity can impact tumor initiation, metabolic reprogramming, angiogenesis,
progression, and response to therapy variously.
Obesity is characterized not only by a generalized expansion of adipose, but also the development
of a progressive metabolic and endocrine dysfunction characterized by profound alterations in the
production of several factors including lipids, hormones, pro-inflammatory cytokines, and a suite
of adipose derived-signaling molecules termed adipokines [13,14]. Adipokines are a heterogeneous
group of peptides, mainly produced by adipose tissue, that fulfill critical regulatory roles in energy
homeostasis and metabolic health [15,16]. Obesity-related alterations in the amounts and/or spectrum
of adipokine release have been linked to metabolic disorders such as hyperlipidemia and type 2
diabetes and are increasingly recognized as a key factor linking obesity with cancer. For example,
adiponectin is an adipokine with established pleiotropic roles in regulating insulin-sensitivity as well
as lipid and glucose homeostasis [4]. Circulating levels of adiponectin are inversely correlated with
adiposity and this is believed to contribute to the increased risk for obesity-related comorbidities such
as type 2 diabetes and metabolic syndrome [4]. Lower levels of this adipokine have also been linked to
an increased risk for several types of cancer [17,18]. In contrast to adiponectin, circulating levels of
the adipokine leptin increase in proportion to fat mass. While different epidemiological studies have
offered conflicting results regarding the impact of leptin on general cancer risk, a recent meta-analysis
of 23 studies reported a positive association with breast cancer risk [19]. Moreover, overexpression
of the receptor for leptin has been found in breast cancer and in particular for higher-grade tumors
associated with metastasis and poor clinical prognosis [20–23].
3. Chemerin
Chemerin is a multifunctional secreted protein with established roles in energy metabolism,
immune function, and fundamental cell processes such as differentiation, proliferation, and
chemotaxis [24,25]. Consistent with its role as an adipokine, evidence from clinical and animal
studies have firmly established that secretion and circulating levels of chemerin increase with adiposity
and decline after bariatric surgery, diet, and exercise-based weight loss [26–35]. In addition to adipose
tissue, chemerin is highly expressed in many other human tissues including the adrenals, liver, female
reproductive organs, mammary tissue, and lung (Data Source: GTEx Analysis Release V7 (dbGaP,
Accession phs000424.v7.p2, accessed on 29 July 2019)) as well as cell types such as intestinal epithelial
cells, platelets, keratinocytes, synovial fibroblasts, and vascular endothelial cells [36–40]. Therefore,
when assessing a role for this adipokine in cancer, the impact of chemerin produced locally within the
affected tissue and/or tumor microenvironment must be considered in addition to systemic levels of
circulating chemerin.
Chemerin is synthesized as pre-prochemerin, which requires N-terminal cleavage of a 19-amino
acid signaling domain prior to its secretion as a 163-amino acid precursor (prochemerin) [37,41–44].
Subsequently, prochemerin undergoes extracellular proteolytic processing at the C-terminus exposing
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the active region and forming active chemerin [37,41,44]. In humans, prochemerin is processed to
at least three active products; chemerin156, chemerin157, and chemerin158, all of which have been
detected in biological fluids, including plasma and serum [42,45,46]. Further proteolytic events
cleave active chemerin isoforms to shorter inactive or low activity proteins [35,47]. Chemerin is the
endogenous ligand for two known cognate signaling receptors, chemokine-like receptor 1 (CMKLR1)
and G protein-coupled receptor 1 (GPR1); herein these are referred to as chemerin receptor 1 (chemerin1)
and chemerin receptor 2 (chemerin2) as established by the International Union of Basic and Clinical
Pharmacology Committee on Receptor Nomenclature [48]. A third chemerin receptor, C-C chemokine
receptor-like 2 (CCRL2), exhibits limited homology with chemerin1 and chemerin2 and is most closely
related to the atypical chemokine receptor family [48]. Rather than directly mediating chemerin
signaling, CCRL2 is thought to function as a chemerin membrane anchoring protein that increases local
chemerin concentrations and presents the ligand to chemerin1 or chemerin2 expressing cells. [49,50]
Depending upon the site of proteolytic cleavage and interaction with either of chemerin1 or chemerin2,
the magnitude and nature of the biological effects of chemerin can vary dramatically (e.g., pro- versus
anti-inflammatory) [24]. Chemerin has been shown to mediate the chemoattraction of several chemerin
receptor-expressing leukocyte subsets that are often present in the tumor microenvironment, including
dendritic cells, natural killer cells, and macrophages [42,51,52]. Therefore, chemerin signaling may
play a role in cancer immunology through these mechanisms.
Circulating chemerin levels correlate positively with adiposity, and it is generally accepted
that major peripheral white adipose depots, such as subcutaneous and visceral fat, are significant
contributors to systemic chemerin levels. However, recent research indicates that locally-derived
chemerin, produced either by tumors or by adipocytes in close proximity to the tumor, may have
auto/paracrine effects that are distinct from the hormonal influence of systemic chemerin. The aim
of this review is to summarize the evidence linking chemerin, and the cognate receptors, to the risk,
mechanism, and prognosis of human cancer. Please note that this review provides complementary
information to the paper by Treeck et al. [53] also published in this special issue.
4. Esophageal and Oral Cancers
Both systemic and tumor-localized chemerin levels are associated with pro-cancer effects
in esophageal and oral carcinoma. Overexpression of chemerin has been demonstrated in oral
squamous cell carcinoma (OSCC), squamous cell carcinoma of the oral tongue (SCCOT), and
oesophageal squamous cancer (OSC) [54–56]. In a study of OSCC patients, increased circulating and
salivary concentrations of both chemerin and the extracellular matrix remodeling enzyme matrix
metalloproteinase-9 (MMP-9) were observed compared to patients with oral pre-malignant lesions
(OPLs) and controls [54]. Table 1 summarizes the serum/plasma chemerin concentrations, as well
as patient demographics (subject groups, numbers, age, sex, and BMI), for this and all other studies
described in the present article. Furthermore, patients with pre-malignant lesions also displayed
elevated levels of chemerin and MMP-9 when compared to healthy controls [54]. Similarly, several
studies have reported increased expression of chemerin in SCCOT tissues compared to adjacent
non-cancerous tissues and in OSC cancer-associated myofibroblasts (CAMs) compared to adjacent
tissue myofibroblasts (ATMs) [55,57]. In SCCOT, overexpression of both chemerin mRNA and protein
was correlated with a number of poor clinical indicators, including lymph node infiltration, microvessel
density, tumor angiogenesis, and advanced clinical stage [54,55,58]. Furthermore, chemerin expression
was greater in advanced-stage SCCOT tumors and thus, was linked to a poor prognosis [55].
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Table 1. Summary of chemerin concentrations and tissue expression data.
Cancer Type
Demographics Serum, Plasma, or
Tissue Chemerin in
ng/mLGroup, n Age in Years Sex BMI kg/m2
OSCC [54]
serum
OSCC, 15 47.7 ± 14.1 M6/F9 22.8 ± 1.1 655 ± 150 †
OPML, 15 42.3 ± 11.0 M5/F10 22.4 ± 1.1 408 ± 85 *
Controls, 15 43.3 ± 11.8 M7/F8 22.7 ± 1.5 187 ± 13
salivary fluid
OSCC, 15 47.7 ± 14.1 M6/F9 22.8 ± 1.1 13.2 ± 3.8 †
OPML, 15 42.3 ± 11.0 M5/F10 22.4 ± 1.1 9.1 ± 1.9 *
Controls, 15 43.3 ± 11.8 M7/F8 22.7 ± 1.5 3.1 ± 0.7
Colorectal [59]
Serum
Patients, 41 55 (32–75) M28/F13 25.8 (16.2–35.5) 390 (250–630)
Controls, 27 43 (18–64) M15/F12 26.6 (21.5–45.8) 340 (270–480)
Colorectal [60] plasma
Patients, 221 50 ± 9 62.1% F 16.5% > 30 148 (50–370)
Gastric [61]
plasma
Patients, 196 44.4% ≥ 60 M112/F84 23.0 ± 3.1 53.1 ± 19.0 *
Controls, 196 55.6% < 60 Matched 23.4 ± 3.5 31.3 ± 11.3
Colorectal [62]
serum
Patients, 32 57.6 ± 6.5 M22/F10 25.8 ± 4.2 377.0 ± 80 *
Controls, 20 58.4 ± 7.2 M14/F6 26.7 ± 5.3 87.8 ± 22.0
Colorectal [63] serum
Survivors, 110 56.3 ± 9.3 M55/F55 23.3 ± 3.1 105 ± 14
Gastric [64]
serum
Patients, 36 47–83 M19/F17 42 *
Controls, 40 31–68 M27/F13 non-obese 28
HCC [65] serum
Patients, 44 71 (50–82) M29/F15 22.5 (15.6–33.5) 130 (80–312)
Thyroid [66]
serum
BMI < 25, 51 41.2 ± 11.9 F51 21.8 ± 2.1 212 ± 47
BMI ≥ 25, 126 55.4 ± 12.7 M26/F100 30.7 ± 4.1 229 ± 50 *
Breast [67]
serum
Metastatic, 37 52.3 ± 11.8 F37 29.1 ± 5.5 250 ± 59
Non-Met, 80 51.7 ± 12.5 F80 28.6 ± 4.9 261 ± 73
All, 117 51.9 ± 12.2 F117 28.7 ± 5.1 257 ± 69
CNS [46]
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Table 1. Cont.
Cancer Type
Demographics Serum, Plasma, or
Tissue Chemerin in
ng/mLGroup, n Age in Years Sex BMI kg/m2
NSCLC [68]
serum
Patients, 110 65.1 M91/F19 26.4 245 *
Controls, 110 65.0 M91/F19 27.7 203
NSCLC [69]
serum
Patients, 189 61.8 ± 11.2 M124/F65
NA
1.78 ± 0.57 *
Controls, 120 62.6 ± 8.9 M69/F51 1.20 ± 0.23
Lung [70]
plasma
Patients, 42 56 (44–78) M26/F16 N/A 1.97 ± 0.37 *




Patients, 25 63.0 ± 9.8 24.5 (21.7–27.8) 272 (221–314) *
Controls, 36 37.6 ± 6.4 M36 26.1 (24.2–29.5) 193 (173–214)
Prostate [72]
serum
All patients, 74 67.1 ± 8.5 M74 27.9 ± 3.3 273 ± 29
BPH, 66 61.5 ± 10.3 M66 27.3 ± 4.0 268 ± 83
WD, 24 64.6 ± 8.5 M24 27.2 ± 3.6 237 ± 72 +
MD, 28 66.7 ± 8.8 M28 28.0 ± 2.8 274 ± 60 +
PD, 22 70.2 ± 7.5 M22 28.3 ± 3.4 313 ± 93 +
Prostate [73]
serum
Non-obese, 25 68 (64–73) M25 23.0 (21.5–24.3) 74.0 (59.4–88.1)
Obese, 37 64 (60–67) M37 26.7 (25.7–27.6) 75.0 (65.6–82.3)
Parentheses indicate the range of reported values. OSCC, oral squamous cell carcinoma; OPML, oral premalignant
lesion; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer; GBM, malignant glioblastoma; ODC,
oligodendrocytoma; NC CNS, non-cancer CNS disease; BPH, benign prostatic hyperplasia; WD, well differentiated
prostate cancer (Gleason score≤ 6); MD, moderately differentiated (Gleason 7); PD, poorly differentiated (Gleason≥ 8).
‡ Number refers to the number of amino acids in the processed chemerin protein, † Significant compared to the
other two groups; * significant compared to control group; + significant compared to other Gleason scores.
The mechanisms by which chemerin may contribute to esophageal tumor progression
are multifaceted involving multiple cell types within the tumor microenvironment (Figure 1).
One mechanism involves a paracrine interaction between chemerin-secreting CAMs and
chemerin1-expressing mesenchymal stromal cells (MSCs), leading to MSC migration into the tumor
microenvironment (Figure 1, left). In in vitro transwell migration assays and transendothelial
migration assays, chemerin stimulated the migration of MSCs via interactions with chemerin1 but
not chemerin2 [57]. Notably, the effects on MSC migration were greater with conditioned media
derived from esophageal CAMs versus that of ATMs [57]. These results were validated in an in vivo
xenograft model, where BALB/c nu/nu mice injected S.C. with OE21 human esophageal carcinoma
cells along with CAMs had more infiltrated MSCs than those mice injected with OE21 cells alone [57].
The in vivo homing of MSCs to the OE21 tumors was reduced by the chemerin1 antagonist CCX832
confirming the effect was dependent on chemerin/chemerin1 signaling. Evidence supported that
chemerin/chemerin1 signaling in the MSCs is relayed via protein kinase C (PKC) and subsequent
phosphorylation and activation of protein kinases p42/44, p38 and JnkII, and matrix MMP-2 secretion,
which contributes to the trans-endothelial migration of MSCs, potentially contributing to cancer
progression [57]. The study by Kumar et al. went a step further by providing additional evidence
for a contextual pro-cancer role for chemerin in these malignancies (Figure 1, right). Unlike with
high concentrations of chemerin (20 ng/mL), low concentrations of chemerin (4 ng/mL) inhibited
approximately 50% of chemerin/chemerin1-mediated MSC migration through a 10-fold increase in the
secretion of macrophage inhibitory factor (MIF) from MSCs [57]. The authors speculated that moderate
levels of chemerin in normal tissue myofibroblasts (NTMs) would act to restrain MSC migration
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through the autoinhibitory action of MIF. However, in the tumor microenvironment, the MIF-inhibitory
mechanism is released owing to higher chemerin concentrations in CAMs, increasing the capacity for
recruiting MSCs to the tumor microenvironment [57].
Figure 1. The mechanisms of tumor-promoting effects of chemerin in the esophageal carcinoma
microenvironment. Chemerin is released from cancer-associated myofibroblasts (CAMs) and esophageal
tumor cells and has autocrine and paracrine tumor-promoting effects in the esophageal carcinoma
microenvironment. These include mediating mesenchymal stromal cell (MSC) transendothelial
migration to the tumor site (A), tumor cell migration and invasion (B), and angiogenesis (C).
In contrast, low chemerin concentrations inhibit MSC migration (D). ECM, extracellular matrix; MAPK,
mitogen-activated protein kinase; MIF, macrophage inhibitory factor; MMP, matrix metalloproteinase;
NTM, normal tissue myofibroblasts; PKC, protein kinase C.
A follow-up study by Kumar et al. expanded on this area of research by demonstrating paracrine
interactions between chemerin-secreting CAMs and the chemerin1-expressing esophageal cancer
cell line OE21. Conditioned media from CAMs, more so than conditioned media from ATMs and
NTMs, stimulated migration and Matrigel invasion of OE21 cells, which could be partially blocked by
chemerin neutralization, siRNA knockdown of chemerin or chemerin1, or pharmacological antagonism
of chemerin1 with CCX832 [56]. The invasion process was mediated through PKC- mitogen-activated
protein kinase (MAPK) signaling but did not require phosphoinositide 3-kinase (PI3K) and led to
MMP1, 2, and 3 secretion, which may facilitate invasion through extracellular matrix degradation
(Figure 1, top-centre) [56].
Chemerin has previously been shown to stimulate angiogenesis [74,75]. Thus, interactions
between tumor cell-secreted chemerin and chemerin1-expressing endothelial cells leading to increased
angiogenesis is another possible mechanism (Figure 1, bottom-centre). Supporting this idea, one
study found that increased chemerin expression in SCCOT was strongly associated with increased
microvessel density, an indicator of angiogenesis [55].
In the metaplasia–dysplasia–carcinoma sequence of Barrett’s esophagus (BE) to high-grade
dysplasia BE and esophageal carcinoma, a significant increase in myeloid dendritic cell (mDC) and
plasmacytoid dendritic cell (pDC) density was observed that coincided with increased expression
of their respective chemotactic factors, macrophage inflammatory protein-3 alpha (MIP3α), and
chemerin in the same regions [76]. However, the metaplasia–dysplasia–carcinoma transition was also
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characterized by the infiltration of immune tolerogenic IL-10high and IL-12low mDCs, which stimulated
the differentiation of immunosuppressive T regulatory (Treg) cells from naïve CD4+ T cells [76]. Thus,
while high tumor chemerin concentrations have an anti-tumoral effect in other cancers [52,77–79],
these effects may be masked in the context of esophageal cancers because of an immune tolerogenic
phenotype. Alternatively, chemerin could be contributing to the immune tolerogenic phenotype, but
this remains to be determined experimentally.
5. Colorectal and Gastric Cancer
Similar to esophageal and oral cancers, the balance of clinical evidence indicates a positive
association between serum chemerin concentrations and the risk for colorectal cancer [59,60,62,63] and
gastric cancer as reviewed in greater detail by Treeck et al. [53] and originally reported by Wang et al. [64]
and Zhang et al. [61] (Table 1). There is considerable variability among these studies with respect to
reported absolute values for serum chemerin, possibly due to methodological differences. In spite of
this variability, there is a consistent finding of elevated serum chemerin in gastric and colorectal cancer
patients. There is also some uncertainty as to the linkage of chemerin to colorectal cancer owing to
inherent differences (e.g., age) between the patient and control groups [59]. However, other studies
have reported significantly higher circulating chemerin levels after considering potential confounds
such as age, sex, BMI, waist circumference, and diet. For example, after adjusting for age and sex,
Eichelmann et al. [60] reported an approximate 2-fold increase in overall risk for all colorectal cancers
between the highest and lowest quartile of serum chemerin concentrations. This association was
strongest for colon cancer (HR = 2.27) and specifically proximal colon cancer (HR 3.97) [60]. Consistent
with these findings, Alkady et al. [62] reported that using a cut off of ≥ 161.5 ng/mL, serum chemerin
had 100% sensitivity and 100% specificity for the presence of colorectal cancer. Increased serum
chemerin was also found to correlate with general fatigue and other cancer-related symptoms in
colorectal cancer patients [63]. Moreover, progressive increases in serum chemerin have been observed
in patients with advanced stages of colorectal cancer [62]. Overall, these results support a cancer and
stage-specific effect on serum chemerin concentrations. These studies are also in general agreement
regarding the potential for the use of chemerin as a biomarker for colorectal cancer independent of
inflammatory markers such as C-reactive peptide (CRP) [59,60,62].
In this issue, Treeck et al. [53], reported that high gastric tumor expression of chemerin, chemerin1,
and chemerin2 were associated with shorter overall patient survival. Consistent with these findings,
the results from several in vitro studies support a tumor-promoting role of chemerin signaling in
gastric cancer (Figure 2). For example, Wang et al. [64] reported that exposure of human gastric cancer
AGS or MKN28 cells to recombinant human chemerin promoted invasiveness in a dose-dependent
fashion in Matrigel invasion assays. This was accompanied by increased expression of a panel of
“pro-invasive” genes including vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), and MMP-7
mRNA suggesting a mechanism whereby increased chemerin could increase the metastatic potential
of gastric cancer cells [80–83]. When the invasion and gene expression assays were repeated in the
presence of various MAPK inhibitors, the extracellular-related kinase (ERK) inhibitor UO126 most
consistently blocked the effects of chemerin versus p38 and c-jUN N-terminal kinase (JNK) inhibitors,
which were less effective. This suggested the effects of chemerin were primarily mediated by ERK
signaling, a pathway with known involvement in the promotion of cell proliferation and migration [84].
However, there was no effect of chemerin on cell proliferation, a finding consistent with that of our
research group which observed no effect of chemerin treatment on the proliferation or viability of AGS
cells [85]. A new pathway for chemerin signaling through Gαi/o and RhoA/Rock was identified, which
activates serum response factor regulated gene expression and chemotaxis of AGS cells [85]. It was
postulated that these effects were chemerin2 receptor-mediated, as AGS cells were found to express
chemerin2 but not chemerin1. In contrast, Kumar et al. detected both chemerin1 and chemerin2 proteins
using immunohistochemistry in both primary gastric cancer cells and AGS cells [86]. Chemerin mRNA
was not expressed in AGS cells [85] nor was secreted chemerin detected in the media of cultured
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AGS cells [86]. However, chemerin was secreted by CAMs at concentrations sufficient to stimulate
migration and morphological transformation of AGS cells [86] supporting a paracrine rather than
autocrine mechanism of signaling. These effects of chemerin were inhibited by the putative chemerin
receptor antagonists CCX832 and α-NETA [86]. Similarly, selective knockdown of either chemerin1 or
chemerin2 resulted in inhibited migration and invasion in AGS cells, while simultaneous knockdown
led to complete inhibition [86], supporting the functional signaling of chemerin1 and chemerin2 in
AGS cells. These observations are consistent with clinical findings showing an increased risk for
gastric cancer with increased serum chemerin. The study by Kumar et al. also uncovered the further
complexity of chemerin signaling in gastric cancer by demonstrating that chemerin inhibited the
secretion of tissue inhibitor of metalloproteinase 1 and 2 (TIMP -1/-2) via a PKC mediated pathway in
AGS cells [86]. As TIMPs inhibit MMP activity, decreased secretion would be expected to increase
metastatic and invasive potential [87]. Interestingly Treeck et al. reported that in contrast to chemerin1
and chemerin2, increased CCRL2 expression in gastric carcinoma was correlated with increased overall
survival [53]. However, the mechanisms of this putative protective effect of CCRL2 remain unknown.
Figure 2. The mechanisms of tumor-promoting effects of chemerin in the gastric carcinoma
microenvironment. Chemerin is released from cancer-associated myofibroblasts (CAMs) and acts on
chemerin1 and chemerin2 receptors present on gastric carcinoma cells to activate several intracellular
signaling pathways. Functionally this signaling leads to increased expression of pro-invasive genes,
reduced secretion of tissue inhibitor of metalloproteinase 1, 2 (TIMP-1/2), and enhanced production
of matrix metalloproteinases (MMPs) leading to migration and invasion of tumor cells and tumor
cell transformation resembling an epithelial–to–mesenchymal transformation (EMT). It is unknown
(?) how and if CCRL2-bound chemerin interacts with chemerin1 and chemerin2 to influence the
tumor-promoting effects of chemerin signaling in gastric carcinoma. ECM, extracellular matrix; ERK1/2,
extracellular-related kinase 1/2; IL-6, interleukin 6; MAPK, mitogen-activated protein kinase; PKC,
protein kinase C; VEGF, vascular endothelial growth factor.
Expression of the non-signaling chemerin receptor, CCRL2, was reported to be reduced by about
2/3 in colorectal cancer patients versus disease-free controls [88]. Unlike chemerin, there was no
correlation in CCRL2 mRNA levels with colorectal cancer stage [88]. While CCRL2 expression was
detectable in several colorectal cell lines (SW480, SW620, LS174T, Caco2), siRNA-mediated knockdown
of CCRL2 mRNA reduced proliferation, colony formation and migration only in LS174T cells [88].
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When rat CC531 colorectal cancer cells were injected into the rat portal vein for liver colonization assays,
the initial low CCRL2 mRNA levels increased during initial colonization of the liver [88]. This suggests
a linkage to tumor cell migration or invasion. Whether or not the increased CCRL2 facilitates chemerin
interactions with chemerin1 or chemerin2 within this context remains to be determined.
6. Skin Cancer
In contrast to the aforementioned cancers, both melanoma and skin squamous cell carcinoma have
been associated with decreased expression of chemerin mRNA and protein [52,89]. Available evidence
suggests that this may promote skin cancer progression and tumor growth through a reduction in the
recruitment of immune cells to the tumor microenvironment via chemerin-dependent mechanisms.
Consistent with this, tumors with higher chemerin expression were associated with improved clinical
outcomes in melanoma [52]. The same study found that an intratumoral injection of chemerin into a
B16 transplantable mouse melanoma model resulted in reduced tumor growth [52]. The beneficial
effects of chemerin in reducing melanoma progression appear to be mediated primarily through the
recruitment of NK cells, and to a lesser extent, other immune effectors such as T and B cells to the
tumor microenvironment [52]. In contrast, it was found that chemerin played little to no role in the
activation of NK cells and had no discernible direct effects on melanoma cells [52].
Chemerin also appears to have an important role in regulating the ratio between beneficial and
harmful immune cells in the tumor microenvironment (Figure 3). As the name suggests, myeloid-derived
suppressor cells (MDSCs) originate from the myeloid-lineage and contribute to tumor progression via
the suppression of appropriate immune responses [90]. MDSCs exert additional pro-cancer effects
through the upregulation of angiogenic and metastatic factors in the tumor microenvironment [90].
Localized chemerin expression in melanoma was associated with an increase in the ratio of immune
effectors (i.e., NK cells, T cells, and dendritic cells) to MDSCs in the tumor microenvironment, ultimately
enhancing anti-tumor responses [52]. Additionally, pDCs play a significant role in melanoma and
have been associated with poor clinical outcomes through the development of an immunosuppressive
microenvironment [91]. Normally pDCs promote anti-viral immunity, but in melanoma, the suppression
of type I interferon (IFN I) production by pDCs triggers immunosuppressive mechanisms including
the recruitment of Treg cells to the tumor microenvironment [91]. Localized chemerin expression in
melanoma has been demonstrated to decrease the presence of pDCs in the tumor microenvironment,
ultimately inhibiting immune escape mechanisms [52].
Figure 3. Chemerin has immune-mediated tumor-suppressive effects in melanoma. In low
chemerin-producing melanoma tumors, there is an increased presence of myeloid-derived suppressor
cells (MDSCs), plasmacytoid dendritic cells (pDCs), and regulatory T-cells (Tregs), which result in a
tumor-promoting immunosuppressive environment. When melanomas produce higher amounts of
chemerin, there is a switch to a tumor-suppressing immunogenic environment characterized by increased
natural killer (NK) cell and cytotoxic T-cell infiltration and reduced infiltration of MDSCs and pDCs.
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7. Hepatocellular Carcinoma
Similar to skin cancer, a number of studies support an anticancer role for chemerin in human
hepatocellular carcinoma [77,78,92]. Collectively, these studies suggested that in certain hepatocellular
carcinomas, hepatic chemerin production may be lowered, thus facilitating further advancement of the
disease [77]. In contrast, increased serum chemerin concentrations have been associated with more
favorable clinical characteristics, such as reduced tumor size, differentiation, and stage and indicate
the potential value of chemerin as a prognostic factor for disease-free survival [78,92]. The clinical
associations between chemerin signaling and hepatocellular carcinoma have been described in detail
by Treeck et al. in this issue [53].
To explore the mechanisms underlying the clinical associations between chemerin signaling and
hepatocellular carcinoma, Lin et al. and Li et al. utilized mouse models in which chemerin expression
was manipulated in several complementary manners [77,92]. Mice injected in the left ventricle with
chemerin-overexpressing portal vein tumor thrombus cells (PVTT-1-Che) only rarely developed
metastatic foci, while those injected with control PVTT-1 cells consistently developed metastases at
distant sites throughout the body [77]. Similarly, mice injected hepatically with PVTT-1-Che cells
exhibited reduced liver tumor foci development, a 1.3-fold increase in survival (54 days versus 41 days)
compared to mice injected with control PVTT-1 cells [77]. This lessening of metastasis and prolongation
of survival was recapitulated by the intraventricular or intraperitoneal injection of recombinant
chemerin to mice that also had an intraventricular or hepatic injection of control PVTT-1 cells [77].
Likewise, when implanted with Hepa1-6 tumor cells, chemerin knockout mice (chemerin-/-) developed
larger liver tumors, more frequent lung metastasis and showed significantly increased mortality as
compared to the wild type mice [92]. Overexpression of chemerin in Hepa1-6 cells resulted in decreased
mortality and decreased liver tumor growth compared to control Hepa1-6 cells injected into wild-type
mice [92].
The study by Lin et al. supports that the hepatocellular protective effects of chemerin
are immune-mediated involving a shift from tumor-infiltrating immunosuppressive and
angiogenesis-stimulating MSDCs to tumor-suppressing interferon γ-secreting T cells (IFNγ+T)
(Figure 4). In support of this conclusion, Hepa1-6 tumors in chemerin-/- mice displayed increased
proportions of MDSCs, tumor-associated macrophages (TAMs) and decreased IFNγ-expressing T-helper
CD4+ and cytotoxic CD8+ T cells compared to Hepa1-6 tumors in wild-type mice [92]. Consistent
with this result, chemerin-overexpression caused a shift from MDSCs to IFN-γ+ T cells in the Hepa1-6
tumors [92]. An impairment but not a complete abolition of the hepatocellular carcinoma-inhibiting
effect of chemerin was observed in T-cell and B-cell deficient Rag1-/- mice and CD8+ T cell-depleted
mice confirming a partial role of CD8+ T cells in the antitumoral effects of chemerin [92]. There were no
differences in Tregs or pDCs regardless of chemerin expression in the Hepa1-6 tumors [92]. Furthermore,
there was no difference in tumor-infiltrating NK cells, which is consistent with the weak but significant
positive correlation observed between human hepatocellular carcinoma chemerin expression levels
and recruitment number of dendritic cells and NK cells to the tumor site [78,92]. A series of in vitro
and in vivo experiments probed the cellular and molecular mechanisms of chemerin suppression of
hepatocellular carcinoma progression. These studies identified that chemerin interacts with chemerin1
and CCLR2 to inhibit nuclear factor kappa B (NF-κB) signaling in tumor cells and endothelial cells.
This leads to reduced production and secretion of the pro-tumorigenic factors, granulocyte-macrophage
colony-stimulating factor (GM-CSF) from tumor cells and IL-6 from hepatocytes, which in turn suppress
the numbers of tumor-infiltrating MDSCs and allows for a restoration of T-cell immunity and reduced
angiogenesis in the tumor microenvironment [92].
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Figure 4. Chemerin has immune-mediated tumor-suppressive effects in hepatocellular carcinoma.
Systemic or hepatocyte-secreted chemerin interacts with chemerin1 and CCLR2 on hepatocellular
carcinoma cells and endothelial cells to inhibit nuclear factor kappa B (NF-κB) signaling. By unknown
mechanisms, this leads to reduced secretion of granulocyte-macrophage colony-stimulating factor
(GM-CSF) from tumor cells and IL-6 from hepatocytes. In turn, this leads to reduced tumor infiltration
of immunosuppressive and pro-angiogenic myeloid-derived suppressor cells (MDSCs) and increased
infiltration of cytotoxic CD8+T-cells. It is unknown (?) how and if CCRL2-bound chemerin interacts with
chemerin1. (−) = Reduction or suppression of a normal pathway and (+) Increase of a normal pathway.
Adding to the complexity of the actions of chemerin in this context, Li et al. demonstrated the
protective effects of chemerin on the progression of hepatocellular carcinoma also involve autocrine
effects of tumor cell-secreted chemerin [77]. These included a reduction in migration and invasion of
multiple hepatocellular carcinoma cell lines in the presence of chemerin overexpression and a reversal
of this effect with chemerin neutralizing antibodies [77]. In agreement with other studies, there was
no impact of chemerin on hepatocellular carcinoma proliferation and apoptosis. Mechanistically,
when chemerin concentrations were low, chemerin1 physically interacted with the tumor suppressor
phosphatase and tensin homolog (PTEN) as demonstrated by immunoprecipitation assays (Figure 5).
This led to greater ubiquitination of PTEN, lowering its activity and suppressive effects on protein
kinase B (AKT) activation. On the other hand, when chemerin concentrations were increased, the
interaction between chemerin1 and PTEN was disrupted, reducing PTEN ubiquitination and increasing
its activity. In turn, AKT activation by phosphorylation was inhibited suppressing migration, invasion,
and metastasis of hepatocellular carcinoma cells. Notably, in the study by Li et al., MMP-1 was increased
along with AKT, whereas PTEN was decreased in metastatic foci of mice with PVTT control tumors.
The opposite pattern was observed in metastatic foci of mice with PVTT-Che tumors. This suggested
the antitumor effects of chemerin involve, in part, MPP-1 which is active in the promotion of tumor
migration through proteolytic functions [87].
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Figure 5. Hepatocellular carcinoma-derived chemerin inhibits tumor cell migration, invasion, and
metastasis via an autocrine mechanism. When chemerin production by hepatocellular carcinoma is
low (left) there is limited autocrine signaling through chemerin1. This results in sequestering of the
tumor suppressor phosphatase and tensin homolog (PTEN) through a direct physical interaction
with chemerin1, allowing for the activation of protein kinase B (AKT) and secretion of matrix
metalloproteinase 1 (MMP-1), which is thought to facilitate migration, invasion, and metastasis.
When chemerin production by hepatocellular carcinoma is high (right), chemerin1 signaling is activated,
the chemerin1-PTEN complex is disrupted, allowing PTEN inhibition of AKT and blockade of migration,
invasion, and metastasis of hepatocellular carcinoma. (+) = Activation, (−) inhibition.
A recent study by Sun et al. reported a modest inhibitory effect of chemerin on the proliferation
of SMMC7721 human hepatoma cells but not QSG7701 immortalized human hepatic cells [93].
This appeared to be a result of S-phase cell cycle block involving reductions in p53, p27, and p21 proteins.
Interestingly, the mechanism involved downregulation of iron transporters and regulatory proteins,
including the divalent metal transporter, transferrin, transferrin receptors 1 and 2, iron regulatory
proteins 1 and 2 and ferritin-H, and ferritin-L leading to decreased cellular iron concentrations [93].
Consistent with this, iron supplementation reversed the effects of chemerin on S-phase cell cycle block
and p53, p27, and p21 proteins. The results of this study contrast with others that did not observe
effects of chemerin on cell proliferation or apoptosis [77,92,93]. The reason for the discrepancy is not
certain, but it could relate to the different cell lines used in the three studies. Furthermore, it is worth
noting that the SMMC7721 and QSG7701 cells are potentially HeLa derivatives as they have been listed
as being at risk for contamination [94,95].
Not all studies support a clear relationship between chemerin and hepatocellular carcinoma.
For example, Imai et al. detected no significant difference in recurrence-free survival or disease-free
survival between patients classified with having low (≤ 130.5 ng/mL) and high (> 130.5 ng/mL) serum
chemerin concentration [65]. Furthermore, no association was found between serum chemerin
and clinical stage of hepatocellular carcinoma in this study [65]. However, a correlation was
observed between serum chemerin concentration and severity of liver disease suggesting that
with advancing liver disease, hepatic chemerin production decreases and may increase the risk
for further advancement of hepatocellular carcinoma [65]. Haberl et al. utilized a mouse model of
low methionine-choline deficient diet-induced non-alcoholic steatohepatitis (NASH) compared to
NASH with dimethylnitrosamine-induced hepatocarcinoma (NASH-HCC) to evaluate the function of
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chemerin in NASH-HCC. Hepatic and serum chemerin, as well as ex vivo activation of chemerin1, did
not differ in the two models. The authors concluded that tumors still develop despite high endogenous
levels of serum and liver chemerin protein [96].
8. Adrenocortical Carcinoma
Adrenocortical carcinoma is a rare, aggressive form of cancer with poor prognosis [97].
Through microarray analysis to identify gene signatures of potential diagnostic value, a substantial
downregulation of chemerin expression in adrenocortical carcinoma versus benign adrenal adenomas
was discovered in two independent cohorts [98,99]. These findings have been replicated in additional
independent sample cohorts, which also included a comparison to control non-cancerous adrenal
tissue [79,100]. Chemerin expression was highest in control tissue, followed by an intermediate expression
in the benign adrenal adenomas and lowest in the carcinomas. A positive correlation was observed for
immunohistochemical detection of the chemerin protein in paired samples, providing evidence that
reduced chemerin expression coincides with reduced chemerin protein [79]. The mechanism of reduced
chemerin expression in adrenocortical carcinoma appears to be through repressive hypermethylation at
5 CpG sites, which could be reversed by the DNA-methyltransferase inhibitor decitabine [79].
Despite the significantly lower chemerin expression, a survival analysis of four independent data
sets comparing subjects with the highest (top 50%) to lowest (bottom 50%) chemerin expression within
adrenocortical carcinoma tissue revealed no significant difference [100]. Somewhat paradoxically, serum
chemerin concentrations were increased in adrenocortical carcinoma subjects versus those with benign
adenoma or healthy controls and were positively associated with longer overall survival [100]. To further
assess the relationship between adrenal chemerin expression and serum chemerin concentrations, the
researchers xenografted immunodeficient scid-γ mice with H295R adrenocortical carcinoma cells with
and without human chemerin overexpression. The tumors, with higher chemerin expression, had higher
serum human chemerin. Based on this result, the authors rationalized that since chemerin decreases in
adrenocortical tumors, the increased serum chemerin concentration must be due to chemerin secretion
from tissues other than the adrenals, but the exact tissues were not identified. Adipose tissue was
ruled out as a contributor to increased serum chemerin for a number of reasons, but this was not
confirmed experimentally [100]. Interestingly, mice transplanted with human chemerin-expressing
H295R tumors had higher serum concentrations of human chemerin but proportionally lower mouse
serum chemerin suggesting a type of negative regulatory feedback mechanism. The overall findings
led the authors to reasonably postulate that the reduction in adrenal tumor chemerin concentrations
could be an immune avoidance mechanism, but increased serum chemerin may counteract this in
some individuals resulting in improved anti-tumor immune responses. While not tested in this study,
it represents an interesting idea for a follow-up.
To evaluate the functional effects of chemerin in adrenocortical carcinoma, Li-Chittenden et al.
performed a series of in vitro studies comparing the effects of transient human chemerin overexpression
in H295R and SW13 adrenocortical carcinoma or HEK293 human embryonic kidney cells to exogenous
chemerin treatment [79]. The effects of the transient transfection were cell-dependent and reduced
the proliferation of the HEK293 cells and the cell invasion of the H295R cells but had no effect on
proliferation or invasion of the SW13 cells. Furthermore, the transient transfection of the chemerin
construct did not affect the migration of any of the cancer cell lines. Treatment with physiological levels
of active chemerin had no impact on cell proliferation, invasion, or migration. The differential effects of
chemerin overexpression versus exogenous treatment have also been observed with respect to adipocyte
function [101]. While the exact mechanism is unknown, possibilities include differential post-translation
processing of recombinant chemerin in a bacterial system versus in human cells, differential proteolytic
processing of endogenous chemerin, or novel intracellular functions independent from chemerin1
and chemerin2 function. In support of the latter possibility, the cells tested in this study had barely
detectable chemerin1 [79]. However, no assessment of chemerin2 levels was made. In further support
of a direct tumor suppressive (rather than immune-mediated) effect of chemerin, H295R cells with
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stable expression of human chemerin had decreased colony formation and invasion in in vitro assays
and formed smaller tumors when xenografted into the flanks immunodeficient T-cell deficient athymic
nude and T, B, and NK-cell deficient and macrophage and dendritic cell-impaired NOD Scid γ mice.
Further probing the tumor-suppressive mechanisms revealed that chemerin inhibits the Wnt/β catenin
pathway, which is commonly activated in adrenocortical carcinoma and associated with higher tumor
grades and decreased overall survival and disease-free survival (Figure 6) [102–104]. Thus, a reduction
of chemerin in benign adrenal adenoma and adrenocortical carcinoma would be expected to lead to
increased Wnt/β-catenin activity. Whether this plays a role in the initiation of adrenocortical carcinoma
remains to be determined. The findings of Li-Chittenden et al. are consistent with previous studies in
mesenchymal stem cells that showed chemerin1 is a Wnt responsive gene that functions as a negative
feedback regulator of the Wnt/β-catenin signaling pathway [105]. Thus, it would be interesting to
determine if the low chemerin1 expression is a factor that contributes to activation in Wnt/β-catenin
activation in adrenocortical carcinoma. A second possible tumor-suppressive mechanism is through
inhibition of p38 MAPK signaling.
Figure 6. Endogenously derived chemerin mediates a tumor-suppressive effect through inhibition
of Wnt/β-catenin signaling in adrenocortical carcinoma. In adrenocortical carcinoma, chemerin
expression becomes suppressed due to CpG hypermethylation resulting in low intracellular chemerin
concentrations. β-catenin accumulates and migrates to the nucleus where TCF/LEF genes are turned
on mediating (+) cell growth, proliferation, and invasion. Based on the known feedback inhibition
of chemerin1 on Wnt/β-catenin signaling, it is also possible that low chemerin1 expression could
contribute to the activation of Wnt/β-catenin in adrenocortical carcinoma cells. When tumor chemerin
production is increased, by unknown (?) intracellular mechanisms (and possibly autocrine signaling
through chemerin1), β-catenin is targeted for phosphorylation and proteasomal degradation reducing
the expression of TCF/LEF genes and inhibiting (−) cell growth, proliferation, and invasion. APC, APC
Regulator of Wnt Signaling Pathway; GSK3β, glycogen synthase kinase 3β; CK-1, casein kinase 1. (?)
unknown or possible but unconfirmed mechanism.
9. Renal Carcinoma
An analysis of chemerin expression in RNA sequencing data available in the Cancer Genome
Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects using the Gene Expression Profiling
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Interactive Analysis (GEPIA) web server revealed that papillary renal cell carcinoma (pRCC) has
significantly upregulated chemerin expression (Figure 7a) [106]. This is opposite to the majority of
tumors that display decreased chemerin. While there is little information regarding the potential impact
of elevated chemerin expression in renal carcinoma, a recent study sheds some light on the matter [107].
pRCC accounts for approximately 20% of all renal cancers. A unique feature of pRCC is the focal
aggregation of foam cell macrophages inside the papillae. In the study by Krawczyk et al., foamy
macrophages were histologically identified in 82% of pRCC tumors and the macrophages expressed cell
surface markers CD689 and CD163 that are characteristic of the M2 anti-inflammatory phenotype [107].
The researchers hypothesized that the pRCC cells must secrete factors that recruit monocytes and
contribute to their differentiation into foamy macrophages. Utilizing freshly isolated primary pRCC
cultures, the prototypical monocyte chemoattract proteins were not detected in conditioned media.
Rather the most abundant secreted cytokines/chemokines were chemerin, interleukin-8 (IL-8), and
CXCL16. Confirming their hypothesis, these cytokines, alone or in combination, stimulated the
migration of human monocytes in transwell chemotaxis assays. Furthermore, conditioned pRCC
medium shifted macrophages from an M1 to M2 phenotype and promoted their lipid accumulation.
Thus, it is possible that elevated chemerin expression in pRCC could contribute to monocyte recruitment
and differentiation into lipid-containing foam cells. However, the exact role chemerin on pRCC tumor
biology and the tumor microenvironment is not known. A GEPIA survival analysis conducted with
data from TCGA and GTEx indicated the quartile of patients with the highest tumor chemerin expression
had better overall survival than those in the lowest quartile (Figure 7b), providing preliminary support
that the differential chemerin expression could be functionally important in pRCC [106].
Figure 7. Chemerin expression is increased in papillary renal cell carcinoma (pRCC or KIRP) and is
associated with higher overall survival. The Gene Expression Profiling Interactive Analysis (GEPIA)
web server [106] was used for RNA sequencing expression analysis of chemerin in pRCC (red bar)
and normal renal samples (blue bar) from the Cancer Genome Atlas (TCGA) and Genotype-Tissue
Expression (GTEx) projects (A). The GEPIA web server survival analysis tool [106] was used to compare
the overall survival of the quartile of pRCC patients with the highest chemerin expression (red line)
versus the quartile of pRCC patients with the lowest chemerin expression (blue line) (B). * p < 0.01. TPM,
transcripts per kilobase million.
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10. Thyroid Cancer
Thyroid carcinoma is the most common of the endocrine cancers, typically affects women
more than men, and is most often observed in the fourth and fifth decades of life. Thyroid cancer
is an obesity-associated cancer with increased risk with increasing BMI and weight gain [6,108].
The mechanisms linking obesity to thyroid cancer are not completely understood, but there has been
considerable interest in the role of adipocytokines. Recently, Warakomski et al. sought to evaluate the
relationship between serum chemerin, IL-6, leptin, and adiponectin and papillary thyroid cancer [66].
Overweight or obese patients (BMI > 25 kg/m2) did not have larger tumor sizes but were more often
at an advanced clinical stage (II, III, or IV). While the overweight and obese subjects had higher
preoperative serum chemerin (Table 1), there was no specific association between serum chemerin
concentration and clinical stage. However, those subjects with higher leptin and IL-6 tended to
have a more advanced clinical stage. While a direct association of chemerin with papillary thyroid
cancer could not be determined in this study, there were a number of important limitations. First, the
majority of study subjects (144) were diagnosed with stage I cancer, and thus, the sample size may
have been too small for the advanced clinical stages to determine a relationship. Second, the study
only evaluated serum chemerin concentration and did not perform any functional studies. GEPIA
Analysis [106] of RNA sequencing data shows that chemerin and chemerin1 are expressed in thyroid
tissue and significantly downregulated in thyroid cancer samples (Figure 8). Chemerin2 and CCRL2
expression were lower and did not differ between tumor samples and normal thyroid tissue. It would
be interesting for future studies to evaluate the relevance of chemerin and chemerin1 downregulation to
thyroid tumor biology and if chemerin signaling has direct effects on thyroid cancer cells.
Figure 8. Chemerin and chemerin1 are decreased in thyroid carcinoma (THCA). The Gene Expression
Profiling Interactive Analysis (GEPIA) web server [106] was used for RNA sequencing expression
analysis of chemerin and chemerin1 in thyroid carcinoma (red bars) and normal renal samples (blue bars)
from the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects. * p < 0.01.
TPM, transcripts per kilobase million.
156
Int. J. Mol. Sci. 2019, 20, 4778
11. Breast Cancer
Studies of the relevance of chemerin to breast cancer have provided conflicting results. As reviewed
in greater detail by Treeck et al. [53], and originally reported by El-Sagheer et al. [109], chemerin protein
expression was higher in cancerous versus adjacent healthy tissues and in metastatic lymph nodes
compared to non-metastatic malignant tissues. Tumour chemerin expression was also negatively
correlated with estrogen and progesterone receptor levels as well as five-year-disease-free survival
rates [109]. In contrast, Pachynski et al. [110] reported that increased chemerin expression promoted the
recruitment of immune effector cells to the tumor microenvironment and thus, initiated anti-cancer
effects. An analysis of several breast cancer databases revealed that chemerin expression was significantly
downregulated in malignant breast tissue compared to adjacent healthy tissue and that low chemerin
expression was associated with poorer survival outcomes [110]. Consistent with this, quantitative
real-time PCR and in situ hybridization demonstrated significantly lower chemerin expression in
invasive/infiltrating ductal carcinoma and invasive/infiltrating lobular carcinoma tissues versus healthy
breast tissue samples [110]. These studies demonstrate an interesting finding that while chemerin
expression is downregulated in breast cancer tissues, protein expression is upregulated. These findings
suggest the potential for translational and post-translational regulatory mechanisms in breast cancer
cells, which differentially affect chemerin mRNA and protein expression. Further research is required
to determine the cause of the inverse relationship between these expression levels.
Pachynski et al. [110] also examined the impact of chemerin expression levels in the EMT6
murine model of mammary carcinoma. While lentiviral-induced expression of chemerin did not
impact cell proliferation in vitro, tumors generated from high chemerin-secreting (HCS) EMT6 clones
exhibited significantly lower growth compared to those derived from low chemerin-secreting (LCS)
secreting or control EMT6 cells in an in vivo xenograft model [110]. Furthermore, there was a
significant increase in the relative proportions of T cells, CD4+ T cells, and NK cells in the HCS-EMT6
tumors compared to controls, and this was associated with tumor suppression [110]. Depletion
experiments indicated a critical role of NK cells and CD8+ T cells in the tumor suppression response to
chemerin, while the depletion of CD4+ T regulatory cells enhanced tumor suppression [110]. Thus, a
plausible mechanism by which chemerin may affect breast cancer progression is via the recruitment
of immune cells to the tumor microenvironment. In contrast to the findings of Pachynski et al. [110],
El-Sagheer et al. [109] suggested a potential for pro-tumorigenic effects via the influence on the breast
cancer stem cell (BCSC) phenotype. It is well established that inflammatory cytokines can promote
epithelial–to–mesenchymal transformation and angiogenesis, among other pro-cancer effects [111,112].
Notably, IL-6, a pro-inflammatory cytokine secreted by several immune cell types, has been shown to
play a role in inducing the de-differentiation of malignant cells to BCSCs [111,113]. Although research
is limited, it is believed that BCSCs contribute to tumor progression and poor prognosis in breast
cancer patients [112,114]. The possibility that chemerin-mediated recruitment of immune effectors to
the tumor microenvironment contributes to poor prognosis via the promotion of BCSC phenotype is
an intriguing possibility that remains to be experimentally tested.
Akin et al. [67] reported correlations between serum chemerin concentrations and several clinical
factors such as diabetes, age of diagnosis, BMI, hypertension, and menopause, but found no significant
difference between serum chemerin levels in breast cancer patients with metastatic and non-metastatic
cancer (Table 1). While these findings suggest that serum chemerin is not associated with breast cancer
stage, an important limitation of this study was the lack of a control group without breast cancer. Thus,
further studies are needed to determine if there is a relationship between chemerin levels and breast
cancer, per se.
As reviewed in greater detail by Treeck et al. [53], and originally reported by Sarmadi et al.,
expression of the atypical chemokine receptor, CCRL2, has been observed in human malignant breast
tissues samples, but not in adjacent non-cancerous tissues and exhibited no significant association
with stage [115]. It has been hypothesized that due to the ability of CCRL2 to sequester chemerin
and thereby limit its ability to act on signaling receptors, the upregulation of CCRL2 in malignant
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breast tissues may function as an immune evasion mechanism [115]. However, this idea conflicts with
observations in hepatocellular carcinoma, where chemerin1 and CCRL2 appear to act cooperatively in
inhibiting infiltration of MDSCs into the tumor microenvironment [92].
12. Ovarian Cancer
In the seminal study that identified chemerin as a ligand for chemerin1, chemerin was found to be
abundant in ascitic fluid of ovarian cancer patients [42]. The authors suggested that chemerin signaling
through chemerin1 could be involved in diseases with a strong inflammatory component, such as
autoimmune disorders and cancer [42]. While this study provided the first suggestion that chemerin
could be involved in ovarian cancer, research in this area is very limited. As reviewed in greater
detail by Treeck et al. [53], and reported originally by Hoffman et al. [116] and Reverchon et al. [117],
experimental evidence exists for differential expression of chemerin and the cognate receptors, as well
as the biological impact of this signaling pathway in several ovary cell types (normal and cancerous).
However, further research is necessary to determine the impact on ovarian cancer development,
progression, and the efficacy of hormonal therapies.
13. Central Nervous System Cancers
At present, investigation of the relevance of chemerin and the cognate receptors to cancers of the
nervous system is very limited. Tummler et al. [118] reported that expression of chemerin1, but not
chemerin2, was elevated (versus neural crest and benign neurofibroma cells) in tumors from patients
with neuroblastoma, a pediatric cancer of the peripheral nervous system. Moreover, a significant
correlation was found between high expression of chemerin1, chemerin2, or CCRL2 and a decrease
in overall survival probability. Exogenous chemerin stimulated MAPK and Akt phosphorylation,
increased calcium mobilization and MMP-2 secretion from neuroblastoma SK-N-AS cells, while
treatment with the putative chemerin1 inhibitorα-NETA reduced the viability and clonogenicity of these
cells. Consistent with the latter, α-NETA impaired tumor growth in vivo in a murine SK-N-AS xenograft
model. Taken together, these data provide evidence that chemerin/CMKLR1 signaling promotes
neuroblastoma development through direct effects on tumor cells and the tumor microenvironment.
Zhao [46] reported that while the relatively inactive chemerin isoform chemerin163 is the major
contributor (~80%) to total plasma chemerin, the majority (~55%) of cerebrospinal fluid chemerin is
comprised of the bioactive isoforms chemerin158 and chemerin157. Silico analysis of published microarray
datasets indicated that chemerin, but not chemerin1 or CCRL2 mRNA levels were elevated in grade III and
IV (malignant) tumors compared with grade II glioma [46]. Furthermore, treatment of human U-87 MG
glioblastoma cells with chemerin157 triggered a dose-dependent transient increase of intracellular calcium
levels. Taken together, these data reinforce the concept that anatomical locations can differ with respect
to the spectrum of chemerin isoforms and indicate that glioblastoma cells both secrete and respond to
chemerin. However, it is important to note that chemerin has not been linked to glioblastoma outcomes
nor to biological effects that directly or indirectly promote the malignancy of glioblastoma cells.
14. Lung Cancer
Much of the research into the role of chemerin in lung cancer stems from clinical studies of patients
with non-small cell lung carcinoma (NSCLC). Several clinical studies have reported that patients
with lung cancer had higher circulating chemerin concentrations than controls and/or that serum
chemerin concentrations were positively associated with several clinical parameters including stage,
lymph node infiltration, and distant metastasis (Table 1) [68–70,119]. While higher serum chemerin
concentrations are generally associated with pro-cancer effects in NSCLC, many findings point to
a role of localized chemerin in promoting anti-cancer effects via the recruitment of NK cells to the
tumor microenvironment [120,121]. Thus, a downregulation of chemerin secretion by tumor cells may
promote immune evasion and consequently, poor clinical outcomes. Further empirical research is
required to fill in the current gaps in the literature with respect to the causal effect of chemerin on lung
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cancer development and progression, as well as its effects on biological indicators of cancer such as
proliferation, metastasis, and invasion. We refer the interested reader to the article by Treeck et al. [53]
in this issue that provides a more complete assessment of chemerin in NSCLC.
15. Pancreatic Cancer
Patients that are positive for pancreatic ductal adenocarcinoma exhibit significantly higher plasma
chemerin concentration than healthy volunteers (Table 1) [71]. Despite this marked difference between
pancreatic cancer patients and healthy controls, this study found no significant correlation between
cancer stage and plasma concentration of chemerin, nor any correlation between chemerin concentration
and resectable versus unresectable tumors [71]. The authors proposed that chemerin concentration
could be used as a biomarker for the presence of cancer, where a plasma concentration of >219.67 ng/mL
showed 80% sensitivity and 83% specificity for the presence of disease [71].
16. Prostate Cancer
No significant difference in serum chemerin concentration was found between patients with
prostate cancer and those with benign prostatic hyperplasia, however, differences were identified
between cancer patients with different Gleason scores, a progressive measurement of prostate cancer
aggressiveness as determined by tumor cell differentiation [72]. Serum chemerin concentration
was observed to increase with Gleason score, where tumors with a score of ≥8, 7, and ≤6 were
significantly different from one another [72]. There was also a positive correlation between the serum
levels of chemerin and IL-6 [72]. Comparing non-obese to obese patients with prostate cancer who
subsequently underwent radical prostatectomy, there was no significant difference found in serum
chemerin concentration based on BMI prior to surgery (Table 1) [73]. Furthermore, serum chemerin was
not found to be a predictive factor for advanced tumor stage in the overall population nor in patients
with a BMI of > 25 kg/m2 [73]. These latter findings argue against a role of adipose-derived chemerin
in prostate cancer. However, while serum chemerin concentrations increased with Gleason score, the
opposite effect was observed for chemerin expression in prostate tumor tissue [122]. Furthermore,
chemerin was downregulated in prostate cancer as compared to benign prostate tissues, with greater
downregulation observed in castration-resistant prostate cancers [123]. While chemerin1 and chemerin2
expression were not evaluated, CCRL2 mRNA and protein levels were reported to be increased in
prostate cancer PC3 cells, and CCRL2 expression increased in prostate cancer tissues versus prostate
tissues from patients with benign prostatic hyperplasia [124]. However, the impact of these changes on
chemerin signaling in tumor cells or the tumor microenvironment has not been evaluated.
17. Conclusions
Obesity is a major global health concern that has been linked to the development of many prevalent
metabolic disorders such as type 2 diabetes, hyperlipidemia, and cardiovascular disease. There is
also an increasing awareness that obesity represents a significant risk factor for the development of
several malignancies. While our current understanding of the pathophysiological mechanisms linking
obesity to cancer is evolving, growing interest has focused on the role of adipocyte-secreted signaling
molecules as key mediators linking these disorders. Among these, circulating levels of the adipokine
chemerin are well established to be directly related to adipose tissue mass and have been implicated in
several obesity-related metabolic comorbidities. Altered levels of chemerin and the cognate receptors,
chemerin1, chemerin2, and CCRL2 have also been identified in several cancer types and many of the
fundamental biological activities (e.g., chemotaxis, proliferation, differentiation) of chemerin have
the potential to affect tumorigenesis and tumor progression. These effects may be elicited through
immune-independent mechanisms that directly impact the growth and tumorigenicity of cancer cells
and/or immune-dependent effects that influence the composition of the tumor microenvironment.
At present, epidemiological studies have introduced the potential utility of this adipokine as a
potential biomarker for several malignancies, and clinical and empirical evidence supports both pro-
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and anti-cancer effects of chemerin. This suggests that the biological actions of chemerin with respect to
cancer are highly contextual and dependent upon a number of factors that are important areas of further
investigation. A fundamental issue in this regard is the large discrepancy (up to three orders of magnitude;
see Table 1) in the reported values of serum/plasma chemerin concentration in the clinical literature—even
among control populations. While this may reflect the inherent heterogeneity of the control populations,
assay-dependent factors may also play a role. It is critical that methodologies are both reported in
appropriate detail and rigorously validated with respect to sensitivity and specificity. Moreover, the
overwhelming majority of studies have utilized methodologies that are unable to distinguish between
chemerin isoforms and/or only test the actions of chemerin157. It will be important going forward
to consider the actions of other known isoforms of chemerin as their relative abundance may differ
depending upon anatomical location and their biological actions may be cell- and tissue-dependent.
Similarly, most research to date has focused on chemerin1-dependent actions of chemerin. Elucidation of
the role of chemerin2 and CCRL2 and the chemerin isoform-selectivity of these receptors in the context
of cancer are priority areas for investigation. Moreover, while there has been considerable interest in
the relationship of systemic concentrations of adipose-derived chemerin to cancer development and
prognosis, comparatively little attention has been applied to the relevance of locally-derived chemerin
secreted from cells located in the affected tissue or tumor microenvironment. This may be of particular
importance to malignancies such as breast cancer where adipocytes are commonly found in close
proximity to tumors and where evidence exists for an influence on tumor development and progression.
Finally, most research regarding the impact of adipokines on cancer has focused on a single molecule.
It is well known that the relative amounts and spectrum of adipokines is affected by adiposity and
adipocyte function. Hence, while challenging, it will be important to apply a more holistic experimental
approach to consider the interactions of multiple adipokines and consider synergistic and/or antagonistic
effects in different tumor types and at different stages of tumor development.
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Abbreviations
AKT protein kinase B
APC APC regulator of Wnt signaling pathway
ATM adjacent tissue myofibroblast
BCSC breast cancer stem cell
BE Barrett’s esophagus
BPH benign prostatic hyperplasia
CA125 cancer antigen 125
CA 15-3 cancer antigen 15-3
CAM cancer associated myofibroblast
CCRL2 C-C Chemokine Receptor-Like 2
CEA carcinoembryonic antigen
chemerin1 chemerin receptor 1
chemerin2 chemerin receptor 2
CK-1 casein kinase 1
CMKLR1 Chemokine-Like Receptor 1
CRP C-reactive peptide
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ERK extracellular-related kinase
GBM malignant glioblastoma
GEPIA Gene Expression Profiling Interactive Analysis
GM-CSF granulocyte-macrophage colony-stimulating factor
GPR1 G Protein-coupled Receptor 1




hGC human granulosa cells
IFN-I type 1 interferon
IFNγ interferon gamma
IFNγT interferon γ-secreting T cells
IL-6 interleukin-6
IL-8 interleukin-8
JNK c-jUN N-terminal kinase
KGN human ovarian granulosa-like tumor
LCS low chemerin-secreting
MAPK mitogen-activated protein kinase
MD moderately differentiated prostate cancer (Gleason 7)
mDC myeloid dendritic cell
MDSC myeloid-derived suppressor cells
MIF macrophage inhibitory factor
MIP3α macrophage inflammatory protein-3 alpha
MMP matrix metalloproteinase
MSC mesenchymal stromal cell
NASH non-alcoholic steatohepatitis
NASH-HCC non-alcoholic steatohepatitis with dimethylnitrosamine-induced hepatocarcinoma
NC CNS non-cancer CNS disease
NF-κB nuclear factor kappa B
NK natural killer
NSCLC non-small cell lung cancer
NTM normal tissue myofibroblast
ODC oligodendrocytoma
OPL oral pre-malignant lesion
OSC oesophageal squamous cancer
OSCC oral squamous cell carcinoma
pRCC papillary renal cell carcinoma
PD poorly differentiated prostate cancer (Gleason ≥8)
pDC plasmacytoid dendritic cell
PI3K phosphoinositide 3-kinase
PKC protein kinase C
PTEN phosphatase and tensin homolog
PVTT-1 portal vein tumor thrombus cells
PVTT-1-Che chemerin-overexpressing portal vein tumor thrombus cells
SCCOT squamous cell carcinoma of the oral tongue
TAM tumor associated macrophage
TCGA The Cancer Genome Atlas
TIMP-1 tissue inhibitor of metalloproteinase 1
TIMP-2 tissue inhibitor of metalloproteinase 2
TME tumor microenvironment
TNM tumor-node-metastasis
TPM transcripts per kilobase million
Treg regulatory T cell
VEGF vascular endothelial growth factor
WD well differentiated prostate cancer (Gleason score ≤ 6)
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Abstract: Chemerin is a multifunctional adipokine with established roles in inflammation,
adipogenesis and glucose homeostasis. Increasing evidence suggest an important function of
chemerin in cancer. Chemerin’s main cellular receptors, chemokine-like receptor 1 (CMKLR1),
G-protein coupled receptor 1 (GPR1) and C-C chemokine receptor-like 2 (CCRL2) are expressed
in most normal and tumor tissues. Chemerin’s role in cancer is considered controversial, since it
is able to exert both anti-tumoral and tumor-promoting effects, which are mediated by different
mechanisms like recruiting innate immune defenses or activation of endothelial angiogenesis. For this
review article, original research articles on the role of chemerin and its receptors in cancer were
considered, which are listed in the PubMed database. Additionally, we included meta-analyses of
publicly accessible DNA microarray data to elucidate the association of expression of chemerin and
its receptors in tumor tissues with patients’ survival.
Keywords: adipokine; chemerin; leukocyte; cancer
1. Chemerin—A Multifunctional Cytokine and Adipokine
Chemerin, also known as retinoic acid receptor responder 2 (RARRES2), is expressed ubiquitously,
but is most abundant in adipose tissue and the liver. Human chemerin is a 163 amino acid protein
whose 20 amino acid N-terminal signal sequence is removed prior to secretion of the biologic inactive
prochemerin into the bloodstream. Chemotactic active forms are produced by C-terminal processing.
Extracellular serine and cysteine proteases generate different chemerin isoforms with chemerin 157 being
the most active variant [1,2]. The biologic activities of chemerin isoforms are primarily mediated by
two receptors, chemokine-like receptor 1 (CMKLR1) and G protein-coupled receptor 1 (GPR1) [3].
Chemerin similarly binds and activates both receptors, which triggers different cellular responses.
Whereas activation of CMKLR1 leads to strong calcium mobilization and ERK1/2 phosphorylation,
chemerin binding to GPR1 only leads to weak activation of both signaling mechanisms [4]. C-C motif
chemokine receptor like 2 (CCRL2) is an additional chemerin receptor without known downstream
signaling, which is thought to affect local activity of chemerin by presenting it to CMKLR1 and
GPR1 [2].
Chemerin is a chemoattractant protein and its role in inflammation was studied in detail.
In experimental pancreatitis chemerin infusion prior to disease induction reduces NF-κB signaling and
thus exerts anti-inflammatory activities [5]. Chemerin activates NF-κB and up-regulates expression
of adhesion molecules in endothelial cells thus enhancing monocyte adhesion and development of
atherosclerosis [6]. In diabetic nephropathy chemerin activates the p38 MAPK pathway and thereby
contributes to inflammation and renal injury [7]. In allergic asthma chemerin is shown to inhibit
CCL2 secretion and subsequent recruitment of inflammatory dendritic cells [8]. Chemerin may be
regarded as an immunoregulatory protein, and dependent on the context, acts as an anti-inflammatory
or pro-inflammatory mediator.
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Circulating chemerin is increased in obesity and may contribute to adiposity-related dyslipidemia,
low-grade inflammation, hypertension and insulin resistance. Chemerin activation of CMKLR1
and GPR1 is not induced in parallel and short, inactive isoforms are elevated in the obese [9].
Detailed evaluation of chemerin processing and the activities of the different isoforms are essential to
clarify the function of chemerin in obesity and its related comorbidities.
Chemerin protein levels are elevated in hypertensive patients, and experimental studies support
a causative role of chemerin in the control of blood pressure [1]. Angiotensin-I-converting enzyme
(ACE) cleaves angiotensin I to produce angiotensin II, a physiological regulator of blood pressure.
Inhibition of ACE exerts antihypertensive effects and lowers serum and renal chemerin protein [10].
ACE removes two C-terminal amino acids from the decapeptide chemerin 145–154 indicating a function
in chemerin processing [11]. Future work that evaluates the role of particularly the short isoforms of
chemerin will help to establish the function of this chemokine in blood pressure control.
In the tightly controlled glucose metabolism, chemerin was shown to regulate glucose-induced
insulin release and insulin-stimulated glucose uptake in skeletal muscle, but did not contribute
to peripheral insulin resistance in general. Chemerin dose, duration of treatment, type of
experimental model and the tissues/cell types analyzed seem to affect chemerin signaling [1,2].
Considering processing of chemerin to different isoforms, which vary in their biological effects and
modulation of chemerin activity by the expression levels of its receptors, it is reasonable to postulate
a complex association of chemerin with traits of the metabolic syndrome [1,2].
Adipose tissue growth in obesity includes adipocyte hyperplasia and hypertrophy [12].
Chemerin and CMKLR1 have been demonstrated to play a fundamental function in clonal
expansion during early adipogenesis [13]. Knock-down of chemerin or CMKLR1 impairs 3T3-L1
cell adipogenesis [14]. Peroxisome proliferator-activated receptor γ (PPARγ) is a crucial regulator
of adipogenesis and also elevates chemerin levels [13]. Chemerin release is strongly induced in
hypertrophic adipocytes and this seems to contribute to higher systemic levels in the obese [15].
Recent studies suggested that chemerin plays an important role in cancer. Chemerin was
found reduced or upregulated in cancer tissues and protective as well as promoting effects on
carcinogenesis were identified. Thus similar to its role in inflammation, where chemerin acts as a pro-
and anti-inflammatory factor, its effect in cancer depends on the disease context [16].
2. Chemerin and Cancer
2.1. Molecular Mechanisms Underlying the Role of Chemerin in Cancer
2.1.1. Chemerin and Leukocyte Recruitment
Chemerin is an important chemoattractant inducing immunocyte recruitment by its receptors
CMKLR1, GPR1 and CCRL2, leading to suppression of tumor growth. Activation of chemoattractant
receptors triggers arrest, diapedesis and infiltration of specialized immune cells into the tumor
microenvironment, regulating the growth and survival of cancer. Anti-tumoral effector immune cells
can slow down the growth of malignancies, like immunostimulatory DC, NK cells and cytotoxic T
cells. On the other hand, cancer cells can escape anti-tumoral immune responses in order to survive by
different mechanisms like the recruitment of immunosuppressive regulatory T cells or myeloid-derived
suppressor cells (MDSC), which are able to inhibit cytotoxic anti-tumor responses. The balance between
pro- and anti-tumoral leukocytes finally determines tumor progression [17].
Chemerin receptors are expressed in normal and cancer tissues and on various immune cells. In an
early study, CMKLR1 was found in human blood to be expressed by plasmacytoid dendritic cells (pDCs)
only, but not in monocytes, neutrophils, eosinophils, lymphocytes or myeloid DCs [18]. A conflicting
study identified CMKLR1 protein not only in all human pDCs, but also in about 40% of myeloid DCs,
and reported expression of this receptor in mature DCs [19]. LPS and interferon (IFN)-γ were reported
to enhance CMKLR1 transcription in macrophages. These inflammatory stimuli induced monocytes
to differentiate to the so-called M1 macrophages. M1 but not M2 macrophages were chemotactic to
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chemerin [20]. Chemerin affects local inflammatory processes, which are characterized by the induction
of pro-inflammatory as well as anti-inflammatory and pro-resolving factors, and thereby can accelerate
its resolution [21].
Chemerin has been shown to promote pDC migration [18]. This subset of dendritic cells produces
type I interferons and has a function in innate and adaptive immune response and cancer. In cancer,
pDCs were reported to exert a decreased or absent IFN-α production and contribute to the establishment
of an immunosuppressive tumor microenvironment [22]. Chemerin further was shown to promote
chemotaxis of macrophages and monocyte derived immature dendritic cells generated by granulocyte
macrophage colony stimulating factor (GM–CSF) and IL-13 [23]. A separate study found that chemerin
attracted pDC but not mDC (derived from monocytes stimulated with GM–CSF and IL-4) [18].
Mature DCs can activate resting NK cells, which in turn either kill or enable maturation of immature
DCs. Chemerin attracts NK cells and mediates co-localization of NK cells with pDC and mDC [24].
In a melanoma model, chemerin transfected cancer cells exhibited a growth inhibitory immune cell
distribution in the tumor microenvironment, which was characterized by a higher number of NK and T
cells and a relative decline of MDSC and pDCs. In vivo experiments showed that chemerin-expressing
mouse B16F0 melanoma grew significantly more slowly than control tumors. Importantly, these tumor
suppressive effects were specifically mediated by NK cells, as only NK cell depletion abrogated the
effect, and required host expression of CMKLR1, as chemerin-expressing tumors showed accelerated
growth in CMKLR1-negative mice [25]. With regard to adrenocortical carcinoma (ACC), studies report
that chemerin is down-regulated in malignant tumors compared to benign or normal tissue [26,27].
These studies also report that increased chemerin serum levels were associated with better overall
survival, and proposed that tumors may downregulate chemerin to escape immune defenses while
host systems may up-regulate chemerin to activate immune responses. Supporting this hypothesis,
mouse xenograft models confirmed that the increased serum chemerin levels do not result from
expression in tumor tissue, but result of host secretion suggesting an important role of chemerin
in host-mediated leukocyte recruitment [27]. Other studies showed that chemerin is expressed in
endothelial cells being triggered by inflammatory cytokines, which resulted in increased dendritic
cell transmigration mediated by CMKLR1 [28]. In mouse models chemerin has also been observed to
suppress M2 macrophage polarization, but to increase the production of pro-inflammatory cytokines
such as IFN-γ [29].
In conclusion, an important mechanism by which chemerin exerts anti-tumoral effects is recruiting
growth inhibitory immune cells like NK cells to the tumor microenvironment. Tumor cells in turn are
reported to reduce chemerin expression to escape immune defense [30].
2.1.2. Intracellular Signaling of Chemerin Receptors
Expression of chemerin and its receptors has been detected in all tumor types tested,
but their expression levels vary between different cancer entities and individual patients
(Supplemental Figure S1) [31]. Using the GEPIA server analyzing RNAseq data of 9736 tumors
and 8587 normal samples of the TCGA and GTEx projects revealed chemerin mRNA expression to be
down-regulated in 23 of 31 cancer entities (74.2%), but to be up-regulated in eight of 31 cancer types tested
(25.8%; Supplemental Figure S2) [32]. Chemerin has been reported to activate both tumor-promoting
and -suppressing intracellular pathways in a receptor- and context-specific manner. Chemerin binding
to CMKLR1, but not to GPR1 or CCRL2, strongly increases intracellular calcium concentration, decreases
cyclic AMP levels and induces the phosphorylation of p42-p44 MAP kinases, through the Gi class of G
proteins [4,23]. Binding of chemerin to CMKLR1 or GPR1 led to recruitment of β-arrestin 1 and 2 [4].
Arrestin binding to the receptors blocks further G protein-mediated signaling, targets receptors for
internalization and redirects signaling to alternative G protein-independent pathways, such asβ-arrestin
signaling [33]. Binding of β-arrestin 1 or β-arrestin 2 exerts opposite effects in cancer progression by
interacting with different signaling pathways, which may depend on the tumor microenvironment [34].
While β-arrestin 1 is reported to act tumor-promoting via interaction with c-Src [35], β-arrestin 2 has
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been shown to inhibit cancer growth and angiogenesis [36]. Chemerin receptor CCRL2 is considered
to exert no specific downstream signaling activities, but to present chemerin to CMKLR1 and possibly
to GPR1 [23,37,38]. A recent study reported that chemerin activates the transcriptional regulator
serum-response factor (SRF) by binding to CMKLR1 and GPR1 through a RhoA and rho-associated
protein kinase (ROCK)-dependent pathway [3]. SRF is a transcription factor, which has important roles
in tumor progression [39,40]. Chemerin-triggered activation of SRF might be an important molecular
mechanism underlying the role of chemerin in cancer. Induction of SRF by chemerin activated its
target gene early growth response-1 (EGR1), a transcription factor, which has been suggested to be
a tumor suppressor due to its growth inhibitory and pro-apoptotic effects [3,41,42]. Various studies
report chemerin-triggered activation of c-FOS via CMKLR1 and SRF [3,43,44]. While c-FOS has been
initially demonstrated to act as an oncogene, which is associated with tumor progression and decreased
survival of cancer patients [45], recent studies also discovered a tumor-suppressing and pro-apoptotic
function of c-FOS in various cancer types including ovarian cancer, hepatocellular carcinoma or
prostate cancer and has been shown to be associated with increased survival in ovarian cancer [46–50].
Furthermore, a recent study demonstrated that chemerin suppresses hepatocellular carcinoma (HCC)
metastasis through upregulation of expression and phosphatase activity of tumor suppressor PTEN
by interfering with PTEN-CMKLR1 interaction, resulting in decreased p-Akt levels, also leading to
suppressed migration, invasion and metastasis of HCC cells in vitro. Positive correlation between
chemerin and PTEN were also observed in HCC clinical samples [51]. In vivo xenograft mouse models
on adrenocortical cancer cells demonstrated that chemerin can decrease the levels of phosphorylated p38
MAPK and β-catenin and was suggested to act as a tumor suppressor [26]. Since the tumor-promoting
role of Wnt/β-catenin and MAPK pathway activities is well established [52,53], chemerin might mediate
tumor inhibition by reducing Wnt/β-catenin and MAPK pathway activity in adrenocortical carcinoma
and, potentially, other cancer types.
In contrast, phosphorylation of p38 and ERK1/2 MAP kinases was reported to be elevated in
gastric cancer cells after treatment with chemerin in vitro, leading to increased invasiveness of these
cells and up-regulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinase
7 (MMP-7) [54]. Given that MAPK pathways are known to enhance tumor progression and invasion
in various cancer types, several other studies support the finding that chemerin may stimulate
tumor growth via these mechanisms in gastric cancers [55,56]. Chemerin-triggered activation of
MMP-7 expression is considered to be an important molecular mechanism underlying the increased
invasiveness of gastric cancer cells, as this protease facilitates tumor cell invasion by degradation of
extracellular matrix components, E-cadherin and integrins [57]. Chemerin-triggered activation of
MMP expression and invasion of cancer cells has been reported in a variety of studies, including ones
on squamous esophageal cancer and neuroblastoma [58,59], supporting the hypothesis that MMP
activation is a mechanism underlying a tumor-promoting effect of chemerin in some tumor types.
In conclusion, with regard to intracellular chemerin receptor signaling, convincing evidence both
for anti-tumoral actions (activation of PTEN, EGR1 and β-arrestin 2 and inhibition of β-catenin and
MAPK activity) and tumor-promoting effects of chemerin (activation of MMP expression, p38 and
ERK1/2 MAPK activity and of β-arrestin 1), were reported in different tumor types. Chemerin receptors
are able to activate distinct signaling pathways, and chemerin seems to differentially regulate
intracellular pathways depending on the tumor type. Thus, more effort is necessary to elucidate the
role of chemerin receptor signaling in different cancer entities (Figure 1).
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Figure 1. Anti-tumoral and cancer-promoting effects of chemerin. Anti-tumoral activities of chemerin,
which are dominant in most cancer entities, include inhibition of MAPK, β-catenin and AKT where the
latter is achieved by PTEN activation. These actions partially are mediated via the β2-arrestin and
RhoA/serum response factor induced signaling. Both pathways are activated by chemerin binding
to GPR1 and CMKLR1. In contrast, tumor-promoting effects are mediated by activation of matrix
metalloproteinases, MAPK, p38 and AKT with involvement of β-arrestin-1. Angiogenesis is partly
enhanced via these pathways. In about 34 of the tumor types tested, chemerin expression is reduced in
cancer tissue when compared to non-tumorous tissues, whereas in about 14 of cancer entities chemerin
expression is elevated. Insulin resistance, inflammation and adipogenesis are influenced by chemerin
and may also contribute to tumor growth. Impact of these factors was not studied in detail so far.
2.1.3. Chemerin and Angiogenesis
The observed up-regulation of VEGF by chemerin leads to another important mechanism,
which might cause a tumor-promoting effect of this adipokine, the activation of angiogenesis.
Angiogenesis plays a central role in tumor growth, since solid cancers cannot grow beyond a limited
size without an adequate blood supply. VEGF is considered as a key factor of angiogenesis,
activating both migration and mitosis of endothelial cells and MMP expression. In a recent
study, chemerin was demonstrated to be potently angiogenic via binding to CMKLR1 present
on endothelial cells, and dose-dependently induced MMP-2 and MMP-9 activity in these cells [60].
These results were supported by a study observing the same effect of chemerin on angiogenesis and
even more demonstrated that chemerin mediated the formation of blood vessels to a similar extent as
VEGF [61]. Another recent study reported chemerin-triggered angiogenesis in mice. Chemerin also
stimulated the differentiation of human umbilical vein endothelium cells (HUVECs) into capillary-like
structures, promoted their proliferation, and functioned as a chemoattractant in migration assays.
Chemerin promoted angiogenesis by phosphorylation of Akt and p42/44 extracellular signal-regulated
kinase (ERK). Knockdown of chemerin receptor CMKLR1, but not of CCRL2, completely inhibited the
chemerin-induced migration and angiogenesis of HUVECs, which indicated that chemerin promoted
the migration and angiogenic activities mainly through CMKLR1 [62]. Taken together, convincing data
clearly suggest that chemerin induces endothelial angiogenesis, and thereby is able to promote
tumor growth.
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2.2. Expression of Chemerin and its Receptors and Cancer Survival
2.2.1. Breast Cancer
The role of chemerin in breast cancer has been only addressed by a very limited number of studies.
A recent study including 117 breast cancer patients reported that serum chemerin levels did not
significantly differ between early or advanced-stage breast cancer [63]. Chemerin and its receptors have
been shown to be expressed in breast cancer tissue by means of immunohistochemistry (IHC) or DNA
microarray analysis [64]. In a recent study demonstrating CCRL2 expression in breast cancer by means of
IHC, increased amounts of CCRL2 were found in breast tumor tissues with high immune cell infiltration.
Its expression was upregulated in the presence of pro-inflammatory cytokines, IL-1β, TNF-α, IL-6
and especially IFN-γ [65]. With regard to chemerin expression in breast cancer tissue, a small study
including 53 patients [66] detected a significantly higher expression of chemerin in malignant tissue
than in the corresponding normal breast tissue (p = 0.001). Moreover, its expression was significantly
higher in metastatic lymph nodes than in the primary tumor (p = 0.01). Chemerin expression was
found to be weakly associated with tumor size (r = 0.235, p = 0.03), lymph node metastasis (r = 0.265,
p = 0.045), distant metastasis (r = 0.267, p = 0.02) and showed good association with tumor grading,
(r = 0.421, p = 0.004). Kaplan–Meier survival analysis revealed that patients with higher chemerin
expression had worse overall survival in comparison to those with a lower chemerin expression,
(p = 0.001). In contrast to this study on a small patients´ collective, in a metaanalysis of publicly
available DNA microarray data of 3951 breast cancer patients, chemerin expression was observed
to be significantly lower in breast cancer tissue than in a normal breast (p = 2.17 × 10−7) and use of
Kaplan–Meier plotter software [64] revealed that high chemerin expression in breast cancer tissue did
not affect overall survival (OS), but turned out to negatively affect relapse-free survival (RFS; p = 0.015;
Figure 2). In contrast, high CMKLR1 expression, which did not significantly differ between normal
and tumorigenic breast, had robust beneficial effects on RFS of breast cancer patients, but did not
affect OS. Chemerin receptor GPR1 was found to be up-regulated in cancer tissue (p = 0.002), and high
expression of GPR1 also led to prolonged RFS (p = 0.00082), but did not affect OS of breast cancer
patients. Tissue expression of CCRL2 chemerin receptor, which was similar in normal and malignant
breast tissue, neither affected RFS nor OS of women with breast cancer.
 
Figure 2. Kaplan–Meier diagrams showing the relapse-free survival (RFS) of 3951 breast cancer patients
depending on expression of chemerin and its receptors CMKLR, GPR1 and CCRL2 in tumor tissue,
based on a metaanalysis of DNA microarray data (http://kmplot.com/analysis/) [64].
In conclusion, with regard to tumor expression of chemerin receptors, this adipokine is suggested
to exert a tumor-suppressive role in breast cancer via binding to CMKLR1 and GPR1. DNA microarray
data from 3951 breast cancer patients demonstrated that high mRNA expression of chemerin receptors
CMKLR1 and GPR1 in tumor tissue was strongly associated with a longer RFS of breast cancer patients,
whereas tissue expression of chemerin slightly decreased RFS and CCRL2 did not significantly affect
patients’ survival. Given that tumor expression of chemerin is not the major source of this adipokine,
the effects of CMKLR1 and GPR1 on survival in this context must be considered to be most relevant,
as they bind chemerin from all sources and have been shown to exert intracellular downstream signaling,
in contrast to CCRL2. The small IHC-based study including 53 patients mentioned above, which came
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to conflicting results, was judged to be less significant. The fact that the OS was not significantly affected
in this 3951 patients collective might be due to the reported tumor-promoting effects of chemerin like
activation of endothelial angiogenesis. However, further studies correlating chemerin serum levels
and activity with survival are needed as well as further attempts to integrate the anti-tumoral and
proposed tumor-promoting effects of this adipokine on survival of breast cancer patients.
2.2.2. Ovarian Cancer
High levels of active chemerin have been found in a large proportion of ascitic fluids of ovarian
carcinomas [67]. Bioactive chemerin and its receptor CMKLR1 have also been detected in human
granulosa cells [68]. A recent study demonstrated expression of CMKLR1 in a granulosa cell tumor
cell line to be higher than in epithelial cancer cells, whereas chemerin expression and secretion were
lower. Treatment with chemerin in vitro was reported not to affect growth of ovarian non-cancer and
cancer cell lines [69]. Using an obesity mouse model, the chemerin/CMKLR1 system was observed to
be upregulated in the serum, ovaries and granulosa cells and was associated with apoptotic ovarian
follicles, oxidative stress and apoptosis biomarkers. Further in vitro experiments confirmed the
apoptotic effect of chemerin on granulosa cells [70]. No publications are available examining the effect
of serum chemerin or its tumor expression on ovarian cancer growth. However, analyzing publicly
available DNA microarray data of 1656 ovarian cancer patients revealed a lower chemerin expression
in ovarian cancer tissue than in normal ovary (p = 0.018), and using the Kaplan–Meier plotter software
revealed that high chemerin expression negatively affected both OS (p= 5.8× 10−5) and progression-free
survival (PFS; p = 0.00024) of ovarian cancer patients [64,71]. In contrast, higher expression of chemerin
receptor CMKLR1 had a beneficial effect both on OS (p = 0.05; Figure 3) and on PFS (p = 0.0009).
GPR1, which was down-regulated in ovarian cancer tissue (p = 0.006), had no significant effect on OS
or on PFS of ovarian cancer patients. Expression of CCRL2, which was similar in normal and cancer
tissue, also did not affect OS or PFS of ovarian cancer patients (Figure 3 and data not shown).
Figure 3. Kaplan–Meier diagrams showing the overall survival (OS) of 1656 ovarian cancer patients
depending on expression of chemerin and its receptors CMKLR1, GPR1 and CCRL2 in tumor tissue,
based on a metaanalysis of DNA microarray data (http://kmplot.com/analysis/) [71].
In conclusion, with regard to tumor expression of chemerin receptors, this adipokine is suggested to
exert a tumor-suppressive role in ovarian cancer via binding to CMKLR1 and CCRL2. The observation
that chemerin was able to induce apoptosis in ovarian follicles via CMKLR1 raises the question,
whether the same effect could be present in ovarian cancer. The results of DNA microarray analyses
of 1656 ovarian cancer patients, demonstrating a significantly decreased survival of patients with
high chemerin tumor expression, seemed not to support this hypothesis, but it has to be considered
that tumor tissue is only a minor source of chemerin. The prolonged OS of patients with high
expression of CMKLR1 and CCRL2 clearly suggested an anti-tumoral effect of serum chemerin
being activated in ovarian cancer tissue. However, further studies, particularly on serum chemerin
levels, on protein expression of its receptors in ovarian cancer tissue and considering the reported
tumor-promoting angiogenic effects of this adipokine, are required to further elucidate the role of
chemerin in ovarian cancer.
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2.2.3. Non-Small-Cell Lung Cancer (NSCLC)
Circulating chemerin has been reported to be elevated and to exert adverse effects in non-small-cell
lung cancer (NSCLC) patients. In a recent case-control study including 220 patients and controls,
NSCLC cases exhibited significantly elevated serum chemerin levels compared to controls. In NSCLC
cases, chemerin was positively associated with tumor and inflammatory biomarkers, number of
infiltrated lymph nodes and NSCLC stage. Serum chemerin was found to be independently associated
with NSCLC [72]. These results were supported by another large study reporting elevated levels
of circulating chemerin in NSCLC patients, and higher levels of chemerin being associated with
advanced TNM stage, lymph node metastasis and distant metastasis. Further analyses revealed
that the higher serum chemerin patients had a shorter OS and PFS compared with lower chemerin
patients and identified serum chemerin to be an independent risk factor for the prognosis of NSCLC
patients [73]. Increased chemerin serum levels in NSCLC patients were also reported in a smaller study,
which could not find any association with clinicopathological parameters [74]. A recent study analyzing
chemerin expression in NSCLC tissue by IHC in 108 patients observed a decreased expression of
this adipokine in about half of the tested patients. Chemerin expression was significantly correlated
with the histological grade and the infiltration of NK cells. NSCLC patients with a lower chemerin
expression had poorer survival rates than those with a higher expression. Multi-variable Cox regression
analysis suggested expression of chemerin to be an independent predictor of a better prognosis for
patients with NSCLC [75].
Analyzing publicly available DNA microarray data of 1926 NSCLC patients revealed that chemerin
expression was significantly down-regulated in lung cancer tissue when compared to normal lung
(p = 0.0009), supporting the results of the study mentioned above [76]. However, in contrast to this
study, the use of Kaplan–Meier plotter software on these data revealed that high chemerin expression
did not affect OS nor time to first progression (FP; Figure 4 and data not shown). CMKLR1, which was
found to be up-regulated in cancer tissue (p = 0.005), positively affected OS of NSCLC patients
(p = 3.5 × 10−6), but not FP. Expression of GPR1 was down-regulated in NSCLC tissue (p = 7.25 × 10−9)
and did not affect patients´ OS or FP. Elevated expression of CCRL2 was found to have a positive effect
on OS and FP of NSCLC patients (p = 0.0002 or p = 0.016, respectively; Figure 4 and data not shown).
Figure 4. Kaplan–Meier diagrams showing the overall survival (OS) of 1926 patients with non-small-cell
lung cancer (NSCLC) depending on expression of chemerin and its receptors CMKLR1, GPR1 and CCRL2
in NSCLC tissue, based on a metaanalysis of DNA microarray data (http://kmplot.com/analysis/) [76].
Importantly, a study performing a genome-wide scan of 307,260 single-nucleotide polymorphisms
(SNPs) in 327 advanced-stage NSCLC patients revealed that only a CMKLR1 SNP was significantly
associated with overall survival [77].
In conclusion, chemerin serum levels have been reported to be elevated in NSCLC patients,
to exert adverse effects on survival and to be an independent risk factor of prognosis of NSCLC patients.
In contrast, gene expression analysis of 1926 NSCLC patients revealed that tumor expression of this
adipokine did not affect survival. In conflict with the above mentioned studies reporting adverse
effects of serum chemerin, the metaanalysis of DNA microarray data demonstrated tumor expression
of CMKLR1 and CCRL2 to exert significant beneficial effects on the OS of NSCLC patients, a fact
that was supported for CMKLR1 by SNP analyses. To address this controversy, further studies are
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needed examining chemerin receptor activation in tumor tissue and their expression on the protein
level to validate the role of chemerin receptors in NSCLC. It also has to be examined to what extent
chemerin-triggered endothelial angiogenesis might contribute to the reported adverse effects of serum
chemerin in this cancer entity.
2.2.4. Gastric Cancer
Two recent studies demonstrated elevated chemerin serum levels in patients with gastric cancer,
which were associated with tumor progression. In the first study, the increase of serum chemerin
levels was shown to be associated with elevated cellular invasiveneness, advanced clinical stages
and non-intestinal type of gastric cancer [54]. These observations were supported by a second study
reporting increased levels of circulating chemerin in gastric cancer patients, which also identified this
adipokine as an independent predictor for five-year mortality (odds ratio (OR), 2.718; p = 0.005) and
adverse event (OR, 2.982; p = 0.003) of gastric cancer. High plasma chemerin levels also were observed
as an independent predictor for shorter OS and RFS and were suggested to be a potential prognostic
biomarker in gastric cancer survival [78]. Chemerin receptors CMKLR1 and GPR1 have been recently
reported to be expressed in gastric cancer tissue, as assessed by IHC. In a gastric cancer cell line,
chemerin stimulated both, cellular migration and invasion, in a CMKLR1- and GPR1-dependent
manner [79]. In line with these studies, the analysis of publicly available DNA microarray data of
876 gastric cancer patients by means of the Kaplan–Meier plotter software [80] demonstrated that
high chemerin tumor expression reduced OS of gastric cancer patients (p = 0.0059; Figure 5) and also
higher tissue expression of CMKLR1 and GPR1 significantly decreased OS of gastric cancer patients
(p = 0.0085 or p = 1.7 × 10−7, respectively). In contrast, elevated expression of CCRL2 increased OS of
these patients (p = 4.2 × 10−10).
Figure 5. Kaplan–Meier diagrams showing the overall survival (OS) of 876 patients with gastric cancer
depending on expression of chemerin and its receptors CMKLR1, GPR1 and CCRL2 in gastric cancer
tissue, based on a metaanalysis of DNA microarray data (http://kmplot.com/analysis/) [80].
In conclusion, all present publications and gene expression data clearly suggest a tumor-promoting
effect of chemerin in gastric cancer. Both high chemerin serum levels and tumor expression were
associated with shorter OS of gastric cancer patients. Chemerin receptors CMKLR1 and GPR1
induced migration and invasion of gastric cancer cells in vitro and were associated with a significantly
decreased OS of gastric cancer patients. Thus, serum chemerin levels and tumor expression of
CMKLR1 and GPR1 might have the potential to act as prognostic biomarkers in gastric cancer survival.
However, further studies are needed to examine chemerin receptor expression on the protein level,
their activation and to elucidate the mechanisms underlying the divergent effect of CCRL2.
2.2.5. Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is linked to inflammation and immunosuppression. Chemerin is
highly expressed in the liver and implicated in the regulation of inflammation. However, the role of
chemerin in HCC remains unclear. A recent study reported that chemerin was significantly decreased
in blood and tumor tissues of HCC patients, and low tumor chemerin expression was associated
with a bad prognosis [81]. Accordingly, two further studies suggested an anti-tumoral effect of
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chemerin in HCC. The first one also reported chemerin to be decreased in HCC tissue, and lower
chemerin expression positively correlated with tumor size and the infiltration of DC and NK cells.
Survival analysis indicated that HCC patients with lower chemerin expression had poorer survival
than those with higher expression (p < 0.001). Multivariable Cox regression analysis revealed that the
chemerin expression level was an independent factor for prognosis (HR 3.034, p = 0.047) [82]. In line
with this study, decreased tumor expression of chemerin was also found to be associated with a poor
prognosis of HCC patients in a second study. Additionally, administration of chemerin effectively
suppressed extrahepatic and intrahepatic metastases of HCC cells, resulting in prolonged survival of
tumor-bearing nude mice [51].
Supporting the mentioned studies suggesting a tumor-suppressive role of chemerin,
the metaanalysis of publicly available gene expression data of 364 patients with HCC by means
of the Kaplan–Meier plotter software [83] revealed that high chemerin expression in cancer tissue
significantly increased patients’ OS (p = 0.00027) and progression-free survival (PFS; p = 0.012).
Higher expression of CMKLR1 did not significantly affect OS of HCC patients, but increased their PFS
(p = 0.0017). Tumor expression of GPR1 or CCRL2 did not significantly alter OS or PFS of patients with
HCC (Figure 6 and data not shown).
Figure 6. Kaplan–Meier diagrams showing the overall survival (OS) of 364 patients with hepatocellular
carcinoma (HCC) depending on expression of chemerin and its receptors CMKLR1, GPR1 and CCRL2
in tumor tissue, based on a metaanalysis of DNA microarray data (http://kmplot.com/analysis/) [83].
In conclusion, the majority of the present data clearly suggest an anti-tumoral role of chemerin in
HCC. However, further studies are needed to elucidate the relationship of serum chemerin levels and
cancer survival, to examine chemerin receptor activation and their tumor expression on the protein level.
2.2.6. Other Cancer Types
In adrenocortical carcinoma (ACC), chemerin has been suggested to act as a tumor-suppressor.
In a genome-wide gene expression study on 85 patients, chemerin expression was found to be strongly
down-regulated in adrenocortical carcinoma when compared to benign tumors and was suggested
to have an excellent diagnostic accuracy for distinguishing benign from malignant adrenocortical
tumors [84]. Another study reported decreased tumor chemerin gene expression, but increased serum
levels of this adipokine as compared with patients with benign adrenocortical tumors. Higher serum
chemerin levels were associated with improved overall survival [27]. The decreased chemerin expression
in ACC was demonstrated to be the result of chemerin gene CpG hypermethylation. In contrast, chemerin
overexpression in ACC cell lines not only reduced cell proliferation, cell invasion and tumorigenicity
in vitro, but also inhibited tumor growth in vivo in immunodeficient mouse xenograft models [26].
In acute myeloid leukemia (AML), a recent study also suggests a tumor-suppressing role of
chemerin, demonstrating that chemerin was down-regulated in the bone marrow mononuclear cells of
AML patients compared to that of healthy controls. In patients with AML, low chemerin expression
correlated with poorer overall survival. It was shown that chemerin was independently able to
prognosticate AML patients, and high chemerin expression was associated with positive prognosis [85].
Chemerin receptor CCRL2 was reported to be overexpressed in AML cells and was suggested to be
a potential therapeutic target [86].
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In melanoma, chemerin was shown to inhibit tumor growth by eliciting antitumor responses
and altering the tumor microenvironment in favor of growth inhibition. Chemerin was found to
be down-regulated in melanoma and high chemerin mRNA expression in tumors correlated with
improved outcome in human melanoma. The anti-tumoral effect of chemerin was associated with
increased recruitment of NK cells and was CMKLR1-dependent [25].
Further research is needed to elucidate the role of chemerin in cancer, particularly with regard to
cancer entities not mentioned here.
3. Conclusions
Chemerin is a pleiotropic protein, which has been demonstrated to affect tumor growth, being able
to exert both anti-tumoral and tumor-promoting effects. The majority of present data report
down-regulation of chemerin in cancer tissue and suggest a tumor-suppressing role of chemerin in
most cancer entities, being mediated by recruiting innate immune defenses and by growth-inhibitory
downstream signaling by chemerin receptors CMKLR1 and GPR1. However, this anti-tumoral effect
seems to be tissue-specific, since e.g., in gastric cancer, all available data suggest a tumor-promoting
role of chemerin, which is mediated by different receptor signal transduction. Although the activating
effect of this protein on endothelial angiogenesis is an important mechanism promoting tumor growth,
it does not seem to significantly affect the beneficial role of chemerin. Association of tumor expression
of chemerin receptors on patients’ survival was observed in most cancer entities. Further studies are
needed to elucidate the role of this protein in different cancer types and to what extent therapeutic
modulation of chemerin might be an option for cancer therapy.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/15/
3750/s1. Figure S1. Tumor tissue expression of chemerin and its receptors as assessed by means of RNA-seq
shown as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by The Cancer
Genome Atlas (TCGA). Data are from the open-access database (www.proteinatlas.org) [31]. The links to the
single genes are: https://www.proteinatlas.org/ENSG00000106538-RARRES2/pathology, https://www.proteinatlas.
org/ENSG00000174600-CMKLR1/pathology, https://www.proteinatlas.org/ENSG00000183671-GPR1/pathology
and https://www.proteinatlas.org/ENSG00000121797-CCRL2/pathology. Figure S2. Comparison of chemerin
mRNA expression in normal and tumor tissues using GEPIA, a newly developed interactive web server for
analyzing the RNA sequencing expression data of 9736 tumors and 8587 normal samples from the TCGA
and the GTEx projects [32]. (http://gepia.cancer-pku.cn/detail.php?gene=RARRES2). Values are expressed
in transcripts per million (TPM). Abbreviations: ACC Adrenocortical carcinoma, BLCA Bladder Urothelial
Carcinoma, BRCA Breast invasive carcinoma, CESC Cervical squamous cell carcinoma and endocervical
adenocarcinoma, CHOL Cholangio carcinoma, COAD Colon adenocarcinoma, DLBC Lymphoid Neoplasm
Diffuse Large B-cell Lymphoma, ESCA Esophageal carcinoma, GBM Glioblastoma multiforme, HNSC Head
and Neck squamous cell carcinoma, KICH Kidney Chromophobe, KIRC Kidney renal clear cell carcinoma,
KIRP Kidney renal papillary cell carcinoma, LAML Acute Myeloid Leukemia, LGG Brain Lower Grade
Glioma LIHC Liver hepatocellular carcinoma, LUAD Lung adenocarcinoma, LUSC Lung squamous cell
carcinoma, MESO Mesothelioma, OV Ovarian serous cystadenocarcinoma, PAAD Pancreatic adenocarcinoma,
PCPG Pheochromocytoma and Paraganglioma, PRAD Prostate adenocarcinoma, READ Rectum adenocarcinoma,
SARC Sarcoma, SKCM Skin Cutaneous Melanoma, STAD Stomach adenocarcinoma, TGCT Testicular Germ
Cell Tumors, THCA Thyroid carcinoma, THYM Thymoma, UCEC Uterine Corpus Endometrial Carcinoma,
UCS Uterine Carcinosarcoma. UVM Uveal Melanoma.
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Link-Lenczowski, P.; Ceranowicz, P.; et al. Chemerin alleviates acute pancreatitis in the rat thorough
modulation of NF-κB signal. Pancreatol. Off. J. Int. Assoc. Pancreatol. 2019, 19, 401–408. [CrossRef]
6. Dimitriadis, G.K.; Kaur, J.; Adya, R.; Miras, A.D.; Mattu, H.S.; Hattersley, J.G.; Kaltsas, G.; Tan, B.K.;
Randeva, H.S. Chemerin induces endothelial cell inflammation: Activation of nuclear factor-kappa β and
monocyte-endothelial adhesion. Oncotarget 2018, 9, 16678–16690. [CrossRef]
7. Shang, J.; Wang, L.; Zhang, Y.; Zhang, S.; Ning, L.; Zhao, J.; Cheng, G.; Liu, D.; Xiao, J.; Zhao, Z.
Chemerin/ChemR23 axis promotes inflammation of glomerular endothelial cells in diabetic nephropathy.
J. Cell. Mol. Med. 2019, 23, 3417–3428. [CrossRef]
8. Zhao, L.; Yang, W.; Yang, X.; Lin, Y.; Lv, J.; Dou, X.; Luo, Q.; Dong, J.; Chen, Z.; Chu, Y.; et al.
Chemerin suppresses murine allergic asthma by inhibiting CCL2 production and subsequent airway
recruitment of inflammatory dendritic cells. Allergy 2014, 69, 763–774. [CrossRef]
9. Chang, S.S.; Eisenberg, D.; Zhao, L.; Adams, C.; Leib, R.; Morser, J.; Leung, L. Chemerin activation in human
obesity. Obesity 2016, 24, 1522–1529. [CrossRef]
10. Huang, H.; Hu, L.; Lin, J.; Zhu, X.; Cui, W.; Xu, W. Effect of fosinopril on chemerin and VEGF expression in
diabetic nephropathy rats. Int. J. Clin. Exp. Pathol. 2015, 8, 11470–11474.
11. John, H.; Hierer, J.; Haas, O.; Forssmann, W.G. Quantification of angiotensin-converting-enzyme-mediated
degradation of human chemerin 145–154 in plasma by matrix-assisted laser
desorption/ionization-time-of-flight mass spectrometry. Anal. Biochem. 2007, 362, 117–125. [CrossRef]
12. Buechler, C.; Wanninger, J.; Neumeier, M. Adiponectin, a key adipokine in obesity related liver diseases.
World J. Gastroenterol. 2011, 17, 2801–2811.
13. Muruganandan, S.; Parlee, S.D.; Rourke, J.L.; Ernst, M.C.; Goralski, K.B.; Sinal, C.J. Chemerin, a novel
peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal
stem cell adipogenesis. J. Biol. Chem. 2011, 286, 23982–23995. [CrossRef]
14. Goralski, K.B.; Mc Carthy, T.C.; Hanniman, E.A.; Zabel, B.A.; Butcher, E.C.; Parlee, S.D.; Muruganandan, S.;
Sinal, C.J. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem.
2007, 282, 28175–28188. [CrossRef]
15. Bauer, S.; Wanninger, J.; Schmidhofer, S.; Weigert, J.; Neumeier, M.; Dorn, C.; Hellerbrand, C.; Zimara, N.;
Schäffler, A.; Aslanidis, C.; et al. Sterol regulatory element-binding protein 2 (SREBP2) activation after excess
triglyceride storage induces chemerin in hypertrophic adipocytes. Endocrinology 2011, 152, 26–35. [CrossRef]
16. Shin, W.J.; Pachynski, R.K. Chemerin modulation of tumor growth: Potential clinical applications in cancer.
Discov. Med. 2018, 26, 31–37.
17. Galon, J.; Angell, H.K.; Bedognetti, D.; Marincola, F.M. The continuum of cancer immunosurveillance:
Prognostic, predictive, and mechanistic signatures. Immunity 2013, 39, 11–26. [CrossRef]
18. Zabel, B.A.; Silverio, A.M.; Butcher, E.C. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis
distinguish plasmacytoid from myeloid dendritic cells in human blood. J. Immunol. 2005, 174, 244–251. [CrossRef]
19. Vermi, W.; Riboldi, E.; Wittamer, V.; Gentili, F.; Luini, W.; Marrelli, S.; Vecchi, A.; Franssen, J.D.; Communi, D.;
Massardi, L.; et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells
to lymphoid organs and inflamed skin. J. Exp. Med. 2005, 201, 509–515. [CrossRef]
20. Herová, M.; Schmid, M.; Gemperle, C.; Hersberger, M. ChemR23, the receptor for chemerin and resolvin E1,
is expressed and functional on M1 but not on M2 macrophages. J. Immunol. 2015, 194, 2330–2337. [CrossRef]
21. Buechler, C.; Pohl, R.; Aslanidis, C. Pro-resolving molecules-new approaches to treat sepsis? Int. J. Mol. Sci.
2017, 18, 476. [CrossRef]
22. Mitchell, D.; Chintala, S.; Dey, M. Plasmacytoid dendritic cell in immunity and cancer. J. Neuroimmunol.
2018, 322, 63–73. [CrossRef]
23. Wittamer, V.; Franssen, J.D.; Vulcano, M.; Mirjolet, J.F.; Le Poul, E.; Migeotte, I.; Brézillon, S.; Tyldesley, R.;
Blanpain, C.; Detheux, M.; et al. Specific recruitment of antigen-presenting cells by chemerin, a novel
processed ligand from human inflammatory fluids. J. Exp. Med. 2003, 198, 977–985. [CrossRef]
24. Parolini, S.; Santoro, A.; Marcenaro, E.; Luini, W.; Massardi, L.; Facchetti, F.; Communi, D.; Parmentier, M.;
Majorana, A.; Sironi, M.; et al. The role of chemerin in the colocalization of NK and dendritic cell subsets
into inflamed tissues. Blood 2007, 109, 3625–3632. [CrossRef]
180
Int. J. Mol. Sci. 2019, 20, 3750
25. Pachynski, R.K.; Zabel, B.A.; Kohrt, H.E.; Tejeda, N.M.; Monnier, J.; Swanson, C.D.; Holzer, A.K.; Gentles, A.J.;
Sperinde, G.V.; Edalati, A.; et al. The chemoattractant chemerin suppresses melanoma by recruiting natural
killer cell antitumor defenses. J. Exp. Med. 2012, 209, 1427–1435. [CrossRef]
26. Liu-Chittenden, Y.; Jain, M.; Gaskins, K.; Wang, S.; Merino, M.J.; Kotian, S.; Kumar Gara, S.; Davis, S.; Zhang, L.;
Kebebew, E. RARRES2 functions as a tumor suppressor by promotingβ-catenin phosphorylation/degradation
and inhibiting p38 phosphorylation in adrenocortical carcinoma. Oncogene 2017, 36, 3541–3552. [CrossRef]
27. Liu-Chittenden, Y.; Patel, D.; Gaskins, K.; Giordano, T.J.; Assie, G.; Bertherat, J.; Kebebew, E. Serum RARRES2 is
a prognostic marker in patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2016, 101, 3345–3352.
[CrossRef]
28. Gonzalvo-Feo, S.; Del Prete, A.; Pruenster, M.; Salvi, V.; Wang, L.; Sironi, M.; Bierschenk, S.; Sperandio, M.;
Vecchi, A.; Sozzani, S. Endothelial cell-derived chemerin promotes dendritic cell transmigration. J. Immunol.
2014, 192, 2366–2373. [CrossRef]
29. Lin, Y.; Yang, X.; Yue, W.; Xu, X.; Li, B.; Zou, L.; He, R. Chemerin aggravates DSS-induced colitis by
suppressing M2 macrophage polarization. Cell. Mol. Immunol. 2014, 11, 355–366. [CrossRef]
30. Shin, W.J.; Zabel, B.A.; Pachynski, R.K. Mechanisms and functions of chemerin in cancer: Potential roles in
therapeutic intervention. Front. Immunol. 2018, 9, 2772. [CrossRef]
31. Uhlen, M.; Zhang, C.; Lee, S.; Sjöstedt, E.; Fagerberg, L.; Bidkhori, G.; Benfeitas, R.; Arif, M.; Liu, Z.; Edfors, F.;
et al. A pathology atlas of the human cancer transcriptome. Science 2017, 357. [CrossRef]
32. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. GEPIA: A web server for cancer and normal gene
expression profiling and interactive analyses. Nucleic Acids Res. 2017, 45, W98–W102. [CrossRef]
33. Cahill, T.J.; Thomsen, A.R.B.; Tarrasch, J.T.; Plouffe, B.; Nguyen, A.H.; Yang, F.; Huang, L.Y.; Kahsai, A.W.;
Bassoni, D.L.; Gavino, B.J.; et al. Distinct conformations of GPCR-β-arrestin complexes mediate
desensitization, signaling, and endocytosis. Proc. Natl. Acad. Sci. USA 2017, 114, 2562–2567. [CrossRef]
34. Song, Q.; Ji, Q.; Li, Q. The role and mechanism of β-arrestins in cancer invasion and metastasis (Review).
Int. J. Mol. Med. 2018, 41, 631–639. [CrossRef]
35. Buchanan, F.G.; Gorden, D.L.; Matta, P.; Shi, Q.; Matrisian, L.M.; DuBois, R.N. Role of β-arrestin 1 in the
metastatic progression of colorectal cancer. Proc. Natl. Acad. Sci. USA 2006, 103, 1492–1497. [CrossRef]
36. Raghuwanshi, S.K.; Nasser, M.W.; Chen, X.; Strieter, R.M.; Richardson, R.M. Depletion of β-arrestin-2
promotes tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 2008, 180, 5699–5706.
[CrossRef]
37. Bondue, B.; Wittamer, V.; Parmentier, M. Chemerin and its receptors in leukocyte trafficking, inflammation
and metabolism. Cytokine Growth Factor Rev. 2011, 22, 331–338. [CrossRef]
38. Yoshimura, T.; Oppenheim, J.J. Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like
2 (CCRL2); two multifunctional receptors with unusual properties. Exp. Cell Res. 2011, 317, 674–684.
[CrossRef]
39. Yin, J.; Lv, X.; Hu, S.; Zhao, X.; Liu, Q.; Xie, H. Overexpression of serum response factor is correlated with
poor prognosis in patients with gastric cancer. Hum. Pathol. 2019, 85, 10–17. [CrossRef]
40. O’Hurley, G.; Prencipe, M.; Lundon, D.; O’Neill, A.; Boyce, S.; O’Grady, A.; Gallagher, W.M.; Morrissey, C.;
Kay, E.W.; Watson, R.W.G. The analysis of serum response factor expression in bone and soft tissue prostate
cancer metastases. Prostate 2014, 74, 306–313. [CrossRef]
41. Nair, P.; Muthukkumar, S.; Sells, S.F.; Han, S.S.; Sukhatme, V.P.; Rangnekar, V.M. Early growth
response-1-dependent apoptosis is mediated by p53. J. Biol. Chem. 1997, 272, 20131–20138. [CrossRef]
42. Krones-Herzig, A.; Adamson, E.; Mercola, D. Early growth response 1 protein, an upstream gatekeeper of
the p53 tumor suppressor, controls replicative senescence. Proc. Natl. Acad. Sci. USA 2003, 100, 3233–3238.
[CrossRef]
43. Muruganandan, S.; Dranse, H.J.; Rourke, J.L.; McMullen, N.M.; Sinal, C.J. Chemerin neutralization blocks
hematopoietic stem cell osteoclastogenesis. Stem Cells 2013, 31, 2172–2182. [CrossRef]
44. Li, L.; Huang, C.; Zhang, X.; Wang, J.; Ma, P.; Liu, Y.; Xiao, T.; Zabel, B.A.; Zhang, J.V. Chemerin-derived
peptide C-20 suppressed gonadal steroidogenesis. Am. J. Reprod. Immunol. 2014, 71, 265–277. [CrossRef]
45. Guo, J.C.; Li, J.; Zhao, Y.P.; Zhou, L.; Cui, Q.C.; Zhou, W.X.; Zhang, T.P.; You, L. Expression of c-fos was associated
with clinicopathologic characteristics and prognosis in pancreatic cancer. PLoS ONE 2015, 10, e0120332. [CrossRef]
46. Mahner, S.; Baasch, C.; Schwarz, J.; Hein, S.; Wölber, L.; Jänicke, F.; Milde-Langosch, K. C-Fos expression is a molecular
predictor of progression and survival in epithelial ovarian carcinoma. Br. J. Cancer 2008, 99, 1269–1275. [CrossRef]
181
Int. J. Mol. Sci. 2019, 20, 3750
47. Oliveira-Ferrer, L.; Rößler, K.; Haustein, V.; Schröder, C.; Wicklein, D.; Maltseva, D.; Khaustova, N.;
Samatov, T.; Tonevitsky, A.; Mahner, S.; et al. c-FOS suppresses ovarian cancer progression by changing
adhesion. Br. J. Cancer 2014, 110, 753–763. [CrossRef]
48. Teng, C.S. Protooncogenes as mediators of apoptosis. Int. Rev. Cytol. 2000, 197, 137–202.
49. Mikula, M.; Gotzmann, J.; Fischer, A.N.M.; Wolschek, M.F.; Thallinger, C.; Schulte-Hermann, R.; Beug, H.;
Mikulits, W. The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene
2003, 22, 6725–6738. [CrossRef]
50. Zhang, X.; Zhang, L.; Yang, H.; Huang, X.; Otu, H.; Libermann, T.A.; DeWolf, W.C.; Khosravi-Far, R.;
Olumi, A.F. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res.
2007, 67, 9425–9434. [CrossRef]
51. Li, J.J.; Yin, H.K.; Guan, D.X.; Zhao, J.S.; Feng, Y.X.; Deng, Y.Z.; Wang, X.; Li, N.; Wang, X.F.; Cheng, S.Q.; et al.
Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. Br. J. Cancer
2018, 118, 1337–1348. [CrossRef]
52. Krishnamurthy, N.; Kurzrock, R. Targeting the Wnt/β-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat. Rev. 2018, 62, 50–60. [CrossRef]
53. Burotto, M.; Chiou, V.L.; Lee, J.M.; Kohn, E.C. The MAPK pathway across different malignancies: A new
perspective. Cancer 2014, 120, 3446–3456. [CrossRef]
54. Wang, C.; Wu, W.K.K.; Liu, X.; To, K.F.; Chen, G.G.; Yu, J.; Ng, E.K.W. Increased serum chemerin level promotes
cellular invasiveness in gastric cancer: A clinical and experimental study. Peptides 2014, 51, 131–138. [CrossRef]
55. Graziosi, L.; Mencarelli, A.; Santorelli, C.; Renga, B.; Cipriani, S.; Cavazzoni, E.; Palladino, G.; Laufer, S.;
Burnet, M.; Donini, A.; et al. Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent
model peritoneal metastasis. Eur. J. Pharmacol. 2012, 674, 143–152. [CrossRef]
56. Fujimori, Y.; Inokuchi, M.; Takagi, Y.; Kato, K.; Kojima, K.; Sugihara, K. Prognostic value of RKIP and p-ERK
in gastric cancer. J. Exp. Clin. Cancer Res. CR 2012, 31, 30. [CrossRef]
57. Rémy, L.; Trespeuch, C. Matrilysine 1 et pathologie cancéreuse. Med. Sci. M/S 2005, 21, 498–502.
58. Kumar, J.D.; Kandola, S.; Tiszlavicz, L.; Reisz, Z.; Dockray, G.J.; Varro, A. The role of chemerin and ChemR23 in
stimulating the invasion of squamous oesophageal cancer cells. Br. J. Cancer 2016, 114, 1152–1159. [CrossRef]
59. Tümmler, C.; Snapkov, I.; Wickström, M.; Moens, U.; Ljungblad, L.; Maria Elfman, L.H.; Winberg, J.O.; Kogner, P.;
Johnsen, J.I.; Sveinbjørnsson, B. Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity
and cell viability in vitro and impairs tumor growth in vivo. Oncotarget 2017, 8, 95135–95151. [CrossRef]
60. Kaur, J.; Adya, R.; Tan, B.K.; Chen, J.; Randeva, H.S. Identification of chemerin receptor (ChemR23) in human
endothelial cells: Chemerin-induced endothelial angiogenesis. Biochem. Biophys. Res. Commun. 2010, 391,
1762–1768. [CrossRef]
61. Bozaoglu, K.; Curran, J.E.; Stocker, C.J.; Zaibi, M.S.; Segal, D.; Konstantopoulos, N.; Morrison, S.; Carless, M.;
Dyer, T.D.; Cole, S.A.; et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J. Clin.
Endocrinol. Metab. 2010, 95, 2476–2485. [CrossRef]
62. Nakamura, N.; Naruse, K.; Kobayashi, Y.; Miyabe, M.; Saiki, T.; Enomoto, A.; Takahashi, M.; Matsubara, T.
Chemerin promotes angiogenesis in vivo. Physiol. Rep. 2018, 6, e13962. [CrossRef]
63. Serkan, A.; Safak, A.; Emre, G.; Elif, H.; Ayse, L.D.; Mustafa, K.A. Serum chemerin level in breast cancer.
Int. J. Hematol. Oncol. 2019, 127–132.
64. Györffy, B.; Lanczky, A.; Eklund, A.C.; Denkert, C.; Budczies, J.; Li, Q.; Szallasi, Z. An online survival
analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of
1809 patients. Breast Cancer Res. Treat. 2010, 123, 725–731. [CrossRef]
65. Sarmadi, P.; Tunali, G.; Esendagli-Yilmaz, G.; Yilmaz, K.B.; Esendagli, G. CRAM-A indicates IFN-γ-associated
inflammatory response in breast cancer. Mol. Immunol. 2015, 68, 692–698. [CrossRef]
66. El-Sagheer, G.; Gayyed, M.; Ahmad, A.; Abd El-Fattah, A.; Mohamed, M. Expression of chemerin correlates
with a poor prognosis in female breast cancer patients. Breast Cancer 2018, 10, 169–176. [CrossRef]
67. Schutyser, E.; Struyf, S.; Proost, P.; Opdenakker, G.; Laureys, G.; Verhasselt, B.; Peperstraete, L.; van de Putte, I.;
Saccani, A.; Allavena, P.; et al. Identification of biologically active chemokine isoforms from ascitic fluid and
elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J. Biol. Chem.
2002, 277, 24584–24593. [CrossRef]
68. Reverchon, M.; Cornuau, M.; Ramé, C.; Guerif, F.; Royère, D.; Dupont, J. Chemerin inhibits IGF-1-induced
progesterone and estradiol secretion in human granulosa cells. Hum. Reprod. 2012, 27, 1790–1800. [CrossRef]
182
Int. J. Mol. Sci. 2019, 20, 3750
69. Hoffmann, M.; Rak, A.; Ptak, A. Bisphenol A and its derivatives decrease expression of chemerin, which
reverses its stimulatory action in ovarian cancer cells. Toxicol. Lett. 2018, 291, 61–69. [CrossRef]
70. Yao, J.; Li, Z.; Fu, Y.; Wu, R.; Wang, Y.; Liu, C.; Yang, L.; Zhang, H. Involvement of obesity-associated
upregulation of chemerin/chemokine-like receptor 1 in oxidative stress and apoptosis in ovaries and granulosa
cells. Biochem. Biophys. Res. Commun. 2019, 510, 449–455. [CrossRef]
71. Gyorffy, B.; Lánczky, A.; Szállási, Z. Implementing an online tool for genome-wide validation
of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients.
Endocr. Relat. Cancer 2012, 19, 197–208. [CrossRef] [PubMed]
72. Sotiropoulos, G.P.; Dalamaga, M.; Antonakos, G.; Marinou, I.; Vogiatzakis, E.; Kotopouli, M.; Karampela, I.;
Christodoulatos, G.S.; Lekka, A.; Papavassiliou, A.G. Chemerin as a biomarker at the intersection of
inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
Lung Cancer 2018, 125, 291–299. [CrossRef] [PubMed]
73. Xu, C.H.; Yang, Y.; Wang, Y.C.; Yan, J.; Qian, L.H. Prognostic significance of serum chemerin levels in patients
with non-small cell lung cancer. Oncotarget 2017, 8, 22483–22489. [CrossRef] [PubMed]
74. Qu, X.; Han, L.; Wang, S.; Zhang, Q.; Yang, C.; Xu, S.; Zhang, L. Detection of chemerin and it’s clinical
significance in peripheral blood of patients with lung cancer. Chin. J. Lung Cancer 2009, 12, 1174–1177.
75. Zhao, S.; Li, C.; Ye, J.B.; Peng, F.; Chen, Q. Expression of chemerin correlates with a favorable prognosis in
patients with non-small cell lung cancer. Lab. Med. 2011, 42, 553–557. [CrossRef]
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Abstract: The chemoattractant adipokine chemerin is related to the metabolic syndrome, which is a risk
factor for different cancers. Recent studies provide evidence that chemerin is an important molecule
in colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Serum chemerin is high in CRC
patients and low in HCC patients and may serve as a differential diagnostic marker for HCC and liver
metastases from CRC. To this end, serum chemerin was measured in 36 patients with CRC metastases,
32 patients with HCC and 49 non-tumor patients by ELISA. Chemerin serum protein levels were,
however, similar in the three cohorts. Serum chemerin was higher in hypertensive than normotensive
tumor patients but not controls. Cancer patients with hypercholesterolemia or hyperuricemia
also had increased serum chemerin. When patients with these comorbidities were excluded from
the calculation, chemerin was higher in CRC than HCC patients but did not differ from controls.
Chemerin did not correlate with the tumor markers carcinoembryonic antigen, carbohydrate antigen
19-9 and alpha-fetoprotein in both cohorts and was not changed with tumor-node-metastasis stage in
HCC. Chemerin was not associated with hepatic fat, liver inflammation and fibrosis. To conclude,
systemic chemerin did not discriminate between CRC metastases and HCC. Comorbidities among
tumor patients were linked with elevated systemic chemerin.
Keywords: alpha-fetoprotein; liver steatosis; hypertension
1. Introduction
Colorectal cancer (CRC) is the third most prevalent cancer worldwide and a leading cause of
tumor-related mortality. The liver is a common site for CRC metastasis [1,2]. Hepatocellular carcinoma
(HCC) typically develops in the cirrhotic liver, but about 20% arise in the non-cirrhotic liver [3].
Discrimination between secondary hepatocarcinoma and HCC may be challenging in those patients.
Clinically it is, however, highly relevant to distinguish primary and metastatic liver tumors. First,
there are different therapies for patients with CRC metastases and HCC. Second, it is important to
identify the primary tumor in metastatic disease [4], therefore biomarkers may be helpful in early
diagnosis. Carcinoembryonic antigen (CEA) is already clinically used as diagnostic and prognostic
marker in CRC [5], and systemic levels were indeed higher in secondary than primary liver tumors.
Sensitivity of serum CEA for CRC metastases was 88% and 25% for HCC [1]. Cancer antigen 19-9
(CA19-9) had a 16% sensitivity for colon cancer and a 7.7% sensitivity for HCC and could be used as an
additional prognostic tool [2,6]. Alpha-fetoprotein (AFP) is a diagnostic biomarker for HCC with a low
sensitivity and specificity, and thus cannot differentiate between HCC and CRC metastases [1].
Recent studies described a role of chemerin in CRC pathophysiology and diagnosis [7–9].
Chemerin is a chemoattractant protein most abundant in adipocytes and hepatocytes [10]. Chemerin is
released from the cells as a biological inert molecule, which is activated by C-terminal proteolysis.
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Chemerin attracts immune cells such as macrophages and natural killer cells [11]. Moreover, chemerin
regulates adipogenesis, angiogenesis and glucose metabolism [12]. Chemerin expression was reduced
in a variety of cancers, and was also low in colon adenomas [13].
High plasma chemerin predicted a greater risk of CRC. Notably, this association was still significant
when CRC risk factors such as age, body mass index and dietary habits were considered [8]. A second
study detected higher chemerin in patients with CRC compared to healthy controls. Here, serum
chemerin positively correlated with tumor-node-metastasis (TNM) stage [7]. In colon cancer patients,
chemerin was increased though it was not associated with TNM classification [9]. Sytemic chemerin
was further positively related to the number of adenomas in patients with colorectal adenomas [14].
Chemerin also plays a role in hepatocellular carcinoma (HCC) and low expression in the tumor
was an independent prognostic factor [15]. Similarly, circulating chemerin levels were about 20-fold
reduced in HCC patients [16]. Chemerin was not related to HCC prognosis [17]. Negative correlations
of chemerin with Child–Pugh score, alanine aminotransferase and bilirubin demonstrated a close and
negative association of serum chemerin with hepatic function in patients with liver cirrhosis [17,18].
In contrast, chronic hepatitis C patients had higher serum chemerin compared to controls, which was
surprisingly negatively correlated with biopsy proven necro-inflammation [19]. Likewise, chemerin
was high in men with alcohol abuse [20]. In patients with non-alcoholic steatohepatitis (NASH) serum
chemerin was either induced or normal [21]. Decline of serum chemerin thus happens particularly in
patients with severely impaired liver function and possibly HCC.
Obesity, hyperglycemia, dyslipidemia and hypertension are components of the metabolic
syndrome, and all of them were linked with the development of cancers [22]. Patients with non-alcoholic
fatty liver disease (NAFLD) have a higher risk for gastrointestinal tumors and the underlying factor is
most likely the close relationship between NAFLD and traits of the metabolic syndrome [23].
Of note, circulating chemerin was positively associated with all of the components of the
metabolic syndrome [10,24,25]. Therefore, chemerin´s association with CRC may in part stem from the
relationship between CRC and features of the metabolic syndrome [7,8,10,14,24,25]. Metabolic diseases
also contribute to HCC development [22]. Whether chemerin correlates with traits of the metabolic
syndrome in patients with cancers is, however, not well studied.
The liver is a common site of metastases from tumors arising in the gastrointestinal tract [26].
Here, we suggested that chemerin in serum may be appropriate to discriminate between colorectal liver
metastases and HCC. A further aim was to identify associations of chemerin levels with components
of the metabolic syndrome in patients with cancers.
2. Results
2.1. Association of Chemerin with Gender, Age and BMI
Serum chemerin was measured in 32 HCC, 36 CRC patients and 49 controls by ELISA (Table 1).
Controls were patients which came to the hospital because of mostly epigastric or stomach pain but without
any cancers [27,28]. HCC patients had higher bilirubin and aminotransferase activities than CRC patients
in accordance with previous studies [29]. Levels of γ-glutamyltransferase were also increased in HCC
patients (Table 1). Control cohort had lower aminotransferase activities than the group of HCC patients
(Table 1). There were fewer female patients in the HCC compared to the control group (Table 1).
Chemerin was comparable in male and female tumor patients in the whole cohort (p = 0.354)
and in the individual subgroups (p = 0.976 for controls, p = 0.540 for CRC and p = 0.511 for HCC).
Levels neither correlated with age (r = 0.20, p = 0.10) nor BMI (r = −0.27, p = 0.83) in the tumor patients.
This was also the case when the two cohorts of cancer patients were analyzed separately (CRC: age:
r = 0.06, p = 0.73; BMI r = 0.09, p = 0.61; HCC: age: r = 0.30, p = 0.10; BMI r = −0.49, p = 0.79). In the
controls chemerin positively correlated with age (r = 0.368, p = 0.009) but not with BMI (r = 0.059,
p = 0.688).
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Table 1. Characteristics of the study group.
Parameter HCC (32 Patients) CRC (36 Patients) Controls (49 Patients) p-Value
Male/Female 27/5 24/12 24/25 #*
Age (years) 63.5 (33.0–85.0) 67.0 (36.0–79.0)35 58.0 (21.0–88.0)
BMI (kg/m2) 27.2 (19.7–44.6) 31 26.6 (16.3–45.4) 26.2 (20.3–39.7)
Prothrombin Time (%) 30.8 (26.7–307.0)30 28.8 (25.2–39.0)35 n.d.
Bilirubin (mg/dl) 0.6 (0.2–2.5) 31 0.5 (0.1–1.0)35 0.5 (0.2–1.9) *
ALT (U/l) 49.5 (17.0–378) 30 28.0 (10.0–81.0) 34 20.0 (12.0–44.0) **;#***
AST (U/l) 36.0 (14.0–502.0) 31 20.5 (11.0–165.0)34 28.0 (20.0–48.0) *; #*
GGT (U/l) 105 (25–807) 27 53 (19–590)33 n.d. **
T2D 15 6 9 **; #**
HC 3 8 8
HT 18 16 18
HU 4 3 n.d.








Median values and range, or number of patients per subgroup are shown. Uppercase numbers refer to the patients
where this laboratory value / feature was known when data were unavailable for the whole cohort. Reference
values for ALT and AST: < 35 U/L for females and < 50 U/L for males, for bilirubin: 0.2–1.4 mg/dL, for GGT: <
40 U/L for females and < 60 U/l for males, for prothrombin time: < 70%. Abbreviations: Alanine aminotransferase,
ALT, aspartate aminotransferase, AST; body mass index, BMI; colorectal cancer, CRC; γ-glutamyltransferase, GGT;
hepatocellular carcinoma, HCC; hypercholesterolemia, HC; hypertension, HT; hyperuricemia, HU; not documented,
n.d.; tumor-node-metastasis, TNM, type 2 diabetes, T2D. The respective p-values are listed in the last column of
the table. * p < 0.05, ** p < 0.01 for comparison of CRC and HCC, #* p < 0.05, #** p < 0.01 and #*** p < 0.001 for
comparison of controls and HCC patients.
2.2. Chemerin, CEA and CA19-9 in HCC and CRC Patients
Chemerin levels were similar in controls, HCC and CRC patients (Figure 1A). The tumor marker
alpha-fetoprotein (AFP; known from 25 HCC patients and 15 CRC patients) did not differ between the
two cohorts of tumor patients (p = 0.07). CEA (known from 20 HCC patients and 32 CRC patients) and
CA19-9 (known from 19 HCC patients and 31 CRC patients) were higher in CRC patients (Figure 1B,C).
Chemerin did not correlate with AFP (r = −0.20, p = 0.22), CEA (r = 0.08, p = 0.57) and CA19-9
(r = 0.15, p = 0.31) in the cancer patients of the whole cohort and when both groups were analyzed
separately (CRC: AFP r = −0.08, p = 0.77, CEA r = 0.18, p = 0.34 and CA19-9 r = 0.31, p = 0.09;
HCC: AFP r = −0.15 p = 0.48, CEA r = −0.19, p = 0.41 and CA19-9 r = −0.42, p = 0.07 ). In the HCC
group chemerin was not associated with tumor size (r = 0.271, p = 0.13), grade (r = 0.044, p = 0.82)
or tumor-node-metastasis (TNM) stage (Figure 1D). Patients without vascular invasion had serum
chemerin similar to those with this development (Figure 1E).
For the CRC cohort, serum was collected shortly before hepatic resection of the metastases whereas
primary tumor was diagnosed up to six years earlier. Therefore, associations of serum chemerin with
tumor stage and grade of CRC were not calculated. In the CRC group, 13 patients received neoadjuvant
chemotherapy before liver resection which was, however, not associated with changes in chemerin
levels (Figure 1F).
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Figure 1. Chemerin and tumor markers. (A) Chemerin in serum of 49 controls, 32 patients with
hepatocellular carcinoma (HCC) and 36 patients with colorectal carcinoma (CRC). (B) CEA in 20 HCC
and 32 CRC patients. (C) CA19-9 in 19 HCC and 31 CRC patients. (D) Correlation of chemerin with
TNM stage in HCC patients (TNM stage: IA/IB/IIA/IIB/III, number of patients 14/8/7/2/1). (E) Chemerin
in 20 HCC patients without and 12 HCC patients with vascular invasion. (F) Chemerin in 13 CRC
patients with and 23 CRC patients without chemotherapy. * p < 0.05, ** p < 0.01.
2.3. Association of Chemerin with Type 2 Diabetes, Hypertension, Hypercholesterolemia and Hyperuricemia
Circulating chemerin is associated with traits of the metabolic syndrome and some studies
described higher levels in type 2 diabetes patients [12,24,30,31]. Chemerin was, however, not increased
in those 21 cancer patients with type 2 diabetes compared to patients without this disease (Figure 2A).
Chemerin was not changed in the 15 type 2 diabetic HCC patients and the 6 CRC patients when both
cohorts were analyzed separately (p = 0.25 for HCC and p = 0.47 for CRC patients). Likewise, the
9 type 2 diabetes patients of the control group did not have high chemerin serum levels (p = 0.09).
It should be noted that there were more type 2 diabetic patients in the HCC cohort than in the CRC
and control group (Table 1).
Figure 2. Serum chemerin and comorbidities in tumor patients. (A) Chemerin in 21 patients with and 47
patients without type 2 diabetes. (B) Chemerin in 34 patients with and 34 patients without hypertension.
(C) Chemerin in 11 patients with and 57 patients without hypercholesterolemia. (D) Chemerin in seven
patients with and 61 patients without hyperuricemia. * p < 0.05, ** p < 0.01.
Chemerin further regulated blood pressure, and was induced in hypertension [12]. Accordingly,
chemerin was higher in the 34 patients with arterial hypertension (Figure 2B). In the HCC subgroup,
the 18 hypertensive patients had higher chemerin than the 14 normotensive patients (p = 0.02).
Moreover, chemerin was elevated in the 16 hypertensive CRC patients when compared to the 20
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normotensive patients (p = 0.03). Although chemerin positively correlated with systolic blood pressure
in the control group (r = 0.337, p = 0.02) serum levels were not induced in the 18 hypertensive patients
(p = 0.36).
In addition, hypercholesterolaemic (11 patients) and hyperuricaemic cancer patients
(seven patients) had elevated systemic chemerin levels (Figure 2C,D). Again, in the control group
chemerin was not changed in the eight patients with hypercholesterolaemia (p = 0.65). Distribution
of hypercholesterolaemia was comparable in the three groups of patients. Hyperuricemia was only
documented in the tumor patients with similar prevalence for CRC and HCC patients (Table 1).
In the HCC group hypercholesterolaemia was diagnosed in three patients and hyperuricaemia
in four patients. In the CRC cohort eight patients were hypercholesterolaemic and three were
hyperuricaemic. The low number of patients suffering from hypercholesterolaemia and hyperuricaemia
in the subgroups may be the reason chemerin changes were not significant (HCC: p = 0.13 for
hypercholesterolaemia and p = 0.12 for hyperuricaemia; CRC: p = 0.15 for hypercholesterolaemia and
p = 0.06 for hyperuricaemia).
The strong association of serum chemerin with comorbidities led us to individually analyze serum
chemerin in patients suffering from hypertension, hypercholesterolemia or hyperuricemia and patients,
which did not have these comorbidities. In the latter cohort chemerin (p = 0.01) and CEA (p = 0.02) were
higher in CRC patients whereas AFP (p = 0.03) was reduced (Figure 3A,B). In the patients suffering
from these comorbidities chemerin was similar in both cohorts. CA19-9 (p = 0.008) was induced in
CRC patients and AST (p < 0.001), ALT (p = 0.001) and GGT (p = 0.003) were lower than in the HCC
patients (Figure 3C,D). Above all, chemerin did not differ between patients with liver tumors and
non-tumorous controls in both subgroups (Figure 3A,C).
Figure 3. Serum chemerin and comorbidities. (A) Chemerin in 27 controls, 14 HCC and 18
CRC patients not suffering from hypertension, hypercholesterolemia or hyperuricemia. (B) Spider
diagram presentation of chemerin, carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9),
alpha-fetoprotein (AFP), γ-glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and bilirubin in the serum of HCC and CRC patients described in A. The spider
diagram shows the respective median values on a logarithmic scale. (C) Chemerin in 22 controls,
18 HCC and 18 CRC patients suffering from hypertension, hypercholesterolemia or hyperuricemia.
(D) Spider diagram presentation of chemerin, CEA, CA19-9, AFP, GGT, ALT, AST and bilirubin in the
serum of HCC and CRC patients described in C. The spider diagram shows the respective median
values on a logarithmic scale. * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.4. Association of Chemerin with Liver Dysfunction
So far, the association of chemerin with hepatic injury was not resolved [21]. In the control group
serum chemerin did not correlate with alanine aminotransferase, aspartate aminotransferase or bilirubin
(Table 2). In the tumor patients, serum chemerin was not associated with alanine aminotransferase,
aspartate aminotransferase, γ-glutamyltransferase or prothrombin time in the whole cohort, and when
CRC and HCC patients were analyzed separately (Table 2). Negative correlations with bilirubin were
identified in the whole cohort (Figure 4A and Table 2) and in CRC patients (Table 2).
Table 2. Correlation of serum chemerin with markers of liver function.
Correlation of Chemerin with: HCC CRC All Tumor Patients Controls




p = 0.170 n.d.

























p = 0.511 n.d.
Correlation coefficient and p-values for the association of chemerin with prothrombin time, bilirubin, alanine
aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyltransferase (GGT) are listed for the whole
cohort, HCC and CRC patients and controls. Significant correlations are marked in bold. Not defined, n.d.
Figure 4. Serum chemerin, bilirubin and alcohol. (A) Correlation of chemerin with bilirubin in 31 HCC
and 35 CRC patients. (B) Chemerin in HCC patients stratified for alcohol intake (No alcohol: 11 patients;
Rare: 5 patients; <15 g/d: 3 patients; > 30 g/d 5 patients). ** p < 0.01.
Chemerin was further not related to alcohol intake which was documented for 24 HCC patients
(11 patients did not consume alcohol, five patients rarely drank alcohol, three patients daily had alcohol
but less than 15 g and five patients daily had more than 30 g) (Figure 4B).
We additionally evaluated potential associations of serum chemerin with histologic liver
abnormalities. In the HCC cohort 16 patients had liver steatosis, 18 had liver inflammation and
23 liver fibrosis. In the CRC group, hepatic steatosis was confirmed by histology in 17 patients,
hepatitis in 13 and liver fibrosis in 17 patients. All of these features were comparable in the cohorts.
Serum chemerin was, however, not related to any of these traits. Accordingly, serum chemerin did not
change with extent of steatosis, inflammation or fibrosis in the whole study group (Figure 5A–C) and
when both cohorts were analyzed separately (HCC: p = 0.71 for steatosis, p = 0.31 for inflammation
and p = 0.75 for fibrosis; CRC: p = 0.77 for steatosis, p = 0.44 for inflammation and p = 0.05 for fibrosis
It is important to note that in the group of tumor patients there was only one patient in the following
subgroups: steatosis grade 3, inflammation grade 2 and fibrosis grade 2. Therefore, statistical test is not
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valid. Chemerin was, however, comparable in patients having no, grade 1 and grade 2 hepatic steatosis.
Levels in patients without and grade 1 hepatic inflammation were also comparable. Chemerin in
patients without, grade 1 and grade 4 hepatic fibrosis did also not differ. It is thus admissible to
conclude that serum chemerin is not associated with hepatic features of liver injury.
Figure 5. Serum chemerin and liver injury in cancer patients. (A) Chemerin in patients stratified
for hepatic steatosis (25 patients: no steatosis; 27 patients grade 1; 5 patients grade 2 and 1 patients
grade 3; Steatosis grade of 10 patients was not known) (B) Chemerin in patients stratified for hepatic
inflammation (28 patients: no inflammation; 29 patients grade 1 and 1 patient grade 2. Inflammation
grade of 9 patients was not known). (C) Chemerin in patients stratified for hepatic fibrosis (28 patients:
no fibrosis; 25 patients grade 1; 1 patient grade 2 and 14 patients grade 4). Number of patients in some
subgroups was 1 and statistical test is not reliable for these subgroups.
3. Discussion
This study showed that serum chemerin did not discriminate patients with CRC metastases
from HCC patients or controls. Moreover, chemerin levels were not changed with hepatic steatosis,
inflammation or fibrosis. TNM stage in HCC patients was not correlated with serum chemerin.
Elevated circulating chemerin in CRC patients was described in recent studies [7,9]. In patients with
adenomas serum chemerin was nearly 50% higher than in healthy controls [14]. Chemerin concentration
of CRC patients was about 15% increased in one CRC cohort whereas the second analysis reported
a more than four-fold induction compared to healthy controls [7,9]. In the present study groups,
chemerin serum levels did not differ between CRC patients with liver metastases and patients without
tumors. This suggests that chemerin is not solely raised in CRC patients but is high in patients suffering
from different diseases. Indeed, higher chemerin was described in psoriasis, inflammatory bowel
disease, coronary artery stenosis, obstructive sleep apnea syndrome and chronic obstructive pulmonary
disease [32–36]. Therefore, high chemerin may be related to inflammatory processes rather than being
a specific marker of CRC. Moreover, chemerin expression was reduced in colon adenomas [13] and
may be low in CRC. Therefore, it is unlikely that increased serum chemerin levels do result from the
tumor tissue [37]. Serum chemerin comes from adipose tissues and the relationship between fat depots
and CRC in tumor patients warrants further investigation.
The mechanisms that contribute to higher serum chemerin in different diseases are presently
unknown. Inflammation increased adipocyte chemerin production whereas hepatic synthesis was not
changed [21,38,39]. Elevated serum chemerin in obesity did not result in enhanced activation of the
chemerin receptor CMKLR1 [40]. Accordingly, C-terminal truncated chemerin isoforms were identified
in human obesity [41]. These short variants cannot activate the chemerin receptor [12]. Future work has
to examine the factors that influence serum chemerin protein levels and activity in health and disease.
In the tumor patients, serum chemerin was induced in those with hypertension,
hypercholesterolemia and hyperuricemia. Accordingly, chemerin was elevated in hypertensive and
dyslipidemic patients in different studies [30,42]. Above all, hypertensive or hypercholesterolaemic
controls enrolled in the present study did not have higher serum chemerin levels. Notably, a positive
correlation of serum chemerin with systolic blood pressure existed in the control cohort. Distribution of
these comorbidities was similar between the three cohorts, and thus higher chemerin should have been
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identified in all groups. This suggests that comorbidity associated induction of chemerin was stronger
in tumor patients than controls. Because there were only few patients in some of the subgroups, future
studies are needed to validate this suggestion.
Moreover, chemerin did not decline in HCC patients when compared to the non-tumor controls.
Chemerin could not discriminate CRC and HCC. HCC patients more often had type 2 diabetes albeit
the prevalence of further comorbidities was comparable in both groups. Type 2 diabetes was not
linked to higher chemerin in accordance with previous studies [30,42]. Notably, when HCC and CRC
patients without hypertension, hyperuricemia or dyslipidemia were compared, chemerin was lower
in HCC. In this subgroup besides chemerin, AFP and CEA also differed with the first being higher
and the second being lower in HCC. When only patients suffering from these comorbidities were
analyzed chemerin was similar in HCC and CRC. Here, transferases were induced in HCC indicating
exaggerated liver injury in HCC patients with these complications. Moreover, CA19-9 was higher in
the CRC patients.
In the cancer patients, tumor markers CEA and CA19-9 were higher in CRC compared to HCC
patients in accordance with previous studies [1,2]. Although tumor markers were not related to
comorbidities CEA was only increased in CRC patients without comorbidities, whereas CA19-9 was
higher in the CRC patients with secondary complication. Specificities of these markers were thus
changed in the two subgroups and future studies have to find out whether this is relevant in the clinical
routine. Above all, this analysis showed that chemerin cannot be recommended as a clinical biomarker
to discriminate between primary and secondary liver tumors.
A further unresolved issue is whether serum chemerin is a marker of liver injury [21]. In HCC
patients chemerin negatively correlated with Child–Pugh score, alanine aminotransferase and bilirubin,
and positively with prothrombin time [17]. Associations of chemerin with aminotransferases and
bilirubin were not identified in patients with liver cirrhosis [43]. In the cohort studied herein, serum
chemerin was negatively correlated with bilirubin in CRC patients whereas associations with further
markers of liver health such as aminotransferases and prothrombin time were not identified in any
cohort. In addition, chemerin did not change in patients with higher grade of steatosis, inflammation
and fibrosis. Limitation of this analysis is that there was only one patient in some of the subgroups
and present findings have to be confirmed in the future. Altogether, these preliminary data exclude a
strong relation between serum chemerin and liver function.
In line with this suggestion, serum chemerin was not changed in non-alcoholic fatty liver disease
(NAFLD) patients with increasing steatosis, inflammation and fibrosis grades [44]. A separate study
identified a trend to raised serum chemerin in morbidly obese NAFLD patients with a higher degree of
liver steatosis [45]. In a similar patient cohort elevated chemerin was reported in patients with portal
inflammation and fibrosis [46]. In chronic hepatitis C serum chemerin was even negatively correlated
with necro-inflammatory grade [19].
Serum chemerin was, however, reduced in patients with decompensated liver cirrhosis when
compared to patients with compensated disease [43]. Here, a negative correlation with Quick
prothrombin time was identified [43]. Coagulation was normal in the patients enrolled in the present
study, and all patients had compensated liver cirrhosis. Therefore, a decline of serum chemerin
is an indicator of severe liver dysfunction [43], whereas levels are quite normal in patients with
compensated disease.
Moreover, chemerin did not correlate with AFP, tumor number or size in a recent study [17]. In the
present cohort, chemerin was not associated with AFP, tumor size, grading, TNM stage or vascular
invasion. Based on these results it is unlikely that serum chemerin may become a robust biomarker of
hepatic injury and HCC.
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4. Materials and Methods
4.1. Patients
Details of the cohorts are summarized in Table 1. Prospective collection of serum of the CRC
patients was done from January 2012 to June 2015. Prospective collection of serum of the HCC patients
was done from May 2012 to May 2015. Inclusion criteria were histologically confirmed HCC or CRC
metastases and age above 18 years. Exclusion criteria was pregnancy.
Liver was histologically examined and scoring was done as suggested by Kleiner et al. [47].
TNM stages were calculated as described [48]. Experiments complied with the guidelines of the
charitable state controlled foundation Human Tissue and Cell Research. Each patient signed a written
informed consent. The study was approved by the ethical committee of the Regensburg University
Hospital (Ethikkommission an der Universität Regensburg) (approval code 15-101-0052, approved on
26 March 2015).
Serum of patients without tumors was obtained from January to June 2008. The cohort included
outdoor patients and hospitalized patients who were referred to the interdisciplinary ultrasound
department of the University Hospital and was used in previous studies to analyze chemerin and
soluble CD163 in serum of controls and patients with non-alcoholic fatty liver disease (NAFLD) [27,28].
Both factors were not changed in the patients with NAFLD [27,28]. The study cohort initially included
56 patients and serum of 49 patients was available for the present study. Patients with hepatobiliary
diseases, malignancies, ascites, drugs that cause hepatic steatosis, inflammatory bowel disease, infection
with the human immunodeficiency virus, chronic alcohol and drug abuse, familial hyperlipidemia
and acute medical conditions with confounding effect on laboratory values, were excluded from the
study. All participants signed a form of written consent, and the study was approved by the local
Ethics Committee. Aliquots of the sera were stored at −80 ◦C and freeze-thaw cycles were avoided.
It is important to note that serum storage time differed for up to 7 years. This is a limitation of our
study. There was no difference in serum chemerin of patients with CRC collected in 2012 (6 patients)
and 2015 (10 patients; p = 0.1). This suggests that a four year storage period at −80 ◦C did not grossly
affect serum chemerin levels. Chemerin levels may decline during 7 year storage but this effect may be
rather small.
4.2. Chemerin ELISA
Chemerin ELISA was purchased from R&D Systems (Wiesbaden, Germany) and performed as
recommended by the distributor. The plate reader used was the iMarkTM Microplate Absorbance
Reader (Bio-Rad, Munich, Germany). Absorbance was measured at 450 nm, with the correction
wavelength set at 540 nm. Serum was diluted 1:500 fold before analysis.
4.3. Laboratory Values
Laboratory values such as bilirubin and tumor markers were routinely measured in the Institute
for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg. Total bilirubin was
determined using the Dimension Vista® Flex® reagent cartridge TBIL (Siemens Healthcare Diagnostics
Inc., Berkeley, CA, USA). Unconjugated bilirubin was solubilized in a caffeine/benzoate/acetate/ethylene
diamine tetraacetic acid mixture. Conjugated bilirubin is soluble in aqueous solvents like water.
Solublized bilirubin in serum was coupled with diazotized sulfanilic acid. Thereby diazo-bilirubin was
produced. This red chromophore absorbs at 540 nm and was measured by the use of a bichromatic
endpoint technique (540 nm, 700 nm).
The ADVIA Centaur® AFP-Assay (Siemens Healthcare GmbH, Erlangen, Germany) and
the ADVIA Centaur CEA Assay are sandwich immunoassays with chemiluminescent detection.
Two different antigen specific antibodies, a polyclonal rabbit and a monoclonal murine antibody,
are used in the assay. ADVIA Centaur® CA 19-9 Assay is a sandwich immunoassay using the same
monoclonal antibody in the solid phase and the Lite-reagent.
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4.4. Statistics
Data are shown as box plots and here the median values, lower and upper quartiles and the
range of the values are given. Statistical tests used were Mann–Whitney U Test (to test for significant
differences between two independent groups), Spearman correlation (non-parametric correlation
analysis), one-way Anova with post-hoc Bonferroni (for comparison of three groups) or Kruskall–Wallis
test (for comparison of more than three groups where one of the groups had only 1 patient) (SPSS
Statistics 25.0 program, International Business Machines Corporation, Armonk, New York, USA).
Chi-square test was used to analyze gender and comorbidity distribution. A value of p < 0.05 was
regarded as significant. Outliners—greater than 1.5 times the interquartile range—are given as circles,
and outliners—greater than 3.0 times the interquartile range—are given as stars.
5. Conclusions
Serum chemerin does not discriminate HCC from CRC metastases. Equally important is that
levels were neither related to measures of liver injury nor to TNM stage of HCC patients. Chemerin was
induced in tumor patients with comorbidities (hypertension, hypercholesterolemia, hyperuricemia),
which has to be considered in future clinical studies.
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Abstract: It is well known that adipokines are endocrine factors that are mainly secreted by white
adipose tissue. Their central role in energy metabolism is currently accepted. More recently, their
involvement in fertility regulation and the development of some reproductive disorders has been
suggested. Data concerning the role of leptin and adiponectin, the two most studied adipokines, in the
control of the reproductive axis are consistent. In recent years, interest has grown about some novel
adipokines, chemerin, visfatin, resistin and apelin, which have been found to be strongly associated
with obesity and insulin-resistance. Here, we will review their expression and role in male and
female reproduction in humans and animal models. According to accumulating evidence, they could
regulate the secretion of GnRH (Gonadotropin-Releasing Hormone), gonadotropins and steroids.
Furthermore, their expression and that of their receptors (if known), has been demonstrated in the
human and animal hypothalamo-pituitary-gonadal axis. Like leptin and adiponectin, these novel
adipokines could thus represent metabolic sensors that are able to regulate reproductive functions
according to energy balance changes. Therefore, after investigating their role in normal fertility, we
will also discuss their possible involvement in some reproductive troubles known to be associated
with features of metabolic syndrome, such as polycystic ovary syndrome, gestational diabetes mellitus,
preeclampsia and intra-uterine growth retardation in women, and sperm abnormalities and testicular
pathologies in men.
Keywords: ovary; testis; adipose tissue; polycystic ovary syndrome; preeclempsia; gestational diabetes;
testicular pathologies
1. Introduction
Nowadays, it is well known that there is a close link between metabolism and reproductive
function [1,2]. Adipose tissue is now considered as an endocrine organ that could influence fertility
through the hormonal secretion of adipokines, which are cytokines involved in various physiological
processes [3–5]. Those biologically active proteins are considered the main regulators of whole body
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energy homeostasis [3,6–8]. Many reviews have already described and discussed the crucial roles of
leptin and adiponectin in different physiological processes including reproduction [9–14]. So, here we
focused on four novel adipokines named chemerin, visfatin, resistin and apelin that have been also
identified and recognised as important regulators of energy metabolism [15–18]. Moreover, several
studies have highlighted their involvement in reproductive functions, in normal or pathological
contexts [19–22]. In this present review, we will discuss the structure of these adipokines and their
roles in the male and female reproductive tract in human and animal models, with a discussion of
their involvement in several female and male reproductive pathologies including polycystic ovary
syndrome and gestational diseases (gestational diabetes mellitus, preeclampsia and intra-uterine
growth retardation) and sperm abnormalities and testicular pathologies, respectively.
2. Structure of Adipokine Genes and Proteins
2.1. Chemerin
Chemerin was identified in 2003 as the product of the rarres2 (retinoic acid receptor responder 2)
gene, which is located on chromosome 7 in humans and is composed of 5 coding exons with a full
length of 1618 bp [23,24]. Expression of this gene is up-regulated by the synthetic retinoid tazarotene
and occurs in a wide variety of tissues [23,24]. This gene encodes a 163 amino acid protein (16 kDa)
secreted in an inactive form as prochemerin, with the secreted form being 20 amino acids shorter due
to the cleavage of the C-terminus by inflammatory and coagulation serine proteases [25] (Figure 1).
The cleavage of the signal peptide results in the release of an inactive precursor (chemerin-S163) into the
extracellular media. The precursor requires further extracellular C-terminal cleavages at various sites to
generate active and deactivated chemerins. For example, the proteolytic cleavage by plasmin, elastase
and cathepsin G activates chemerin and generates various isoforms (chemerin-K158, -S157 and -F156,
respectively) (Figure 1). Further cleavage of bioactive chemerin by chymase produces chemerin-F154
and terminates its activity [26]. Thus, several isoforms of chemerin have been identified that are
dependent on processing by various serine and cysteine proteases (Figure 1). The role of these various
forms is still unclear. Chemerin mRNA is detected in a wide range of different tissues in various species
including humans, rodents, bovine and poultry [27]. In humans, it is most abundantly expressed in
white adipose tissues, the liver and the placenta, and to a lesser extent in brown adipose tissue, the
lungs, skeletal muscles, kidneys, ovaries, and the heart [28]. Chemerin is a cytokine described as an
important regulator of several physiological processes such as blood pressure control, immune system
regulation, angiogenesis and inflammation [26]. It was first discovered in human inflammatory fluids
as a potential ligand of an orphan G protein-coupled receptor related to chemokine receptors called
ChemR23 or CMKLR1 (Chemokine-Like Receptor 1, cf. paragraph 3.1).
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Figure 1. Structure and specific forms of human chemerin. The initial preprochemerin and its different
products are processed by different proteases related to inflammation. The signal peptide (purple) is
cleaved prior to secretion. Then, the C-terminus is cleaved by different proteases giving several active
isoforms such as chemerin F156, chemerin S157 and chemerin K158.
2.2. Visfatin
Visfatin/NAMPT (nicotinamide phosphoribosyltransferase) was originally cloned in 1994 as a
cytokine named pre-B-cell colony enhancing factor (PBEF) from a human peripheral blood lymphocyte
cDNA library [29]. The mRNA for PBEF is 2.4 kb long and codes for a 52-kDa secreted protein.
The 3′ untranslated region is 69% AT and contains multiple TATT motifs. There are two atypical
polyadenylation signals, AATAAA, located upstream of the 3′ end. The protein lacks a typical signal
sequence for secretion. Human PBEF has ubiquitous expression, although it is predominantly expressed
in the human bone marrow, liver, and muscles [29]. In 2001, a study identified the gene nadV; its presence
allows nicotinamide adenine dinucleotide (NAD)-independent growth of the Gram-negative bacteria
Haemophilus influenza and Actinobacillus pleuropneumoniae. The authors found NadV to have significant
sequence homology to PBEF, thereby suggesting a novel role for PBEF in NAD biosynthesis [30].
Indeed, in 2002 the murine homologue of PBEF was found to be an enzyme catalysing the reaction
between nicotinamide and 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide
(NMN), an intermediate in the biosynthesis of NAD [31]. The crystal structure of a dimeric PBEF, now
called NAMPT, in the presence and absence of NMN further underscores NAMPT as an important
enzyme in NAD biosynthesis [32] (Figure 2). At the same time, visfatin has been identified as a cytokine
hormone and an enzyme involved in metabolic (obesity, type II diabetes) and immune disorders [33].
In humans, visfatin plasma concentrations are positively correlated with measures of obesity [34].
In mammals, visfatin or NAMPT exists as two forms, the intra- and extracellular forms, iNAMPT
and eNAMPT, respectively [35] (Figure 2). In mice, the protein expression of iNAMPT is highest in
brown adipose tissue (BAT), and the liver and kidneys, at intermediate levels in the heart, low in
white adipose tissue (WAT), and the lungs, spleen, testis, and skeletal muscle, and under detectable
levels in the pancreas and brain [35]. While the function of iNAMPT has been firmly established as an
NAD biosynthetic enzyme and having an important role in sirtuin activation in mitochondria, the
function of eNAMPT is controversial. eNAMPT is released by a number of normal cell types, such as
adipocytes, hepatocytes, myocytes, pancreatic cells, neurons and immune cells [35,36]. Moreover, it
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has been shown that eNAMPT is released under pathological conditions by cancer cells and that it
could be used as a marker for cancer development [37–39].
Figure 2. Structure and specific forms of human visfatin. Human visfatin can be found under the
intra-cellular form of nicotinamide phosphoribosyltransferase (iNAMPT) having an enzymatic role
to produce NAD+ (nicotinamide adenine dinucleotide), and under the extracellular form (eNAMPT)
with the same role. Visfatin acts also as a cytokine that could act on target cells. NAMPT catalyzes the
reaction between nicotinamide and 5-phosphoribosyl-1-pyrophosphate (PRPP) to yield nicotinamide
mononucleotide (NMN), an intermediate in the biosynthesis of NAD+.
2.3. Resistin
Resistin (Retn) is a pro-inflammatory adipokine that was first identified in mice about 20 years
ago, where it was identified as “adipose-tissue-specific secretory factor” (ADSF) [40], “found in the
inflammatory zone 3” (FIZZ3) [41] and eventually renamed “resistin” (or “resistance to insulin”) due
to its ability to resist the action of insulin [42]. The gene coding for human resistin is located on
chromosome 19p13.2 and spans 1369 bp, with three introns and four exons [43]. Resistin is a 108-amino
acid propeptide, which includes a signal peptide, a variable region, and a conserved C-terminus [42]
(Figure 3). Resistin (12.5 kDa) circulates in human blood as a dimeric protein consisting of two 92-amino
acid polypeptides that are linked by a disulphide bridge and forms high- and low-molecular weight
complexes (Figure 3). Indeed, a common feature of resistin is the existence of a motif (10–11 cysteine-rich)
at the carboxyl terminus that could support the globular domain of the resistin monomer via the
formation of 5 disulphide bridges [44,45] (Figure 3). Disulphide and non-disulphide bonds also play an
important role in the formation of dimer, trimer, and hexamer forms of circulating resistin. In mice, the
Retn gene is almost exclusively expressed in white adipocytes and blood cells [42], whereas peripheral
blood mononuclear cells (PBMCs), macrophages, and bone marrow cells are the primary source of
circulating resistin in humans [46]. In rodents, resistin represents a clear pathogenic factor in the severity
of insulin resistance (IR) [42]. However, in humans, despite initially being proposed as the potential link
between obesity and diabetes [47], this adipokine does not represent a major determinant of IR. Indeed,
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plasma human resistin seems to be correlated wth IR as a consequence of obesity itself rather than as an
independent causative factor [47].
Figure 3. Structure and specific forms of human resistin. Human resistin is composed by a signal
peptide (purple), a variable region (green) and a C-terminal domain. Resistin can be found under
the monomeric form and can form dimeric and trimeric proteins thanks to disulfide bridges. Then,
disulfide and non-disulfide bridges can be involved in the formation of the hexameric protein.
2.4. Apelin
APJ, now known as apelin receptor, was considered as an orphan G protein-coupled receptor.
In 1998, a Japanese team purified a peptide that is able to bind the APJ orphan receptor, named
apelin, from bovine stomach extracts [48]. Apelin is widely expressed in various types of tissues and
organs such as the central nervous system and peripheral tissues, including the hypothalamus, adipose
tissue, skeletal muscle, digestive system and the ovary [49–52]. The human apelin gene is found on
chromosome Xq25-q26.1. The apelin gene sequence contains an intron of around 6kb in length with
recognised intron/exon boundaries interrupting the ORF (Open Reading Frame) at the position encoding
Gly22. Similar to the rat preproapelin cDNA, the reported start codon for human preproapelin does
not appear to conform to the Kozak consensus sequence, again due to the presence of an adenosine
immediately following the start codon. The cDNA of apelin encodes a 77-amino-acid preproprotein
(Figure 4). The N-terminal sections of bovine and human proteins are rich in hydrophobic amino acids,
indicating that these represent secretory signal sequences. The amino acid sequence of the isolated
bovine peptide corresponds to the deduced sequence of the bovine preproprotein from position 42
to position 58. These results suggest that apelin is one of the processing products derived from the
C-terminal portion of the preproprotein [48]. To date, the main active forms of apelin are apelin-13, -17
and 36 and the pyroglutaminated isoform of apelin-13 (Pyr(1)-apelin 13), which is characterised by a
higher resistance to degradation [53] (Figure 4). In the heart, the described predominant form is the
Pyr(1)-apelin-13 [54]. Pyr(1)-apelin-13, apelin-13 and apelin-36 have comparable efficacy and potency
in human cardiovascular tissues [54], whereas apelin-17 appears to be the most efficient in promoting
apelin receptor internalisation [55]. The rat, bovine and human preproapelin sequences for the last 23
C-terminal amino acids share a sequence homology of 100% [48].
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Figure 4. Structure and specific forms of human apelin. Human apelin is first of all found under
the preproapelin form (77 amino acids) that will be cleaved by endopeptidases acting on basic
amino-acid-rich regions giving the proapelin (55 amino-acids) and then the other tissue-dependent
active isoforms (36, 17, 13 and Pyr-13 amino-acids). PCSK3 (proprotein convertase subtilisin/kexin 3) is
involved in the cleavage of proapelin to apelin-13.
3. Adipokines Receptors and Signalling Pathways
3.1. Chemerin
The first chemerin receptor identified was CMKLR1, originally named ChemR23. It has been
described as an orphan G protein-coupled receptor and was cloned to identify novel chemotactic factor
receptors [56]. Subsequently, it has been found to be expressed in monocyte-derived dendritic cells
and macrophages and as a co-receptor for SIV (Simian Immunodeficiency Virus) and some primary
HIV-1 (Human Immunodeficiency Virus-1) strains, and is known as ChemR23 [57]. A second receptor,
named LPS (LipoPolySaccharide) inducible C-C chemokine receptor-related gene (L-CCR), has been
discovered in mouse macrophage activation [58] and its orthologue in human, firstly named as Human
Chemokine Receptor (HCR), have been identified in a human neutrophil cDNA library [59]. Firstly,
this receptor was considered as an orphan receptor. A third receptor named G Protein Receptor 1
(GPR1), has also been identified as an orphan receptor in humans and rodents, and is involved in
peptide transmission in brain functioning [60]. Also, besides CMKLR1, orphan receptors GPR1 and
CCRL2 have been identified by in vitro assays as spare receptors for chemerin (Figure 5, [61,62]. Those
three receptors are protein G-coupled receptors with seven-transmembrane domains. The expression
of CMKLR1 mRNA was detected in a wide variety of tissues such as haematopoietic tissues [24,56,63],
adipocytes [64], endothelial cells [65], osteoclasts [66] and ovarian cells [67]. CCRL2 has been found to
be expressed in cell types such as macrophages [68], mast cells [62], lung epithelial cells [69] and the
ovary [67]. Contrary to CMKLR1 and CCRL2, GPR1 expression has not been found in immune cells but
has been reported in central nervous system cells [60,70], murine brown adipose tissue, white adipose
tissue, and skeletal muscle. GPR1 is mainly expressed in vascular cells in white adipose tissue [16].
Chemerin binding to CMKLR1 enhances leukocyte chemotaxis [71]. Chemerin binding to CCRL2 does
not mediate cell signalling, but might present chemerin to nearby CMKLR1-positive cells to promote
its function and play a key role in immune responses, inflammation, and other physiological processes
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(Figure 5, [62]. GPR1 is an active receptor of chemerin and could regulate glucose homeostasis in
the development of obesity because glucose intolerance was found to be increased in Gpr1-knockout
mice fed a high-fat diet compared to wild-type (WT) mice. Within the mice ovary, it has been shown
that chemerin/GPR1 signalling regulates progesterone secretion during the processes of follicular
development, corpus luteum formation, and PGF2α-induced luteolysis [72].
Figure 5. Receptors used by chemerin, visfatin, resistin and apelin for their signaling pathways.
chemerin can bind three different receptors that are CMKLR1, GPR1 and CCRL2. CMKLR1 and GPR1
are coupled with intracellular Gαi proteins. The last receptor doesn’t have any active signaling pathway
identified until now suggesting a putative role of co-receptor for CCRL2. Apelin has its own receptor
called APJ coupled with intracellular Gq and Gαi proteins. Resistin could bind receptors such as CAP-1,
ROR-1 and TLR-4 but it has to be confirmed. No receptor for visfatin has been identified until now.
Chemerin binding to CMKLR1 activates the three Gαi subtypes and the two Gαo isoforms
(Figure 5). Chemerin stimulates the increase in intracellular calcium and a decrease of cyclic AMP in
CMKLR1-expressing CHO cells that are dependent on Gαi signalling [24]. It further uses the RhoA-
and Rho-associated protein kinase-dependent pathway downstream of GPR1 and CMKLR1 to activate
the transcriptional regulator serum-response factor [73]. Mitogen-activated protein kinase ERK1/2
is phosphorylated upon chemerin treatment in various cells, including endothelial cells, adipocytes,
and skeletal muscle cells. The activation of ERK1/2 at low, but not high, chemerin concentrations was
described in adipocytes [65,74]. Chemerin further activated p38 mitogen-activated protein kinase, Akt
and phosphoinositide 3-kinase [26]. Short periods of incubation with chemerin were shown to activate
Akt in hepatocytes, whereas prolonged treatment of up to two hours led to a decline in phosphorylated
Akt in these cells [75]. The same study reports that chemerin binding weakened the association of
phosphatase and tensin homolog (PTEN) with CMKLR1. This enhanced the activity of PTEN and
subsequently led to decreased Akt phosphorylation. The nuclear factor kappa B (NFkB) pathway
is activated by chemerin in skeletal muscles cells [76]. Chemerin thus activates various signalling
pathways, with effects that are dependent on incubation time and dose.
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3.2. Visfatin
The receptor of visfatin is still unknown (Figure 5) and the exact cellular mechanism of extracellular
visfatin (eNAMPT) remains unclear, even though various authors have implicated intracellular insulin
receptor signalling pathways in the action of visfatin [77–80].
3.3. Resistin
Like visfatin, the receptor of resistin remains unknown and the molecular mechanism of resistin
action is unclear. However, recent reports have suggested potential receptors for resistin (Figure 5).
In humans, there are two putative resistin receptors: adenylyl cyclase-associated protein 1 (CAP 1) [81]
and toll-like receptor 4 (TLR4) [82]. Studies have involved the use of an isoform of decorin (DCN) [83],
as this is supposed to be a receptor of resistin. Moreover, mouse receptor tyrosine kinase-like orphan
receptor 1 (ROR1) has been identified as a putative receptor for resistin [84]. It is well known that
resistin activates signalling pathways in different tissues such as Akt, MAPK (Mitogen-Activated
Protein Kinases, ERK1/2 and p38), Stat-3 (signal transducer and activator of transcription 3) and PPAR
gamma (PPARγ).
3.4. Apelin
Apelin receptor (APJ) was first identified in 1993 as a class A (rhodopsin-like) orphan G
protein-coupled receptor which shows high homology with the angiotensin II (AngII) receptor [85].
The gene encoding APJ is intronless and is known as APLNR in humans. The APLNR gene encodes a
380-amino acid protein and is located on chromosome 11q12 [85]. The promoter of the rat APLNR gene
does not include a TATA box, but contains a potential CAAT box at −1257 bp and a number of activator
protein 1 and specificity protein 1 (Sp1) motifs [86]. There are two transcriptional start sites at −247 and
−210 bp [86]. The protein structure of APJ is typical of a GPCR (G protein-coupled receptor), containing
seven hydrophobic transmembrane domains, with consensus sites for phosphorylation by protein
kinase A (PKA), palmitoylation and glycosylation (Figure 5, [85]. The apelin system is able to activate a
high number of signalling pathways through various G proteins. Apelin-13 and apelin-36 activate the
phosphorylation of ERK1/2 in Chinese hamster ovary (CHO) cells stably expressing mouse APJ [87].
The phosphorylation, and thus activation, of Akt has been shown to be a downstream effector of apelin
signalling; this was first shown to occur via a PTX-sensitive G-protein and PKC [87]. The same study
showed that Apelin induces the dual phosphorylation of the S6 ribosomal protein kinase (p70S6K)
in human umbilical vein endothelial cells (HUVECs), where apelin promotes cell proliferation via
PTX-sensitive, ERK1/2-, mammalian target of rapamycin (mTOR)-, and Akt-dependent intracellular
cascades. In the absence of ligands, the apelin receptor is also able to heterodimerise with other GPCRs
and activate signalling pathways.
4. Adipokines and Reproductive Functions at the Hypothalamo-Pituitary Level in
Non-Pathological Conditions
4.1. Chemerin
In the hypothalamus, the expression of chemerin and its receptors was observed within the
tanycytes and ependymal cells (Figure 6), with increased expression reported for long (LD) versus short
(SD) photoperiods, pointing to a physiological role. [88]. In the pituitary, RARRES2 gene expression has
been found in baboons and chimpanzees [89] (Figure 7). Furthermore, in rats, chemerin administration
(8 and 16 μg/kg) decreased both food intake and body weight compared to vehicle, possibly associated
with a significant increase in serotonin synthesis and release, in the hypothalamus [90]. These results
suggest an important role of chemerin in hypothalamus–pituitary function especially in feeding
behaviour; however, interactions between chemerin and the central nervous system involved in
reproduction need further investigation. No in vivo or in vitro studies have investigated the effect of
chemerin on pituitary cells.
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Figure 6. Expression and effects on GnRH (Gonadotropin-Releasing Hormone) release of chemerin,
visfatin, resistin and apelin in hypothalamus. Increase/stimulation. Decrease/inhibition. ND: not
determined. CSF: cerebrospinal fluid.
Figure 7. Expression and effects on gonadotropic cells of chemerin, visfatin, resistin and apelin in
pituitary. Increase/stimulation. Decrease/inhibition. ND: not determined.
4.2. Resistin
In rodents, resistin is expressed in the hypothalamus in a region responsible for energy balance [91]
(Figure 6). Maillard et al. (2017) showed staining by immunohistochemistry of resistin in the anterior
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lobe of the mouse pituitary (Figure 7). Resistin 1 and 10 ng/mL decreased LH (Luteinizing Hormone)
secreted by LβT2 cells. Furthermore, a 0.01; 0.1 and 1 ng/mL resistin concentration significantly decreased
mouse pituitary cell LH secretion, but 10 ng/mL resistin did not significantly affect LH release [92]
(Figure 7). Thus, the effect of resistin on pituitary cells seems to be dependent on the concentration.
In LβT2 mouse cells, resistin (1 ng/mL) increased phosphorylation in the AMPK and ERK1/2 signalling
pathways (Figure 7). Furthermore, resistin has been shown to be regulated by gonadotrophins from the
pituitary [93]. All of these data suggest a potential role of resistin in the hypothalamo-pituitary axis.
4.3. Visfatin
Visfatin has been found in the cerebrospinal fluid but its origin is not known [94]. Visfatin is present
in the mouse brain, hypothalamic area (Figure 6) and pituitary, as well as in LβT2 mouse gonadotrophin
cells [92]. By immunohistochemistry, visfatin was localised in the anterior and intermediate lobes of the
pituitary and seems to be co-localised with βLH (Figure 7). In LβT2 cells, LH secretion was decreased
by visfatin stimulation from 0.1 to 10 ng/mL, whereas visfatin did not affect LH secretion in the primary
mouse pituitary cells [92]. Thus, visfatin could play a regulatory role at the hypothalamo-pituitary level.
4.4. Apelin
Apelin receptor (APJ) has been characterised in the mouse central nervous system by
immunohistochemistry (Figure 6). APJ was localised in hypothalamic nuclei, such as arcuate, supraoptic
and paraventricular nuclei, and in the anterior pituitary, implying potential roles in the control of
reproduction [95]. These brain regions are known to be the central control points of energy utilisation
and reproductive behaviour. The intraperitoneal injection of apelin-13 in mice reduced LH, FSH (Follicle
Stimulating Hormone) and testosterone serum levels and showed negative effects on the reproductive
function (Figure 7). However, in these mice, no measurement of GnRH release was performed. Based
on these results, the authors suggested that the inhibitory effect of apelin on testosterone levels was due
to a direct action of apelin on gonadotropic cells [96–98].
5. Adipokines and Reproductive Functions at the Gonad Level in Non-Pathological Conditions
5.1. Ovary
5.1.1. Chemerin
Under normal physiological conditions, chemerin and CMKLR1 have been shown to be expressed
in the mouse ovary [74]. Another study went further, demonstrating that the chemerin system is
expressed within the human ovary at mRNA and protein levels, but also has a functional role in
ovarian physiology (Figure 8). This study showed that chemerin and its receptor CMKLR1 are present
and active in human granulosa cells. Chemerin reduces IGF-1 (Insulin Like Growth Factor 1)-induced
steroidogenesis and cell proliferation through a decrease in the activation of IGF-1R signalling pathways
in primary human granulosa cells (hGCs) [67]. Chemerin also inhibits FSH-induced mRNA and protein
expression of aromatase and p450scc in rodent granulosa cells [99,100] (Figure 8). In bovine species,
chemerin and its three receptors CMKLR1, GPR1 and CCRL2 are expressed within the ovary and
recombinant chemerin decreases in vitro steroidogenesis and cholesterol synthesis at the basal level as
well as after IGF-1 and/or FSH induction [101] (Figure 8). This down-regulation is associated with a
reduction in protein levels of STAR (Steroid Acute Regulatory protein), cytochrome P450 family 19
subfamilies A member 1, and 3-Hydroxy-3-Methylglutaryl-CoA Reductase and the phosphorylation of
MAPK ERK1/2, which is dependent on CMKLR1. Moreover, human recombinant chemerin also inhibits
bovine oocyte maturation at the germinal vesicle stage and decreases MAPK ERK1/2 phosphorylation
in oocytes and cumulus cells [101] (Figure 8). In avian species, it has also been demonstrated that
chemerin and its three receptors are expressed in the hen ovary and that chemerin plasma concentration
is positively correlated with egg hatchability [102]. Chemerin and its receptors are also expressed in
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turkeys, more particularly in the theca and granulosa cells, with higher levels in theca cells. Moreover,
this study showed that chemerin plasma concentrations decreased during the laying period [103]. All of
these data suggest that chemerin could be a key hormone linking reproductive and metabolic functions.
Figure 8. Expression and effects of chemerin, visfatin, resistin and apelin on the ovarian follicle.
Increase/stimulation. Decrease/inhibition.
5.1.2. Resistin
Resistin has been shown to be expressed within the ovaries of rodent and bovine species [104].
More precisely, resistin is expressed by theca cells, luteinised granulosa cells of the corpus luteum
and oocytes, but its expression is very weak in granulosa cells. By contrast, in bovine species, resistin
is expressed by granulosa cells of growing follicles, with its expression decreasing in the corpus
luteum and being almost undetectable in oocytes (Figure 8). Furthermore, in these cells, the authors
observed that recombinant resistin can modulate steroidogenesis and proliferation in a basal state or in
response to IGF-1 in vitro [104] (Figure 8). Another study showed that resistin inhibits steroidogenesis
of undifferentiated (small follicles) granulosa cells and mitogenesis of differentiated (large follicle)
granulosa cells [105]. These results highlighted a huge species difference between rat and bovine species
in terms of resistin expression and its effects [104]. In a porcine model, resistin is expressed by theca cells,
but also and more abundantly in granulosa cells of growing follicles (Figure 8). In these cells, resistin
supports the survival of in vitro cultured porcine follicles (Figure 8). It also has a positive effect on
steroidogenesis and mitosis on ovarian cells [106]. In the greater Asiatic yellow bat (Scotophilus heathii),
resistin is expressed in the ovary, more precisely by the theca cells, as in rats, with an increase in
expression around the ovulation period. Moreover, recombinant resistin alone on cultured bat granulosa
cells preferentially stimulates progesterone secretion. Furthermore, resistin increases androgenic action
in the ovary [107,108].
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In humans, resistin expression has been demonstrated in luteinised granulosa cells recovered after
follicle punction in a programme of in vitro fertilisation [109,110]. In 2009, a study demonstrated that
ovarian hormones did not have any effects on resistin concentrations in serum [111]. However, resistin
itself influences in vitro ovarian functions. Indeed, Munir et al. demonstrated that resistin enhances
mRNA expression and the activity of 17alpha-hydroxylase in human theca cells in the presence of
forskolin and insulin [112] (Figure 8). This finding confirms the results obtained in rat testes, where
resistin increases testosterone secretion in a dose-dependent manner [93]. In contrast, Reverchon et al.
showed that resistin decreases IGF-1-induced steroidogenesis in primary human granulosa cells. These
effects were confirmed by Messini et al. in response to FSH [113]. Despite its negative effect on the
regulation of ovarian steroidogenesis [110,114] (Figure 8), resistin does not seem to play a key role in
human ovarian physiology. Indeed, its levels in follicular fluid have been repeatedly found to be lower
than in plasma [110,115], suggesting that human granulosa cells, while expressing resistin protein [110],
are unlikely to secrete it into follicular fluid or the circulation. Varnagy et al. showed that resistin levels
in follicular fluid were a positive predictor of oocyte and embryo number, indicating a beneficial effect
of this adipokine on the outcome of in vitro fertilisation procedures [116]. However, this finding has
not been confirmed by other authors, who concluded that resistin cannot play a significant role in the
maturation and development of oocytes [115,117]. This discrepancy could be explained by the number
of patients and also by the experimental design.
5.1.3. Visfatin
In the chicken model, this adipokine is widely expressed in a lot of tissues, in a sex-dependent
manner (Figure 8). It has been found in hen ovaries at both the mRNA and protein levels [118], and an
in vitro study has shown that visfatin inhibits progesterone production in granulosa cells through STAR
and HSD3B at basal level or after IGF-1 stimulation [119]. Still in birds, visfatin is expressed mainly by
theca cells and more weakly by granulosa cells of turkey follicles. During a laying cycle, its concentration
in serum significantly decreases in the same model [103]. In cows, visfatin is expressed within the ovary
in theca, granulosa, cumulus cells and oocytes. Contrary to the chicken model, visfatin increases in vitro
steroidogenesis and potentialises IGF-1 effects by increasing STAR and HSD3B expression, as well as E2
and P4 secretion [120] (Figure 8). In mice, visfatin is also expressed within the ovary and more precisely
in stromal cells, endothelial cells, granulosa cells and cumulus cells. Its main production comes from
granulosa cells and increases during follicular growth. The administration of visfatin during ovulation
induction in aged female mice improves the developmental competency of oocytes [121] (Figure 8).
Furthermore, Shen et al. found a significant positive correlation between visfatin concentration in
follicular fluid and the number of retrieved oocytes in women [122], confirming a possible positive role
of this adipokine in female reproductive function. However, visfatin concentration in follicular fluid
has been shown to be similar [122] or lower [123] than in serum, and no correlation was found between
visfatin plasma and follicular fluid levels [122]. Hence, circulating visfatin concentration does not
seem to contribute significantly to visfatin concentration in follicular fluid [122] which could, therefore,
be independently and differently regulated at the ovarian level. In humans, visfatin is expressed in
granulosa cells, but also in cumulus cells and oocytes, and less abundantly in theca cells. Moreover,
recombinant human visfatin increases cell proliferation and E2 and P4 production by luteinized human
granulosa cells [124]. Thus, as in bovine species and mice, visfatin has a positive effect on steroidogenesis
in human granulosa cells [124].
5.1.4. Apelin
Apelin and APJ have been detected by in situ hybridisation in the corpus luteum (CL) of the rat
ovary [125]. In mice, the apelin system is found in the corpus luteum but also in theca cells of follicles,
showing a species difference between mice and rats [95]. In bovine species, this adipokine is also
expressed in the early and mid-luteal stages of the corpus luteum to then decline during the regression
phase. More precisely, apelin was localised in the smooth muscle cells of intraluteal arterioles, and
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responded to PGF2-alpha at the periphery of CL in cows [126]. In porcine species, the expression of
apelin and APJ increased with ovarian follicular growth [127]. In humans, apelin and its receptor are
expressed by granulosa, cumulus, and theca cells with a putative weak expression in oocytes (Figure 8).
Even if plasma apelin levels are largely dependent on the assay, apelin concentration in follicular
fluid seems to be higher than in plasma [128,129]. It can thus be speculated that follicular apelin is
partly derived by granulosa cell production and regulates the function of granulosa cells in a paracrine
and/or autocrine manner. Indeed, although mice lacking apelin or APJ genes are viable and fertile [52],
some in vitro evidence suggests a potential role of apelin in the control of ovarian function. Indeed,
it enhances progesterone and oestradiol secretion in human and porcine granulosa cells [52,96,127]
(Figure 8). In primary human granulosa cells, Apelin-13 and Apelin-17 isoforms are both able to
increase basal and IGF-1-induced progesterone and oestradiol secretion, which was associated with an
increase in HSD3B protein concentration and AKT and MAPK ERK1/2 phosphorylation [52]. Apelin
also improves rat, bovine and porcine granulosa cell proliferation [127], and seems to be involved in
the regulation of bovine corpus luteum luteolysis processes [126] and oocyte maturation [97]. Notably,
apelin has been suggested to be implicated in bovine follicular atresia [96] and, in different animal
species, both the mRNA and protein levels of apelin and APJ changed during follicular growth with
the highest expression in large follicles [127]. In bovine species, apelin exerts a negative effect on
in vitro oocyte maturation through blocking of the meiotic progression at the germinal vesicle stage [97]
(Figure 8).
In summary, chemerin and the apelin system, resistin and visfatin are expressed in the ovary of
various species. The effects of these adipokines mainly studied in vitro are dependent on the species
but also on the dose used, experimental design and probably on the methodological uncertainties.
In primary human granulosa cells, chemerin and resistin inhibit in vitro steroidogenesis induced by
IGF-1, whereas visfatin and apelin improve it (Figure 9).
Figure 9. Effects of chemerin, visfatin, resistin and apelin on steroidogenesis in vitro in primary human
granulosa cells. Chemerin and resistin are known to inhibit IGF-1 (Insulin Like Growth Factor 1)-
induced steroidogenesis whereas visfatin and apelin exert stimulatory effects.
5.2. Testis
Recent reports have pointed to an emerging role of adipokine in male reproductive functions.
Indeed, it has been shown that obesity is positively correlated with defective spermatogenesis, especially
in developed countries where semen quality is seriously lowered. Furthermore, obesity is associated
with decreased testosterone concentrations and sperm motility [98]; however, the action by which
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testosterone production is reduced remains unclear. The link between obesity, adipokine and male
fertility problems needs to be elucidated. The effect of adiponectin and leptin in male fertility has
already been described [19]. In this section, we will focus on the role of other novel adipokines
(chemerin, apelin, visfatin, resistin) in male reproductive functions.
5.2.1. Chemerin
Chemerin and its three receptors CMKLR1, GPR1 and CCRL2 are expressed in rat and human
male reproductive tracts. [130,131]. Chemerin, CMKLR1 and GPR1 proteins are specifically localised in
Leydig cells of the human and rat testis [132] (Figure 10). In rat primary Leydig cell cultures, chemerin
suppressed the testosterone production induced by human chorionic gonadotropin (hGC, [133])
(Figure 10). This is associated with an inhibition of gene and protein expression of the 3β-hydroxysteroid
dehydrogenase and MAPK ERK1/2 phosphorylation [133]. The C-20 chemerin derived peptide presents
similar effects to chemerin, suggesting that this peptide can present similar functions as the different
peptide forms of chemerin [130]. In mice deleted for CMKLR1 (CMKLR1−/−), the plasma testosterone
level is lower compared to in wild-type animals [134]. Furthermore, in cultured Leydig cells isolated
from CMKLR1−/−mice, gene expression of HSD3B, STAR, P450scc, Sf1, Gata4 and Insl3 was significantly
decreased compared to wild-type mice. All of these data suggest that chemerin plays an important
role in male steroidogenesis, as in females. In humans, chemerin is present in seminal plasma at lower
concentrations than in human blood plasma [135]. Obesity is associated with reduced sperm motility
and lower testosterone serum levels, and it is known that chemerin secretion is increased in the case of
obesity, suggesting that chemerin could have a negative effect on sperm motility/maturation in the
epididymis through direct effects on spermatozoa or indirect effects during epidydimal maturation.
Figure 10. Expression and effects of chemerin, visfatin, resistin and apelin on testicular function.
Increase/stimulation. Decrease/inhibition.
5.2.2. Visfatin
Visfatin is present in rodent and human testes [136,137]. It is also expressed in pre-pubertal
and adult chicken testes, and more particularly in the nucleus of sertoli cells, and Leydig cells [138]
(Figure 10). In humans, visfatin concentrations in seminal plasma is higher than in blood plasma [139]
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suggesting local production or by the male annex glands. Moreover, visfatin is present in the human
spermatozoa and is regulated in a maturation-dependent manner [137]. In rats, visfatin increased
testosterone production through Ras1 kinase from in vitro cultured Leydig cells [140] (Figure 10).
Moreover, Jeremy et al. showed that visfatin protein expression in the rodent testis is decreased by a
D-galactose treatment which induces aging [136]. The visfatin expression is specifically decreased in
Leydig cells and decreases serum testosterone levels. These data suggest an important role of visfatin
in testicular aging by regulating spermatogenesis and steroidogenesis [136].
5.2.3. Resistin
Resistin has been found to be expressed in the testis and seminiferous tubules of rats, and especially
in Sertoli and Leydig cells. Resistin is equally expressed in mouse Leydig cell lines (MA-10 and
TM3) [141]. In rat Leydig cells, in vitro stimulation with resistin increased both basal and human
chorionic gonadotropin (hCG)-stimulated testosterone production [93] (Figure 10). Roumaud et al.
cited that exposure to a low resistin concentration (10 ng/mL = obesity physiological concentration)
increases Leydig cell proliferation [141]. These data suggest that resistin could positively regulate
Leydig cell steroidogenesis and proliferation.
5.2.4. Apelin
Apelin is found in the rat testis [142]. Only one study showed that the intracerebroventricular
infusion of apelin-13 in male rats significantly reduced serum testosterone levels compared to the
control group [143] (Figure 10). Histological analyses demonstrated a reduction in the number of
Leydig cells, suggesting that apelin may play a role in the central regulation and decrease testosterone
release by suppressing LH secretion (Figure 10).
6. Adipokines and Pregnancy
6.1. Adipokines and Uterus
Chemerin was first identified in normal human myometrial cells and fibroidic cells by microarray
and real-time quantitative polymerase chain reaction (RT–qPCR) [144]. Later, it was demonstrated that
chemerin is expressed in human primary cultures of stromal cells and extravillous trophoblast cells
from pregnant women. Moreover, data indicate that chemerin is up-regulated during decidualisation
and might contribute to natural killer (NK) cell accumulation and vascular remodelling during early
pregnancy [145]. In the human and rat myometrium, visfatin had similar dose-dependent effects on
the inhibition of both spontaneous and oxytocin-induced contractions of pregnant rat and human
myometrial tissue in vitro [146]. In the mouse model, visfatin is also expressed by the uterus and
its expression varies during the sexual cycle. Indeed, it appeared that E2 and P4 regulate visfatin
expression explaining variations during sexual cycle expression in mice uterus [113].
Only one study has demonstrated that resistin is expressed within the uterus, by showing
that this adipokine is expressed in the ovine uterus and that its expression varies according to the
nutritional status of the animal, an observation that strengthens the link between nutritional status
and reproductive activity [147]. First evidence of apelin expression in the uterus appeared in 2001
in a study showing the purification of the apelin-36 isoform by gel filtration chromatography from
uterine tissue extracts from rats [148]. As in rats, apelin and its receptor appear to be expressed in the
mouse uterus [95]. In humans, an in vitro study brought evidence that apelin had inhibitory effects
on uterine contractility by down-regulating spontaneous and oxytocin-induced contractions in the
human myometrium [149]. Similar results have since been found in rats [150].
6.2. Adipokines and Placenta
Acting as a chemoattractant, chemerin has been hypothesised to play a role in placentation.
Indeed, this adipokine is produced by the rat placenta during gestation and has also been found
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to be expressed in human placenta. Chemerin plays a role in placentation by regulating NK cell
accumulation and endothelial cell morphogenesis during early pregnancy, along with the expression of
this adipokine in stromal cells and extravillous trophoblast cells; however, this expression remains low
compared to that in the liver and adipose tissues [145,151]. It has also been found to be expressed within
the umbilical cord, playing a protective role by regulating umbilical vein endothelial cell-induced
nitric oxide signalling in preeclampsia [152]. Finally, the chemerin/GPR1 system has been found to
be expressed in mice and human placenta with a putative role as a feedback mechanism that could
regulate the carbohydrate balance during pregnancy [153].
Visfatin has been immunolocalised throughout gestation in the amniotic epithelium and
mesenchymal cells as well as the chorionic cytotrophoblast and parietal decidua. This adipokine is
constitutively expressed by the foetal membranes during pregnancy. It increased the expression of IL-6
and IL-8 and may be important in both normal spontaneous labour and infection-induced preterm
labour [154]. It has also been linked with the initiation of normal labour with a role at the end of the
signalling cascade. Indeed, a previous study demonstrated that visfatin activates pro-inflammatory
cytokine release and phospholipid metabolism in the human placenta via activation of the NF-κB
pathway, leading to normal labour [155,156]. Its production has also been linked to the equilibrium and
homeostasis of amniotic fluid by regulating its reabsorption by the amniotic fluid through stimulation
of VEGFR2 ((Vascular endothelial growth factor receptor 2) expression in the placenta [157]. In vitro,
the PPAR-γ signalling pathway has been linked to the regulation of visfatin by IL-6 in BeWo (Placental
cell line cell), providing a novel insight into the roles of visfatin in trophoblastic cells [158].
In a rat model, resistin expression has been demonstrated in the placenta under normal
conditions [159]. First evidence of its expression in the human placenta was provided by Yura et al. in
2003 [160] with a study showing that this adipokine is produced by the placenta with a maximum at
full-term pregnancy. Resistin mRNA and protein are also localised to the syncytiotrophoblast and
EVTs in early gestation and the syncytiotrophoblast in late gestation [160]. Maternal serum levels in the
first and second trimesters are relatively constant and comparable to values in non-pregnant women.
However, resistin levels and placental mRNA expression are increased by the third trimester [161].
Because adipose resistin expression remains unchanged during pregnancy, placental production is
likely a major source of resistin in the maternal circulation. Such changes in resistin levels could
contribute to the decrease in insulin sensitivity during the latter half of pregnancy, which is beneficial
for the rapid growth of the foetus [162]. In the human placenta, resistin could affect glucose-uptake,
presumably by decreasing the cell surface glucose transporter [163].
The apelin system is also expressed within the human placenta under normal conditions [164].
In rats, apelin expression is lower than in the brain, with a localisation of the protein in the perivascular
smooth muscle [165]. In the same species, in cases of induced hypertension by nitric oxide treatment, the
apelin receptor, but not apelin itself, is up-regulated in the placenta. The authors of this study concluded
that this suggests that the apelinergic system may control foetal growth and cardiovascular functions in
utero [133]. In humans again, labour down-regulates apelin expression in foetal membranes. Furthermore,
a role of apelin in the regulation of pro-inflammatory and pro-labour mediators, like interleukin
(IL)-1β-induced IL-6, IL-8 release and cyclooxygenase-2, is suggested in foetal membranes [166]. Moreover,
apelin controls foetal and neonatal glucose homeostasis and is altered by foetal growth restriction induced
by maternal under-nutrition [167]. Finally, apelin seems to be implicated in trophoblastic amino acid
transport by stimulating amino acid uptake by the placenta [168].
7. Adipokines and Female Reproductive Pathologies
7.1. Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a very common endocrinopathy affecting 6% to 13% of
women of reproductive age and one of the leading causes of female poor fertility [169]. According to
recommendations in 2018 from the international evidence-based guidelines, its diagnosis requires the
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presence of at least two of the following criteria: oligo/anovulation, hyperandrogenism and polycystic
ovary morphology on ultrasound (corresponding to a follicle number per ovary >20 and/or an ovarian
volume >10 mL on either ovary) [170]. Despite its high prevalence and relevant impact on female
health, the aetiology of PCOS, and notably the causal relationship between reproductive and metabolic
features, has not yet been fully elucidated. Typically, PCOS is associated with visceral obesity [171] and
an original adipose tissue dysfunction, possibly due to an in utero androgen hyperexposure, which is
supposed to play a key role in determining both insulin-resistance (IR) and altered androgen metabolism
characterising this syndrome [172]. Indeed, 50 to 90% of PCOS females have IR to a significantly greater
extent than age- and body mass index (BMI)-matched control women [173] and present a significantly
increased risk of developing type 2 diabetes [174]. Hyperinsulinaemia derived from insulin-resistant
states would further stimulate the intrinsically increased androgen biosynthesis, characterising theca
cells of PCOS ovaries [175]. In turn, androgen excess, observed in 60 to 80% of women suffering from
PCOS [176] and further exacerbated by abdominal obesity, might play a crucial role in preferentially
determining the expansion of visceral adipose tissue, contributing to IR and thus creating a vicious
cycle ([172].
7.1.1. Chemerin
Chemerin has been discovered as a novel adipokine associated with obesity and metabolic syndrome
in 2007 [64]. Its strong interaction with insulin metabolism is evident. Indeed, insulin profoundly
enhances chemerin secretion from adipose tissue [177], while chemerin has been demonstrated to
modulate insulin signalling and glucose disposal in in vitro and animal studies [178], inducing an
insulin-resistant state in both adipocytes and skeletal muscle [142].
Independently from insulin and obesity, the existence of a correlation between Chemerin and PCOS
has repeatedly been evoked [179]. Serum and ovarian levels of chemerin have been shown to be elevated
in a dihydrotestosterone (DHT)-induced rat PCOS model [99] and, despite some discordant data [180],
most of the authors report higher plasma chemerin concentrations in PCOS women [177,181–183]
(Figure 11). These patients also seem to present increased chemerin expression in the subcutaneous and
omental adipose tissue [177] (Figure 11); very recently, Wang et al. demonstrated that chemerin follicular
fluid concentration and its mRNA levels in granulosa cells were higher in PCOS normal-weight patients
than in controls [184] (Figure 11), a finding that we have confirmed subsequently in our laboratory
(Bongrani et al., in press).
Interestingly, circulating chemerin levels were greater in PCOS hyperandrogenic women compared
to the euandrogenic ones [180] and positively correlated with free androgen index [180] and total
testosterone levels [184]. Furthermore, in DHT-treated rats, CMKLR1 gene deletion protected against
the negative effects of chronic androgen treatment on progesterone secretion, cycling and ovulation [185].
As testosterone treatment has been demonstrated to up-regulate the expression of chemerin and its
receptors in vitro [184], Lima et al. suggested that negative androgen effects on ovary could be partly
mediated by this adipokine [186] (Figure 12). Indeed, hyperandrogenism would increase ovarian
chemerin, which, in turn, functions as a chemoattractant ligand for blood monocytes expressing
CMKLR1. Inflammatory monocyte-derived CMKLR1+M1 macrophages, attracted to chemerin-rich
ovarian follicles, would induce granulosa cell apoptosis contributing to the antral follicular growth
arrest associated with the hyperandrogenic pro-inflammatory state characteristic of PCOS [186]
(Figure 12). It is noteworthy that elevated chemerin levels in the DHT-induced rat PCOS model
were positively related to increased granulosa cell apoptosis [19] and that women presenting higher
chemerin concentrations in follicular fluid had significantly fewer oocytes and lower high-quality
embryo rates [184], suggesting that chemerin could actually be involved in folliculogenesis disruption
at the origin of PCOS [19] (Figure 12).
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Figure 11. Effects of chemerin, visfatin, resistin and apelin on ovarian physiology, plasma and adipose
tissue in polycystic ovarian syndrome (PCOS) as compared to control patients. Increase/stimulation.
Decrease/inhibition.
Figure 12. Description of PCOS syndrome and possible involvement of chemerin, visfatin, resistin and
apelin in this syndrome.
As described in paragraph 5.1, the expression of chemerin and its receptors in human ovarian
cells has been largely demonstrated [67] and the role of the chemerin/CMKLR1 pathway in follicle
function and steroidogenesis has repeatedly been evoked [185]. Indeed, chemerin acts as an important
negative regulator of ovarian steroidogenesis, inhibiting the IGF-1-induced secretion of progesterone
and oestradiol in human granulosa cells [67] and suppressing the FSH-induced expression of aromatase
and P450scc in cultured rat pre-antral follicles and granulosa cells [99,187]. Remarkably, chemerin
concentration has been shown to be higher in follicular fluid than in plasma [67] and, in contrast to
serum chemerin, the rise of follicular chemerin in women with PCOS has been demonstrated to be
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independent of changes in adiposity [186]. Thus, chemerin regulation at the ovarian level seems to be
different from the systemic one, suggesting that this adipokine could play a paracrine and/or autocrine
regulatory role in the ovary. Moreover, by negatively affecting steroidogenesis and participating in
androgen induction of antral follicle growth arrest, chemerin seems to be strongly involved in the
pathogenesis of anovulatory infertility characterising PCOS patients [186] (Figure 12).
7.1.2. Visfatin
Despite some conflicting results [188–190], a recent meta-analysis revealed that plasma visfatin
levels are significantly increased in subjects presenting overweight/obesity, IR, metabolic syndrome
and cardiovascular diseases [191], with visfatin expression seeming to be modulated by some
insulin-sensitising agents. Indeed, 3 month-treatment with metformin in PCOS women resulted
in a significant decrease in serum visfatin concentration [192]. Although two studies failed to highlight
a significant difference between PCOS and healthy women [193,194] (Figure 11), most of the authors,
and particularly the recent Sun et al. meta-analysis [195], found significantly higher plasma visfatin
levels in PCOS patients [123,192,196–202] (Figure 11). Similarly, in PCOS women, visfatin expression
in adipose tissue was increased independent of BMI [201] (Figure 11) and visfatin concentrations
in follicular fluid were similar [123] or higher [202] in comparison with BMI-matched normally
ovulatory women (Figure 11). Interestingly, the adipose tissue of PCOS women is characterised by
an up-regulating alteration of lipolysis due to a selective increase in the function of protein-kinase
A hormone-sensitive lipase complex [203] and 50% higher responsiveness to norepinephrine then
healthy adipose tissue [203]. Since visfatin seems to be released during the lysis of fat cells rather
than being secreted [204], the increased visfatin concentrations observed in PCOS women are possibly
derived from this up-regulated lipolysis [123]. Visfatin is also known to display pro-inflammatory
properties and immune functions [78,205] and, within adipose tissue, it has been demonstrated to be
secreted not only by adipocytes, but also by inflammatory cells, such as macrophages [199]. As PCOS
is characterised by low-grade inflammation, this could additionally explain its association with higher
visfatin levels.
Interestingly, Panidis et al. found a positive correlation between circulating visfatin and plasma
LH, evoking a possible role of this adipokine in the hypothalamo-pituitary-ovarian axis dysregulation
observed in PCOS [200] (Figure 12). It is also noteworthy that serum visfatin levels have been found to
be significantly higher in PCOS hyperandrogenic women than in the euandrogenic ones [193] and
in PCOS hirsute adolescents when compared with non-hirsute patients [194]. Furthermore, despite
some discordant results [123,195], a positive association between circulating visfatin and markers
of hyperandrogenism has repeatedly been highlighted [193,194,198,200], even independent from
insulin-sensitivity and other confounding factors [199]. As previously described, visfatin exerts an
insulin-mimetic action and insulin can stimulate theca cell androgen synthesis, notably in IR-related
hyperinsulinaemic conditions [193]. Thus, visfatin could be implicated in PCOS pathogenesis by
influencing ovarian androgen secretion because of its insulin-like action [199] (Figure 12).
In conclusion, whether visfatin plays a role in the physiopathology of PCOS remains a matter of
debate and further studies are needed to elucidate its significance. However, high visfatin levels seem
to be an intrinsic characteristic of PCOS, suggesting that this adipokine could be a potential biomarker
for this syndrome [195].
7.1.3. Resistin
Interestingly, in a randomised placebo-controlled study involving overweight women suffering
from PCOS, circulating levels of resistin were significantly decreased by the insulin-sensitising agent
rosiglitazone [206]. However, although a significant correlation between plasma resistin and IR or
type 2 diabetes has been reported [207], most of the studies do not confirm the existence of such an
association [47,115,208–210] (Figure 11). In particular, Panidis et al. showed that plasma resistin levels
did not differ between PCOS and control normal-weight women, even though the former were more
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insulin-resistant. Furthermore, after stepwise multiple regression analysis, circulating resistin was
not associated with any parameter independent of BMI, suggesting that it correlated with IR as a
consequence of obesity itself rather than as an independent causative factor [47] (Figure 11).
As discussed above, resistin involvement in human female reproduction is known. However,
at present, the existence of an association between resistin and PCOS is largely debated. Indeed,
variations in the resistin gene promoter were not associated with PCOS phenotypes [211] (Figure 12)
and data concerning plasma resistin levels in PCOS women are inconsistent. While some authors
pointed out significantly higher resistin concentrations in the plasma of PCOS patients [112,209,212,213]
(Figure 11), no difference between PCOS and healthy women has been reported by several
others [47,115,190,208,210,214] (Figure 11). Similarly, resistin concentrations in follicular fluid did not
differ between normal-weight PCOS and healthy women [115] (Figure 11). On the contrary, resistin
mRNA levels in adipocytes have been found to be twice as high in PCOS patients compared to
controls [214] (Figure 11) and significantly decreased after laparoscopic ovarian electrocautery [215],
suggesting that, although systemic resistin does not seem to be actively involved in PCOS pathogenesis,
it may act as a local determining factor for this syndrome [47,214] (Figure 12).
Remarkably, in humans, Seow et al. found greater mRNA resistin levels in the adipocytes of PCOS
women presenting higher serum testosterone levels [214] (Figure 11) and the study of Munir et al.
showed that circulating resistin in the PCOS group, but not in controls, was positively correlated with
plasma testosterone [112]. Thus, it has been suggested that some important differences in polycystic
ovaries may facilitate the responsiveness of theca cells to resistin, which may synergise with insulin to
increase androgen synthesis [112].
In conclusion, in light of the data collected so far, resistin does not seem to be a major determining
factor in PCOS pathogenesis. However, its role in ovarian theca cells and, notably, in androgen
production deserves to be further investigated.
7.1.4. Apelin
Data about the existence of an association between circulating apelin and IR in PCOS are
still inconsistent. Indeed, plasma apelin levels have been found to correlate negatively [216], but
also positively [196] with HOMA-IR (Homeostatic Model Assessment for Insulin Resistance), and
most studies have excluded the existence of any significant association between this adipokine and
IR [128,191,217,218]. It is therefore unlikely that apelin could represent a marker of insulin-sensitivity
in women with PCOS.
In our laboratory, we repeatedly found that apelin concentration in follicular fluid and levels
of apelin and its receptor APJ mRNA in granulosa cells are higher in PCOS patients than in healthy
controls [52] (Figure 11). More conflicting data are, however, available for circulating apelin in
PCOS women, with an almost equal number of authors reporting significantly lower [128,129,217],
higher [196,218] or unchanged [216,219] levels compared to control women (Figure 11).
Interestingly, in our laboratory we recently demonstrated that, independent of PCOS diagnosis,
apelin and APJ expression in granulosa cells and follicular fluid is increased in women presenting
a high number of ovarian small antral follicles resulting from the failure in selection of a dominant
follicle (Bongrani et al., in press). Hence, according to these data, apelin could be significantly involved
in PCOS pathogenesis, markedly contributing to the arrest of follicular development (Figure 12). It is
currently admitted that folliculogenesis disruption observed in PCOS is derived from an increased
responsiveness of small follicles to FSH in terms of oestradiol and progesterone synthesis, inducing a
premature responsiveness to LH [220]. As a consequence, PCOS anovulatory women present higher
LH and oestradiol levels, as well as lower FSH concentrations, than those in the normal early follicular
phase [220]. Interestingly, in rats, apelin is expressed in the arcuate supraoptic and paraventricular
hypothalamic nuclei and suppresses LH, FSH and prolactin secretion [221]. Furthermore, in women with
PCOS a negative correlation between plasma apelin and LH levels has repeatedly been found [128,216]
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(Figure 12), strongly suggesting a role of this adipokine in the hormonal regulation of ovarian function,
especially with regard to follicular development.
In conclusion, current knowledge strongly supports the involvement of apelin in follicular growth
arrest and hypothalamus-pituitary-ovary axis perturbations at the origin of ovulatory dysfunction
typically associated with PCOS, encouraging further studies about the role of this adipokine in
reproductive function.
7.2. Gestational Diseases
During pregnancy, the placenta secretes cytokines, including TNF-alpha, IL-6 and IL-1β, and
increases both their local and systemic levels, which is believed to be important in determining
foetal allograft fate [222]. As described in paragraph 6.3, several adipokines, such as adiponectin,
leptin, resistin, visfatin and apelin, are also secreted by the placenta [223] and have been implicated
in metabolic adaptations to normal gestation, as well as in preeclampsia and other complications
of pregnancy [224]. Moreover, some of these molecules are postulated to play a significant role in
creating a favourable environment for implantation and placental development [222]. In contrast
to adiponectin and leptin, studies about the regulation of chemerin, visfatin, resistin and apelin in
gestational diabetes, preeclampsia and intrauterine growth restriction are limited. Furthermore, data
are mostly descriptive, not allowing clarification of the physiological significance of the dysregulation
of these novel adipokines in pregnancy complications.
7.2.1. Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM) is defined as a carbohydrate intolerance first detected
in pregnancy, which affects approximately 14% of pregnancies worldwide (International Diabetes
Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium, 2017). It poses serious risks for the mother
and developing foetus. Moreover, although it usually resolves following delivery, in the long-term,
women with a past history of GDM and babies born of GDM pregnancies are at an increased risk of
obesity, type 2 diabetes mellitus and cardiovascular diseases [225]. Pregnancy is a unique condition
characterised by transient physiological IR, which progresses with advancing gestation, aimed at
facilitating delivery of nutrients to the foetus. In fact, slightly elevated glycaemia makes glucose
available to be transported across the placenta to fuel foetal growth. IR also promotes endogenous
hepatic glucose production and lipolysis in adipose tissue, resulting in a further increase in blood
glucose and free fatty acid concentrations [225]. Pregnant women compensate for these changes
through hypertrophy and hyperplasia of pancreatic β-cells, as well as increased glucose-stimulated
insulin secretion [226]. Failure of this compensatory response gives raise to maternal hyperglycaemia
or GDM [227]. Thus, GDM is usually the result of β-cell dysfunction on a background of chronic IR
during pregnancy. IR is mainly attributed to placental hormones and increased maternal adiposity,
although the underlying mechanisms are not fully understood [223]. Recently, several new potential
mediators of IR have been identified and, among these, adipokines seem to play a key role [223].
Chemerin
Chemerin has been suggested to constitute an insulin-sensitising factor which may counteract
IR [228]. Contrary to normal pregnancy, which is associated with increased plasma chemerin levels
that decrease post-partum, Hare et al. showed that circulating chemerin was reduced in GDM
women and did not change with the normalisation of glucose tolerance following delivery [228]
(Figure 13). However, a recent meta-analysis by Zhou et al., evaluating 11 studies carried out between
2010 and 2017 and including a total of 742 GDM patients and 840 normal pregnant women [229],
reported that the overall levels of plasma chemerin in GDM women were significantly increased when
compared with healthy pregnant ones and that this difference was more evident in the second- than
in the third-trimester. The authors thus concluded that chemerin may play a powerful role in the
pathophysiology of GDM by increasing IR and promoting subclinical inflammation [229] (Figure 13).
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These results are, however, contradicted by a previous review, evaluating various adipokines in GDM,
which demonstrated that adiponectin, leptin and TNF-alpha are more likely than chemerin, resistin
and visfatin to play a role in the pathogenic mechanism of GDM [230] (Figure 13). Finally, no difference
in chemerin levels, either in the early third trimester or at delivery, was reported between healthy and
GDM women by Van Poppel et al. [231] (Figure 13). They instead demonstrated that, compared to
infants from healthy mothers, newborns from GDM patients had higher chemerin levels in arterial
but not venous cord blood, probably reflecting a higher pro-inflammatory status in the foetus of
pregnancies complicated by GDM [231]. In summary, although chemerin seems to contribute to the
increasing IR and subclinical inflammation that is characteristic of GDM, at present, data concerning
its role in the physiopathology of this pregnancy complication are still controversial and do not allow a
unique conclusion.
Figure 13. Putative involvement of plasma levels of chemerin, visfatin, resistin and apelin in gestational
diabetes mellitus. Increase/stimulation. Decrease/inhibition.
Visfatin
Visfatin promotes adipogenesis and exerts insulino-mimetic effects [223]. In normal pregnancy,
it may improve insulin sensitivity during the second and third trimesters and its up-regulation in
the IR state during gestation may be part of a physiological feedback mechanism to improve insulin
signalling [223]. However, there are huge discrepancies in reports about visfatin levels in pregnancies
complicated by GDM. Higher serum visfatin levels in GDM women compared to normal glucose
tolerance controls were observed in a nested case-control study, but no relationship with fasting plasma
glucose, insulin, IR or BMI could be obtained [232] (Figure 13). On the contrary, two cross-sectional
studies found that, in women with GDM, circulating visfatin was positively correlated with fasting
and post-glucose load insulin in the third trimester [233], and that GDM was independently associated
with increased maternal plasma visfatin concentrations [234]. Subsequently, Ferreira et al. reported
increased levels of visfatin in the first trimester of women who later developed GDM, suggesting
that this adipokine could be a biomarker of this pregnancy complication [235] (Figure 13). However,
many other studies reported lower visfatin levels in GDM patients [236,237] (Figure 13). Differences in
study design, including the number of patients, gestational age and BMI, may contribute to explain
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the different results between studies. In conclusion, further research is still needed to clarify the
relationship between visfatin and obesity and any causal association with IR and GDM. In particular,
prospective studies are required to evaluate whether visfatin can be predictive of GDM.
Resistin
The role of resistin in managing glucose homeostasis remains unclear, as most studies have failed
to show a correlation between plasma resistin levels and insulin sensitivity in humans [223]. Resistin is
expressed in the human placenta and, in normal pregnancy, it is up-regulated in the third trimester,
possibly contributing to the decrease in insulin sensitivity [160]. In GDM, the studies available so
far did not give unique results. Circulating resistin has been shown to be elevated in women with
GDM compared to normal pregnancies [161,238] (Figure 13). Nevertheless, Kuzmicki et al. could not
demonstrate an independent relationship between serum resistin concentration and insulin levels
or IR [238]. Contrary to these results, another study found lower resistin levels in GDM patients in
comparison with euglycaemic controls [239] (Figure 13) and most case-control studies reported no
difference in circulating resistin levels in women with and without GDM [162,240] (Figure 13), a finding
further confirmed in a large prospective study [241] (Figure 13) and in a recent meta-analysis [242]
(Figure 13). Moreover, no difference was reported in resistin release from placental and subcutaneous
adipose tissue obtained from normal pregnant subjects and GDM women [243]. Collectively, current
data suggest that resistin may mediate IR during pregnancy, but it is unlikely to have a central role in
glucose homeostasis and the development of GDM.
Apelin
Apelin is known to be an adipokine implicated in glucose homeostasis, and is found to be
increased in obese and T2DM individuals [240]. Although its presence has been documented in human
placental tissue [164], very few studies have addressed the expression of apelin in human pregnancy.
An increase in apelin fat mRNA expression was observed only in early gestation, suggesting that
apelin is not associated with hyperinsulinaemia of late pregnancy, but rather related to adipose tissue
accumulation [223]. In GDM, cross-sectional studies of circulating apelin have contradictory results,
including unchanged and increased levels [230] (Figure 13). Moreover, no association between plasma
apelin concentration or apelin/APJ mRNA expression and GDM or the indices of IR was noted in a
study involving 101 GDM patients and 101 women with normal glucose tolerance between 24 and
32 weeks of gestation and 20 GDM and 16 healthy controls at term [244]. In light of these data, it seems
thus unlikely that apelin is directly involved in GDM physiopathogenesis.
7.2.2. Preeclampsia
Preeclampsia (PE) is a pregnancy complication affecting 4.6% of pregnant women worldwide [245]
and a major contributor to foetal, neonatal and maternal morbidity and mortality [246]. It may
develop from 20 weeks of gestation up to 6 weeks postpartum [246] and is characterised by the de
novo development of arterial hypertension associated with one of the following features: proteinuria,
maternal organ impairment (comprising renal insufficiency, hepatic cytolysis, neurological complication
or haematological disorder like thrombocytopenia or haemolysis) and uteroplacental dysfunction,
including foetal growth restriction [247]. Indeed, PE is associated with small-for gestational age (SGA)
neonates in 10–25% of cases [248]. The pathophysiology of PE has not yet been fully elucidated, but
abnormal placentation and imbalance between angiogenic and anti-angiogenic factors (including
VEGF, PIGF (Placental growth factor), soluble fms-like tyrosine kinase 1 and endoglin) appear to be
major contributors [222]. Initial incomplete trophoblast invasion and abnormal uterine spiral artery
remodelling induce uteroplacental ischemia. This is followed by the release of placental factors, such as
inflammatory cytokines and reactive oxygen species, into maternal circulation; these are able to trigger
a broad intravascular inflammatory response, which is another essential step for the development
of PE [247]. Like GDM, PE shares risk factors with metabolic syndrome including IR, subclinical
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inflammation and obesity [248] and women with a history of hypertensive pregnancy disorders present
a 1.4 to 3-times higher risk of future cardiovascular diseases compared to women with normotensive
pregnancies [249].
Chemerin
Despite its high expression in human placenta [74] and its well-known association with obesity,
glucose metabolism and metabolic syndrome [64], data concerning the possible involvement of
chemerin in physiological and pathological pregnancy is really poor. To the best of our knowledge,
only one study in a small number of subjects has investigated chemerin in PE. Interestingly, maternal
serum chemerin concentrations were significantly increased in preeclamptic women compared to
healthy pregnant ones [250] (Figure 14). Furthermore, patients with severe PE had higher chemerin
levels than those with mild PE, and circulating chemerin was independently correlated with markers
of dyslipidaemia and PE severity, suggesting that chemerin regulation of glycolipid metabolism may
contribute to the pathogenesis of this pathological condition [250] (Figure 14). Chemerin is also known
as a pro-inflammatory adipokine, induced by TNF-alpha and enhancing macrophage adhesion [19],
and as a potent angiogenic factor, inducing gelatinolytic activity of endothelial cells [64,154]. Hence,
its role in PE might be more relevant and involve other aspects of its physiopathology, which deserve
more in depth investigation.
Figure 14. Putative involvement of plasma levels of chemerin, visfatin, resistin and apelin in preeclampsia
and intrauterine growth restriction. Increase/stimulation. Decrease/inhibition.
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Visfatin
The presence of visfatin transcript and protein has been detected in human foetal membranes
and placenta [154] and pregnant women present higher circulating visfatin levels compared to
non-pregnant subjects [234]. Notably, in normal pregnancies, median maternal plasma visfatin
concentrations peak in the second trimester of gestation, between 19 and 26 weeks, and show a nadir
between 27 and 34 weeks [234,251]. In women with PE, circulating visfatin levels have been reported to
be increased [252,253] (Figure 14), similar [224] (Figure 14) or decreased [254] (Figure 14) compared to
healthy pregnant women. Notably, Fasshauer et al. found that, after multivariate analysis, PE remained
a significant predictor of circulating visfatin, independent of HOMA-IR and BMI [252]. Moreover,
in the Mazaki-Tovi et al. study of patients with PE, there was no significant difference in maternal
visfatin concentration between those with or without an SGA neonate, suggesting that the effect of
FGR, which is known to increase visfatin levels (as described later), was overwhelmed by PE [224].
The authors proposed that in the presence of common risk factors for PE and SGA, high maternal
visfatin concentrations could have beneficial metabolic effects, resulting in increased insulin-sensitivity
and thus protecting mothers from PE [224]. Nevertheless, Hu et al. reported contrasting results, i.e.,
markedly decreased visfatin levels in preeclamptic women, irrespective of their BMI, and speculated an
involvement of this adipokine in the exaggerated IR that characterises this pathological condition [254]
(Figure 14). In light of these data and because visfatin is known to improve glucose tolerance, it has
been suggested that the up-regulation of maternal visfatin concentration in IR-associated pregnancy
complications may be part of a physiological feedback mechanism aimed at improving insulin
signalling [223,251]. Furthermore, visfatin expression has recently been shown to be significantly
related to TNF-alpha and IL-6 mRNA expression in placental tissues [223] and recombinant visfatin
treatment of human foetal membranes causes a significant increase in inflammatory cytokines including
IL-1β, TNF-alpha and IL-6 [154]. Thus, elevated visfatin levels observed in PE could additionally be
associated with the pro-inflammatory state characteristic of this and other pregnancy complications.
Resistin
Resistin is expressed in human placenta, and mainly in trophoblastic cells [246]. Plasma resistin
levels in pregnant women are significantly higher compared to those in non-pregnant controls and
resistin gene expression, as well as its circulating concentrations, is more prominent as pregnancy
advances [160]. As resistin gene expression is higher in the placenta than in adipose tissue, where it
remains unchanged throughout pregnancy [160], it has been postulated that placental resistin may
contribute to the physiological decrease in insulin-sensitivity occurring in the second half of human
pregnancy [255]. Data about resistin levels in PE are discordant. Indeed, Haugen et al. reported higher
resistin concentrations in women affected by PE compared to normal pregnant controls [256] Figure 14).
However, such a difference was lost after controlling for IR and, as resistin placental gene expression
was unchanged, it probably mostly depended on altered renal function in preeclamptic patients, which
contributes to elevate resistin plasma concentrations [256]. In contrast to this report, Cortelazzi et al.
and Chen et al. found that circulating resistin levels were lower in preeclamptic women than in the
normotensive healthy pregnant ones, possibly due to reduced placental production because of the
smaller size of the placenta [161,162] (Figure 14). Finally, Hendler et al. failed to find a difference in
serum resistin concentrations between pregnant women with and without PE [257] (Figure 14). Hence,
according to these data, resistin does not seem to be the main determinant of IR observed in PE [223].
However, as resistin is known to exert pro-inflammatory effects and stimulates IL-6 and TNF-alpha
synthesis [258], it may be involved in the exaggerated maternal inflammatory response associated with
PE pathogenesis.
Apelin
Because of its cardiovascular protective action and its role in the regulation of fluid homeostasis
and insulin metabolism, the apelin/APJ system has been supposed to play a role in adaptation to
pregnancy and regulation of foetal growth [259]. Additionally, embryonic expression studies in animals
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indicate that apelin is an important angiogenic factor required for normal blood vessel growth and
endothelial cell proliferation [223]. Nevertheless, reports studying the expression and the function of
this adipokine in human pregnancy are very few. Although apelin is known to be up-regulated in
obesity and hyperinsulinaemia states in humans and mice [50], apelin fat mRNA expression seems
to increase only in the early period in pregnant rats, suggesting that it may not be associated with
physiological IR occurring in late pregnancy [223]. Furthermore, a recent study analysing maternal
apelin concentrations in pregnant women failed to show any significant correlation between apelin
and insulin levels [260]. In light of these data, apelin contribution to the regulation of maternal insulin
sensitivity therefore seems limited. Nevertheless, several recent works have highlighted the important
role of apelin in PE physiopathology. Indeed, although some authors showed higher maternal
levels [261] (Figure 14) and increased placenta expression [164] (Figure 14) of apelin in preeclamptic
pregnant women compared to healthy ones, most of the reports demonstrated a down-regulation of
the apelin/APJ system in hypertensive pregnant disorders [259,262] (Figure 14). Notably, Yamaleyeva
et al. found 30% lower content of apelin in the chorionic villi of preeclamptic patients compared
to villi obtained from women with a normal gestation and proposed that lower apelin levels in the
preeclamptic placenta might diminish its opposing modulation of vasoconstrictor mediators, which
results in the increased blood pressure defining PE [259]. Indeed, the blood pressure-lowering action of
apelin is well documented in several animal models and in patients with heart failure [263] and apelin
is known to act on vascular smooth muscle cells, inducing either vasodilatation or vasoconstriction
via different pathways [259]. Additionally, in the study of Yamaleyeva et al., apelin release from the
chorionic villi was reduced by angiotensin II administration, suggesting a potential interaction between
apelin and the renin-angiotensin system [259]. The beneficial effects of apelin in PE have also been
suggested by a very recent report using a rat model in which PE symptoms were induced by reducing
uterine perfusion pressure. In this model, apelin treatment significantly reversed the elevation in
blood pressure and increased the total foetal weight, resulting in higher embryo survival rates [263].
Interestingly, these effects were obtained by improving the impaired eNOS/NO (endothelial nitric oxide
synthase/nitric oxide) signalling pathway and preventing the activation of oxidative stress, which is
one of the key features of PE pathogenesis [263].
Noteworthy, very recently, another component of the apelin-APJ system, named elabela has
been postulated to be actively involved in PE development. Indeed, elabela is a new endogenous
peptide ligand for the APJ receptor, which seems to play a crucial role in embryonic development [229].
Ho et al. demonstrated that deletion of the elabela gene in mice caused PE-like symptoms and that
the administration of elabela to pregnant elabela-null mice prevented the increase in maternal blood
pressure, proteinuria and FGR [264]. The authors thus proposed that the loss of Elabela might perturb
early placental development, resulting in its inadequate perfusion. However, whether this effect is
obtained via a paracrine role in angiogenesis or, indirectly, by inducing vasodilatation and regulating
fluid balance, is currently unknown [264,265]. It needs to be underlined that these results have not
been confirmed in humans, as no difference was found in placental transcript abundance or circulating
levels of elabela in preeclamptic women compared to controls [266].
In conclusion, because of its involvement in angiogenesis and the regulation of blood pressure
and fluid balance, the apelin/APJ system might play an important role in PE pathogenesis, encouraging
further studies about its physiological relevance in pregnancy and its complications.
7.2.3. Intra-Uterine Growth Retardation
Foetal growth restriction (FGR) is defined by an estimated foetal weight less than the 10th percentile
for the population at a given gestational age. It is a common complication of gestation, affecting up to 25%
of pregnancies in low- to middle-income countries [267]. It derives from a placental failure to adequately
supply oxygen and nutrients to the developing foetus, thus resulting in stunted foetal growth [268].
This phenomenon, named placental insufficiency, is idiopathic in up to 60% of cases and it is due to
a physiological deficiency in uterine spiral arteries remodelling, resulting in restricted uteroplacental
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perfusion. In the foetus, hypoxia results in so-called brain-sparing, which is the preferential blood
flow redistribution to vital organs like the brain, myocardium and adrenal glands, inducing a decrease
in foetal weight and an altered foetal organ development that are associated with increased rates of
neonatal mortality and morbidity [268]. Interestingly, in addition to placental insufficiency, FGR shares
with PE several mechanisms of disease, including the anti-angiogenic state, the increased maternal
intravascular inflammatory response [224] and the excessive maternal IR [269]. Furthermore, SGA
neonates are more likely to develop metabolic complications, such as glucose metabolism disorders
and adipose tissue dysfunction, later in life [270]. Several maternal adipokines are already known
to link maternal nutrient status and adipose tissue metabolism to placental nutrient transport, thus
contributing to foetal organ development and growth patterns in utero [222].
Chemerin
Although chemerin is actively involved in glucose and lipid metabolism [64] and its expression is
elevated in the human placenta [74], its role in foetal growth has poorly been studied and, to the best
of our knowledge, no report about chemerin involvement in FGR is currently available.
Visfatin
Given its insulin-mimetic action and as its expression in human placenta is limited to the villous
capillary of the foetal endothelium, visfatin has been proposed to play a role in the transfer of glucose
from the maternal to the foetal circulation [246]. The existence of a relationship between this adipokine
and foetal growth has further been suggested by recent findings of elevated visfatin concentrations in
cord blood [255]. Remarkably, all of the authors studying visfatin in the third trimester of pregnancies
complicated by FGR reported higher maternal levels compared to control pregnant women with
appropriate-for-gestational-age infants [224,251,260] (Figure 14). Visfatin has thus been proposed as
a novel marker that is up-regulated in pregnant women with SGA neonates [251] (Figure 14). With
regard to visfatin concentration in cord blood, however, data are more controversial. Indeed, while
Ibanez et al. and Malamitsi-Puchner et al. found higher visfatin levels in SGA neonates compared to
the appropriate-for-gestational-age ones [260,271] (Figure 14), Mazaki-Tovi et al. failed to highlight any
difference between these two groups [224] (Figure 14). Similarly, the latter authors reported that visfatin
concentration in foetal circulation was lower than in the maternal one and observed no significant
correlation between the two [224] (Figure 14). This finding is in contrast with Malamitsi-Puchner et al.,
who showed that maternal and foetal visfatin concentrations were similar and significantly correlated
each other [260] (Figure 14). Interestingly, Mazaki-Tovi et al. proposed that increased visfatin levels
in SGA neonates might be linked to their different and/or altered visceral adiposity, which seems to
contribute to the development of IR and impaired glucose metabolism in adulthood [224,272] (Figure 14).
Resistin
As resistin gene expression is higher in term placenta than in first trimester placental tissue and
its levels in cord blood samples are elevated, resistin has been postulated to be involved in the control
of foetal energy expenditure and deposition of adipose tissue [255]. Indeed, resistin is supposed to
act as a feedback regulator of adipogenesis, exerting an inhibitory effect on adipose conversion [255].
Cord serum resistin levels have been found to be higher in growth-restricted pregnancies and lower
in macrosomic foetuses when compared to normal ones [243,273] (Figure 14), further suggesting
the existence of a negative correlation between maternal and cord blood resistin and birth weight.
However, these results are not confirmed by other authors, who demonstrated no difference in resistin
maternal [223] (Figure 14) and cord blood [274] (Figure 14) concentrations, as well as in placental resistin
expression [275] (Figure 14) between FGR and normal pregnancies. Furthermore, in the study of Yeung
et al., who analysed adipokines in newborn dried blood spots, resistin was inconsistently associated
with birth size after accounting for the other measures [276]. In light of the currently available data,
therefore, it is difficult to speculate on a specific role for resistin in foetal energy metabolism.
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Apelin
Apelin and APJ have been identified at high levels in human placenta and, notably, in
cytotrophoblasts, syncytiotrophoblasts and foetal endothelial cells, suggesting that apelin may have a
paracrine action on human chorionic villi [164]. As apelin concentration is twice as high in umbilical
cord blood than in maternal circulation [260] (Figure 14) and a positive correlation between maternal
and foetal plasma apelin was observed in full-term normal pregnancies, a transplacental transfer of
this adipokine with a potential impact on foetal growth has been suggested [259]. Notably, Mayeur et
al. demonstrated that maternal intravenous apelin administration increased transplacental transport
of glucose in a rodent model, either inducing the vasodilatation of placental vessels or, indirectly,
modulating maternal blood pressure [167]. Interestingly, reducing the food intake of rat mothers
significantly decreased their apelin levels, while a higher apelin expression was observed at the
foeto-maternal interface, evoking a possible compensatory response of FGR foetuses to increase their
glucose supply and improve their growth [167]. In light of these data, apelin seems to therefore have a
beneficial role in foetal glucose homeostasis. However, despite such promising results in animals, to
the best of our knowledge, only one study in humans has investigated this adipokine in pregnancies
complicated by FGR and it did not find any difference in maternal apelin levels between FGR and
normal pregnancies [260].
8. Adipokines and Male Reproductive Pathologies
In recent years, interest in the role of novel adipokines in male fertility has steadily grown. Indeed,
a recent meta-analysis suggested that resistin and visfatin affect spermatogenesis [277] and a new study
demonstrated that long treatment of human cultured Sertoli cells with chemerin, visfatin and resistin
at high concentrations, which are often observed in obese men, significantly suppressed FSH receptor
expression and up-regulated that of the cytochrome P450 CYP26A1, inducing a phenotype characteristic
of the pre-pubertal state [278]. Thus, it has been postulated that these adipokines negatively affect
Sertoli cell maturation, possibly contributing to testis dysfunction and fertility perturbations associated
with obesity [278]. However, although the presence of chemerin and visfatin has been detected in the
human testis, data concerning the pathogenic role of novel adipokines in male reproductive disorders
are currently very poor.
With regard to chemerin, Thomas et al. reported that its concentration in seminal fluid was
negatively correlated with spermatic motility and positively correlated with sperm concentration [139],
while Bobjer et al. showed a negative correlation between plasma chemerin and LH, oestradiol
and SHBG levels [279]. Furthermore, they found that, even after adjusting for BMI, serum chemerin
concentration was lower in subfertile men compared to healthy controls, suggesting that, despite its
positive association with BMI, this adipokine is independently linked to reproductive function [279].
Interestingly, vasectomised patients presented lower sperm chemerin levels than healthy men [139],
evoking a local secretion of chemerin in the male genital tract, although chemerin levels in seminal
fluid have repeatedly been found to be significantly lower than in blood plasma [135,139].
In light of the current knowledge, the expression of resistin in the testis has been detected only
in rodents [20]. However, collectively, the studies carried out in men suggest a negative role of this
adipokine in male fertility. Indeed, while some authors found no significant correlation between
plasma resistin levels and sperm parameters [139], our laboratory recently showed that circulating
resistin is negatively correlated with sperm vitality and normomorphic sperm percentage [135]. This
finding agrees with the results obtained by Moretti et al., who highlighted a negative correlation
between resistin levels in seminal fluid and sperm vitality and motility [280]. Very interestingly, they
also demonstrated that seminal resistin was increased in patients presenting a leukocytospermia or a
varicocele, two pathological conditions characterised by a local pro-inflammatory state, and positively
correlated with levels of pro-inflammatory markers such as elastase, TNF-alpha and IL-6 [280]. Resistin
could thus represent a marker of inflammation in the male genital tract and its increased levels in
pathological situations like leukocytospermia might be related to alterations in sperm parameters [20].
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Although visfatin has been demonstrated to be produced by human spermatozoa, notably the
immature ones [137], and its levels are 100 times higher in seminal fluid than in blood plasma [139],
no consistent data are available regarding its role in male reproductive disorders. In a very recent
study carried out in obese and diabetic rats, plasma visfatin was negatively correlated with semen
quality parameters, testosterone and LH levels and degenerative changes in the testis, suggesting that
this adipokine may play a role in the physiopathology of male infertility associated with obesity and
diabetes [281]. It must, however, be kept in mind that several authors failed to find any significant
correlation between seminal and plasma visfatin and sperm parameters in humans [139].
As for visfatin, the literature for apelin is very poor and limited to animal studies. Notably, Sandal
et al. demonstrated that the intracerebroventricular infusion of apelin-13 in male rats significantly
suppressed LH release and decreased the number of Leydig cells, both resulting in a reduction in
plasma testosterone levels [143]. However, at present, this possible role of apelin in the central
regulation of male reproduction has not been confirmed, especially in humans.
9. Conclusions
Adipokines (chemerin, resistin, visfatin and apelin) and their cognate receptors (CMKLR1,
GPR1, CCRL2 for chemerin and APJ for apelin) are expressed in peripheral tissues but also in the
reproductive tract (from hypothalamus-pituitary, gonads) in both males and females of different species,
including humans. Thus, these hormones could contribute to regulate the reproductive functions and
consequently participate to explain some reproductive disorders. However, until now, most of the
data come from in vitro experiments, and in vivo studies are limited. Sometimes, the in vitro data are
contradictory, which can be explained by differences depending on the species but also by the use of
different concentrations of tested adipokines and/or different experimental design. Transgenic mice
where these adipokines or adipokine receptors are specifically deleted in the reproductive cells do
not yet exist. Therefore, it is difficult to discriminate the effects of local adipokines production from
systemic production. Moreover, most of these adipokines exist under various forms (ex-chemerin
and apelin) and until now it has not been possible to detect all of these specific forms. Thus, the
concentration in plasma as well as in the follicular fluid and seminal plasma of these various forms of
adipokines as well as their effect in the reproductive tract remain to be investigated. For chemerin,
some recombinant forms and specific enzyme-linked immunosorbent assays (ELISAs) have been
developed in humans and mice but future studies are needed to further define the potential mechanistic
role of these isoforms in reproduction. Interestingly, plasma and/or tissue expression of chemerin,
resistin, visfatin and apelin might be associated with various female reproductive disorders including
PCOS syndrome, gestational diabetes, preeclampsia, and uterine growth restriction. The involvement
of these adipokines has been less studied in male reproductive pathologies. Finally, all of the data
suggest that additional studies are necessary to better understand the role and molecular mechanism
of adipokines in the control of fertility in order to potentially use them as prognostic markers and/or
therapeutic targets in different reproductive disorders.
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Abbreviations
ACE2 Angiotensin converting enzyme 2
ADSF Adipocyte-specific secretory factor
Akt Retroviral oncogene also named Protein Kinase B
AMPK AMP-activated Protein Kinase
APJ Tissue Inhibitors of MetalloProteinases
APLNR Apelin receptor
BAT Brown Adipose Tissue
BeWo Placental cell line
BMI Body Mass Index
CCRL2 C-C Motif Chemokine Receptor Like 2
ChemR23 Chemerin Receptor 23
CHO cells Chinese hamster ovary cells
CL Corpus Luteum
CMKLR1 Chemokine-Like Receptor 1





ERK1/2 Extracellular signal-Regulated Kinases 1 & 2
EVTs Extravillous trophoblasts
FSH Follicle Stimulating Hormone
Gata4 GATA binding protein 4.
GnRH Gonadotropin-Releasing Hormone
GPCR G protein-coupled receptors
GPR1 G protein-coupled receptor 1
hCG human Chorionic Gonadotropin
HCR C-terminal receptor binding domain
HIV Human Immunodeficiency Virus
HSD3B 3β-Hydroxysteroid dehydrogenase
HUVECs Human umbilical vein endothelial cells
IGF-1 Insulin like Growth Factor 1




KGN Steroidogenic human granulosa-like tumor cell line
LH Luteinizing Hormone
MAPK Mitogen-Activated Protein Kinases
mTOR
mammalian Target Of Rapamycin Complex 1 or
mechanistic target of rapamycin
NAD Nicotinamide Adenine Dinucleotide
NadV Nicotinamide phosphoribosyltransferase NadV
NAMPT Nicotinamide phosphoribosyltransferase
NFkB Transcription factor Nuclear Factor-kappa B
NK cells Natural Killer cells
NMN Nicotinamide MonoNucleotide
ORF Open reading frame
P4 Progesterone
P450 CYP26A1 Cytochrome P450 CYP26A1
PBEF Pre-B-cell colony-enhancing factor
PBMCS Peripheral Blood Mononuclear Cells
PE PreEclempsia
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PGF2alpha Prostaglandin F2alpha
PIGF Placental growth factor
PKA Protein Kinase A
PKC Protein Kinase C
PPAR Peroxisome Proliferator-Activated Receptor
PPAR gamma Peroxisome proliferator-activated receptor gamma
PTEN Phosphatase and TENsin homolog
PTX sensitive Pertussis Toxin sensitive
RARRES2 Retinoic Acid Receptor Responder protein 2
Retn Resistin
RhoA Ras homolog gene family, member A
ROR1 Receptor tyrosine kinase-like orphan receptor 1
SF1 Steroidogenic Factor 1
SHBG Sex Hormone-Binding Globulin
SIRT1 Member of the sirtuin family
SIV Simian Immunodeficiency Virus
StAR Steroid Acute Regulatory protein
STAT3 Signal transducer and activator of transcription 3
T2DM Type 2 Diabetes Mellitus
TLR4 Toll Like Receptor 4
TNF alpha Tumor Necrosis Factor alpha
VEGF Vascular endothelial growth factor
VEGFR2 Vascular endothelial growth factor receptor 2
WAT White Adipose Tissue
WT Wild Type
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Abstract: Chemerin (CHEM) may act as an important link integrating energy homeostasis and
reproductive functions of females, and its actions are mediated by three receptors: chemokine-like
receptor 1 (CMKLR1), G protein-coupled receptor 1 (GPR1), and C-C motif chemokine receptor-like
2 (CCRL2). The aim of the current study was to compare the expression of CHEM and its
receptor (CHEM system) mRNAs (quantitative real-time PCR) and proteins (Western blotting
and fluorescent immunohistochemistry) in the selected areas of the porcine hypothalamus responsible
for gonadotropin-releasing hormone production and secretion: the mediobasal hypothalamus,
preoptic area and stalk median eminence during the oestrous cycle and early pregnancy. Moreover,
plasma CHEM concentrations were determined using ELISA. The expression of CHEM system
has been demonstrated in the porcine hypothalamus throughout the luteal phase and follicular
phase of the oestrous cycle, and during early pregnancy from days 10 to 28. Plasma CHEM levels
and concentrations of transcripts and proteins of CHEM system components in the hypothalamus
fluctuated throughout pregnancy and the oestrous cycle. Our study was the first experiment to
demonstrate the presence of CHEM system mRNAs and proteins in the porcine hypothalamus and
the correlations between the expression levels and physiological hormonal milieu related to the
oestrous cycle and early pregnancy.
Keywords: chemerin; chemerin receptors; hypothalamus; oestrous cycle; early pregnancy; pig
1. Introduction
Chemerin (CHEM), encoded by the gene retinoic acid receptor responder 2 (RARRES2) or
tazarotene-induced gene 2 (TIG2), is a chemotactic factor for immune cells engaged in the processes
of innate and acquired immunity [1]. CHEM is also an adipokine protein produced and secreted by
the adipose tissue, which is considered to be involved in the major metabolic and inflammatory
processes [2,3]. In mammalian cells, CHEM is initially synthesised as a 163 amino acid (aa)
pre-prochemerin. The N-terminal truncation of 20 aa signal peptide results in the release of 143 residue
prochemerin into the blood. Several isoforms of CHEM have been reported that are dependent on the
proteolytic cleavage at its C-terminus by various serine and cysteine proteases. Thus, this process serves
Int. J. Mol. Sci. 2019, 20, 3887; doi:10.3390/ijms20163887 www.mdpi.com/journal/ijms245
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as a key regulatory mechanism to determine the local and systemic concentrations of active CHEM
which exerts local biological actions [4]. In the plasma from healthy humans, inert CHEM precursor
is the dominant isoform. However, the different CHEM isoforms in human blood (CHEM-A155,
-S157 and -K158), cerebrospinal fluid (CHEM-K158), hemofiltrate (CHEM-F154) and synovial fluid
(CHEM-K158) have also been reported, thus indicating that complex prochemerin processing occurs
in vivo [5].
CHEM binds with three G-protein coupled receptors: chemokine-like receptor 1 (CMKLR1),
in humans also termed as chemerin receptor 23 (ChemR23), G protein-coupled receptor 1 (GPR1),
and C-C motif chemokine receptor-like 2 (CCRL2). Of these, CMKLR1 has been the best investigated,
and it uses ERK1/2 and Akt kinases for signal transduction. GPR1 is structurally similar to CMKLR1
but its biological function has not been fully investigated. Nevertheless, GPR1 probably has different
functions from CMKLR1, because of its presence in different tissues. CCRL2 is clearly different from
the two other receptors. It is unable to transduce signals, but binds the N-terminal region of CHEM,
exposing the C-terminal region of the hormone molecule to CMKLR1 receptors on the adjacent cells.
Therefore, its role is limited to presenting the adipokine to the neighbouring cells with CMKLR1
receptors. The various CHEM isoforms are implied to regulate a biochemical cascade by competition
binding to the corresponding receptors. Of these, CHEM-S157 and CHEM-F156 demonstrate the
highest affinity to CMKLR1, while other isoforms such as prochemerin, CHEM-K158, or CHEM-F154
bind to the receptor with lower affinity (for review see [6]).
Of all four components of the CHEM system (the hormone and its three receptors), most studies
have been focused on CHEM alone and CMKLR1. The adipokine mRNA expression was found mainly
in the mouse liver, white adipose tissue and placenta, with lower levels also in the ovaries [2], and in
the human liver and pancreas [7]. The expression of the RARRES2 gene was also found in the ovaries
of women [8] and rodents [2,9], and in the hypothalamus of mice and rats [10,11]. CMKLR1 gene
expression in mice was detected mainly in the white adipose tissue, with lower levels found in the
lungs, heart and placenta [2]. In humans, the highest expression of this receptor was identified in the
lymph nodes and spleen [8]. The expression of CMKLR1 was identified in the ovaries of women [8]
and rats [9], and in the hypothalamus of rats [11,12]. GPR1 is predominantly expressed in the central
nervous system of humans [13] although the expression was also found in the mouse adipose tissue,
human skin [14] and granulosa cells [8]. The third CHEM receptor, CCRL2, was also found in the
hypothalamus of rats [11]. Most of the research focused on the expression of the CHEM system
has been carried out on humans and rodents and data related to farm animals, including pigs, are
still missing.
There is a close relationship between nutritional status and reproductive success in animals.
The metabolic processes and reproductive system functions are controlled by a number of hormones.
It can be assumed that in addition to hormones affecting only the selected metabolic processes or
reproductive organs or structures, there are also other hormones creating a link controlling both the
metabolic status and reproductive system functions. Based on sparse literature data, a hypothesis
can be put forward that CHEM is one such hormone. CHEM is likely to have pleiotropic properties.
It influences, for example, food intake, energy homeostasis, adipose tissue function, obesity-related
parameters (BMI, blood pressure, cholesterol level), and modulates insulin sensitivity [6,15]. Reduced
feed intake, body mass and adiposity, and higher glucose tolerance was found in mice with a
disrupted CMKLR1 gene as compared to the control animals [16]. Moreover, the adipokine is closely
related to the female reproductive process. It was described as an important regulator of ovarian
steroidogenesis and follicular development [8,9,17,18]. High circulating CHEM levels appear to be
associated with pregnancy disorders such as polycystic ovary syndrome (PCOS) [19], pre-eclampsia [20]
and endometriosis [21]. It has been also reported that CHEM production in the uterus is up-regulated
during decidualization, and that CHEM could play a crucial role in vascular remodelling during early
pregnancy of women [22].
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In the existing body of research, there are no studies investigating the expression of the CHEM
system in the hypothalamic structures responsible for the synthesis of gonadotropin-releasing hormone
(GnRH) and the possible impact of hormonal status of the animals connected with the phase of the
oestrous cycle and early pregnancy on CHEM and its receptors expression. For this reason, the aim
of the present study was to investigate the expression of CHEM system genes and proteins in the
specialised hypothalamic structures (mediobasal hypothalamus—MBH, preoptic area—POA, stalk
median eminence—SME) involved in the synthesis and secretion of GnRH (the key hypothalamic
factor controlling the pituitary gland and, indirectly, ovaries), and serum CHEM levels during the
oestrous cycle and early pregnancy, associated with the implantation of embryos.
2. Results
2.1. The Distribution of CHEM, CMKLR1, GPR1 and CCRL2 in the Porcine Hypothalamus
The immunofluorescence staining has shown the presence of CHEM and its 3 receptors—CMKLR1,
GPR1 and CCRL2—in some regions of the pig hypothalamus both during the oestrous cycle (days 10
to 12; Figures 1 and 2) as well as during early gestation (days 15 to 16 of pregnancy; Figures 3 and 4).
CHEM-immunoreactive (CHEM-IR) (Figure 1G,H and Figure 3G,H), GPR1-immunoreactive (GPR1-IR)
(Figure 1C,D and Figure 3C,D) and CCRL2-immunoreactive (CCRL2-IR) (Figure 1E,F and Figure 3E,F)
neurons were the most abundant in the paraventricular nucleus, which is the part of MBH, both during
early gestation and during the oestrous cycle. However, CMKLR1-immunoreactive (CMKLR1-IR) cells
in this brain region displayed slightly weaker immunoreactivity (Figure 1A,B and Figure 3A,B). Other
hypothalamic regions which showed immunoreactivity of CHEM and its receptors were the preoptic
region (Figures 2 and 4) and the anterior hypothalamic area. POA exhibited high immunoreactivity of
CHEM (Figure 2G,H and Figure 4G,H), GPR1 (Figure 2C,D and Figure 4C,D), CCRL2 (Figure 2E,F
and Figure 4E,F) and CMKLR1 (Figure 2A,B and Figure 4A,B). In the anterior hypothalamic area,
only single CHEM-IR and CMKLR1-IR cells were identified. Additionally, in the diagonal band of
Broca, a part of POA, GPR1 showed very high immunoreactivity (Figure 4C), whereas CHEM-IR and
CMKLR1-IR cells were observed sporadically.
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Figure 1. The distribution of the chemerin system in the porcine mediobasal hypothalamus (MBH)
during the oestrous cycle. Immunoreactivity of chemokine-like receptor 1 (CMKLR1; A and B), G
protein-coupled receptor 1 (GPR1; C and D), C-C motif chemokine receptor-like 2 (CCRL2; E and F)
and chemerin (G and H) during the oestrous cycle (days 10 to 12) in the hypothalamus of the pig at the
level of the paraventricular nucleus. Scale bar: 200 μm, applies to A, C, E, G; scale bar: 100 μm, applies
to B, D, F, H.
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Figure 2. The distribution of the chemerin system in the porcine preoptic area (POA) during the
oestrous cycle. Immunoreactivity of chemokine-like receptor 1 (CMKLR1; A and B), G protein-coupled
receptor 1 (GPR1; C and D), C-C motif chemokine receptor-like 2 (CCRL2; E and F) and chemerin
(G and H) during the oestrous cycle (days 10 to 12) in the hypothalamus of the pig at the level of the
preoptic area. Scale bar: 200 μm, applies to A, C, E, G; scale bar: 100 μm, applies to B, D, F, H.
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Figure 3. The distribution of the chemerin system in the porcine mediobasal hypothalamus (MBH)
during early pregnancy. Immunoreactivity of chemokine-like receptor 1 (CMKLR1; A and B), G
protein-coupled receptor 1 (GPR1; C and D), C-C motif chemokine receptor-like 2 (CCRL2; E and F)
and chemerin (G and H) during early pregnancy (days 15 to 16) in the hypothalamus of the pig at the
level of the paraventricular nucleus. Scale bar: 200 μm, applies to A, C, E, G; scale bar: 100 μm, applies
to B, D, F, H.
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Figure 4. The distribution of the chemerin system in the porcine preoptic area (POA) during early
pregnancy. Immunoreactivity of chemokine-like receptor 1 (CMKLR1; A and B), G protein-coupled
receptor 1 (GPR1; C and D), C-C motif chemokine receptor-like 2 (CCRL2; E and F) and chemerin
(G and H) during early pregnancy (days 15 to 16) in the hypothalamus of the pig at the level of the
preoptic area. The white arrow indicates the diagonal band of Broca. Scale bar: 200 μm, applies to A, C,
E, G; scale bar: 100 μm, applies to B, D, F, H.
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2.2. CHEM System Gene and Protein Expression in MBH during the Oestrous Cycle
During the oestrous cycle, the concentrations of CMKLR1 mRNA were significantly higher on
days 17 to 19 when compared to days 2 to 3, whereas protein contents of this receptor were higher
on days 10 to 12 of the cycle than in other studied periods of the cycle (Figure 5A,B; p < 0.05). GPR1
gene expression during the cycle was the highest on days 2 to 3 in relation to days 14 to 16 and 17 to
19. The protein contents of GPR1 were the highest on days 17 to 19 when compared to other studied
periods of the cycle (p < 0.05; Figure 5C,D). Higher CCRL2 mRNA expression was noted on days 2 to 3
and 14 to 16, whereas protein contents of this receptor were greater on days 10 to 12 in comparison to
days 2 to 3 and 14 to 16 (p < 0.05; Figure 5E,F). The highest expression of RARRES2 was observed on
days 2 to 3 and 10 to 12 when compared to days 17 to 19 of the cycle (p < 0.05; Figure 5G).
Figure 5. Cont.
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Figure 5. Chemerin system expression in the porcine mediobasal hypothalamus (MBH) during the
oestrous cycle. Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B),
G protein-coupled receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2;
E and F), as well as chemerin (RARRES2) mRNA content (G) in the porcine MBH on days: 2 to 3,
10 to 12, 14 to 16 and 17 to 19 of the oestrous cycle. Gene expression was determined by qPCR.
Protein expression was determined by Western blotting; upper panels: representative immunoblots;
lower panels: densitometric analysis of CMKLR1/GPR1/CCRL2 proteins relative to actin protein.
Representative actin blots are identical for all chemerin receptors though proteins have been analysed
on different gels. Results are presented as means ± SEM (n = 5). Bars with different superscripts differ
(one-way ANOVA at p < 0.05 followed by Tuckey post-hoc test at p < 0.05).
2.3. CHEM System Gene and Protein Expression in MBH during Pregnancy
During pregnancy, the highest CMKLR gene expression was observed on days 15 to 16, lower
on days 12 to 13, and the lowest on days 10 to 11 and 27 to 28. CMKLR1 protein contents in MBH
were greater on days 27 to 28 when compared to days 10 to 11 and 12 to 13 of gestation (p < 0.05;
Figure 6A,B). The lowest GPR1 gene expression was noted on days 10 to 11 in relation to other studied
stages of pregnancy. Similarly, the lowest protein contents were observed on days 10 to 11, higher on
days 15 to 16, and the highest on days 27 to 28 of pregnancy (p < 0.05; Figure 6C,D). The expression
of CCRL2 gene was higher on days 15 to 16 related to other studied periods of gestation, whereas
protein contents were elevated on days 12 to 13 and 15 to 16 in comparison to days 10 to 11 (p < 0.05;
Figure 6E,F). The highest expression of RARRES2 gene was observed on days 12 to 13, lower on days
10 to 11, and the lowest on days 15 to 16 and 27 to 28 of pregnancy (p < 0.05; Figure 6G).
2.4. CHEM System Gene and Protein Expression in MBH—Pregnancy vs. Oestrous Cycle
Comparing the studied stages of early pregnancy and days 10 to 12 of the oestrous cycle,
significantly higher expression of CMKLR1 gene in MBH was observed on days 15 to 16 and 12 to 13 of
gestation in relation to days 10 to 12 of the oestrous cycle. The protein concentrations of this receptor
were lower on days 12 to 13 of gestation, compared to days 10 to 12 of the cycle (p < 0.05; Figure 7A,B).
The expression of the GPR1 gene was enhanced on days 12 to 13, 15 to 16 and 27 to 28 of pregnancy
when compared to days 10 to 12 of the cycle. Significantly higher GPR1 protein contents were observed
on days 27 to 28 and 15 to 16 of gestation in relation to days 10 to 12 of the oestrous cycle (p < 0.05;
Figure 7C,D). The expression of the CCRL2 gene was elevated on days 15 to 16 of pregnancy compared
to the cycle. The protein contents of this receptor were higher on days 10 to 12 of the cycle compared to
the studied stages of pregnancy (p < 0.05; Figure 7E,F). Higher levels of RARRES2 mRNA contents were
observed on days 10 to 12 of the cycle than during the studied stages of gestation (p < 0.05; Figure 7G).
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Figure 6. Chemerin system expression in the porcine mediobasal hypothalamus (MBH) during
early pregnancy. Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G
protein-coupled receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and
F), as well as chemerin (RARRES2) mRNA content (G) in the porcine MBH on days: 10 to 11, 12 to
13, 15 to 16 and 27 to 28 of pregnancy. Gene expression was determined by qPCR. Protein expression
was determined by Western blotting; upper panels: representative immunoblots; lower panels:
densitometric analysis of CMKLR1/GPR1/CCRL2 proteins relative to actin protein. Representative
actin blots are identical for all chemerin receptors though proteins have been analysed on different gels.
Results are presented as means ± SEM (n = 5). Bars with different superscripts differ (one-way ANOVA
at p < 0.05 followed by Tuckey post-hoc test at p < 0.05).
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Figure 7. Chemerin system expression in the porcine mediobasal hypothalamus (MBH)—pregnancy
vs. oestrous cycle. Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G
protein-coupled receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and
F), as well as chemerin (RARRES2) mRNA content (G) in the porcine MBH on days: 10 to 11, 12 to
13, 15 to 16 and 27 to 28 of pregnancy, and on days 10 to 12 of the oestrous cycle. Gene expression
was determined by qPCR. Protein expression was determined by Western blotting; upper panels:
representative immunoblots; lower panels: densitometric analysis of CMKLR1/GPR1/CCRL2 proteins
relative to actin protein. Representative actin blots are identical for all chemerin receptors though
proteins have been analysed on different gels. Results are presented as means ± SEM (n = 5). Bars with
different superscripts differ (one-way ANOVA at p < 0.05 followed by Tuckey post-hoc test at p < 0.05).
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2.5. CHEM System Gene and Protein Expression in POA during the Oestrous Cycle
In the porcine POA, the highest CMKLR1 gene expression was observed on days 17 to 19 of the
cycle when compared to days 2 to 3 and 10 to 12, whereas the lowest on days 10 to 12 of the cycle in
relation to days 14 to 16 and 17 to 19. The highest protein contents of this receptor were noted on days
10 to 12 compared to other phases of the cycle (p < 0.05; Figure 8A,B). Although the differences in
GPR1 gene expression between the studied phases of the oestrous cycle were negligible, the higher
protein concentrations were observed on days 14 to 16 compared to days 2 to 3 and 17 to 19 of the
cycle (p < 0.05; Figure 8C,D). The expression of the CCRL2 gene was higher on days 17 to 19 than
on days 14 to 16 of the oestrous cycle. The protein concentrations of CCRL2 were higher on days 10
to 12 compared to other phases of the cycle (p < 0.05; Figure 8E,F). In POA, higher RARRES2 gene
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Figure 8. Chemerin system expression in the porcine preoptic area (POA) during the oestrous cycle.
Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G protein-coupled
receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and F), as well as
chemerin (RARRES2) mRNA content (G) in the porcine POA on days: 2 to 3, 10 to 12, 14 to 16 and 17 to
19 of the oestrous cycle. Gene expression was determined by qPCR. Protein expression was determined
by Western blotting; upper panels: representative immunoblots; lower panels: densitometric analysis
of CMKLR1/GPR1/CCRL2 proteins relative to actin protein. Representative actin blots are identical for
all chemerin receptors though proteins have been analysed on different gels. Results are presented as
means ± SEM (n = 5). Bars with different superscripts differ (one-way ANOVA at p < 0.05 followed by
Tuckey post-hoc test at p < 0.05).
2.6. CHEM System Gene and Protein Expression in POA during Pregnancy
During early pregnancy in POA, the highest CMKLR1 gene expression was observed on days 10
to 11, lower on days 27 to 28, and the lowest on days 15 to 16 when compared to days 10 to 11 and 27
to 28 of gestation. Protein contents of this receptor were higher on days 27 to 28 related to days 10 to 11
of pregnancy (p < 0.05; Figure 9A,B). The contents of the GPR1 mRNA were the highest on days 27
to 28 compared to other stages of pregnancy, whereas the lowest on days 15 to 16 in relation to days
10 to 11 and 27 to 28 of gestation. Similarly, the highest protein concentrations of GPR1 were noted
on days 27 to 28, lower on days 12 to 13 and the lowest on days 10 to 11 and 15 to 16 of pregnancy
(p < 0.05; Figure 9C,D). The expression of the CCRL2 gene in this tissue was the highest on days 27 to
28, lower on days 10 to 11, whereas the lowest on days 12 to 13 and 15 to 16 of gestation. The protein
concentrations of this receptor were higher on days 27 to 28 than on days 10 to 11 of pregnancy (p < 0.05;
Figure 9E,F). The expression of the RARRES2 gene was much more pronounced on days 27 to 28 than
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Figure 9. Chemerin system expression in the porcine preoptic area (POA) during early pregnancy.
Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G protein-coupled
receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and F), as well as
chemerin (RARRES2) mRNA content (G) in the porcine POA on days: 10 to 11, 12 to 13, 15 to 16 and 27
to 28 of pregnancy. Gene expression was determined by qPCR. Protein expression was determined by
Western blotting; upper panels: representative immunoblots; lower panels: densitometric analysis of
CMKLR1/GPR1/CCRL2 proteins relative to actin protein. Representative actin blots are identical for all
chemerin receptors though proteins have been analysed on different gels. Results are presented as
means ± SEM (n = 5). Bars with different superscripts differ (one-way ANOVA at p < 0.05 followed by
Tuckey post-hoc test at p < 0.05).
2.7. CHEM System Gene and Protein Expression in POA—Pregnancy vs. Oestrous Cycle
Comparing the studied stages of pregnancy and days 10 to 12 of the oestrous cycle, higher
CMKLR1 gene expression was noted on days 10 to 11 of pregnancy, whereas lower on days 15 to 16 in
relation to days 10 to 12 of the cycle. Protein concentrations of this receptor were higher on days 27 to
28 of pregnancy compared to days 10 to 12 of the cycle (p < 0.05; Figure 10A,B). The expression of GPR1
gene during the mid-luteal phase was lower than on days 27 to 28 and 10 to 11 of pregnancy. Protein
contents of this receptor on days 10 to 12 of the cycle were lower than on days 27 to 28 of pregnancy and
days 12 to 13 of pregnancy (p < 0.05; Figure 10C,D). Higher contents of CCRL2 mRNA were observed
on days 27 to 28 of and 10 to 11 of gestation in relation to days 10 to 12 of the cycle. The highest protein
concentrations of this receptor were noted on days 10 to 12 of the cycle in comparison to the studied
stages of gestation (p < 0.05; Figure 10E,F). An elevated expression of the RARRES2 gene was observed
on days 10 to 12 of the cycle in relation to days 10 to 11, 12 to 13 and 15 to 16 of gestation (p < 0.05;
Figure 10G).
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Figure 10. Chemerin system expression in the porcine preoptic area (POA)—pregnancy vs. oestrous
cycle. Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G protein-coupled
receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and F), as well as
chemerin (RARRES2) mRNA content (G) in the porcine POA on days: 10 to 11, 12 to 13, 15 to 16 and 27
to 28 of pregnancy, and on days 10 to 12 of the oestrous cycle. Gene expression was determined by qPCR.
Protein expression was determined by Western blotting; upper panels: representative immunoblots;
lower panels: densitometric analysis of CMKLR1/GPR1/CCRL2 proteins relative to actin protein.
Representative actin blots are identical for all chemerin receptors though proteins have been analysed
on different gels. Results are presented as means ± SEM (n = 5). Bars with different superscripts differ
(one-way ANOVA at p < 0.05 followed by Tuckey post-hoc test at p < 0.05).
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2.8. CHEM System Gene and Protein Expression in SME during the Oestrous Cycle
During the oestrous cycle, the expression of the CMKLR1 gene in SME was significantly decreased
on days 2 to 3 in relation to other phases of the cycle. However, the protein concentrations of this
receptor were increased only on days 10 to 12 compared to other phases of the cycle (p < 0.05;
Figure 11A,B). The highest GPR1 mRNA contents were noted on days 17 to 19 compared to days 2
to 3 and 14 to 16, whereas the lowest on days 2 to 3 in relation to days 10 to 12 and 17 to 19 of the
cycle. The differences in this receptor protein concentrations during the oestrous cycle were negligible
(p < 0.05; Figure 11C,D). The expression of the CCRL2 gene was the highest on days 10 to 12, lower on
days 17 to 19, whereas the lowest on days 2 to 3 and 14 to 16 of the cycle. An elevated contents of
CCRL2 protein were observed on days 14 to 16 and 17 to 19 in relation to days 2 to 3 and 10 to 12 of the
cycle (p < 0.05; Figure 11E,F). The expression of RARRES2 gene was enhanced on days 17 to 19 when
compared to other studied stages of the cycle (p < 0.05; Figure 11G).
Figure 11. Cont.
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Figure 11. Chemerin system expression in the porcine stalk median eminence (SME) during the oestrous
cycle. Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G protein-coupled
receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and F), as well as
chemerin (RARRES2) mRNA content (G) in the porcine SME on days: 2 to 3, 10 to 12, 14 to 16 and 17 to
19 of the oestrous cycle. Gene expression was determined by qPCR. Protein expression was determined
by Western blotting; upper panels: representative immunoblots; lower panels: densitometric analysis
of CMKLR1/GPR1/CCRL2 proteins relative to actin protein. Representative actin blots are identical for
all chemerin receptors though proteins have been analysed on different gels. Results are presented as
means ± SEM (n = 5). Bars with different superscripts differ (one-way ANOVA at p < 0.05 followed by
Tuckey post-hoc test at p < 0.05).
2.9. CHEM System Gene and Protein Expression in SME during Pregnancy
During pregnancy, an elevated levels of CMKLR1 mRNA were observed on days 27 to 28 comparing
to other stages of early pregnancy. Protein concentrations of this receptor were the highest on days 12
to 13 in relation to days 10 to 11 and 27 to 28, and the lowest on days 10 to 11 compared to days 12 to
13 and 15 to 16 of pregnancy (p < 0.05; Figure 12A,B). The expression of the GPR1 gene was the highest
on days 27 to 28 of pregnancy, lower on days 15 to 16, whereas the lowest on days 10 to 11 and 12 to
13 of gestation. The concentrations of GPR1 protein were elevated on days 12 to 13 and 27 to 28 of
pregnancy in relation to the remaining stages of pregnancy (p < 0.05; Figure 12C,D). The highest CCRL2
gene expression was noted on days 27 to 28, whereas the lowest on days 10 to 11 when compared to
days 15 to 16 and 27 to 28 of pregnancy. The protein contents of this receptor were the highest on days
27 to 28 in relation to days 10 to 11 and 15 to 16, whereas the lowest on days 10 to 11 compared to days
12 to 13 and 27 to 28 of pregnancy (p < 0.05; Figure 12E,F). The highest expression of the RARRES2
gene was observed on days 27 to 28 of gestation, whereas the lowest on days 12 to 13 in relation to
days 15 to 16 and 27 to 28 of pregnancy (p < 0.05; Figure 12G).
Figure 12. Cont.
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Figure 12. Chemerin system expression in the porcine stalk median eminence (SME) during early
pregnancy. Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G
protein-coupled receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and
F), as well as chemerin (RARRES2) mRNA content (G) in the porcine SME on days: 10 to 11, 12 to 13,
15 to 16 and 27 to 28 of pregnancy. Gene expression was determined by qPCR. Protein expression
was determined by Western blotting; upper panels: representative immunoblots; lower panels:
densitometric analysis of CMKLR1/GPR1/CCRL2 proteins relative to actin protein. Representative
actin blots are identical for all chemerin receptors though proteins have been analysed on different gels.
Results are presented as means ± SEM (n = 5). Bars with different superscripts differ (one-way ANOVA
at p < 0.05 followed by Tuckey post-hoc test at p < 0.05).
2.10. CHEM System Gene and Protein Expression in SME—Pregnancy vs. Oestrous Cycle
Comparing the studied stages of pregnancy and days 10 to 12 of the oestrous cycle, significantly
lower CMKLR1 gene expression was noted on days 10 to 12 of the oestrous cycle in relation to days 12
to 13, 15 to 16 and 27 to 28 of gestation. Protein concentrations of this receptor were significantly higher
on days 10 to 12 of the cycle compared to the studied stages of pregnancy (p < 0.05; Figure 13A,B).
The expression of the GPR1 gene during the mid-luteal phase of the cycle was lower than on days 15 to
16 and 27 to 28 of gestation. Protein contents of this receptor on days 10 to 12 of the oestrous cycle did
not differ from the studied stages of gestation (p < 0.05; Figure 13C,D). The gene expression of CCRL2
was lower on days 10 to 12 of the cycle compared to days 15 to 16 and 27 to 28 of pregnancy. Protein
contents of this receptor on days 10 to 12 of the oestrous cycle did not differ from the studied stages of
gestation (p < 0.05; Figure 13E,F). The gene expression of RARRES2 on days 10 to 12 of the cycle was
higher than on days 12 to 13 of pregnancy, whereas lower than on days 27 to 28 of gestation (p < 0.05;
Figure 13G).
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Figure 13. Chemerin system expression in the porcine stalk median eminence (SME)—pregnancy vs.
oestrous cycle. Gene and protein expression of chemokine-like receptor 1 (CMKLR1; A and B), G
protein-coupled receptor 1 (GPR1; C and D) and C-C motif chemokine receptor-like 2 (CCRL2; E and
F), as well as chemerin (RARRES2) mRNA content (G) in the porcine SME on days: 10 to 11, 12 to
13, 15 to 16 and 27 to 28 of pregnancy, and on days 10 to 12 of the oestrous cycle. Gene expression
was determined by qPCR. Protein expression was determined by Western blotting; upper panels:
representative immunoblots; lower panels: densitometric analysis of CMKLR1/GPR1/CCRL2 proteins
relative to actin protein. Representative actin blots are identical for all chemerin receptors though
proteins have been analysed on different gels. Results are presented as means ± SEM (n = 5). Bars with
different superscripts differ (one-way ANOVA at p < 0.05 followed by Tuckey post-hoc test at p < 0.05).
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2.11. CHEM Concentrations in the Blood Plasma
During the oestrous cycle, the highest concentrations of CHEM in the blood plasma were observed
on days 2 to 3 (p < 0.05; Figure 14A). During early pregnancy, significantly higher CHEM contents in
the plasma were noted on days 15 to 16 comparing to days 10 to 11 and 27 to 28 (p < 0.05; Figure 14B).
Comparing the studied stages of early pregnancy and days 10 to 12 of the cycle, significantly higher
concentrations of CHEM in the blood plasma were observed on days 15 to 16 of gestation in relation to
the cycle (p < 0.05; Figure 14C).
 
Figure 14. Chemerin concentrations in the porcine blood plasma. Concentrations of chemerin in the
porcine blood plasma was determined during the oestrous cycle on days: 2 to 3, 10 to 12, 14 to 16 and
17 to 19 (A), during early pregnancy on days: 10 to 11, 12 to 13, 15 to 16 and 27 to 28 (B) and compared
between early pregnancy and days 10 to 12 of the oestrous cycle (C). The hormone content in blood
plasma was evaluated using ELISA. Results are presented as means ± SEM (n = 5). Bars with different
superscripts differ (one-way ANOVA at p < 0.05 followed by Tuckey post-hoc test at p < 0.05).
3. Discussion
The present study was the first experiment to report the expression of CHEM and its receptors
genes and proteins in the porcine hypothalamic structures, MBH, POA and SME, responsible for GnRH
production and secretion, during the oestrous cycle and early pregnancy. In our immunohistochemical
analyses, CHEM and its receptors were localised in the porcine paraventricular nucleus, which is
the part of mediobasal hypothalamus and in the preoptic region during the oestrous cycle and early
pregnancy. In the diagonal band of Broca, a part of preoptic region, very high immunoreactivity of
GPR1 was observed. To date, the RARRES2 gene was expressed in the hypothalamus of mice and
rats [10,11]. In the brain of mice, RARRES2 mRNA expression was restricted to the dorsal ventricular
wall of the anterior, medial and posterior hypothalamus [10]. In turn, in the brain of rats, RARRES2
mRNA was present in the tanycytes and ependymal cells layer lining the ventral third ventricle and
SME of the hypothalamus, and CMKLR1 transcript was found in the prefrontal cortex, hippocampus,
cerebellum, ependymal cell layer and SME [11,12]. The transcripts of RARRES2 were also present in the
hypothalamus of baboons and chimpanzees [23]. GPR1 is expressed abundantly in the human brain,
such as hippocampus, glioblastoma cells, brain-derived fibroblast-like cells lines and microglia [13].
In the ependymal cell layer and SME of rats, the gene expression of third CHEM receptor, CCRL2 is
also localised [11]. After CHEM injection, the expression of the cytoskeletal protein vimentin, a marker
for estimating hypothalamic plasticity, was increased in the ependymal cell region of rats. It has been
suggested that CHEM plays an important role in the structural remodelling of the hypothalamus [11].
The above and our studies indicate that the hypothalamus is capable of synthesising the discussed
adipokine. The local production of CHEM and the presence of specific receptors suggest that the
hormone exerts a direct effect on the hypothalamus with possible autocrine and/or paracrine action of
CHEM in the brain.
CHEM is also delivered to the central nervous system (CNS) with the blood. It was found
in the cerebrospinal fluid (CSF) of humans and the CHEM-158K protein is the dominant CHEM
isoform. The total levels of cleaved and noncleaved CHEM were significantly lower in the CSF
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samples from patients with a variety of CNS diseases than in the plasma. In turn, in normal human
plasma, the prochemerin form (CHEM-163S) dominated, whereas CHEM-158K represented only a
small percentage of the total CHEM, and CHEM-157S was barely detectable. Thus, under normal
conditions, the majority of circulating CHEM exists in the relatively inactive prochemerin form and
requires proteolytic processing to bioactive CHEM isoforms. Only about 18% of CHEM is cleaved
in normal plasma, whereas in CSF samples the fraction ranges about 50%. It has been implied that
considerable proteolysis of CHEM is taking place in this extravascular compartment. Moreover, the
differences between the total amount of CHEM as well as the extent of its cleavage that was found in
the CSF supported the hypothesis of local CHEM synthesis and processing [24].
In the human blood, relatively high levels of CHEM (100–200 ng/mL) have been detected [25].
Plasma CHEM levels are correlated with BMI, body mass and adipose tissue mass. A statistically
significant correlation has also been found between the adipokine level, and age and sex. Higher CHEM
levels were found in women and older subjects than in men and younger subjects [3]. Our present
studies indicate the higher levels of porcine plasma CHEM during the early-luteal phase (oestradiol
(E2) and progesterone (P4) plasma concentrations are at moderate levels) than during the mid- and
late-luteal phases (P4 levels are high in the porcine blood) and follicular phase (E2 levels are high in the
porcine blood) of the oestrous cycle. The above results suggest that sex hormones, particularly gonadal
steroids, may affect the synthesis of CHEM. Such a correlation has been documented for androgens
increasing the levels of CHEM in women [19,26] and female rats [17]. A stimulatory effect of insulin on
the synthesis of CHEM and its plasma levels was also demonstrated [19]. The levels of CHEM also
change throughout pregnancy and between pregnancy and the oestrous cycle. In the present study,
during the beginning of implantation, porcine plasma CHEM contents were enhanced compared to
the period of embryos migration within the uterus, end of implantation and mid-luteal phase of the
oestrous cycle. In the blood of pregnant women, CHEM levels were significantly higher than in the
non-pregnant ones [27]. Moreover, plasma levels of CHEM were significantly elevated during late
gestation when compared to the early gestation of humans [27], but the reverse correlation was found
in rats [28]. This may indicate species–specific differences in the activity of CHEM.
To our knowledge, this is the first study that compares CHEM system genes expression and
proteins concentrations in the hypothalamus within the oestrous cycle and early pregnancy and
between these physiological periods. Our obtained results indicate that CHEM expression levels were
determined by the stage of the oestrous cycle and early pregnancy and these results confirmed the
hypothesis that steroid hormones may regulate the synthesis of CHEM. The expression of CMKLR1
and CCLR2 proteins in most hypothalamic structures increased during the mid-luteal phase of the
oestrous cycle, which seems to suggest the up-regulating effect of P4. In POA, the expression of GPR1
protein was also stimulated during the luteal phase of the cycle. However, GPR1 protein contents
in MBH were enhanced during the follicular phase, when plasma levels of oestrogens are very high.
In addition, the concentrations of CHEM receptors proteins in the porcine hypothalamic structures
generally increase with the advancement of pregnancy from days 10 to days 28. In our previous
study, in the porcine peripheral blood plasma from days 10 to days 28 of pregnancy, a statistically
significant decrease in the mean of P4 levels was observed [29]. These results may suggest an inverse
pattern between the expression of CHEM receptors and the levels of P4 during pregnancy. The role
of steroids in the regulation of CHEM system was also investigated in humans and the results are
also unclear. The findings of an inverse association of E2 and CHEM levels have been observed in a
clinical study comprising both lean and overweight men and women [30], but no significant effects of
steroids on CHEM protein production in the control human subcutaneous adipose tissue explants were
reported [19]. It cannot be ruled out that other hormones regulating the oestrous cycle, such as the
pituitary luteinizing hormone (LH), may be involved in the regulation of CHEM expression. Men with
elevated LH levels had lower CHEM contents in relation to those with the normal range of LH [31].
Further studies would be recommended to identify the exact mechanisms of the relationship between
the contents of CHEM and steroid/other hormones. Moreover, in our study, we have also observed the
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higher GPR1 and lower CCRL2 protein concentrations in the porcine MBH and POA during the early
pregnancy versus the oestrous cycle. These findings supported the idea that CHEM/GPR1/CCRL2
could be the one of the regulators of pregnancy at the hypothalamic level. However, the possible roles
of CHEM in the maintenance of pregnancy should be investigated in further studies.
Some lines of evidence suggest that CHEM regulates hypothalamic hormones secretion connected
with feeding behaviour. A direct stimulating effect of CHEM on hypothalamic agouti-related peptide
and pro-opiomelanocortin gene expression was observed in rats after injecting a single dose of CHEM
(8 μg/kg) in the arcuate nucleus [32]. These results are in good agreement with reports indicating that
the administration of the major dosage of CHEM (16 g/kg) increased mRNA contents of both cocaine
and amphetamine-regulated transcript (CART) and neuropeptide Y [15]. The above results confirmed
the role of CHEM in the regulation of hypothalamic modulators. However, there is a lack of data on
the role of CHEM on the reproductive functions at the brain level, in the hypothalamus and pituitary
through the regulation of GnRH, LH and follicle-stimulating hormone production. Several studies
have reported the direct role of CHEM on the gonads. The expression of the RARRES2 gene was found
in the ovaries of women [8], rodents [2,9] and cows [33]. Mammalian ovaries are also sensitive to
CHEM: CMKLR1 expression was identified in the ovaries of women [8] and rats [9], while CMKLR1,
GPR1 and CCLR2 expression was noticed in the ovaries of cows [33]. A clear effect of CHEM on
ovarian steroidogenesis was demonstrated and reflected by the inhibition of FSH-induced secretion
of P4 and E2 by granulosa cells in rats [9,18], cows [33] and the insulin-like growth factor 1-induced
secretion of both steroids in granulosa cells in women [8]. The presence of the CHEM system in
hypothalamic structures responsible for GnRH synthesis and secretion observed in our study implies
that the discussed hormone regulates GnRH generation. Therefore, it cannot be excluded that the
adipokine can affect the gonads indirectly via effects on the central hypothalamic–pituitary–gonadal
axis, i.e., by affecting the GnRH hypothalamic neurons and/or the gonadotrophs of the pituitary;
however, this hypothesis needs to be verified.
4. Materials and Methods
4.1. Experimental Animals and Tissue Collection
Experimental animals were mature gilts (Large White × Polish Landrace), about 7–8 months old,
weighing 120–130 kg, descended from private breeding. All individuals were given access to water
and forage ad libitum. Forty animals were assigned to one of eight experimental groups (n = 5 in
each group) as follows: days 2 to 3 (early luteal phase, the presence of corpora hemorrhagica), 10 to
12 (mid-luteal phase, the phase when the corpus luteum activity is high and similar to that noted
during pregnancy), 14 to 16 (late luteal phase, the period of luteolysis) and 17 to 19 (follicular phase)
of the oestrous cycle, and 10 to 11 (migration of the embryos within the uterus), 12 to 13 (maternal
recognition of pregnancy), 15 to 16 (beginning of implantation) and 27 to 28 (end of implantation)
of pregnancy. Cyclic gilts were monitored daily for an oestrous behaviour in the presence of a boar.
The day of the onset of the second oestrous was designated as day 0 of the oestrous cycle. The phase of
the oestrous cycle was also confirmed based on ovaries morphology [34]. In the case of pregnant pigs,
the insemination was performed on days 1 to 2 of the oestrous cycle. Pregnancy was confirmed by the
presence and morphology of conceptuses. On days 10 to 11 and 12 to 13 of pregnancy, conceptuses
were obtained by the flushing of uterine horns with 20 mL of sterile phosphate-buffered saline (PBS),
whereas on days 15 to 16 and 27 to 28 of pregnancy, by dissection from the endometrium. Within a few
minutes after slaughter, blood samples were collected and the hypothalamus was dissected. Blood
samples were placed into heparinised tubes, centrifuged (2500× g, 15 min, 4 ◦C) and the obtained
plasma was stored at −80 ◦C. Each hypothalamic block was divided into: MBH, POA and SME as
described by Sesti and Britt [35]. The mediobasal hypothalamus was defined as a block of tissue bound
rostrally by the optic chiasma, caudally by mammillary body, laterally by the hypothalamic sulci and
dorsally by a cut 5 mm deep. POA was limited rostrally approximately 5 mm anterior to the optic
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chiasma and caudally by the rostral border of MBH. The stalk median eminence was easily detached
from the MBH and was cut away at its junction with the pituitary gland. Preoptic areas and MBH
from days 15 to 16 of pregnancy and 10 to 12 of the cycle were divided in two parts, from which one
half intended for immunofluorescent staining was placed in 4% buffered paraformaldehyde (pH = 7.4,
4 ◦C), whereas other halves, along with all the rest of the POAs, MBHs and SMEs were frozen in liquid
nitrogen and stored at −80 ◦C until RNA and protein isolation.
Tissue samples were taken from animals intended for commercial slaughter and meat processing.
All studies were conducted in accordance with ethical standards of the Animal Ethics Committee at
the University of Warmia and Mazury in Olsztyn. The animals used in the study were reared and
transported under conditions specified in the “Act on the protection of animals used for scientific or
educational purposes” (Poland, 2015).
4.2. Fluorescent Immunohistochemistry of the Porcine Hypothalamus
The tissue blocks were fixed by immersion for 24 h in 4% buffered paraformaldehyde (pH = 7.4;
4 ◦C). Following fixation, the brains were washed in 0.1 M PBS and then cryoprotected for 3–5 days in
graded solutions (19% and 30%) of sucrose (Sigma Aldrich, St. Louis, MO, USA) at 4 ◦C until they
sank. The tissue blocks comprised of the hypothalamus and adjoining structures were frozen and
cut into 18 μm thick cryostat coronal sections and stored at −80 ◦C. Frozen sections were processed
for double-labelling immunofluorescence by means of primary antisera raised in different species.
The sections were air-dried for 30 min, washed 3 times in cold PBS and incubated for 1 h with
blocking buffer (0.1 M PBS, 10% normal donkey serum, 0.01% bovine serum albumin, 1% Tween,
0.05% thimerosal, 0.01% NaN3). Then sections were incubated overnight at room temperature with a
solution of rabbit polyclonal antibodies against CMKLR1 (0.5 μg/uL, ab230442, Abcam, Cambridge,
UK), or GPR1 (1.25 μg/uL, ab188977, Abcam, Cambridge, UK), or CCRL2 (0.67 μg/uL, ab85224, Abcam,
Cambridge, UK), or CHEM (0.5 μg/uL, ab203040, Abcam, Cambridge, UK). In order to show the
binding sites of the antisera with antigens, the sections were incubated with the Alexa Fluor 555
donkey anti-rabbit antibodies (0.5 μg/uL, A-31572, Molecular Probes, Eugene, OR, USA). After staining,
scraps were washed in PBS and mounted with carbonate-buffered glycerol (pH 8.6) and cover slipped.
All steps of the staining procedures were conducted in humid chambers at room temperature. Standard
controls, i.e., the omission and replacement of primary antisera by non-immune sera were applied to test
antibody and method specificity. The lack of any immunoreactions indicated specificity. The sections
were analysed with an Olympus BX51 microscope equipped with a CC-12 digital camera (Soft Imaging
System GMBH, Münster, Germany). Images were acquired with Cell-F software (Olympus GmbH,
Hamburg, Germany).
4.3. Quantitative Real-Time PCR
Total RNA from MBH, POA and SME samples was isolated using the peqGold TriFast isolation
system (Peqlabs, Erlangen, Germany). RNA quantity and quality were determined spectrometrically
(Infinite M200 Pro, Tecan, Männedorf, Switzerland). First strand cDNA was synthesised using the
Omniscript RT Kit (Qiagen, Hilden, Germany) in a total volume of 20 μL with 1 μg of RNA, 0.5 μg
oligo(dT)15 (Roche, Basel, Switzerland) at 37 ◦C for 1 h and was terminated by the incubation at
93 ◦C for 5 min. Specific primer pairs used to amplify parts of RARRES2, CMKLR1, GPR1, CCRL2,
ubiquitin C (UBC) and 18S ribosomal RNA (18sRNA) genes are detailed in Table 1. Specific primers
for RARRES2, CMKLR1, GPR1 and CCRL2 were designed with the Primer Express 3.0 software (Life
Technologies, Camarillo, CA, USA) and their specificities were confirmed by comparison of their
sequences with the sequences of corresponding genes deposited in a GenBank database. Due to the
calculation of the statistical significance of the match, the Basic Local Alignment Search Tool (BLAST)
was used. Quantitative real-time PCR (qPCR) analysis was carried out using PCR System 7300 (Applied
Biosystems Inc., Foster, CA, USA), as described previously by Smolinska et. al. [36]. Briefly, the qPCR
reaction included 10 ng of cDNA, the appropriate forward and reverse primers at the concentrations
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detailed in Table 1, 12.5 μL Power SYBR Green PCR Master Mix (Applied Biosystems Inc., Foster,
CA, USA), and RNase-free water in a final volume of 25 μL. The constitutively expressed genes, UBC
and 18sRNA, were used as an internal control to verify the qPCR. To ensure that UBC and 18sRNA
were suitable reference genes for this study, we revealed that their expression was stable between the
tested tissues and during the oestrous cycle and early pregnancy. Real-time conditions were as follows:
Initial denaturation and enzyme activation at 95 ◦C for 10 min, followed by 40 cycles of denaturation
at 95 ◦C for 15 s, annealing at 60 ◦C for 1 min and elongation at 70 ◦C for 1 min. Negative controls
were performed by substitution of cDNA with water. All samples were in duplicate. The specificity of
amplification was tested at the end of the qPCR by melting curve analysis. Levels of gene expression
were calculated using the ΔΔCt method and normalised using the geometrical means of reference
gene expression levels: UBC and 18sRNA. The Ct values for all non-template controls were under the
detection threshold.
Table 1. Characteristics of primers used in the study.

































RARRES2: chemerin; CCRL2: C-C motif chemokine receptor like 2; CMLKR1: chemokine-like receptor 1; GPR1:
G protein-coupled receptor 1; UBC: Ubiquitin C; 18sRNA: 18S ribosomal RNA; F: forward; R: reverse.
4.4. Western Blotting
Tissue preparation and lysis, as well as Western blotting analysis was performed essentially
as described by Smolinska et al. [39] with a few modifications. Briefly, equal amounts of porcine
MBH, POA and SME protein lysates (30 μg of total proteins) were resolved by SDS-PAGE (12.5%
gel) for separating CMKLR1, GPR1, CCRL2 and actin, and then transferred to PVDF membranes
and blocked for 1 h at room temperature in Tris-buffered saline Tween-20 (TBST) containing 5%
skimmed milk powder. After blocking, PVDF membranes were incubated overnight with rabbit
polyclonal CMKLR1 (1 μg/uL, ab230442, Abcam, Cambridge, UK), CCRL2 (3.33 μg/uL, ab85224,
Abcam, Cambridge, UK), actin (6.58 μg/uL, A2066, Sigma-Aldrich, St. Louis, MO, USA) antibodies
or mouse polyclonal GPR1 (2.0 μg/uL, ab169331, Abcam, UK) in TBST. Actin immunoblots were
used as an internal control for equal loading and to quantify porcine CMKLR1, GPR1 and CCRL2
proteins. In order to examine immunoreactive bands, PVDF membranes were incubated with goat
anti-rabbit antibodies for CMKLR1, CCRL2 and actin (0.25 μg/uL, sc-2054, Santa Cruz, Santa Cruz,
CA, USA) or goat anti-mouse antibodies for GPR1 (0.5 μg/uL, 115-035-003, Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA) conjugated with horse radish peroxidase (HRP) diluted in
TBST containing 5% skimmed milk. PVDF membranes were incubated with Immobilon Western
Chemiluminescent HRP Substrate (Merck Millipore, Burlington, MA, USA) and visualised using G:
Box EF Gel Documentation System (Syngene, Cambridge, UK) with GeneSnap software. The same
protocol was performed in relation to the adipose tissue used as the positive controls. The quality of
the experiment was confirmed using reference protein, actin, the expression of which did not vary
across the oestrous cycle and pregnancy or between the studied tissues. The results of Western blotting
analyses were quantified by densitometric scanning of immunoblots with Image StudioTM Lite version
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5.2 software (LI-COR, Lincoln, NE, USA). Data were expressed as the ratio of CHEM receptors proteins
relative to actin proteins in arbitrary optical density units.
4.5. Enzyme-Linked Immune-Sorbent Assay (ELISA) of CHEM
The concentrations of CHEM protein in plasma were determined using a commercial ELISA kit
(FineTest, Wuhan Fine Biotech Co., Ltd., Wuhan, China) according to the manufacturer’s protocol.
The range of standard curve was 0.156–10 ng/mL. The sensitivity of the assay was defined as the
least protein concentration that could be differentiated from zero samples, which was <0.1 ng/mL.
According to the manufacturer, no significant cross-reactivity or interference between CHEM and
homologous proteins assayed has been observed. Species cross-reactivity has not been specifically
determined. Absorbance values were measured at 450 nm using an Infinite M200 Pro reader with
Tecan i-control software (Tecan, Männedorf, Switzerland). The data were linearised by plotting the log
of CHEM concentrations versus the log of the optical density and the best fit line was determined by
regression analysis. Intra-assay coefficient of variation of the ELISA assay for CHEM was 3.89%.
4.6. Statistical Analysis
Data are presented as means ± S.E.M. from five different observations. Differences between
groups were analysed by one-way ANOVA followed by Tukey’s honest significant difference post-hoc
test. Statistical analyses were performed using Statistica Software (StatSoft Inc., Tulsa, OH, USA).
Values for p < 0.05 were considered statistically significant.
5. Conclusions
The presented data indicated, for the first time, the presence of CHEM and its receptors in the
hypothalamic structures responsible for GnRH production and secretion, which suggest that the
adipokine exerts autocrine/paracrine effects on GnRH synthesis and/or secretion. Moreover, the
observed changes in CHEM system expression levels may be dependent on the influence of ovarian
steroids and other hormones controlling reproductive processes. Our present findings expand our
knowledge of the potential role of CHEM as a key neuromodulator of reproductive functions.
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Abstract: Adipokines are a potential link between reproduction and energy metabolism and could
partly explain some infertilities related to some pathophysiology, such as polycystic ovary syndrome
(PCOS). However, adipokines were predominantly assessed in blood samples, while very little
is known concerning their variations in follicular fluid (FF) and ovarian granulosa cells (GCs) of
PCOS women. Thus, the objectives of our study were to investigate adiponectin, chemerin, resistin,
visfatin, omentin, and apelin ovarian expression in PCOS women in comparison with controls
and women with only a polycystic ovary morphology. In total, 78 women undergoing an in vitro
fertilization procedure were divided into three groups: 23 PCOS women, 28 women presenting
only ≥12 follicles per ovary (ECHO group), and 27 control women. Each group almost equally
included normal weight and obese women. Follicular fluid (FF) concentration and granulosa cells
(GCs) mRNA expression of adipokines and their receptors were assessed by ELISA and RT-qPCR,
respectively. Omentin levels in FF and GC were higher in PCOS than in ECHO and control women,
while apelin expression was increased in both PCOS and ECHO groups. FF chemerin concentration
was predominant in normal-weight PCOS women compared to BMI (Body Mass Index)-matched
ECHO and control women, while GC mRNA levels were higher in the obese PCOS group than in
the ECHO one. Compared to PCOS, ECHO women had increased FF adiponectin concentrations
and lower plasma AMH levels. The FF concentration of all adipokines was higher in obese subjects
except for adiponectin, predominant in normal-weight women. In conclusion, women with PCOS
expressed higher GC chemerin and omentin, whereas the ECHO group presented higher levels of FF
adiponectin and apelin and lower plasma AMH and LH concentrations. Chemerin, omentin, and
apelin expression was differently regulated in women with PCOS, suggesting their possible role in
follicular growth arrest and ovulatory dysfunction characterizing PCOS pathogenesis.
Keywords: adipokines; PCOS; polycystic ovary morphology; follicular fluid; human granulosa cells
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1. Introduction
Polycystic ovary syndrome (PCOS) is a very common endocrinopathy affecting 6% to 13% of
women of reproductive age and is one of the leading causes of female poor fertility [1]. It was initially
described as the association of anovulation and clinical and/or biological hyperandrogenism (1990
National Institutes of Health-Sponsored conference). In 2003, the Rotterdam Consensus Conference
introduced polycystic ovaries on ultrasound (corresponding to a follicle number per ovary ≥12 and/or
an ovarian volume ≥10 mL) as a supplementary, not mandatory, diagnostic criterion [2]. Thus, PCOS
diagnosis currently requires the presence of at least two of these three criteria: Oligo/anovulation,
hyperandrogenism, and polycystic ovaries morphology (PCOM) [3]. Despite its typical association with
insulin resistance (IR), abdominal obesity [4], and an increased risk of developing type 2 diabetes [5],
the causal relationship between reproductive and metabolic features in PCOS has not yet been fully
elucidated. Adverse effects of obesity on fertility have largely been discussed and investigated [6,7].
Notably, in PCOS, it has been suggested that an original adipose tissue dysfunction, possibly due to in
utero androgen hyperexposition and leading to excessive visceral fat depots, may play a key role in
determining both IR and altered androgen metabolism [8].
It is well known that white adipose tissue can act as a metabolically active tissue able to synthetize
and secrete many endocrine compounds called adipokines [9,10]. The involvement of these molecules in
human fertility has been earning growing interest in the last years. Leptin implication in the interaction
between energy metabolism and the reproductive system is nowadays widely admitted [11,12]. More
recently, it has been demonstrated that several other adipokines may play a role in female reproductive
function, and notably in ovarian physiology [13]. Indeed, in vitro investigations demonstrated that
adiponectin receptors AdipoR1 and AdipoR2 [14], chemerin and its receptor chemerin chemokine-Like
Receptor 1 (CMKLR1) [15], resistin [16], visfatin [17], omentin [18], apelin, and its receptor APJ
(Apelin Receptor) [19] are expressed at both mRNA and protein levels in human granulosa cells (GCs).
Moreover, some of these adipokines have been in vitro demonstrated to be implicated in human ovarian
follicle function [20] and modulation of steroidogenesis [14–17,19,21]. Plasma levels of adiponectin [4],
chemerin [22,23], resistin [24,25], visfatin [26,27], omentin [28,29], and apelin [19] seem to vary in
women with PCOS, but the literature is poor, and results are often discordant [19,30–34]. Further,
adipokines were predominantly assessed in blood samples, while very little is known concerning their
variations in follicular fluid (FF) and GCs of women with PCOS [19,35–37].
The aim of our study was to investigate the concentration in FF and the mRNA expression in GC
of adiponectin, chemerin, resistin, visfatin, omentin, and apelin and some of their receptors in PCOS
women. Further, to improve the understanding of PCOS etiology that is still under debate, and to
identify adipokines potentially involved in its physiopathology, we chose to compare PCOS subjects to
a cohort of women presenting only PCOM on ultrasound, without any other characteristic feature of
PCOS. This condition, which we named “ECHO”, has in addition significant clinical interest, since it is
well known that a high number of ovarian follicles is a major risk factor of ovarian hyperstimulation
syndrome during a medically assisted reproduction (MAR) procedure [38].
2. Results
2.1. Anthropometric, Clinical, and Hormonal Data
Anthropometric, clinical, and hormonal data as well as IVF procedure outcomes are detailed in
Table 1 and Figure 1. As expected, BMI was higher in obese groups and cycles were longer in PCOS
compared to ECHO and control women. ECHO and PCOS groups were characterized by a greater
follicle count compared to controls; a significant, not predictable difference was also found between
normal-weight and obese women. Plasma AMH and LH levels were higher in PCOS women compared
to controls. Interestingly, as regards AMH, we observed a highly statistically significant difference
also between PCOS and ECHO groups. Concerning IVF procedure outcomes, oocytes and embryos
numbers were greater in ECHO and PCOS women. No difference in plasma FSH and oestradiol levels
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was observed between the groups. No woman of the ECHO and control groups and only 6 out of
23 women with PCOS presented a clinical and/or biological hyperandrogenism. Plasma testosterone
concentrations determined with the same kit for each group are reported in Table 1.











NW Controls (n = 12) 31.08 ± 3.82 21.77 ± 2.07 28.46 ± 2.15 6.78 ± 3.19 43.33 ± 14.39 0.33 ± 0.20 (n = 5)
NW ECHO (n = 13) 31.69 ± 5.88 20.84 ± 1.86 30.25 ± 2.54 6.40 ± 2.15 42.85 ± 16.01 0.28 ± 0.15 (n = 6)
NW PCOS (n = 13) 29.54 ± 3.36 20.68 ± 1.96 98.54 ± 67.77 * 5.86 ± 1.66 41.55 ± 14.85 0.88 ± 0.93 (n = 6)
Obese Controls (n = 15) 33.80 ± 4.62 33.13 ± 2.29 28.97 ± 2.21 6.71 ± 3.49 43.23 ± 17.24 0.41 ± 0.19 (n = 5)
Obese ECHO (n = 15) 32.73 ± 4.50 31.53 ± 3.33 29.89 ± 1.30 5.68 ± 1.09 35.23 ± 13.43 0.43 ± 0.08 (n = 5)
Obese PCOS (n = 10) 30.10 ± 3.25 33.38 ± 2.12 76.11 ± 61.79 # 4.86 ± 1.64 34.13 ± 6.99 0.49 ± 0.24 (n = 7)
Condition Effect p = 0.07 p = 0.14 p < 0.0001 p = 0.13 p = 0.38 -
BMI Effect p = 0.15 p < 0.0001 p = 0.37 p = 0.28 p = 0.13 -
Interaction p = 0.65 p = 0.32 p = 0.46 p = 0.78 p = 0.57 -
Note: BMI = Body Mass Index; FSH = Follicle-Stimulating Hormone; NW = Normal-Weight; * indicated significant
difference (p < 0.001) between Normal-Weight PCOS women and Normal-Weight ECHO/Control women; # indicated
significant difference (p < 0.001) between Obese PCOS and Obese ECHO/Control women. The values are expressed
as mean ± standard deviation.
2.2. FF Adiponectin and AdipoR1 Expression in GC Varied Mainly According to BMI
Adiponectin concentration in FF was clearly significantly higher in normal-weight women then
in obese ones (Figure 2A). According to pathological status, we observed a significant difference
only within the normal-weight group, with greater levels of adiponectin in ECHO as compared to
PCOS women (Figure 2A). Likewise, AdipoR1 was predominantly expressed in GCs of normal-weight
women (Figure 2B). However, differences in pathological condition were limited to the obese group,
with ECHO and PCOS women showing greater AdipoR1 expression compared to controls (Figure 2B).
Both adiponectin concentration in FF and AdipoR1 expression in GCs were negatively correlated with
BMI (r = −0.748 and r = −0.288, respectively, Table 2). FF adiponectin was also negatively correlated
with plasma E2 (r = −0.30, Table 2), while a positive correlation was observed between AdipoR1
expression and follicles (r = 0.554, p < 0.001), oocytes (r = 0.286, p < 0.05), and embryos number (r =
0.309, p < 0.05). No significant correlation was found between adiponectin concentration in FF and
AdipoR1 expression.
Table 2. Correlations between follicular fluid concentration of adipokines and clinical parameters,
hormonal data, and in vitro fertilization procedure outcomes (n = 62).
Parameter Adiponectin Chemerin Resistin Visfatin Omentin Apelin
BMI (kg/m2) r = −0.748 *** r = 0.725 *** r = 0.799 *** r = 0.275 * r = 0.446 *** r = 0.441 ***
Cycle duration (d) NS NS NS NS r = 0.421 *** NS
Follicles Count (n) NS NS NS r = −0.352 ** NS r = 0.480* **
AMH (ng/mL) NS NS NS r = −0.284 * NS NS
Estradiol (ng/L) r = −0.300 * NS NS NS NS r = −0.284 *
Oocytes Retrieved (n) NS NS NS r = −0.37** NS r = 0.300*
Embryos (n) NS NS NS r = −0.262* NS r = 0.268*
Note: BMI = Body Mass Index; AMH = Anti-Müllerian Hormone. NS = Not Statistically Significant; * p < 0.05;
** p < 0.01; *** p < 0.001.
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Figure 1. Clinical parameters, hormonal data, and in vitro fertilization procedure outcomes in patients
of different studied groups. (A) Follicle counts assessed by transvaginal ultrasound, (B) plasma AMH
concentration, (C) plasma LH concentration, (D) number of oocytes withdrawn during transvaginal
retrieval, and (E) number of embryos obtained after in vitro fertilization. For A panel, see Table 1
for the data number per group. For the B, C, D, and E panels, the data were pooled in three groups
(n = 27, n = 28, n = 23 for controls, ECHO, and PCOS groups, respectively) according to the pathological
condition, as the BMI effect was not significant and no interaction between the BMI and pathological
condition effect was found. The values are expressed as mean ± standard errors of means. ◦◦ indicates
significant difference (p < 0.01) between normal-weight and obese subjects; * indicates significant
difference vs. controls (* p < 0.05, ** p < 0.01, *** p < 0.001); ### indicates significant difference (p < 0.001)
vs. ECHO women.
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Figure 2. Follicular fluid adiponectin and chemerin concentration and mRNA expression of
AdipoR1(Adiponectin receptor 1), CMKLR1, and CCRL2 in granulosa cells of obese and normal-weight
PCOS, ECHO, and control groups. (A) Follicular fluid (FF) adiponectin concentration assessed by
ELISA and (B) AdipoR1 mRNA levels in granulosa cells (GCs) quantified by RT-PCR within the six
different groups; (C, D) chemerin levels in FF and GC; (E, F) mRNA levels of CMKLR1 and CCLR2 in
GC. The values are expressed as mean ± standard errors of means (n = 12 for normal-weight controls,
n = 13 for normal-weight ECHO, n = 13 for normal-weight PCOS, n = 15 for obese controls, n = 15 for
obese ECHO, and n = 10 for obese PCOS). ◦ indicates significant difference between normal-weight and
obese subjects (◦◦ p < 0.01, ◦◦◦ p < 0.001); * indicates significant difference vs. controls (*** p < 0.001);
# indicates significant difference vs. ECHO women (# p < 0.05, # # # p < 0.001).
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2.3. Chemerin (FF and GC mRNA Expression) Was Higher in Obese Subjects and in Women with PCOS
Chemerin expression both in FF and GC was greater in obese women than in normal-weight
women (Figure 2C,D). Concerning pathological status, chemerin concentration in FF was clearly
predominant in women with PCOS, but a statistically significant difference was found only in the
normal-weight group (Figure 2C). Otherwise, chemerin expression in GC varied only within the obese
group, with significantly higher levels in PCOS compared to ECHO women (Figure 2D). Interestingly,
chemerin follicular concentration positively correlated with chemerin mRNA levels in GC (r = 0.64,
p < 0.001) and both strongly positively correlated with BMI (r= 0.725 and r= 0.694, respectively, Table 2).
2.4. CMKLR1 and CCRL2 mRNA Expression in GC was Markedly Reduced in Obese Women
Contrary to chemerin, mRNA levels of its receptor, CMKLR1, were almost undetectable in obese
women (Figure 2E). However, in line with what was seen for chemerin, in the normal-weight group,
CMKLR1 expression was predominant in women with PCOS, even if the difference with the ECHO
group failed to reach statistical significance (Figure 2E). C-C Chemokine Receptor-Like 2 (CCRL2)
expression varied only according to BMI, with higher mRNA levels in GCs of normal-weight women
compared to the obese ones (Figure 2F). No significant modification was observed according to
pathological status. G Protein-Coupled Receptor 1 (GPR1) expression did not change in any condition
(data not shown). A positive correlation was observed between CMKLR1 expression and follicle count
(r = 0.520, p < 0.001), cycle duration (r = 0.337, p = 0.01), plasma AMH (r = 0.353, p < 0.01), plasma
LH (r = 0.306, p < 0.05), and plasma E2 concentrations (r = 0.091, p < 0.05). Remarkably, CMKLR1
mRNA levels were negatively correlated with BMI (r = −0.622, p <.001). Indeed, chemerin expression
both in FF and GC was negatively correlated with the mRNA levels of all its receptors, although
statistical significance was found only between FF chemerin and CCRL2 (r = 0.342, p < 0.05) and
between chemerin mRNA levels in GC and CMKLR1 (r = −0.46, p < 0.001).
2.5. FF Resistin Was Higher in Obese Women
Resistin concentration in FF was markedly higher in obese women than in the normal-weight
ones (Figure 3A) and, interestingly, it was positively correlated with BMI (r = 0.799, Table 2). In the
normal-weight group, the highest resistin levels were observed in ECHO and PCOS women (Figure 3A).
Resistin mRNA levels in GCs did not vary according to either BMI or pathological condition. Unlike
chemerin, FF resistin did not significantly correlate with resistin expression in GCs.
2.6. Visfatin Modifications Were Restrained to Its Concentration in FF
As for resistin, visfatin expression varied only in FF and mainly according to BMI, with higher levels
in obese subjects compared to the normal-weight ones (Figure 3B). However, follicular concentration
of visfatin was lower in ECHO and PCOS women compared to controls, especially in the obese group
(Figure 3B). FF visfatin was positively correlated with BMI (r = 0.275, Table 2) and negatively correlated
with plasma AMH concentration (r = −0.284) and follicles (r = −0.352), oocytes (r = −0.37), and embryo
number (r = −0.262) (Table 2). No significant modification nor correlation was found for visfatin
mRNA levels in GCs.
2.7. Omentin Expression (FF and GC mRNA) Was Markedly Predominant in Women with PCOS
Omentin concentration was significantly higher in the FF of obese women (Figure 3C). Remarkably,
independently from BMI, omentin levels were markedly more elevated in PCOS than in ECHO and
control women (Figure 3C). Interestingly, obese ECHO women showed lower omentin follicular
concentrations than controls (Figure 3C). The same significant results were found concerning omentin
expression in GCs (Figure 3D). Further, omentin concentration in FF was strongly positively correlated
with omentin mRNA levels in GCs (r = 0.824, p < 0.001) and both positively correlated with BMI
(r = 0.446 for follicular omentin, Table 2, and r = 0.464 for GC omentin mRNA levels, p < 0.001).
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A positive correlation was also observed between follicular omentin concentration and cycle duration
(r = 0.421, Table 2).
Figure 3. Follicular fluid resistin, visfatin, and omentin concentration and mRNA expression of omentin
in granulosa cells of obese and normal-weight PCOS, ECHO, and control groups. (A) Follicular fluid
(FF) resistin, (B) visfatin, and (C) omentin concentrations assessed by ELISA; (D) mRNA omentin levels
in granulosa cells (GCs) quantified by RT-PCR within the six different groups. The values are expressed
as mean ± standard errors of means (n = 12 for normal-weight controls, n = 13 for normal-weight
ECHO, n = 13 for normal-weight PCOS, n = 15 for obese controls, n = 15 for obese ECHO, and n = 10
for obese PCOS). ◦◦◦ indicates significant difference (p < 0.001) between normal-weight and obese
subjects; * indicates significant difference vs. controls (* p < 0.05, ** p < 0.01, *** p < 0.001); ### indicates
significant difference (p < 0.001) vs. ECHO women.
2.8. Apelin and Its Receptor APJ Were Mostly Expressed in Obese Subjects and in ECHO/PCOS Women
Both apelin FF levels and apelin expression in GCs were significantly higher in obese than in
normal-weight women (Figure 4A and B) and positively correlated with BMI (r = 0.441, Table 2, and
r = 0.554, p < 0.001, respectively). According to pathological status, apelin was mostly expressed in
ECHO and PCOS women in both the normal-weight and obese groups (Figure 4A and 4B). Interestingly,
limited to FF concentration, apelin was significantly lower in normal-weight PCOS than in ECHO
women (Figure 4A). A positive correlation was found between follicle count and both apelin levels
in FF (r = 0.480, Table 2) and apelin expression in GC (r = 0.301, p < 0.05). Follicular apelin also
positively correlated with oocytes and embryo numbers (r = 0.30 and r = 0.268, respectively, Table 2)
and negatively correlated with plasma E2 concentration (r = −0.284, Table 2). Apelin mRNA levels in
GCs were correlated with cycle duration (positive correlation, r = 0.289, p < 0.05) and plasma FSH
(negative correlation, r = −0.298, p < 0.05). Concerning APJ, we found the same significant results,
with a predominant expression of this receptor in the obese group and women with PCOS (Figure 4C).
Further, like apelin, mRNA levels of APJ positively correlated with BMI (r = 0.510, p < 0.001) and cycle
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duration (r = 0.402, p < 0.01) and negatively correlated with plasma FSH concentration (r = −0.282,
p < 0.05). Notably, APJ expression was strongly positively correlated with apelin expression in GCs
(r = 0.866, Figure 4G) and apelin concentration in FF (r = 0.749, Figure 4E right panel), which in turn
were strongly positively correlated to each other (r = 0.821, Figure 4D).
Figure 4. Follicular fluid apelin concentration, mRNA expression of apelin and its receptor, APJ, in GCs
of obese and normal-weight PCOS, ECHO, and controls groups and correlations of apelin FF levels
and apelin or APJ mRNA expression in GCs. (A) Follicular fluid (FF) apelin concentration assessed by
ELISA; (B) apelin and (C) APJ mRNA levels in granulosa cells (GC) quantified by RT-PCR within the
six different groups; (D) correlation between FF concentration and GC expression of apelin; correlations
between APJ mRNA levels in GCs; and (E) apelin FF concentration and (F) apelin mRNA levels in
GCs. The values are expressed as mean ± standard errors of means (n = 12 for normal-weight controls,
n = 13 for normal-weight ECHO, n = 13 for normal-weight PCOS, n = 15 for obese controls, n = 15
for obese ECHO, and n = 10 for obese PCOS). ◦◦◦ indicates significant difference (p < 0.001) between
normal-weight and obese subjects; *** indicates significant difference (p < 0.001) vs. controls; ###
indicates significant difference (p < 0.001) vs. ECHO women.
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3. Discussion
Our study aimed to improve the understanding of PCOS etiology, and to identify adipokines
potentially involved in its physiopathology. Thus, we analyzed the adipokines’ profile at the ovarian
level (FF and GC) in normal-weight and obese women with PCOS diagnosis in comparison with
women presenting only a PCOM, a condition that we named “ECHO”. This condition, as discussed
above, has per se a significant clinical interest and, to the best of our knowledge, there are no data
available about adipokines expression in the FF and GCs of these women. We evaluated adiponectin,
chemerin, resistin, visfatin, omentin, and apelin concentrations in FF samples, as well as the expression
of the same adipokines and some of their receptors in GCs. The results are discussed below for each
single adipokine.
3.1. Adiponectin
Adiponectin is one of the better known and most abundant circulating adipokines. It is mainly
produced by white adipocytes and secreted into plasma circulation as three oligomeric complexes,
whose medium and high molecular weight isoforms represent 90% of circulating protein. It acts mainly
through two G protein-coupled receptors, AdipoR1, which is ubiquitously expressed, and AdipoR2,
which is mainly located in white adipose tissue and liver [30]. Its involvement in energy metabolism
as an insulin-sensitizing, anti-inflammatory, and anti-atherogenic molecule is largely admitted [30]
and obesity and insulin-resistant states have been associated with reduced plasma adiponectin
concentrations [4]. In agreement with literature data, we found that adiponectin concentration in FF
and AdipoR1 mRNA expression in GCs were markedly higher in normal-weight women then in the
obese ones and both negatively correlated with BMI. Interestingly, we also observed that within the
normal-weight group, FF adiponectin levels were significantly lower in PCOS compared to ECHO
women. Consistent with our findings, despite some conflicting results [30], PCOS women have
been reported to present lower adiponectin concentrations in serum [4,39] and FF [35,40], as well
as a decreased expression of AdipoR1 and AdipoR2 in adipose tissue [5]. Although adiponectin
dysregulation may be one of the possible mechanisms responsible for impairment of insulin-sensitivity
in women with PCOS, the reduction of adiponectin levels in serum seems to be independent of IR
severity [41]. Thus, adiponectin might play a role in the pathogenesis of other characteristic features of
PCOS. In particular, several authors evoked a possible role of this adipokine in folliculogenesis [35,40].
Notably, Campos et al. reported that adiponectin acts directly and indirectly, through the interaction
with LH and insulin, on GCs by inducing the expression of genes associated with periovulatory
maturation of ovarian follicles [42]. It is therefore noteworthy that in our study, AdipoR1 expression in
GCs was positively correlated with follicles, oocytes, and embryo count. On the other hand, contrary to
what is reported in the literature [40], we did not find any significant difference in AdipoR2 expression.
In addition, mRNA AdipoR1 levels varied only in the obese group, being greater in PCOS and ECHO
women compared to controls. The meaning of our findings is currently unknown and deserves to be
further elucidated. Although adiponectin involvement in PCOS pathogenesis is supported by several
evidences, including genomic analyses [30], it is possible that the limited data we obtained are due
to the fact that we only investigated GCs. In our study, we did not find any correlation between FF
adiponectin concentration and AdipoR1/AdipoR2 expression in GCs. Hence, since adiponectin levels
are twice higher in FF than in plasma [14], theca cells might represent the key actor in the metabolism
of adiponectin as the main cell responsible for its production in FF and then the most likely target of
its effects.
3.2. Resistin
Resistin is a small cysteine-rich protein mainly expressed by macrophages [43] and within adipose
tissue, it is predominantly released by omental non-adipocyte resident inflammatory cells [44]. Its
relevance and physiological role in humans are currently unclear. Notably, Panidis et al. showed
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that circulating resistin was higher in overweight women with PCOS but did not differ between
PCOS and control women with a normal BMI, although the first were more insulin resistant [45].
Further, after stepwise multiple regression analysis, serum resistin levels were not associated with any
parameter independent of BMI, suggesting that they correlated with IR as a consequence of obesity
itself, rather than as an independent causative factor [45]. In accordance with these data, in our study,
we found that resistin concentration in FF was significantly higher in obese women compared to the
normal-weight ones and positively correlated with BMI. As regards PCOS women, some authors noted
higher plasma resistin concentrations in overweight/obese patients compared to the normal-weight
ones, independently from PCOS diagnosis [45]. However, others showed no difference in serum
resistin levels between obese and non-obese PCOS women [25] and most of the studies failed to
find a significant correlation between circulating resistin and BMI [37,46]. Interestingly, within the
normal-weight group of patients, we observed higher resistin levels in the FF of ECHO and PCOS
women compared to controls. Other studies, however, showed no difference in FF resistin concentration
between PCOS and healthy normal-weight women [37]. Indeed, the association of resistin with PCOS
is largely debated. Resistin mRNA and protein have been detected in granulosa, theca, cumulus cells,
and oocytes from human ovarian follicles [16]. In human granulosa cells, recombinant resistin has been
reported to decrease IGF-1-induced progesterone and estradiol secretion [16], which was associated
with a reduction in P450scc and P450 aromatase levels [16], indicating a role for resistin in the regulation
of ovarian steroidogenesis. However, data concerning serum resistin levels in women affected by
PCOS are inconsistent. While some authors pointed out significantly higher resistin concentrations
in the plasma of women with PCOS [24,25], no difference between PCOS and healthy women was
reported by several others [37,45]. Interestingly, resistin mRNA levels in adipocytes were twice higher
in women with PCOS compared to controls and significantly decreased after laparoscopic ovarian
electrocautery [47,48], suggesting that although systemic resistin does not seem to be actively involved
in PCOS pathogenesis, it may act as a local determining factor for this syndrome [45,48]. However, it is
noteworthy that in agreement with previous literature data [37], in our study, FF resistin levels did
not correlate with any reproductive outcome, making it unlikely that resistin plays a role in oocytes’
maturation and development. Unlike other adipokines, we observed that resistin mRNA levels in
GCs did not vary either according to BMI or pathological condition and did not correlate with FF
concentration. Resistin levels in FF have been repeatedly found to be lower than in plasma [16,37].
It is therefore unlikely that human GCs, while expressing resistin protein [16], secrete it into FF or
circulation. Furthermore, according to our findings and considering that follicular resistin seems to
derive primarily from blood plasma, the regulation of resistin expression appears to be different at the
systemic and ovarian level.
3.3. Visfatin
Visfatin, previously described as a growth factor for early B-cells called pre-B cell colony enhancing
factor (PEBF) [49], was later characterized by Fukuhara et al. as a peptide predominantly expressed in
and secreted from visceral adipose tissue in both humans and mice [50]. Although visfatin has been
proposed as a potential link between visceral obesity and increased metabolic risk [51], data concerning
the relationship between this adipokine, obesity, and IR are widely discordant. In our study, visfatin
concentration in FF was significantly higher in the obese group than in the normal-weight one and
positively correlated with BMI. Despite some conflicting results [52], a recent meta-analysis revealed
that plasma visfatin is significantly increased in subjects presenting overweight/obesity, IR, metabolic
syndrome, and cardiovascular diseases [53]. A positive association between circulating visfatin and
BMI has been reported by several authors [26,27,34,51] but not confirmed by others [52]. On the
contrary, the role of visfatin in the regulation of female reproductive functions is supported by several
evidences. Indeed, it is expressed in human myometrium, placenta, and human fetal membranes,
where it seems to be involved in placentation [17]. In the ovary, its presence has been demonstrated
in human follicles, notably in oocytes, cumulus, and GCs and less abundantly in theca cells [17,53].
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In human GCs, it has been reported to enhance IGF-1-induced progesterone and estradiol secretion,
thus showing a positive effect on steroidogenesis [17]. In our study, we observed significantly lower
levels of visfatin in the FF of obese ECHO and PCOS women compared to obese healthy controls,
a result not in line with literature data. Indeed, in previous studies, FF visfatin was shown to be
similar [54] or higher [36] in women with PCOS when compared to BMI-matched normally ovulatory
women. Similarly, as regards circulating visfatin, although two studies failed to highlight a significant
difference between PCOS and healthy women [34], most of the authors found significantly higher
levels in women with PCOS [26,27,36,54,55]. The decrease in visfatin concentration observed in the FF
of the PCOS and ECHO women of our study, which is characterized by a high antral follicle count
deriving from follicular growth arrest, suggests a positive effect of visfatin on female reproductive
function, and notably folliculogenesis. Indeed, Shen et al. found a significant positive correlation
between visfatin concentration in FF and the number of retrieved oocytes [53] and the administration
of visfatin during ovulation induction in aged female mice improved the developmental competency
of oocytes [56]. However, it needs to be underlined that in our study, follicular visfatin was negatively
correlated with follicle, oocyte, and embryo numbers, as well as with plasma AMH concentration.
As for resistin, visfatin mRNA levels in GCs did not vary either according to BMI or pathological
condition and did not correlate with FF concentration. Visfatin levels in FF have been shown to be
similar [53] or lower [54] compared to those in plasma and no correlation was found between visfatin
concentrations in plasma and FF [53]. In light of our results, the possibility of an ovarian origin for this
adipokine, although previously evoked [53], seems thus unlikely.
3.4. Apelin
Apelin is a bioactive peptide originally identified in bovine stomach extract as the endogenous
ligand of the orphan G protein-coupled receptor, APJ [57]. Its expression has been detected in several
organs, like the stomach, brain, lung, uterus, and ovary, as well as in the endothelium of small
arteries [57], indicating that the apelin/APJ system may play a pivotal role in multiple physiological
functions. In particular, apelin seems to be involved in the regulation of food intake, energy metabolism,
cardiovascular system, angiogenesis, and neuroendocrine functions [57]. In our study, we found that
apelin concentration in FF as well as apelin and APJ mRNA expression in GCs were significantly
higher in obese than in normal-weight women and positively correlated with BMI. These results
already reported by Roche et al. [19] are consistent also with literature data about circulating apelin
levels [58]. As the existence of a correlation between serum apelin levels and IR in PCOS is still a
matter of debate [59], apelin, rather than as a marker of insulin sensitivity, may play a role in other
characteristic features of PCOS, such as ovulatory dysfunction. Indeed, apelin and APJ expression has
been detected in human ovarian follicles, GCs, theca cells, and oocytes and in vitro studies suggest
a potential role of apelin in the control of several aspects of ovarian function [19]. Indeed, apelin
enhances progesterone and estradiol secretion in human and porcine GC cultures [19,60], it improves
rat, bovine, and porcine GC proliferation, and it seems to be involved in the regulation of the bovine
corpus luteum luteolysis process [61] and oocyte maturation [62]. In our study, we demonstrated that
both apelin concentration in FF and apelin/APJ mRNA expression in GCs positively correlated with
antral follicle count and were significantly higher in PCOS and ECHO groups, both characterized by
the accumulation of small antral follicles resulting from the failed selection of a dominant follicle. Thus,
according to these observations, apelin may play a key role in follicular growth arrest at the origin of
PCOM. In support of this hypothesis, apelin has been suggested to be implicated in bovine follicular
atresia [63] and in different animal species; both protein and mRNA levels of apelin and APJ have
been reported to change during follicular growth, with the highest expression in large follicles [60,63].
Folliculogenesis disruption in PCOS is thought to be due to an increased responsiveness to FSH in
terms of oestradiol and progesterone production and to a premature responsiveness to LH in small
follicles [64]. Consequently, in PCOS anovulatory women, plasma estradiol levels are slightly higher
and FSH levels are lower than in the normal early follicular phase [64]. While keeping in mind that
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correlations may be merely spurious, without causative significance, very interestingly, we found
that apelin mRNA levels in GCs were negatively correlated with plasma FSH levels and positively
correlated with cycle duration, strongly supporting that apelin could also participate in hormonal
disturbances at the origin of PCOS pathogenesis. Indeed, this adipokine has been identified in the
arcuate supraoptic and paraventricular hypothalamic nuclei [62], it has been demonstrated to suppress
LH secretion in rats [65], and a negative correlation between plasma apelin and LH levels has repeatedly
been shown in humans [66,67]. In our study, FF concentration and GC mRNA expression of apelin
was strongly positively correlated with each other and with APJ expression. Further, even if plasma
apelin levels largely depend on the dosage method, FF apelin concentration seems to be higher than
the plasma one [59]. Thus, follicular apelin may partly derive by GC production and act in a paracrine
and/or autocrine manner on GCs themselves.
3.5. Omentin
Omentin, also known as intelectin-1, is a novel adipokine identified from the cDNA library
of omental adipose tissue by Yang et al. and predominantly produced by visceral fat depots [68].
Despite some discordant results [29], serum omentin levels have been shown to be inversely related to
obesity [69,70] and to increase after weight loss [71]. Contrarily to what was reported in plasma, in
our study, we found that FF concentration and GC mRNA expression of omentin were significantly
higher in obese women compared to the normal-weight ones and positively correlated with BMI.
We also demonstrated that omentin expression in both FF and GCs was significantly higher in
women with PCOS compared to controls and ECHO women. These results, already shown by
Cloix et al. [18], once again disagree with literature data concerning plasma omentin levels. Indeed,
most of the studies investigating omentin expression in PCOS women found lower plasma omentin
concentrations [28,29,69,70], as well as decreased omentin mRNA and protein levels in adipose
tissue [72]. Several factors have been evoked to explain such results. First, it has been repeatedly
reported that serum omentin levels are inversely related with HOMA-IR/fasting insulin [29,69,70,72]
and an in vitro study supported the role of hyperinsulinemia in lessening omentin expression in
adipose tissue [72]. Hormonal disturbances, and notably hyperandrogenism, have been suggested as
another key factor contributing to a decrease of omentin synthesis in PCOS women [29,70]. Indeed, as
for some other adipokines, plasma omentin levels are higher in women than in men [73] and negatively
correlate with androgens’ levels [29,70]. At last, omentin may also be regulated by inflammation, as its
expression is altered in inflammatory states [28] and PCOS is actually considered as a proinflammatory
condition [74]. According to these observations, the higher omentin expression that we found in FF
and GCs in PCOS women suggests that omentin production at the ovarian level is independent from
insulin action and differently regulated in these patients. Furthermore, in our study, FF concentration
and GC expression of omentin positively correlated with each other, strongly supporting the hypothesis
that follicular omentin is at least partially produced by GCs. Interestingly, Cloix et al. showed that in
PCOS women, but not in controls, omentin concentration is doubled in FF compared to in plasma [18].
Whether omentin is implicated in PCOS pathogenesis is, however, still to be demonstrated. In humans,
omentin is expressed in reproductive tissues, including the placenta and ovary [70], and it has been
shown to enhance, through induction of visfatin expression, GC IGF-1-induced steroidogenesis and
IGF-1R signaling [18]. Thus, it has been suggested that omentin and visfatin, modulating insulin
sensitivity in GC, could affect ovarian function. Indeed, insulin and IGF-1 act synergistically with FSH
to increase GC estrogens’ synthesis and with LH to enhance theca cells’ androgen production [18].
Interestingly, circulating omentin has already been shown to be positively correlated with serum
estradiol and negatively correlated with the LH/FSH ratio [29]. Mahde et al. also found higher serum
omentin levels in PCOS women with irregular cycles compared to those with regular ones [69], data
that agree with our finding of a positive correlation between follicular omentin and cycle duration,
further confirming the possible role of this adipokine in ovulatory dysfunction characteristics of PCOS.
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3.6. Chemerin
Chemerin, also known as Retinoic Acid Receptor Responder protein 2 (RARRES2), is a small
chemotactic protein originally identified as the natural ligand of the G-protein coupled receptor
CMKLR1 [75]. Initially known as a proinflammatory cytokine involved in adaptative and innate
immunity [76], in 2007, it was discovered as a novel adipokine associated with obesity and metabolic
syndrome [77] and shown to promote adipogenesis and adipocyte metabolism [78]. In addition to
CMKLR1, two other receptors, GPR1 and CCRL2, were reported to bind chemerin with high affinity, but
at present data concerning their functional relevance are poor [75]. In our study, chemerin expression in
both FF and GCs was greater in obese women than in the normal-weight ones and strongly positively
correlated with BMI. This is consistent with Bozaoglu et al.’s data, showing that chemerin and CMKLR1
were highly expressed in mature adipocytes and upregulated in the adipose tissue of obese animals [77].
Circulating chemerin levels have also been reported to be higher in obese subjects compared to those
with a normal BMI and significantly correlated with metabolic syndrome parameters, such as BMI,
triglycerides, and fasting serum insulin [23]. Nevertheless, BMI alone does not seem to be a predictive
factor for circulating chemerin [31]. Indeed, the existence of a correlation between this adipokine and
PCOS has repeatedly been evoked [79]. Our findings showed that both chemerin FF concentration and
chemerin and CMKLR1 mRNA levels in GCs were predominant in women with PCOS. The same results
have recently been found by Wang et al. in a cohort of non-obese women [21]. Further, serum and
ovarian chemerin levels have been shown to be elevated in a dihydrotestosterone (DHT)-induced rat
PCOS model [21] and, despite few discordant data [31], the literature widely reports higher chemerin
levels in the plasma and adipose tissue of PCOS women [22]. Chemerin has been demonstrated to act as
an important negative regulator of ovarian steroidogenesis [80], inhibiting IGF-1-induced secretion of
progesterone and estradiol in human GCs [15] and suppressing FSH-induced expression of aromatase
and P450scc in cultured rat preantral follicles and GCs [21,81]. Furthermore, in DHT-treated rats,
elevated chemerin levels and down-regulated aromatase expression were positively related to increased
GC apoptosis [80], suggesting that chemerin may be involved in the antral follicular growth arrest
associated to the hyperandrogenic proinflammatory state characterizing PCOS [82]. While keeping in
mind that correlations may be merely spurious, without causative significance, it is noteworthy that
in our study CMKLR1 expression in GCs was significantly positively correlated with follicle count,
cycle duration, and plasma AMH, LH, and estradiol levels. As for apelin and omentin, we found
that the follicular concentration of chemerin strongly positively correlated with its mRNA levels in
GCs, suggesting that follicular chemerin may be partly produced in the ovary. Indeed, chemerin and
CMKLR1 expression has been demonstrated in human and mouse placenta [78], in human, mouse, and
rat ovary [21], and more recently in human granulosa and theca cells [15]. In support of this hypothesis,
the concentration of this adipokine has been shown to be higher in FF than in plasma [15] and the
rise of follicular chemerin in PCOS women has been demonstrated to be independent of changes in
its plasma concentration and adiposity, strongly indicating that chemerin is independently regulated
at the ovarian level [82]. Interestingly, in our study, CMKLR1 and chemerin expression seemed to
be inversely regulated as regards adiposity. Indeed, contrarily to chemerin, CMKLR1 mRNA levels
were higher in GCs of normal-weight women and negatively correlated with BMI. Further, chemerin
and CMKLR1 levels in GCs negatively correlated with each other, suggesting the possibility of a
negative feedback between chemerin and its receptor. Such a regulatory mechanism has already been
proposed by Bozaoglu et al. in adipose tissue, but finally, chemerin’s role in the regulation of CMKLR1
expression in adipocytes seems quite limited [77]. As an alternative, these findings could be due to
a resistance mechanism to chemerin action at the ovarian level. Indeed, as hyperinsulinemia in the
IR states, the high chemerin levels found in obese women could be a compensatory response to the
lack of CMKLR1 in GCs. This is, however, a pure hypothesis, since no data is at the moment available
about whether and how this chemerin resistance may occur.
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3.7. ECHO Condition
In our study, we chose to compare women with PCOS and controls to a third group of women
presenting at least 12 small antral follicles per ovary without any other criterium necessary for PCOS
diagnosis, i.e., hyperandrogenism and/or oligo-anovulation. Besides allowing us to better understand
adipokines’ role in PCOS physiopathology, the “ECHO condition” has relevant clinical interest.
Indeed, despite some discordant results [83], it has repeatedly been reported to be associated with
hyperandrogenism and IR [84,85]. PCOM is also encountered in about 30% of young asymptomatic
women [85], but its actual meaning in this condition is currently unknown [86]. There is little evidence
to suggest that its sole presence has any significant risk to subsequent health, except for circumstances
in which women with PCOM require a gonadotropin treatment, such as during an IVF procedure [86].
Indeed, due to polycystic ovaries’ extreme sensitivity to FSH, an antral follicle count greater than 24
is considered a major risk factor of ovarian hyperstimulation syndrome and nowadays is routinely
recommended for the pre-treatment identification of patients at risk [38]. Interestingly, we found that
FF concentration and GC mRNA expression of omentin, chemerin, and APJ (for the last two, these
observations were limited to the obese group) were significantly lower in ECHO compared to PCOS
women, suggesting that these molecules could play a physiopathological role in other main features of
PCOS, such as anovulatory infertility. On the contrary, the ECHO group was characterized by higher
FF adiponectin levels, possibly reflecting a lower IR compared to the PCOS group or, more intriguingly,
a beneficial effect of adiponectin on follicular maturation and subsequent ovulation. Surprisingly,
we also observed that, despite no difference in terms of follicle numbers between the two groups,
ECHO women presented lower plasma AMH levels than women with PCOS. It has been demonstrated
that AMH plays a key role in protecting growing follicles from premature maturation, directly by
inhibiting the recruitment of primordial follicles and indirectly by opposing the effects of FSH. For
this reason, it is considered an endocrine marker of the number of small antral follicles [87]. Indeed,
plasma AMH concentration was reported to be two to three-fold higher in women with PCOS than in
normal ovulatory women [88] and in vitro studies demonstrated that GCs of normo-ovulatory and
anovulatory PCOS women produce, respectively, 4-fold and 75-fold higher AMH levels compared
to controls [89]. Serum AMH levels are therefore considered to reflect the severity of PCOS [90]
and notably, the ovulatory disturbances characteristic of this disease [87]. In addition, Homburg
et al. reported that AMH levels can be used to differentiate women with PCOS from women with
PCOM alone and controls [91], further strengthening our results. As for AMH, plasma LH levels in
the ECHO group were intermediate between controls and women with PCOS. Women with PCOM
had already been reported to present a hormonal profile, as well as a per-follicle AMH production,
intermediate between normal and PCOS women, suggesting that isolated PCOM might represent a
PCOS-like phenotype characterized by a mild GC dysfunction, not yet sufficient to affect the ovulatory
process [86]. Our findings also agree with literature data showing a tight positive correlation between
LH and AMH [86] and support the role of AMH in hormonal alterations at the origin of the ovulatory
dysfunction observed in women with PCOS [92].
3.8. Limitations and Perspectives
Although this study provided meaningful information, it has some limitations. Firstly, it was a
retrospective and observational study and, as such, it did not permit determination of whether the
modifications in adipokines’ concentration were at the origin of the development of polycystic ovaries
in PCOS, or rather a consequence or a compensatory response. Secondly, we studied only women
requiring IVF and hence under controlled ovarian stimulation, a condition that surely modifies the
normal functions of the female reproductive system. Thus, our results might not be generalized to all
PCOS and ECHO women. Finally, data about the IR state were not available for most of the women
included in the study. This could have given us more information about patients’ hormonal profile
and, mostly, helped us to better understand and interpret adipokines’ modifications. Our current
understanding of the role of chemerin, omentin, and apelin in PCOS is far from complete and deserves
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further studies. Notably, it would be of importance to elucidate the molecular mechanisms involved in
their effects on GCs and, above all, to study their expression and action on theca cells, which play a key
role in the hyperandrogenism characterizing PCOS women.
4. Materials and Methods
4.1. Ethics Approval
Study was conducted according to principles set in the Declaration of Helsinki. Informed
consent was signed by each participant and study protocol was approved by the Institutional Review
Board (Authorization protocol 2016_075, 1 January 2016) Ethic Committee of University Hospital of
Tours, France).
4.2. Study Population
Biological samples and clinical data of a total of 78 women undergoing an in vitro fertilization
(IVF) procedure between 2011 and 2017 at the referral center for reproductive medicine of University
Hospital of Tours were analyzed.
Three groups of patients were created: 23 women suffering from PCOS (PCOS group), 28 women
presenting ≥12 follicles per ovary on transvaginal ultrasound without other criteria necessary for
diagnosis of PCOS (ECHO group), and 27 women affected by another cause of infertility requiring a
MAR procedure (control group). Each group almost equally included normal weight (BMI 18–25 kg/m2)
and obese (BMI > 30 kg/m2) women. A total of 6 groups was then analyzed. Diagnosis of PCOS
followed 2003 Rotterdam Consensus Conference Criteria [2]. All women with PCOS presented an
oligo/anovulation and follicle count ≥12 per ovary. Clinical and/or biological hyperandrogenism was
reported for 6 out of 23 of them. Signs of clinical hyperandrogenism included acne, alopecia, and
hirsutism as evaluated by a physician experienced in the field. No woman included in the ECHO and
control groups had clinical and/or biological hyperandrogenism and all were characterized by normal
ovulatory cycles. They underwent an IVF procedure because of male infertility, tubal sterility, ovarian
insufficiency, endometriosis, or a combination of male and female causes. The antral follicle number
was assessed in the early follicular phase by transvaginal ultrasound scans of the ovaries performed by
experienced sonographers. Blood samples for hormonal evaluations were collected between day 3
and day 5 of the menstrual cycle before the IVF stimulation protocol. Plasma levels of testosterone,
oestradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were measured
using an Immulite® 2500 immunoassay analyzer (Siemens, Munich, Germany). However, none of the
control and ECHO women included in our study showed clinical and biological hyperandrogenism.
Plasma anti-Mullerian hormone (AMH) was determined by Eurofin Biomnis (Lyon, France).
4.3. Collection of FF Samples and Isolation of GCs
GCs were obtained from preovulatory follicles during oocyte retrieval preceding IVF. The
controlled ovarian stimulation protocol and IVF procedures employed have already been reported [93].
After isolation of cumulus-oocyte complexes, FF was recovered and centrifuged (400× g, 10 min) to
separate cell remnants. The supernatant was stored at −80 ◦C for later analyses. GCs were isolated from
erythrocytes with 20 min of centrifugation at 400× g on two layers of discontinuous Percoll gradient
(40%, 60% in Ham’s F-12 medium; GIBCO-BRL/Life Technologies, Lyon, France). The 40% fraction was
collected and treated with hemolytic medium (NH4Cl 10 mM in Tris HCL, pH 7.5; Sigma Aldrich,
Saint Quentin-Fallavier, France) to remove the remaining erythrocytes. Following centrifugation, the
pellet was washed with fresh medium (Ham’s F-12) and stored at −80 ◦C for later use.
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4.4. Adipokines Concentration in FF
Adiponectin, chemerin, resistin, visfatin, omentin, and apelin concentrations were measured by
ELISA in FF samples. ELISA R&D Bio-Techne Ltd. kits (Abingdon, United Kingdom, intra-assay
coefficients of variations<6% and inter-assay coefficients of variations≤8%) were used for all adipokines.
4.5. RNA Extraction and Real-Time Quantitative PCR (qPCR)
Total RNA from GCs was extracted with TRIzol reagent according to the manufacturer’s procedure
(Sigma Aldrich, Saint Quentin-Fallavier, France). The concentration and the purity of isolated RNA
were determined with a NanoDrop spectrophotometer (Peqlab Biotechnologie GmbH, Erlangen,
Germany). The integrity of RNA was checked on 1.25% agarose-formaldehyde gels. The cDNA
was generated by reverse transcription (RT) of total RNA (1 μg) and real-time quantitative PCR was
performed as reported previously [18]. Briefly, total RNA (1 μg) was denatured and reverse transcripted
in a 20 μL reaction mixture containing 50 mM Tris-HCL (pH 8.3), 75 mM KCL, 3 mM MgCl2, 200 mM of
each deoxynucleotide triphosphate, 50 pmol of oligo(dT), 15.5 IU of ribonuclease inhibitor, and 15 IU
of Moloney Murine Leukaemia Virus (M-MLV) reverse transcriptase. The mixture was incubated for 1
h at 37 ◦C. Targeted cDNAs were quantified by real-time PCR using SYBR Green Supermix (Bio-Rad,
Marnes la Coquette, France) and 250 nM of specific primers (as mentioned below) in a total volume
of 20 μL in a MyiQ Cycle device (Bio-Rad). Samples were tested in duplicate on the same plate and
PCR amplification with water instead of cDNA was done systemically as a negative control. After
incubation for 2 min at 50 ◦C and a denaturation step of 10 min at 95 ◦C, samples were subjected to
40 cycles (30 s at 95 ◦C, 30 s at 60 ◦C, 30 s at 72 ◦C), followed by the acquisition of the melting curve. The
levels of mRNA expression were standardized to the geometric mean of three reference genes (GAPDH,
beta-actin, and PPIA), which has been reported as an accurate normalization procedure [94]. The
relative amounts of gene transcripts (R) were calculated according to the equation: R= (Egene−Ct gene)/
(geometric mean (EGAPDH−Ct GAPDH; EBETA ACTIN −Ct BETA ACTIN; EPPIA−Ct PPIA)), where E is the primer
efficiency and Ct is the cycle threshold.
The primers’ efficiency (E) was performed from serial dilutions of a pool of
obtained cDNA and ranged from 1.8 to 2. The specific primer pairs used were:
Adiponectin: Fw (forward) 5′-GAAAGGAGATCCAGGTCTTATTG-3′ and Rev (reverse)
5′-TCAGCAAAACCACTATGATGG-3′; AdipoR1: Fw 5′-TTCTTCCTCATGGCTGTGATGT-3′ and
Rev 5′-AAGAAGCGCTCAGG-AATTCG-3′; AdipoR2; Fw 5′-CCACCACCTTGCTTCATCTA-3′
and Rev 5′-GATACTGAGGGGTGGCAAAC-3′; visfatin or NAMPT: Fw
5′-CAGCAGAACACAGTACCATA-3′ and Rev 5′-CTCTAAGATAAGGTGGCAGC-3′; omentin: Fw
5′-GGATTTGTTCAGTTCAGGGTATTTAA-3′ and Rev 5′-GCCTCTGGAAAGTATCCTCCT-3′; resistin
Fw: 5′-GGACAGGAGCTAATACCCAGAAC-3′ and Rev 5′-GGAAAAGGAGGGGAAATGAA-3′; apelin:
Fw 5′-CTCTGGCTCTCCTTGACCG-3′ and Rev 5′-GGCCCATTCCTTGACCCTC-3′; apelin receptor (APJ):
Fw 5′-CTATCCTGTTTTCTGAGTGTGAGG-3′ and Rev 5′-CTAAGGGCTGGAGCACTAATTATC-3′;
chemerin (rarres2): Fw 5′-CCCAATGGGAGGAAACG-3′ and Rev 5′-CCAGGGAAGTAGAAGCTGTG-3′;
CMKLR1: Fw 5′-CCCAATCCATATCACCTATGCC-3′ and Rev 5′-GTCCCGAAAACCCAGTGGTA-3′;
CCRL2: Fw 5′-CACATAACTAGGAAGTGGCAGAAC-3′ and Rev 5′-AGCGTAGGCTCTGACCAAAT-3′;
GPR1:Fw 5′-CTGTCATTTGGTTCACAGGA-3′ and Rev 5′-AACAACCTGAGGTCCACATC-3′; GADPH:
Fw 5′-TGCACCACCAACTGCTTAGC-3′ and Rev 5′GGCATGGACTGTGGTCATGAG-3′; PPIA: Fw
5′-CTGAGCACTGGAGAGAAAGG-3′ and Rev 5′-AGGAATGATCTGGTGGTTAAG-3′; beta Actin; Fw
5′-CTTCTACAATGAGCTGCGTGTG-3′ and Rev 5′- GTGAGGATCTTCATGAGGTAGTCAGTC-3′. PCR
products were analyzed on an agarose gel (1.5%) stained with ethidium bromide and the cDNA fragment
of interest was confirmed after sequencing by Genewiz (Leipzig, Germany).
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4.6. Statistical Analyses
Values are reported as mean ± standard deviation (SD). Statistical analyses included two-way
ANOVA, followed by Bonferroni post-hoc tests. For each parameter, we examined the effect of BMI and
pathological condition, and the interaction between these two parameters. In case of a not-significant
BMI effect and no interaction, the data for subsequent analysis were pooled in three groups according
to pathological status (controls, PCOS, and ECHO). In all other cases, normal-weight and obese
groups were investigated separately. Correlations were analyzed by simple regression analysis and
the correlation-Z-test. Neither adjustment for age nor any other factor was made. StatView software
(version version 9.3, Distributors: SAS Institute Inc., SAS Campus Drive, Cary NC 27513, USA) was
used, with p < 0.05 as a threshold statistically significant level.
5. Conclusions
In conclusion, we showed in a cohort of women affected by infertility that chemerin and omentin
expression in FF and GCs is electively increased in the PCOS group, while ECHO women are
characterized by high levels of adiponectin, apelin, and APJ, as well as lower plasma AMH and LH
levels. We also demonstrated that the regulation at the ovarian level of these adipokines differs from the
systemic one, suggesting that follicular chemerin, omentin, and apelin may be at least partly produced
by GCs and act in an autocrine and/or paracrine manner on ovarian follicles’ cells, modulating their
functions and, in particular, steroid production. FF concentration of all adipokines varied according to
BMI, with resistin, visfatin, chemerin, omentin, and apelin levels higher in obese subjects in contrast
with a predominant adiponectin expression in normal-weight women. Our findings thus provide
novel insights into the role of chemerin, omentin, and apelin in follicular growth arrest and ovulatory
dysfunction characterizing PCOS pathogenesis.
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Abstract: Rheumatic diseases encompass a diverse group of chronic disorders that commonly affect
musculoskeletal structures. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most
common, leading to considerable functional limitations and irreversible disability when patients
are unsuccessfully treated. Although the specific causes of many rheumatic conditions remain
unknown, it is generally accepted that immune mechanisms and/or uncontrolled inflammatory
responses are involved in their etiology and symptomatology. In this regard, the bidirectional
communication between neuroendocrine and immune system has been demonstrated to provide
a homeostatic network that is involved in several pathological conditions. Adipokines represent
a wide variety of bioactive, immune and inflammatory mediators mainly released by adipocytes
that act as signal molecules in the neuroendocrine-immune interactions. Adipokines can also be
synthesized by synoviocytes, osteoclasts, osteoblasts, chondrocytes and inflammatory cells in the joint
microenvironment, showing potent modulatory properties on different effector cells in OA and RA
pathogenesis. Effects of adiponectin, leptin, resistin and visfatin on local and systemic inflammation
are broadly described. However, more recently, other adipokines, such as progranulin, chemerin,
lipocalin-2, vaspin, omentin-1 and nesfatin, have been recognized to display immunomodulatory
actions in rheumatic diseases. This review highlights the latest relevant findings on the role of the
adipokine network in the pathophysiology of OA and RA.
Keywords: adipokine; rheumatic diseases; inflammation; osteoarthritis; rheumatoid arthritis
1. Introduction
According to the World Health Organization “Musculoskeletal disorders comprise more than
150 diagnoses that affect the locomotor system—that is, muscles, bones, joints and associated tissues
such as tendons and ligaments—and are the second largest contributor to disability worldwide [1].
Musculoskeletal conditions generally comprise disorders that affect joints such as osteoarthritis
(OA) and rheumatoid arthritis (RA). Although both diseases have an inflammatory component, the
underlying pathological mechanisms are different.
OA is the most common joint disease affecting 18% of the population above 60 years of age
although young individuals, especially juvenile athletes, can also suffer from this disorder [2]. It has
been demonstrated that it is triggered mainly by biomechanical stress and joint overload, although
obesity and metabolic disease are also considered key risk factors for its development [3–5]. Cartilage,
subchondral bone, and synovium are the main tissues involved in OA pathogenesis. In recent years,
the important contribution of pro-inflammatory mediators such as cytokines, reactive oxygen species
(ROS), nitric oxide, and matrix degrading enzymes have been reported [6].
RA is a severe autoimmune disorder, characterized by chronic inflammation of diarthrodial joints,
leading to cartilage and bone destruction. RA affects 1% of the population worldwide and is related to
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loss of physical function, quality of life and high prevalence of comorbid conditions [7]. RA develops
in genetically susceptible individuals, under the influence of environmental factors, as well as with
the involvement of epigenetic mechanisms. It is a heterogeneous disorder with diverse pathogenic
mechanisms and variable clinical forms [8,9].
Unraveling the mechanisms that underlie both immune regulation and resolution of inflammation
is crucial for the design of new strategies to treat these two highly prevalent rheumatic disorders.
One of the approaches to understand these mechanisms is the study of the neuro-endocrine-immune
systems balance, which is crucial for the maintenance of homeostasis and the effective adaptation to
stressors [10,11]. This intricate communication and their regulatory mechanisms rely in the presence of
common mediators such as neurotransmitters, cytokines, hormones and their receptors. In this sense,
on the one hand, dysregulation in immune-endocrine integrated circuitries have been involved in the
development of chronic metabolic diseases, comprising obesity, diabetes, and metabolic syndrome [12].
On the other hand, RA has been defined as an example of a disease resulting from abnormal interactions
between these systems [13]. Reversal of abnormal cellular phenotypes in this disease has also been
shown: As an example, synovial fibroblasts (SF) from RA patients (RASF) could be reprogrammed
from a cartilage-degrading phenotype towards a regulatory type by hormones/neurotransmitters [14].
Interestingly, adipose tissue has been shown to be not only involved in the energetic homeostasis
but also to act as an endocrine organ by secreting a diverse array of factors referred as adipocytokines.
Products of adipose tissue include adipokines, cytokines, chemokines and complement factors [15].
Adipokines are bioactive proteins, which have emerged as modulators of inflammatory and immune
response, exerting key roles in rheumatic diseases, both at local and systemic level. Adipose tissue is
not the only source of adipokines. Immune cells, chondrocytes as well as synoviocytes also synthesize
these mediators. In musculoskeletal disorders, autocrine, paracrine and endocrine pathways acting
on target cells and tissues such as bone, cartilage and synovial membrane have been described [16].
Higher levels of adipokines in both serum and synovial fluid from RA patients compared with healthy
controls have been reported [17,18]. Moreover, an inflammatory profile in the infrapatellar fat pad
(IPFP) of OA patients has been described [19]. Overall, increasing evidence postulates that adipokines
play an important role in both immune-mediated rheumatic disease and in degenerative disorders
such as OA. In the next sections, we will disclose the most recent data about the role played by these
mediators in these two rheumatic diseases.
2. Pathophysiology of Osteoarthritis and Rheumatoid Arthritis
2.1. Osteoarthritis
OA is a chronic rheumatic disease, considered one of the leading causes of substantial physical and
psychological disability worldwide. OA is a complex multifactorial disorder [20,21], where mechanical,
genetic, biological, biochemical and metabolic factors are involved. It is characterized by cell stress and
extracellular matrix (ECM) degradation, resulting in an imbalance in joint tissue metabolism [22–24].
Although cartilage degradation is the main event in the pathology, OA affects the whole joint, including
the remodeling of adjacent subchondral bone, osteophyte formation and synovial inflammation, which
might culminate in pain, loss of joint function, and disability in advanced stages [21,24–31].
OA cartilage is characterized by an increase of ECM remodeling, cartilage calcification and
angiogenesis [32,33]. Chondrocytes have receptors for responding to mechanical stress and
inflammatory mediators, many of which are also receptors for ECM components, including
cartilage-degradation products [31,34–36]. Activated chondrocytes acquire a hypertrophic phenotype,
proliferating and increasing the release of inflammatory cytokines and chemokines, stress-induced
intracellular signals, ROS, and matrix-degrading enzymes, including aggrecanases and matrix
metalloproteinases (MMPs). In addition, ECM protein production is decreased. Depletion of aggrecan
and degradation of type II collagen are the main events in cartilage destruction when the process
becomes irreversible [37–40].
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Changes in subchondral bone are related to cartilage remodeling, thus playing an important
role in OA progression by the release of catabolic mediators that promote an abnormal metabolism
in chondrocytes [30,41]. Production of inflammatory and degradative mediators by joint cells also
induces the synovial inflammation. Synovitis is characterized by synovial hyperplasia, with SF and
synovial macrophage proliferation, as well as immune cell infiltration. These cells release inflammatory
mediators including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), among other cytokines
and chemokines which aggravate inflammation [31,42,43]. In addition, SF produce matrix-degrading
enzymes, also contributing to cartilage ECM degradation [28,29,44].
2.2. Rheumatoid Arthritis
RA is a severe and chronic systemic inflammatory autoimmune disease with unknown etiology
that mainly affects peripheral joints symmetrically, leading to progressive articular damage and joint
dysfunction. One of the hallmarks of RA is the persistent inflammatory infiltration of the synovial
sublining layer that contributes to generate a microenvironment in which stromal cells display a
hyper-activated phenotype, releasing several pro-inflammatory and tissue damaging mediators to
the joint space [45,46]. Although many of the underlying causes of RA are still unclear, systemic
and local immune dysregulation is considered to orchestrate its pathogenesis. In fact, this disease is
characterized by the production of autoantibodies such as anti-citrullinated protein antibody (ACPA)
and rheumatoid factor (RF), as well as by increased levels of e.g., TNF-α, IL-1β and IL-6 which are
recognised as central pro-inflammatory cytokines involved in chronic synovitis, osteoclast formation
and subsequent erosive joint damage. In this context, SF and synovial macrophages are recognized to
play a key role in driving RA pathology [8,47,48].
RASF characteristically exhibit an autonomous pathogenic phenotype that includes the capability
for hyperproliferation and migration, thus contributing to synovial hyperplasia and spreading RA
to unaffected joints [8,47,49]. Likewise, resident and monocyte-derived RA synovial macrophages
display a pro-inflammatory profile that has been linked to the pathological activity of RASF, and the
number of these cells in the synovium of affected joints has been shown to correlate with disease
activity and joint erosion [50–52]. Furthermore, it is generally accepted that endothelial cells under
synovial inflammatory conditions also contribute to chronic synovitis via angiogenesis and recruitment
of immune cells in RA [53].
3. Adiponectin
Adiponectin has previously been described as an anti-inflammatory adipokine mainly produced
and secreted by adipocytes [54]. The highly complex adiponectin molecules exist in different isoforms,
the globular form, the trimer (low molecular weight, LMW), the hexamer (middle molecular weight,
MMW) and the multimeric (high molecular weight, HMW) adiponectin. LMW, MMW and HMW
represent the main circulating forms of adiponectin while the monomer only seems to occur as an
intermediate in adipocytes [55].
Two receptors are mainly responsible for adiponectin signaling and the adiponectin isoforms
differ in their affinity to the respective receptors [56]. Other receptors such as T cadherin [57–60]
and PAQR3 [61] have also been discussed. Mainly anti-inflammatory effects at the systemic level
have been described for adiponectin in atherosclerosis but also for example in metabolic syndrome,
type 2 diabetes mellitus [56,62]. In contrast, adiponectin seems to have opposing effects on effector
cells of arthritis. Adiponectin was one of the first adipokines to be evaluated in the pathophysiology
of arthritis. Numerous studies found that cultured RASF respond to adiponectin by an increase
of pro-inflammatory factors including prostaglandin E2, IL-6, IL-8, MMPs-1, -13 [56,62]. However,
a stronger pro-inflammatory effect of the HMW isoforms has been described in contrast to LMW
adiponectin in these cells [56,62]. For some cell types, even opposing effects have been described for
specific adiponectin isoforms. For example, IL-6 secretion was induced by HMW adiponectin in human
monocytes (but had no such effect on lipopolysaccharide (LPS)-activated monocytes), while LMW
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adiponectin reduced IL-6 and increased IL-10 secretion in LPS-activated monocytes [63]. Other cell
types including chondrocytes, endothelial cells and lymphocytes showed a mainly pro-inflammatory
response to adiponectin [56,62]. Bone cells are affected as well by adiponectin in both OA and RA [15].
3.1. Adiponectin in OA
A recent meta-analysis showed that the systemic adiponectin concentration is higher in OA
patients compared to healthy controls [64] and a cross-sectional study described that serum adiponectin
and leptin were significantly and negatively associated with bone mineral density in OA of the knee in
contrast to resistin [65]. Furthermore, serum adiponectin levels were found to be significantly lower
in OA patients with metabolic syndrome when compared to OA without metabolic syndrome [66]
independent of the body mass index (BMI) [67]. In the context of OA, adiponectin was associated with
pain while resistin and visfatin were mainly associated with disability [68]. Interestingly, adiponectin
serum levels were shown to be negatively associated with serum MMP-13 in OA-related knee structural
abnormalities [69]. The synovial tissue and IPFP of OA patients with metabolic syndrome secreted less
adiponectin compared to those OA patients with metabolic syndrome, whereas leptin was increased in
OA patients with metabolic syndrome. Adipokine secretion by tissue reflected the systemic adipokine
levels observed in these patients [66]. In another study, evaluation of perisynovial and infrapatellar
adipose tissue depots revealed differences that were influenced by the BMI of the patient. Compared to
adipocytes in the IPFP and synovium of lean OA patients, obese patients showed significantly larger
adipocytes with increased synovial fibrosis, macrophage infiltration and toll-like receptor (TLR) 4 gene
expression in those patients while adiponectin expression in the synovium was lower in obese patients
compared to lean patients [70].
3.2. Adiponectin in RA
Systemic adiponectin levels have been described to be increased in chronic-inflammatory RA
and to be associated with disease activity and radiographic disease progression [56,62]. However, the
correlation with disease activity has been shown in some studies but not by others [62], a discrepancy
which still needs to be elucidated. Besides serum levels, synovial fluid concentrations of adiponectin
are increased in RA [17,71]. In RA patients, subcutaneous abdominal adipose tissue has been found
to secrete more adiponectin compared to subcutaneous abdominal adiposetissue from OA patients,
and the amount of adiponectin secreted from this tissue positively correlated with the 28-joint disease
activity score (DAS28) and disease duration [72].
Interestingly, RA patients with higher baseline adiponectin showed a more pronounced
improvement in inflammatory parameters after anti-TNF-α treatment [73]. Along this line, anti-IL-6
treatment significantly increased adiponectin and reduced chemerin levels in RA patients independently
of the disease treatment response [74].
In another recent study, adiponectin indirectly affected T follicular helper cells (Tfh), which did
not directly respond to adiponectin, by activating these cells via adiponectin stimulation of RASF,
mainly through IL-6. Liu et al. confirm that intraarticular injection of adiponectin increased synovial
inflammation with an increased frequency of Tfh in adiponectin-treated collagen-induced arthritis
(CIA) mice [75]. Targeting specific adiponectin isoforms using therapeutic antibodies specifically
against MMW/HMW adiponectin reduced the IL-6 and IL-8 induction in osteoblasts induced by those
isoforms [76]. In addition, Lee et al. showed that antibodies against MMW/HMW as well as against
MMW alone significantly ameliorated CIA in mice and that hence both these adiponectin isoforms
may contribute to progression of arthritis.
In another recent study, Qian and colleagues suggested a potential cardiovascular protective role
of IL-6 inhibition. Adiponectin and osteopontin (OPN) levels were increased and associated with each
other in RA serum [77], and RASF stimulation with adiponectin led to a dose-dependent increase in
OPN, which in turn caused increased monocyte (RAW264.7) migration. This increased migration could
be inhibited by blocking OPN. In vivo, OPN silencing reduced the amount of tartrate-resistant acid
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phosphatase positive osteoclasts and bone erosion in collagen-induced arthritis (CIA) mice. Therefore,
enhanced bone erosion in RA is suggested to be mediated by the induction of OPN in SF, thus increasing
the differentiation and recruitment of osteoclast precursors [77].
4. Leptin
Discovered in 1994 by Jeffrey Friedman et al. [78], leptin is the main adipokine secreted by
adipocytes, with a positive correlation with white adipose tissue mass [79,80]. It is a 16kDa
non-glycosylated protein encoded by the LEP (ob) gene, involved in appetite and obesity regulation
by the induction of anorexigenic factors and suppression of orexigenic neuropeptides. Leptin is
also implicated in basal metabolism, insulin secretion, bone mass, and reproduction among other
functions [78,80,81]. In addition to food intake- and eating-related hormones, leptin synthesis is
regulated by energy status, sex hormones and inflammatory mediators [82]. Leptin is mainly secreted
by adipose tissue but it is able to act peripherally and centrally, in the hypothalamus, by its release
to circulation [83]. Its biological effects are mediated by binding to the long form of leptin receptor
(LEPR), which belongs to the class I cytokine receptor superfamily [84].
Leptin is considered a pro-inflammatory adipokine involved in the “low-grade inflammatory
state” described in overweight and obese people [85]. In the immune system, leptin modulates
both innate and adaptive immunity: it activates proliferation and phagocytosis of monocytes and
macrophages, regulates cytotoxicity of natural killer (NK) cells, modulates neutrophils chemotaxis,
induces proliferation and inhibits memory T CD4 cells, suppresses type 2 T helper (Th2) phenotype
in favour of Th1, and modulates T regulatory (Treg) activity [80,86]. Most immune cells express
LEPR at their surface, which has also been described for chondrocytes, SF and osteoblasts [87,88].
In addition, pro-inflammatory cytokines induce leptin synthesis in acute infection and sepsis [89].
Involvement of leptin has been described in several physiological and pathophysiological conditions,
including vascular function, reproduction, immunity, and inflammation, as well as in rheumatic
diseases [80,90–94].
4.1. Leptin in OA
Increased leptin levels in serum and synovial fluid from OA patients have been described to be
involved in the physiopathology [95–99] and to be associated with pain and disease severity [99,100].
Single nucleotide polymorphisms (SNP) in the leptin gene and its receptor are linked to OA
development [101,102]. Moreover, DNA methylation in OA chondrocytes correlates with leptin
expression [103], which associates with the BMI [96]. Fan et al. reported different genes associated with
the leptin-induced OA phenotype in rats by microarray analysis, including genes related to MMPs,
inflammatory factors, growth factors, apoptosis, and osteogenesis [104].
In OA chondrocytes, leptin increased the production of the pro-inflammatory cytokine IL-1β,
as well as matrix-degrading enzymes, including MMP-1, -3, -9, and -13 [80,96,103], suggesting a
role in the inflammatory and degradative process that takes place during OA. Accordingly, leptin
also increased MMP-2, MMP-9, a disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS)-4 and ADAMTS-5, while it decreased fibroblast growth factor (FGF) and proteoglycan
synthesis in rats cartilage [105]. Moreover, leptin induced activation of type 2 nitric oxide synthase
(NOS2) in human and mouse chondrocytes, with the involvement of JAK2, PI3K, MEK1 and p38
MAPK signaling [106,107]. By contrast, Dumond et al. showed an anabolic effect of leptin in rat
chondrocytes [108]. Leptin also induced changes in chondrogenic progenitor cells causing senescence
by the inhibition of their migratory and chondrogenic potential, and the induction of their osteogenic
transformation [109].
A role of leptin in OA subchondral bone has also been described, showing an increased expression
which is related to high levels of alkaline phosphatase, osteocalcin, collagen type I and transforming
growth factor β (TGF-β) [110]. Finally, in relation to the inflammatory process, an increase of IL-6, IL-8
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and chemokine ligand 3 (CCL3) by leptin has been described in CD4+T cells from OA patients [111]. In
addition, Griffin et al. showed that leptin-impaired mice did not develop knee OA inflammation [112].
4.2. Leptin in RA
In RA, higher leptin serum levels are related to disease course and activity [113–116]. In addition
to the activity, leptin in serum and synovial fluid has also been linked to disease duration and joint
erosion [117].
Several authors have reported the involvement of leptin in joint inflammation by the modulation
of different inflammatory mediators. Correlation of leptin and IL-17 has been reported in plasma
from RA patients [118]. In addition, leptin induced IL-6 and IL-8 expression in SF from RA and OA
patients, where JAK2/STAT3, NF κB, and AP-1 signaling pathways were involved [119,120]. Leptin
also increased expression of the vascular cell adhesion molecule (VCAM)-1 in human and murine
chondrocytes, and is involved in leukocyte extravasation during RA and OA inflammatory processes.
JAK2, PI3K and MAPK intracellular signaling was shown to play a role in this context [87]. Moreover,
induction of MAPK signaling by leptin has also been described in RASF [120].
Correlation of leptin with RA pathology has been shown in animal models. Busso et al. reported
less severe arthritis in leptin-deficient mice, accompanied with a reduction in IL-1β and TNF-α
levels [121]. In addition, leptin injection in CIA mice increased Th17 response, exacerbating RA
severity and increasing synovial hyperplasia and joint damage [122]. Serum leptin concentrations also
correlated with body fat percentage in RA patients, working as an obesity marker [123]. Cardiovascular
risk is another factor associated to obesity and RA pathology. Accordingly, Batun et al. reported an
association between leptin and IL-6 concentrations with cardiovascular risk in these patients [124].
5. Resistin
Resistin is a dimeric cysteine-rich protein that circulates as a 108-amino acid homodimer in
human blood [125]. In humans, this adipokine is mainly produced by macrophages whereas in mice
it is primarily secreted by adipocytes [126]. In line with this, human resistin has been primarily
associated with inflammatory responses by promoting immune cell recruitment [127–129], whereas in
mice it has been mostly linked to the development of type 2 diabetes and obesity-mediated insulin
resistance [130,131]. However, conflicting results have been published regarding the modulatory role
of resistin on inflammatory responses, and whether this adipokine induces anti- or pro-inflammatory
effects on cells may depend on both the tissue and organ context and the disease studied [125].
Nevertheless, it is accepted that resistin is generally involved in inflammation and insulin resistance,
and subsequently in the development of different pathologies such as coronary artery disease,
atherosclerosis, type 2 diabetes, psoriasis and colorectal cancer [132–136]. In this sense, resistin has also
emerged as an adipokine implicated in the pathogenesis of OA and RA given its immunomodulatory
effects and the ability to enhance the activated phenotype of the effector cells involved in these
rheumatic diseases [98,129].
5.1. Resistin in OA
Numerous clinical studies have revealed that serum, plasma and synovial fluid resistin levels are
increased in OA patients compared with healthy subjects [98,137], suggesting that this adipokine may
act as a linker between the inflammatory process and the altered metabolism of joint tissues in the
pathogenesis of OA [138].
Resistin levels in the synovial fluid of OA joints have been found to exhibit a positive association
with symptomatic and radiographic severity as well as with articular cartilage damage. Moreover,
such levels of resistin have been reported to correlate with resistin released from cultured OA
cartilage [139–141]. Likewise, presence of inflammatory and catabolic factors in synovial fluid,
including IL-6, MMP-1, MMP-3 and collagen type II C-telopeptide fragments, also exhibited a positive
correlation with synovial fluid resistin levels [141,142]. Furthermore, these adipokine levels have been
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linked with pain and disability in OA patients with join effusion [143], although no association with
knee cartilage volume has been found [97,144].
Interestingly, in vitro studies have shown that resistin-stimulated human articular chondrocytes
display an upregulated expression of several pro-inflammatory mediators, including TNF-α, IL-6 and
IL-12 [145], and different cartilage catabolic enzymes and mediators, such as MMP1, MMP3, ADAMTS-4
and inducible cyclooxygenase (COX)-2, as well as a decreased production of some components of
cartilage ECM such as type II collagen and the proteoglycan aggrecan [146–148]. This ability of resistin
to promote catabolic over anabolic activity in OA chondrocytes has been confirmed in a recent study,
which further found that resistin modulates the expression of several microRNAs (miRNA) involved
in the pathogenesis of OA [149]. Accordingly, resistin stimulation of meniscal tissue explants from
OA patients resulted in a significant increase of sulfated glycosaminoglycan depletion [150] similar to
the dose-dependent loss of proteoglycan in murine cartilage [148]. Furthermore, resistin has also has
been found to induce the expression of monocyte chemoattractant protein-1 (MCP-1) by SF from OA
patients and to subsequently promote the monocyte migration and infiltration in synovium [151].
However, some inconsistent results have been published regarding the involvement of resistin
circulating levels in the pathophysiology of OA. On the one hand, serum levels of resistin have
demonstrated a positive correlation with bone marrow lesions and cartilage degradation, also
showing an association with different scoring systems for measuring severity, progression and
pain in OA [141,152]. Likewise, plasma resistin levels in OA were shown to be associated with
progression of radiographic knee [153]. On the other hand, other authors have not found any
significant relationship between serum resistin and OA radiographic severity, bone mineral density,
pain or cartilage damage [65,97,98,142,154]. Nevertheless, such serum levels exhibited a weak but
positive association with histological signs of synovial inflammation in OA patients [98]. Therefore,
while the potential pathogenic role of serum/plasma resistin levels needs to be further investigated,
there is evidence of the involvement of synovial fluid resistin in OA pathogenic mechanisms by
promoting pro-inflammatory responses and cartilage catabolic activity.
5.2. Resistin in RA
Resistin is present in blood plasma or serum, synovial fluid, and synovial tissue of RA patients.
Synovial stromal cells, including SF, and infiltrating immune cells, such as macrophages and B cells,
express resistin in joints affected by RA [155,156]. Higher resistin levels in synovial sublining layers
and also in synovial fluid from RA patients compared with OA have been described [17,155,157].
Regarding the potential pathological impact of synovial resistin levels in RA, it has been shown that
increased levels correlate with RA disease activity, joint damage [71], and inflammation intensity
defined by the intra-articular leukocytes count and IL-6 levels [128]. Conversely, in another study,
synovial fluid resistin did not show any significant relationship with inflammation degree based on
C-reactive protein (CRP) levels [155].
Besides, the available data concerning the circulating resistin levels in RA patients have also
generated conflicting conclusions. Although most studies describe no differences between serum or
plasma resistin levels in RA patients and controls [71,113,128,156,158], other authors have reported
higher resistin serum levels in RA when compared with healthy controls or with OA patients [155,159].
There is evidence that resistin serum levels in RA patients are positively correlated with inflammatory
markers, such as erythrocyte sedimentation rate (ESR) and CRP levels, as well as with the degree
of disease activity measured by DAS28 [113,155,160]. Another study also demonstrated a positive
correlation between circulating levels of this adipokine and TNF-α levels in blood from RA patients [161],
whereas no relationship with TNF-α, CRP levels, leukocytes counts, or with other pro-inflammatory
cytokines such as IL6, IL8, or MCP-1 was found by other authors [128,155].
Despite these controversial results regarding correlations between resistin levels in circulating
blood or in the joint with parameters of disease activity, there is a general agreement that this adipokine
is involved in the pathogenesis of RA. In fact, the intra-articular injection of recombinant resistin
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in healthy mice induced leukocyte infiltration and hyperplasia of the synovia, leading to a joint
inflammation similar to human arthritis [128]. Furthermore, in vitro stimulation of human synovial
fluid leukocytes and peripheral blood mononuclear cells (PBMC) with resistin induced the secretion of
IL-6, IL-1 and TNF-α by an NF κB-dependent pathway, providing a positive feedback circuit in PBMC
by stimulating also its own production [128]. Likewise, stimulatory effect of this adipokine on IL-12 and
TNF-α release by both murine and human macrophages was demonstrated to be mediated by the NF
κB pathway [127]. More recently, the ability of resistin to increase the production of pro-inflammatory
chemokines by SF has been shown [162]. Moreover, resistin has been considered as a key factor
triggering angiogenesis in RA affected joints through the upregulation of vascular endothelial growth
factor (VEGF) expression in endothelial progenitor cells and causing the homing of these cells to the
synovium [163].
The potential involvement of resistin in the RA inflammatory cascade is also sustained by the
rapid reduction of its serum levels observed in patients after anti-TNF-α therapy, showing a close
association with the inflammation marker CRP [164,165]. Accordingly, a downregulation of resistin
gene expression in CD4 Th lymphocytes and CD14 monocytes in RA patients responding to TNF-α
inhibitor therapy has recently been demonstrated, showing an increased expression in patients who
failed to respond to the therapy [166]. In addition, recent studies in a Chinese population have
demonstrated the association of SNP in the resistin gene with RA susceptibility as well as with its
clinicopathological characteristics [167,168].
6. Visfatin
Visfatin is also called pre-B-cell colony-enhancing factor (PBEF) for its ability to promote B cell
precursor differentiation (in synergy with IL-7) or nicotinamide phosphoribosyl-transferase (Nampt)
due to its enzymatic activity. However, whether altered systemic or local visfatin levels are associated
with changes in the nicotinamide adenine dinucleotide content due to the Nampt activity of visfatin is
not well studied. It is produced by adipose tissue but also other tissues such as the liver, bone marrow,
and muscle tissue. Visfatin can be induced by inflammatory factors such as TNF-α, IL-1β, IL-6, LPS
and chemokines as well as itself [15,56,62].
Hypoxia as found in inflamed joints may also play a role since hypoxia-inducible factor 2alpha
(HIF-2α) directly induced visfatin in chondrocytes [169]. In turn, visfatin is able to induce a
pro-inflammatory response in a large number of different cell types [115]. In contrast to adiponectin,
visfatin is primarily pro-inflammatory. These pro-inflammatory responses have also been described in
the effector cells of joints affected by arthritis, for example in SF, lymphocytes, monocytes, chondrocytes
or bone cells [15,170]. However, although visfatin is increased in both OA and RA, compared to healthy
controls, the levels differ between these two diseases. Likewise, the potential to respond to visfatin is
similar in OA- and RA-derived cells but the responses, although pro-inflammatory in both cases, differ
in strength between RA and OA [11,29].
Visfatin is also associated with insulin-like effects: It regulates insulin secretion, insulin receptor
phosphorylation and insulin-related intracellular signaling [171,172] but the work by Fukuhara et al.
(2007) that originally reported visfatin to interact with the insulin receptor was retracted. Therefore, as
of now, visfatin does not have a known receptor and several studies showed that its effects are at least
in part due to its Nampt activity [173].
Another mechanism includes its influence on insulin-like growth factor-1 (IGF-1) function.
Amongst others, IGF-1 is involved in cartilage synthesis and repair by stimulating proteoglycan and
collagen type II synthesis. Visfatin has been shown to inhibit these IGF-1 functions, independently of
IGF-1 receptor activation [174]. Altered levels of miRNAs may be another means how visfatin mediates
its effects as a range of miRNAs were either increased (miR-155, -34a, -181a) or decreased (miR-140,
-146a) in OA chondrocytes by visfatin [149].
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6.1. Visfatin in OA
Systemic visfatin levels are increased in OA patients compared to healthy controls [175,176] but
serum levels are lower compared to chronic-inflammatory diseases such as RA. However, OASF
respond to visfatin even at low concentrations with increased secretion of pro-inflammatory factors
such as IL-8, MCP-1 and other chemokines [170]. Visfatin also induced IL-6 and TNF-α in SF from OA
patients, which was mediated by the repression of the miRNA miR-199a-5p via different signaling
pathways including ERK, p38, and JNK [177].
A cell culture study on OA suggests a catabolic effect of visfatin because treatment of human
chondrocytes with IL-1β resulted in an increased synthesis of the matrix-degrading enzymes MMP-3,
MMP-13, ADAMTS-4 and ADAMTS-5 and a decreased synthesis of the extracellular matrix component
aggrecan [178]. In line with these effects, visfatin significantly reduced viability, induced apoptosis as
well as MMP-1 and MMP-13 secretion in OA chondrocytes [149].
6.2. Visfatin in RA
In RA patients, systemic visfatin levels have been shown to be increased in comparison to OA
patients and healthy donors and a positive correlation between visfatin and RA disease activity and
inflammatory parameters such as CRP has been described [56,62,115]. According to a recent study,
visfatin expression is associated with reduced atherosclerotic risk in RA patients [179].
Animal models have also shown a potential role of visfatin in RA. In a murine CIA model,
visfatin-deficient mice displayed reduced bone destruction, inflammation and disease progression [180].
In this study from Li and coworkers, visfatin has been shown to be required for osteoclastogenesis. In
another study, use of the selective inhibitor APO866, which inhibits the Nampt activity of visfatin,
reduced the severity of arthritis in a CIA mouse model and the production of pro-inflammatory
cytokines in the affected mouse joints [173].
7. Other Adipokines in OA and RA
7.1. Progranulin
Human progranulin (PGRN, also known as granulin/epithelin precursor) is a glycoprotein of
approximately 75–80 kDa which is composed of seven granulin/epithelin repeats (granulins) that
can undergo enzymic proteolysis into small homologous subunits. Both full-length protein and its
constituent granulin peptides are biologically active although often with anti- and pro-inflammatory
actions, respectively [181]. PGRN was originally described as an autocrine growth factor that stimulates
chondrocyte differentiation and proliferation [182], as well as endochondral ossification [183,184].
Moreover, PGRN has also been identified as an adipokine with anti-inflammatory properties mainly
mediated by its competitive binding to TNF-α receptors (TNFR1 and TNFR2), which disturbs
TNF-α-induced responses [80,185].
Multiple studies have reported significantly increased PGRN levels in cartilage, synovial fluid,
as well as in serum from OA and RA patients compared with healthy donors, with higher levels in
RA [186–188]. Regarding the potential pathogenic role of PGRN, a correlation between circulating
PGRN levels and disease activity has been shown in RA patients [189]. In this sense, a recent study in
Hispanic RA patients found a correlation between changes in serum PGRN levels and RA progression
scores over time, although serum concentrations of PGRN did not predict the clinical response to
TNF-α-antagonist therapy [190]. The presence of antibodies against PGRN (PGRN-abs) has been
detected in sera from patients with different rheumatic diseases, including RA, showing neutralizing
effects on PGRN plasma levels [191]. More recently, it has been proved that PGRN-abs positive RA
patients exhibit higher disease activity compared to negative patients, and that a pattern of increased
rates of PGRN-abs is observed in the serum of RA patients with poorer outcome [192].
PGRN is secreted by a broad spectrum of cells, including adipocytes, macrophages and
chondrocytes [193], and an increased expression of this adipokine has been found during chondrocytes
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differentiation in vitro, in the IPFP from OA patients [186], as well as in cells infiltrating the sublining
layer of RA synovium [187]. Hence, the increased expression of PGRN at local sites of inflammation is
suggested to be linked to its ability to initiate immune activation by recruiting fibroblasts, macrophages
and neutrophils at the site of inflammation [194]. However, on the other hand, it is now generally
accepted that PGRN is also an important mediator in the maintenance of cartilage integrity. This
adipokine is able to inhibit the ADAMTS-7/-12 mediated degradation of cartilage oligomeric matrix
protein by interfering with direct interactions between these catabolic enzymes and their substrate, as
well as by inhibiting the TNF-α-induced expression of both ADAMTS in human chondrocytes [195].
Furthermore, treatment with PGRN has been demonstrated to inhibit proteoglycan loss and the
expression of catabolic inflammatory biomarkers induced by TNF-α in cultured human cartilage [196].
In fact, PGRN has been described to trigger anabolic pathways in human cartilage and primary
chondrocytes by binding to TNFR2, and to inhibit the IL-1β and LPS induced catabolic metabolism in
chondrocytes by blocking TNFR1 [193,197]. In addition, a negative modulation of Wnt/catenin signaling
by PGRN has been shown, with the consequent reduction of osteophyte formation and cartilage
degeneration [198,199]. PGRN has also demonstrated a protective effect on osteoblast differentiation
under an inflammatory milieu by blocking the inhibitory effects of TNF-α on this process [200]. Despite
its chondro- and osteoprotective potential, increased PGRN levels as observed in both OA and RA
patients are obviously not sufficient to compensate for the catabolic effect of other mediators [181].
Interestingly, an association between serum PGRN levels, functional impairment and disease
activity has been found in RA patients [189], in which the balance between PGRN and TNF-α
also showed a direct correlation with disease progression [186]. In this regard, different
animal models of both OA and RA have demonstrated that loss of PGRN expression results
in hyper-susceptibility to develop more severe disease phenotypes [185,196]. Along this line, a
recent study has showed that the miR-29b-3p promotes disease development and chondrocyte
apoptosis in an OA rat model by modulating PGRN expression [201]. Accordingly, administration
of recombinant PGRN or the PGRN-derived atsttrin in OA and RA animal models protected against
the development of such rheumatic disorders by, at least in part, inhibiting the TNF-α/TNFR
signaling in vivo [183,185,196,202–204]. Moreover, atsttrin-transduced mesenchymal stem cells have
demonstrated to inhibit cartilage degeneration in an OA murine model after intra-articular injection,
and to reduce the TNF-α induced expression of pro-inflammatory molecules by human primary
chondrocytes [197].
Other studies in animal arthritis models have shown that PGRN also exerts its immunosuppressive
effect by promoting the differentiation, proliferation and recruitment of Treg cells under inflammatory
conditions, as well as by inducing IL-10 production [185,205,206]. In this regard, more recently, a study
described higher levels of PGRN and human B regulatory cells in RA patients, but without finding a
correlation between them [189].
7.2. Chemerin
Chemerin is expressed as a 163 amino acid residues-long adipokine that becomes activated after
hydrolization by cysteine or serine proteases [207]. The precursor is composed of a hydrophobic signal
peptide sequence, a cystatin fold-containing domain, and a labile C terminus. Removal of the signal
sequence results in a 143-amino acid secreted preform (prochemerin or chem163S) with low biological
activity. Different cleaved isoforms of chemerin have been described depending on the location.
Cleavage of the last four amino acids from chem163S rise to chem158K, and removal of the C-terminal
lysine from chem158K, results in chem157S, the most active chemerin form. In addition, chem156F, a
chemerin C-terminal peptide, is functionally active in vitro [208,209]. Anti-inflammatory properties
have been described by mouse chem156S, homologous to human chem157S, on macrophage [210] and
in a LPS-induced acute lung injury model [211]. Chemerin plays an important role in the development
of coronary atherosclerosis, metabolic syndrome and other diseases [212]. It is also involved in innate
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and adaptative immunity working as a chemoattractant for NK cells, macrophages and dendritic
cells [213,214].
In relation to rheumatic diseases, chondrocytes and SF from RA and OA patients express both
chemerin and its receptor chemokine-like receptor 1 (CMKLR1) [208,215,216]. In addition, Zhao et al.
described the presence of chem156F in synovial fluid samples from patients with OA and RA [208].
Chemerin induced expression of inflammatory and degradative mediators in these cells, including IL-6,
CCL2, and MMP-3 in RASF, CCL2, and TLR4 in SF from RA and OA patients, and IL-1β in chondrocytes.
In addition, chemerin stimulated SF motility and leukocyte migration to the joint [209,216–218].
Cleaved isoforms of chemerin have been described in synovial fluid samples from RA and
OA patients [208]. Ma et al. reported higher levels of chemerin in the synovial fluid and synovial
membrane of knee OA patients compared to controls. Chemerin levels also correlated with serum
levels of CRP and OA severity [219,220]. Similar results were obtained in patients with OA of the
temporomandibular joint, with higher levels this adipokine in synovial fluid and correlation with OA
severity and pain [221]. A recent study in a rat OA model showed that chemerin aggravated the disease
by inducing activation of Akt/ERK signaling, and by increasing the expression of MMP-1, MMP-3, and
MMP-13 in IL-1β activated chondrocytes as well as by decreasing their proliferative capability [222].
In RA, chemerin plasma levels correlated with disease activity and BMI, which is a risk factor
in the pathology, arising as a biomarker of meta-inflammation [223]. In addition, the IL-6 inhibitor
tocilizumab has an anti-inflammatory and antithrombotic/fibrinolytic role and is able to decrease serum
chemerin levels in RA patients [74].
7.3. Lipocalin-2
LCN2 is an adipokine produced in joint tissues in response to both mechanical loading and
inflammatory mediators [218,224,225]. Specifically, LCN2 expression in chondrocytes is induced
by IL-1β, LPS, dexamethasone, adipokines (leptin and adiponectin) [218,226,227] and by osteoblast
conditioned medium [228], establishing also a feedback regulatory loop with the catabolic factor
nitric oxide [229]. In osteoblasts, the inflammatory molecules TNF-α and IL-17 [230] can induce
an upregulated expression of this adipokine, which is able to shift the balance between pro- and
anti-osteoclastogenic factors toward a more catabolic metabolism [227,231]. In this sense, a recent
study confirmed the catabolic effects of LCN2 in osteoblasts and chondrocytes from OA osteochondral
junctions, also showing that osteoblasts induced its expression in a paracrine manner [228].
Although there are data pointing to the involvement of LCN2 in the joint pathophysiology of
OA and RA, further studies are needed to elucidate its role in human development of such rheumatic
diseases. LCN2 concentration was found to be elevated in synovial fluid of patients with OA and
RA, with higher levels in RA [224,225,232]. In OA patients, elevated LCN2 levels in synovial fluid
and cartilage have been linked to cartilage matrix destruction given its ability to reduce chondrocyte
proliferation and to form a covalent complex with MMP-9 that blocks its auto-degradation [224,225,227].
However, studies in mice have shown that LCN2 overexpression in mouse cartilage is not enough
to induce OA pathogenesis, and that its absence has no consequences in the induction of cartilage
destruction in Lcn2-knockout mice [233]. Regarding RA patients, serum levels of this adipokine have
been reported to be an indicator for structural damage in early-stage RA, but not for monitoring disease
activity [234]. Likewise, induced LCN2 expression in neutrophils by the granulocyte macrophage
colony-stimulating factor has been linked with synovial cell proliferation and inflammatory cell
infiltration in RA synovium [225]. Of note, glucocorticoids (normally used to treat OA and RA)
have been described to induce the expression of LCN2 by mouse chondrocytes in synergy with IL-1,
suggesting that this adipokine may mediate some of the degradative effects on cartilage described
after prolonged treatment with such drugs [235].
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7.4. Vaspin
The adipokine vaspin belongs to a serine protease inhibitor family known to be associated with
insulin resistance as well as metabolic syndrome [236]. Also, a link between vaspin and artherosclerosis
and cardiovascular disease has been suggested [237]. Vaspin is expressed in several tissues including
subcutaneous adipose tissue, skin, stomach and skeletal muscle [238]. In OA patients undergoing joint
surgery, it was detected in cartilage, synovium and osteophytes [239]. In the same study, it was found
that vaspin serum levels exceeded synovial fluid levels in paired samples.
Studies investigating potential inflammation-related effects of this adipokine are not always in
agreement, which may be due to differences between the studied diseases including RA, OA, PsA,
juvenile idiopathic arthritis and ankylosing spondylitis. For example, vaspin has been shown to be
involved in skeletal muscle inflammation [238] and its serum levels were associated with inflammation
in RA [165,240] and with the development of clinically manifest RA after follow up (in contrast to other
adipokines) [241]. In an animal study, Transgenic mice overexpressing vaspin showed specific changes
in metabolism- and inflammation-related markers: Glucose tolerance was improved, the mice were
resistant to high-fat diet induced obesity and had lower systemic IL-6 levels [242]. Cellular effects for
this adipokine have also been observed, mainly in the context of metabolism. For example, vaspin has
been described to modulate adipocyte differentiation and glucose homeostasis [243]. In the context of
human coronary atheromatous plaques, the pro-inflammatory phenotype of human macrophages was
suppressed by vaspin [244].
Systemically, serum levels of vaspin were found to be higher in psoriatic arthritis (PsA) patients
compared to healthy controls [245], whereas levels were lower in OA patients compared to healthy
controls [239]. In synovial fluid, vaspin levels were significantly higher in RA compared to OA patients
with a tendency to correlate with DAS28 in the RA group [246]. However, an association of serum vaspin
with the inflammation markers CRP or ESR could not be identified in this study. Interestingly, inhibiting
inflammation in RA patients by short-term treatment with high-dose glucocorticoids increased vaspin
levels [165], suggesting an association with inflammation albeit probably not in a causal manner. On
the other hand, in juvenile idiopathic arthritis, vaspin level did not differ significantly compared
to healthy controls [247] and there was no association between disease activity and vaspin serum
levels [248]. Interestingly, in patients with ankylosing spondylitis low vaspin levels were related to
endothelial dysfunction [249].
However, vaspin also affected bone cells and chondrocytes in vitro: Human osteoblasts were
protected from apoptosis [250] and osteoclastogenesis was inhibited in the pre-osteoblast cell
line MC3T3-E1 [251], the murine macrophage cell line RAW264.7 and bone marrow-derived cells.
Furthermore, in the RAW264.7 cells, vaspin reduced the RANKL-induced expression of cathepsin K
and MMP-9 [252]. Vaspin was also able to inhibit the IL-1β [253] as well as the leptin [254] induced
production of catabolic and pro-inflammatory mediators in murine or rat chondrocytes, respectively.
These are potential pathomechanisms by which vaspin might contribute to certain arthritic diseases.
7.5. Omentin-1
Omentin was discovered as a secretory glycoprotein binding to galactofuranosyl residues on
microorganisms as well as a lactoferrin-binding protein. Its role in omental adipose tissue, hence
its name, was described in patients with Crohn’s disease. But omentin is also highly abundant in
plasma of healthy donors [255]. Most studies point towards omentin as an anti-inflammatory molecule.
For example, this adipokine showed anti-inflammatory and anti-atherogenic properties in obese
individuals [256] and a negative association with inflammatory bowel disease and metabolic syndrome
has been described [255,257,258].
As far as rheumatic diseases are concerned, the role of omentin is rather inconclusive. In serum,
omentin was found to be higher in juvenile idiopathic arthritis (JIA) [247] and PsA [248] patients
compared to healthy controls. Furthermore, serum levels were higher in JIA patients with active
synovitis in comparison to those without active joints [247]. On the other hand, in synovial fluid,
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omentin levels were found to be lower in chronic-inflammatory RA compared to OA [246]. For RA,
an association of omentin with the inflammation marker CRP at baseline has been reported [241].
The level of omentin-1 in synovial fluid of OA patients negatively correlated with self-reported pain
and physical disability (as measured by the WOMAC score) in OA patients [259], intended to reflect
symptomatic severity in OA. This is in line with the observed inverse correlation between synovial
fluid omentin-1 and radiographic severity as assessed by the Kellgren-Lawrence grading [260].
In synovial tissue, omentin was expressed in the synovial lining layer as well as perivascularly ;
however, no difference was detectable between RA and OA tissues [261]. In RA, omentin concentrations
were inversely associated with MMP-3 levels and influenced by different factors such as disease activity
but showed no association with endothelial activation and atherosclerosis in this study [262].
The knowledge regarding specific effects of omentin on different cell types in synovial tissue
and systemic inflammation is very limited. For example, the response of RA and OA SF towards
omentin was very low [67], suggesting that other effector cells may respond to omentin. Interestingly,
Calvet et al. observed a non-significant trend between adiponectin and omentin levels was observed
when other adipokines were included in the multivariate linear statistical model using the partial
correlation coefficient (PCC) for interpretation [143].
7.6. Nesfatin
Nesfatin-1 (nesfastin) is an N-terminal 82-amino-acid peptide nucleobindin-2-derived adipokine,
involved in satiety induction and energy homeostasis. Nesfatin was first described as an anorexigenic
molecule secreted by the hypothalamus [263] but it is also secreted by subcutaneous adipose tissue,
gastric mucosa, pancreatic cells, and testes [264].
Higher nesfatin levels have been detected in serum from OA patients compared to controls [265,266].
Moreover, nesfatin serum and synovial fluid concentrations have been associated with radiographic
severity in OA [266], where its levels also correlated with CRP and IL-18 in serum and synovial fluid,
respectively. In addition, nesfatin has been detected in human and murine chondrocytes, inducing
pro-inflammatory mediators such as COX-2, IL-8, IL-6, and CCL3 in chondrocytes from OA patients [95].
In contrast, recent studies also described this adipokine as an anti-inflammatory molecule [264,267]
able to reduce cardiovascular risk [268,269].
In relation to RA, a study demonstrated a positive association between nesfastin and rheumatoid
factor in RA patients. In addition, nesfatin concentration correlated with MMP-2, and reduced
atherosclerosis in these patients [179].
Akour et al.also described nesfatin activation by the endocrine growth factor FGF21 [270], which
has been described as a new adipokine related to BMI in RA patients [271]. Association between
FGF21 and rheumatic diseases would be of interest as FGF21 ameliorates CIA by regulating oxidative
stress and inflammatory response [272,273]. In addition, FGF21, also inhibits macrophage-mediated
inflammation [274] and down-regulates Th17-IL17 axis in CIA mice [275]. In relation to OA, FGF21
concentration in serum and synovial fluid is associated with radiographic knee bone loss [276].
8. Concluding Remarks
Common consequences of two of the most prevalent rheumatic diseases, OA and RA, are severe
long-term pain and loss of locomotor function, with the subsequent negative impact on health care
burden and social system. In order to reduce such socio-economic costs it is necessary to progress in
the diagnosis, treatment and in the identification of disease severity biomarkers which requires a more
detailed understanding of the diverse factors involved in the initiation and progression of these joint
diseases. While the complex etiology of OA and RA are still unclear, and despite the differences between
the pathophysiology underlying these joint degenerative diseases, it is now generally accepted that
they share similar inflammatory pathways that contribute to synovitis and the loss of balance between
cartilage and subchondral bone, leading to the progressive destruction of affected joints [6,8,31,45].
307
Int. J. Mol. Sci. 2019, 20, 4091
This review summarized the more relevant clinical and experimental lines of evidence for
the connection between classic and novel adipokines and the cellular and molecular pathogenic
characteristics of two of the most common rheumatic diseases, OA and RA. However, given the
pleiotropic action of these molecules and their immunomodulatory effects at both local and systemic
levels, the study of their role in the pathogenesis and progression of rheumatic diseases is very complex
and has generated conflicting results. In this sense, both pro- and anti-inflammatory effects have
been associated with the same adipokine, evidencing that their biological actions depend on the
inflammatory context and the disease conditions (Figure 1). Moreover, the correlation between the
levels of a particular adipokine in the synovial fluid and the activity/progression of a rheumatic disease
may disappear when circulating levels are considered. In fact, when it has been studied whether there
is an relationship between synovial and serum levels of adipokines with the development of arthritis
in autoantibody-positive individuals at risk of RA, only a significant association between serum levels
of vaspin and the disease development was found [241], thus evidencing the complexity of assessing
their potential as diagnostic biomarkers.
 
Figure 1. Graphical schematic representation of the role of classic and novel adipokines in two rheumatic
diseases: osteoarthritis (OA) and rheumatoid arthritis (RA). A variety of adipokines produced by
adipose tissue (blue line of arrows) as well as by chondrocytes, osteoclasts, osteoblasts, synoviocytes
and inflammatory cells (blue dashed line and blue line formed by arrows), contribute to multiple
pathological mechanisms (solid arrows) involved in the development of OA and RA. Although there are
differences between the pathogenesis of OA and RA, common mechanisms have also been identified that
affect cartilage extracellular matrix (ECM) integrity, dysregulation of bone metabolism, the pathogenic
phenotype of synovial fibroblasts and macrophages, modulation of the immune system and synovial
angiogenesis. Depending on the context, both pro- and anti-inflammatory effects have been associated
with some adipokines, such as visfatin and resistin. Adipokines with a dominant pro-inflammatory
role in arthritis are shown with a light red background, whereas those in which an anti-inflammatory
action predominates are shown with a green background.
308
Int. J. Mol. Sci. 2019, 20, 4091
All in all, it is worthy to note that the contribution of adipokines to the pathogenesis of rheumatic
diseases should be understood as cross-talking networks that coordinate with other molecular mediators
to orchestrate the activity of effector cells involved in OA and RA. In this regard, activated resident
cells in joints affected by these rheumatic diseases are probably the main contributors to the increased
levels of adipokines detected in synovium, consequently suggesting that antagonizing local specific
adipokines may be a viable option for the development of new therapeutic strategies. However, further
research is needed to determine the exact contribution of the adipokine network to rheumatic disorders,
which would also help to identify which adipokine could be considered a potential diagnostic and/or
prognostic biomarker for OA and RA.
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LEPR Leptin receptor
NK Natur killer
Th2 Type 2 T helper cells
Treg T regulatory cells
SNP Single nucleotide polymorphism
ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs
NOS2 Type 2 nitric oxide synthase
TGF-β Transforming growth factor β
CCL3 Chemokine ligand 3
VCAM-1 Vascular cell adhesion molecule-1
COX-2 Catabolic cyclooxygenase-2
miRNA MicroRNA
MCP-1 Monocyte chemoattractant protein-1
CPR C-reactive protein
PBMC Peripheral blood mononuclear cells
VEGF Vascular endothelial growth factor
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PBEF Pre-B-cell colony-enhancing factor
Nampt Nicotinamide phosphoribosyl-transferase
HIF-2α Hypoxia-inducible factor 2alpha
IGF-1 Insulin-like growth factor-1
PGRN Progranulin
TNFR TNF-α receptors
PGRN-abs Antibodies against Progranulin
CMKLR1 Chemokine-like receptor 1
LCN2 Lipocalin-2
PsA Psoriatic arthritis
JIA Juvenile idiopathic arthritis
WOMAC Western Ontario and McMaster Universities Arthritis Index
PCC Partial correlation coefficient
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Abstract: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease.
Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody
used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA
patients. Height, weight, disease activity scores, lipid profile and atherogenic indices (AI), leptin,
adiponectin, resistin, interleukin-6, and high-sensitivity C-reactive protein (CRP) were measured
before and four months after initiation of TCZ in 40 RA patients and 40 healthy controls. Following
TCZ treatment, total cholesterol, high density lipoprotein (HDL), and triglycerides were significantly
elevated, but no significant changes in weight, body mass index (BMI), low density lipoprotein (LDL),
and AI were observed. Compared with controls, significantly higher adiponectin levels were measured
in the RA group at baseline. Following TCZ treatment, resistin levels and the leptin-to-adiponectin
ratio increased, adiponectin levels decreased, and leptin levels remained unchanged. No correlation
was found between the change in adipokine serum levels and changes in the disease activity indices,
nor the lipid profile. In conclusion, the changes observed suggest a protective role for TCZ on
the metabolic and cardiovascular burden associated with RA, but does not provide a mechanistic
explanation for this phenomenon.
Keywords: rheumatoid arthritis; tocilizumab; lipids; adipokines; adiponectin; resistin; leptin
1. Introduction
Rheumatoid arthritis (RA), a chronic inflammatory disease with typical bone erosion and damage,
is also associated with an increased incidence of metabolic syndrome and cardiovascular disease
(CVD). Although CVD risk factors such as obesity, smoking, hypertension, and diabetes are also
increased in RA patients, systemic inflammation caused by RA itself seems to contribute to CVD
risk in these patients. Chronic low-grade inflammation—often assessed by C-reactive protein (CRP),
an acute phase reaction protein—is associated with accelerated atherosclerosis, increased CVD risk,
and increased mortality [1]. Hence, it is suggested that successful treatment of RA patients so as to
reduce the inflammatory burden may decrease CVD risk [2–4]. This has already been shown for the
administration of tumor necrosis factor-alpha (TNF-α) inhibitors [5].
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Adipokines, cytokines secreted mostly by white adipose tissue, are involved in inflammation,
endothelial dysfunction, and atherosclerosis, placing them as possible molecular links between RA,
the metabolic syndrome, and CVD risk [2,6–8]. However, their putative role as key inflammatory
mediators contributing to CVD risk is still controversial, as their serum levels vary. For instance,
the pro-inflammatory adipokine leptin has been shown to variably exhibit either elevated or similar
serum levels in RA patients relative to healthy controls, while resistin, another pro-inflammatory
adipokine, has been shown to have either elevated, similar, or reduced levels relative to healthy controls.
Surprisingly, the serum and synovial fluid level of the anti-inflammatory adipokine adiponectin was
found to be consistently elevated in RA patients [3,4,6,7,9–13]. Notably, the levels of these three
major adipokines—leptin, resistin, and adiponectin—were shown to correlate with insulin resistance.
The leptin-to-adiponectin ratio (LAR) is used to assess insulin resistance among type-2 diabetes mellitus
patients and healthy individuals [14–18], while resistin levels were found to correlate with insulin
resistance in septic patients [6].
Tocilizumab (TCZ), a human monoclonal antibody that targets the interleukin-6 (IL-6) receptor,
is a novel biologic disease-modifying anti-rheumatic drug (bDMARD) effective in treating RA
in humans [19]. TCZ has been shown to worsen dyslipidemia, a significant adverse metabolic effect
that was attributed to the blockage of IL-6 and its ability to induce the expression of apolipoproteins
in the liver [20]. However, despite that dyslipidemia is known to be associated with TCZ treatment,
this biologic agent was not found to increase CVD risk in RA patients [21]. We hypothesized that TCZ
might affect adipokine levels, thus exerting a cardioprotective role in RA patients.
Our aim in the present study was to evaluate the effects of TCZ treatment on serum lipid and
adipokine levels in RA patients compared with healthy controls, and to evaluate whether any changes
in adipokine profile mediated by TCZ are cardioprotective.
2. Results
2.1. Patient Characteristics
The average age of the 40 patients in the RA group was 57.5 years, and 82.5% were women,
with a mean disease duration of 7.7 ± 5.6 years. All participants completed the four month follow-up.
Their demographic and clinical characteristics are summarized by disease activity class (DAS28-CRP
score) at baseline (Table 1).
Table 1. Patients demographic and clinical characteristics according to disease activity at baseline
(disease activity score-28 joint count (DAS28)-C-reactive protein (CRP)).
Characteristic
Moderate Disease Activity
(DAS ≤ 5.1) (n = 15)
High Disease Activity
(DAS > 5.1) (n = 25)
Total
(n = 40) p Value
Age (years) 60 ± 14.96 56.04 ± 7.90 57.53 ± 11.07 NS
Gender (% female) 13 (86.7%) 20 (80%) 33 (82.5%) NS
RF positive (%) 8 (53.3%) 13 (54.2%) 21 (53.8%) NS
Anti-CCP positive (N) (%) 6 (10) (60.0%) 6 (13) (46.2%) 12/23 (52.2%) NS
Disease duration (years) 6.46 ± 5.71 8.44 ± 5.52 7.7 ± 5.6 NS
Concomitant Diseases
Ischemic heart disease (%) 1 (6.7%) 0 (0.0%) 1 (2.5%) NS
Diabetes mellitus (%) 3 (20.0%) 5 (20.0%) 8 (20.0%) NS
Hypertension (%) 5 (33.3%) 7 (28%) 12 (30%) NS
Chronic obstructive lung
disease (%) 1 (6.7%) 0 (0%) 1 (2.5%) NS
Dyslipidemia (%) 6 (40.0%) 13 (52.0%) 19 (47.5%) NS
Prior malignancy (%) 1 (6.7%) 0 (0.0%) 1 (2.5%) NS
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(DAS ≤ 5.1) (n = 15)
High Disease Activity
(DAS > 5.1) (n = 25)
Total
(n = 40) p Value
Therapy at Baseline
Methotrexate 8 (53.3%) 19 (76.0%) 27 (67.5%) NS
Sulfasalazine 1 (6.7%) 4 (16.0%) 5 (12.5%) NS
Hydroxycholoroquine 1 (6.7%) 3 (12.0%) 4 (10.0%) NS
Leflunomide 0 (0.0%) 3 (12.0%) 3 (7.5%) NS
Corticosteroid dose
in milligrams (mean + SD) 3 ± 5.92 7.2 ± 10.52 5.63 ± 9.22 NS
Statin use 6 (40%) 15 (56%) 20 (50%) NS
Anti-diabetic therapy 3 (20.0%) 5 (20.0%) 8 (20.0%) NS
* anti-CCP = anti-cyclic citrullinated peptide, (N) = number, NS = not significant, RF = rheumatoid factor, SD =
standard deviation.
There were no significant differences between the groups with respect to demographics, clinical
parameters, comorbidities, and medical regimen.
The majority of the patients responded clinically to TCZ after four months of treatment (Table 2) with
a reduction in disease activity as assessed by CDAI (25 patients, 62.5%) or DAS28-CRP (22 patients, 55%).







Inflammation Scores and Markers
DAS28-CRP score 5.45 ± 1.06 3.46 ± 1.37 <0.0001
CDAI score 36.59 ± 12.48 20.0 ± 12.56 <0.0001
28-tender joint count 12.48 ± 6.47 5.93 ± 5.21 <0.0001
28-swollen joint count 9.25 ± 5.39 4.06 ± 4.18 <0.0001
Patient global assessment of disease activity (0–100 mm) 76.45 ± 19.15 56.78 ± 23.18 <0.0001
Provider global assessment of disease activity (0–100 mm) 72.1 ± 15.5 44.1 ± 26.1 <0.0001
CRP (mg/dL) 1.33 ± 1.8 0.13 ± 0.42 <0.0001
hsCRP (mg/dL) 3.37 ± 2.0 0.74 ± 1.36 <0.001
IL-6 (pg/mL) 28.4 ± 94.42 69.28 ± 109.05 <0.001
Anthropometric Measurements
Weight (kg) 74.5 ± 17.52 75.31 ± 16.91 NS*
BMI (kg/m2) 27.77 ± 6.6 27.96 ± 6.45 NS
Lipid Profile and Atherogenic Indices
Total cholesterol (mg/dl) 199.4 ± 52.71 220.83 ± 53.39 0.003
LDL (mg/dl) 123.67 ± 36.87 131.38 ± 36.95 NS
HDL (mg/dl) 54.53 ± 19.0 59.0 ± 23.27 0.039
TG (mg/dl) 139.56 ± 68.53 167.67 ± 106.93 0.04
AI (HDL/cholesterol) 3.79 ± 0.78 3.96 ± 1.13 NS
AI of plasma [log(TG/HDL)] 0.93 ± 0.09 0.95 ± 0.11 NS
RA Therapy
Prednisone (Mean ± SD) 5.63 ± 9.21 5.13 ± 8.28 NS
Methotrexate (%) 27 (67.5%) 25 (62.5%) NS
Sulfasalazine (%) 5 (12.5%) 1 (2.5%) NS
Hydroxychloroquine (%) 4 (10%) 3 (7.5%) NS
Leflunomide (%) 3 (7.5%) 1 (2.5%) NS
AI = atherogenic index, BMI = body mass index, CDAI = clinical disease activity index, CRP = C-reactive protein,
hsCRP = high sensitivity CRP, DAS28-CRP = disease activity score-28 joint count, HDL = high density lipoproteins,
IL-6 = interleukin-6, LDL = low density lipoproteins, SD = standard deviation, TG = triglycerides. * not significant.
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Following four months of treatment, 27.5% and 15% of the patients achieved low disease activity
or remission by CDAI and DAS28-CRP criteria, respectively. There were no significant changes
in concomitant medications including doses of corticosteroids, statins, or other disease modifying
agents (DMARDs) during the four months of follow-up.
The effects of TCZ treatment on serum samples are summarized in Table 2. Following four months
of treatment, CRP and hsCRP levels decreased significantly, while IL-6 levels increased significantly,
demonstrating the predictable pharmacological effect of TCZ.
2.2. TCZ Effects on Metabolic Parameters
Upon recruitment, 25 RA patients were overweight (BMI > 25) and 11 were obese (BMI > 30).
There were no significant changes in weight or BMI following four months of treatment. Total
cholesterol, HDL, and TG levels increased significantly following treatment, with the increase in LDL
not reaching statistical significance. Of note, three patients had incalculable LDL levels owing to
hypertriglyceridemia. Atherogenic indices did not change significantly following treatment (Table 2).
2.3. TCZ Effects on Adipokine Levels
Before TCZ treatment, adiponectin levels adjusted to BMI and statin treatment were higher in RA
patients compared with healthy controls (p < 0.0001), whereas LAR was decreased (p = 0.03) (Table 3).
TCZ treatment normalized the adiponectin and resistin levels, which decreased to the levels observed
in the healthy control group. Only leptin levels continued to increase after four months of treatment.
Table 3. Serum adipokine levels in healthy controls compared with RA patients before and after four



















Mean (± SD) 3.75 ± 1.63 5.59 ± 2.39 4.53 ± 2.12
<0.0001 0.17 0.0001Median 3.56 5.33 4.44
Leptin (pg/mL)
Mean (± SD) 21.92 ± 21.63 25.15 ± 26.36 29.36 ± 30.25
0.84 0.92 0.125Median 15.05 19.38 15.95
Resistin (pg/mL)
Mean (± SD) 21.53 ± 8.19 16.25 ± 7.17 20.42 ± 8.06
0.63 0.63 0.001Median 20.24 14.73 19.91
Leptin/
Adiponectin ratio
Mean (± SD) 6.44 ± 6.44 5.52 ± 6.08 7.99 ± 7.84
0.03 0.59 0.002Median 4.36 3.93 4.90
SD = standard deviation; * p value adjusted to BMI and statin; ** p value adjusted to BMI, statin treatment,
and disease duration.
Following four months of TCZ treatment, significant changes in the levels of adiponectin, resistin,
and LAR were noted after adjustment to BMI, statin treatment, and disease duration. Adiponectin
levels decreased (p ≤ 0.0001), whereas resistin and LAR increased. The adipokine profile following
four months of TCZ treatment trended to the levels measured in the control group, and no statistically
significant differences were found between the patient group after treatment and controls in the three
adipokine levels or the LAR measured in the study (Table 3).
The changes in the serum levels of the three adipokines prior to starting TCZ treatment and after
four months of treatment did not correlate with the changes in the clinical and metabolic parameters
that are associated with the risk of CVD (Table 4). The only significant correlation we found was
a positive correlation between the changes in HDL values and levels of leptin.
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Table 4. Correlation between the changes in adipokine levels and clinical and biochemical parameters
of RA reflecting cardiovascular disease (CVD) risk and disease activity, before and after four months of
TCZ treatment.
ΔDAS28 ΔCDAI ΔhsCRP ΔHDL ΔLDL ΔTG ΔCholesterol ΔAI ΔAI-Plasma
ΔAdiponectin
r 0.026 0.020 −0.045 0.160 0.162 −0.005 0.257 0.106 −0.085
p 0.875 0.902 0.782 0.365 0.393 0.979 0.135 0.549 0.633
ΔLeptin
r 0.186 0.025 −0.009 0.390 0.208 −0.008 0.200 −0.196 −0.217
p 0.250 0.879 0.957 0.023 0.270 0.964 0.248 0.267 0.218
ΔLAR
r −0.026 −0.078 −0.041 0.177 0.157 0.013 0.000 −0.194 −0.121
p 0.876 0.631 0.803 0.318 0.408 0.938 1.000 0.273 0.494
ΔResistin
r 0.068 0.096 −0.058 0.009 0.240 −0.086 0.165 0.097 −0.008
p 0.679 0.555 0.722 0.961 0.201 0.619 0.345 0.586 0.963
AI = atherogenic index, CDAI = clinical disease activity index, hsCRP = high sensitive CRP, DAS28-CRP = disease
activity score-28 joint count, HDL = high density lipoproteins, LDL = low density lipoproteins, SD = standard
deviation, TG = triglycerides. r = Pearson’s correlation coefficient, p = significance value.
There were no statistically significant differences in the adipokine levels when patients were
stratified into responders and non-responders according to DAS28-CRP or CDAI score response after
adjustment to BMI, statin treatment, and disease duration.
3. Discussion
In this study, we show that TCZ treatment improves disease activity and reduces the inflammatory
burden in RA patients, as has been shown before. As expected, disease activity scores were significantly
reduced with TCZ treatment, as were the values of hsCRP, a measure considered to reflect vascular
inflammation and that serves as a predictor of cardiovascular events [1]. However, this improvement
in disease activity was accompanied by increased dyslipidemia, as previously reported for TCZ.
Therefore, we asked whether adipokines, which are the hypothesized link between inflammation and
increased CVD risk, were responsible for this effect. Contrary to this hypothesis, we show that there is
no correlation between changes in adipokine serum levels as a result of TCZ treatment and changes
in the disease activity or lipid profile, indicating that the adipokines we examined do not directly
regulate these parameters in our cohort.
Our RA study population was more overweight and obese (60% and 27.5%, respectively) than
the general population in Israel (49% and 16%, respectively, in 2012) [22], and the four months of
treatment with TCZ did not affect their BMI. The increased prevalence of obesity among our RA
patients may be explained by the metabolic impact of the inflammatory state, which limits physical
activity, as well as by prolonged corticosteroid treatment. However, the effects of TCZ on obesity
are still controversial. Similar to our study, other studies found no significant change in weight or
BMI in TCZ-treated non-diabetic RA patients over a period of three [23] or six months [24], or when
patients were stratified to responders versus non-responders according to the DAS28-CRP criteria [25].
In contrast, Younis et al. demonstrated a significant rise in weight and BMI in TCZ-treated RA patients
over a period of four months [26]. As TCZ blocks IL-6 signaling and leads to its elevated serum levels,
as we demonstrated here, the metabolic effects of increased IL-6 should be taken into consideration.
Elevated IL-6 levels in cancer patients are associated with cachexia, and IL-6 inhibitors have been
suggested as possible treatment adjuncts in cancer patients in order to prevent this catabolic effect [27].
In line with the documented ability of TCZ to induce dyslipidemia, we observed significantly
elevated levels of total cholesterol, HDL, and TG, as well as a rise in LDL that did not reach statistical
significance in our RA patients following four months of TCZ treatment. While the elevated lipid profile
raises concerns about its potential to increase CVD risk in RA patients, we did not detect changes in the
two atherogenic indices we evaluated. Notably, atherogenic indices fluctuate less among RA patients
and are considered more reliable in the assessment of CVD risk in these patients [28,29]. This finding is
consistent with previous studies reporting elevation in the lipid profile with no change in atherogenic
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indices following TCZ treatment [23,28,30,31]. Moreover, the increase in HDL, which is considered
to have a cardioprotective role in the general healthy population, could potentially mitigate this
concern. The reported increase in RA patients of HDL particles, which might possess anti-inflammatory
and athero-protective properties, indicates that the effects of TCZ on CVD risk are complex and
still unclear [32].
Adipokines, and particularly leptin, are important mediators of the pathophysiology of RA and
its comorbidities [10,12,33]. Xibillé-Friedmann et al. found that leptin, but not adiponectin, levels
predict disease activity and response to conventional DMARD treatment in RA patients [34]. Indeed,
many studies have shown elevated serum levels of adiponectin, leptin, and resistin in RA patients
relative to healthy controls [3,4,6,7,9–13]. However, the literature is inconsistent regarding the effects
of TCZ treatment on serum levels of adipokines in RA patients. We found that adiponectin levels
decreased following therapy, while resistin levels and LAR increased following therapy. In contrast,
Fioravanti et al. showed that after six months of TCZ treatment, resistin and leptin serum levels were not
significantly changed, but the adiponectin level was increased [24]. Tournadre et al. showed no change
in resistin and adiponectin levels, but a reduction in leptin serum levels [35]. Schultz et al. demonstrated
that after three months of treatment, TCZ increased adiponectin levels, but did not change leptin levels,
leading to a reduction in LAR [23]. In comparison, other treatments, such as infliximab (anti-TNFα),
were found to decrease resistin levels [36], or did not have any effect on leptin and adiponectin levels
in patients with RA [37,38]. Thus, the effects of TCZ are not straightforward, and may depend on
additional, yet unknown factors.
Most of the above noted studies only compared the adipokine levels in RA patients before and
after TCZ treatment. Therefore, it is noteworthy that we show here that in comparison with healthy
controls, TCZ treatment normalized adipokine levels. The ability of TCZ to normalize adiponectin
and resistin levels and to bring them closer to levels found in the healthy control group demonstrates
a positive effect of TCZ on metabolism, in addition to its anti-inflammatory properties, and may hint at
a putative cardioprotective role of this biologic agent. However, the increase in LAR and resistin levels,
which have been shown to have pro-atherogenic and insulin resistant effects [5,14,17], cast doubt on
this supposition.
Possible explanations for the differences between our study results and those of other studies
include small sample sizes, demographic differences such as age and race, differences in disease
duration, and treatment. BMI differences between study populations in the different studies may
also be significant because BMI directly impacts leptin levels [6,10,23,34]. Of note, there were no
significant changes in conventional DMARDs or prednisone dose in our RA patients throughout the
study, suggesting that these medications were not confounding factors in our assessments.
Finally, we show that the change in the adipokine levels did not correlate with most of the known
biochemical parameters that are associated with increased CVD risk or with RA disease activity.
The only exception was the positive correlation found between the changes in HDL and leptin levels.
HDL levels were previously found to negatively correlate with leptin and positively correlate with
adiponectin in a healthy cohort, suggesting a link between leptin, insulin resistance, and the metabolic
syndrome, as well as a cardioprotective role for adiponectin [39]. However, such a link would imply
that other CVD risk factors, such as LDL, total cholesterol, or TG levels, should also correlate with
leptin levels, which was not found in our study. Therefore, it is likely that the positive correlation
between HDL and leptin levels that we observed is not representative, probably resulting from the
small patient cohort. In contrast, the lack of correlation between adipokine levels with other parameters
of CVD risk that we observed is similar to a previous study [24]. Taken together, our findings do
not support a direct link between the adipokines leptin, resistin, and adiponectin and the reduction
in CVD risk observed following initiation of TCZ treatment in RA patients, and may suggest that other
adipokines or cytokines may play a greater role in mediating this effect, as was recently suggested [24],
or that other mechanisms play a cardioprotective role in RA patients treated with this biologic agent.
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Our results should be viewed with certain limitations, specifically the short follow-up period
of four months and the relatively small sample size. Our study analyzed serum levels of only a few
selected adipokines, and other adipokines could be included in a larger study. Because of the variation
between serum and synovial fluid concentrations of various pro-inflammatory and anti-inflammatory
mediators in RA patients [40], future studies should also include a comparison between serum and
synovial fluid adipokine levels.
In conclusion, the impact of TCZ treatment on the metabolic profile of RA patients is complex.
When taking all the changes recorded in our patients’ lipid and adipokine profiles into consideration,
the following findings should be highlighted: the rise in HDL, the lack of worsening in atherogenic
indices, and the normalization of adiponectin and resistin levels in TCZ responders in comparison with
healthy controls. These changes suggest a protective role for TCZ on the metabolic and cardiovascular
burden associated with RA, but still do not provide a mechanistic explanation for this phenomenon.
4. Methods
4.1. Study Population
Forty RA patients with active disease who were suitable candidates for TCZ treatment were
recruited from rheumatology clinics in two medical centers in Israel. All patients met the 2010 American
College of Rheumatology/European League Against Rheumatism (ACR/EULAR) RA criteria [41].
Patients were treated with 8 mg/kg TCZ infusions every four weeks. All other medical decisions
were at the treating physicians’ discretion. Patients with diagnosis of another inflammatory arthritis
or neoplastic disease were excluded. Parameters collected at baseline and after four months of
TCZ treatment included demographic data, height, weight, calculated body mass index (BMI)
(weight/height2), patient comorbidities with emphasis on CVD risk factors, current medications,
and physical examination data with a focus on swollen and tender joint counts.
Laboratory variables studied included complete blood count and chemistry panel, lipid panel,
CRP, and rheumatoid factor (RF), all analyzed by standard methods in a central laboratory. Total
cholesterol, high density lipoprotein (HDL), and triglyceride (TG) levels were used to calculate the
atherogenic index (AI, total cholesterol/HDL) and the AI of plasma (the base 10 logarithm of TG/HDL).
Blood samples were obtained for the analysis of adipokines (leptin, adiponectin, and resistin), as well
as for measurement of IL-6 levels and high sensitivity CRP (hsCRP). Leptin and adiponectin levels
were used to calculate the LAR.
The control group of 40 volunteers without inflammatory diseases, renal failure, CVD or
malignancies was age-and gender-matched with the RA group. Blood samples from this group
were drawn at recruitment and tested for leptin, adiponectin, resistin, LAR, IL-6, and hsCRP levels.
The study protocol was approved by the local institutional review boards of the participating
medical centers, and informed consent was obtained from all participants at recruitment (approval
number at Carmel Medical Center CMC-0018-11 on 23 March 2011; approval number at Bnei Zion
Medical Center BNZ043-11 on 27 July 2011).
4.2. Assessment of Clinical Response
Clinical response was assessed using the disease activity score-28 joint count (DAS28-CRP) and
clinical disease activity index (CDAI) scores. Patients were categorized as responders by DAS28-CRP
if their score was reduced by more than 1.2 points (ΔDAS28-CRP ≥ 1.2), and their total DAS28-CRP
score was <5.1 following four months of treatment; this represents moderate-to-large response to
therapy according to the EULAR response criteria [42]. Patients were categorized as responders by
CDAI if they demonstrated a reduction of at least one disease activity class after four months of
treatment (i.e., from high disease activity (CDAI > 22) to moderate disease activity (CDAI 10–22) or
from moderate disease activity to low disease activity or remission (CDAI < 10) [43,44].
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4.3. Biochemical Analysis
Blood samples were drawn at baseline and after completing four months of TCZ therapy,
immediately centrifuged at 1200 rpm, and stored at −80 ◦C until analysis. Serum concentrations of
leptin, adiponectin, resistin, and IL-6 were determined using DuoSet enzyme-linked immunosorbent
assay (ELISA) kits (R&D systems, Minneapolis, MN, USA), and hsCRP concentrations were determined
using the hsCRP enzyme-linked immunosorbent assay (ELISA) kit (AssayPRO, St. Charles, MO, USA),
according to manufacturer’s instructions.
4.4. Statistical Analysis
Continuous data are presented as mean ± standard deviation (SD) and median; categorical
variables as numbers and percentages. The changes in the DAS28-CRP and CDAI scores, total
cholesterol, HDL, TG, weight, and BMI levels between baseline and follow-up visits in RA patients
were analyzed by paired t-test.
ANCOVA models adjusted to baseline BMI and statin treatment were used to compare the
log-transformed adipokine concentrations in the RA and control groups. Mann–Whitney test was
used to compare serum concentrations of IL-6 and hsCRP between the two groups, as appropriate.
Correlation between the changes in adipokine levels and clinical and biochemical parameters of RA
reflecting CVD risk before and after four months of TCZ treatment was calculated using Pearson’s
correlation coefficient. The changes in adipokine serum concentrations in the RA group between
baseline (before treatment) and follow-up time, four months after TCZ treatment, adjusted to BMI,
statin treatment, and RA disease duration, were analyzed by linear mixed models with repeated
measures. All tests were two-sided and p values of <0.05 were considered statistically significant.
All statistical analyses were done using SPSS, version 24.0 (IBP Corp. Released 2016, IBM SPSS Statistics
for Windows, version 24.0. Armonk, NY, USA: IBM Corp).
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Abstract: Sepsis represents a major global health burden. Early diagnosis of sepsis as well as guiding
early therapeutic decisions in septic patients still represent major clinical challenges. In this context,
a whole plethora of different clinical and serum-based markers have been tested regarding their
potential for early detection of sepsis and their ability to stratify patients according to their probability
to survive critical illness and sepsis. Adipokines represent a fast-growing class of proteins that
have gained an increasing interest with respect to their potential to modulate immune responses
in inflammatory and infectious diseases. We review current knowledge on the role of different
adipokines in diagnostic work-up and risk stratification of sepsis as well as critical illness. We discuss
recent data from animal models as well as from clinical studies and finally highlight the limitations of
these analyses that currently prevent the use of adipokines as biomarkers in daily practice.
Keywords: critical illness; sepsis; adipokines; biomarker; prognosis; ICU
1. Introduction
1.1. Critical Illness and Sepsis
Sepsis has recently been defined as “life-threatening organ dysfunction caused by a dysregulated
host response to infection” [1–3]. In the United States, up to two percent of patients admitted to hospital
suffer from sepsis. Half of these patients need treatment in an intensive care unit (ICU), representing
10% of all admissions [4]. Sepsis is still the leading cause of death among ICU patients. Between
28.3% and 41% of all sepsis patients will not survive their acute illness, with multi-organ failure being
the most important cause of death [5]. In addition, survivors often show severe prolonged physical,
neurological, and psychological limitations. Notably, the severity of sepsis correlates with the extent of
post-sepsis disabilities in surviving patients [6], highlighting the need for early diagnosis and early
treatment of this disease.
1.2. Biomarkers for Critical Illness and Sepsis
Adapting the diagnostic and therapeutic management to the personalized characteristics and
needs of each individual patient represents one of the main challenges of precision medicine in the 21st
century. In the last decade, many different treatment approaches were approved based on specific
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genetic characteristics such as anti-EGFR directed therapies in patients with RAS wild-type colorectal
cancer [7]. Thus, providing individualized or personalized medicine requires the availability of specific
“biomarkers” that allow stratification of patients into different subgroups [8]. The National Institutes
of Health (NIH) define a biomarker as “any substance, structure, or process that can be measured
in the body or its products and influence or predict the incidence or outcome of disease” or, more
broadly, as “almost any measurement reflecting an interaction between a biological system and a
potential hazard, which may be chemical, physical, or biological. The measured response may be
functional and physiological, biochemical at the cellular level, or a molecular interaction” (reviewed
in the work of [9]). Because, in recent years, manifold specific sepsis therapies have failed, current
effective treatment strategies consist of detecting sepsis as early as possible, fluid resuscitation, and
anti-infective treatments [1]. Especially easily accessible biomarkers, for example, from patients’ serum,
might provide an important tool in the diagnostic process of sepsis at an early stage, to detect subgroups
of patients with a high-risk profile and to monitor disease progression [10]. At present, microbiological
cultures are widely accepted as the gold standard for diagnosis of septic disease [11]. However, in
most cases, the results from microbiological cultures are only available days after sample collection
and are associated with high rates of false negative results, leading to an ongoing search for other
markers that might serve as surrogate for the presence of sepsis [12]. The C-reactive protein (CRP) has
been identified as an inexpensive, but sensitive surrogate for infection and inflammation [13]. Named
for its ability to bind the C-polysaccharide of Streptococcus pneumoniae, it represents an acute-phase
protein that is secreted by hepatocytes in response to infection, inflammation, and tissue damage [13].
However, to distinguish between sepsis and non-infectious disease etiology, CRP lacks specificity, and
elevated CRP serum levels are also common in patients with inflammatory (but not infectious) diseases
states such as cancer, thromboembolic- or cardiovascular diseases, and burns [13]. Moreover, owing to
the hepatic provenience of CRP, in the case of severe liver failure, CRP levels may be falsely low and
may rather reflect the degree of hepatic dysfunction than sepsis or inflammation [14], limiting its use in
clinical routine. Besides CRP, procalcitonin (PCT) was more recently established in clinical routine to
identify patients with septic disease. PCT represents a precursor-hormone of calcitonin. It is produced
by various organs and, in healthy individuals, the liver is considered to be the most important source
of PCT [15]. During infection, PCT is secreted by cytokine-activated macrophages as well as by the
parenchyma of many organs, leading to a dramatic increase in circulating PCT levels [15]. Despite
that different guidelines recommend the use of PCT to distinguish between sepsis and non-septic
cause of disease in critically ill patients, recent meta-analyses have demonstrated that the use of PCT
for guidance of therapy had no influence on further therapeutic procedures for ICU patients [11,16].
Moreover, the use of PCT is further hampered by the lack of a clear cut-off defining sepsis in patients
with critical illness [17].
In addition to CRP and PCT, interleukin-6 (IL-6) has been suggested as a biomarker in the context
of critical illness and sepsis. IL-6 represent the most potent inducer for the secretion of acute phase
proteins in the liver. IL-6 serum concentrations were elevated in the blood of patients with septic
disease and IL-6 concentrations were associated with the severity of sepsis. Moreover, patients with
elevated IL-6 levels demonstrated an impaired prognosis compared with patients with lower levels [18].
However, similar to CRP and PCT, IL-6 concentrations were also elevated in non-septic disease states,
limiting its specificity for the assessment of sepsis in patients with critical illness [19]. Therefore, owing
to a lack in specificity and sensitivity of available markers for critical illness and sepsis, innovative
biomarkers reflecting novel pathophysiological concepts are eagerly awaited to improve the outcome
of patients treated on medical ICU. In this context, adipokines might represent biological plausible
markers for diagnosis of sepsis and prognosis estimation in critically ill patients, because many
processes that are regulated by or reflected by adipokines are involved in the pathophysiology of
critical illness and sepsis. As an example, hyperglycemia, impaired glucose tolerance, and insulin
resistance are commonly observed in critically ill patients with sepsis or septic shock and have been
correlated with an impaired prognosis of these patients [20]. On the basis of these recent findings, many
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authors have measured serum concentrations of different adipokines in serum and plasma of critically
ill patients with or without sepsis. Here, we review these previous data on the role of adipokines in
diagnostic work-up and risk stratification of sepsis as well as critical illness.
2. Adipokines
Until recently, the adipose tissue was only considered an energy storage organ, but many
novel studies have demonstrated that it is deeply integrated into different physiological and
pathophysiological regulatory processes including the regulation of diseases associated with systemic
inflammatory responses [21]. In this context, it became obvious that the adipose tissue is able to secrete
different factors that are collectively referred to as adipokines [22]. In obese patients, the secretory
profiles of adipose tissue are decisively altered dependent on the degree of overweight. Secretion of
almost all known adipokines is upregulated in patients with obesity, promoting systemic inflammation
and the development of metabolic diseases. In detail, next to leptin, TNF, and IL-6, elevated levels
of a broad panel of other proinflammatory adipokines (resistin, retinol-binding protein 4 (RBP4),
lipocalin 2, IL-18, angiopoietin-like protein 2 (ANGPTL2), monocyte chemoattractant protein 1 (MCP1),
CXC-chemokine ligand 5 (CXCL5), nicotinamide phosphoribosyltransferase (NAmPT)) were found to
be upregulated in obese patients (reviewed in the work of [21]). In contrast, adiponectin expression
was shown to be lower in adipocytes of obese patients. In line, data from animal models revealed
that adiponectin is protective against metabolic and cardiovascular diseases that might develop in the
context of obesity. Thus, it seems likely that the inflammatory response and metabolic dysfunction
occurring in patients with obesity represent the consequence of a disturbed balance in the secretion of
pro- and anti-inflammatory adipokines.
The concept of adipokines as regulators of body homeostasis and responders to injurious threats
might be of tremendous relevance for understanding the pathophysiology of critical illness and sepsis.
Moreover, concentrations of adipokines can be easily determined in clinical routine, and different
authors have suggested using adipokines as biomarkers in treated ICU patients. Within this review,
we aim at summarizing available data on the most relevant adipokines in critical illness and sepsis and
discuss limitations of the present analyses that have prevented the use of adipokine measurements in
clinical routine until now.
3. Selected Adipokines with a Potential Role in Critical Illness and Sepsis
The following section will give an overview of the most relevant adipokines in the context of
critical illness as sepsis. Table 1 summarizes the most significant findings with respect to adipokine
regulation in critically ill patients.
3.1. Omentin
Omentin represents a relatively new member of the adipokine family and is mainly secreted by the
visceral adipose tissue [23]. Experimental data support a decisive role of omentin in the inflammatory
crosstalk. As such, it negatively influences a TNFa dependent activation of well-known inflammatory
signaling pathways such as p38 or JNK. Clinical data further suggest aberrant omentin serum levels in
patients with obesity, inflammatory bowel disease, diabetes mellitus, or coronary heart disease [24,25].
In patients with critical illness and/or sepsis, only little is known on a potential role of omentin as
a biomarker for the assessment of disease severity or the patients’ clinical outcome. Our group has
assessed omentin serum levels in a cohort of n = 117 ICU patients with different disease etiologies.
While serum omentin levels at admission to the ICU or 72 h after did not differ between ICU patients
and healthy controls and were independent of disease etiology and the presence of sepsis, low omentin
serum levels were an independent predictor for overall survival [26]. However, these data need further
validation before omentin might be implemented into clinical risk prediction scores.
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3.2. C1q/TNF-Related Protein 1 (CTRP1)
The CTRP1 represents a member of the CTRP family that consists of 15 proteins that are involved
in numerous physiological and pathophysiological processes such as the immune defense, systemic
inflammation, cell differentiation and apoptosis, and autoimmunity [27]. CTRP1 is known to regulate
important processes within the systemic energy homeostasis and insulin sensitivity and is, for
example, involved in PI3K-dependent signaling pathways to induce intracellular glucose transport by
insulin [28,29]. Moreover, CTRP1 stimulates human vascular smooth muscle cells, which results in an
upregulation of pro-inflammatory cytokines such as interleukin 6 (IL-6), monocyte chemoattractant
protein 1 (MCP1), and intracellular adhesion molecule 1 (ICAM1) [30].
In critically ill patients, recent data suggest a significant upregulation of CTRP1 compared with
healthy controls [31]. Moreover, CTRP1 levels were significantly higher in patients who fulfilled
the criteria of sepsis compared with non-sepsis patients. Importantly, our group showed a strong
correlation with markers of systemic inflammation (CRP, IL-6, and PCT), obesity/diabetes (BMI and
HbA1c), liver function and cholestasis (bilirubin, GGT, GLDH, AP), and renal function (creatinine,
urea). Although these data clearly link CTRP1 to inflammatory and metabolic disturbance in critically
ill patients, especially in those patients with septic disease stage, circulating CTRP1 levels were not
indicative for the patients’ short- or long-term mortality [31]. In a different cohort of n = 539 patients
undergoing coronary angiography for the evaluation of coronary artery disease, CTRP1 was likewise
correlated to obesity and the presence of metabolic syndrome or type 2 diabetes, but circulating levels
of CTRP were also a significant predictor of major adverse cardiovascular events such as cardiovascular
death, non-fatal myocardial infarction, and non-fatal stroke over a follow-up period of eight years [32].
3.3. C1q/TNFa-Related Protein 3 (CTRP3)
Similar to CTRP1, CTRP3 is a recently recognized adipokine that is also involved in various
physiological and pathophysiological processes such as food intake and metabolism, inflammation,
vascular disorders, and tumor metastases [33]. CTRP3 is expressed by visceral and subcutaneous
adipose tissue [34] and is generally referred to as a “beneficial” mediator as it lowers levels of glucose,
inhibits gluconeogenesis, and exerts anti-inflammatory effects [35,36]. In line, serum levels of CTRP3
are reduced in patients with obesity or diabetes [29].
In terms of septic disease, animal models suggest an anti-inflammatory and protective role of
CTRP3. As an example, intramyocardial overexpression of CTRP3 in mice resulted in a significantly
attenuated myocardial dysfunction in an LPS-induced model of sepsis [37]. In human critical illness,
circulating CTRP3 levels were found to be reduced. In a cohort of n = 218 patients, both critically
ill patients with (n = 145) or without (n = 73) sepsis had significantly decreased plasma CTRP3
levels compared with healthy controls [38]. Moreover, low CTRP3 levels were directly associated
with the presence of sepsis among ICU patients. Interestingly, we did not observe an association of
CTRP3 levels with obesity or diabetes in ICU patients, arguing that critical illness might overrule the
regulation mechanisms of CTRP3 in non-critically ill patients. In line, CTRP3 plasma concentrations
were inversely correlated with inflammatory cytokines and standard markers of sepsis such as CRP and
PCT. Importantly, the authors described a direct association between low CTRP3 levels (<620.6 ng/mL)
and an increased overall mortality [38]. Although these data need to be confirmed in further trials, it
suggests a clinically relevant role of CTRP3 as a potential new diagnostic and prognostic biomarker in
patients with critical illness and sepsis.
3.4. Leptin and Leptin-Receptor
Leptin represents a 16 kDa hormone that was initially described in 1994 and has since been
extensively studied for its regulatory role with respect to food intake, glucose homeostasis, and energy
expenditure [39,40]. It mainly originates from adipocytes and was also found to be involved in
cell-mediated immunity as well as inflammatory cytokine crosstalk [41]. There is a direct correlation of
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circulating leptin levels with body fat mass; starvation or malnutrition leads to low serum concentrations,
while obesity increases leptin serum levels [42].
Several clinical studies have evaluated the role of circulating leptin as a biomarker in the context
of critical illness, but the results are partly inconclusive. In a first study of n = 137 critically ill patients
(95 with sepsis, 42 without sepsis), serum leptin concentrations at admission to ICU were similar
compared with healthy controls and did not differ between septic and non-septic patients [43]. Similar
results were obtained for the soluble leptin receptor, which is known to form complexes with circulating
leptin. In line, a smaller series of patients with severe sepsis revealed no significant regulation of
serum leptin levels in septic disease [44]. Contrarily, serum leptin levels were significantly elevated in
septic patients compared with non-septic patients in a cohort of n = 331 patients with critical illness
from a medical ICU [41]. In a longitudinal study including patients with sepsis, leptin levels were
significantly higher compared with controls and showed a positive correlation with insulin levels and
insulin resistance. Interestingly, a decline of leptin serum levels was found during prolonged sepsis,
which was, however, not related to survival [45]. A potential explanation for these contradictory results
might relate to different sampling time points, divergent BMI or feeding state prior and during sepsis,
or from heterogeneous cohorts in terms of disease etiology.
In terms of a prognostic marker, low leptin serum levels (<10 ng/mL) were associated with an
adverse outcome in a cohort of 230 adult patients with severe secondary peritonitis [46]. Moreover,
elevated leptin-receptor receptor levels (>32 ng/mL) were associated with an impaired overall survival
compared with patients with low serum levels (<32 ng/mL) [44].
3.5. Visfatin
Visfatin, which is also referred to as pre-B-cell colony-enhancing factor (PBEF) given its initial
identification in lymphocytes, represents an adipokine with key functions in the process of systemic
inflammation. It was shown that visfatin acts as a chemoattractant to recruit neutrophils and promotes
their survival [47,48], and is further capable of stimulating cytokine release from monocytes [49].
Visfatin has also been associated with human critical illness and sepsis and was primarily suggested as
a diagnostic marker. In septic infants, visfatin serum levels were significantly elevated compared with
healthy controls and showed a positive correlation with CRP, PCT, and IL-6 [50]. At a cut-off value of
10 ng/mL, visfatin revealed a sensitivity and specificity of 92% and 94%, respectively, for the diagnosis
of neonatal sepsis.
In a larger study including 229 critically ill medical ICU patients, circulating visfatin levels were
also significantly higher in ICU patients when compared with healthy controls [51]. Visfatin serum
levels were highest in patients who fulfilled the diagnostic criteria for sepsis, and visfatin concentrations
strongly correlated with disease severity and organ failure. Although visfatin serum levels were
comparable between patients with or without type 2 diabetes or obesity, the authors observed a
significant correlation between visfatin levels and biomarkers of liver and kidney dysfunction and
other adipokines such as resistin and leptin. Most importantly, high visfatin levels upon admission to
ICU were associated with both an increased ICU as well as long-term mortality [51].
3.6. Resistin
Resistin was first described in 2001 as an adipokine. Data from rodent models revealed an
association between resistin and the presence of metabolic diseases including obesity and type 2
diabetes. In these studies, elevated serum levels of glucose as well as hyperinsulinemia correlated with
an increase in resistin [52]. When translating data from animal models to humans, it is important to
consider that the protein sequences of murine and human resistin demonstrate important differences [53].
Moreover, in mice, adipocytes represent the main source of circulating resistin, while in humans, resistin
seems to be mainly secreted by macrophages [54,55], suggesting that the role of resistin in humans
and mice may vary. In this context, data from a ‘humanized mouse’ model in which only human
resistin was produced by macrophages suggested that human resistin might display pro-inflammatory
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characteristics mediating insulin resistance [56]. Therefore, a role of resistin in the pathophysiology of
critical illness and sepsis seemed likely. Just recently, it was demonstrated that serum levels of resistin
are elevated in patients with critical illness compared with controls [20]. Moreover, patients with sepsis
displayed further elevated resistin concentrations compared with non-septic patients, suggesting
a link between inflammation and infection and the secretion of resistin in humans. In line, serum
resistin concentrations were closely correlated to inflammatory parameters such as CRP, the leukocyte
count, PCT, and cytokines such as IL6 and TNF [20]. Moreover, elevated resistin levels indicated an
impaired prognosis [20]. Notably, these data were subsequently corroborated by similar findings of
different groups, demonstrating that elevated resistin concentrations correlate with disease severity,
inflammatory cytokine, lactate levels, and serum creatinine concentrations in patients with severe
sepsis and septic shock [57,58]. These data might at least partly be explained by the fact that resistin
represents a uremic toxin, inhibiting neutrophils and thereby modulating sepsis-related immune
responses at concentrations that can be found in patients with end-stage kidney failure [59]. In line
with these data from adult patients, recently, Gokmen et al. demonstrated that resistin levels are
elevated in preterm infants with sepsis, concluding that resistin may represent a marker for sepsis in
premature infants [60].
3.7. Adiponectin
Adiponectin represents an adipokine of 30 kDa that is exclusively secreted by adipocytes and
has been extensively studied for its role in glucose and lipid metabolism and in the context of insulin
resistance [61]. In obese and patients with diabetes mellitus, circulating levels of adiponectin are
reduced compared with healthy individuals [62]. Moreover, circulating adiponectin levels negatively
correlate with serum levels of low-density lipoprotein cholesterol and triglycerides, blood pressure,
and insulin resistance [63], arguing for a protective function of adiponectin in human metabolic
homoeostasis. This concept is supported by animal studies suggesting an anti-inflammatory and
protective role of adiponectin in mouse models of sepsis [64,65].
Only limited data on a regulation of adiponectin in critical illness and sepsis are available. In a
study evaluating circulating levels of adiponectin in 170 critically ill patients at admission to the ICU,
the authors found comparable adiponectin levels in ICU patients with or without sepsis and healthy
controls [66]. Similar to patients without critical illness, ICU patients with obesity or preexisting
diabetes mellitus displayed significantly reduced levels of circulating adiponectin. Interestingly,
although not regulated in ICU patients, the authors found that low adiponectin levels at ICU admission
are an independent positive predictive marker for short-term and overall survival [66]. During
the clinical course of critical illness, two studies have reported low to normal levels of circulating
adiponectin. In a small series of patients, plasma adiponectin concentrations in an ICU cohort at day 3
and day 7 after admission were significantly lower compared with healthy control samples [67]. In line,
a study including 318 patients with respiratory critical illness revealed low adiponectin levels, which
were enhanced by insulin therapy and returned to normal when critical illness was sustained [68].
3.8. Retinol Binding Protein 4
Retinol binding protein 4 (RBP4) is involved in the transport of hepatic retinol to distant organs.
Levels of circulating RBP4 have been linked to metabolic diseases such as insulin resistance, obesity,
metabolic syndrome, diabetes, and fatty liver disease, representing chronic inflammatory diseases [68].
Recently, the group of Langouche et al. demonstrated in 318 critically ill patients that those patients with
sepsis had significantly lower RBP4 levels than those with other disease etiologies [68]. In a different
study, RBP4 levels were also lower in ICU patients, regardless of whether or not sepsis was present,
compared with controls [69]. Interestingly, in these patients, liver cirrhosis was associated with further
reduced RBP4 concentrations and RBP4 was correlated with markers of liver dysfunction. Interestingly,
RBP4 concentrations were independent on the presence of obesity or preexisting diabetes and were
not associated with overall survival in the analyzed cohort. In contrast, Chen et al. demonstrated
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that baseline RBP levels predicted short-term mortality in critically ill patients with underlying
liver disease. Interestingly, in this analysis, those patients that survived ICU treatment displayed
significantly increased RBP4 levels after ICU discharge [70], highlighting the potential of this biomarker
in predicting survival in patients treated on a medical ICU.
Table 1. Overview of regulated adipokines in critically illness and sepsis.
Adipokine
Circulating Adipokine Levels in




1 Omentin − + [26]
2 CTRP1 ↑ −/(+) [31,32]
3 CTRP3 ↓ + [38]
4 Leptin and Leptin Receptor −/↑ + [41,43–46]
5 Visfatin ↑ + [50,51]
6 Resistin ↑ + [20,57,58]
7 Adiponectin −/↓ + [66–68]
8 RBP4 ↓ −/(+) [68–70]
CTRP1: C1q/TNFa-related protein 1, CTRP3: C1q/TNFa-related protein 3, RBP4: retinol binding protein 4, −:
no regulation/no prognostic relevance, +: prognostic relevance, ↑: elevated circulating levels, ↓: decreased
circulating levels.
4. Discussion and Outlook
Adipokines represent a growing class of proteins that exert a wide range of metabolic effects.
Moreover, adipokines have been shown to withhold regulatory effects in immune responses during
inflammation and infectious disease. Because adipokines are secreted into the blood, recent studies
have analyzed their potential as biomarkers in many different pathological conditions. While many
papers found an association between serum levels of adipokines and the presence of sepsis and/or the
prognosis of patients with critical illness, it is important to highlight some limitations that apply at
least for most of the available studies. Many of the available studies featured a retrospective design
and the missing longitudinal approach may have induced a bias. Moreover, some of the analyzed
cohorts were extremely heterogeneous and relatively small in terms of patients’ numbers; therefore,
larger prospective studies are needed to finally infer about the role of circulating adipokines in patients
with critical illness, a collective of patients with a still unacceptably poor prognosis. Within this review,
we summarized available data on the potential role of these proteins in critically ill and septic patients.
We highlight that, despite that their use as single marker might be limited owing to a lack of sensitivity
and specificity, measurements of circulating adipokines might be integrated into available and future
scoring systems for the diagnosis of sepsis and risk stratification of critically ill patients.
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Abstract: Adiponectin, an adipokine derived from the adipose tissue, manifests anti-inflammatory
effects in the metabolically active organs and is, therefore, beneficial in various metabolic diseases
associated with inflammation. However, the role of adiponectin in alleviating the hypothalamic
inflammation connected to the pathogenesis of obesity has not yet been clearly interrogated. Here,
we identified that the systemic administration of adiponectin suppresses the activation of microglia
and thereby reverses the hypothalamic inflammation during short-term exposure to a high-fat diet.
Additionally, we show that adiponectin induces anti-inflammatory effects in the microglial cell line
subjected to an exogenous treatment with a saturated free fatty acid. In conclusion, the current
study suggests that adiponectin suppresses the saturated free fatty acid-triggered the hypothalamic
inflammation by modulating the microglial activation and thus maintains energy homeostasis.
Keywords: energy metabolism; inflammation; hypothalamus; microglia; adiponectin
1. Introduction
Inflammation is one of the major pathological causes implicated in the development of obesity
and its related metabolic disorders [1–3]. Chronic inflammation triggered by over-nutrition results
in perturbation of the activity of hypothalamic neurons, which govern the whole-body energy
balance [4–6]. Recent studies report that microglia, the resident macrophages of the central nervous
system (CNS), respond to the elevation of saturated free fatty acid (FFA) following consumption of
the fat-rich diet and thereby trigger the hypothalamic inflammation [6]. This results in abnormal
functioning of the neuronal circuit that controls the energy homeostasis.
Adiponectin, an adipokine derived from adipose tissue, has been reported as beneficial in
alleviating multiple physiological disturbances [7–9]. It helps in alleviating a variety of metabolic
diseases by ameliorating the cellular stresses including inflammation, oxidative stress, and endoplasmic
reticulum stress [7,8,10–12]. Although, a recent study identified an anti-inflammatory effect of
adiponectin in the CNS [11], the role of adiponectin in rectifying the hypothalamic inflammation
during early over-nutrition period remains elusive. Therefore, this study was aimed at identification
of the contribution of adiponectin in regulating the hypothalamic inflammation and the microglial
function. We evaluated the inflammatory responses and microglial activation utilizing mice model
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treated for a short-term with fat-rich diet and a microglial cell line treated with a saturated FFA. In crux,
the current study unravels the potential contribution of adiponectin in preventing the initiation of
inflammatory response in the hypothalamic microglial cells in an early stage of obesity development.
2. Results
2.1. Adiponectin Reverses the Hypothalamic Inflammation Induced by Short-Term Exposure to High Fat Diet
In order to verify if adiponectin exerts anti-inflammatory effect in the hypothalamus during the
early over-nutrition period, we evaluated the pattern of the hypothalamic inflammation after treatment
with high fat diet (HFD) for 4 weeks combined with the systemic administration of globular adiponectin,
which has a more potent effect on their identified functions [13]. In line with the previous finding
that identified a reduction in circulating adiponectin level during short-term exposure to a fat-rich
diet [13], we also confirmed a reduction in adiponectin mRNA level in epididymal white adipose tissue
(eWAT) 4 weeks after high-fat diet treatment (Figure 1A). In accordance with the previous reports, we
observed that HFD treatment resulted in a drastic increase in the expression levels of mRNA encoding
inflammatory cytokines such as IL-1β (Figure 1B), IL-6 (Figure 1C), TNF-α (Figure 1D) as well as Cox-2
gene (Figure 1E), the rate-limiting enzyme involved in the synthesis of the prostaglandin E2, which
controls the cellular inflammatory process. This elevation of mRNA levels was effectively reversed by
a systemic treatment with adiponectin for five days. Furthermore, we observed that an elevation in the
levels of hypothalamic Iba-1 and CD11b mRNA, the molecular markers of microglia, in HFD-treated
group was almost completely rescued by the systemic treatment with adiponectin (Figure 1F,G). These
findings suggest that adiponectin treatment exerts anti-inflammatory effects on the hypothalamus
following short-term HFD exposure, at least in part, via targeting the microglial cells.
Figure 1. Systemic administration of adiponectin reverses the hypothalamic inflammation in response
to short-term HFD treatment. C57BL/6 mice were fed either a Standard diet (STD) or a HFD for 4 weeks
followed by i.p. injection of adiponectin or saline (as a control group) for 5 days. (A) The level of
adiponectin mRNA in eWAT was significantly elevated 4 weeks after HFD treatment. The elevated
mRNA levels of hypothalamic genes involved in inflammatory processes such as (B) IL-1β, (C) IL-6,
and (D) TNF-α and (E) Cox-2 observed in HFD-treated group were significantly reversed by i.p
administration of adiponectin. Adiponectin treatment dampened the increase in the mRNA levels of
hypothalamic (F) Iba-1 and (G) CD11b, markers for microglia activation, in response to HFD treatment.
Results are presented as mean ± SEM. n = at least 5 mice per group. * p < 0.05, ** p < 0.01 for effects of
adiponectin on HFD-treated group versus effects of adiponectin on STD-treated group. CTL, control
group; ADN, adiponectin-treated group.
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2.2. Adiponectin Suppresses the Microglial Activation Induced by Short-Term Exposure to HFD
To determine whether adiponectin relieves the development of HFD-triggered hypothalamic
inflammation by targeting the hypothalamic microglial cells, we identified the presence of adiponectin
receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) in the hypothalamic glial cells utilizing
cultured primary microglia and astrocytes (Figure 2A). We also validated the purification of a single
cell type determined by a strong expression of Iba-1, a molecular marker for microglia participating
in membrane ruffling and phagocytosis in activated microglia (Figure 2B) [14], or GFAP, a molecular
marker for astrocytes (Figure 2C). Based on the anti-inflammatory effects of adiponectin on hypothalamic
inflammation triggered by short-term HFD treatment, we next performed immunohistochemistry (IHC)
using an antibody against Iba-1 on brain slices from mice fed either a STD or a HFD combined with
adiponectin to evaluate the impact of adiponectin treatment on microglia activation in the hypothalamus.
We observed that the HFD treatment resulted in an increase in body weight (Figure 2D) and WAT
weight (Figure 2E) as compared to the STD-treated group. On the contrary, the systemic administration
of adiponectin for 7 days did not alter the increase in the body weight and WAT weight seen in the
HFD-treated group (Figure 2D,E). Consistent with our cellular data, we observed that adiponectin
treatment effectively reverses the microglial activation in the hypothalamus characterized by increased
in a number of microglia (Figure 2F,G). In addition, we found that systemic treatment of adiponectin
blocked the increase in microglia soma area in the HFD-treated hypothalamus (Figure 2H). However,
adiponectin did not rescue the elevated of Iba-1 intensity seen in the HFD-treated hypothalamus
(Figure 2I). These findings indicate that adiponectin reverses the effects of HFD on the hypothalamic
inflammation by ameliorating the microglial activation during the early over-nutrition period.
Figure 2. Cont.
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Figure 2. Adiponectin rescues the microglial activation caused by short-term exposure to high fat
diet. (A) RT-PCR bands indicate the presence of AdipoR1 and AdipoR2 in both primary microglia and
astrocytes. Confirmation of purification of microglia and astrocytes, as determined by levels of (B) Iba-1
and (C) GFAP mRNAs. (D) Changes of body weight and (E) white adipose tissue weight seen in mice
fed with either a STD or a HFD for 4 weeks followed by i.p. injection of adiponectin or saline (as a
control group) for 5 days. (F) Representative images showing immunohistochemistry staining of Iba-1
in the sections of the hypothalamus from each group. Scale bar = 100 μm. The increased (G) number
of microglial cells, and (H) soma area of microglia, observed in the hypothalamus of mice exposed
to HFD were reversed by systemic adiponectin administration. (I) Adiponectin treatment did not
alter the increased intensity of Iba-1 signals seen in the hypothalamus of mice fed a HFD. Results are
presented as mean ± SEM. n = 5 mice per group. *** p < 0.001 for effects of adiponectin on HFD-treated
group versus effects of adiponectin on STD-treated group or Iba-1 mRNA level in astrocyte versus Iba-1
mRNA level in microglia; * p < 0.05 for GFAP mRNA level in astrocyte versus GFAP mRNA level in
microglia. NS, not significant; CTL, control group; ADN, adiponectin-treated group.
2.3. Adiponectin Improves Palmitic Acid-Induced Inflammatory Responses in the Microglial Cells
The consumption of fat-rich diet results in an elevation in the levels of circulating free fatty acids
which cause the obesity pathogenesis linked to the hypothalamic inflammation [15,16]. Our previous
study identified that the levels of saturated free fatty acid were elevated in both the hypothalamus
and sera of mice fed a HFD for 4 weeks [17]. Therefore, to verify the anti-inflammatory role of
adiponectin in alleviating the microglial inflammation induced by over-nutrition, we further evaluated
the anti-inflammatory effect of adiponectin in the BV-2 microglial cell line by an administration of
palmitic acid, a saturated free fatty acid followed by adiponectin treatment. We confirmed that single
treatment of adiponectin did not alter cell viability (Figure 3A) or IL-1β release (Figure 3B) in cultured
BV-2 microglial cells. However, adiponectin treatment led to a reduction in IL-6 secretion (Figure 3C).
These findings indicated that adiponectin itself did not affect cellular inflammation and degeneration.
In accordance with previous reports, palmitic acid treatment induced increase in the mRNA levels
of inflammatory cytokines such as IL-1β (Figure 3D), IL-6 (Figure 3E) and TNF- α (Figure 3F), and
Cox-2 gene (Figure 3G) in cultured BV-2 microglial cells. This elevation of inflammatory responses
triggered by palmitic acid was completely rescued by an exogenous adiponectin treatment. Moreover,
the administration of adiponectin reversed the palmitic acid-induced release of IL-1β (Figure 3H) and
IL-6 (Figure 3I) in the BV-2 microglial cells. These observations confirmed that adiponectin treatment
reverses the development of hypothalamic inflammation and the associated microglial activation.
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Figure 3. Adiponectin rescues the palmitic acid-induced inflammation in the microglial cell line.
The BV-2 cells were seeded at a density of 5 × 105 cells/well and pretreated with adiponectin at indicated
concentration for 1 h followed by palmitic acid (200 μM) treatment for 4 h. Exogenous treatment
of adiponectin did not change cell viability (A) or IL-1β release (B), but reduced IL-6 secretion (C).
The palmitic acid-induced elevations of IL-1β (D), IL-6 (E) TNF- α (F) and Cox-2 (G) mRNA levels were
reversed by adiponectin treatment in the BV-2 cells as determined by qPCR analysis. The palmitic
acid-induced increase of IL-1β (H) and IL-6 (I) cytokine release was reversed by adiponectin treatment
in the BV-2 cells as determined by ELISA. Results are presented as mean ± SEM. * p < 0.05 and ** p < 0.01
for palmitic acid-treated group versus vehicle-treated group; # p < 0.05 and ## p < 0.01 for palmitic acid
+ adiponectin (ADN)-treated group versus palmitic acid-treated group.
2.4. Adiponectin Reverses the Palmitic Acid-Induced Alterations in the Intracellular Signaling Molecules
Involved in Inflammation
In order to further verify anti-inflammatory functions of adiponectin, we evaluated the
phosphorylation of ERK, a molecular component of intracellular signal transduction in the inflammatory
signaling pathway [18,19], and the level of IkB-α protein, which inhibits the activity of NF-κB
transcription factor regulating the expression of multiple inflammatory cytokines [20]. As shown in
the Figure 4, adiponectin reversed the palmitic acid-induced phosphorylation of ERK (Figure 4A) and
degradation of IkB-α (Figure 4B). These observations suggest that adiponectin treatment suppresses
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the microglial inflammation in response to saturated FFA, at least in part, via modulating the general
signaling molecules linked to the development of cellular inflammation.
Figure 4. Adiponectin reverses palmitic acid-induced changes of the inflammatory mediators in
the microglial cells. The BV-2 cells were seeded at a density of 1 × 106 cells/well and pretreated
with adiponectin for 1 h followed by a palmitic acid (200 μM) treatment for 30 min or 4 h. Palmitic
acid-induced phosphorylation of ERK (A) and reduction of IkB-α synthesis (B) were reversed by
adiponectin treatment at indicated concentration. Results are presented as mean ± SEM. ** p < 0.01 and
*** p < 0.005 for palmitic acid-treated group versus vehicle-treated group; # p < 0.05, ## p < 0.01 and
### p < 0.005 for palmitic acid + adiponectin (AND)-treated group versus palmitic acid-treated group.
3. Discussion
The present study highlights the beneficial effects of adiponectin in the alleviating the hypothalamic
inflammation triggered by the over-nutrition that causes the disturbance in the functioning of
hypothalamic neurons that regulate the whole-body energy metabolism.
Multiple lines of evidence have suggested that chronic inflammation in the hypothalamic neuronal
circuit, which controls the appetite and energy expenditure, causes a variety of cellular stresses and
thereby results in the energy imbalance [4–6]. The adipose tissue is a specialized connective tissue that
functions as a major storage site for fats in the body [21–23]. However, it has been well established
that the adipose tissue also acts as an endocrine organ besides regulating the energy balance [22,24,25].
The adipose tissue communicated with the hypothalamus by releasing multiple chemical messengers
that systemically propagate the signals reflecting nutrient availability for the homeostatic control of
energy homeostasis [21,22,26]. In addition, the adipose tissue also regulates the obesity pathogenesis by
secreting a variety of inflammatory cytokines and adipokines that deteriorate the cellular stresses such
as inflammation, endoplasmic reticulum stress, and oxidative stresses [21,22]. Although majority of
the adipokines act as proinflammatory factors, adiponectin displays anti-inflammatory properties that
potentially improve the dysfunction of metabolic controls in the body [8,27,28]. In the CNS, adiponectin
inhibits neuronal degeneration by ameliorating the cellular stresses including inflammation [10,11,29].
A growing body of evidence suggested that the microglial cells essentially participates in the
development of the neuronal inflammation [16,30,31] and the reactive gliosis is an important cellular
event for both acute and chronic inflammation triggered by the over-nutrition [32,33]. Therefore, it is
not surprising that the anti-inflammatory role of adiponectin in the microglial cells is coupled to the
improvement of metabolic abnormalities. Since adiponectin binds via adiponectin receptors, AdipoR1
and AdipoR2 in the microglial cells, we confirmed the presence of these receptors in the microglial cells.
It has been quite well established that the short-term exposure of HFD results in an increased
hypothalamic inflammation accompanied by the reactive gliosis of both microglia and astrocytes [5,6,34].
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Intriguingly, mice having HFD for a couple of days displayed a significant increase in the inflammatory
cytokines expression in the hypothalamus [5,6]. In line with this notion, we verified the role of
adiponectin in ameliorating the hypothalamic inflammation during the consumption of the short-term
fat-rich diet. Furthermore, we verified that adiponectin successfully reverses the inflammatory
responses in the hypothalamic microglia during early over-nutrition period by observing the reduced
microgliosis as determined by the accumulation of Iba-1 protein and the altered number and morphology
of microglial cells.
A variety of substances are involved in the obesity-related pathogenesis. Among them, saturated
FFAs are critical substances that trigger the inflammation in brain during early obesity period [16].
We observed that adiponectin effectively rescues the palmitic acid-induced microglial inflammation via
regulation of the intracellular signaling molecules that mediate the inflammatory responses. Although
there are substantial evidences highlighting the pathogenic factors associated with obesity and their
impact on the development of metabolic dysfunction [35,36], the pathogenic substances involved in
the initiation of hypothalamic inflammation during early over-nutrition period remain unexplored.
Thus, it is also valuable to investigate the cellular and molecular responses following induction or
prevention of the hypothalamic inflammation during early over-nutrition period. Indeed, previous
studies indicated that adiponectin levels are slightly elevated during short-term exposure to HFD [37].
Therefore, we suggest that the anti-inflammatory effects of adiponectin might be due to the homeostatic
response to suppress the hypothalamic inflammation induced by the multiple humoral factors such
saturated FFAs and adipokines. However, the beneficial effects of adiponectin treatment on the severe
obesity associated with the chronic inflammation need to be determined. Therefore, further studies are
required to identify the beneficial effects of adiponectin in alleviating the cellular stresses following
long-term treatment of adiponectin to the obesity model accompanied by chronic hypothalamic
inflammation and the cellular lipotoxicity. Collectively, the current study identifies a reversible effect
exerted by adiponectin treatment on the initiation of the hypothalamic inflammation during early
over-nutrition period and provides novel insight into the strategies to prevent early disruption of the
energy homeostasis.
4. Materials and Methods
4.1. Animals
Seven-week-old C57B/L6 mice (Dae Han Bio Link, Eumseong, Korea) were maintained under
specific pathogen-free conditions at 22 ◦C and given access to food and water ad libitum. To examine
the effects of adiponectin on early obesity stage-induced hypothalamic inflammation, mice were
adapted for a week, randomly divided into two groups and fed either a standard diet (STD, 10%
calories from fat, Research Diet Inc., New Brunswick, NJ, USA) or a high-fat diet (HFD, 60% of calories
from fat, Research Diets Inc.) for four weeks. The components of the HFD and STD are indicated
in Table 1. For adiponectin treatment, mice were given intraperitoneal (i.p) injections of globular
adiponectin (3 mg/kg, Lugen Sci, Bucheon, Korea) for five days. Brains and serum were collected 3 h
after last injection. In addition, body weight and epididymal fat weight were measured when tissue
was harvested. The experimental procedure is described in a flowchart (Figure 5). All the animal
care and experimental procedures were performed in accordance with the protocols approved by the
Institutional Animal Care and Use Committee (IACUC) at the Incheon National University (permission
number: INU-2016-001).
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g% kcal% g% kcal%
Protein 26.2 20 19.2 20
Carbohydrate 26.3 20 67.3 70
Fat 34.9 60 4.3 10
g kcal g kcal
Casein80-mesh 200 800 200 800
L-Cystine 3 12 3 12
Cornstarch 0 0 315 1260
Maltodextrin 10 125 500 35 140
Sucrose 68.8 275.2 350 1400
Cellulose BW200 50 0 50 0
Soybean oil 25 225 25 225
Lard 245 2205 20 180
Mineral mix S10026 10 0 10 0
Dicalcium phosphate 13 0 13 0
Calcium carbonate 5.5 0 5.5 0
Potassium citrate 16.5 0 16.5 0
Vitamin mix V10001 10 40 10 40
Choline bitartrate 2 0 2 0
FD and C dye 0.05 0 0.05 0
Figure 5. Flowchart showing the experimental procedure. Arrows indicate the start of treatment,
sample preparation and analysis.
4.2. Immunohistochemistry
Mice were anesthetized and perfused transcardially with 0.9% saline (w/v), followed by fixation
with 4% paraformaldehyde in phosphate buffer (PB, 0.1 M, pH 7.4). Brains were isolated and post-fixed
overnight with 4% paraformaldehyde PB buffer before the coronal sections (50 μm thickness) were
prepared using a vibratome (5100 mz Campden Instruments; Leicestershire, UK). After washing in PB
several times, the sections were preincubated with 0.3% Triton X-100 (Sigma-Aldrich, St. Louis, MO,
USA) for 30 min at room temperature (RT) and then incubated with Iba-1 antibody (1:1000 dilution,
Wako, Osaka, Japan) for overnight at RT. For diaminobenzidine- (DAB-) based Iba-1 IHC, sections
were extensively washed and incubated with biotinylated anti-rabbit secondary antibody, ABC reagent
(Vector Laboratories, Burlingame, CA, USA), and DAB substrate (Vector Laboratories).
4.3. Cell Culture and Treatments
The murine microglial BV-2 cells were maintained in Dulbecco′s modified Eagle medium (DMEM)
with high glucose (Gibco BRL, Grand Island NY, USA), containing 5% (v/v) fetal bovine serum (Gibco
BRL, Grand Island NY, USA) and incubated at 37 ◦C in humidified 5% CO2. For gene expression assay,
cells were seeded at a density of 5 × 105 cells/well in 12-well plate. After 24 h, the attached cells were
pre-treated with adiponectin (100 ng/mL or 1000 ng/mL) for 1 h followed by the treatment with 200 μM
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palmitic acid (Sigma-Aldrich) for 4 h. The palmitic acid was dissolved in ethanol and conjugated into
10% bovine serum albumin (BSA).
4.4. Primary Astrocyte Culture
Following decapitation of five-day-old C57BL/6 mice, the diencephalon was removed under
sterile conditions and triturated in Dulbecco’s modified Eagle′s medium (DMEM) F-12 containing
1% penicillin-streptomycin. The cell suspension was filtered through a 100-μm sterile cell strainer
to remove debris and fibrous layers. The suspension was centrifuged, and the pellet resuspended
in DMEM F-12, containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The cells
were then grown in this culture medium in 75-cm3 culture flasks at 37 ◦C and 5% CO2. When the cells
reached confluence (at approximately nine days), microglia were separated from adhered astrocytes
by shaking the culture at approximately 250 rpm for 2 h. The cells were then seeded onto 12-well
tissue culture plates, previously coated with poly-d-lysine hydrobromide (50 μg/mL), after which
they were distributed at 7.5 × 104 cells/well and incubated at 37 ◦C with 5% CO2. For the astrocyte
primary culture, the adhered cells were harvested using 0.05% trypsin-ethylenediamine tetraacetic
acid, resuspended in DMEM F-12 containing 10% FBS and 1% penicillin-streptomycin, and centrifuged
for 5 min at 1000 rpm. The cells were then seeded at a concentration of 5 × 105 cells/mL in culture
plates previously treated with poly-l-lysine hydrobromide (50 μg/mL), and grown for 24 h.
4.5. Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated from the hypothalamus, cultured BV-2 cells, primary microglia and
primary astrocytes, and reverse-transcribed to make cDNA using maxime RT PreMix kit (Intron
Biotechnology, Seoul, Korea). Real-time PCR amplification of the cDNA was analyzed with SYBR
Green Real-time PCR Master Mix (Toyobo Co., Ltd., Osaka, Japan) in a Bio-Rad CFX 96 Real-Time
Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The results were analyzed by the
CFX Manager software and normalized to the housekeeping gene β-actin. Primer sequences
used are IL-1β F-AGGGCTGCTTCCAAACCTTTGAC, R-ATACTGCCTGCCTGAAGCTCTTGT;
IL-6 F-CCACTTCACAAGTCGGAGGCTTA, R-GCAAGTGCATCATCGTTGTTCATAC; TNF-α
F-TGGGACAGTGACCTGGACTGT, R-TTCGGAAAGCCCATTTGAGT; Cox-2F-TGCTGTACAA
GCAGTGGCAA, R-AGGGCTTTCAATTCTGCAGCC; Iba-1 F-AGCTTTTGGACTGCTGAAGG,
R-TTTGGACGGCAGATCCTCATC; CD11b F-CCACTCATTGTGGGCAGCTC, R-GGGCAGCTT
CATTCATCATGTC; Adiponectin F-GTTGCAAGCTCTCCTGTTCC, R-TCTCCA GGAGTGCCATCTCT;
GFAP F-TCAATGACCGCTTTG CTAGC, R-ACTCGTGCAGCCTTACACAG; β-Actin F-TGGAATCCT
GTGGCATCCATGAAAC, R-TAAAACGCAGCTCAGTAACAGTAACAGTCCG.
4.6. Measurement of Cytokine Levels
Supernatant from cultured BV-2 cells were collected 1 h after adiponectin (100 ng/mL or 1000 ng/mL)
treatment followed by administration of palmitic acid (200 μM) for 24 h. The concentration of released
cytokines was measured using mouse IL-1β and IL-6 DuoSet (R&D Systems, Minneapolis, MN, USA)
according to the manufacturer′s instructions.
4.7. Immunoblot Analysis
BV-2 cells were seeded at a density of 1 × 106 cells/well in 6-well plate and pre-treated with
adiponectin (100 ng/mL or 1000 ng/mL) for 1 h followed by palmitic acid treatment for 30 min or 4 h.
The cells were rinsed with phosphate buffered saline (PBS), followed by scraping and resuspension of
the cell pellet in RIPA lysis buffer containing protease inhibitors, and centrifuged to remove debris,
unbroken cells and cellular nuclei. The samples containing 20 μg of total protein were subjected
to immunoblot analysis using polyclonal antibodies including anti-phospho-ERK, anti-ERK (Cell
Signaling, Danvers, MA, USA), anti-IκBα (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
anti-β-actin (Sigma-Aldrich, St. Louis, MO, USA). Quantification of band intensity was conducted
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using Image J software. The band intensities were normalized by dividing their values by the value for
the total ERK protein, or β-actin protein, for the same sample on the same blot.
4.8. Statistical Analysis
Statistical analyses were performed by Prism 6.0 software (GraphPad Software, San Diego, CA,
USA). All the data are expressed as mean ± SEM. An unpaired t test was performed to analyze the
significance between the two experimental groups. Two-way ANOVA analysis was performed to
detect the interaction between two treatments. Significance was taken at p < 0.05.
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Abstract: First seen as a fat-storage tissue, the adipose tissue is considered as a critical player in
the endocrine system. Precisely, adipose tissue can produce an array of bioactive factors, including
cytokines, lipids, and extracellular vesicles, which target various systemic organ systems to regulate
metabolism, homeostasis, and immune response. The global effects of adipokines on metabolic
events are well defined, but their impacts on brain function and pathology remain poorly defined.
Receptors of adipokines are widely expressed in the brain. Mounting evidence has shown that leptin
and adiponectin can cross the blood–brain barrier, while evidence for newly identified adipokines is
limited. Significantly, adipocyte secretion is liable to nutritional and metabolic states, where defective
circuitry, impaired neuroplasticity, and elevated neuroinflammation are symptomatic. Essentially,
neurotrophic and anti-inflammatory properties of adipokines underlie their neuroprotective roles in
neurodegenerative diseases. Besides, adipocyte-secreted lipids in the bloodstream can act endocrine
on the distant organs. In this article, we have reviewed five adipokines (leptin, adiponectin, chemerin,
apelin, visfatin) and two lipokines (palmitoleic acid and lysophosphatidic acid) on their roles
involving in eating behavior, neurotrophic and neuroprotective factors in the brain. Understanding
and regulating these adipokines can lead to novel therapeutic strategies to counteract metabolic
associated eating disorders and neurodegenerative diseases, thus promote brain health.
Keywords: adipokine; adipose-brain axis; brain health; neurodegeneration; depression
1. Introduction
Adipose tissues are recognized as highly dynamic endocrine tissues exhibiting extensive
physiological functions [1]. Adipose tissue is composed of mature adipocytes as well as the stromal
vascular fraction, where adipose-derived stem cells, blood cells, fibroblasts, and nerves reside [2].
White and brown adipose tissues are the two fat tissues in mammals. The adipocytes in white and
brown adipose tissues are morphologically and functionally distinct. Brown adipose tissues are
accountable for thermogenesis by their abundant mitochondria and extensive vascularization [3,4],
whereas white adipose tissues are preferably responsible for energy storage in the form of triglycerides.
During fasting conditions, insulin inhibits lipolysis in white adipose tissues, where triglycerides are
hydrolyzed into fatty acids and glycerol to generate energy [5]. In response to the nutritional states,
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adipose tissue plays an endocrine role by synthesizing and secreting bioactive compounds termed
adipokines. Adipokine secretion is essential to energy and metabolic homeostasis [6]. Adipsin and
leptin are the first adipokines identified [7,8]. Since then, many pivotal adipokines, such as adiponectin,
resistin, and tumor necrosis factor α (TNF-α), have been extensively studied in metabolism and
metabolic syndromes [9]. Novel adipokines, including chemerin, omentin, apelin, and adipocyte fatty
acid-binding protein, have been identified by their metabolic functions resembling former adipokines
and their alterations afflicted by metabolic diseases in humans [10].
The adipose-brain axis was first established with the discovery of leptin as an endocrine hormone
targeting the hypothalamus to regulate energy balance, satiety, metabolism, and body weight [11].
It was later demonstrated that leptin signaling is also involved in hippocampal neuroplasticity [12].
De la Monte et al. have suggested that energy metabolism, glucose utilization, and insulin
sensitization are compromised in Alzheimer’s disease (AD) patients, whereas these pathological
symptoms may contribute to AD neuropathology [13–16]. Since AD neuropathology highly resembles
the pathology of diabetes mellitus, AD is now recognized as the ‘type 3 diabetes’. Adiponectin
promotes insulin sensitivity [17], whereas adiponectin deficiency exacerbates insulin resistance [18]
and AD neuropathology [19]. Concerns are raised regarding how metabolic syndromes are linked to
neurodegenerative diseases and mood disorders [20,21]. Given that adipose tissue is a major organ to
regulate metabolism through adipokines, understanding the central function of adipokines in the brain
can illustrate how the adipose-brain crosstalk works to prevent metabolic diseases and to promote
brain health.
Metabolic dysfunction could share common molecular mechanisms with neurodegenerative
diseases [22]. Therefore, emerging studies aim at investigating how adipose tissue exerts
neuroprotective effects and influences neuroplasticity through secreting adipokines. Notably, several
adipokines can cross the blood–brain barrier and act on the brain directly [1], while a damaged barrier
will hinder adipose-secreting compounds entering the brain [23]. At present, it is noticeable that
adipokines can modulate neuroplasticity. Accumulated studies have shown that leptin and adiponectin
pathways can regulate cell proliferation [24,25], survival [19,26,27], and synaptic plasticity [12,28]
by modulating cellular metabolism [29,30] and suppressing inflammatory response [31–33] in the
brain. Previous studies focus on the acute action of leptin on synaptic plasticity, whereas recent
studies report insulin resistance afflicts circulating leptin levels and affects central neuroplasticity and
cognitive functions. Besides, animal studies have demonstrated a possible link between metabolic
disorders with aberrant circulating adipokine levels and cognitive behavioral deficits [34–38] or
neuropathology [39–41].
This review summarizes the emerging evidence on the roles of five adipokines, including leptin,
adiponectin, chemerin, apelin, and visfatin, on promoting neuroplasticity. Furthermore, this review
will discuss how diet-, obesity-, and diabetes-related conditions alter the adipokine levels and impair
neuroplasticity and cognitive function in terms of mood as well as learning and memory.
2. Effects of Conventional and Novel Adipokines on the Brain
The neuroendocrine roles of leptin and adiponectin have been widely studied. Leptin and
adiponectin receptors are widely expressed across many brain regions, in particular, the hippocampus,
a critical region for spatial learning and memory formation, and emotional regulation [42]. Both
leptin and adiponectin are shown to affect synaptic plasticity in the hippocampus. However,
the neuroprotective effects of other adipokines, including chemerin, apelin, and visfatin, are
mostly unknown.
2.1. Leptin
Leptin is mostly secreted by white adipose tissue to regulate energy homeostasis by suppressing
food intake and thereby reducing weight loss [43]. Circulating leptin levels are positively correlated
with adiposity [44] and caloric intake [45–49]. In the obese population, increased adiposity is the
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primary cause of hyperleptinemia, a condition with high circulating leptin levels [44]. Obese subjects
are refractory to the anorexigenic effect of leptin due to leptin resistance in the brain and peripheral
tissues [50]. Similarly, patients with type 2 diabetes mellitus comorbid with obesity show both
insulin-resistance and hyperleptinemia [51]. Multiple studies have demonstrated the effectiveness
of exogenous leptin administration on improving insulin resistance in different obese and diabetic
rodent models. Mouse models that feature obesity, hyperglycemia, hyperinsulinemia, particularly
db/db (leptin-deficient) mice, and Zucker fa/fa (loss-of-function leptin receptor) rats resemble type 2
diabetic conditions in humans. Infusion of recombinant leptin for seven days is sufficient to ameliorate
hyperglycemia and hyperinsulinemia in leptin-deficient ob/ob mice [52]. Leptin treatment can also
improve insulin resistance, and glucose and lipid imbalances in some type 2 diabetic models [53–56].
However, mice receiving chronic (>20 weeks) high-fat diet are resistant to leptin even when leptin
is directly infused into the cerebral ventricle of the brain [57–60]. Prominently, leptin also fails to
improve diabetes and insulin resistance in type 2 diabetic patients comorbid with obesity [61,62]. These
suggest that leptin replacement therapy is feasible when deficient. However, further elevation in the
leptin-resistant state will not improve metabolic syndrome.
Adiposity hinges on excessive caloric intake and accumulation, whereas food consumption is a
complex behavior integrating energy homeostasis, reward system, and stress. Leptin is an appetite
hormone, where leptin receptors are expressed in multiple brain regions [63]. Leptin exerts dual
actions to regulate anorexigenic-mediated energy homeostasis [64] as well as to suppress the food-cued
reward circuit in the hypothalamus [65,66]. Hypothalamus is the main target of leptin in the brain by
eliciting a homeostatic response to energy accumulation in accord with nutritional states. In response
to energy accumulation, leptin inhibits orexigenic neurons expressing neuropeptide Y (NPY) and
agouti-related peptide (AgRP) as well as activates the anorexigenic proopiomelanocortin (POMC)
neurons in the hypothalamic arcuate nucleus (ARC). The inclusive anorexigenic effect prevails during
energy accumulation after feeding together with an increased body fat oxidation, and hence suppresses
leptin synthesis and secretion in a negative feedback loop [67]. On the other hand, plasma leptin levels
are decreased by fasting before fat depletion [68], which in turn, disinhibits orexigenic action and
stimulates the appetite.
Hedonic behavior in response to food is mediated by the mesolimbic circuit involving
endocannabinoid [69], orexinergic [70], and dopaminergic signaling. The food-induced hedonic
circuit can possibly override homeostatic feeding. The lateral hypothalamic (LH) together with the
mesolimbic reward circuit, which involves the ventral tegmental area (VTA) and nucleus accumbens
(NAc) predominate the hedonic circuit, where leptin elicits anorectic action by inhibiting multiple
signaling along the circuit [71–73]. Orexin is a neuropeptide that mediates energy sensing, appetite,
body weight, and reinforces reward behaviors [74–76]. Orexin-expressing neurons located in the LH
innervate in the VTA, where leptin receptors are expressed [77]. Leptin can suppress activities of
orexin-expressing neurons in the LH, as shown in electrophysiological recordings [77]. Besides, intra-LH
leptin infusion abolishes high-fat diet-conditioned place preference mediated by orexin-expressing
neurons [77]. Of note, endocannabinoid signaling is in part involved in the leptin inhibitory action
on orexin-expressing neurons. Leptin deficiency and high-fat diet could enhance cannabinoid
receptor-mediated presynaptic inhibitory control of orexin-expressing neurons in the hypothalamic
ARC [69]. These findings taken together suggest the leptin suppresses hedonic behavior in the
hypothalamus involving orexigenic and endocannabinoid signaling. In addition, dopamine release in
the NAc is an adaptive response to palatable food consumption in association with reward learning and
incentive salience [78–80]. A recent review has comprehensively addressed the crosstalk of leptin and
dopamine signaling in inhibiting the food reward system through the LH-VTA-NAc neural circuit [81].
The LH GABA-ergic projection to the VTA expresses leptin receptors [82]. Leptin promotes GABA
release from the LH to VTA is associated with reduced food consumption in leptin-deficient mice [82].
The inhibitory effect of leptin in the reward circuit is further supported by the lentiviral-mediated
knockdown of the leptin receptor in the LH [83]. Finally, leptin receptors are also expressed in
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dopaminergic innervation from the VTA to the NAc. Intra-VTA infusion of leptin suppresses food
intake [84]. Inhibition of dopaminergic neuron activity in the VTA neurons [85] and the reduced
dopamine levels in the NAc [86] may downregulate the reward system. The underlying molecular
signaling for leptin inhibition in the VTA dopaminergic neuron may activate the Janus kinase-signal
transducer and activator of transcription proteins JAK/STAT/PI3K/mTOR pathway [84,87]. Significantly,
long-term overexpression of leptin in the VTA causes leptin receptor desensitization [88]. Conversely,
adenoviral-mediated knockdown of leptin receptor in the VTA promotes food intake and sucrose
preference [89], and leptin antagonism or knockout in the VTA increases NAc dopamine levels [90].
The abovementioned studies concertedly suggest the overconsumption behavior and continuous body
weight gain regardless of hyperleptinemia in obese subjects [91]. Enlarged adipocyte is the culprit of
hyperleptinemia. And potentially, instead of exhibiting a stronger anorexigenic effect or a stronger
inhibition of hedonic reward, prolonged hyperleptinemia may desensitize the leptin receptor-mediated
signaling [60]. These result in a vicious cycle of hedonic eating and obesity.
Excessive caloric intake and energy accumulation are not the only causes of obesity. Chronic
atypical antipsychotic medication is obesogenic in association with severe metabolic disorders, including
hyperglycemia, insulin resistance, and hyperleptinemia [92–98]. In particular, weight gain, increased
food consumption, and hyperleptinemia are frequently reported in psychotic patients receiving
olanzapine medication [99,100]. Significant elevation of circulating leptin is detected in schizophrenic
subjects receiving haloperidol medication (pre, typical antipsychotic treatment) versus risperidone
and clozapine medication (post, atypical antipsychotic treatment) [101]. Elevated leptin levels and
weight gain in schizophrenic patients treated with atypical antipsychotics may be involved in an
adiposity-induced feedback mechanism [102]. Rodent studies further support the fact that the atypical
antipsychotics, namely risperidone and olanzapine, are obesogenic as well as induce leptin expression
and secretion [103–106]. Essentially, antipsychotics can act on multiple neuroendocrine pathways.
Alongside with serotoninergic antagonism that may underline hedonic feeding behaviors and atypical
weight gain [107–109], some atypical antipsychotics can contravene energy homeostasis by inhibiting
peripheral adrenergic system [97]. β-3 antagonism by atypical antipsychotics can not only disrupt
energy homeostasis [110,111] but also induce hyperleptinemia [112]. In sum, atypical antipsychotics
are obesogenic by contravening brain anorexigenic and reward circuit as well as disrupting normal
adipocyte functioning.
Besides, leptin receptors are found in the hippocampus and neocortex, suggesting their possible
roles in the cognitive process [63]. Leptin resistance in obese and diabetic patients can be linked to
impaired leptin receptor signaling [64] and leptin insensitivity at the blood–brain barrier [50,113].
Although both leptin mRNA and protein expressions are widely detected in the brain [114,115],
circulating leptin can pass through the blood–brain barrier [116] and could function as a neurotrophic
factor in modulating neuroplasticity and cognitive functions [117]. db/db mice, which show loss of
function in leptin receptor signaling, display neuronal atrophy in the hippocampus, including reduced
hippocampal progenitor cell proliferation [118], reduced dendritic branching and dendritic spine [119].
Besides, both db/db mice and Zucker fa/fa rats show spatial memory deficits in the Morris water maze
task [118,120,121] and exhibit despair behaviors [122], suggesting that impaired leptin signaling could
affect structural plasticity in the hippocampus. HFD-induced diabetic model [123] and db/db mice [124]
display hyperleptinemia and leptin resistance. Enhancing leptin levels enhances neuroplasticity and
cognitive function in rodents under physiological conditions. For example, intraperitoneal injection
with 1 mg/kg recombinant leptin continuously for 14 days promotes hippocampal cell proliferation
and survival of newborn neurons in healthy male mice [24]. An in vitro study has demonstrated
that leptin promotes dendritic branching and spine maturation in cultured primary neurons [125].
Moreover, leptin elicits a rapid antidepressant effect by reducing depression-like behavior in the
forced swim test and tail suspension test [126]. Intrahippocampal infusion with leptin immediately
after training improves memory processing in T-maze footshock avoidance and step down passive
avoidance tests [127], suggesting that leptin has a direct effect on influencing hippocampal function
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and enhances behavioral outcome. Notably, previous studies have shown that leptin treatment
via systemic injection or intra-hippocampus injection to the dorsal part can improve spatial and
context-cued learning and memory. Nonetheless, a study has reported that leptin infusion in the
ventral hippocampus, but not in the dorsal hippocampus, impairs memory consolidation for the spatial
location of food [128]. A recent review suggests that activating the leptin signaling pathway, specifically
in the ventral hippocampus, could suppress spatial working memory [129]. Mechanisms of how
leptin affects structural plasticity in the hippocampus are still unclear. Leptin receptors are coupled
to JAK/STAT and PI3K/Akt signaling cascades in hippocampal neurons. Activation of the above
cascades increases the production of manganese superoxide dismutase (Mn-SOD), an antioxidant
enzyme, as well as the anti-apoptotic protein Bcl-xL. The synergistic antioxidant and anti-apoptotic
effects may stabilize the mitochondrial membrane potential, and hence lessen mitochondrial oxidative
stress to promote neuronal proliferation in the hippocampus [26]. Leptin treatment could increase
hippocampal cell proliferation and survival by increasing mitochondrial functioning. In addition,
leptin can also promote synaptogenesis via increasing expression of microRNA-132 (miR-132) [119].
Leptin induces long-term potentiation (LTP) by modulating post-synaptic signaling pathway and
glutamatergic N-methyl-D-aspartate (NMDA) receptor. LTP is considered as a cellular mechanism
of learning and memory formation. The NMDA receptor-dependent LTP in the CA1 region of the
hippocampus underlies spatial memory formation [130]. Both db/db mice and Zucker fa/fa rats with
defective leptin receptors impair hippocampal LTP formation [120], whereas infusion of 1μM leptin into
the hippocampal dentate gyrus enhances LTP [131]. Ex vivo studies also show that leptin can increase
pharmacologically-isolated NMDA receptor-mediated excitatory postsynaptic currents (EPSCs) in the
CA1 region in acute rat hippocampal slices [132] (Table 1).
Neuroprotective effects of leptin have also been shown in animal models. Eight weeks of systemic
infusion with leptin reduces amyloid-β levels in the brain and serum of six-month old CRND8
transgenic mouse model of AD. Leptin treatment also improves object recognition and contextual fear
learning [133]. Moreover, intracerebroventricular injection of leptin (1 μg) for ten days improves spatial
memory in Y-maze and water maze tasks, as well as restores LTP in the CA1 region in an Aβ-induced
AD rat model [134]. The neuroprotective effects of leptin could be linked to a leptin/JAK2/STAT3
signaling pathway [135] or leptin mediated PI3K/Akt/mTOR signaling pathway [136]. In sum, leptin
can directly modulate structural and synaptic plasticity, however prolonged elevation in leptin levels
could be detrimental to neuroplasticity under hyperleptinemia condition.
2.2. Adiponectin
Adiponectin is secreted by white adipose tissue and exerts anti-inflammatory effects on both
endocrine and cardiovascular systems [137,138]. Adiponectin receptors (AdipoRs) express differentially
in peripheral tissues. AdipoR1 is highly expressed in skeletal muscle, while AdipoR2 is abundant
in the liver [139]. Hypoadiponectinemia, a condition of low circulating adiponectin, is commonly
observed in obese and type 2 diabetic patients [140–142]. In line with clinical evidence, diabetic and
obese mice also have reduced adiponectin expression in adipose tissues as well as the blood [143–146].
Circulating adiponectin levels are reduced in obesity [140–142], whereas the expressions of adiponectin
receptors are increased, as evidenced by higher mRNA expressions of AdipoR1 in skeletal muscle
in obese subjects [147] and AdipoR2 in insulin-resistant subjects [148]. Recombinant adiponectin
treatment can reduce body weight and increase hepatic and muscular insulin sensitivity in an
adiponectin-deficient mouse model [149]. Similarly, patients receiving rosiglitazone, an insulin
sensitizer targeting the adipose tissue, experience increased plasma adiponectin by approximately
two-fold [150]. These findings indicate that upregulating adiponectin expression can improve insulin
sensitivity. Adiponectin receptors (AdipoR) are widely expressed in rodent brains, including the
hypothalamus, brainstem, prefrontal cortex, and hippocampus, suggesting its role in the CNS in
addition to its role in metabolism [27,139,151–159]. Overnight fasting by food deprivation for
sixteen hours concomitantly downregulates mRNA expression of adiponectin and upregulates mRNA
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expression levels of AdipoR1 and APPL1 in the hypothalamic ARC [160], a brain area in the mediobasal
hypothalamus regulating energy and glucose homeostasis [161].
Adiponectin could enter the blood–brain barrier since the low-molecular weight trimeric form of
adiponectin is detectable in cerebrospinal fluid after intravenous injection in adiponectin-deficient
mice [25,162]. Prominently, adiponectin is involved in energy homeostasis and appetite in concordance
with leptin. A recent investigation shows that adiponectin promotes anorexigenic POMC activity in
the hypothalamic ARC [163] possibly through PI3-K signaling [164]. Adiponectin elicits an excitatory
effect on POMC neurons in a leptin-receptor dependent manner [163], whereas leptin synergistically
potentiates adiponectin excitatory effect on POMC neuronal activity [163]. Simultaneously, adiponectin
inhibits the neighboring orexigenic NPY/AgRP neurons, which then disinhibit POMC activity [163].
Further studies show that adiponectin action on the hypothalamic POMC activity may occur in
a glucose-dependent reciprocal manner. Adiponectin infusion in the cerebral ventricle exerts an
orexigenic effect at high glucose levels but is anorexigenic at low glucose levels [165]. Moreover,
adiponectin increases the anorexigenic POMC activity at low glucose levels (2.5–5 mM), mimicking
the fasting and physiological states, but decreases the POMC activity at high glucose levels (10 mM),
mimicking a fed state [165] in electrophysiological recordings. The state-dependent adiponectin
mechanism of action may act differentially on different molecular pathways: Adiponectin inhibits
POMC neurons at high glucose via AMPK signaling, while it activates POMC neurons at low glucose
via PI3-K signaling [165]. In contrast to the glucose-dependent effect in POMC, adiponectin enhances
the activity of inhibitory GABA-ergic NPY neurons in a glucose-independent fashion [166]. Altogether,
at low glucose conditions, adiponectin suppresses orexigenic NPY neurons and activates anorexigenic
POMC neurons to attenuate appetite and food intake under conditions of fasting or low blood glucose.
On the other hand, at high glucose levels, feeding behavior is nullified [165] as adiponectin inhibits
both anorexigenic and orexigenic activities. Since leptin resistance and hypoadiponectinemia are
symptomatic in obese and type 2 diabetic subjects, disrupted interplay of leptin and adiponectin
may collectively impair anorectic actions and thus promote caloric intake and energy accumulation
in obese and diabetic conditions. Hypoadiponectinemia is often documented in patients receiving
atypical antipsychotics medication, including olanzapine and clozapine, in association with increased
adiposity and hyperleptinemia [68,167,168]. Specifically, clozapine medication leads to body weight
gain, high triglyceride profile, and hypoadiponectinemia [169,170]. GABA-facilitated orexigenic NPY
activation and the subsequent suppression of anorexigenic POMC activity is suggested to be a potential
mechanism of olanzapine-induced obesity [171]. The disrupted hypothalamic control of energy
homeostasis may, therefore, lead to hyperleptinemia and hypoadiponectinemia. Still, some atypical
antipsychotics, including risperidone and quetiapine, do not affect adiponectin levels [168,172–174].
AdipoR1 is expressed in dopaminergic neurons in the VTA [175]. The adiponectin receptor
expression implicates the crosstalk of adiponectin and dopamine signaling pathways. Hedonic
behaviors and affective behaviors are intertwined by dopamine signaling [176–179]. Recent research
dissecting the role of adiponectin receptor in mediating anxiety reveals that intra-VTA infusion of
adiponectin or the adiponectin receptor agonist AdipoRon suppresses dopaminergic neuron firing in
an AdipoR1-dependent manner [175]. However, impaired adiponectin signaling due to adiponectin
haploinsufficiency or AdipoR1 ablation increases dopaminergic activity and anxiety behavior.
Adiponectin action shares similarities with the inhibitory action of leptin on the VTA dopaminergic
neurons. Importantly, anxiety symptoms are often comorbid with metabolic disorders [180], where
hypoadiponectinemia is indicative in obese and type 2 diabetic subjects [140,141,181]. It is speculated
that the interplay of leptin and adiponectin may also exist in the VTA dopaminergic neurons to
modulate reward and affective behaviors.
Patients with type 2 diabetes or dementia display decreased adiponectin levels [182–184]. High fat
diet-induced and streptozotocin-induced diabetic conditions reduce AdipoR1 and AdipoR2 expressions
in the hippocampus [27]. Adiponectin knockout reduces proliferating cells, differentiating cells, and
cell survival in the hippocampus [185]. Adiponectin stimulates the proliferation of hippocampal
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progenitors through p38MAPK/GSK-3β/β-catenin cascade [157]. Moreover, adiponectin deficiency
reduces the dendritic length, branching, and spine density of dentate granule neurons, particularly in
early-born granule neurons in the hippocampal dentate gyrus [185]. Low levels of adiponectin are
associated with cognitive dysfunction [184]. Chronic adiponectin deficiency impairs spatial memory
and learning and induces anxiety-like behavior [19]. Moreover, AdipoR1 knockdown causes metabolic
dysfunction and neurodegeneration in an association with the cognitive deficit in Morris water
maze [186]. Overexpression of adiponectin in the brain [25] or infusion of recombinant adiponectin
into the cerebral ventricle induces antidepressant effects [158,187,188]. The antidepressant effect could
be linked to the activation of the AdipoR1/APPL1/AMPK pathway [25]. Rosiglitazone, a blood–brain
barrier-impermeable PPARγ-selective agonist, enhances adiponectin levels and elicits antidepressant-
and anxiolytic-like effects in wild-type mice, but not adiponectin-deficient mice or mice pretreated
with PPARγ-selective antagonist [189].
The pro-cognitive effect of adiponectin in AD could be linked to its anti-inflammatory effect and
enhanced effects on synaptic plasticity. Globular adiponectin predominantly binds to AdipoR1 and
inhibits nuclear factor-κB (NF-κB) activation in macrophages, which in turn, suppresses its production of
pro-inflammatory cytokines [190,191]. Therefore, adiponectin may reduce the extracellular deposition
of amyloid-β via its suppressive effect on microglial activation. Moreover, adiponectin attenuates
streptozotocin-induced Tau hyperphosphorylation and cognitive deficits through PI3K/Akt/GSK-3β
pathway [192]. Activating AMPK can suppress GSK-3β action on Tau phosphorylation, whereas
chronic adiponectin deficiency fails to phosphorylate AMPK, which in turn, enables GSK3β action
on promoting Tau hyperphosphorylation, and subsequently results in AD-like neuropathology [19].
Nine-month-old adiponectin-deficient, 5×FAD mice show microglia activation together with elevated
TNFα and IL-1β levels in the cortex and hippocampus [193]. In accordance with the previous study,
an in vivo study illustrates that globular adiponectin exerts anti-inflammatory effects on microglia
by reducing IL-1β, IL-6, and TNFα [33]. Pre-treatment with adiponectin can diminish TNFα and
IL-1β release in vitro [193]. Adiponectin potentially exerts anti-inflammatory action on microglia
via AdipoR1/NF-κB signaling [33,193]. Other studies have further demonstrated that adiponectin
exhibits anti-inflammatory response dependent on PPARγ [194] or IL-4/STAT6 signaling pathway [191].
Recently, an ex vivo study has demonstrated that adiponectin exhibits a beneficial effect on hippocampal
synaptic plasticity in 5×FAD mice. Acute perfusion for 10-min or 2-h incubation of 2.7 nM adiponectin
can induce LTP in the hippocampal CA1 region in five to six months old 5×FAD mice. Acute incubation
of adiponectin also increases expressions of AdipoR1 and AdipoR2, increases protein expressions of
GluA1, GluN1, GluN2B, and PSD-95 as well as elicits anti-apoptotic and anti-inflammatory effects [195].
These findings suggest that adiponectin inhibits neuronal apoptosis and inflammatory mechanisms
and promotes hippocampal long-term potentiation. Taken together, these data have suggested the
neuroprotective and neurogenic effects of adiponectin in the hippocampus (Table 1).
2.3. Chemerin
Chemerin is a novel adipokine that acts autocrine, paracrine, and endocrine on different
tissues [196] by binding to either chemokine-like receptor 1 [197], chemokine receptor-like receptor
2 [198] or G protein-coupled receptor 1 [199]. Chemerin is highly expressed in white adipose
tissue [200] and acts as a pro-inflammatory cytokine [201] and anti-inflammatory cytokine. It promotes
adipogenesis [200], angiogenesis [202], and inflammation [203]. Clinical study has shown that change
of chemerin levels is linked to obesity because the circulating levels of chemerin is positively correlated
with high body-mass index and elevated obesity-related biomarkers [204–206]. Similarly, high fat
diet-induced obese mice display an increase in plasma chemerin levels, and this increase can be reduced
by overnight fasting [207]. Another study has shown that chemerin administration exacerbates the
glucose intolerance in obese and diabetic mice by reducing hepatic glucose uptake [208]. Chemerin
deficiency results in insulin resistance in adipose tissue and liver, leading to elevated hepatic glucose
production and increased blood glucose levels [209]. On the other hand, chemokine-like receptor 1
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knockout mice have reduced glucose uptake in adipose tissue and skeletal muscle [210], whereas
high-fat diet further exacerbates glucose intolerance, hyperinsulinemia and enhances insulin resistance
in these mice [211].
Activation of the chemerin signaling pathway plays a vital role in the neuroendocrine axis
by regulating appetite. Chemerin receptors are highly expressed in multiple rodent brain regions,
including the prefrontal cortex, hippocampus, and hypothalamus [212]. Continuous intracerebral
infusion of chemerin into photoperiodic-sensitive F344 rats can promote food intake [213], whereas
chemokine-like receptor 1 deficiency reduces food intake and body weight [210]. Chemerin can also
aggravate glucose intolerance [208]. Consistently, clinical data indicate that circulating chemerin levels
are increased in patients with obesity, diabetes, and cardiovascular diseases [214].
A recent study has shown that intranasal administration of human recombinant chemerin
(rh-chemerin) exerts neuroprotective effects in a rat model of neonatal hypoxia-ischemia brain
injury [215]. Intranasal treatment with chemerin significantly reduces infarct volume and attenuates
developmental delay 24 h after hypoxic-ischemic encephalopathy. Chemerin treatment significantly
improves cognitive and sensorimotor performance in animals with hypoxic-ischemic encephalopathy.
Moreover, recombinant chemerin treatment significantly reduces apoptosis and the expressions of
pro-apoptotic markers [215], suggesting a neuroprotective role of chemerin. Chemerin signaling is
proposed to mediate neuro-inflammatory action in the brain. It is reported that the expression of
chemokine like receptor 1 (CMKLR1) is upregulated in AD patients, suggesting the role of central
chemerin signaling in the progression of AD [216]. Systemic lipopolysaccharide administration is known
to upregulate CMKLR1 expression and promote neuroinflammation [216]. This study has reported
that CMKLR1 and Aβ42 are colocalized in hippocampal neurons of APP/PS1 AD mice, and CMKLR1 is
involved in Aβprocessing and clearance. CMKLR1 is detected in the hippocampus and prefrontal cortex,
two critical brain regions involved in the pathology of depression [217]. Intracerebral administration
of chemerin elicits antidepressant effects [218]. In the lipopolysaccharide-induced depression mouse
model, intracerebral administrations of chemerin receptor agonist: Eicosapentaenoic acid-derived
resolvins E1 (1 ng) or E2 (10 ng) produce antidepressant effects depending on ChemR23/mTORC1
pathway in the medial prefrontal cortex and hippocampal dentate gyrus [218] (Table 1), suggesting
activating chemerin signaling could be a novel antidepressant target.
2.4. Apelin
Apelin, a peptide hormone secreted by adipocytes, is involved in insulin secretion [219], glucose
and lipid metabolism [220], angiogenesis [221], blood pressure regulation [222], and food intake [223].
Apelin has similar properties as physical exercise does in metabolism, and so given entitled it as an
exerkine [224]. Apelin can be proteolytically cleaved into several bioactive forms, including apelin-13,
-17, and -36, as well as the pyroglutaminated apelin-13 isoform [225]. Apelin receptors are widely
distributed in rodent brain and systemic tissues [226].
Apelin is necessary for balancing the fat composition and promoting insulin sensitivity.
Apelin-knockout mice exhibit obese and diabetic symptoms, including increased abdominal fat
mass, glucose intolerance, hyperinsulinemia, and hypo-adiponectinemia [227]. High-fat diet and
high-sucrose consumption aggravate glucose and insulin intolerance in apelin-deficient mice [228].
Clinical study has reported a positive correlation between plasma insulin levels and apelin expression in
adipocytes from obese subjects. Given this insulin-sensitizing property, apelin has become a promising
therapeutic target for treating obesity and diabetes. Single intravenous injection of 200 pmol/kg
Pyr(1)-apelin-13 can improve glucose intolerance in high-fat diet-induced obese and insulin-resistant
mice [229]. Chronic apelin treatment (two to four weeks) improves insulin sensitivity, lowers blood
glucose levels, and protect the animals from hyperinsulinemia and glucose intolerance in mice with
obesity or insulin resistance [228,230]. Apelin treatment can also significantly reduce adiposity and
plasma triglycerides [230]. Apelin is involved in lipid metabolism by inhibiting isoproterenol-induced
lipolysis in cultured adipocytes [227]. Moreover, exogenous apelin reduces the number of differentiated
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adipocytes and increases the size of lipid droplets inside the cells, suggesting that apelin might suppress
lipolysis [231]. In vitro studies reveal that apelin-13 and [Pyr1]-apelin-13 improve glycemia in an
AMPK/eNOS-dependent [229] and PI3K/Akt-dependent [232] pathways respectively. These findings
have collectively suggested that apelin treatment could be useful in reducing adiposity, improving
insulin sensitivity, and improving diabetic conditions.
Similar to other adipokines, apelin exhibits anti-inflammatory properties [232] and possesses
neuroprotective effects [233]. In an ischemia/reperfusion (I/R) stroke rat model, the post-stroke
intracerebral injection of apelin-13 can significantly reduce the infarct volume [234]. Similarly,
intracerebral infusion of apelin-13 significantly decreases blood–brain barrier permeability and increases
vascular endothelial growth factor levels in post-stroke mice [235]. Furthermore, post-stroke treatment
with intranasal apelin-13 for three days can reduce infarct volume, reduce neuronal apoptosis, suppress
inflammation, and increase angiogenesis [236]. In mice with traumatic brain injury, intracerebral
administration of apelin-13 reduces brain damage via suppressing autophagy [237]. Apelin-13 also
elicits an anti-inflammatory effect by inhibiting microglia and astrocyte activation and upregulates
hippocampal BDNF and TrkB expression in streptozotocin-induced sporadic AD rats. Furthermore,
the apelin-13 treatment also promotes learning and memory performance, as evidenced by its effect on
improving novel object recognition and spatial recognition through the BDNF/TrkB pathway [238].
In a rat model of depression, apelin-13 treatment elicits antidepressant effect and improves recognition
memory via activating phosphatidylinositol 3-kinases (PI3K) and extracellular signal-regulated kinase
1/2 (ERK1/2) signaling pathways. The hippocampus is thought to be the critical brain region mediating
the antidepressant-like response of apelin [239,240]. Similarly, intracerebral infusion of apelin-13 can
ameliorate depression-like phenotypes in rats subjected to chronic restraint stress. Apelin-13 can also
suppress hypothalamic-pituitary-adrenal axis hyperactivity, promote hippocampal BDNF expression,
and restore hippocampal glucocorticoid receptor functions in rats with chronic stress [241] (Table 1).
2.5. Visfatin (Nicotinamide phosphoribosyltransferase, NAMPT)
Nicotinamide phosphoribosyltransferase (NAMPT) is an enzyme which catalyzes the biosynthesis
of nicotinamide adenine dinucleotide (NAD+) in mammals [242]. There are two isoforms of
NAMPT: Intracellular NAMPT (iNAMPT) and extracellular NAMPT (eNAMPT or visfatin) [242].
Growing evidence shows that NAD+/NADH metabolism in adipose tissue is linked to obesity and
insulin resistance. In humans, visceral adipose NAMPT expression and serum NAMPT levels are
positively correlated with obesity [243]. In mice, adipose NAMPT expression and NAD+ contents
are markedly reduced by high-fat diet feeding [244,245], but increased by caloric restriction [246,247].
Adipocyte-specific Nampt knockout mice show severe insulin resistance in multiple organs under a
chow-fed condition, which is independent of body weight and adiposity [248]. Loss of Nampt causes
adipose tissue inflammation, increases plasma free fatty acid concentrations, and decreases adiponectin.
Notably, oral administration with nicotinamide mononucleotide, a key NAD+ intermediate, can restore
adipose tissue NAD+ biosynthesis and significantly restore insulin resistance, plasma adiponectin
and free fatty acid concentrations in adipocyte-specific Nampt knockout mice. On the other hand,
visfatin is secreted from white adipose tissue through sirtuin1 (SIRT1)-mediated deacetylation of
iNAMPT [249]. At present, it remains uncertain whether visfatin can cross the blood–brain barrier.
However, adipose-secreted visfatin serves as a neuroendocrine factor. Adipose tissue-specific Nampt
knockout mice display a significant reduction in circulating visfatin, as well as reduced hypothalamic
NAD+ content and SIRT1 activity [249]. On the other hand, adipose-specific Nampt knock-in mice show
increases in hypothalamic NAD+ content, SIRT1 activity, and neural activity in response to fasting.
Therefore, adipose-secreted visfatin has a strong implication on modulating brain functions.
Visfatin protects neurons against ischemia-induced injury because NAMPT overexpression can
reduce infarct volume and improve long-term neurologic outcomes [250]. In a transient global cerebral
ischemia model with 20-min carotid arteries occlusion, intracerebral infusion of 100 ng visfatin in the
hippocampal CA3 region during cerebral reperfusion can reduce the caspase-3 activation and Bax/Bcl-2
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ratio [251]. Visfatin can significantly reduce apoptosis and necrotic cell death in the CA1 region of
the hippocampus, with improved memory deficits in I/R rats. The suppressed pro-apoptotic and
enhanced anti-apoptotic mechanisms could contribute to the neuroprotective effects of visfatin [250].
In another study, transgenic mice overexpressing NAMPT globally increase NAD+ content and
neuronal survival in the hippocampal dentate gyrus [252]. These mice also display better learning and
memory performance in the water maze test upon middle cerebral artery occlusion. Post-ischemic
intraperitoneal administration with nicotinamide mononucleotide for seven days can improve adult
hippocampal neurogenesis [252]. Nicotinamide mononucleotide and NAD+ promotes proliferation
and differentiation of neural stem cells in a NAMPT/NAD+/SIRT manner [252]. An in vitro study has
concluded that cultured glia, but not neuron, can secrete visfatin under oxygen-glucose deprivation
stress. Treatment of wild-type visfatin, but not H247A-mutant enzymatic-dead visfatin, can significantly
attenuate oxygen-glucose deprivation-elicited cell death in both cultured mouse neuron and glia.
Treatment of neutralizing antibody can, in turn, abolish the protective effect of extracellular visfatin on
cell viability [253].
Although the neuroprotective benefits of visfatin towards neurodegenerative diseases require
further investigation, growing evidence has indicated that NAD+ administration can improve cellular
energetics and extend life span in rodents [254]. The evidence leads to the idea that the administration
of NAD+ precursors, including nicotinamide mononucleotide and nicotinamide riboside, is a potential
treatment to forestall disease progress in AD by improving brain energetics [255]. In the AD
rat model with an intracerebral infusion with Aβ amyloid, intraperitoneal administration of 500
mg/kg nicotinamide mononucleotide improves learning and memory performance in water maze
task [256]. Nicotinamide mononucleotide also attenuates Aβ oligomer-induced neuronal cell death,
prevents long-term potentiation deficit, restores NAD+ and ATP levels, and eliminates reactive oxygen
species in organotypic hippocampal slices [256]. Moreover, nicotinamide riboside treatment exhibits
pro-cognitive function by increasing cortical NAD+ content and restoring long-term potentiation
deficit in the hippocampal CA1 region of the Tg2576 AD mouse model. This study has suggested that
treatment upregulating the NAMPT/NAD+ axis could prevent Aβ accumulation in the brain [257]
(Table 1).
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3. Novel Adipocyte-Derived Messengers on Brain Health
Lipokine refers to fatty acids that act like hormones and modulate lipid metabolism [258]. Notably,
adipose tissue, which is one of the systemic sites with active lipid metabolism, secretes various
lipids into the bloodstream to communicate with distant organs. Coincidentally, alterations in lipid
metabolism may implicate the onset of brain diseases. For example, apolipoprotein E (ApoE) mediates
systemic cholesterol metabolism and acts as a cholesterol carrier to neurons in the central nervous
system. Human carriers of mutated apolipoprotein E allele ε4 are associated with an increased risk of
AD [259]. Moreover, post-mortem studies have shown that AD patients display abnormal levels of
ceramides, n-3 polyunsaturated fatty acids (PUFA), and PUFA-derived signaling lipids [260–264].
Lipokines, including monounsaturated palmitoleic acid and lysophosphatidic acid (LPA can
exert endocrine effects on systemic tissues and have potential crosstalk with the central nervous
system. Palmitoleic acid is a highly abundant fatty acid in the serum. Its circulating levels fluctuate
dependent on metabolic states. Obese children and adults exhibit a higher plasma palmitoleic acid
content compared to healthy control [265,266]. Besides, the change of palmitoleate could be associated
with an increased risk of obesity, dyslipidemia, and insulin resistance [265–268]. On the other hand,
lysophospholipid is a prominent class of lipid signaling molecules, whereas LPA is a crucial member.
Circulating LPAs are synthesized by autotaxin, a phosphodiesterase produced by adipocytes [269].
Circulating autotaxin levels increase in obesity and insulin resistance [270–276], which is positively
correlated with an increase in circulating lysophosphatidic acid [277,278]. A high-fat diet can perturb
lipid composition in the brain. The altered lipid composition is evidenced by a surge of palmitoleic
acid composition in the mouse brain after 14 days of high carbohydrate and high fatty acid diets [279].
Congruently, high-fat diet causes a significant elevation of LPA in mouse cortex after eight weeks of
high-fat diet [280]. Importantly, over-nutritious food has detrimental effects on brain plasticity because
brain diseases could be linked to dysregulated lipid metabolism [281–286]. The effects of palmitoleic
acid and lysophosphatidic acid on brain health warrant further investigation.
3.1. Palmitoleic Acid (16:1n7)
Palmitic acid (16:0) is the most common saturated fatty acid in the human body. It can be consumed
through diet or synthesized from other fatty acids, carbohydrates, and amino acids endogenously [287].
Under normal physiological conditions, palmitic acid accumulation is prevented by desaturation
to palmitoleic acid (16:1n7) or by elongation to stearic acid (18:0), then further desaturation to oleic
acid (18:1) [288,289]. Abnormal levels of palmitic acid have been documented in neurodegenerative
diseases [290–292] that are related to dysregulated palmitic acid biosynthesis. Palmitoleic acid,
a monounsaturated fatty acid, primarily originates from stearoyl-CoA desaturase 1-mediated de
novo lipogenesis from palmitic acid in humans [287]. Palmitoleic acid is highly abundant in serum
and adipose tissues [293]. cis-palmitoleate has been associated with increased insulin sensitivity
and decreased lipid accumulation in the liver [258]. Various animal models have illustrated that
cis-palmitoleate reduces the expressions of pro-inflammatory cytokines and adipokines in association
with metabolic syndromes [258,294,295]. In vitro study also shows that palmitoleic acid increases
lipolysis and lipase content in white adipose tissue in a PPARα-dependent manner [296]. Other
than adipose tissues, palmitoleic acid can enhance whole-body glucose disposal [297] and improve
circulating lipid profiles in both rodents and humans [298]. Therefore, palmitoleic acid is considered
a lipokine.
Fatty acid-binding proteins (FABP) are lipid chaperones that regulate lipid trafficking and responses
in cells [299,300]. In humans, circulating adipose-derived fatty acid-binding protein (A-FABP) levels
are substantially higher than other adipokines, including leptin, resistin, TNF-α, and IL-6 [301–303].
Circulating A-FABP is markedly increased in both obese men and women [304], suggesting that
A-FABP may involve in modulating insulin sensitivity and lipid metabolism in distant organs. Of note,
A-FABP is also considered as an adipokine, which is secreted from adipocyte-derived exosomes by
exocytosis [305]. Critically, deficiencies in A-FABP and epidermal fatty acid-binding protein (E-FABP)
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can activate SCD1 activity, leading to a subsequent elevation in palmitoleate concentration in adipose
tissue [306,307]. A-FABP deficient mice exhibit improvement in systemic glucose, lipid metabolism
and insulin resistance in association with diet-induced and genetically-disposed obesity [308]. The
A-FABP and E-FABP double mutant mice are resistant to diet-induced obesity, insulinemia, type 2
diabetes, dyslipidemia, and fatty liver disease [309,310]. The dysregulated SCD1-mediated de novo
synthesis of palmitoleic acid enhances whole-body glucose and fatty acid metabolism [311].
Although it requires more solid evidence to demonstrate the effect of adipocyte-secreted palmitoleic
acid and A-FABP on brain health, it is reported that stearoyl-CoA desaturase activity and levels of
palmitoleic acid in the brain are associated with AD [312]. Liquid chromatography-mass spectrometry
analysis has revealed elevated levels of several monounsaturated fatty acids, including palmitoleic
acid, in the mid-frontal cortex, temporal cortex, and hippocampus of AD patients as compared to
their age-matched counterparts [312]. This increase is strongly associated with cognitive dysfunction
and the increased expression of stearoyl-CoA desaturase in the brain [266,313–317]. Further studies
have shown that AD patients have increased expressions of various stearoyl-CoA desaturase isoforms,
including SCD-1 [312]. Coherently, stearoyl-CoA desaturase activity is negatively correlated to
cognitive measures [312]. Levels of free palmitoleic acid and the desaturation index are decreased
in frontal cortices in aged dogs treated with antioxidant, and vice versa [318]. The study implicates
that altering stearoyl-CoA desaturase activity and reducing palmitoleic acid levels in the brain may
improve cognitive performance [318].
3.2. Lysophosphatidic Acid
Neuroinflammation is commonly associated with type 2 diabetes [319], and obesity [320].
High-fat diet feeding results in profound central and peripheral inflammation [321,322]. Autotaxin
is a lysophospholipase that synthesizes lysophosphatidic acid (LPA). Autotaxin is also regarded
as an adipokine due to its role in promoting adipocyte differentiation [269]. Evidence suggests
that the autotaxin-mediated LPA biosynthesis contributes to the majority of extracellular LPA, in
which adipocyte-specific autotaxin contributes to most of the circulating LPA [269,272]. Further
investigations suggest that circulating LPA and autotaxin levels are linked to adipocyte differentiation
and obesity [269,271]. Autotaxin expression is upregulated in obese patients and obese db/db mice
due to the accumulation of triglycerides in the adipocytes [271]. A recent study has reported that
adipose-derived autotaxin serves as an inflammatory cytokine of diet-induced obesity [323].
LPA signaling mediates inflammation [324], angiogenesis [325], brain development [326], and
neurogenesis [327] in the brain. Specifically, LPA exerts a pleiotropic effect on various brain cell
types, including neurons, astrocytes, microglia, and oligodendrocytes that show LPA receptors
expression [328]. LPA promotes neuronal differentiation in cortical neural progenitor cells through
LPA1 receptor/Gi/o pathway [329], whereas axonal branching is induced in hippocampal cell cultures
through LPA3 receptor/Gq/Rho family GTPase 2 (Rnd2) pathway [330]. Mainly, LPA1 is essential
in mediating synaptic plasticity and learning. In vitro studies have shown that overexpression of
LPA1 increases dendritic spine density and size [331], potentially through protein kinase C (PKC)/Rho
and PKC/Rac cascades [332,333]. It is speculated that LPA1 deficiency can cause schizophrenia-like
behaviors, including impaired spatial memory retention and increased anxiety-like behavior [334–336].
Furthermore, the role of LPA and its receptors in anxiety-like behavior and learning has been confirmed
by later studies using LPA1-null mice. These mice show normal survival but display aberrant
hippocampal neurogenesis and decreased BDNF levels [327], as well as increased anxiety-like behavior
and memory deficits [337]. LPA mediates astrocyte proliferation through the LPA1 receptor [338].
Interestingly, LPA promotes astrocyte-neuronal crosstalk through laminin-mediated EGFR/MAPK
signaling to facilitate neuronal differentiation [339]. LPA triggers microglial migration through a
Ca2+-dependent K+ channel [340,341], and reduces oxidative stress [342,343]. Moreover, LPA can
promote the retraction of oligodendrocyte processes in mature oligodendrocytes [344] as well as
promotes the formation of oligodendrocyte processes in differentiating oligodendrocytes [345].
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In addition to a metabolic disorder, an altered systemic lipid metabolism may have a neurological
impact [346] through autotaxin-LPA signaling. Clinical study has reported that mild cognitive
impairment and AD patients have significantly higher levels of autotaxin in cerebrospinal fluid [347].
Furthermore, the autotaxin levels are positively correlated to neuroinflammatory markers, β-amyloid,
and tau in the cerebrospinal fluid [347]. In vitro study has shown that LPA could increase Aβproduction
by upregulating the expression of β-secretase expressions in the N2a neuroblastoma cell line expressing
wild-type presenilin 1 and Swedish mutant APP [348]. Potentially, LPA-induced BACE1 promoter
activation is mediated by PKCδ/MEK/MAPK/p90RSk/CREB signaling cascades [348–353]. Moreover,
LPA may be involved in tau hyperphosphorylation and paired helical filaments formation, which
are the pathological patterns in AD brains through Gα12/13/RhoA/Rock/GSK-3β pathway [354,355],
suggesting potential connection among LPA, microfilament dynamics, and AD pathogenesis.
4. Conclusions
It is an emerging research field to understand the functions of different adipokines in regulating
eating behavior, hippocampal plasticity, and neuronal protection. This review has denoted five
adipokines (leptin, adiponectin, chemerin, apelin, and visfatin) and two lipokines (palmitoleic acid and
lysophosphatidic acid) (Figure 1). The review has summarized the currently available evidence for their
novel function in the brain. First, it is evident that the aberrant adipokine production not only renders
the susceptibility to metabolic syndromes in genetically deficient rodent models of various adipokines
but also the vulnerability to neurodegeneration, especially in models of impaired leptin-signaling.
Accumulated evidence has indicated that diet-induced obese or diabetic rodent models show abnormal
levels of leptin, adiponectin, chemerin, apelin, and visfatin. Notably, circulating adiponectin and
visfatin levels are reduced in diet-induced obesity, with associated impairments in hippocampal
plasticity and cognitive behaviors [356]. Due to the multifaceted effect of adipokines on systemic and
brain health, dysregulated adipokine secretion could be one of the causes that underlie the comorbidity
of metabolic syndromes with neurodegenerative disorders [357,358]. Thus, all these investigations have
highlighted the prominent roles of adipokines on brain health. Second, evidence also shows that leptin
and adiponectin can elicit their action directly in the brain by crossing the blood–brain barrier. Leptin
is not only a satiety regulator through anorexigenic and dopaminergic controls, but ample evidence
also supports its role in promoting neuroplasticity in the hippocampus [12]. On the other hand,
adiponectin is a chief metabolic regulator in glucose and fatty acid metabolism with insulin-sensitizing
ability in both peripheral and central systems. Current findings have suggested the direct effect of
adiponectin on synaptic plasticity [195,359] and microglial activation [193]. Both exogenous leptin and
adiponectin can exert pro-cognitive effects in mouse models. Besides, leptin and adiponectin signaling
pathways are defective in AD brains [360]. Hence, increasing leptin and adiponectin signaling can
be a potential therapeutic target for AD [361,362]. Third, emerging literature has also revealed the
central function of three novel adipokines: Chemerin, apelin, and visfatin. Inflammatory response
and apoptosis are typical in neurodegenerative diseases [363,364] and ischaemic stroke [365,366].
These novel adipokines are potential therapeutic targets, which modulate anti-inflammatory and
anti-apoptotic effects in the hippocampus. Finally, this review has highlighted lipokines are a lipid
signaling molecule secreted by adipocytes with potential endocrine effect acting on the brain [367].
Still, the potential of lipokines is mostly unknown, future studies will be required to illustrate its
properties and function in neuroplasticity and cognitive functions.
Overall, adipokines emerge as viable therapeutic targets towards neurodegenerative
diseases. Adipokine-based therapeutic approaches could be future pharmaceuticals to obliterate
neurodegenerative disorders. More in-depth investigations on the above-mentioned adipokines and
its crosstalk with the brain can open up new therapeutic targets to treat neurodegenerative diseases.
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Figure 1. Potential mechanism of adipokine actions on brain health. Adiponectin and leptin can cross
the blood–brain barrier to promote neuroplasticity. Other adipokines and lipokines show profound
effects on mediating neurogenic and neuroinflammatory mechanisms.
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